TRIPLE-S MANAGEMENT CORP (Form: 10-Q, Received: 11/08/2018 14:56:44)

Exhibit 10.1

CONTRACT BETWEEN

ADMINISTRACIÓN DE SEGUROS DE SALUD DE PUERTO RICO (ASES)

and

TRIPLE-S SALUD, INC.

for

PROVISION OF PHYSICAL & BEHAVIORAL HEALTH SERVICES UNDER THE GOVERNMENT HEALTH PLAN PROGRAM

Contract No.: 2019-000052

Account No.: 256-5325 to 5330

Page 1 of 324

TABLE OF CONTENTS

ARTICLE 1	GENERAL PROVISIONS	7

ARTICLE 2	DEFINITIONS	10

ARTICLE 3	ACRONYMS	30

ARTICLE 4	ASES RESPONSIBILITIES	33

ARTICLE 5	ELIGIBILITY AND ENROLLMENT	36

ARTICLE 6	ENROLLEE SERVICES	52

ARTICLE 7	COVERED SERVICES AND BENEFITS	75

ARTICLE 8	INTEGRATION OF PHYSICAL AND BEHAVIORAL HEALTH SERVICES	130

ARTICLE 9	PROVIDER NETWORK	134

ARTICLE 10	PROVIDER CONTRACTING	162

ARTICLE 11	UTILIZATION MANAGEMENT	179

ARTICLE 12	QUALITY IMPROVEMENT AND PERFORMANCE PROGRAM	186

ARTICLE 13	FRAUD, WASTE, AND ABUSE	195

ARTICLE 14	GRIEVANCE AND APPEAL SYSTEM	203

ARTICLE 15	ADMINISTRATION AND MANAGEMENT	217

ARTICLE 16	PROVIDER PAYMENT MANAGEMENT	219

ARTICLE 17	INFORMATION MANAGEMENT AND SYSTEMS	226

ARTICLE 18	REPORTING	238

ARTICLE 19	ENFORCEMENT – INTERMEDIATE SANCTIONS	252

ARTICLE 20	ENFORCEMENT – LIQUIDATED DAMAGES AND OTHER REMEDIES	258

ARTICLE 21	CONTRACT TERM	265

ARTICLE 22	PAYMENT FOR SERVICES	266

ARTICLE 23	FINANCIAL MANAGEMENT	275

Page 2 of 324

ARTICLE 24	PAYMENT OF TAXES	288

ARTICLE 25	RELATIONSHIP OF PARTIES	288

ARTICLE 26	INSPECTION OF WORK	288

ARTICLE 27	GOVERNMENT PROPERTY	289

ARTICLE 28	OWNERSHIP AND USE OF DATA AND SOFTWARE	289

ARTICLE 29	CRIMINAL BACKGROUND CHECKS	290

ARTICLE 30	SUBCONTRACTS	291

ARTICLE 31	REQUIREMENT OF INSURANCE LICENSE	294

ARTICLE 32	CERTIFICATIONS	294

ARTICLE 33	RECORDS REQUIREMENTS	296

ARTICLE 34	CONFIDENTIALITY	298

ARTICLE 35	TERMINATION OF CONTRACT	304

ARTICLE 36	PHASE-OUT AND COOPERATION WITH OTHER CONTRACTORS	311

ARTICLE 37	INSURANCE	312

ARTICLE 38	COMPLIANCE WITH ALL LAWS	313

ARTICLE 39	CONFLICT OF INTEREST AND CONTRACTOR INDEPENDENCE	314

ARTICLE 40	CHOICE OF LAW OR VENUE	315

ARTICLE 41	ATTORNEY’S FEES	315

ARTICLE 42	SURVIVABILITY	315

ARTICLE 43	PROHIBITED AFFILIATIONS WITH INDIVIDUALS DEBARRED AND SUSPENDED	315

ARTICLE 44	WAIVER	316

ARTICLE 45	FORCE MAJEURE	316

ARTICLE 46	BINDING	316

Page 3 of 324

ARTICLE 47	TIME IS OF THE ESSENCE	316

ARTICLE 48	AUTHORITY	317

ARTICLE 49	ETHICS IN PUBLIC CONTRACTING	317

ARTICLE 50	CONTRACT LANGUAGE INTERPRETATION	317

ARTICLE 51	ARTICLE AND SECTION TITLES NOT CONTROLLING	317

ARTICLE 52	LIMITATION OF LIABILITY/EXCEPTIONS	317

ARTICLE 53	COOPERATION WITH AUDITS	318

ARTICLE 54	OWNERSHIP AND FINANCIAL DISCLOSURE	318

ARTICLE 55	AMENDMENT IN WRITING	320

ARTICLE 56	CONTRACT ASSIGNMENT	320

ARTICLE 57	SEVERABILITY	320

ARTICLE 58	ENTIRE AGREEMENT	321

ARTICLE 59	INDEMNIFICATION	321

ARTICLE 60	NOTICES	322

ARTICLE 61	OFFICE OF THE COMPTROLLER	323

ATTACHMENT 1:	DESIGNATED LAWS

ATTACHMENT 2:	NETWORK ADEQUACY URBAN AND NON-URBAN AREA MAP

ATTACHMENT 3:	GHP UNIVERSAL ENROLLEE GUIDELINES HANDBOOK

ATTACHMENT 4:	CPTET CENTERS AND COMMUNITY-BASED ORGANIZATIONS FOR HIV/AIDS

ATTACHMENT 5:	MASTER FORMULARY

ATTACHMENT 6:	RETAIL PHARMACY REIMBURSEMENT LEVELS

ATTACHMENT 7:	UNIFORM GUIDE FOR SPECIAL COVERAGE

ATTACHMENT 8:	COST-SHARING

ATTACHMENT 9:	ENROLLMENT MANUAL

Page 4 of 324

ATTACHMENT 10:	GUIDELINES FOR CO-LOCATION OF BEHAVIORAL HEALTH PROVIDERS IN PMG SETTINGS

ATTACHMENT 11:	PER MEMBER PER MONTH PAYMENTS

ATTACHMENT 12:	INITIAL DELIVERABLE DUE DATES

ATTACHMENT 13:	REFERENCED ASES NORMATIVE LETTERS

ATTACHMENT 14:	PROGRAM INTEGRITY PLAN DEVELOPMENT GUIDELINES

ATTACHMENT 15:	FORMULARY A-102: EVIDENCE OF LACK OF PROVIDERS AND PROVIDERS REFUSAL TO CONTRACT

ATTACHMENT 16:	LIST OF REQUIRED REPORTS

ATTACHMENT 17:	EHR ADOPTION PLAN

ATTACHMENT 18:	BUSINESS ASSOCIATE AGREEMENT

ATTACHMENT 19:	HEALTH CARE IMPROVEMENT PROGRAM (HCIP) MANUAL

ATTACHMENT 20:	NETWORK ADEQUACY REQUIREMENTS

ATTACHMENT 21:	GUIDELINES FOR REVERSE CO-LOCATION OF PRIMARY CARE PHYSICIANS IN MENTAL HEALTH SETTINGS

ATTACHMENT 22:	STERILIZATION CONSENT FORM

ATTACHMENT 23:	POLICIES AND PROCEDURES FOR REFUNDING OF FEDERAL SHARE OF MEDICAID OVERPAYMENTS TO PROVIDERS

ATTACHMENT 24:	CARRIER PATIENT VOLUME CERTIFICATON FORM EP-02-2015

ATTACHMENT 25:	HIGH UTILIZERS PROGRAM

ATTACHMENT 26:	ENCOUNTER DATA REQUIREMENTS

ATTACHMENT 27:	POLICY FOR MEDICATION EXCEPTION REQUESTS

ATTACHMENT 28:	HIGH COST HIGH NEED (HCHN) RATE CELL ASSIGNMENT

ATTACHMENT 29:	MATERNITY KICK PAYMENT METHODOLOGY

ATTACHMENT 30:	TRADING PARTNER AGREEMENT

Page 5 of 324

THIS CONTRACT , is made and entered into by and between the Puerto Rico Health Insurance Administration (Administración de Seguros de Salud de Puerto Rico, hereinafter referred to as “ASES” or “the Administration”), a public corporation of the Government of Puerto Rico (“the Government” or “Puerto Rico”), with employer identification number 66-0500678 and ( Triple-S Salud, Inc. ) (“the Contractor”), a managed care organization duly organized and authorized to do business under the laws of Puerto Rico, with employer identification number 66-0555677 .

WHEREAS, pursuant to Title XIX of the Federal Social Security Act, codified as 42 USC 1396 et seq. (“the Social Security Act”), and Act No. 72 of September 7, 1993 of the Laws of Puerto Rico (“Act 72”), a comprehensive program of medical assistance for needy persons exists in Puerto Rico;

WHEREAS, ASES is responsible for health care policy, purchasing, planning, and regulation pursuant to Act 72, as amended, and other sources of law of Puerto Rico designated in Attachment 1 to this Contract, and pursuant to this statutory provision, ASES has established a managed care program under the medical assistance program, known as “GHP,” “GHP Program,” “the Government Health Plan”, or “MI Salud”;

WHEREAS, the Puerto Rico Health Department (“the Health Department”) is the single State agency designated to administer medical assistance in Puerto Rico under Title XIX of the Social Security Act of 1935, as amended, and is charged with ensuring the appropriate delivery of health care services under the Medicaid and the Children’s Health Insurance Program (“CHIP”) in Puerto Rico, and ASES manages these programs pursuant to a delegation of authority to ASES;

WHEREAS, GHP serves a mixed population including not only the Medicaid and CHIP populations, but also other eligible individuals as established in Act 72;

WHEREAS, ASES seeks to comply with Puerto Rico’s public policy objectives of creating an integrated system of physical and Behavioral Health Services, with an emphasis on preventative services and access to quality care;

WHEREAS, ASES issued a Request for Proposals (“the RFP”) for physical and Behavioral Health Services on February 9-16, 2018, which, except as provided in Article 58 below, are expressly incorporated as if completely restated herein;

WHEREAS, ASES has received from the Contractor a proposal in response to the RFP, “Contractor’s Proposal,” which, except as provided in Article 58 below, is expressly incorporated as if completely restated herein; and,

WHEREAS, ASES accepts the Contractor’s Proposal to provide the services contemplated under this Contract for ASES;

NOW, THEREFORE , FOR AND IN CONSIDERATION of the mutual promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASES and the Contractor (each individually a “Party” and collectively the “Parties”) hereby agree as follows:

Page 6 of 324

ARTICLE 1

GENERAL PROVISIONS

1.1

General Provisions

1.1.1

The Contractor shall assist the Government by providing and delivering services under the GHP through described tasks, obligations, and responsibilities included in this Contract.

1.1.2

The Contractor shall maintain the staff, organizational, and administrative capacity and capabilities necessary to carry out all the duties and responsibilities under this Contract.

1.1.3

The Contractor shall not make any changes to the following without explicit prior written approval from the Executive Director of ASES or his or her designee:

1.1.3.1

Its business address, telephone number, facsimile number, and e-mail address;

1.1.3.2

Its corporate status or nature;

1.1.3.3

Its business location;

1.1.3.4

Its corporate structure;

1.1.3.5

Its ownership, including but not limited to the new owner’s legal name, business address, telephone number, facsimile number, and e-mail address; and/or

1.1.3.6

Its incorporation status.

1.1.4

The Contractor shall notify ASES within five (5) Business Days of a change in the following:

1.1.4.1

Its solvency (as a result of a non-operational event);

1.1.4.2

Its corporate officers or executive employees; or

1.1.4.3

Its Federal employee identification number or Federal tax identification number.

1.1.5

Unless otherwise specified herein, all documentation, including policies and procedures that the Contractor is required to maintain, shall be given prior written approval from ASES. All documentation, including the Deliverables listed in Attachment 12 to this Contract, must be submitted to ASES in English.

1.1.6

Unless otherwise specified, the Contractor shall notify ASES and/or the Puerto Rico Medicaid Program of any applicable provisions Immediately.

Page 7 of 324

1.1.7

Pursuant to 42 CFR 438.602(i), the Contractor shall not be located outside of the United States.

1.1.8

All Administrative Functions of the Contractor must be located within the United States. The following Administrative Functions must be located in Puerto Rico:

1.1.8.1

Care Management;

1.1.8.2

Marketing;

1.1.8.3

Utilization Management determinations, including Prior Authorization determinations;

1.1.8.4

Management of Enrollee and Provider Grievances and Appeals;

1.1.8.5

Decision-making authority related to Enrollee Services;

1.1.8.6

Decision-making authority related to Provider Services, such as claims dispute resolution and credentialing activities; and

1.1.8.7

Network management activities.

1.2

Background

1.2.1

The Government Health Plan (“GHP”), also known as MI Salud, has the following objectives:

1.2.1.1

Ensure appropriate and timely access to Covered Services for Enrollees across Puerto Rico, including facilitating and promoting access to preventive care.

1.2.1.2

Require Contractors to provide Island-wide coverage and access to Covered Services Island-wide in all geographic areas of Puerto Rico. This may be achieved through sub-contractual relationships.

1.2.1.3

Encourage competition among Contractors resulting in improvements of quality outcomes.

1.2.1.4

Require Contractors to partner with Government-owned specialty hospitals.

1.2.1.5

Encourage Contractors to partner with local provider entities, such as Primary Medical Groups (PMGs), provider groups, and provider associations to leverage island-based best practices and maintain existing Enrollee-provider relationships.

1.2.1.6

Require Contractors to propose and demonstrate cost saving initiatives, programs, and value-based payment models for Provider reimbursement to address High Cost High Needs (HCHN) Program Enrollees in Puerto Rico.

Page 8 of 324

1.2.1.7

Establish HCHN Program cohorts with enhanced Contractor management and cost-saving requirements.

1.2.1.8

Promote provider-based care coordination models that address social determinants of health and are likely to reduce health care expenditures.

1.2.1.9

Require Contractors to implement best practices to address high utilizers of services that are more appropriately delivered in less costly settings; for example, strategies to decrease non-emergent use of the emergency room.

1.3

Groups Eligible for Services Under the GHP

1.3.1

The Contractor will be responsible for providing services to all persons determined eligible for the GHP and enrolled in the Contractor’s Plan. The groups to be served under the GHP shall hereinafter be referred to collectively as “Eligible Persons.” The groups are subject to change and currently include:

1.3.1.1

Medicaid and CHIP. All Medicaid and CHIP eligibility categories covered in the Puerto Rico Medicaid and CHIP State Plans are eligible to enroll in the GHP and shall be referred to hereinafter as “Medicaid and CHIP Eligibles”, also known as the “Federal population.”

1.3.1.2

Other Groups (Non-Medicaid and CHIP Eligibles). The following groups, which receive services under the GHP without any Federal financial participation, will be referred to hereinafter as “Other Eligible Persons.”

1.3.1.2.1

The “State Population,” formerly known as the “Commonwealth Population,” is currently comprised of individuals, regardless of age, who meet State eligibility standards established by the Puerto Rico Medicaid Program but do not qualify for Medicaid or CHIP.

1.3.1.2.2

Any other group of Other Eligible Persons may be added during the Contract Term as a result of a change in laws or regulations.

1.4

Geographic Scope of the Contract

1.4.1

The Contractor is responsible for the delivery of services under the GHP Island-wide.

Page 9 of 324

1.5

Delegation of Authority

1.5.1

Federal law and Puerto Rico law limit the capacity of ASES to delegate decisions to the Contractor. All decisions relating to public policy and to the administration of the Medicaid, CHIP, and the Puerto Rico government health assistance program included in the GHP rest with the Puerto Rico Medicaid Program and ASES.

1.6

Availability of Funds

1.6.1

This Contract is subject to the availability of funds on the part of ASES, which in turn is subject to the transfer of Federal, Puerto Rico, and municipal funds to ASES. If available funds are insufficient to meet its contractual obligations, ASES reserves the right to terminate this Contract, pursuant to Section 35.5.

1.7

Cooperation, Assistance and Compliance with Special Projects

1.7.1

The Contractor shall provide to ASES and any other agency of the Government all necessary cooperation, assistance, and compliance with requirements in the development and implementation of any special project of ASES and any other agency of the Government or the Federal Government. The Contractor acknowledges that this is a sine qua non of this Contract and that it will comply with ASES change requests related to such projects as these are implemented due to State or Federal mandate.

ARTICLE 2

DEFINITIONS

Whenever capitalized in this Contract, the following terms have the respective meaning set forth below, unless the context clearly requires otherwise.

Act 72: The law of Puerto Rico adopted on September 7, 1993, as subsequently amended, which created ASES and empowered ASES to administer certain government health programs.

Act 408: The Puerto Rico Mental Health Code (Act No. 408 of October 2, 2000, as amended), which established the public policy and procedures regarding the delivery of Behavioral Health services in Puerto Rico.

Abandoned Call: A call initiated to a Call Center that is ended by the caller before any conversation occurs or before a caller is permitted access to a caller-selected option.

Abuse: Provider practices that are inconsistent with sound fiscal, business, or medical practices, and that result in unnecessary costs to the GHP Program or in reimbursement for services that are not Medically Necessary or that fail to meet professionally recognized standards for the provision of health care. It also includes Enrollee practices that result in unnecessary costs to the GHP.

Access: Adequate availability of Benefits to fulfill the needs of Enrollees.

Page 10 of 324

Adverse Benefit Determination: The denial or limited authorization of a requested service, including the type or level of service; the reduction, suspension, or termination of a previously authorized service, requirements for medical necessity appropriateness, setting or effectiveness of a covered benefit; the denial, in whole or part, of payment for a service (including in circumstances in which an Enrollee is forced to pay for a service); the failure to provide services in a timely manner (within the timeframes established by this Contract or otherwise established by ASES); the failure of the Contractor to act within the timeframes provided in 42 CFR 438.408(b); or the denial of an Enrollee’s request to dispute a financial liability, including cost-sharing, co-payments, premiums, deductibles, co-insurance, and other Enrollee financial liabilities. For a resident of a rural area, the denial of an Enrollee's request to exercise his or her right, under 42 CFR 438.52(b)(2)(ii), to obtain services outside the network.

Actuarial Report: Actuarial reports the Contractor is required to submit in accordance with Article 18 of this Contract.

Administrative Functions: The contractual obligations of the Contractor under this Contract, other than providing Covered Services; include, without limitation, Care Management, Utilization Management, Credentialing Providers, Network management, Quality Improvement, Marketing, Enrollment, Enrollee services, Claims payment, Information Systems, financial management, and reporting.

Administrative Law Hearing: The Appeal process administered by the Government and as required by Federal law, available to Enrollees after they exhaust the Contractor’s Grievance and Appeal System.

Administrative Referral: A Referral of an Enrollee by the Contractor to a Provider or facility located outside the PPN, when the Enrollee’s PCP or other PMG physician does not provide a Referral within the required time period.

Adult: An individual age twenty-one (21) or older unless otherwise specified.

Advance Directive: A written instruction, such as a living will or durable power of attorney, granting responsibility over an individual’s health care, as defined in 42 CFR 489.100, and as recognized under Puerto Rico law under Act 160 of November 17, 2001, as amended, relating to the provision of health care when the individual is incapacitated.

ADFAN: Families and Children Administration (Administración de Familias y Niños), which is responsible for foster care children in the custody of the Government.

Affiliate: Any person, firm, corporation (including, without limitation, service corporation and processional corporation), partnership (including, without limitation, general partnership, limited partnership and limited liability partnership), limited liability company, joint venture, business trust, association or other entity or organization that now or in the future directly or indirectly controls, is controlled by, or is under common control with the Contractor.

Agent: An entity that contracts with ASES to perform Administrative Functions, including but not limited to: fiscal Agent activities; Outreach, eligibility, and Enrollment activities; and systems and technical support.

Page 11 of 324

Aggregate Lifetime Dollar Limit: For purposes of compliance with Behavioral Health parity requirements in 42 CFR part 438, subpart K, a dollar limitation on the total amount of specified benefits that may be paid under a contractor.

Ambulatory Services Units: Ambulatory clinics that mainly provide health services to children, families, and adults, which are staffed by an interdisciplinary team responsible for the appropriate treatment and referral processes.

Ancillary Services: Professional services, including laboratory, radiology, physical therapy, and respiratory therapy, which are provided in conjunction with other medical or hospital care.

Annual Dollar Limit: For purposes of compliance with Behavioral Health parity requirements in 42 CFR part 438, subpart K, a dollar limitation on the total amount of specified benefits that may be paid in a twelve (12) month period under a contractor.

Annual Open Enrollment Period: The annual period of three (3) months from November 1 through January 31 during which Enrollees have one (1) opportunity to select a different contractor, without cause.

Appeal: An Enrollee request for a review of an Adverse Benefit Determination. It is a formal petition by an Enrollee, an Enrollee’s Authorized Representative, or the Enrollee’s Provider, acting on behalf of the Enrollee with the Enrollee’s written consent, to reconsider a decision in the case that the Enrollee or Provider does not agree with an Adverse Benefit Determination taken.

ASES: Administración de Seguros de Salud de Puerto Rico (the Puerto Rico Health Insurance Administration), the Government entity responsible for oversight and administration of the GHP Program, or its Agent.

ASES Data: All Data created from Information, documents, messages (verbal or electronic), reports, or meetings involving, arising out of or otherwise in connection with this Contract.

ASES Information: All proprietary Data and/or Information generated from any Data requested, received, created, provided, managed and stored by Contractors, - in hard copy, digital image, or electronic format - from ASES and/or Enrollees (as defined in Article 2) necessary or arising out of this Contract, except for the Contractor’s Proprietary Information.

ASSMCA: Administración de Servicios de Salud Mental y Contra la Adicción (the Puerto Rico Mental Health and Anti-Addiction Services Administration), the government agency responsible for the planning and establishment of mental health and substance abuse policies and procedures and for the coordination, development, and monitoring of all Behavioral Health Services rendered to Enrollees in the GHP.

At Risk: When a Provider agrees to accept responsibility to provide, or arrange for, any service in exchange for the Per Member Per Month Payment (PMPM).

Authorized Certifier: The Contractor’s CEO, CFO, or an individual with delegated authority to sign for and who reports directly to the CEO and/or CFO.

Page 12 of 324

Authorized Representative: A person given written authorization by an Enrollee to make health-related decisions on behalf of an Enrollee, including, but not limited to: Enrollment and Disenrollment decisions, filing Complaints, Grievances and Appeals, and the choice of a PCP or PMG.

Auto-Assignment: The assignment of an Enrollee to a PMG and a PCP by ASES, the Contractor or the Puerto Rico Medicaid Program.

Auto-Enrollment: The Enrollment of a Potential Enrollee in a GHP Plan without any action by the Potential Enrollee, as provided in Article 5 of this Contract.

Basic Coverage: The physical and Behavioral Health Services available to all GHP Enrollees (as distinguished from Special Coverage, which is available only to Enrollees with certain diagnoses after a registration process). The GHP Covered Services are listed in Article 7 of this Contract.

Behavioral Health: The umbrella term for mental health conditions (including psychiatric illnesses and emotional disorders) and substance use disorders (involving addictive and chemical dependency disorders). The term also refers to preventing and treating co-occurring mental health conditions and substance use disorders (“SUDs”).

Behavioral Health Facility: A facility for the delivery of outpatient, inpatient or stabilization Behavioral Health Services, which houses at least two (2) Providers. These facilities include:

(i)	Psychiatric hospitals (or a unit within a general hospital)

(ii)	Emergency or stabilization units

(iii)

Partial hospitalization units

(iv)	Intensive ambulatory services units

(v)	Ambulatory services units/clinics

(vi)	Residential units

(vii)

Addiction service units (detoxification, ambulatory, inpatient, and residential)

Benefits: The services set forth in this Contract, for which the Contractor has agreed to provide, arrange, and be held fiscally responsible, including Basic Coverage, dental services, Special Coverage, High Cost High Needs Program, and Administrative Functions.

Blocked Call: A call that cannot be connected Immediately because no circuit is available at the time the call arrives or because the telephone system is programmed to block calls from entering the queue when the queue is backed up beyond a defined threshold.

Breach: As defined in 45 CFR 164.402, the acquisition, access, use, or disclosure of Protected Health Information in a manner not permitted under 45 CFR 164, subpart E which compromises the security or privacy of such Information.

Business Continuity and Disaster Recovery (“BC-DR”) Plan: A documented plan (process) to restore vital and critical Information/health care technology systems in the event of business interruption due to human, technical, or natural causes. The plan focuses mainly on technology systems, encompassing critical hardware, operating and application software, and tertiary elements required to support the operating environment. It must support the process requirement to restore vital business Data inside the defined business requirement, including an emergency mode operation plan as necessary. The BC-DR also provides for continuity of health care in the event of plan terminations.

Page 13 of 324

Business Days: Traditional workdays, including Monday, Tuesday, Wednesday, Thursday, and Friday. Puerto Rico Holidays, as defined in the Law for Compliance with the Fiscal Plan, Act No. 26 of April 29, 2017, or any other law enacted during the duration of this Contract regarding this subject, are excluded.

Calendar Days: All seven days of the week.

Call Center: A telephone service facility equipped to handle a large number of inbound and outbound calls. This facility must meet all requirements set forth in Section 6.8 of this Contract.

Capitation: A contractual agreement through which a Contractor or Provider agrees to provide specified health care services to Enrollees for a fixed amount per month.

Care Management: An Administrative Function comprised of a set of Enrollee-centered steps to ensure that an Enrollee with intensive needs, including catastrophic or high-risk conditions, receives the necessary services in a supportive, effective, efficient, timely, and cost-effective manner.

Care Manager: A professional with at least a Bachelor of Arts or a Bachelor of Science in a health or Behavioral Health-related field who helps Enrollees access the services they need for their recuperation and for the implementation of their individual treatment plans.

Centers for Medicare & Medicaid Services (“CMS”): The agency within the US Department of Health and Human Services with responsibility for the Medicare, Medicaid, and the Children’s Health Insurance Programs (“CHIP”).

Center for the Collection of Municipal Revenues: A municipal entity, independent from any other governmental agency, in charge of notifying, assessing, collecting, receiving, and distributing the public funds arising from property tax, state subsidy, electronic lottery and any other fund created by law in favor of the municipalities of Puerto Rico.

Certification: As provided in Section 5.1.2 of this Contract, a decision by the Puerto Rico Medicaid Program that a person is eligible for services under the GHP Program because the person is Medicaid Eligible, CHIP Eligible, or a member of the State Population. Some public employees and pensioners may enroll in GHP without first receiving a Certification.

Children’s Health Insurance Program (“CHIP”): Puerto Rico’s Children’s Health Insurance Program established pursuant to Title XXI of the Social Security Act.

CHIP Eligible: A child eligible to enroll in the GHP Program because he or she is eligible for CHIP.

Chronic Condition: An ongoing physical, behavioral, or cognitive disorder, with a duration of at least twelve (12) months with resulting functional limitations, reliance on compensatory mechanisms (medications, special diet, assistive devices, etc.) and service use or need beyond that which is normally considered routine.

Page 14 of 324

Claim: Whether submitted manually or electronically, a bill for services, a line item of services, or a bill detailing all services for one (1) Enrollee.

Clean Claim: A Claim received by the Contractor for adjudication, which can be processed without obtaining additional information from the Provider of the service or from a Third Party. It includes a Claim with errors originating in the Contractor’s Claims system. It does not include a Claim from a Provider who is under investigation for Fraud, Waste, or Abuse, or a Claim under review to determine Medical Necessity.

Cold-Call Marketing: Any unsolicited personal contact by the Contractor with a Potential Enrollee, for the purposes of Marketing.

Co-Location: An integrated care model in which Behavioral Health Services are provided in the same site as Primary Care.

Complaint: An expression of dissatisfaction about any matter other than an Adverse Benefit Determination that is resolved at the point of contact rather than through filing a formal Grievance.

Contract: The written agreement between ASES and the Contractor; comprised of the Contract, any addenda, appendices, attachments, or amendments thereto.

Contract Term: The duration of time that this Contract is in effect, as defined in Article 21 of this Contract.

Contractor: The Managed Care Organization that is a Party of this Contract, licensed as an insurer by the Puerto Rico Commissioner of Insurance (“PRICO”), which contracts hereunder with ASES under the GHP program for the provision of Covered Services and Benefits to Enrollees on the basis of PMPM Payments.

Co-Payment: A cost-sharing requirement which is a fixed monetary amount paid by the Enrollee to a Provider for certain Covered Services as specified by ASES.

Corrective Action Plan: The detailed written plan required by ASES from the Contractor to correct or resolve a deficiency or event causing the assessment of a liquidated damage or sanction against the Contractor.

Cost Avoidance: A method of paying Claims in which the Provider is not reimbursed until the Provider has demonstrated that all available health insurance, and other sources of Third Party Liability, have been exhausted.

Countersignature: An authorization provided by the Enrollee’s PCP, or another Provider within the Enrollee’s PMG, for a prescription written by another Provider to be dispensed. No Countersignature shall be required if the Provider writing the prescription is within the PPN.

Covered Services: Those Medically Necessary health care services (listed in Article 7 of this Contract) provided to Enrollees by Providers, the payment or indemnification of which is covered under this Contract.

Page 15 of 324

Credentialing: The Contractor’s determination as to the qualification of a specific Provider to render specific health care services.

Credible Allegation of Fraud: Any allegation of Fraud that has been verified by another State, the Government, or ASES, or otherwise has been preliminary investigated by the Contractor, as the case may be, and that has indicia of reliability that comes from any source.

Cultural Competency: A set of interpersonal skills that allow individuals to increase their understanding, appreciation, acceptance, and respect for cultural differences and similarities within, among, and between groups and the sensitivity to know how these differences influence relationships with Enrollees. This requires a willingness and ability to draw on community-based values, traditions and customs, to devise strategies to better meet culturally diverse Enrollee needs, and to work with knowledgeable persons of and from the community in developing focused interactions, communications, and other supports.

Daily Basis: Each Business Day.

Data: A series of meaningful electrical signals that may be manipulated or assigned.

Data Set: Demographic, health, or other Informational elements suitable for specific use.

Deductible: In the context of Medicare, the dollar amount of Covered Services that must be incurred before Medicare will pay for all or part of the remaining Covered Services.

Deemed Newborn: A newborn whose mother is Medicaid or CHIP Eligible on the date of delivery and is eligible from the date of birth.

Deliverable: A document, manual, or report submitted to ASES by the Contractor to exhibit that the Contractor has fulfilled the requirements of this Contract.

Disenrollment: The termination of an individual’s Enrollment in the Contractor’s Plan.

Domestic Violence Population: Certain survivors of domestic violence referred by the Office of the Women’s Advocate.

Dual Eligible Beneficiary: An Enrollee or Potential Enrollee eligible for both Medicaid and Medicare.

Durable Medical Equipment: Equipment, including assistive technology, which: (i) can withstand repeated use; (ii) is used to service a health-related or functional purpose; (iii) is ordered by a Health Care Provider to address an illness, injury, or disability; and (iv) is appropriate for use in the home, work place, or school.

Early and Periodic Screening, Diagnostic, and Treatment (“EPSDT”) Program: A Medicaid-mandated program that covers screening and diagnostic services to determine physical and mental deficiencies in Enrollees less than twenty-one (21) years of age, and health care, prevention, treatment, and other measures to correct or ameliorate any deficiencies and Chronic Conditions discovered.

Page 16 of 324

Effective Date of Contract: The day the Contract is executed by both Parties.

Effective Date of Disenrollment: The date, as defined in Section 5.3.3 of this Contract, on which an Enrollee ceases to be covered under the Contractor’s Plan.

Effective Date of Eligibility: The eligibility period specified for each population covered under the GHP as described in Section 5.1.3 of the Contract.

Effective Date of Enrollment: shall have the meaning prescribed to it in Section 5.2.2 of the Contract.

Electronic Funds Transfer (“EFT”): Transfer of funds between accounts using electronic means such as a telephone or computer rather than paper-based payment methods such as cash or checks.

Electronic Health Record (“EHR") System: An electronic record of health-related information on an individual that is created, gathered, managed, and consulted upon by authorized health care clinicians and staff and certified by The Office of the National Coordinator’s Authorized Testing and Certification Bodies (“ONC-ATCBs”).

Eligible Person: A person eligible to enroll in the GHP Program, as provided in Section 1.3.1 of this Contract, by virtue of being Medicaid Eligible, CHIP Eligible, or an Other Eligible Person.

Emergency Medical Condition: As defined in 42 CFR 438.114, a medical or Behavioral Health condition, regardless of diagnosis or symptoms, manifesting itself in acute symptoms of sufficient severity (including severe pain) that a prudent layperson, who possesses an average knowledge of health and medicine, could reasonably expect the absence of immediate medical attention to result in placing the health of the individual (or, with respect to a pregnant woman, the health of the woman or her unborn child) in serious jeopardy, serious impairments of bodily functions, serious dysfunction of any bodily organ or part, serious harm to self or other due to an alcohol or drug abuse emergency, serious injury to self or bodily harm to others, or the lack of adequate time for a pregnant women having contractions to safely reach a another hospital before delivery. The Contractor may not impose limits on what constitutes an Emergency Medical Condition based only, or exclusively, on diagnoses or symptoms.

Emergency Services: As defined in 42 CFR 438.114, any Physical or Behavioral Health Covered Services (as described in Section 7.5.9) furnished by a qualified Provider in an emergency room that are needed to evaluate or stabilize an Emergency Medical Condition or a Psychiatric Emergency that is found to exist using the prudent layperson standard.

Encounter: A distinct set of services provided to an Enrollee in a face-to-face setting on the dates that the services were delivered, regardless of whether the Provider is paid on a Fee-for-Service, Capitated, salary, or alternative payment methodology basis. Encounters with more than one (1) Provider, and multiple Encounters with the same Provider, that take place on the same day in the same location will constitute a single Encounter, except when the Enrollee, after the first Encounter, suffers an illness or injury requiring an additional diagnosis or treatment.

Encounter Data: (i) All Data captured during the course of a single Encounter that specify the diagnoses, comorbidities, procedures (therapeutic, rehabilitative, maintenance, or palliative), pharmaceuticals, medical devices, and equipment associated with the Enrollee receiving services during the Encounter; (ii) The identification of the Enrollee receiving and the Provider(s) delivering the health care services during the single Encounter; and (iii) A unique (i.e., unduplicated) identifier for the single Encounter.

Page 17 of 324

Enrollee: A person who is currently enrolled in the Contractor’s GHP Plan, as provided in this Contract, and who, by virtue of relevant Federal and Puerto Rico laws and regulations, is an Eligible Person listed in Section 1.3.1 of this Contract.

Enrollment: The process by which an Eligible Person becomes an Enrollee of the Contractor’s Plan.

Experience of Care and Health Outcomes (“ECHO”) Survey: A survey constructed to merge the most desirable aspects of the Mental Health Statistics Program’s Consumer Survey (“MHSIP”) and the Consumer Assessment of Behavioral Health Services (“CABHS”) Instrument in order to capture as many unique aspects of mental health and substance abuse-related services while limiting redundancy. The survey is a product of nearly six (6) years of research and testing by CAHPS grantees at the Harvard Medical School, with extensive input from behavioral health care experts.

External Quality Review Organization (“EQRO”): An organization that meets the competence and independence requirements set forth in 42 CFR 438.354 and performs analyses and evaluations on the quality, timeliness, and Access to Covered Services and Benefits that the Contractor furnishes to Enrollees.

Federally Qualified Health Center (“FQHC”): An entity that provides outpatient health programs pursuant to Section 1905(l)(2)(B) of the Social Security Act.

Fee-for-Service: A method of reimbursement based on payment for specific Covered Services on a service-by-service basis rendered to an Enrollee.

Formulary of Medications Covered (“FMC”): A published subset of pharmaceutical products used for the treatment of physical and Behavioral Health conditions developed by the PPA after clinical recommendations from the Pharmacy and Therapeutics (P&T) Committee and financial review from the Pharmacy Benefits Financial Committee.

Foster Care Population: Children who are in the custody of the Department of Family’s ADFAN Program and enrolled in the GHP.

Fraud: An intentional deception or misrepresentation made by a person with the knowledge that the deception could result in some unauthorized benefit or financial gain to him/herself or some other person. It includes any act that constitutes Fraud under applicable Federal or Puerto Rico law.

General Network: The entire group of Providers with Provider Contracts with the Contractor, including those that are and those that are not members of the Contractor’s Preferred Provider Network.

GHP Plan: A Managed Care Organization under contract with ASES that offers services under the Government Health Plan (“GHP”) Program.

Page 18 of 324

GHP Service Line: The Enrollee support Call Center that the Contractor shall operate as described in Section 6.8 of this Contract, containing two components: the Information Service and the Medical Advice Service.

The Government Health Plan (or “the GHP”): The government health services program (also referred to as “MI Salud”) offered by the Government, and administered by ASES, which serves a mixed population of Medicaid Eligible, CHIP Eligible, and Other Eligible Persons, and emphasizes integrated delivery of physical and Behavioral Health services.

Grievance: An expression of dissatisfaction about any matter other than an Adverse Benefit Determination.

Grievance and Appeal System: The overall system that includes Complaints, Grievances, and Appeals at the Contractor level, as well as access to the Administrative Law Hearing process.

Health Care Acquired Conditions : A medical condition for which an individual was diagnosed that could be identified by a secondary diagnostic code described in Section 1886(d)(4)(D)(iv) of the Social Security Act.

Health Care Provider: An individual engaged in the delivery of health care services as licensed or certified by Puerto Rico in which he or she is providing services, including but not limited to physicians, podiatrists, optometrists, chiropractors, psychologists, psychiatrists, licensed Behavioral Health practitioners, dentists, physician assistant, physical or occupational therapists and therapists assistants, speech-language pathologists, audiologists, registered or licensed practical nurses (including nurse practitioners, clinical nurse specialist, certified registered nurse anesthetists, and certified nurse midwives), licensed certified social workers, registered respiratory therapists, and certified respiratory therapy technicians.

Health Certificate: Certificate issued by a physician after an examination that includes Venereal Disease Research Laboratory (“VDRL”) and tuberculosis (“TB”) tests if the individual suffers from a contagious disease that could incapacitate him or her or prevent him or her from doing his or her job, and does not represent a danger to public health.

Health Information Exchange (“HIE”): The secure and effective electronic transmission (push–pull) of the Protected Health Information of patients between Providers, across organizations, community or hospital system, within a jurisdiction and/or between jurisdictions. HIE is also an entity that provides services to enable the electronic sharing of health Information.

Health Information Organization (“HIO”): “An organization that oversees and governs services related to the exchange of health-related Information among organizations according to nationally recognized standards,” as defined in The National Alliance for Health Information Technology Report to the Office of the National Coordinator for Health Information Technology.

Health Information Technology for Economic and Clinical Health (“HITECH”) Act: Public Law 111-5 (2009). When referenced in this Contract, it includes all related rules, regulations, and procedures.

Page 19 of 324

Health Care Effectiveness Data and Information Set (“HEDIS”): A set of standardized performance measures developed by the National Committee for Quality Assurance (“NCQA”) to measure and compare MCO performance.

Health Insurance Portability and Accountability Act (“HIPAA”): A law enacted in 1996 by the US Congress. When referenced in this Contract, it includes all related rules, regulations, and procedures.

High Cost High Needs (HCHN) Program: A set of contractual obligations specific to a cohort of Enrollees, as specified in Section 7.8.3 and Attachment 28 to this Contract, with specific conditions that require specialized care management and a dedicated team of Providers due to the cost or elevated needs associated with treatment of the condition.

Immediately: Within twenty-four (24) hours, unless otherwise provided in this Contract .

Implementation Date of the Contract: The date on which the Contractor shall commence providing Covered Services and other Benefits under this Contract after it has passed a readiness review; the expected implementation date of this Contract is November 1, 2018.

Incident: The attempted or successful unauthorized access, use, disclosure, modification, or destruction of Information or interference with system operations in an Information System.

Incurred-But-Not-Reported (“IBNR”): Estimate of unpaid Claims liability, including received but unpaid Claims.

Indian: An individual, defined in Title 25 of the U.S.C. sections 1603(c), 1603(f), 1603(f) or who has been determined eligible, as an Indian, pursuant to 42 C.F.R. 136.12 or Title V of the Indian Health Care Improvement Act, to receive health care services from Indian Health Care Providers (Indian Health Services, an Indian Tribe, Tribal Organization, or Urban Indian Organization-I/T/U) or through Referral under Contract Health Services.

Information: Data to which meaning is assigned, according to context and assumed conventions; meaningful fractal Data for decision support purposes.

Information Service: The component of the GHP Service Line, a Call Center operated by the Contractor (described in Section 6.9), intended to assist Enrollees with routine inquiries, which shall be fully staffed between the hours of 7:00 a.m. and 7:00 p.m. (Atlantic Time), Monday through Friday, excluding Puerto Rico holidays.

Information System(s): A combination of computing and communications hardware and software that is used in: (i) the capture, storage, manipulation, movement, control, display, interchange and/or transmission of Information, i.e., structured Data (which may include digitized audio and video) and documents; and/or (ii) the processing of such Information for the purposes of enabling and/or facilitating a business process or a related transaction.

Initial Auto-Enrollment : The process by which an Eligible Person enrolled with a GHP contractor prior to November 1, 2018 is Auto-Enrolled with a contractor by ASES with an effective date of November 1, 2018.

Page 20 of 324

Initial Auto-Enrollment Enrollee : An Eligible Person enrolled prior to November 1, 2018 with a GHP contractor who is Auto-Enrolled with a Contractor’s Plan during Initial Auto-Enrollment.

Integration Plan: The service delivery plan under the GHP Program, providing physical and Behavioral Health Services in close coordination, to ensure optimum detection, prevention, and treatment of physical and Behavioral Health conditions.

International Statistical Classification of Diseases and Related Health Problems Tenth Revision (“ICD-10”) : A medical classification list created by the World Health Organization that notes various Medical Records including those used for coding diseases, signs, symptoms, abnormal findings, complaints, social circumstances, and external causes of injury or disease.

Island-wide: All geographic areas that comprise the entirety of Puerto Rico, including Vieques and Culebra, for which the Contractor is responsible for the delivery of Covered Services.

List of Excluded Individuals and Entities (“LEIE”): A database of individuals and entities excluded from Federally-funded health care programs maintained by the Department of Health and Human Services Office of the Inspector General.

List of Medications by Exception (“LME”): List of medications that are not included in the FMC, but that have been evaluated and approved by ASES’s Pharmacy and Therapeutics (P&T) Committee to be covered only through an exception process if certain clinical criteria are met. Covered outpatient drugs that are not included on the LME may still be covered under an Exception Request in compliance with Section 7.5.12.10.1.2 and Attachment 27 to this Contract, unless statutorily excluded.

MA-10: Form issued by the Puerto Rico Medicaid Program, entitled “Notice of Action Taken on Application and/or Recertification,” containing the Certification decision (whether a person was determined eligible or ineligible for Medicaid, CHIP, or the State Population).

Managed Care Organization (“MCO”): An entity that is organized for the purpose of providing health care and is licensed as an insurer by the Puerto Rico Commissioner of Insurance (“PRICO”), which contracts with ASES for the provision of Covered Services and Benefits Island-wide on the basis of PMPM Payments, under the GHP program.

Marketing: Any communication from the Contractor to any Eligible Person or Potential Enrollee that can reasonably be interpreted as intended to influence the individual to enroll in the Contractor’s Plan, or not to enroll in another plan, or to disenroll from another plan.

Marketing Materials: Materials that are produced in any medium, by or on behalf of the Contractor that can reasonably be interpreted as intended to market to Potential Enrollees.

Medicaid: The joint Federal/state program of medical assistance established by Title XIX of the Social Security Act.

Medicaid Eligible: An individual eligible to receive services under Medicaid, who is eligible, on this basis, to enroll in the GHP Program.

Page 21 of 324

Medicaid Fraud Control Unit (“MFCU”): The Unit created by the Puerto Rico Department of Justice under Administrative Order 2018-002 to investigate and prosecute Medicaid Provider Fraud as well as patient abuse and neglect in health care facilities, as defined in Section 1903(q) of the Social Security Act, found at 42 USC 1396b(q).

Medicaid Management Information System (“MMIS”): Computerized system used for the processing, collecting, analyzing, and reporting of Information needed to support Medicaid and CHIP functions. The MMIS consists of all required subsystems as specified in the State Medicaid Manual.

Medical Advice Service: The twenty-four (24) hour emergency medical advice toll-free phone line operated by the Contractor through its GHP Service Line service, described in Section 6.8 of this Contract.

Medical Record: The complete, comprehensive record of an Enrollee including, but not limited to, x-rays, laboratory tests, results, examinations and notes, accessible at the site of the Enrollee’s PCP, or Network Provider, that documents all health care services received by the Enrollee, including inpatient care, outpatient care, Ancillary, and Emergency Services, prepared in accordance with all applicable Federal and Puerto Rico rules and regulations, and signed by the Provider rendering the services.

Medically Necessary Services: Those services that meet the definition found in Section 7.2 of this Contract.

Medicare: The Federal program of medical assistance for persons age sixty-five (65) and over, certain disabled persons under Title XVIII of the Social Security Act, and persons with End Stage Renal Disease.

Medicare Part A: The part of the Medicare program that covers inpatient hospital stays, skilled nursing facilities, home health, and hospice care.

Medicare Part B: The part of the Medicare program that covers physician, outpatient, home health, and Preventive Services.

Medicare Part C: The part of the Medicare program that permits Medicare recipients to select coverage among various private insurance plans.

Medicare Part D: The part of the Medicare programs that covers prescription drugs.

Medicare Platino: A program administered by ASES for Dual Eligible Beneficiaries, in which MCOs or other insurers under contract with ASES function as Medicare Part C plans to provide services covered by Medicare, and also to provide a “wrap-around” Benefit of Covered Services and Benefits under the GHP.

National Provider Identifier (“NPI”): The 10-digit unique-identifier numbering system for Providers created by the Centers for Medicare & Medicaid Services (CMS), through the National Plan and Provider Enumeration System.

Page 22 of 324

Negative Determination or Redetermination Decision: The decision by the Puerto Rico Medicaid Program that a person is not initially eligible or no longer eligible for services under the GHP Program (because the person no longer meets the eligibility requirements for Medicaid, CHIP, or Puerto Rico’s government health assistance program).

Network Adequacy Standards: The Provider-to-Enrollee Ratios; Provider Per Municipality requirements; Required Network Provider requirements, and Time and Distance requirements developed in accordance with 42 CFR 438.68, as defined by ASES in Section 9.4 to measure the adequacy and appropriateness of the Contractor’s provider network to meet the needs of the enrolled population.

Network Provider: A Medicaid-enrolled Provider that has a Provider Contract with a Contractor under the GHP Program. This term includes Providers in the General Network and Providers in the PPN.

New Enrollee : An Eligible Person who became a Potential Enrollee after November 1, 2018.

Non-Emergency Medical Transportation (“NEMT”): A ride, or reimbursement for a ride, provided so that an Enrollee with no other transportation resources can receive Covered Services from a Provider. NEMT does not include transportation provided on an emergency basis, such as trips to the emergency room in life threatening situations.

Non-Urban Area: For purposes of measuring Network Adequacy, defined by ASES as municipalities with populations at or below 49,999 people.

Notice of Adverse Benefit Determination: The written notice described in Section 14.4.3, in which the Contractor notifies both the Enrollee and the Provider of an Adverse Benefit Determination.

Notice of Disposition: The notice in which the Contractor explains in writing the results and the date of resolution of a Complaint, Grievance, or Appeal to the Enrollee and the Provider.

Office of the Inspector General: The Federal office within the Department of Health & Human Services tasked with protecting the integrity of federal health care programs as well as the health and welfare of program beneficiaries.

Office of the Patient Advocate: An office of the Government created by Act 11 of April 11, 2001, as amended by Act 77 of June 24, 2013, which is tasked with protecting the patient rights and protections contained in the Patient’s Bill of Rights Act.

Office of the Women’s Advocate: An office of the Government created by Act 20 of April 11, 2001, as amended, which is tasked, among other responsibilities, with protecting victims of domestic violence.

Open Enrollment Period : A period of ninety (90) Calendar Days during which Enrollees have one (1) opportunity to select a different contractor, without cause, as set forth in Section 5.2.5.

Page 23 of 324

Other Eligible Person: A person eligible to enroll in the GHP Program under Section 1.3.1.2 of this Contract who is not Medicaid- or CHIP Eligible. This group is comprised of the State Population and certain public employees and pensioners.

Outreach: Means, among other things, of educating or informing the Contractor’s Enrollees about GHP, managed care, and health issues.

Out-of-Network Provider: A Provider that does not have a Provider Contract with the Contractor under GHP; i.e., the Provider is not in either the General Network or the PPN.

Overpayment: Any funds that a person or entity receives which that person or entity is not entitled to under Title XIX of the Social Security Act as defined in 42 CFR 438.2. Overpayments shall not include funds that have been subject to a payment suspension or that have been identified as a Third Party Liability as set forth in Section 23.4.

Patient’s Bill of Rights Act: Act 194 of August 25, 2000, a law of Puerto Rico relating to patient rights and protection.

Patient Protection and Affordable Care Act (“PPACA”): Public Law 111-148 (2010) and the Health Care and Education Reconciliation Act of 2010 (Public Law 111-152 (2010), including any and all rules and regulations thereunder.

Payment Hold: The situation when a Provider who owes funds to Puerto Rico, such Provider cannot be paid until the amounts owed to Puerto Rico are repaid or an acceptable repayment plan is in place, as determined by ASES.

Pediatric Enrollee: An Enrollee aged zero (0) through twenty (20) (inclusive) unless otherwise specified.

Performance Improvement Projects (“PIPs”): Projects consistent with 42 CFR 438.330.

Per Member Per Month (“PMPM”) Payment: The fixed monthly amount, developed in accordance with actuarially sound principles and practices as specified in 42 CFR 438.4, that the Contractor is paid by ASES for each Enrollee to ensure that Benefits under this Contract are provided. This payment is made regardless of whether the Enrollee receives Benefits during the period covered by the payment.

Protected Health Information (“PHI”): As defined in 45 CFR 160.103, individually identifiable health Information that is transmitted by electronic media, maintained in electronic media, or transmitted or maintained in any other form or medium.

Pharmacy Benefit Manager (“PBM”): An entity under contract with ASES under the GHP Program, responsible for the administration of pharmacy Claims processing, formulary management, drug Utilization review, pharmacy network management, and Enrollee Information Services relating to pharmacy services.

Pharmacy Program Administrator (“PPA”): An entity, under contract with ASES, responsible for implementing and offering support to ASES and the contracted PBMs in the negotiation of rebates and development of the Maximum Allowable Cost (“MAC”) List.

Page 24 of 324

Physician Incentive Plan: Any compensation arrangement between a Contractor and a physician or PMG that is intended to advance Utilization Management and is governed by 42 CFR 438.3(i).

Plan: The Contractor’s Managed Care Organization offering services to Enrollees under the GHP.

Post-Stabilization Services: Covered Services, relating to an Emergency Medical Condition or Psychiatric Emergency, that are provided after an Enrollee is stabilized, in order to maintain the stabilized condition or to improve or resolve the Enrollee’s condition.

Potential Enrollee: A person who has been Certified by the Puerto Rico Medicaid Program as eligible to enroll in the GHP (whether on the basis of Medicaid eligibility, CHIP eligibility, or eligibility as a member of the State Population), but who has not yet enrolled with the Contractor.

Preferential Turns: The policy of requiring Network Providers to give priority in treating Enrollees from the island municipalities of Vieques and Culebra, so that they may be seen by a Provider within a reasonable time after arriving at the Provider’s office. This priority treatment is necessary because of the remote locations of these municipalities, and the greater travel time required for their residents to seek medical attention.

Preferred Provider Network (“PPN”): A group of Network Providers that (i) GHP Enrollees may access without any requirement of a Referral or Prior Authorization; (ii) provides services to GHP Enrollees without imposing any Co-Payments on Medicaid or CHIP-Eligible populations; and (iii) meets the Network requirements described in Article 9 of this Contract.

Prevalent Non-English Language: A non-English language spoken by a significant number or percentage of Potential Enrollees and current Enrollees in Puerto Rico, as determined by the Government.

Preventive Services: Health care services provided by a physician or other Provider within the scope of his or her practice under Puerto Rico law to detect or prevent disease, disability, Behavioral Health conditions, or other health conditions; and to promote physical and Behavioral Health and efficiency.

Primary Care: All health care services and laboratory services customarily furnished by or through a general practitioner, family physician, internal medicine physician, obstetrician/gynecologist, pediatrician, or other licensed practitioner as authorized by ASES, to the extent the furnishing of those services is legally authorized where the practitioner furnishes them.

Primary Care Physician: A licensed medical doctor (MD) who is a Provider and who, within the scope of practice and in accordance with Puerto Rico certification and licensure requirements, is responsible for providing all required Primary Care to Enrollees. The PCP is responsible for determining services required by Enrollees, provides continuity of care, and provides Referrals for Enrollees when Medically Necessary.

Primary Medical Group (“PMG”): A grouping of associated Primary Care Physicians and other Providers for the delivery of services to GHP Enrollees using a coordinated care model. PMGs may be organized as Provider care organizations, or as another group of Providers who have contractually agreed to offer a coordinated care model to GHP Enrollees under the terms of this Contract.

Page 25 of 324

Prior Authorization: Authorization granted by the Contractor to determine whether the service is Medically Necessary. In some instances, this process is a condition for receiving the Covered Service.

Provider: Any physician, hospital, facility, or other Health Care Provider who is licensed or otherwise authorized to provide physical or Behavioral Health Services in the jurisdiction in which they are furnished.

Provider Per Municipality Requirements: Required number of specified Providers per municipality that must be included in the Contractor’s provider network per Section 9.4.3.3.

Provider-to-Enrollee Ratio: Ratios established in Section 9.4 as part of the Network Adequacy Standards that are applicable to the Contractor’s General Network and PPN.

Provider Contract: Any written contract between the Contractor and a Provider that requires the Provider to order, refer, provide or render Covered Services under this Contract. The execution of a Provider Contract makes the Provider a Network Provider.

Psychiatric Emergency: A set of symptoms characterized by an alteration in the perception of reality, feelings, emotions, actions, or behavior, requiring immediate therapeutic intervention in order to avoid immediate damage to the patient, other persons, or property. A Psychiatric Emergency shall not be defined on the basis of lists of diagnoses or symptoms.

Puerto Rico Health Department (“the Health Department”): The Single State Agency charged with administration of the Puerto Rico Medicaid Program, which (through the Puerto Rico Medicaid Program) is responsible for Medicaid and CHIP eligibility determinations.

Puerto Rico Insurance Commissioner’s Office (“PRICO”): The Government agency responsible for regulating, monitoring, and licensing insurance business.

Puerto Rico Medicaid Program: The subdivision of the Health Department that conducts eligibility determinations under GHP for Medicaid, CHIP, and the State Population.

Quality Assessment and Performance Improvement Program (“QAPI”): A set of programs aimed at increasing the likelihood of desired health outcomes of Enrollees through the provision of health care services that are consistent with current professional knowledge; the QAPI Program includes incentives to comply with HEDIS standards, to provide adequate Preventive Services, and to reduce the unnecessary use of Emergency Services.

Quality Management/Quality Improvement (“QM/QI”): The process of developing and implementing strategies to ensure the delivery of available, accessible, timely, and Medically Necessary Services that meet optimal clinical standards. This includes the identification of key measures of performance, discovery and Data collection processes, identification and remediation of issues, and systems improvement activities.

Recertification: A determination by the Puerto Rico Medicaid Program that a person is again eligible for services under the GHP Program.

Page 26 of 324

Reconsideration: The process for an Enrollee to request that ASES re-evaluate a denial of a Disenrollment request from a contractor that precedes the Administrative Law Hearing process, as provided by Act 72 of September 7, 1993, as amended.

Redetermination : The periodic re-evaluation of eligibility of an individual for Medicaid, CHIP, or the State Population, conducted by the Puerto Rico Medicaid Program.

Referral: A request by a PCP, Psychiatrist, Psychologist, or any other type of Provider in the PMG for an Enrollee to be evaluated and/or treated by a different Provider, usually a specialist. Referrals shall be required only for services outside the Contractor’s PPN.

Reinsurance: An agreement whereby the Contractor transfers risk or liability for losses, in whole or in part, sustained under this Contract. A Reinsurance agreement may also exist at the Provider level.

Remedy: ASES’s means to enforce the terms of the Contract through liquidated damages and other sanctions.

Request for Proposals (“RFP”): The Request for Proposals issued by the Government on February 9-16, 2018.

Required Network Providers: Specific Providers or types of Providers that must be included in the Contractor’s provider network per Section 9.4.3.4.

Retention Fund: The amount of Withhold by ASES of the monthly PMPM Payments otherwise payable to the Contractor in order to incentivize the Contractor to meet performance targets under the Health Care Improvement Program described in Section 12.5.3. This amount shall be equal to the percent of that portion of the total PMPM Payment that is determined to be attributable to the Contractor’s administration of the Health Care Improvement Program described in Sections 12.5 and 22.4. Amounts withheld will be reimbursed to the Contractor in whole or in part (as set forth in Sections 12.5 and 22.4) in the event of a determination by ASES that the Contractor has complied with the quality standards and criteria established by Section 12.5.

Reverse Co-location : An integrated care model in which physical health services are available to Enrollees being treated in Behavioral Health settings.

Runoff Period: The period of time as explained in Section 35.1.5.

Rural Health Clinic or Center (“RHC”): A clinic that is located in an area that has a Provider shortage. An RHC provides primary Care and related diagnostic services and may provide optometric, podiatry, chiropractic, and Behavioral Health Services. An RHC employs, contracts, or obtains volunteer services from Providers to provide services.

Serious Emotional Disturbance (“SED”): Children and youth who currently or at any time during the past year have had a diagnosable mental, behavioral, or emotional disorder to meet diagnostic criteria in the following ICD-10 codes: F-20 Schizophrenia, F-31 Bipolar Disorder, F-33 Major Depressive Disorder, F-41 Other Anxiety Disorders, and F-50 Eating Disorders.

Page 27 of 324

Serious Mental Illness (“SMI”): Individuals eighteen (18) years of age or older, who currently or at any time during the past year have had a diagnosable mental, behavioral, or emotional disorder to meet diagnostic criteria in the following categories of ICD-10: F20.0 Paranoid schizophrenia; F20.1 Disorganized schizophrenia; F20.2 Catatonic schizophrenia; F20.3 Undifferentiated schizophrenia; F20.9 Schizophrenia, unspecified; F25 Schizoaffective Disorder; F28 Other non-organic psychotic disorders; F31.2 Bipolar disorder, current episode manic, sever, with psychotic symptoms; F31.5 Bipolar disorder, current episode depressed, severe, with psychotic symptoms; F31.6 Bipolar disorder, current episode mixed, severe, with psychotic symptoms; F33.3 Major Depressive disorder, recurrent, severe with psychotic symptoms.

Service Authorization Request: An Enrollee’s request for the provision of a service.

Span of Control: Information Systems and telecommunications capabilities that the Contractor operates or for which it is otherwise legally responsible according to the terms and conditions of this Contract. The Contractor’s Span of Control also includes systems and telecommunications capabilities outsourced by the Contractor.

Special Coverage: A component of Covered Services provided by the Contractor, described in Section 7.7, which are more extensive than the Basic Coverage services, and for which Enrollees are eligible only by “registering.” Registration for Special Coverage is based on intensive medical needs occasioned by serious illness.

“State Population” (formerly known as the “Commonwealth Population”): A group eligible for participation in the GHP as Other Eligible Persons, with no Federal financial participation supporting the cost of their coverage, which is comprised of low-income persons and other groups listed in Section 1.3.1.2.1.

Subcontract: Any written contract between the Contractor and Subcontractor to perform a specified part of the Contractor’s obligations under this Contract.

Subcontractor: Any organization or person, including the Contractor’s parent, subsidiary or Affiliate, who has a Subcontract with the Contractor to provide any function or service for the Contractor specifically related to securing or fulfilling the Contractor’s obligations to the Government under the terms of this Contract. Subcontractors do not include Providers unless the Provider is responsible for services other than providing Covered Services pursuant to a Provider Contract.

Systems Unavailability: As measured within the Contractor’s Information Systems’ Span of Control, when a system user does not get the complete, correct full-screen response to an input command within three (3) minutes after pressing the “Enter” or any other function key.

Telecommunication Device for the Deaf (“TDD” ) : Special telephone devices with keyboard attachments for use by individuals with hearing impairments who are unable to use conventional phones.

Terminal Condition: A condition caused by injury, illness, or disease, from which, to a reasonable degree of certainty, will lead to the patient’s death in a period of, at most, six (6) months.

Page 28 of 324

Termination Date of the Contract: The dated designated by ASES as the date that services under this Contract shall end, pursuant to Article 35 of this Contract.

Termination Plan: The plan referenced in Article 35.

Third Party: Any person, institution, corporation, insurance company, public, private, or governmental entity who is or may be liable in Contract, tort, or otherwise by law or equity to pay all or part of the medical cost of injury, disease, or disability of an Enrollee.

Third Party Liability (“TPL”): Legal responsibility of any Third Party to pay for health care services.

Time and Distance Standards: A standardized measure of mileage and travel time for Enrollees in Urban and Non-Urban Areas to access a set of identified Network Providers as specified in Section 9.4 and developed by ASES in accordance with 42 CFR 438.68.

Urban Area: For purposes of measuring Network Adequacy, defined by ASES as municipalities with populations of at least 50,000 people. Urban Areas are San Juan, Carolina, Trujillo Alto, Caguas, Guaynabo, Bayamón, Toa Alta, Toa Baja, Vega Baja, Rio Grande, Humacao, Arecibo, Ponce, Aguadilla, Mayaguez. ASES will notify Contractors if this list of Urban Areas changes.

Utilization: The rate patterns of service usage or types of service occurring within a specified time frame.

Utilization Management (“UM”): A service performed by the Contractor which seeks to ensure that Covered Services provided to Enrollees are in accordance with, and appropriate under, the standards and requirements established by the Contract, or a similar program developed, established, or administered by ASES.

Warm Transfer: A telecommunications mechanism in which the person answering the call facilitates the transfer to a Third Party, announces the caller and issue, and remains engaged as necessary to provide assistance.

Waste: Health care spending that can be eliminated without reducing quality of care.

Week: The traditional seven-day week, Sunday through Saturday.

Well Baby Care: The battery of screenings (listed in Section 7.5.3.1) provided to children as part of Puerto Rico’s (“EPSDT”) Program.

Withhold: A percentage of payments or set dollar amounts that ASES deducts from its payment to the Contractor as a penalty, or that a Contractor deducts from its payment to a Network Provider, depending on specific predetermined factors.

Page 29 of 324

ARTICLE 3

ACRONYMS

The acronyms included in this Contract stand for the following terms:

ACH	Automated Clearinghouse
ACIP	Advisory Committee on Immunization Practices
ADAP	AIDS Drug Assistance Program
ADFAN	Puerto Rico Administración de Familias y Niños, or Families and Children Administration
AHRQ	Agency for Health Care Research and Quality
AICPA	American Institute of Certified Public Accountants
ASES	Administración de Seguros de Salud, or Puerto Rico Health Insurance Administration
ASSMCA	Puerto Rico Mental Health and Anti-Addiction Services Administration or Administración de Servicios de Salud Mental y Contra la Adicción
ASUME	Minor Children Support Administration
BC-DR	Business Continuity and Disaster Recovery
CAHPS	Consumer Assessment of Health Care Providers and Systems
CEO	Chief Executive Officer
CFO	Chief Financial Officer
CFR	Code of Federal Regulations
CHIP	Children's Health Insurance Program
CLIA	Clinical Laboratory Improvement Amendment
CMS	Centers for Medicare & Medicaid Services
CPTET	Centro de Prevención y Tratamiento de Enfermedades Transmisibles, or Communicable Diseases Prevention and Treatment Center
DME	Durable Medical Equipment
DOJ	The Puerto Rico Department of Justice
DSM	Diagnostic and Statistical Manual for Mental Disorders
ECHO	Experience of Care and Health Outcomes Survey
ECM	Electronic Claims Management
EDI	Electronic Data Interchange
EFT	Electronic Funds Transfer
EIN	Employer Identification Number
EMTALA	Emergency Medical Treatment and Labor Act

Page 30 of 324

EPLS	Excluded Parties List System
EPSDT	Early and Periodic Screening, Diagnostic, and Treatment
EQRO	External Quality Review Organization
ER	Emergency Room
FAR	Federal Acquisition Regulation
FMC	Formulary of Medications Covered
FDA	Food and Drug Administration
FFS	Fee-for-Service
FQHC	Federally Qualified Health Center
FTP	File Transfer Protocol
GHP	Government Health Plan
HEDIS	The Health Care Effectiveness Data and Information Set
HCIP	Health Care Improvement Program
HHS	US Department of Health & Human Services
HHS-OIG	US Department of Health & Human Services Office of the Inspector General
HIE	Health Information Exchange
HIO	Health Information Organization
HIPAA	Health Insurance Portability and Accountability Act of 1996
HITECH	The Health Information Technology for Economic and Clinical Health Act of 2009, 42 USC 17391 et. seq
IBNR	Incurred-But-Not-Reported
ICD-10	International Statistical Classification of Diseases and Related Health Problems (10 ^th edition)
LEIE	List of Excluded Individuals and Entities
LME	List of Medications by Exception
MAC	Maximum Allowable Cost
M-CHAT	Modified Checklist for Autism in Toddlers
MCO	Managed Care Organization
MD	Medical Doctor
MHSIP	Mental Health Statistics Improvement Program
MMIS	Medicaid Management Information System
NCQA	National Committee for Quality Assurance
NEMT	Non-Emergency Medical Transportation

Page 31 of 324

NPI	National Provider Identifier
NPL	National Provider List
NPPES	National Plan and Provider Enumeration System
NQMC	National Quality Measures Clearinghouse
ONCHIT	Office of the National Coordinator for Health Information Technology
P&T	Pharmacy and Therapeutics
PBM	Pharmacy Benefit Manager
PCP	Primary Care Physician
PHI	Protected Health Information
PIP	Performance Improvement Projects
PMG	Primary Medical Group
PPA	Pharmacy Program Administrator
PPACA	Patient Protection and Affordable Care Act
PPN	Preferred Provider Network
PRHIEC	Puerto Rico Health Information Exchange Corporation
QAPI	Quality Assessment Performance Improvement Program
RFP	Request for Proposals
Rh	Rhesus
RHC	Rural Health Clinic/Center
SAMHSA	Substance Abuse and Mental Health Services Administration
SAS	Statements on Auditing Standards
SMI	Serious Mental Illness
SED	Serious Emotional Disturbance
SSN	Social Security Number
SUDs	Substance Use Disorders
TDD	Telecommunication Device for the Deaf
TPL	Third Party Liability
UM	Utilization Management
US or USA	United States of America
USC	United States Code

Page 32 of 324

ARTICLE 4

ASES RESPONSIBILITIES

4.1

General Provision

4.1.1

ASES will be responsible for administering the GHP. ASES will administer contracts, monitor Contractors’ performance, and provide oversight of all aspects of the Contractors’ operations.

4.2

Legal Compliance

4.2.1

ASES will comply with, and will monitor the Contractor’s compliance with, all applicable Puerto Rico and Federal laws and regulations, including but not limited to those listed in Attachment 1 to this Contract.

4.3

Coordination with Contractor’s Key Staff

4.3.1

ASES will make diligent, good-faith efforts to facilitate effective and continuous communication and coordination with the Contractor in all areas of the GHP operations.

4.3.2

Specifically, ASES will designate individuals within ASES who will serve as liaisons to corresponding individuals on the Contractor’s staff, including:

4.3.2.1

A program integrity staff member;

4.3.2.2

A quality oversight staff member;

4.3.2.3

A financial management staff member;

4.3.2.4

A Grievance and Appeal System staff member; and

4.3.2.5

An Information Systems coordinator.

4.4

Information Systems and Reporting

4.4.1

ASES reserves the right to modify, expand, or delete the requirements contained in Article 17 with respect to the Data that Contractor is required to submit to ASES, or to issue new requirements, subject to consultation with Contractor and to cost negotiation, if necessary. Unless otherwise stipulated in the Contract or mutually agreed upon by the Parties, the Contractor shall have ninety (90) Calendar Days from the day on which ASES issues notice of a required modification, addition, or deletion, to comply with the modification, addition, or deletion. Any payment made by ASES that is based on data submitted by the Contractor is contingent upon the Contractor’s compliance with the Certification requirements contained in 42 CFR 438.606.

4.4.2

ASES will make available a secure FTP server, accessible via the Internet, for receipt of electronic files and reports from the Contractor. The Contractor shall provide a similar system for ASES to transmit files and reports deliverable by ASES to the Contractor. When such systems are not operational, ASES and the Contractor shall agree mutually on alternate methods for the exchange of files.

Page 33 of 324

4.4.3

ASES will deliver to the Contractor the following information:

4.4.3.1

On a Daily Basis:

4.4.3.1.1

Certifications and Negative Redetermination Decisions;

4.4.3.1.2

Enrollment rejections and errors.

4.4.3.2

On a Daily and monthly Basis: Eligibility Data (including Certification and Negative Redetermination Decisions); and

4.4.3.3

On a monthly Basis: PMPM Payments.

4.5

Readiness Review

4.5.1

ASES shall conduct readiness reviews of the Contractor’s operations three (3) months before the start of a new managed care program and when the Contractor will provide or arrange for the provision of Covered Services to new eligibility groups. Such review will include, at a minimum, one (1) on-site review, at dates and times to be determined by ASES. These reviews may include, but are not limited to, desk and on-site reviews of documents provided by the Contractor, walk-through(s) of the Contractor’s facilities, Information System demonstrations, and interviews with the Contractor’s staff. ASES will conduct the readiness review to confirm that the Contractor is capable and prepared to perform all Administrative Functions and to provide high-quality services to GHP Enrollees.

4.5.2

The Contractor shall submit policies and procedures and other Deliverables specified by ASES in accordance with Attachment 12 to this Contract. The Contractor shall make any changes requested by ASES to policies and procedures or other Deliverables in the timeframes specified by ASES.

4.5.3

ASES’s review will document the status of the Contractor’s compliance with the program standards set forth in this Contract. A multidisciplinary team appointed by ASES will conduct the readiness review. The scope of the readiness review will include, but not be limited to, the review and/or verification of:

4.5.3.1

Provider Network composition and Access;

4.5.3.2

Staff;

4.5.3.3

Provider Credentialing;

Page 34 of 324

4.5.3.4

Call Center;

4.5.3.5

Care Management;

4.5.3.6

Marketing Materials;

4.5.3.7

Content of Provider contracts;

4.5.3.8

EPSDT plan;

4.5.3.9

Enrollee services capability;

4.5.3.10

Comprehensiveness of Quality and Utilization Management strategies;

4.5.3.11

Policies and procedures for the Grievance and Appeal System;

4.5.3.12

Financial management, including financial reporting and monitoring and financial solvency;

4.5.3.13

Contractor litigation history, current litigation, audits and other government investigations both in Puerto Rico and in other jurisdictions;

4.5.3.14

Information Systems management, including claims management, encounter data and enrollment information management, systems performance, interfacing capabilities, and security management functions and capabilities; and

4.5.3.15

All other matters which ASES may deem reasonable in order to determine the Contractor’s compliance with the requirements of this Contract.

4.5.4

The readiness review may assess the Contractor’s ability to meet any requirements set forth in this Contract and the documents referenced herein.

4.5.5

Potential Enrollees may not be enrolled in a GHP Plan until ASES has determined that the Contractor is capable of meeting these standards. A Contractor’s failure to pass the readiness review may result in immediate Contract termination. If the Contract is terminated in accordance with this Section 4.5.5 of this Contract, ASES shall not make any payments to the Contractor and shall have no liability for any costs incurred by the Contractor.

4.5.6

ASES will provide the Contractor with a summary of findings from the readiness review, as well as areas requiring remedial action with the timeframes to correct the findings.

Page 35 of 324

ARTICLE 5

ELIGIBILITY AND ENROLLMENT

5.1

Eligibility

5.1.1

The Government has sole authority to determine eligibility for the GHP, as provided in Federal law and Puerto Rico’s State Plan, with respect to the Medicaid and CHIP Eligibles; and, with respect to the Other Eligible Persons listed in Section 1.3.1.2, as provided in Article VI, Section 5 of Act 72 and other Puerto Rico law and regulation.

5.1.2

The Puerto Rico Medicaid Program’s determination that a person is eligible for the GHP is contained on Form MA-10, titled “Notification of Action Taken on Application and/or Recertification.” A person who has received an MA-10 shall be referred to hereinafter as a “Potential Enrollee.” The Potential Enrollee may access Covered Services using the MA-10 as a temporary Enrollee ID Card from the first day of the eligibility period specified on the MA-10 even if the person has not received an Enrollee ID Card. Only Medicaid, CHIP, and State Enrollees receive an MA-10 and may access Covered Services with the MA-10 as a temporary Enrollee ID Card.

5.1.3

Effective Date of Eligibility. ASES shall provide the Effective Date of Eligibility for services under the GHP to the Contractor for all Potential Enrollees as follows:

5.1.3.1

Effective Date of Eligibility for Medicaid and CHIP Eligibles (see Section 1.3.1.1) is the eligibility period specified on the Form MA-10 which is the first day of the month in which the Potential Enrollee submits its eligibility application with the Medicaid Program Office and they shall be eligible to be enrolled as of that date. For Medicaid and Chip populations, the eligibility period specified on the MA-10 may be retroactive up to three (3) months before the first day of the month in which the Potential Enrollee submits its eligibility application with the Medicaid Program Office. Retroactive eligibility is calculated independently for each of the three (3) months for which retroactive eligibility may be granted and during which services may be retroactively covered.

5.1.3.2

Effective Date of Eligibility for the State Population (see Section 1.3.1.2.1) is the eligibility period specified on the Form MA-10 and they shall be eligible to be enrolled as of that date.

5.1.3.3

Public employees and pensioners (see Section 1.3.1.2) shall be eligible to enroll in the GHP according to policies determined by the Government and their eligibility, Enrollment and Disenrollment processes and timeframes shall be determined through such policies. The Puerto Rico Medicaid Program and ASES do not play a role in determining the eligibility for public employees and pensioners, except in cases where the employee or pensioner seeks coverage based on income and the Medicaid Program evaluates whether income eligibility standards are met.

Page 36 of 324

5.1.3.4

Effective Date of Eligibility for Enrollees that have been Recertified is the date immediately following the expiration of the twelve (12) month period.

5.1.4

Termination of Eligibility

5.1.4.1

A Medicaid, CHIP, or State Enrollee who is determined ineligible for the GHP after a Redetermination conducted by the Puerto Rico Medicaid Program shall remain eligible for services under the GHP until the eligibility expiration date specified in the MA-10 issued by the Puerto Rico Medicaid Program for the current period of eligibility. This rule applies unless the Enrollee notifies the Puerto Rico Medicaid Program that their circumstances of eligibility have changed or as otherwise stated in Attachment 9 to this Contract.

5.1.4.2

An Enrollee who is a public employee or pensioner (see Section 1.3.1.2) shall remain eligible until disenrolled from the GHP by the applicable Government agency.

5.1.5

ASES Notice to Contractor

5.1.5.1

ASES will receive a file with Certification and Negative Redetermination Decision Data from the Puerto Rico Medicaid Program on a Daily Basis concerning the Enrollment status of the Medicaid, CHIP, and State Populations, and shall notify the Contractor of a Certification or Negative Redetermination Decision within one (1) Business Day of receiving notice of it via said file. ASES shall forward these Data to the Contractor in an electronic format agreed to between the Parties (the “Daily Update/Carrier Eligibility File Format”).

5.1.5.2

The applicable Government agency will directly notify the Contractor of the Enrollment and Disenrollment status of public employees and pensioners.

5.2

Enrollment

5.2.1

The Contractor shall coordinate with ASES as necessary for all Enrollment and Disenrollment functions.

5.2.1.1

The Contractor shall accept all Potential Enrollees into its Plan without restrictions, unless otherwise authorized by ASES. The Contractor shall not discriminate against individuals eligible to enroll on the basis of religion, race, color, national origin, sex, sexual orientation, gender identity, or disability, and will not use any policy or practice that has the effect of discriminating on the basis of religion, race, color, national origin, sex, sexual orientation, gender identity, or disability on the basis of health, health status, pre-existing condition, or need for health care services.

Page 37 of 324

5.2.1.2

The Contractor shall maintain adequate capacity to ensure prompt and voluntary Enrollment of all Potential Enrollees on a Daily Basis and in the order in which they apply or are Auto-Enrolled by ASES per Section 5.2.4.

5.2.1.3

The Contractor shall provide Potential Enrollees with specific Information allowing for prompt, voluntary, and reliable Enrollment.

5.2.1.4

The Contractor guarantees the maintenance, functionality, and reliability of all systems necessary for Enrollment and Disenrollment.

5.2.2

Effective Date of Enrollment

5.2.2.1

Except as provided below, Enrollment, whether chosen or automatic, will be effective (hereinafter referred to as the “Effective Date of Enrollment”) the same date as the period of eligibility specified on the MA-10.

5.2.2.1.1

The Effective Date of Enrollment for all Initial Auto-Enrollment Enrollees is November 1, 2018.

5.2.2.2

Changes in Enrollment requested by the Enrollee received during the first twenty (20) Calendar Days of the month will be effective the first Calendar Day of the following month (e.g., requests received January 10 ^th will be effective February 1 ^st ). Changes in Enrollment received after the first twenty (20) Calendar Days of the month will be effective the first Calendar Day of the second month following the request to change Enrollment (e.g., requests received January 25 ^th will be effective March 1 ^st ).

5.2.2.3

Effective Date of Enrollment for Newborns. The Effective Date of Enrollment for a newborn whose mother is Medicaid or CHIP Eligible on the date of delivery (Deemed Newborn) is the date of his or her birth. The Effective Date of Enrollment for a newborn whose mother is a State Population Enrollee is the Effective Date of Eligibility established by the Puerto Rico Medicaid Program. A newborn shall be Auto-Enrolled pursuant to the procedures set forth in Section 5.2.6.

Page 38 of 324

5.2.3

Term of Enrollment . The Term of Enrollment with Contractor shall be a period of twelve (12) consecutive months for all GHP Enrollees, unless a different contractor is selected during the applicable Open Enrollment Period described in Section 5.2.5, and except in cases in which the Puerto Rico Medicaid Program has designated an eligibility period shorter than twelve (12) months for an Enrollee who is a Medicaid or CHIP Eligible or a member of the State Population, in which case that same period shall also be considered the Enrollee’s Term of Enrollment. Such a shortened eligibility period may apply, at the discretion of the Puerto Rico Medicaid Program, when an Enrollee is pregnant, is homeless, or anticipates a change in status (such as receipt of unemployment benefits or in family composition). Notwithstanding this Section, Section 5.3.3 controls the Effective Date of Disenrollment.

5.2.3.1

Deemed Newborns have a Term of Enrollment of up to thirteen (13) months.

5.2.3.2

Pregnant Enrollees with a Term of Enrollment that expires during pregnancy or within sixty (60) Calendar Days of the post-partum period shall have an extended Term of Enrollment that expires on the last day of the month after sixty (60) Calendar days counted from the beginning of the post-partum period.

5.2.3.3

Except as otherwise provided in this Section 5.2, and notwithstanding the Term of Enrollment provided in Section 5.2.3, Enrollees shall remain enrolled in the Contractor’s Plan until the occurrence of an event listed in Section 5.3 (Disenrollment).

5.2.4

Auto-Enrollment . ASES shall apply an algorithm developed in accordance with the requirements in 42 CFR 438.54 to conduct Initial Auto-Enrollment prior to November 1, 2018. The Contractor shall have the policies and procedures necessary, and as shall be approved in writing by ASES, to comply with Initial Auto-Enrollment as of the Effective Date of the Contract for the Medicaid and CHIP Eligibles and members of the State Population, excluding State Employees eligible under Law 95.

5.2.4.1

The Foster Care Population and Domestic Violence Population will be Auto-Enrolled in one contractor’s plan and are not eligible to enroll into another contractor’s plan.

5.2.5

Open Enrollment Periods

5.2.5.1

Initial Auto-Enrollment Enrollees. Initial Auto-Enrollment Enrollees will have one (1) opportunity to change contractors without cause during their Open Enrollment Period, which shall begin on November 1, 2018 and end on January 31, 2019.

5.2.5.2

New Enrollees. New Enrollees to the GHP will have the opportunity to select a contractor during the Medicaid eligibility process with the Puerto Rico Medicaid Program. If the New Enrollee does not select a contractor, the Puerto Rico Medicaid Program will select a contractor on behalf of the New Enrollee. New Enrollees shall be permitted to select a different contractor once without cause, regardless of how the initial selection of contractor was made, during their Open Enrollment Period, which shall begin on the New Enrollee’s Effective Date of Enrollment.

Page 39 of 324

5.2.5.3

All Enrollees. All Enrollees will have the opportunity to select a contractor without cause during the Annual Open Enrollment period.

5.2.5.3.1

If a New Enrollee’s Open Enrollment Period in Section 5.2.5.2 coincides with the Annual Open Enrollment Period, the Open Enrollment Period in Section 5.2.5.2 controls.

5.2.5.4

When an Enrollee ceases to be part of the Domestic Violence or Foster Care Populations but continues to be an Eligible Person, the Enrollee may select a new contractor during an Open Enrollment Period.

5.2.5.5

When an Enrollee ceases to be eligible for the Platino Program but continues to be an Eligible Person, the Enrollee may select a new contractor during an Open Enrollment Period.

5.2.5.6

If the Enrollee does not make a change in contractor during the Open Enrollment Period, the Enrollee will remain enrolled with his/her current contractor.

5.2.6

Enrollment Procedures for All Enrollees Except Newborns

5.2.6.1

Upon receipt of notices in accordance with Section 5.1.5 of this Contract, the Contractor shall comply with the Auto-Enrollment process and issue to the Enrollee a notice informing the Enrollee of the PMG and PCP they are assigned to and their rights to change the PMG or PCP without cause during the applicable Open Enrollment Period. Effective November 1, 2018, such changes may be requested through ASES’s designated enrollment counselor.

5.2.6.2

The Contractor shall issue to the Enrollee an Enrollee ID Card and a notice of Enrollment, as well as an Enrollee Handbook and Provider Directory either in paper or electronic form, subject to the requirements of Section 6.10.8 and 6.10.9; or, such notice of Enrollment, an ID Card, an Enrollee Handbook, and a Provider Directory may be sent to the Enrollee via surface mail or electronically, subject to the requirements of Section 6.10.8 and 6.10.9 within five (5) Business Days of Enrollment.

Page 40 of 324

5.2.6.3

The notice of Enrollment that the Contractor issues will clearly state the Effective Date of Enrollment that applies per Section 5.2.2. The notice of Enrollment will explain that the Enrollee is entitled to receive Covered Services through the Contractor. The notice will inform the Enrollee of his or her limited right to disenroll, per Section 5.3 of this Contract. The notice shall advise the Enrollee of the Enrollee’s right to select a different PCP or to change PMGs, as described in Section 5.4, and will encourage the Enrollee to pursue this option if he or she is dissatisfied with care or services.

5.2.6.3.1

All Enrollees must be notified at least annually of their disenrollment rights as set forth in Section 5.3 and 42 CFR 438.56. Such notification must clearly explain the process for exercising this disenrollment right, as well as the alternatives available to the Enrollee based on their specific circumstance.

5.2.7

Procedures for Auto-Enrollment of Newborns

5.2.7.1

The Contractor shall notify ASES and the Puerto Rico Medicaid Program in writing of any Enrollees who are expectant mothers Immediately at the moment of diagnosis of the pregnancy or at least sixty (60) Calendar Days before the expected date of delivery.

5.2.7.2

The Contractor shall promptly, upon learning that an Enrollee is an expectant mother, mail a newborn Enrollment packet to the expectant mother (i) instructing her to register the newborn with the Puerto Rico Medicaid Program within ninety (90) Calendar Days of birth by providing evidence of the newborn’s birth; (ii) notifying an expectant mother that is a Medicaid or CHIP Enrollee that the Deemed Newborn will be Auto-Enrolled in the GHP; (iii) informing an expectant mother that is a Medicaid or CHIP Enrollee that unless she visits the Contractor’s office to select a PMG and PCP, the Deemed Newborn will be Auto-Assigned to the mother’s PMG and to a PCP who is a pediatrician; and (iv) informing the expectant mother that she will have ninety (90) Calendar Days after the date in which the Puerto Rico Medicaid Program notifies that the Deemed Newborn has been registered to disenroll from Plan or to change the child’s PMG and PCP, without cause.

5.2.7.3

The Contractor shall provide assistance to any expectant mother or guardian who contacts the Contractor wishing to make a PCP and PMG selection for her newborn and record that selection, per Section 5.4.

5.2.7.4

If the mother or guardian has not made a PCP and PMG selection at the time of the Deemed Newborn’s birth, the Contractor shall, within one (1) Business Day of the birth, Auto-Assign the Deemed Newborn to a PCP who is a pediatrician and to the Contact Member’s PMG.

Page 41 of 324

5.2.7.5

Within one (1) Business Day of acknowledging, either by concurrent review or hospital notification of the birth of a Deemed Newborn to a Medicaid or CHIP Enrollee, the Contractor shall ensure the submission of a newborn notification form to ASES and to the Puerto Rico Medicaid Program; such form shall be given prior written approval by ASES and the Puerto Rico Medicaid Program.

5.2.7.6

The Contractor shall participate in any meeting, working group, or other mechanism requested by ASES in order to ensure coordination among the Contractor, ASES, and the Puerto Rico Medicaid Program in order to implement Deemed Newborn Auto-Enrollment.

5.2.8

Contractor Notification Procedures Related to Redeterminations and Open Enrollment Periods

5.2.8.1

The Contractor shall inform Enrollees who are Medicaid- and CHIP Eligibles and members of the State Population of an impending Redetermination through written notices. Such notices shall be provided ninety (90) Calendar Days, sixty (60) Calendar Days, and thirty (30) Calendar Days before the scheduled date of the Redetermination.

5.2.8.1.1

The written notices shall inform the Enrollee that, if he or she is Recertified, his or her Term of Enrollment with the Contractor’s Plan will automatically renew unless a different contractor is selected during the Open Enrollment Period described in Section 5.2.5.3. The written notices must also specify that the Enrollee may change his or her PMG and/or PCP selection without cause during the applicable Open Enrollment Period.

5.2.8.2

The Contractor shall provide Enrollees and their representatives with sixty (60) Calendar Days written notice before the start of the Open Enrollment Period described in Section 5.2.5.3 of the right to disenroll or to change PMG or PCP without cause during such Open Enrollment Period.

5.2.8.3

Upon the receipt of written request from ASES, the Contractor shall provide a report for a specific period of time containing documentation that the Contractor has furnished the notices required in this Section 5.2.7.

Page 42 of 324

5.2.8.4

The form letters used for the notices in this Section 5.2.8 shall fall within the requirements in Section 6.2.1 that the Contractor seek advance written approval from ASES of certain documents.

5.2.9

Specific Contractor Responsibilities Regarding Dual Eligible Beneficiaries . At the time of Enrollment, the Contractor shall provide Potential Enrollees who are Medicaid-eligible and are also eligible for Medicare Part A or Medicare Part A and Part B (“Dual Eligible Beneficiaries”) with the information about their Covered Services and Co-Payments that is listed in Section 6.13. Members of the State Population (see section 1.3.1.2.1) who are Medicare-eligible shall not be considered Dual Eligible Beneficiaries.

5.3

Disenrollment

5.3.1

Disenrollment occurs only when the Medicaid Program determines that an Enrollee is no longer eligible for the GHP; or when Disenrollment is requested by the Contractor or Enrollee, and approved by ASES, as provided in Sections 5.3.4 and 5.3.5. The Foster Care Population and Domestic Violence Populations may not disenroll from their Auto-Enrolled GHP Plan.

5.3.2

All Disenrollments will be processed by ASES, and ASES will issue notification to the Contractor. Such notice shall be delivered via file transfer to the Contractor on a Daily Basis simultaneously with Information on Potential Enrollees within five (5) Calendar Days of a final determination on Disenrollment.

5.3.2.1

Disenrollment decisions and processing are the responsibility of the Puerto Rico Medicaid Program and ASES; however, notice to Enrollees of Disenrollment shall be issued by the Contractor. The Contractor shall issue such notice in person or via surface mail to the Enrollee within five (5) Business Days of a final Disenrollment decision, as provided in Sections 5.3.4 and 5.3.5.

5.3.2.2

Each notice of Disenrollment shall include information concerning:

5.3.2.2.1

The Effective Date of Disenrollment;

5.3.2.2.2

The reason for the Disenrollment;

5.3.2.2.3

The Enrollee’s right to request a Reconsideration from ASES and of ASES’s Administrative Law Hearing process, as provided by Act 72 of September 7, 1993;

5.3.2.2.4

The right to re-enroll in the GHP upon receiving a Recertification from the Puerto Rico Medicaid Program, if applicable; and

Page 43 of 324

5.3.2.2.5

Disenrollment shall occur according to the timeframes in Section 5.3.3 (the “Effective Date of Disenrollment”).

5.3.3

The Effective Date of Disenrollment is as follows:

5.3.3.1

Except as otherwise provided in this Section 5.3, Disenrollment will take effect as of the Effective Date of Disenrollment specified in the daily eligibility file sent to the Contractor by ASES as set forth in Attachment 9 to this Contract.

5.3.3.2

When Disenrollment is effectuated at the Contractor’s or the Enrollee’s request, as provided in Sections 5.3.4 and 5.3.5 of this Contract, Disenrollment shall take effect no later than the first day of the second month following the month that the Contractor or Enrollee requested the Disenrollment. If ASES fails to make a decision on the Enrollee’s request before this date, the Disenrollment will be deemed granted. If the Enrollee’s request is denied by ASES, the Enrollee may request, verbally or in writing, a Reconsideration by ASES and the Reconsideration process shall be completed in time to permit the Disenrollement (if approved) to take effect in accordance with this timeframe.

5.3.3.3

If an Enrollee is no longer eligible under the GHP, and Disenrollment under this Section 5.3.3 falls:

5.3.3.3.1

When the Enrollee is an inpatient at a hospital, ASES shall postpone the Effective Date of Disenrollment so that it occurs on the last day of the month in which the Enrollee is discharged from the hospital, or the last day of the month following the month in which Disenrollment would otherwise be effective, whichever occurs earlier;

5.3.3.3.2

During a month in which a Medicaid, CHIP or State Enrollee is pregnant, or on the date the pregnancy ends, ASES shall postpone the Effective Date of Disenrollment so that it occurs on the last day of the month in which the 60-day post-partum period ends;

5.3.3.3.3

When the Enrollee is in the process of appealing a denial of a Disenrollment request by ASES through either ASES’s Reconsideration process, ASES’s Administrative Law Hearing process (after exhausting the Reconsideration process), or the Puerto Rico Medicaid Department’s dedicated hearing process on Disenrollments due to loss of eligibility, as applicable, then ASES shall postpone the Effective Date of Disenrollment until a decision is rendered after the hearing; or

Page 44 of 324

5.3.3.3.4

During a month in which an Enrollee is diagnosed with a Terminal Condition, ASES shall postpone the Effective Date of Disenrollment so that it occurs on the last day of the following month.

5.3.3.4

For the public employees and pensioners who are Other Eligible Persons referred to in Section 1.3.1.2.2, Disenrollment shall occur according to the timeframes set forth in a Normative Letter issued by ASES annually.

5.3.4

Disenrollment Initiated by the Contractor

5.3.4.1

The Contractor has a limited right to request that an Enrollee be disenrolled without the Enrollee’s consent. The Contractor shall notify ASES upon identification of an Enrollee who it knows or believes meets the criteria for Disenrollment.

5.3.4.2

The Contractor shall submit Disenrollment requests to ASES, and the Contractor shall honor all Disenrollment determinations made by ASES. ASES’s decision on the matter shall be final, conclusive, and not subject to appeal by the Contractor.

5.3.4.3

The following are acceptable reasons for the Contractor to request Disenrollment:

5.3.4.3.1

The Enrollee’s continued Enrollment in the Contractor’s Plan seriously impairs the ability to furnish services to either this particular Enrollee or other Enrollees;

5.3.4.3.2

The Enrollee demonstrates a pattern of disruptive or abusive behavior that could be construed as non-compliant and is not caused by a presenting illness;

5.3.4.3.3

The Enrollee’s use of services is fraudulent or abusive (for example, the Enrollee has loaned his or her Enrollee ID Card to other persons to seek services);

5.3.4.3.4

The Enrollee is placed in a long-term care nursing facility or intermediate care facility for the intellectually disabled;

5.3.4.3.5

The Enrollee’s Medicaid or CHIP eligibility category changes to a category ineligible for the GHP; or

5.3.4.3.6

The Enrollee has died or moved out of Puerto Rico, thereby making him or her ineligible for Medicaid or CHIP or is otherwise ineligible for the GHP.

Page 45 of 324

5.3.4.4

ASES will approve a Disenrollment request by the Contractor, in ASES’s discretion, only if ASES determines:

5.3.4.4.1

That it is impossible for the Contractor to continue to provide services to the Enrollee without endangering the Enrollee or other GHP Enrollees; and

5.3.4.4.2

That an action short of Disenrollment, such as transferring the Enrollee to a different PCP or PMG, will not resolve the problem.

5.3.4.5

The Contractor may not request Disenrollment for any discriminatory reason including, but not limited, to the following:

5.3.4.5.1

Adverse changes in an Enrollee’s health status;

5.3.4.5.2

Missed appointments;

5.3.4.5.3

Utilization of medical services;

5.3.4.5.4

Diminished mental capacity;

5.3.4.5.5

Pre-existing medical condition;

5.3.4.5.6

The Enrollee’s attempt to exercise his or her rights under the Grievance and Appeal System; or

5.3.4.5.7

Uncooperative or disruptive behavior resulting from the Enrollee’s special needs.

5.3.4.6

The request of one (1) PMG to have an Enrollee assigned to a different PMG, per Section 5.4, shall not be sufficient cause for the Contractor to request that the Enrollee be disenrolled from the Plan. Rather, the Contractor shall, if possible, assign the Enrollee to a different and available PMG within the Plan.

5.3.4.7

When requesting Disenrollment of an Enrollee for reasons described in Section 5.3.4.3, the Contractor shall document at least three (3) interventions over a period of ninety (90) Calendar Days that occurred through treatment and Care Management to resolve any difficulty leading to the request. The Contractor shall also provide evidence of having given at least one (1) written warning to the Enrollee, with a certified return receipt requested, regarding implications of his or her actions.

5.3.4.8

If the Enrollee has demonstrated abusive or threatening behavior as defined by ASES, only one (1) Contractor intervention, and a subsequent written attempt to resolve the difficulty, are required.

Page 46 of 324

5.3.4.9

In the event that the Contractor seeks Disenrollment of an Enrollee, the Contractor shall notify the Enrollee of the availability of ASES’s Reconsideration process and Administrative Law Hearing process, as provided by Act 72 of September 7, 1993, as amended.

5.3.4.10

The Contractor shall maintain policies and procedures to comply with the Puerto Rico Patients’ Bill of Rights Act and with the Medicaid Regulations of 42 CFR 438.100, to ensure that the Enrollee’s exercise of Grievance rights does not adversely affect the services provided to the Enrollee by the Contractor or by ASES.

5.3.5

Disenrollment Initiated by the Enrollee

5.3.5.1

All Enrollees must be notified at least annually of their disenrollment rights as set forth in Section 5.3 and 42 CFR 438.56. Such notification shall clearly explain the process for exercising this disenrollment right, as well as the coverage alternatives available to the Enrollee based on their specific circumstance.

5.3.5.2

An Enrollee wishing to request Disenrollment must submit an oral or written request to ASES or to the Contractor. If the request is made to the Contractor, the Contractor shall forward the request to ASES, within five (5) Business Days of receipt of the request, with a recommendation of the action to be taken.

5.3.5.3

An Enrollee may request Disenrollment from the Contractor’s Plan without cause once during the applicable Open Enrollment Period in accordance with Section 5.2.5.

5.3.5.4

An Enrollee may request Disenrollment from the Contractor’s Plan for cause at any time. ASES shall determine whether the reason constitutes a valid cause. The following constitute cause for Disenrollment by the Enrollee:

5.3.5.4.1

The Enrollee moves outside of Puerto Rico;

5.3.5.4.2

The Contractor’s Plan does not, due to moral or religious objections, cover the health service the Enrollee seeks.

5.3.5.4.3

The Enrollee needs related services to be performed at the same time, and not all related services are available within the network. The Enrollee’s PCP or another Provider in the Contractor’s Network have determined that receiving services separately would subject the Enrollee to unnecessary risk.

5.3.5.4.4

Other acceptable reasons for Disenrollment at Enrollee request, per 42 CFR 438.56(d)(2), including, but not limited to, poor quality of care, lack of Access to Covered Services, or lack of Providers experienced in dealing with the Enrollee’s health care needs; and

Page 47 of 324

5.3.5.4.5

The Enrollee has become eligible for a Platino Program, or has experienced a change in his or her eligibility as a member of the Domestic Violence or Foster Care Populations.

5.3.5.5

If the Contractor fails to refer a Disenrollment request within the timeframe specified in Section 5.3.3, or if ASES fails to make a Disenrollment determination so that the Enrollee may be disenrolled by the first day of the second month following the month when the Disenrollment request was made, per Section 5.3.3, the Disenrollment shall be deemed approved for the effective date that would have been established had ASES or the Contractor complied with Section 5.3.3.

5.3.5.6

ASES shall make the final decision on Enrollees’ requests for Disenrollment. ASES may approve or disapprove the request based on the reasons specified in the Enrollee’s request, or upon any relevant Information provided to ASES by the Contractor about the Disenrollment request.

5.3.5.7

If the Enrollee’s request for Disenrollment under this Section is denied, the Contractor shall provide the Enrollee with a notice of the decision in a format and content consistent with Section 14.5.15. The notice shall include the grounds for the denial and shall inform the Enrollee of his or her right to use the Reconsideration process, and to have access to an Administrative Law Hearing after first exhausting ASES’s Reconsideration process.

5.3.5.8

Use of the Contractor’s Grievance and Appeal System . ASES may at its option require that the Enrollee seek redress through the Contractor’s Grievance and Appeal System before ASES makes a determination on the Enrollee’s request for Disenrollment. The Contractor shall Immediately inform ASES of the outcome of the Grievance process. ASES may take this Information into account in making a determination regarding the request for Disenrollment. The Grievance process shall be completed in time to permit the Disenrollment (if approved) to be effective in accordance with the timeframe specified in Section 5.3.3; if the process is not completed within the specified timeframe, then the Disenrollment will be deemed approved by ASES.

5.3.6

Disenrollment During Termination Hearing Process . If ASES notifies the Contractor of its intention to terminate the Contract as provided in Article 35, ASES may allow Enrollees to disenroll Immediately without cause. In the event of such a Termination, ASES must provide Enrollees with the notice required by 42 CFR 438.10, listing their options for receiving services following the Termination Date of the Contract.

Page 48 of 324

5.3.7

ASES shall ensure, through the obligations of the Contractor under this Contract that Enrollees receive the notices contained in Section 5.2.7 (Re-Enrollment Procedures). While these notices shall be issued by the Contractor, per Section 5.2.7, ASES shall provide the Contractor with the information on Certifications and Negative Redetermination Decisions (see Section 5.1.5.1) needed for the Contractor to carry out this responsibility.

5.3.8

Enrollment Database

5.3.8.1

The Contractor shall maintain an Enrollment database that includes all Enrollees, and contains, for each Enrollee, the Information specified in the Carrier Billing File/Carrier Eligibility File format.

5.3.8.2

The Contractor shall notify the Puerto Rico Medicaid Program Immediately when the Enrollment database is updated to reflect a change in the place of residence of an Enrollee.

5.3.8.3

The Contractor shall secure any authorization required from Enrollees under the laws of Puerto Rico in order to allow the US Department of Health and Human Services, the Medicaid Fraud Control Unit, ASES, and its Agents to review Enrollee Medical Records, in order to evaluate the Information and determine quality, appropriateness, timeliness, and cost of services performed under this Contract; provided that such authorization shall be limited by the Contractor’s obligation to observe the confidentiality of Enrollees’ Protected Health Information, as provided in Article 34.

5.3.9

Notification to ASES and the PBM of New Enrollees and of Completed Disenrollments

5.3.9.1

The Contractor shall notify ASES and the PBM of new Enrollees and of completed Disenrollments on a routine Daily Basis; or at any time, if requested by ASES. Such notification will be made through electronic transmissions.

5.3.9.2

The notification will include all new Enrollees as of the Business Day before the notification is issued, and will be sent no later than the following Business Day after the Enrollment process has been completed (as signified by issuance of the Enrollee ID Card, either in person or by surface mail) or the Disenrollment process has been completed (as signified by the issuance of a Disenrollment notice).

5.3.10

In the event that the Contractor must update information previously submitted to ASES about a new Enrollment, including a change in coverage code, or that the Contractor must add a new Enrollee who was previously omitted, such update must occur the next Business Day after the information is updated or a new Enrollee is added. ASES reserves the authority not to accept any new additions or corrections to a particular month’s Enrollment Data after two (2) Business Days past the date on which ASES notifies the Contractor of the rejected subscriptions , as set forth in Attachment 9 to this Contract.

Page 49 of 324

5.4

Change of a Primary Medical Group (“PMG”) and Primary Care Physician (“PCP”)

5.4.1

Change of a PMG and PCP

5.4.1.1

During the ninety (90) Calendar Days period following the Effective Date of Enrollment (the Open Enrollment Period), the Enrollee can change his/her Auto-Assigned or selected PMG and PCP without cause. The Contractor can offer counseling and assistance to the Enrollee in selecting a different PCP and PMG. Enrollees under the Foster Care Population and Domestic Violence Population classification are not assigned to a PCP or PMG.

5.4.1.2

The Contractor shall advise certain Enrollees to choose a physician other than, or in addition to, a general practice physician as their PCP, as follows:

5.4.1.2.1

Female Enrollees age twelve (12) and older will be recommended to choose an obstetrician/gynecologist as a PCP.

5.4.1.2.2

Enrollees under twenty-one (21) years of age will be recommended to choose a pediatrician as a PCP.

5.4.1.2.3

Enrollees with conditions that are included in HCHN Program in Section 7.8.3 will be recommended to choose an internist or other appropriate specialist as a PCP.

5.4.1.3

Per Section 5.2.7, following the Contractor’s notice to an expectant mother of a Deemed Newborn’s upcoming Auto-Enrollment in the Contractor’s Plan, the Contractor shall record any notice it receives from the mother or guardian concerning the selection of a PCP or PMG for the Deemed Newborn. The Contractor shall ensure that such selections take effect as of the date of the Deemed Newborn’s birth.

5.4.1.4

In order to comply with the PMG Capitation payment process, if an Enrollee changes PCP/PMG during the first five (5) Calendar Days of the month, the change will be effective in the next subsequent month of the change. If Enrollee changes PCP/PMG after the fifth (5 ^th ) day of the month, the change will be effective in the second (2 ^nd ) subsequent month of the change. The Enrollee can still receive services until the change is effective from the originally assigned PCP/PMG

Page 50 of 324

5.4.1.5

The Contractor shall permit Enrollees to change their PMG or PCP at any time with cause. The following shall constitute cause for change of PMG or PCP:

5.4.1.5.1

The Enrollee’s religious or moral convictions conflict with the services offered by Providers in the PMG;

5.4.1.5.2

The Enrollee needs related services to be provided concurrently; not all services are available within the Preferred Provider Network associated with a PMG; and the Enrollee’s PCP or any other Provider has determined that receiving the services separately could expose the Enrollee to an unnecessary risk; or

5.4.1.5.3

Other reasons, including a deterioration of the Provider-Enrollee relationship where the Enrollee no longer feels comfortable receiving services from the Provider, poor quality of care, unavailability of appointments, inaccessibility to Covered Services, and inaccessibility to Providers with the experience to address the health care needs of the Enrollee.

5.4.1.6

The Contractor shall permit Enrollees to change their PMG and/or PCP for any reason, within certain timeframes:

5.4.1.6.1

During the ninety (90) Calendar Days following the Effective Date of Enrollment (Open Enrollment Period);

5.4.1.6.2

At least every twelve (12) months, following the ninety (90) Calendar Days after the Effective Date of Enrollment; or

5.4.1.6.3

At any time, during time periods in which the Contractor is subject to intermediate sanctions, as defined in 42 CFR 438.702(a)(3).

5.4.1.7

A Contractor may change an Enrollee’s PMG at the request of the PCP or another Provider within that PMG, in limited situations, when appropriately documented, as follows:

5.4.1.7.1

The Enrollee’s continued participation in the PMG seriously impairs the PMG’s ability to furnish services to either this particular Enrollee or other Enrollees;

Page 51 of 324

5.4.1.7.2

The Enrollee demonstrates a pattern of disruptive or abusive behavior that could be construed as non-compliant and that is not caused by a presenting illness; or

5.4.1.7.3

The Enrollee’s use of services is fraudulent or abusive (for example, the Enrollee has loaned his or her Enrollee ID Card to other persons to seek services).

5.5

Transition of Care During Contractor Change

5.5.1

The Contractor must ensure continued access to services during an Enrollee’s transition from one Contractor to another by complying with the following:

5.5.1.1

Ensure the Enrollee has access to services consistent with the access they previously had, and is permitted to retain their current Provider for ninety (90) Calendar Days if that Provider is not a Network Provider;

5.5.1.2

Refer Enrollee to appropriate Network Providers;

5.5.1.3

Fully and timely comply with requests for historical utilization data from the new contractor or other entity in compliance with Federal and State laws;

5.5.1.4

Ensure that the Enrollee’s new Provider is able to obtain copies of the Enrollee’s medical records, as appropriate;

5.5.1.5

Comply with any other necessary procedures specified by CMS or ASES to ensure continued access to services to prevent serious detriment to the Enrollee’s health or reduce the risk of hospitalization or institutionalization.

ARTICLE 6

ENROLLEE SERVICES

6.1

General Provisions

6.1.1

The Contractor shall have policies and procedures, prior approved by ASES and submitted in accordance with Attachment 12 to this Contract, that explain how it will ensure that Enrollees and Potential Enrollees:

6.1.1.1

Are aware of their rights and responsibilities;

6.1.1.2

How to obtain physical and Behavioral Health Services;

6.1.1.3

What to do in an emergency or urgent medical situation;

Page 52 of 324

6.1.1.4

How to request a Grievance, Appeal, or Administrative Law Hearing;

6.1.1.5

How to report suspected Incident of Fraud, Waste, and Abuse;

6.1.1.6

Have basic information on the basic features of managed care; and

6.1.1.7

Understand the Contractor’s responsibilities to coordinate Enrollee care.

6.1.2

The Contractor’s informational materials must convey to Enrollees and Potential Enrollees that GHP is an integrated program that includes both physical and Behavioral Health Services, and must also explain the concepts of Primary Medical Groups and Preferred Provider Networks.

6.1.3

The information conveyed in the Contractor’s written materials shall conform with ASES’s Universal Enrollee Handbook, included as Attachment 3 to this Contract.

6.1.4

The Contractor shall convey Information to Enrollees and Potential Enrollees via written materials and via telephone, internet, and face-to-face communications, and shall allow Enrollees to submit questions and to receive responses from the Contractor.

6.1.5

The Contractor shall ensure that the informational materials disseminated to all GHP Enrollees accurately identify differences among the categories of Eligible Persons.

6.1.6

The Contractor shall provide Enrollees with at least thirty (30) Calendar Days written notice of any significant change in policies concerning Enrollees’ Disenrollment rights (see Section 5.3), right to change PMGs or PCPs (see Section 5.4), or any significant change to any of the items listed in the Enrollee Handbook (Section 6.4) or Enrollee Rights and Responsibilities (section 6.5), regardless of whether ASES or the Contractor caused the change to take place. This Section 6.1.6 shall not be construed as giving the Contractor the right to change its policies and procedures without prior written approval from ASES.

6.1.7

The Contractor shall use the definitions for managed care terminology set forth by ASES in all of its written and verbal communications with Enrollees, in accordance with 42 CFR 438.10(c)(4)(i).

6.1.8

The Contractor shall provide instructions to Enrollees and Potential Enrollees on how to access continued services pursuant to its transition of care process as specified in Section 5.5 and in accordance with 42 CFR 438.62.

Page 53 of 324

6.2

ASES Approval of All Written Materials

6.2.1

The Contractor shall submit to ASES for review and prior written approval all materials meant for distribution to Enrollees, including but not limited to, Enrollee Handbooks, Provider Directories, ID cards and, upon request, any other additional, but not required, materials and Information provided to Enrollees designed to promote health and/or educate Enrollees.

6.2.2

All materials must be submitted to ASES in paper and electronic file media, in the format prescribed by ASES. The Contractor shall submit the reading level and the methodology used to measure it concurrent with all submissions of written materials and include a plan that describes the Contractor’s intent for the use of the materials.

6.2.3

ASES reserves the right to notify the Contractor to discontinue or modify written materials after approval.

6.2.4

Except as otherwise provided below, written materials described in this Article 6 must be submitted to ASES for review at least forty-five (45) Calendar Days before their printing and distribution, as required by Act 194 of August 2000. This requirement applies to:

6.2.4.1

The materials described in this Article 6 distributed to all Enrollees, including the Enrollee Handbook;

6.2.4.2

Policy letters, coverage policy statements, or other communications about Covered Services under the GHP distributed to Enrollees; and

6.2.4.3

Standard letters and notifications, such as the notice of Enrollment required in Section 5.2.6.3, the notice of Redetermination required in Section 5.2.8.1, and the notice of Disenrollment required in Section 5.3.2. The Contractor shall use model Enrollee notices developed by ASES whenever available.

6.2.5

The Contractor shall provide ASES with advance notice of any changes made to written materials that will be distributed to all Enrollees. Notice shall be provided to ASES at least forty-five (45) Calendar Days before the effective date of the change. Within fifteen (15) Business Days of receipt of the materials, ASES will respond to the Contractor’s submission with either an approval of the materials, recommended modifications, or a notification that more review time is required. If the Contractor receives no response from ASES within fifteen (15) Business Days of ASES’s receipt of the materials, the materials shall be deemed approved. Except as otherwise provided in this Section 6.2.5, the Contractor may distribute the revised written materials only upon written approval of the changes from ASES.

Page 54 of 324

6.3

Requirements for Written Materials

6.3.1

The Contractor shall maintain written policies and procedures governing the development and distribution of written materials including how the Contractor will meet the requirements in this Section 6.3, with such policies and procedures to be submitted in accordance with Attachment 12 to this Contract for prior written approval from ASES. The Contractor shall, at a minimum, have policies and procedures regarding the process for developing/creating, proofing, approving, publishing, and mailing the (i) Enrollee Handbook, (ii) Provider Directory, and (iii) form letters within contractual standards and timeframes. The Contractor shall include a separate set of policies and procedures for the items listed above.

6.3.2

The Contractor shall make all written materials available through auxiliary aids and services or alternative formats, and in a manner that takes into consideration the Enrollee’s or Potential Enrollee’s special needs, including Enrollees and Potential Enrollees who are visually impaired or have limited reading proficiency. The Contractor shall notify all Enrollees and Potential Enrollees that Information is available in alternative formats, and shall instruct them on how to access those formats. Consistent with Section 1557 of PPACA and 42 CFR 438.10(d)(3), all written materials must also include taglines in the prevalent languages, as well as large print, with a font size of no smaller than 18 point, to explain the availability of written and oral translation to understand the Information provided and the toll-free and TTY/TDD telephone number of the GHP Service Line.

6.3.3

Once an Enrollee has requested a written material in an alternative format or language, the Contractor shall at no cost to the Enrollee or Potential Enrollee (i) make a notation of the Enrollee or Potential Enrollee’s preference in the Contractor’s system and (ii) provide all subsequent written materials to the Enrollee or Potential Enrollee in such format unless the Enrollee or Potential Enrollee requests otherwise.

6.3.4

Except as provided in Sections 1.1.5 and 6.4 (Enrollee Handbook) and subject to Section 6.3.8, the Contractor shall make all written information available in Spanish or other applicable Prevalent Non-English Language, as defined in Section 6.3.8 below, with a language block in English, explaining that (i) Enrollees may access an English translation of the Information if needed, and (ii) the Contractor will provide oral interpretation services into any language other than Spanish or English, if needed. Such translation or interpretation shall be provided by the Contractor at no cost to the Enrollee. The language block and all other content shall comply with 42 CFR 438.10(d)(2) and Section 1557 of PPACA.

6.3.5

If oral interpretation services are required in order to explain the Benefits covered under the GHP to a Potential Enrollee who does not speak either English or Spanish, the Contractor must, at its own cost, make such services available in a third language, in compliance with 42 CFR 438.10(d)(4).

Page 55 of 324

6.3.6

All written materials shall be worded such that they are understandable to a person who reads at the fourth (4 ^th ) grade level.

6.3.7

All written materials must be clearly legible with a minimum font of size twelve (12) point with the exception of Enrollee ID cards and unless otherwise approved in writing by ASES.

6.3.8

Within ninety (90) Calendar Days of a notification from ASES that ASES has identified a Prevalent Non-English Language other than Spanish or English (with “Prevalent Non-English Language” defined as a language that is the primary language of more than five percent (5%) of the population of Puerto Rico), all written materials provided to Enrollees and Potential Enrollees shall be translated into and made available in such language.

6.3.9

The Contractor shall provide written notice to Enrollees of any material changes to written materials previously distributed to Enrollees at least thirty (30) Calendar Days before the effective date of the change.

6.4

Enrollee Handbook Requirements

6.4.1

The Contractor shall produce at its sole cost, and shall mail or make electronically available, subject to the requirements of Section 6.10.8 and 6.10.9, to all new Enrollees, an Enrollee Handbook including information on physical health, Behavioral Health, and all other Covered Services offered under the GHP. The Contractor shall distribute the Enrollee Handbook either simultaneously with the notice of Enrollment referenced in Section 5.2.5.3 or within five (5) Calendar Days of sending the notice of Enrollment via surface mail.

6.4.2

Upon request of an Enrollee or his/her Authorized Representative for a replacement or additional copy of the Enrollee Handbook, the Contractor shall send an Enrollee Handbook within ten (10) Calendar Days. The Contractor shall give the person requesting an Enrollee Handbook the option to get the Information from the Contractor’s website or to receive a printed document.

6.4.3

The Contractor shall either:

6.4.3.1

Mail or make electronically available, subject to the requirements of Sections 6.10.8 and 6.10.9, to all Enrollees an Enrollee Handbook on at least an annual basis, after the initial distribution of the Enrollee Handbook at Enrollment; or

6.4.3.2

At least annually, as required by 42 CFR 438.10, mail or make electronically available, subject to the requirements of Sections 6.10.8 and 6.10.9, to all Enrollees a Handbook supplement that includes Information on the following:

Page 56 of 324

6.4.3.2.1

The Contractor’s service area;

6.4.3.2.2

Benefits covered under the GHP;

6.4.3.2.3

Any cost-sharing imposed by the Contractor; and

6.4.3.2.4

To the extent available, quality and performance indicators, including Enrollee satisfaction.

6.4.3.3

The Contractor is not required to mail an Enrollee Handbook to an Enrollee who may have been disenrolled and subsequently reenrolled if Enrollee was provided an Enrollee Handbook within the past year. The Contractor is also not required to mail an Enrollee Handbook to new Enrollees under the age of twenty-one (21) if an Enrollee Handbook has been mailed within the past year to a member of that Enrollee’s household. However, this exception does not apply to pregnant Enrollees under the age of twenty-one (21).

6.4.4

The Contractor shall use the Universal Beneficiary Guide, provided by ASES and included as Attachment 3 to this Contract, as a model for its Enrollee Handbook; however, the Contractor shall ensure that its Enrollee Handbook meets all the requirements listed in this Section 6.4.

6.4.5

Pursuant to the requirements set forth in 42 CFR 438.10, the Enrollee Handbook shall include, at a minimum, the following:

6.4.5.1

A table of contents;

6.4.5.2

An explanation of the purpose of the Enrollee ID Card and a warning that transfer of the card to another person constitutes Fraud;

6.4.5.3

Information about the role of the PCP and how to choose a PCP;

6.4.5.4

Information about the PMG, how to choose a PMG, and which Benefits may be accessed through the PMG;

6.4.5.5

Information about the PPN associated with the Enrollee’s PMG, and the benefits of seeking services within the PPN;

6.4.5.6

Information about the circumstances under which Enrollees may change to a different PMG;

6.4.5.7

Information about what to do when family size changes, including the responsibility of new mothers who are Medicaid Eligible to register their newborn with the Puerto Rico Medicaid Program and to apply for the Enrollment of the newborn;

Page 57 of 324

6.4.5.8

Appointment procedures;

6.4.5.9

Information on the amount, duration and scope of Benefits and Covered Services, including how the scope of Benefits and services differs between Medicaid and CHIP Eligibles and Other Eligible Persons. This must include Information on the EPSDT Benefit and how Enrollees under the age of twenty-one (21) and entitled to the EPSDT Benefit may access component services;

6.4.5.10

An explanation of how physical health and Behavioral Health services are integrated under the GHP, and how to access specialized Behavioral Health Services;

6.4.5.11

Information on how to access local resources for Non-Emergency Medical Transportation (“NEMT”);

6.4.5.12

An explanation of any service limitations or exclusions from coverage, including any restrictions on the Enrollee’s freedom of choice among network Providers;

6.4.5.13

Information on where and how Enrollees may access Benefits not available from or not covered by the Contractor’s Plan;

6.4.5.14

The Medical Necessity definition used in determining whether services will be covered (see Section 7.2);

6.4.5.15

A description of all pre-certification, Prior Authorization, or other requirements for treatments and services;

6.4.5.16

The policy on Referrals for specialty care and for other Covered Services not provided by the Enrollee’s PCP;

6.4.5.17

Information on how to obtain after-hours coverage;

6.4.5.18

An explanation of cost-sharing, including:

6.4.5.18.1

The differences in cost-sharing responsibilities between Medicaid- and CHIP Eligibles and Other Eligible Persons, and

6.4.5.18.2

The cost-sharing responsibilities of Dual Eligible Beneficiaries, as well as the other information for Dual Eligible Beneficiaries listed in Section 6.13;

Page 58 of 324

6.4.5.19

Notice of all appropriate mailing addresses and telephone numbers to be utilized by Enrollees seeking Information or authorization, including the Contractor’s toll-free telephone line and website address;

6.4.5.20

A description of Utilization Management policies and procedures used by the Contractor;

6.4.5.21

A description of Enrollee rights and responsibilities as described in Section 6.5;

6.4.5.22

The policies and procedures for Disenrollment, including when Disenrollment may be requested without Enrollee consent by the Contractor and Information about Enrollee’s right to request Disenrollment, and including notice of the fact that the Enrollee will lose Access to services under the GHP if the Enrollee chooses to disenroll;

6.4.5.23

Information on Advance Directives, including the right of Enrollees to file directly with ASES or with the Puerto Rico Office of the Patient Advocate, Complaints concerning Advance Directive requirements listed in Section 7.10 of this Contract;

6.4.5.24

A statement that additional Information, including the Provider Guidelines (see Section 10.2.1 of the Contract) and Information on the structure and operations of the GHP and Physician Incentive Plans, shall be made available to Enrollees and Potential Enrollees upon request;

6.4.5.25

Information on the extent to which, and how, after-hours and emergency coverage are provided, including:

6.4.5.25.1

What constitutes an Emergency Medical Condition and a Psychiatric Emergency;

6.4.5.25.2

The fact that Prior Authorization is not required for Emergency Services;

6.4.5.25.3

Notice that:

6.4.5.25.3.1

Under no circumstances will a Medicaid or CHIP Enrollee be charged a Co-Payment for the treatment of any Emergency Medical Condition or Psychiatric Emergency;

6.4.5.25.3.2

No Co-Payments shall be charged for Medicaid and CHIP children under twenty-one (21) years under any circumstances.

Page 59 of 324

6.4.5.25.3.3

For Medicaid or CHIP Enrollees, Co-Payments may apply to non-emergency services provided in an emergency room pursuant to Attachment 8 to this Contract on Cost-Sharing; and

6.4.5.25.3.4

For Other Eligible Persons, Co-Payments apply to Emergency Services outside the Enrollee’s PPN, but the Enrollee may avoid a Co-Payment by using the GHP Service Line (see Section 6.8).

6.4.5.25.4

The process and procedures for obtaining Emergency Services, including the use of the 911 telephone systems or its local equivalent;

6.4.5.25.5

The scope of Post-Stabilization Services offered under the GHP as detailed in Section 7.5.9.4;

6.4.5.25.6

The locations of emergency rooms and other locations at which Providers and hospitals furnish Emergency Services and Post-Stabilization Services covered under the GHP; and

6.4.5.25.7

The fact that an Enrollee has a right to use any hospital or other setting for Emergency Services;

6.4.5.26

An explanation of the Redetermination process, including:

6.4.5.26.1

Disenrollment as a consequence of a Negative Redetermination Decision; and

6.4.5.26.2

The Re-Enrollment period that follows a new Certification.

6.4.5.27

Information on the Contractor’s Grievance and Appeal System policies and procedures, as described in Article 14 of this Contract. This description must include the following:

6.4.5.27.1

The right to file a Grievance and Appeal with the Contractor;

6.4.5.27.2

The requirements and timeframes for filing a Grievance or Appeal with the Contractor;

6.4.5.27.3

The availability of assistance in filing a Grievance or Appeal with the Contractor;

6.4.5.27.4

The toll-free numbers that the Enrollee can use to file a Grievance or an Appeal with the Contractor by phone;

6.4.5.27.5

The right to an Administrative Law Hearing after exhaustion of the Contractor’s Grievance and Appeal System, the method for obtaining a hearing, and the rules that govern representation at the hearing;

Page 60 of 324

6.4.5.27.6

Notice that if the Enrollee files an Appeal or a request for an Administrative Law Hearing and requests continuation of services, the Enrollee may be required to pay the cost of services furnished while the Appeal is pending, if the final decision is adverse to the Enrollee;

6.4.5.27.7

Any Appeal rights that ASES chooses to make available to Providers to challenge the failure of the Contractor to cover a service;

6.4.5.27.8

Instructions on how an Enrollee can report suspected Fraud, Waste, or Abuse, and protections that are available for whistleblowers;

6.4.5.27.9

Information on the family planning services and supplies, including the extent to which, and how, Enrollees may obtain such services or supplies from out-of-network providers, and that an Enrollee cannot be required to obtain a referral before choosing a family planning Provider;

6.4.5.27.10

Information on non-coverage of counseling or referral services based on Contractor’s moral or religious objections, as specified in Section 7.13 and how to access these services from ASES; and

6.4.5.27.11

Instructions on how to access oral or written translation services, Information in alternative formats, and auxiliary aids and services, as specified in Sections 6.3 and 6.11.

6.4.5.28

A description of the model of care for treatment of Enrollees with each HCHN condition.

6.4.6

The Enrollee Handbook in both English and Spanish shall be submitted to ASES for review and prior written approval. Submission of the Enrollee Handbook by the Contractor shall be in accordance with the timeframes specified in Attachment 12 to this Contract.

6.4.7

The Contractor shall be responsible for producing the Enrollee Handbook in both English and Spanish.

6.5

Enrollee Rights and Responsibilities

6.5.1

The Contractor shall have written policies and procedures regarding the rights of Enrollees and shall comply with any applicable Federal and Puerto Rico laws and regulations that pertain to Enrollee rights, including those set forth in 42 CFR 438.100, and in the Puerto Rico Patient’s Bill of Rights Act 194 of August 25, 2000; the Puerto Rico Mental Health Law Act 408 of October 2, 2000, as amended and implemented; and Law 77 of July 24, 2013 which created the Office of the Patient Advocate. These rights shall be included in the Enrollee Handbook. At a minimum, the policies and procedures shall specify the Enrollee’s right to:

Page 61 of 324

6.5.1.1

Receive information pursuant to 42 CFR 438.10;

6.5.1.2

Be treated with respect and with due consideration for the Enrollee’s dignity and privacy;

6.5.1.3

Have all records and medical and personal information remain confidential;

6.5.1.4

Receive information on available treatment options and alternatives, presented in a manner appropriate to the Enrollee’s condition and ability to understand;

6.5.1.5

Participate in decisions regarding his or her health care, including the right to refuse treatment;

6.5.1.6

Be free from any form of restraint or seclusion as a means of coercion, discipline, convenience, or retaliation, as specified in 42 CFR 482.13(e) and other Federal regulations on the use of restraints and seclusion;

6.5.1.7

Request and receive a copy of his or her Medical Records pursuant to 45 CFR Parts 160 and 164, subparts A and E, and request to amend or correct the record as specified in 45 CFR 164.524 and 164.526;

6.5.1.8

Choose an Authorized Representative to be involved as appropriate in making care decisions;

6.5.1.9

Provide informed consent;

6.5.1.10

Be furnished with health care services in accordance with 42 CFR 438.206 through 438.210;

6.5.1.11

Freely exercise his or her rights, including those related to filing a Grievance or Appeal, and that the exercise of these rights will not adversely affect the way the Enrollee is treated;

6.5.1.12

Receive Information about Covered Services and how to access Covered Services and Network Providers;

Page 62 of 324

6.5.1.13

Be free from harassment by the Contractor or its Network Providers with respect to contractual disputes between the Contractor and its Providers;

6.5.1.14

Participate in understanding physical and Behavioral Health problems and developing mutually agreed-upon treatment goals;

6.5.1.15

Not be held liable for the Contractor’s debts in the event of insolvency; not be held liable for the Covered Services provided to the Enrollee for which ASES does not pay the Contractor; not be held liable for Covered Services provided to the Enrollee for which ASES or the Contractor’s Plan does not pay the Provider that furnishes the services; and not be held liable for payments of Covered Services furnished under a contract, Referral, or other arrangement to the extent that those payments are in excess of the amount the Enrollee would owe if the Contractor provided the services directly; and

6.5.1.16

Only be responsible for cost-sharing in accordance with 42 CFR 447.50 through 42 CFR 447.56 and as permitted by the Puerto Rico Medicaid and CHIP State Plans and Puerto Rico law as applicable to the Enrollee.

6.6

Provider Directory

6.6.1

The Contractor shall develop, maintain, and mail or make electronically available, subject to the requirements of Sections 6.10.8 and 6.10.9 to all new Enrollees a Provider Directory in a manner reasonably calculated to reach Enrollees within five (5) Calendar Days of sending the notice of Enrollment referenced in Section 5.2.5.3.

6.6.1.1

The Contractor is not required to mail a Provider Directory to an Enrollee who may have been disenrolled and subsequently reenrolled if Enrollee was provided a Provider Directory within the past year. The Contractor is also not required to mail a Provider Directory to new Enrollees under the age of twenty-one (21) if a Provider Directory has been mailed to a member of that Enrollee’s household. However, this exception does not apply to pregnant Enrollees under the age of twenty-one (21).

6.6.2

The Contractor shall update the paper Provider Directory once a month, and distribute it to Enrollees upon Enrollee request.

6.6.3

The Contractor shall make the Provider Directory available on its website in a machine readable file and format as specified by CMS.

6.6.4

The Provider Directory shall include the names, provider group affiliations, locations, office hours, telephone numbers, websites, cultural and linguistic capabilities, completion of Cultural Competency training, and accommodations for people with physical disabilities of current Network Providers. This includes, at a minimum, Information sorted by PCPs; specialists; dentists; FQHCs and RHCs; Behavioral Health Providers/clinics, including detox clinics; pharmacies; hospitals, including locations of emergency settings and Post-Stabilization Services, with the name, location, hours of operation, and telephone number of each facility/setting. The Provider Directory shall also identify all Network Providers that are not accepting new patients. Any subcontractors of ASES, such as the PBM, will collaborate with the Contractor to provide information in a format mutually agreed upon for the generation of the Provider Directory.

Page 63 of 324

6.6.5

The Provider Directory shall include all Network Providers grouped by PMG.

6.6.6

The Provider Directory must be indexed alphabetically and by specialty.

6.6.7

The Contractor shall submit the Provider Directory to ASES for review and prior written approval in the timeframe specified in Attachment 12 to this Contract.

6.6.8

The Contractor shall update and amend the Provider Directory on its website within three (3) Calendar Days of any changes as well as produce and distribute annual updates to all Enrollees. The Contractor shall maintain on its website an updated Provider Directory that includes all identified Information above and that is searchable by Provider type, distance from Enrollee’s address, and/or whether the Network Provider is accepting new patients. Information on how to access this Information shall be clearly stated in both the Enrollee and Provider sections of the website.

6.6.9

On a monthly basis, the Contractor shall submit to ASES any changes and edits to the Provider Directory. Such changes shall be submitted electronically in the format specified by ASES.

6.7

Enrollee Monthly Utilization Report

6.7.1

The Contractor shall send a quarterly utilization report to Enrollees in accordance with Act 114 of July 30, 2010.

6.8

Enrollee Identification (ID) Card

6.8.1

The Contractor shall furnish to all new Enrollees an Enrollee ID card made of durable plastic material. The card shall be mailed to the Enrollee via surface mail within five (5) Business Days of sending the notice of Enrollment referenced in Section 5.2.5.3.

6.8.2

The Enrollee ID Card must, at a minimum, include the following information:

6.8.2.1

The “GHP” logo;

Page 64 of 324

6.8.2.2

The Enrollee’s name;

6.8.2.3

A designation of the Enrollee as a Medicaid Eligible, a CHIP Eligible, or an Other Eligible Person;

6.8.2.4

The Enrollee’s Medicaid or CHIP identification number, if applicable;

6.8.2.5

The Enrollee’s Plan group number, when applicable;

6.8.2.6

The Effective Date of Enrollment in the GHP;

6.8.2.7

The Master Patient Identifier, which shall not be altered in format or content by the Contractor;

6.8.2.8

The applicable Co-Payment levels for various services outside the Enrollee’s PPN and the assurance that no Co-Payment will be charged for a Medicaid Eligible Person and for CHIP children under twenty-one (21) years under any circumstances;

6.8.2.9

The PCP’s and the PMG’s names;

6.8.2.10

The name and telephone number(s) of the Contractor;

6.8.2.11

The twenty-four (24) hour, seven (7) day a Week toll-free GHP Service Line Medical Advice Service phone number;

6.8.2.12

A notice that the Enrollee ID Card may under no circumstances be used by a person other than the identified Enrollee; and

6.8.2.13

Instructions to obtain Emergency Services

6.8.3

The Contractor shall reissue the Enrollee ID Card in the following situations and timeframes:

6.8.3.1

Within ten (10) Calendar Days of notice if an Enrollee reports a lost, stolen, or damaged ID Card and requests a replacement;

6.8.3.2

Within ten (10) Calendar Days of notice if an Enrollee reports a name change;

6.8.3.3

Within twenty (20) Calendar Days of the effective date of a change of PMG or change or addition of a PCP, as provided in Section 5.4.

6.8.4

The Contractor may charge a fee of five dollars ($5.00) to replace lost, damaged, or stolen Enrollee ID Cards; provided, however, that the Contractor may not charge a replacement fee because of a name change or change of PMG or PCP, and that the Contractor may not charge a replacement fee in any circumstance for Medicaid and CHIP Eligibles.

Page 65 of 324

6.8.5

The Contractor shall submit a front and back sample Enrollee ID Card to ASES for review and prior written approval according to the timeframe specified in Attachment 12 to this Contract.

6.8.6

The Contractor must require an Enrollee to surrender his or her ID Card in each of the following events:

6.8.6.1

The Enrollee disenrolls from the GHP;

6.8.6.2

The Enrollee requests a change to his or her PCP or PMG, and is therefore issued a new Enrollee ID Card; or

6.8.6.3

The Enrollee requests a new ID card because his or her existing card is damaged.

6.9

GHP Service Line (Toll Free Telephone Service)

6.9.1

The Contractor shall operate a toll-free telephone number, “GHP Service Line” equipped with caller identification and automatic call distribution equipment capable of handling the high expected volume of calls. The GHP Service Line shall have two components:

6.9.1.1

An Information Service to respond to questions, concerns, inquiries, and Complaints regarding the GHP from the Enrollee, Enrollee’s family, or Enrollee’s Authorized Representative; and

6.9.1.2

A Medical Advice Service to advise Enrollees about how to resolve non-emergency medical or Behavioral Health concerns.

6.9.2

The Contractor shall establish, operate, monitor, and support an automated call distribution system for the GHP Service Line that supports, at a minimum:

6.9.2.1

Capacity to handle the high call volume;

6.9.2.2

A daily analysis of the quantity, length, and types of calls received;

6.9.2.3

A daily analysis of the amount of time it takes to answer the call, including Blocked and Abandoned Calls;

6.9.2.4

The ability to measure average waiting time; and

6.9.2.5

The ability to monitor calls from a remote location by a Third Party, such as ASES.

6.9.3

Hours of Operation

6.9.3.1

The Information Service shall be fully staffed between the hours of 7:00 a.m. and 7:00 p.m. (Atlantic Time). Monday through Friday, excluding Puerto Rico holidays. The Contractor shall have an automated system available between the hours of 7:00 p.m. and 7:00 a.m. (Atlantic Time) Monday through Friday and during all hours on weekends and holidays. This automated system must provide callers with operating instructions on what to do in case of an emergency and shall include, at a minimum, a voice mailbox for callers to leave messages. The Contractor shall ensure that the voice mailbox has the required capacity to receive all messages. A Contractor’s representative shall reply to one hundred percent (100%) of messages by the next Business Day.

Page 66 of 324

6.9.3.2

The Medical Advice Service shall be fully staffed and available to Enrollees twenty-four (24) hours per day, seven (7) days per Week.

6.9.4

Staffing

6.9.4.1

The Contractor shall be responsible for the required staffing of the GHP Service Line with individuals who are able to communicate effectively with GHP Enrollees.

6.9.4.2

The Contractor shall make key staff responsible for operating the GHP Service Line available to meet with ASES staff on a regular basis, as requested by ASES, to review reports and all other obligations under the Contract relating to GHP Service Line.

6.9.4.3

All staff shall be hired and must complete a training program at least fifteen (15) Calendar Days before the staff provides GHP Service Line services. Such training program shall include, but will not be limited to, systems, policies and procedures, and telephone scripts.

6.9.4.4

For the Information Service, the Contractor shall ensure that Call Center attendants receive the necessary training to respond to Enrollee questions, concerns, inquiries, and Complaints from the Enrollee or the Enrollee’s family relating to this Contract regarding topics, including but not limited to Covered Services (both physical and Behavioral Health), Grievances and Appeals, the Provider Network, and Enrollment and Disenrollment.

6.9.4.5

For the Medical Advice Service, the Contractor shall ensure that Call Center attendants are registered nurses with the necessary training to advise Enrollees about appropriate steps they should take to resolve a physical or Behavioral Health complaint or concern.

6.9.4.6

The Contractor shall ensure that GHP Service Line Call Center staff is trained to identify Behavioral Health concerns and, where appropriate, to transfer Enrollee callers to the appropriate Call Center representative for assistance.

Page 67 of 324

6.9.4.7

The Contractor shall ensure that GHP Service Line Call Center staff is trained to identify situations in which an Enrollee may need services that are offered through the Department of Health rather than through the GHP, and GHP Service Line staff shall provide the Enrollee with Information on where to access these services.

6.9.4.8

The Contractor shall ensure that GHP Service Line Call Center staff is trained to provide to Medicaid and CHIP Eligible Enrollees Information on how to access local NEMT resources to enable an Enrollee without available transportation to receive Medically Necessary Services.

6.9.4.9

The Contractor shall ensure that GHP Service Line Call Center staff are trained to process and fulfill requests by Enrollees and Potential Enrollees to receive, by surface mail, the Enrollee Handbook, the Provider Directory, or the Provider Guidelines. The Contractor shall fulfill such requests by mailing the requested document within five (5) Business Days of the request.

6.9.5

The Contractor may provide the Information Service and the Medical Advice Service as separate phone lines with a “Warm Transfer” capability, or as separate dialing options within one (1) phone line.

6.9.6

The Contractor shall have the capability of making out-bound calls.

6.9.7

The GHP Service Line shall be equipped to handle calls in Spanish and English, as well as, through a Telecommunication Device for the Deaf (TDD) for calls from Enrollees who are hearing-impaired. For callers who speak neither English nor Spanish, the Contractor shall provide interpreter services free of charge to Enrollees. The Contractor shall not permit Enrollees’ family members, especially minor children, or friends, to provide oral interpreter services, unless specifically requested by the Enrollee.

6.9.8

All calls shall be recorded, identifying the date and time, the type of call, the reason for the call, and the resolution of the call.

6.9.9

The Contractor shall generate a call identification number for each phone call made by an Enrollee to the Medical Advice Service. Enrollees who use this service to seek advice on their health condition before visiting the emergency room will not be responsible for any Co-Payment otherwise imposed for emergency room visits (as provided under Section 7.11.4) outside the Enrollee’s PPN, provided that the Enrollee presents his or her GHP Service Line call identification number at the emergency room. Under no circumstance will a Co-Payment be imposed on a Medicaid or CHIP Eligible Enrollee for treatment of an Emergency Medical Condition or Psychiatric Emergency (regardless of whether the Enrollee uses the Medical Advice Service). The Medical Advice Service does not apply to emergency services obtained outside of Puerto Rico; however, Enrollees should be able to access both the Medical Advice Service and the Information Service lines from the US.

Page 68 of 324

6.9.10

The Contractor shall develop GHP Service Line policies and procedures, including staffing, training, hours of operation, Access and response standards, transfers/Referrals, monitoring of calls via recording and other means, and compliance with other performance standards to be prior approved in writing by ASES.

6.9.11

The Contractor shall develop GHP Service Line quality criteria and protocols. These protocols shall, at a minimum:

6.9.11.1

Measure and monitor the accuracy of responses and phone etiquette in GHP Service Line (including through recording phone calls) and take corrective action as necessary to ensure the accuracy of responses and appropriate phone etiquette by staff;

6.9.11.2

Provide for quality calibration sessions between the Contractor’s staff and ASES;

6.9.11.3

Require that, on a monthly basis, the average speed of answer is at least eighty percent (80%) of calls answered within thirty (30) seconds;

6.9.11.4

Require that, on a monthly basis, the Blocked Call rate does not exceed three percent (3%); and

6.9.11.5

Require that, on a monthly basis, the rate of Abandoned Calls does not exceed five percent (5%).

6.9.12

The above standards serve as minimum requirements for each GHP Service Line service. The Contractor may elect to establish more rigorous performance standards. The Contractor may elect to establish different quality criteria for the Medical Advice Service than for the Information Service; provided, however, the standards governing the Medical Advice Service are stricter than the standards for the Information Service.

6.9.13

The Contractor must develop and implement a GHP Service Line Outreach Program to educate Enrollees about the GHP Service Line service and to encourage its use. The Outreach program shall include, at a minimum, the following components:

6.9.13.1

A section on GHP Service Line in the Enrollee Handbook;

6.9.13.2

Contact information for GHP Service Line on the Enrollee ID Card and on the Contractor’s website; and

Page 69 of 324

6.9.13.3

Informational flyers on the GHP Service Line to be placed in the offices of the Contractor and the Network Providers.

6.9.14

All documents and communication materials included in this Outreach program must explain that (i) by using the Medical Advice Service before visiting the emergency room, and presenting their call identification number at the emergency room, Enrollees can avoid any emergency room Co-Payments otherwise applicable under Section 7.11.4 of this Contract for services outside the PPN; and (ii) in no event will Co-Payments be imposed for services to treat an Emergency Medical Condition or Psychiatric Emergency for Medicaid or CHIP Eligibles. All written materials included in the Outreach Program must be written at a fourth (4 ^th ) grade reading level and must be available in Spanish and English.

6.9.15

The Contractor shall prepare scripts addressing the questions expected to arise most often for both the Information Service and the Medical Advice Service. The Contractor shall submit these scripts to ASES for review and prior written approval according to the timeframe specified in Attachment 12 to this Contract. It is the responsibility of the Contractor to maintain and update these scripts and to ensure that they are developed at the fourth (4 ^th ) grade reading level. The Contractor shall submit revisions to the script to ASES for written approval prior to use.

6.9.16

The Contractor shall submit the following written materials referred to in this Section 6.8 to ASES for review and prior written approval according to the timeframe specified in Attachment 12 to this Contract:

6.9.16.1

GHP Service Line policies and procedures;

6.9.16.2

GHP Service Line quality criteria and protocols;

6.9.16.3

GHP Service Line Outreach Program; and

6.9.16.4

Scripts and training materials for GHP Service Line Call Center employees.

6.10

Internet Presence/Website

6.10.1

The Contractor shall provide on its website general and up-to-date information about the GHP and about the Contractor’s Plan, including the Provider Network, customer services, GHP Service Line, and its Grievance and Appeal System. The Enrollee Handbook and the Provider Directory shall be available on the website. All information must be written at a fourth (4 ^th ) grade level and must be available in Spanish and English.

6.10.2

The Contractor shall maintain an Enrollee portal that allows Enrollees to access a searchable Provider Directory that shall be updated within three (3) Business Days of any change to the Provider Network.

Page 70 of 324

6.10.3

The website must have the capability for Enrollees to submit questions and comments to the Contractor and receive responses. The Contractor shall reply to Enrollee questions within two (2) Business Days.

6.10.4

The website must comply with the Marketing policies and procedures and with requirements for written materials described in Sections 6.2 and 6.3 of this Contract and must be consistent with applicable Puerto Rico and Federal laws.

6.10.5

The Contractor shall submit website screenshots, active website URLs, and provide ASES access to website development portals upon request, for review and approval of information on the website relating to the GHP Program according to the timeframe specified in Attachment 12 to this Contract.

6.10.6

The Contractor’s website shall provide secured online access to the Enrollee’s historical and current information.

6.10.7

The Contractor’s website shall prominently feature a link to the ASES website, www.ases.pr.gov.

6.10.8

Any Enrollee Information required under 42 CFR 438.10, including the Enrollee Handbook, Provider Directory, FMC and LME, and Enrollee notices, may not be provided electronically or on the Contractor’s website unless such Information (1) is readily accessible, (2) is placed on the Contractor’s website in a prominent location, (3) is provided in a form that can be electronically retained and printed, and (4) includes notice to the Enrollee that the Information is available in paper form without charge and can be provided upon request within five (5) Business Days.

6.10.9

The Enrollee Handbook, Provider Directory, FMC and LME may be provided electronically instead of paper form if all required elements of Section 6.10.8 are satisfied. However, the Contractor must provide the Enrollee Handbook, Provider Directory, and FMC and LME in paper form upon request by the Enrollee at no charge and within five (5) Business Days. If the Enrollee Handbook is provided by e-mail, the Contractor must first obtain the Enrollee’s agreement to receive the Enrollee Handbook by e-mail. If the Enrollee Handbook is posted on the Contractor’s website, the Contractor must first advise the Enrollee in paper or electronic form that the information is available on the internet, and must include the applicable website address, provided that Enrollees with disabilities who cannot access this information online are provided auxiliary aids and services upon request and at no cost.

6.11

Cultural Competency

6.11.1

In accordance with 42 CFR 438.206, the Contractor shall have a comprehensive written Cultural Competency plan describing how the Contractor will ensure that services are provided in a culturally competent manner to all Enrollees. The Cultural Competency plan must describe how the Providers, individuals, and systems within the Contractor’s Plan will effectively provide services to people of all diverse cultural and ethnic backgrounds, disabilities, and regardless of gender, sexual orientation, gender identity, or religion in a manner that recognizes values, affirms, and respects the worth of the individual Enrollees and protects and preserves the dignity of each individual.

Page 71 of 324

6.11.2

The Contractor shall submit the Cultural Competency plan to ASES for review and approval according to the timeframe specified in Attachment 12 to this Contract.

6.11.3

The Contractor may distribute a summary of the Cultural Competency plan, rather than the entire document, to Providers if the summary includes Information on how the Provider may access the full Cultural Competency plan on the Contractor’s website. This summary shall also detail how the Provider can request a hard copy from the Contractor at no charge to the Provider.

6.12

Interpreter Services

6.12.1

The Contractor shall provide oral interpreter services to any Enrollee or Potential Enrollee who speaks any language other than English or Spanish as his or her primary language, regardless of whether the Enrollee or Potential Enrollee speaks a language that meets the threshold of a Prevalent Non-English Language. This also includes the use of auxiliary aids and services such as TTY/TDD and the use of American Sign Language. The Contractor is required to notify its Enrollees of the availability of oral interpretation services and to inform them of how to access oral interpretation services. There shall be no charge to an Enrollee or Potential Enrollee for interpreter services or other auxiliary aids.

6.13

Enrollment Outreach

6.13.1

The Contractor shall participate in any Enrollment Outreach activities as prescribed by ASES or the Puerto Rico Medicaid Program.

6.14

Special Enrollee Information Requirements for Dual Eligible Beneficiaries

6.14.1

The Contractor shall inform a Potential Enrollee who is a Dual Eligible Beneficiary:

6.14.1.1

That the Dual Eligible Beneficiary is eligible for services under the GHP with the limits stated in Section 7.12 of this Contract;

6.14.1.2

That the GHP Plan will cover Medicare Part B Deductibles and co-insurance subject to the requirements in Section 23.5.1, but not Medicare Part A Deductibles;

6.14.1.3

That the Dual Eligible Beneficiary may not be simultaneously enrolled in the GHP and in a Medicare Platino plan, for the reason that the Platino plan already includes GHP Benefits; and

Page 72 of 324

6.14.1.4

That as an Enrollee in the Contractor’s Plan, the Dual Eligible Beneficiary may access Covered Services only through the PMG, not through the Medicare Provider List.

6.15

Marketing

6.15.1

For purposes of this section only, “Contractor” shall also include Contractor’s Subcontractors and Network Providers to the extent that such Subcontractors and Network Providers are conducting Marketing activities.

6.15.2

Prohibited Activities . The Contractor is prohibited from engaging in the following activities:

6.15.2.1

Directly or indirectly engaging in door-to-door, telephone, e-mail, texting or other Cold-Call Marketing activities;

6.15.2.2

Offering any favors, inducements or gifts, promotions, or other insurance products that are designed to induce Enrollment in the Contractor’s Plan;

6.15.2.3

Distributing plans and materials that contain statements that ASES determines are inaccurate, false, or misleading. Statements considered false or misleading include, but are not limited to, any assertion or statement (whether written or oral) that the Contractor’s Plan is endorsed by the Federal Government or Government, or similar entity;

6.15.2.4

Distributing materials that, according to ASES, mislead or falsely describe the Contractor’s Provider Network, the participation or availability of Network Providers, the qualifications and skills of Network Providers (including their bilingual skills); or the hours and location of network services;

6.15.2.5

Seeking to influence Enrollment in conjunction with the sale or offering of any private insurance; and

6.15.2.6

Asserting or stating in writing or verbally that the Enrollee or Potential Enrollee must enroll in the Contractor’s Plan to obtain or retain Benefits.

6.15.2.7

Marketing Contractor’s Plan to Enrollees or Potential Enrollees prior to October 1, 2018.

6.15.3

Allowable Activities . The Contractor shall be permitted to perform the following Marketing activities:

Page 73 of 324

6.15.3.1

Distribute general information through mass media (i.e., newspapers, magazines and other periodicals, radio, television, the Internet, public transportation advertising, and other media outlets);

6.15.3.2

Make telephone calls, mailings and home visits only to Enrollees currently enrolled in the Contractor’s plan, for the sole purpose of educating them about services offered by or available through the Contractor;

6.15.3.3

Distribute brochures and display posters at Provider offices that inform patients that the Provider is part of the GHP Provider Network; and

6.15.3.4

Attend activities that benefit the entire community, such as health fairs or other health education and promotional activities.

6.15.4

If the Contractor performs an allowable activity, the Contractor must conduct that activity Island-wide.

6.15.5

All materials shall be in compliance with the informational requirements in 42 CFR 438.10.

6.15.6

ASES Approval of Marketing Materials

6.15.6.1

The Contractor shall submit a detailed description of its Marketing plan and copies of all Marketing Materials (written and oral) that it or its Subcontractors plan to distribute to ASES for review and prior written approval according to the timeframe specified in Attachment 12 to this Contract. This requirement includes, but is not limited to posters, brochures, websites, and any materials that contain statements regarding the Benefit package and Provider Network-related materials. Neither the Contractor nor its Subcontractors shall distribute any Marketing Materials without prior written approval from ASES.

6.15.6.1.1

The Contractor may begin Marketing activities using the materials and marketing plan approved by ASES beginning on October 1, 2018.

6.15.6.2

The Contractor may not initiate Marketing or distribute Marketing Materials of its GHP Plan until ASES has granted its written authorization for all Contractors to initiate Marketing at the same time.

6.15.6.3

The Contractor shall submit any changes to previously approved Marketing Materials and receive written approval from ASES of the changes before distribution.

Page 74 of 324

6.15.6.4

The Contractor must comply with ASES’ Normative Letter 18-0807, and any superseding Normative Letters, related to the review and approval of the Contractors Marketing Materials included in Attachment 13 to this Contract.

6.15.7

Provider Marketing Materials

6.15.7.1

The Contractor is responsible for ensuring that not only its Marketing activities, but also the Marketing activities of its Subcontractors and Providers, meet the requirements of this Section 6.14.

6.15.7.2

The Contractor shall collect from its Providers any Marketing Materials they intend to distribute and submit these to ASES for review and written approval prior to distribution.

6.15.7.3

The Contractor shall provide for equitable distribution of all Marketing Materials without bias toward or against any group.

ARTICLE 7

COVERED SERVICES AND BENEFITS

7.1

Requirement to Provide Covered Services

7.1.1

The Contractor shall at a minimum provide Medically Necessary Covered Services to Enrollees as of the Effective Date of Enrollment (including the retroactive period specified in Section 5.1.3.1) pursuant to the program requirements of the GHP, and the Puerto Rico Medicaid State Plan and CHIP Plan. The Contractor shall not impose any other exclusions, limitations, or restrictions on any Covered Service, and shall not arbitrarily deny or reduce the amount, duration, or scope of a Covered Service solely because of the diagnosis, type of illness, or condition.

7.1.1.1

In accordance with Section 2702 of the PPACA and 42 CFR 438.3(g), the Contractor must have mechanisms in place to prevent payment for the following Provider preventable conditions and must require all providers to report on such Provider preventable conditions associated with Claims for payment or Enrollee treatments for which payment would otherwise be made. The Contractor must report all identified Provider preventable conditions to ASES as follows:

7.1.1.1.1

All hospital acquired conditions as identified by Medicare other than deep vein thrombosis (DVT)/Pulmonary Embolism (PE) following total knee replacement or hip replacement surgery in pediatric and obstetric patients for inpatient hospital services; and

Page 75 of 324

7.1.1.1.2

Any incorrect surgical or other invasive procedure performed on a patient; any surgical or other invasive procedure performed on the incorrect body part; or any surgical or other invasive procedure performed on the incorrect patient for inpatient and non-institutional services.

7.1.2

The Contractor shall not deny Covered Services based on pre-existing conditions, the individual’s genetic Information, or waiting periods.

7.1.3

The Contractor shall not be required to provide a Covered Service to a person who is not an Eligible Person.

7.1.4

The Contractor shall not be required to pay for a Covered Service if:

7.1.4.1

The Enrollee paid the Provider for the service. This rule does not apply in circumstances where a Medicaid or CHIP Eligible Enrollee incurs out-of-pocket expenses for Emergency Services provided in the other USA jurisdictions. In such a case, the expenses will be reimbursed under the GHP; or

7.1.4.2

The service was provided by a person or entity that does not meet the definition of a Network Provider (with the exception of Medical Emergencies and cases where the service was Prior Authorized by the Contractor).

7.1.5

The Contractor shall make a best effort to conduct an initial screening of each Enrollee within ninety (90) days of the Effective Date of Enrollment for all new Enrollees, including subsequent attempts if the initial attempt to contact the Enrollee is unsuccessful.

7.2

Medical Necessity

7.2.1

Based on generally accepted medical practices specific to the medical or Behavioral Health condition of the Enrollee at the time of treatment, Medically Necessary Services are those that relate to (i) the prevention, diagnosis, and treatment of health impairments; (ii) the ability to achieve age-appropriate growth and development; or (iii) the ability to attain, maintain, or regain functional capacity. The scope of Medically Necessary Services must not be any more restrictive than that of Puerto Rico’s Medicaid program. Additionally, Medically Necessary services must be:

7.2.1.1

Appropriate and consistent with the diagnosis of the treating Provider and the omission of which could adversely affect the eligible Enrollee’s medical condition;

7.2.1.2

Compatible with the standards of acceptable medical practice in the medical community;

Page 76 of 324

7.2.1.3

Provided in a safe, appropriate, and cost-effective setting given the nature of the diagnosis and the severity of the symptoms;

7.2.1.4

Not provided solely for the convenience of the Enrollee or the convenience of the Provider or hospital; and

7.2.1.5

Not primarily custodial care (for example, foster care).

7.2.2

In order for a service to be Medically Necessary, there must be no other effective and more conservative or substantially less costly treatment, service, or setting available.

7.3

Experimental or Cosmetic Procedures

7.3.1

In no instance shall the Contractor cover experimental or cosmetic procedures, except as required by the Puerto Rico Patient’s Bill of Rights Act or any other Federal or Puerto Rico law or regulation. Breast reconstruction after a mastectomy and surgical procedures that are determined to be Medically Necessary to treat morbid obesity shall not be regarded as cosmetic procedures.

7.4

Covered Services and Administrative Functions

7.4.1

Benefits under the GHP are comprised of four categories: (i) Basic and Behavioral Health Coverage, (ii) dental services, (iii) Special Coverage, (iv) High Cost High Needs Program, and (v) Administrative Functions. The scope of these items is covered in Sections 7.5 – 7.8, in the order listed.

7.4.2

The Contractor may cover services or settings that are in lieu of those covered under the State plan if ASES has approved the in lieu of service or setting as a medically appropriate and cost effective substitute. If approved by ASES, the Contractor may offer the in lieu of service or setting to Enrollees, as appropriate, but shall not require an Enrollee to use an in lieu of service or setting. The utilization and actual cost of approved in lieu of services or settings will be taken into account in developing the component of the PMPM Payment that represents the covered Medicaid State Plan services or settings, unless a statute or regulation explicitly requires otherwise. Approved in lieu of services or settings will be communicated to Contractors via a Normative Letter or other standard method of communication of formal GHP policy.

7.5

Basic and Behavioral Health Coverage

7.5.1

Basic and Behavioral Health Coverage is available to all GHP Enrollees, except as provided in the table below. Basic Coverage includes the following categories:

Page 77 of 324

	BASIC COVERAGE SERVICES		GHP ELIGIBILITY GROUPS COVERED
	Preventive Services		All
	Diagnostic Test Services		All
	Outpatient Rehabilitation Services		All
	Medical and Surgical Services		All
	Emergency Transportation Services		All (Services outside Puerto Rico available only for Medicaid and CHIP Eligibles)
	Maternity and Pre-Natal Services		All
	Emergency Services		All (Services outside Puerto Rico available only for Medicaid and CHIP Eligibles)
	Hospitalization Services		All
	Behavioral Health Services		All
	Pharmacy Services		All (Note: Claims processing and adjudication Services provided by PBM; not covered under this Contract.)

7.5.2

Exclusions from Basic Coverage

7.5.2.1

The following services are excluded from all Basic Coverage. In addition, exclusions specific to each category of Covered Services are noted in Sections 7.5.3 – 7.5.12 below.

7.5.2.1.1

Expenses for personal comfort materials or services, such as, telephone use, television, or toiletries;

7.5.2.1.2

Services rendered by close family relatives (parents, children, siblings, grandparents, grandchildren, or spouses);

7.5.2.1.3

Weight control treatment (obesity or weight gain) for aesthetic reasons. As noted, procedures determined to be Medically Necessary to address morbid obesity shall not be excluded;

7.5.2.1.4

Sports medicine, music therapy, and natural medicine;

7.5.2.1.5

Services, diagnostic testing, or treatment ordered or rendered by naturopaths, naturists, or iridologists;

7.5.2.1.6

Health Certificates, except as provided in Section 7.5.3.2.10 (Preventive Services);

Page 78 of 324

7.5.2.1.7

Epidural anesthesia services;

7.5.2.1.8

Educational tests or services;

7.5.2.1.9

Peritoneal dialysis or hemodialysis services (covered under Special Coverage, not Basic Coverage);

7.5.2.1.10

Home Health and Hospice care for Adults;

7.5.2.1.11

Services received outside the territorial limits of Puerto Rico, except as provided in Sections 7.5.7.11 (Emergency Transportation) and 7.5.9.3 (Emergency Services);

7.5.2.1.12

Expenses incurred for the treatment of conditions resulting from services not covered under the GHP (maintenance prescriptions and required clinical laboratories for the continuity of a stable health condition, as well as any emergencies which could alter the effects of the previous procedure, are covered);

7.5.2.1.13

Judicially ordered evaluations for legal purposes;

7.5.2.1.14

Travel expenses, even when ordered by the Primary Care Physician;

7.5.2.1.15

Psychological, psychometric, and psychiatric tests and evaluations to obtain employment or insurance, or for purposes of litigation;

7.5.2.1.16

Eyeglasses, contact lenses and hearing aids for Adults;

7.5.2.1.17

Acupuncture services;

7.5.2.1.18

Sex change procedures;

7.5.2.1.19

Organ and tissue transplants, except skin, bone and corneal transplants.; and

7.5.2.1.20

Treatment for infertility and/or related to conception by artificial means including tuboplasty, vasovasectomy, and any other procedure to restore the ability to procreate.

7.5.2.1.21

Mechanical respirators and ventilators with oxygen supplies are covered without limits as required by local law to Enrollees under age twenty-one (21). The Contractor must cooperate with ASES and DOH to provide any necessary information as directed by ASES. All Durable Medical Equipment (DME) is not covered; however, DME may be covered on a case-by-case basis under an exceptions process.

Page 79 of 324

7.5.3

Preventive Services

7.5.3.1

Well Baby Care. The Contractor shall provide the following Preventive Services as Covered Services under the Well Baby Care Program:

7.5.3.1.1

One (1) annual comprehensive evaluation by a certified Provider, which complements other services for children and young adults provided pursuant to the periodicity scheme of the American Academy of Pediatrics and Title XIX (EPSDT); and

7.5.3.1.2

Other services, as needed.

7.5.3.2

Other Preventive Services. The Contractor shall provide the following Preventive Services as Covered Services for all GHP Enrollees:

7.5.3.2.1

All immunizations shall be provided for Pediatric Enrollees, and those necessary according to age, gender, and health condition of the Enrollee, including but not limited to: influenza and pneumonia, and vaccines for children and adults with high risk conditions such as pulmonary, renal, diabetes and heart disease, among others.

7.5.3.2.1.1

The Puerto Rico Department of Health shall provide and pay for vaccines to Enrollees ages zero (0) and eighteen (18), excluding those in the State Population, through the Children’s Immunization Program. The Contractor shall cover the administration of the vaccines provided by the Puerto Rico Department of Health.

7.5.3.2.1.2

The Contractor shall provide and pay for the immunizations of Enrollees in the State Population ages zero (0) and eighteen (18), all Enrollees ages nineteen (19) to twenty (20), and those necessary according to age, gender and health condition of the Enrollee, including but not limited to influenza and pneumonia vaccines for Enrollees over sixty-five (65) years and adults with high risk conditions such as pulmonary, renal, diabetes, and heart disease, among others.

Page 80 of 324

7.5.3.2.1.3

The Contractor shall cover the administration of all the vaccines according to the fee schedule established by the Puerto Rico Health Department. The Contractor shall contract with immunization providers, duly certified by the Puerto Rico Department of Health, to provide immunization services.

7.5.3.2.1.4

The Contractor shall administer the immunizations without any charge or deductible.

7.5.3.2.2

Hearing exam, including hearing screening for newborns prior to their leaving the hospital nursery;

7.5.3.2.3

Evaluation and nutritional screening;

7.5.3.2.4

Medically Necessary laboratory exams and diagnostic tests, appropriate to the Enrollee’s age, sex, and health condition, including, but not limited to:

7.5.3.2.4.1

Prostate and gynecological cancer screening according to accepted medical practice, including Pap smears (for Enrollees over age eighteen (18)), mammograms (for Enrollees age forty (40) and over), and Prostate-Specific Antigen (PSA) tests when Medically Necessary; and

7.5.3.2.4.2

Sigmoidoscopy and colonoscopy for colon cancer detection in Adults age fifty (50) years and over, classified in risk groups according to accepted medical practice;

7.5.3.2.5

Nutritional, oral, and physical health education;

7.5.3.2.6

Reproductive health counseling and family planning . Enrollees shall be free to choose the method of family planning in accordance with 42 CFR 438.210(a)(4)(ii)(C). The Contractor shall cover the following family planning services:

7.5.3.2.6.1

Education and Counseling;

7.5.3.2.6.2

Pregnancy testing;

7.5.3.2.6.3

Infertility assessments;

Page 81 of 324

7.5.3.2.6.4

Sterilization services in accordance with 42 CFR 441.200, subpart F.

7.5.3.2.6.5

Laboratory services;

7.5.3.2.6.6

At least one of every class and category of FDA-approved contraceptive method as specified by ASES’s Normative Letter 15-1012 (Attachment 13);

7.5.3.2.6.7

At least one of every class of FDA-approved contraceptive medication as specified in ASES’s Normative Letter 15-1012 (Attachment 13 to this Contract);

7.5.3.2.6.8

Cost and insertion removal of non-oral products, such as long acting reversible contraceptives (LARC) as specified in ASES’s Normative Letter 15-1012 (Attachment 13 to this Contract); and

7.5.3.2.6.9

Other FDA-approved contraceptive medications or methods not covered by sections 7.5.3.2.6.6 or 7.5.3.2.6.7 of the Contract, when it is Medically Necessary and approved through a Prior Authorization or through an exception process and the prescribing Provider can demonstrate at least one of the following situations:

7.5.3.2.6.9.1

Contra-indication with drugs that are in the ASES’s Normative Letter 15-1012 (Attachment 13 to this Contract) that the Enrollee is already taking, and no other methods available in the ASES’s Normative Letter 15-1012 (Attachment 13 to this Contract) that can be used by the Enrollee;

7.5.3.2.6.9.2

History of adverse reaction by the Enrollee to the contraceptive methods covered as specified by ASES’s Normative Letter 15-1012 (Attachment 13 to this Contract);

7.5.3.2.6.9.3

History of adverse reaction by the Enrollee to the contraceptive medications covered as specified by ASES’s Normative Letter 15-1012 (Attachment 13 to this Contract);

Page 82 of 324

7.5.3.2.7

Syringes for home medicine administration, if deemed Medically Necessary;

7.5.3.2.8

Annual physical exam and follow-up for diabetic patients according to the Diabetic Patient Treatment Guide and Health Department protocols; and

7.5.3.2.9

Health Certificates are covered under the GHP, provided that cost sharing and/or deductibles applicable for necessary procedures and laboratory testing related to generating a Health Certificate will be the Enrollee’s responsibility. Such certificates shall include:

7.5.3.2.9.1

Venereal Disease Research Laboratory (“VDRL”) tests;

7.5.3.2.9.2

Tuberculosis (“TB”) tests; and

7.5.3.2.9.3

Any Certification for GHP Enrollees related to eligibility for the Medicaid Program (provided at no charge).

7.5.4

Diagnostic Test Services

7.5.4.1

The Contractor shall provide the following diagnostic test services as Covered Services:

7.5.4.1.1

Diagnostic and testing services for Enrollees under age twenty-one (21) required by EPSDT, as defined in Section 1905(r) of the Social Security Act;

7.5.4.1.2

Clinical labs, including but not limited to, any laboratory order for disease diagnostic purposes, even if the final diagnosis is a condition or disease whose treatment is not a Covered Service;

7.5.4.1.3

Hi-tech Labs;

7.5.4.1.4

X-Rays;

7.5.4.1.5

Electrocardiograms;

7.5.4.1.6

Radiation therapy (Prior Authorization required);

7.5.4.1.7

Pathology;

Page 83 of 324

7.5.4.1.8

Arterial gases and Pulmonary Function Test;

7.5.4.1.9

Electroencephalograms;

7.5.4.1.10

Diagnostic services for Enrollees who present learning disorder symptoms; and

7.5.4.1.11

Services related to a diagnostic code included in the Diagnostic and Statistical Manual of Mental Disorders (“DSM IV or DSM V”).

7.5.4.2

The following shall not be considered diagnostic test services covered under the GHP:

7.5.4.2.1

Polysomnography studies; and

7.5.4.2.2

Clinical labs processed outside of Puerto Rico.

7.5.5

Outpatient Rehabilitation Services

7.5.5.1

The Contractor shall provide the following outpatient rehabilitation services as Covered Services:

7.5.5.1.1

Medically Necessary outpatient rehabilitation services for Enrollees under age twenty-one (21), as required by EPSDT, Section 1905(r) of the Social Security Act;

7.5.5.1.2

Physical therapy (limited to a maximum of fifteen (15) treatments per Enrollee condition per year, unless Prior Authorization of an additional fifteen (15) treatments is indicated by an orthopedist or physiatrist or chiropractor);

7.5.5.1.3

Occupational therapy, without limitations; and

7.5.5.1.4

Speech therapy, without limitations.

7.5.6

Medical and Surgical Services

7.5.6.1

The Contractor shall provide the following medical and surgical services as Covered Services:

7.5.6.1.1

Early and Periodic Screening, Diagnostic and Treatment (“EPSDT”) services, as defined in Section 1905(r) of the Social Security Act;

7.5.6.1.2

Primary Care Physician visits, including nursing services;

7.5.6.1.3

Specialist treatment, once referred by the selected PCP if outside of the Enrollee’s PPN;

Page 84 of 324

7.5.6.1.4

Sub-specialist treatment, once referred by the selected PCP if outside of the Enrollee’s PPN;

7.5.6.1.5

Physician home visits when Medically Necessary;

7.5.6.1.6

Respiratory therapy, without limitations;

7.5.6.1.7

Anesthesia services (except for epidural anesthesia);

7.5.6.1.8

Radiology services;

7.5.6.1.9

Pathology services;

7.5.6.1.10

Surgery;

7.5.6.1.11

Outpatient surgery facility services;

7.5.6.1.12

Nursing services;

7.5.6.1.13

Voluntary sterilization of men and women of legal age and sound mind, provided that they have been previously informed about the medical procedure’s implications, and that there is evidence of Enrollee’s written consent by completing the Sterilization Consent Form included as Attachment 22 to this Contract;

7.5.6.1.14

Prosthetics, including the supply of all extremities of the human body including therapeutic ocular prosthetics, segmental instrument tray, and spine fusion in scoliosis and vertebral surgery;

7.5.6.1.15

Ostomy equipment for outpatient-level ostomized patients;

7.5.6.1.16

Transfusion of blood and blood plasma services, without limitations, including the following:

7.5.6.1.16.1

Antihemophilic recombinant factor VIII;

7.5.6.1.16.2

Antihemophilic recombinant factor IX;

7.5.6.1.16.3

Anti-inhibitor coagulant complex (Feiba); and

7.5.6.1.16.4

Antihemophilic factor VIII, human/Von Willebrand factor complex.

7.5.6.1.17

Services to patients with Level 1 or Level 2 of chronic renal disease (Levels 3 to 5 are included in Special Coverage in Section 7.7).

Page 85 of 324

7.5.6.1.17.1

Chronic renal disease Levels 1 and 2 are defined as follows:

7.5.6.1.17.1.1

Level 1. GFR (Glomerular Filtration – ml/min. per 1.73m² per corporal area surface) over 90; slight damage when protein is present in the urine.

7.5.6.1.17.1.2

Level 2. GFR between 60 and 89, a slight decrease in kidney function.

7.5.6.1.17.2

When GFR decreases to under 60 ml/min per 1.73 m², the Enrollee must be referred to a nephrologist for proper management. The Enrollee will be registered for Special Coverage.

7.5.6.1.18

Skin, bone and corneal transplants.

7.5.6.2

While cosmetic procedures shall be excluded from Covered Services, breast reconstruction after a mastectomy and surgical procedures Medically Necessary to treat morbid obesity shall not be considered to be cosmetic procedures.

7.5.6.3

Mechanical respirators and ventilators with oxygen supplies are covered without limits as required by local law to Enrollees under age twenty-one (21). All Durable Medical Equipment (DME) is not covered; however, DME may be covered on a case-by-case basis under an exceptions process.

7.5.6.4

Abortions are covered in the following instances: (i) life of the mother would be in danger if the fetus is carried to term; (ii) when the pregnancy is a result of rape or incest; and (iii) severe and long lasting damage would be caused to the mother if the pregnancy is carried to term, as certified by a physician.

7.5.7

Emergency Transportation Services

7.5.7.1

The Contractor shall provide Emergency Transportation Services, including but not limited to, maritime and ground transportation, in emergency situations as Covered Services.

7.5.7.2

Emergency transportation services shall be available twenty-four (24) hours a day, seven (7) days per Week throughout Puerto Rico.

7.5.7.3

Emergency transportation services do not require Prior Authorization.

Page 86 of 324

7.5.7.4

The Contractor shall ensure that adequate emergency transportation is available to transport any Enrollees experiencing an Emergency Medical Conditions or a Psychiatric Emergency, or whose conditions require emergency transportation because of their geographical location.

7.5.7.5

The Contractor may not impose limits on what constitutes an Emergency Medical Condition or a Psychiatric Emergency on the basis of lists of diagnoses or symptoms.

7.5.7.6

Aerial emergency transportation services are provided and paid for by the Government of Puerto Rico under a separate contract. The Contractor shall coordinate the provision of aerial emergency transportation on behalf of its Enrollees when Medically Necessary utilizing the Provider designated by the Government of Puerto Rico.

7.5.7.7

The Contractor shall bear the expenses of providing emergency transportation and shall adhere to Puerto Rico laws and regulations concerning emergency transportation, including applicable fees as established by the Public Service Commission of the Government of Puerto Rico (CSP for its acronym in Spanish).

7.5.7.8

The Contractor shall provide Category II and Category III Ambulance Services pursuant to Regulation No. 6737 of the Public Service Commission.

7.5.7.8.1

Category II Ambulances are Ambulances utilized for the transportation of ill, injured, hurt, and disabled patients equipped with the specifications set by the Department of Heath of Puerto Rico. Fees paid for Type III ambulances are set by Provision 57.37 of the Public Service Commission.

7.5.7.8.2

Category III Ambulances must comply with all the requirements of Category II Ambulances, have advanced stabilization equipment and are specially designed and equipped as established from time to time by the Ambulance Certification Office of the Department of Health of Puerto Rico.

7.5.7.9

The Contractor may not retroactively deny a Claim for emergency transportation services because the Enrollee’s condition, which at the time of service appeared to be an Emergency Medical Condition or a Psychiatric Emergency under the prudent layperson standard, was ultimately determined to be a non-emergency.

7.5.7.10

In any case in which an Enrollee is transported by ambulance to a facility that is not a Network Provider, and, after being stabilized, is transported by ambulance to a facility that is a Network Provider, all emergency transportation costs, provided that they are justified by prudent layperson standards, will be borne by the Contractor.

Page 87 of 324

7.5.7.11

The Contractor shall be responsible for timely payment for emergency transportation services in the other USA jurisdictions for Enrollees who are Medicaid or CHIP Eligibles, if the emergency transportation is associated with an Emergency Service in the other USA jurisdictions covered under Section 7.5.9.3.1.2 of this Contract. If, in an extenuating circumstance, a Medicaid or CHIP Eligible Enrollee incurs out-of-pocket expenses for emergency transportation services provided in the other USA jurisdictions, the Contractor shall reimburse the Enrollee for such expenses in a timely manner, and the reimbursement shall be considered a Covered Service.

7.5.7.12

Emergency transportation services will be subject to periodic reviews and/or audits by applicable governmental agencies and ASES to ensure quality of services.

7.5.8

Maternity and Pre-Natal Services

7.5.8.1

The Contractor shall provide the following maternity and pre-natal services as Covered Services:

7.5.8.1.1

Pregnancy testing;

7.5.8.1.2

Medical services, during pregnancy and post-partum;

7.5.8.1.3

Physician and nurse obstetrical services during vaginal and caesarean section deliveries, and services to address any complication that arises during the delivery;

7.5.8.1.4

Treatment of conditions attributable to the pregnancy or delivery, when medically recommended;

7.5.8.1.5

Hospitalization for a period of at least forty-eight (48) hours in cases of vaginal delivery, and at least ninety-six hours (96) in cases of caesarean section;

7.5.8.1.6

Anesthesia, excluding epidural;

7.5.8.1.7

Incubator use, without limitations;

7.5.8.1.8

Fetal monitoring services, during hospitalization only;

7.5.8.1.9

Nursery room routine care for newborns;

7.5.8.1.10

Circumcision and dilatation services for newborns;

Page 88 of 324

7.5.8.1.11

Transportation of newborns to tertiary facilities when necessary;

7.5.8.1.12

Pediatrician assistance during delivery; and

7.5.8.1.13

Delivery services provided in free-standing birth centers.

7.5.8.2

The following are excluded from maternity and pre-natal Covered Services:

7.5.8.2.1

Outpatient use of fetal monitor;

7.5.8.2.2

Treatment services for infertility and/or related to conception by artificial means;

7.5.8.2.3

Services, treatments, or hospitalizations as a result of a provoked non-therapeutic abortion or associated complications are not covered. The following are considered to be provoked abortions:

7.5.8.2.3.1

Dilatation and curettage (CPT Code 59840);

7.5.8.2.3.2

Dilatation and expulsion (CPT Code 59841);

7.5.8.2.3.3

Intra-amniotic injection (CPT Codes 59850, 59851, 59852);

7.5.8.2.3.4

One or more vaginal suppositories (e.g., Prostaglandin) with or without cervical dilatation (e.g., Laminar), including hospital admission and visits, fetus birth, and secundines (CPT Code 59855);

7.5.8.2.3.5

One or more vaginal suppositories (e.g., Prostaglandin) with dilatation and curettage/or evacuation (CPT Code 59856); and

7.5.8.2.3.6

One or more vaginal suppositories (e.g., Prostaglandin) with hysterectomy (omitted medical expulsion) (CPT Code 59857); and

7.5.8.2.4

Differential diagnostic interventions up to the confirmation of pregnancy are not covered. Any procedure after the confirmation of pregnancy will be at the Contractor’s own risk.

7.5.8.3

The Contractor shall implement a pre-natal and maternal program, aimed at preventing complications during and after pregnancy, and advancing the objective of lowering the incidence of low birth weight and premature deliveries.

Page 89 of 324

7.5.8.3.1

The program shall include, at a minimum, the following components:

7.5.8.3.1.1

A pre-natal care card, used to document services utilized;

7.5.8.3.1.2

Counseling regarding HIV testing;

7.5.8.3.1.3

Pregnancy testing;

7.5.8.3.1.4

A RhoGAM injection for all pregnant women who have a negative Rhesus (“Rh”) factor according to the established protocol;

7.5.8.3.1.5

Alcohol screening of pregnant women with the 4P-Plus instrument;

7.5.8.3.1.6

Smoking cessation counseling and treatment;

7.5.8.3.1.7

Post-partum depression screening using the Edinburgh post-natal depression scale;

7.5.8.3.1.8

Post-partum counseling and Referral to the WIC program;

7.5.8.3.1.9

Dental evaluation during the second trimester of gestation; and

7.5.8.3.1.10

Educational workshops regarding pre-natal care topics (importance of pre-natal medical visits and post-partum care), breast-feeding, stages of childbirth, oral and Behavioral Health, family planning, and newborn care, among others.

7.5.8.3.2

The Contractor shall ensure that eighty-five percent (85%) of pregnant Enrollees receive services under the Pre-Natal and Maternal Program. The Contractor shall submit its pre-natal and Maternal Program maternal wellness plan to ASES according to the timeframe specified in Attachment 12 to this Contract, and shall submit reports quarterly concerning the usage of services under this program.

7.5.8.4

The Contractor shall provide reproductive health and family planning counseling. Such services shall be provided voluntarily and confidentially, including circumstances where the Enrollee is under age eighteen (18). Family planning services will include, at a minimum, the following:

Page 90 of 324

7.5.8.4.1

Education and counseling;

7.5.8.4.2

Pregnancy testing;

7.5.8.4.3

Infertility assessment;

7.5.8.4.4

Sterilization services in accordance with 42 CFR 441.200, subpart F;

7.5.8.4.5

Laboratory services;

7.5.8.4.6

Cost and insertion/removal of non-oral products, such as long acting reversible contraceptives (LARC) as specified by ASES’s Normative Letter 15-1012 (Attachment 13 to this Contract);

7.5.8.4.7

At least one of every class and category of FDA-approved contraceptive medication as specified in ASES’s Normative Letter 15-1012 (Attachment 13 to this Contract);

7.5.8.4.8

At least one of every class and category of FDA-approved contraceptive method as specified in ASES’s Normative Letter 15-1012 (Attachment 13 to this Contract); and

7.5.8.4.9

Other FDA-approved contraceptive medications or methods not covered by sections 7.5.8.4.7 or 7.5.8.4.8 of the Contract, when it is Medically Necessary and approved through a Prior Authorization or through an exception process and the prescribing Provider can demonstrate at least one of the following situations:

7.5.8.4.9.1

Contra-indication with drugs that are in ASES’s Normative Letter 15-1012 (Attachment 13 to this Contract) that the Enrollee is already taking, and no other methods available in the ASES’s Normative Letter 15-1012 (Attachment 13 to this Contract) that can be used by the Enrollee.

7.5.8.4.9.2

History of adverse reaction by the Enrollee to the contraceptive methods covered as specified by ASES’s Normative Letter 15-1012 (Attachment 13 to this Contract); or

7.5.8.4.9.3

History of adverse reaction by the Enrollee to the contraceptive medications that are in ASES’s Normative Letter 15-1012 (Attachment 13 to this Contract).

Page 91 of 324

7.5.8.5

Maternity services, including family planning and postpartum services must be covered for a sixty (60) Calendar Day period, beginning on the day the pregnancy ends. These services will also be covered for any remaining days in the month in which the sixtieth (60 ^th ) day falls.

7.5.9

Emergency Services

7.5.9.1

The Contractor shall cover and pay for Emergency Services where necessary to treat an Emergency Medical Condition or a Behavioral Health Emergency. The Contractor shall ensure that Medical and Behavioral Health Emergency Services are available twenty-four (24) hours a day, seven (7) days per Week. The Contractor shall ensure that emergency rooms and other Providers qualified to furnish Emergency Services have appropriate personnel to provide physical and Behavioral Health Services. All Emergency Services must be billed appropriately to the Contractor based on the applicable treatment and site of care. No Prior Authorization will be required for Emergency Services, and the Contractor shall not deny payment for treatment if a representative of the Contractor instructed the Enrollee to seek Emergency Services.

7.5.9.2

Emergency Services shall include, but are not limited to, the following:

7.5.9.2.1

Emergency room visits, including medical attention and routine and necessary services;

7.5.9.2.2

Trauma services;

7.5.9.2.3

Operating room use;

7.5.9.2.4

Respiratory therapy;

7.5.9.2.5

Specialist and sub-specialist treatment when required by the emergency room physician;

7.5.9.2.6

Anesthesia;

7.5.9.2.7

Surgical material;

7.5.9.2.8

Laboratory tests and X-Rays;

7.5.9.2.9

Post-Stabilization Services, as provided in Section 7.5.9.4 below;

Page 92 of 324

7.5.9.2.10

Care as necessary in the case of a Psychiatric Emergency in an emergency room setting;

7.5.9.2.11

Drugs, medicine and intravenous solutions used in the emergency room; and

7.5.9.2.12

Transfusion of blood and blood plasma services, without limitations, including:

7.5.9.2.12.1

Antihemophilic recombinant factor VIII;

7.5.9.2.12.2

Antihemophilic recombinant factor IX;

7.5.9.2.12.3

Anti-inhibitor coagulant complex (Feiba); and

7.5.9.2.12.4

Antihemophilic factor VIII, human/Von Willebrand factor complex.

7.5.9.3

Emergency Services Within and Outside Puerto Rico

7.5.9.3.1

The Contractor shall make Emergency Services available:

7.5.9.3.1.1

For all Enrollees, throughout Puerto Rico and notwithstanding whether the Emergency Services Provider is a Network Provider; and

7.5.9.3.1.2

For Medicaid and CHIP Eligibles, in Puerto Rico or in the other USA jurisdictions, when the services are Medically Necessary and could not be anticipated, notwithstanding that Emergency Services Providers outside of Puerto Rico are not Network Providers. The Contractor shall be responsible for fulfilling payment for Emergency Services rendered in the other USA jurisdictions in a timely manner. If, in an extenuating circumstance, a Medicaid or CHIP Eligible Enrollee incurs out-of-pocket expenses for Emergency Services provided in the other USA jurisdictions, the Contractor shall reimburse the Enrollee for such expenses in a timely manner, and the reimbursement shall be considered a Covered Service.

7.5.9.3.2

In covering Emergency Services provided by Puerto Rico Providers outside the Contractor’s Network, or by Providers in the other USA jurisdictions, the Contractor shall pay the Provider at least the average rate paid to Network Providers.

Page 93 of 324

7.5.9.4

Post-Stabilization Services

7.5.9.4.1

The Contractor shall cover Post-Stabilization Services obtained from any Provider, regardless of whether the Provider is in the General Network or PPN, that are administered to maintain the Enrollee’s stabilized condition for one (1) hour while awaiting response on a Prior Authorization request. The attending Emergency Room physician or other treating Provider shall be responsible for determining whether the Enrollee is sufficiently stabilized for transfer or discharge. That determination will be binding for the Contractor with respect to its responsibility for coverage and payment.

7.5.9.4.2

An Enrollee who has been treated for an Emergency Medical Condition or Behavioral Health Emergency shall not be held liable for any subsequent screening or treatment necessary to stabilize or diagnose the specific condition in order to stabilize the Enrollee.

7.5.9.4.3

Financial Responsibility

7.5.9.4.3.1

The Contractor shall be financially responsible for Post-Stabilization Services obtained within or outside the Contractor’s General Network. These services will be subject to Prior Authorization by a Network Provider or any other Contractor representative.

7.5.9.4.3.2

The Contractor must limit cost-sharing for Post-Stabilization Services upon inpatient admission to Enrollees to amounts no greater than what the Contractor would charge Enrollee if services were obtained through the Contractor’s General Network.

7.5.9.4.3.3

The Contractor shall be financially responsible for Post-Stabilization Services obtained within or outside the Contractor’s Network that are not given Prior Authorization by a Network Provider or other Contractor representative, but are administered to maintain, improve, or resolve the Enrollee’s stabilized condition if:

7.5.9.4.3.3.1

The Contractor does not respond to a request for Prior Authorization within one (1) hour;

Page 94 of 324

7.5.9.4.3.3.2

The Contractor cannot be contacted; or

7.5.9.4.3.3.3

The Contractor and the treating physician cannot reach an agreement concerning the Enrollee’s care, and the participating Network Provider is not available for consultation. In this situation, the Contractor must give the treating physician the opportunity to consult with the participating Network Provider and the treating physician may continue with care of the patient until the Network Provider is reached or one of the criteria in 42 CFR 422.113(c)(3) is met.

7.5.9.4.3.4

The Contractor’s financial responsibility for Post-Stabilization Services that it has not Prior Authorized ends when:

7.5.9.4.3.4.1

A Network Provider with privileges at the treating hospital assumes responsibility for the Enrollee’s care;

7.5.9.4.3.4.2

A Network Provider assumes responsibility for the Enrollee’s care through transfer;

7.5.9.4.3.4.3

A Contractor representative and the treating physician reach an agreement concerning the Enrollee’s care; or

7.5.9.4.3.4.4

The Enrollee is discharged.

7.5.9.5

Coverage of Services Ultimately Determined to be Non-Emergencies. The Contractor shall not retroactively deny a Claim for an emergency screening examination because the condition, which appeared to be an Emergency Medical Condition or a Psychiatric Emergency under the prudent layperson standard, turned out to be non-emergency in nature.

7.5.9.6

Enrollee Use of GHP Service Line. The Contractor shall train Emergency Services Providers concerning the GHP Service Line Medical Advice Service, and shall make Providers aware that:

7.5.9.6.1

An Enrollee who consults this service before visiting the emergency room shall not be responsible for any Co-Payment, provided that he or she presents his or her GHP Service Line call identification number when he or she arrives at the emergency room;

Page 95 of 324

7.5.9.6.2

No Co-Payments shall be charged for Medicaid and CHIP children under twenty-one (21) years of age under any circumstances.

7.5.9.6.3

No Co-Payments shall be imposed, or required, to an Enrollee to receive treatment for an Emergency Medical Condition or Psychiatric Emergency who is a Medicaid or CHIP Eligible; and the Contractor shall not deny payment for Emergency Services when the Enrollee seeks Emergency Services at the instruction of the Contractor or its Agent (including a GHP Service Line representative).

7.5.9.7

Coverage of All Emergency Medical Conditions and Psychiatric Emergencies

7.5.9.7.1

The Contractor shall not deny payment for treatment of an Emergency Medical Condition or a Psychiatric Emergency, including cases in which the absence of immediate medical attention would not have resulted in the outcomes specified in the definition of Emergency Medical Condition or a Psychiatric Emergency in this Contract and in 42 CFR 438.114(a).

7.5.9.7.2

The Contractor shall not refuse to cover an Emergency Medical Condition or a Psychiatric Emergency based on the emergency room Provider, hospital, or fiscal Agent not notifying the Enrollee’s PCP or the Contractor of the Enrollee’s screening or treatment within ten (10) Calendar Days following the Enrollee’s presentation for Emergency Services.

7.5.10

Hospitalization Services

7.5.10.1

The Contractor shall provide hospitalization services, including the following:

7.5.10.1.1

Access to a nursery;

7.5.10.1.2

Access to a semi-private room (bed available twenty-four (24) hours a day, every Calendar Day of the year, including Puerto Rico holidays);

7.5.10.1.3

Access to an isolation room for physical or Behavioral Health reasons;

Page 96 of 324

7.5.10.1.4

Food, including specialized nutrition services;

7.5.10.1.5

Regular nursing services;

7.5.10.1.6

Specialized room use, such as operation, surgical, recovery, treatment and maternity, without limitations;

7.5.10.1.7

Drugs, medicine, and contrast agents, without limitations;

7.5.10.1.8

Availability of materials such as bandages, gauze, plaster, or any other therapeutic or healing material;

7.5.10.1.9

Therapeutic and maintenance care services, including the use of the necessary equipment to offer the service;

7.5.10.1.10

Specialized diagnostic tests, such as electrocardiograms, electroencephalograms, arterial gases, and other specialized tests that are available at the hospital and necessary during the Enrollee's hospitalization;

7.5.10.1.11

Supply of oxygen, anesthetics, and other gases including administration;

7.5.10.1.12

Respiratory therapy, without limitations;

7.5.10.1.13

Rehabilitation services while Enrollee is hospitalized, including physical, occupational, and speech therapy;

7.5.10.1.14

Outpatient surgery facility use; and

7.5.10.1.15

Transfusion of blood and blood plasma services, without limitations, including:

7.5.10.1.15.1

Antihemophilic recombinant factor VIII;

7.5.10.1.15.2

Antihemophilic recombinant factor IX;

7.5.10.1.15.3

Anti-inhibitor coagulant complex (Feiba); and

7.5.10.1.15.4

Antihemophilic factor VIII, human/Von Willebrand factor complex.

7.5.10.2

Hospitalization for services that would normally be considered outpatient services or for diagnostic purposes only, is not a Covered Service under the GHP.

7.5.11

Behavioral Health Services

7.5.11.1

Covered Behavioral Health Services include the following:

Page 97 of 324

7.5.11.1.1

Evaluation, screening, and treatment of individuals, couples, families and groups;

7.5.11.1.2

Outpatient services with psychiatrists, psychologists, and social workers;

7.5.11.1.3

Hospital or outpatient services for substance and alcohol abuse disorders;

7.5.11.1.4

Behavioral Health hospitalization;

7.5.11.1.5

Intensive outpatient services;

7.5.11.1.6

Immediate access to Emergency or crisis intervention Services twenty-four (24) hours a day, seven (7) days a Week (services outside of Puerto Rico available only for Medicaid and CHIP Eligibles);

7.5.11.1.7

Detoxification services for Enrollees intoxicated with alcohol or illegal substances, whether as a result of substance abuse, a suicide attempt, or accidental poisoning;

7.5.11.1.8

Long-lasting injected medicine clinics;

7.5.11.1.9

Escort/professional assistance and ambulance services when needed;

7.5.11.1.10

Prevention and secondary-education services;

7.5.11.1.11

Pharmacy coverage and access to medicine for a maximum of twenty-four (24) hours, in compliance with Act No. 408;

7.5.11.1.12

Medically Necessary clinical laboratories;

7.5.11.1.13

Treatment for Enrollees diagnosed with Attention Deficit Disorder (with or without hyperactivity). This includes, but is not limited to, neurologist visits and tests related to this diagnosis’s treatment; and

7.5.11.1.14

Substance abuse treatment.

7.5.11.2

Opiate Addiction Treatment

7.5.11.2.1

The Contractor shall provide appropriate services for Enrollees in need of Buprenorphine treatment due to a diagnosis of opiate addiction. The Contractor shall cover all services related to assessment, treatment, and monitoring of opiate addiction including:

Page 98 of 324

7.5.11.2.1.1

Prescriptions for Buprenorphine or any other medically appropriate medications included on the FMC;

7.5.11.2.1.2

Comprehensive medical examination (CPT Code 99205);

7.5.11.2.1.3

Extended office visits (CPT Code 99215);

7.5.11.2.1.4

Brief office visit (CPT Code 99211);

7.5.11.2.1.5

Psychiatric Diagnostic Interview Exam – New Patient (CPT Code 90801);

7.5.11.2.1.6

Individual Therapy with Medical Evaluation and Management (CPT Code 90807);

7.5.11.2.1.7

Pharmacologic Management (CPT Code 90862);

7.5.11.2.1.8

Drug Urine Toxicology (CPT Code 80100);

7.5.11.2.1.9

Blood Test Basic Metabolic Panel (CPT Code 80048);

7.5.11.2.1.10

Blood Test CBC (CPT Code 85025);

7.5.11.2.1.11

TB Test – Skin (CPT Code 86580), but only in conjunction with the prescription of Buprenorphine for the treatment of opiate addiction;

7.5.11.2.1.12

HIV Test (CPT Code 86703), but only in conjunction with the prescription of Buprenorphine for the treatment of opiate addiction;

7.5.11.2.1.13

Hepatitis Panel (CPT Code 80074), but only in conjunction with the prescription of Buprenorphine for the treatment of opiate addiction;

7.5.11.2.1.14

Individual Counseling (CPT Code 90806);

7.5.11.2.1.15

Group Counseling (CPT Code 90853);

7.5.11.2.1.16

Mental Health Assessment by Non-Physician Professional (CPT Code H0031); and

Page 99 of 324

7.5.11.2.1.17

Alcohol and substance abuse Services, Treatment Plan Development and Modification (CPT Code T007).

7.5.11.3

Inpatient Behavioral Health Services are covered in Institutions for Mental Diseases (IMD), as defined in 42 CFR 435.1010, so long as the facility is a hospital providing psychiatric or substance use disorder, inpatient care or a sub-acute facility providing psychiatric or substance use disorder crisis residential services as follows:

7.5.11.3.1

Inpatient Behavioral Health Services for Enrollees aged twenty-one (21) through sixty-four (64) are covered in an IMD setting for up to fifteen (15) days within the month for which the PMPM Payment would be made in accordance with 42 CFR 438.6(e). Prospective rate development for the PMPM Payments will account for utilization and cost of short term stays in an IMD in accordance with 42 CFR 438.6(e).

7.5.11.3.2

Inpatient Behavioral Health Services for Enrollees aged zero (0) to twenty (20) and aged sixty-five (65) and older are covered in accordance with the State Plan.

7.5.11.4

The Contractor shall have Providers trained and certified by the Substance Abuse and Mental Health Services Administration (“SAMHSA”) to provide opiate addiction treatment. The training and certification of the Providers by SAMHSA may be evidenced with either (i) a copy of the letter issued by SAMHSA to the Provider certifying his/her training and certification or (ii) a copy of the Controlled Substance Registration Certification issued by the Drug Enforcement Administration with the identification number assigned to the Provider by SAMHSA. Evidence of SAMHSA certification shall be included in the Provider’s Credentialing file maintained by the Contractor.

7.5.11.5

The Contractor shall establish and strengthen relationships (if needed, through memoranda of understanding) with ASSMCA, ADFAN, the Office of the Women’s Advocate, and other government or nonprofit entities, in order to improve the delivery of Behavioral Health Services.

7.5.11.6

Behavioral Health Parity

7.5.11.6.1

As required by 42 CFR 438.3(n)(1), the Contractor shall provide services in compliance with the requirements in 42 CFR part 438, subpart K regarding parity in Behavioral Health services.

Page 100 of 324

7.5.11.6.2

The Contractor shall not have an Aggregate Lifetime or Annual Dollar Limits (see 42 CFR 438.905(b)) on any Behavioral Health service.

7.5.11.6.3

As specified in 42 CFR 438.910(b)(1), the Contractor shall not apply any Financial Requirement or Treatment Limitation to Behavioral Health services in any classification (inpatient, outpatient, emergency care, or prescription drugs) that is more restrictive that the predominant Financial Requirement or Treatment Limitation of that type applied to substantially all medical/surgical services in the same classification furnished to Enrollees (whether or not the benefits are furnished by the same Contractor).

7.5.11.6.4

In accordance with 42 CFR 438.910(b)(2), the Contractor shall provide Behavioral Health services in all benefit classifications (inpatient, outpatient, emergency care, and prescription drugs).

7.5.11.6.5

The Contractor shall not apply any cumulative Financial Requirements (see 42 CFR 438.910(c)(3)) for Behavioral Health services.

7.5.11.6.6

In accordance with 42 CFR 438.910(d), the Contractor shall not impose a non-quantitative treatment limitation (NQTL) for Behavioral Health services in any classification (inpatient, outpatient, emergency care, or prescription drugs) unless, under the policies and procedures of the Contractor as written and in operation, any processes, strategies, evidentiary standards, or other factors used in applying the NQTL to Behavioral Health services in the classification are comparable to, and are applied no more stringently than, the processes, strategies, evidentiary standards, or other factors used in applying the NQTL for medical/surgical services in the same classification. NQTLs include, but are not limited to, medical management standards; standards for provider participation, including reimbursement rates; fail-first policies; exclusions based on failure to complete a course of treatment; and restrictions based on geographic location, facility type, provider specialty, other criteria that limit the scope or duration of services; and standards for providing access to out-of-network Providers (see 42 CFR 438.910(d)(2)).

7.5.11.6.7

The Contractor shall work with ASES and other Government agencies to ensure that all Enrollees are provided access to a set of services that meets the requirements of 42 CFR part 438, subpart K regarding parity in Behavioral Health services, regardless of what Behavioral Health services are provided by the Contractor.

Page 101 of 324

7.5.11.6.8

The Contractor shall cooperate with ASES to establish and demonstrate initial and ongoing compliance with 42 CFR part 438, subpart K regarding Behavioral Health parity. This shall include but not be limited to participating in meetings, providing information (documentation, data, etc.) requested by ASES to assess parity compliance, working with ASES to resolve any non-compliance, and notifying ASES of any changes to benefits or limitations that might impact parity compliance.

7.5.11.6.9

If requested by ASES, the Contractor shall conduct an analysis to determine compliance with 42 CFR part 438, subpart K regarding Behavioral Health parity and provide the results of the analysis to ASES in the format and timeframes specified by ASES.

7.5.11.6.10

As specified in 42 CFR 438.915(a), the Contractor shall make available the criteria for medical necessity determinations for Behavioral Health services to any Enrollee, Potential Enrollee, or Provider upon request.

7.5.11.6.11

As specified in 42 CFR 438.915(b), the Contractor shall make available to the Enrollee the reason for any denial by the Contractor of reimbursement or payment for Behavioral Health services to the Enrollee.

7.5.12

Pharmacy Services

7.5.12.1

The Contractor shall provide pharmacy services under the GHP in accordance with Section 1927 of the Social Security Act and 42 CFR 438.3(s), including the following:

7.5.12.1.1

All costs related to prescribed medications for Enrollees, excluding the Enrollee’s Co-Payment where applicable;

7.5.12.1.2

Drugs on the Formulary of Medications Covered (FMC);

7.5.12.1.3

Drugs included on the LME, but not in the FMC (through the exceptions process explained in Section 7.5.12.10 and Attachment 27 to this Contract); and

7.5.12.1.4

In some instances, through the exceptions process, drugs that are not included on either the FMC or the LME.

Page 102 of 324

7.5.12.2

The Contractor may not impose restrictions on available prescription drugs beyond those stated in the FMC, LME, or any other drug formulary approved by ASES.

7.5.12.3

The following drugs are excluded from the pharmacy component of Covered Services:

7.5.12.3.1

Rebetron or any other medication prescribed for the treatment of Hepatitis C treatment (Enrollees to be referred to the Health Department, upon Referral to the Health Department by a Network Provider. This medication is not provided through the GHP); and

7.5.12.3.2

Medications delivered directly to Enrollees by a Provider that does not have a pharmacy license, with the exception of medications that are traditionally administered in a doctor’s office, such as injections.

7.5.12.4

Prescriptions ordered under the pharmacy services Benefit are subject to the following Utilization controls:

7.5.12.4.1

Consistent with the requirements of Section 1927(d)(5) of the Social Security Act, some or all prescription drugs may be subject to Prior Authorization, which shall be implemented and managed by the PBM or the Contractor, according to policies and procedures established by the ASES Pharmacy and Therapeutic (“P&T”) Committee and decided upon in consultation with the Contractor when applicable.

7.5.12.4.2

The Contractor shall ensure that Prior Authorization for pharmacy services is provided for the Enrollee in the following timeframes, including outside of normal business hours.

7.5.12.4.2.1

The decision whether to grant a Prior Authorization of a prescription must not exceed twenty-four (24) hours from the receipt of the Enrollee’s Service Authorization Request and the standard information needed to make a determination is provided. Such standard information to make a determination includes the following: the prescription, a supporting statement setting forth the clinical justification and medical necessity for the prescribed medication, and expected duration of treatment, as required by the protocol for the medication. The Contractor shall provide notice on a Prior Authorization request by telephone or other telecommunication device in the required timeframes. In circumstances where the Contractor or the Enrollee’s Provider determines that the Enrollee’s life or health could be endangered by a delay in accessing the prescription drug, the Contractor shall provide at least a seventy-two (72) hour supply of the prescription drug unless the drug is statutorily excluded from coverage under Section 1927(d)(2) of the Social Security Act. In such cases, Prior Authorization must be provided as expeditiously as the Enrollee’s health requires, and no later than within twenty-four (24) hours following the Service Authorization Request.

Page 103 of 324

7.5.12.4.2.2

The Contractor may extend the time allowed for Prior Authorization decisions, where:

7.5.12.4.2.2.1

The Enrollee, or the Provider, requests the extension; or

7.5.12.4.2.2.2

The Contractor justifies to ASES a need for the extension in order to collect additional information, such that the extension is in the Enrollee’s best interest.

7.5.12.4.3

Prescriptions written by a Provider who is outside the PPN may be filled only upon a Countersignature from the Enrollee’s PCP, or another assigned PCP from the PMG in case of absence or unavailability of the Enrollee’s PCP. A Countersignature request made to the PCP shall be acted upon within three (3) Calendar Days of the request of the prescribing Provider or, if the Enrollee’s health is in danger, within twenty-four (24) hours.

7.5.12.4.4

The Contractor shall not require a PCP Countersignature on prescriptions written by a Provider within the PPN.

7.5.12.5

The Contractor shall use bioequivalent drugs approved by the Food and Drug Administration (“FDA”), provided they are classified as “AB” and authorized by regulations, unless the Provider notes a contra-indication in the prescription. Nonetheless, the Contractor shall not refuse to cover a drug solely because the bioequivalent drug is unavailable; nor shall the Contractor impose an additional payment on the Enrollee because the bioequivalent is unavailable.

Page 104 of 324

7.5.12.6

The Contractor shall observe the following timeframe limits with respect to prescribed drugs:

7.5.12.6.1

Medication for critical conditions will be covered for a maximum of thirty (30) Calendar Days and for additional time, where Medically Necessary.

7.5.12.6.2

Medication for Chronic Conditions or severe Behavioral Health conditions will be covered for a maximum of thirty (30) Calendar Days, except at the beginning of therapy where, upon a Provider’s recommendation, a minimum of fifteen (15) Calendar Days shall be prescribed in order to reevaluate compliance and tolerance. Under a doctor’s orders, a prescription may be refilled up to five (5) times.

7.5.12.6.3

For maintenance drugs that require Prior Authorization, the Prior Authorization will be effective for a term of six (6) months, unless there are contra-indications or side effects, in which case the term may be shorter, or unless associated with a formulary exception request, as set forth in Attachment 27 to this Contract, in which case the term may be approved for up to twelve (12) months.

7.5.12.6.4

The prescribing Provider shall re-evaluate pharmacotherapy as to compliance, tolerance, and dosage within ninety (90) Calendar Days of having prescribed a maintenance drug. Dosage changes will not require Prior Authorization. Changes in the drug used may require Prior Authorization.

7.5.12.7

Special considerations, including cooperation with Puerto Rico governmental entities other than ASES, govern coverage of medications for the following conditions:

7.5.12.7.1

Medications for Treatment of HIV/AIDS

7.5.12.7.1.1

The following HIV/AIDS medications are excluded from the ASES FMC: Viread®, Emtriva®, Truvada®, Fuzeon®, Atripla®, Epzicom®, Selzentry®, Intelence®, Isentress/Insentress HD®, Edurant®, Complera®, Stribild®, Descovy®, Triumeq®, Genvoya®, Tivicay® and Odefsey®.

7.5.12.7.1.2

Because of an agreement between the Health Department and ASES, Enrollees diagnosed with HIV/AIDS may access the medications listed above through Health Department clinics. The Contractor is not At Risk for the coverage of these medications.

Page 105 of 324

7.5.12.7.1.3

The Contractor shall inform Providers about this agreement, and shall require Providers to refer Enrollees for whom these medications are Medically Necessary to CPTET Centers (Centros de Prevención y Tratamiento de Enfermedades Transmisibles) or community-based organizations, where the Enrollee may be screened to determine whether the Enrollee is eligible for the AIDS Drug Assistance Program (“ADAP”).

7.5.12.7.1.4

A list of CPTET Centers and community-based organizations that administer these medications is included as Attachment 4 to this Contract.

7.5.12.7.2

Medications for Chronic Conditions for Children with Special Health Needs. Directions for prescriptions for chronic use drugs for children with special health needs shall cover therapy for thirty (30) Calendar Days, and if necessary up to five (5) refills of the original prescription, according to medical opinion of a certified Provider. When Medically Necessary, additional prescriptions will be covered.

7.5.12.7.3

Medications for Enrollees with Opiate Addictions. See Section 7.5.11.2.1.1 above.

7.5.12.8

Except as provided in Section 7.5.12.3.2, all prescriptions must be dispensed by a pharmacy under contract with the PBM that is duly authorized under the laws of the Puerto Rico, and is freely selected by the Enrollee. The PBM shall maintain responsibility for ensuring that the pharmacy services network complies with the terms specified by ASES.

7.5.12.9

Prescribed drugs must be dispensed at the time and date, as established by the Puerto Rico Pharmacy Law, when the Enrollee submits the prescription for dispensation.

7.5.12.10

Use of FMC Medications. The Contractor shall ensure that drugs on the FMC are used whenever possible.

7.5.12.10.1

In the following two categories of exceptional cases, however, the Contractor shall cover drugs not included on the FMC, upon submission of acceptable written documentation of the medical justification for the drug from the Provider, in accordance with Attachment 27 to this Contract.

Page 106 of 324

7.5.12.10.1.1

The Contractor shall cover drugs included on the LME (Attachment 5 to this Contract) in lieu of a FMC drug, only as a part of an exceptions process, upon a showing that no drug listed on the FMC is clinically effective for the Enrollee.

7.5.12.10.1.2

The Contractor shall cover a drug that is not included on either the FMC or the LME, only as part of an exceptions process, provided that the drug is being prescribed for a use approved by the FDA or for a medically accepted indication, as defined in Section 1927(k)(6) of the Social Security Act for the treatment of the condition.

7.5.12.10.2

In addition to demonstrating that the drug is being prescribed for a medically accepted indication, as defined in Section 1927(k)(6) of the Social Security Act and as referenced in Section 7.5.12.10.1.2 above, a Provider prescribing a drug not on the FMC or LME must follow the process in Attachment 27 to this Contract and provide the Contractor with the necessary medical documentation to demonstrate that:

7.5.12.10.2.1

The drug does not have any bioequivalent on the market; and

7.5.12.10.2.2

The drug is clinically indicated because of:

7.5.12.10.2.3

Contra-indication with drugs that are in the FMC or LME that the Enrollee is already taking, and scientific literature’s indication of the possibility of serious adverse health effects related to the taking the drug;

7.5.12.10.2.3.1

History of adverse reaction by the Enrollee to drugs that are on the FMC or LME;

7.5.12.10.2.3.2

Therapeutic failure of all available alternatives on the FMC or LME; or

7.5.12.10.2.3.3

Other special circumstances.

Page 107 of 324

7.5.12.11

In the event the Comprehensive Cancer Center of Puerto Rico (“Centro Comprensivo de Cancer”) participates as a covered entity in the 340B Drug Pricing Program, ASES reserves the right to modify coverage and pricing for such 340B eligible cancer drugs.

7.5.12.12

Role of Pharmacy Benefit Manager

7.5.12.12.1

Pharmacy services are administered primarily by a Pharmacy Benefit Manager (“PBM”) under contract with ASES. The Contractor shall work with the PBM as well as the Pharmacy Program Administrator (“PPA”) selected by ASES as needed, and as provided in this Section 7.5.12.11, in order to ensure the successful provision of pharmacy services.

7.5.12.12.2

The Contractor shall be obligated to accept the terms and conditions of the contract that ASES awards to a PBM. The Contractor shall use the procedures, guidelines, and other instructions implemented by ASES through the PBM. The Contractor and the PBM shall coordinate all the required efforts to achieve the integrated model of rendering all Covered Services to Enrollees under the GHP Program.

7.5.12.12.3

Among other measures, to enhance cooperation with the PBM, the Contractor shall:

7.5.12.12.3.1

Work with the PBM to improve Information flow and to develop protocols for Information-sharing;

7.5.12.12.3.2

Establish, in consultation with the PBM, the procedures to transfer funds for the payment of Claims to the pharmacy network according to the payments cycle specified by the PBM; and

7.5.12.12.3.3

Coordinate with the PBM to establish customer service protocols concerning pharmacy services.

7.5.12.13

Claims Processing and Administrative Services for Pharmacy. The Contractor shall:

7.5.12.13.1

Assume the cost of implementing and maintaining online connection with the PBM;

7.5.12.13.2

Cover all of its own costs of implementation, including but not limited to payment processes, Utilization review and approval processes, connection and line charges, and other costs incurred to implement the payment arrangements for pharmacy Claims;

Page 108 of 324

7.5.12.13.3

Review Claims payments summary reports for each payment cycle and transfer funds required for payment to pharmacies;

7.5.12.13.4

Review denials and rejections of Claims;

7.5.12.13.5

Maintain an appropriately staffed phone line that is available twenty-four (24) hours a day, seven (7) days a week to provide for the Prior Authorization of drugs, according to the established policies, the FMC, and the LME; and

7.5.12.13.6

Electronically submit on a daily basis a list of all Contractor’s Network Providers, and a list of Enrollees to the PBM. Submit the PBM Member History Move file included in Attachment 9 to this Contract whenever an Enrollee previously enrolled with a different contractor selects Contractor as its new Plan.

7.5.12.14

Fraud Investigations. The Contractor shall develop tracking mechanisms for detecting Fraud, Waste, and Abuse related to pharmacy services, and shall forward Fraud, Waste, and Abuse Complaints from Enrollees related to pharmacy services to the PBM and to ASES.

7.5.12.15

Formulary Management Program

7.5.12.15.1

The Contractor shall select two (2) members of its staff to serve on a cross-functional committee, the Pharmacy Benefit Financial Committee, tasked with rebate maximization and/or evaluating recommendations regarding the FMC and LME from the P&T Committee and the PPA and PBM as applicable. The Pharmacy Benefit Financial Committee will also review the FMC and LME from time to time and evaluate additional recommendations on potential cost-saving pharmacy initiatives, under the direction and approval of ASES.

7.5.12.15.2

The Contractor shall select a member of its staff to serve on a cross-functional subcommittee tasked with assisting in the evaluation of additional potential cost-saving pharmacy initiatives as needed.

7.5.12.15.3

The Contractor shall select two (2) members of its staff to serve as non voting advisors to the P&T Committee. These advisors must be available to answers questions and provide requested information relevant to the tasks performed by P&T Committee.

Page 109 of 324

7.5.12.16

Utilization Management and Reports. The Contractor shall:

7.5.12.16.1

Perform drug Utilization reviews that meet the standards established by both ASES and Federal authorities, including the operation of a drug utilization review program as required in 42 CFR Part 456, Subpart K;

7.5.12.16.2

Develop and distribute protocols that will be subject to ASES approval, when necessary; and

7.5.12.16.3

Provide to ASES annually a detailed description of its drug utilization program activities.

7.5.12.17

Communication with Providers. The Contractor shall ensure the following communications with Providers:

7.5.12.17.1

The Contractor shall advise Providers regarding the use of the FMC as a first option at the moment of prescribing and of the need to observe the exceptions process when filling a prescription for a drug not on the FMC.

7.5.12.17.2

The Contractor shall advise Providers that they may not outright deny medication because it is not included on ASES’s FMC or LME. A medication not on the FMC or LME may be provided through the exceptions process described in Section 7.5.12.10 and Attachment 27 to this Contract.

7.5.12.17.3

The Contractor shall advise Providers on the availability of the bioequivalent versions of brand-name drugs and that such bioequivalent versions should be prescribed instead of brand-name drugs as available and appropriate.

7.5.12.18

Cooperation with the Pharmacy Program Administrator (“PPA”)

7.5.12.18.1

The Contractor shall receive updates to the FMC and LME from the PPA. The Contractor shall adhere to these updates.

7.5.12.18.2

Any rebates shall be negotiated by the PPA and retained in their entirety by ASES. The Contractor shall neither negotiate, collect, nor retain any pharmacy rebate for Enrollee Utilization of brand drugs included on ASES’s FMC or LME.

Page 110 of 324

7.5.12.19

Information on Pharmacy Benefits Coverage. The Contractor shall provide Information on the FMC and LME in electronic or paper form, including which generic or brand medications are covered, and what formulary tier each medication is on. Drug lists that are published on the Contractor’s website must be in a machine readable file and format as specified by CMS.

7.5.12.20

The Contractor must submit, on a quarterly basis, all or specifically requested drugs administered by a Provider in his or her office to an Enrollee following the format established by ASES. This report must include the description of the NDC, HCPCS J-Code, as applicable, and the drug dosage, form and quantity. The Contractor must comply with the Normative Letters 16-1129 and 17-0619.

7.6

Dental Services

7.6.1

The Contractor shall provide the following dental services as Covered Services for Pediatric Enrollees:

7.6.1.1

All preventative and corrective services mandated by the EPSDT requirement;

7.6.1.2

Orthodontic services to EPSDT eligible children as medically necessary, subject to Prior Authorization, to prevent and restore oral structures to health and function. Orthodontic services for cosmetic purposes are not covered.

7.6.1.3

Pediatric Pulp Therapy (Pulpotomy);

7.6.1.4

Stainless steel crowns for use in primary teeth following a Pediatric Pulpotomy;

7.6.1.5

Anesthesia services, subject to prior authorization, for a child, or Enrollees with physical or mental handicaps in compliance with Federal and State laws. These special conditions include, but are not limited to, (a) autism, (b) severe retardation, (c) severe neurologic impairment, (d) significant attention deficit disorders with hyperactivity, (e) significant or severe mental disorders, (f) disabled or unable to follow commands, and (g) any other circumstance that in the dentist’s professional judgment, impairs cooperation and feasibility to adequately perform the dental procedure. Prior authorization determinations must be made within two (2) Calendar Days.

7.6.2

The Contractor shall provide the following dental services as Covered Services for Adults:

7.6.2.1

Preventive dental services;

Page 111 of 324

7.6.2.2

Restorative dental services;

7.6.2.3

One (1) comprehensive oral exam per year;

7.6.2.4

One (1) periodical exam every six (6) months;

7.6.2.5

One (1) defined problem-limited oral exam;

7.6.2.6

One (1) full series of intra-oral radiographies, including bitewings, every three (3) years;

7.6.2.7

One (1) initial periapical intra-oral radiography;

7.6.2.8

Up to five (5) additional periapical/intra-oral radiographies per year;

7.6.2.9

One (1) single film-bite radiography per year;

7.6.2.10

One (1) two-film bite radiography per year;

7.6.2.11

One (1) panoramic radiography every three (3) years;

7.6.2.12

One (1) cleanse every six (6) months;

7.6.2.13

One (1) Prophylaxis, every six (6) months;

7.6.2.14

Amalgam restoration;

7.6.2.15

Resin restorations;

7.6.2.16

Root canal;

7.6.2.17

Palliative treatment;

7.6.2.18

Oral surgery; and

7.6.2.19

Anesthesia services, subject to prior authorization, for adults with physical or mental handicaps in compliance with federal and local law.

7.7

Special Coverage

7.7.1

The Special Coverage Benefit is designed to provide services for Enrollees with special health care needs caused by serious illness. Certain Special Coverage conditions may also be a qualifying condition subject under the HCHN Program (e.g., cancer).

7.7.2

The Contractor shall provide ASES with the strategy implemented for the identification of populations with special health care needs in order to identify any ongoing special conditions of Enrollees that require a treatment plan and regular care monitoring by appropriate Providers.

Page 112 of 324

7.7.3

The Contractor shall implement a system for screening Enrollees for Special Coverage and registering Enrollees who qualify. The Contractor shall design a form, with prior written approval from ASES, to be used by Providers in submitting a registration for Special Coverage.

7.7.4

The registration system for Special Coverage shall emphasize speedy processing of the registration that requires the Contractor, once it receives the notification from the Provider, to register the Enrollee in Special Coverage within seventy-two (72) hours.

7.7.5

Once a Provider supplies all the required information for the Contractor to process a registration and the Contractor processes such information, Special Coverage shall take effect retroactively as of the date the Provider reaches a diagnosis, including documentation of test results, for any condition included in Special Coverage. In case Information is submitted to the Contractor after the diagnosis was reached, coverage can be made retroactive up to sixty (60) Calendar Days before the date on which Provider submitted the registration request.

7.7.6

According to the timeframes specified in Attachment 12 to this Contract, the Contractor shall submit proposed protocols to be established for Special Coverage to ASES for prior written approval, including:

7.7.6.1

Registration procedures;

7.7.6.2

Formats established for registration forms;

7.7.6.3

Forms of notices to be issued to the Enrollee and to the Provider to inform them of the Contractor’s decision concerning Special Coverage;

7.7.6.4

Protocols for the development of a treatment plan;

7.7.6.5

Provisions for ensuring that Enrollees with Special Coverage have Immediate Access to specialists appropriate for the Enrollee’s condition and identified needs; and

7.7.6.6

A summary of the Contractor’s strategy for the identification of populations with special health care needs.

7.7.7

The protocols shall emphasize both the need for a speedy determination and the need for screening evaluations to be conducted by competent Providers with appropriate expertise.

Page 113 of 324

7.7.8

The Contractor shall complete, monitor, and routinely update a treatment plan for each Enrollee who is registered for Special Coverage at least every twelve (12) months, or when the Enrollee’s circumstances or needs change significantly, or at the request of the Enrollee. In the event an Enrollee qualifies for both Special Coverage and the HCHN Program, the treatment plan developed under the HCHN program must comply with this provision.

7.7.8.1

The treatment plan shall be developed by the Enrollee’s PCP, with the Enrollee’s participation, and in consultation with any specialists caring for the Enrollee. The Contractor shall require, in its Provider Contracts with PCPs, that Special Coverage registration treatment plans be submitted to the Contractor for review and approval in a timely manner.

7.7.9

Autism

7.7.9.1

The physical and Behavioral Health Services that the autism population needs to access through specialists such as gastroenterologists, neurologists, allergists, and dentists, will be offered through Special Coverage. Attachment 7 to this Contract includes the mandated procedures for this condition.

7.7.9.2

The Contractor shall require in its Provider Contracts with PCPs that the PCP carry out the Modified Checklist for Autism in Toddlers (“M-CHAT R/F”) In its last version for the screening of autism spectrum disorders at eighteen (18) or twenty-four (24) months of age, or in any other age range established by the Department of Health. The Contractor and Providers should follow the “Protocolo Uniforme de TEA” government plan version, published by the Department of Health.

7.7.9.3

The Contractor shall also require, through its Provider Contracts, that PCPs administer the Ages and Stages Questionnaire (“ASQ”) to the parents of child Enrollees. This questionnaire must be completed when the child is nine (9), eighteen (18), and thirty (30) months old, or at any other age established by the Health Department. Each Contractor shall acquire the license for the exclusive use of the questionnaire for child Enrollees in the GHP and transmit the questionnaire to PCPs and train and educate them in its use.

7.7.10

Services provided under Special Coverage shall be subject to Prior Authorization by the Contractor.

7.7.11

Special Coverage shall include in its scope the following services, provided, however, that an Enrollee shall be entitled only to those services Medically Necessary to treat the condition that qualified the Enrollee for Special Coverage:

Page 114 of 324

7.7.11.1

Coronary and intensive care services, without limit;

7.7.11.2

Maxillary surgery;

7.7.11.3

Neurosurgical and cardiovascular procedures, including pacemakers, valves, and any other instrument or artificial devices (Prior Authorization required);

7.7.11.4

Peritoneal dialysis, hemodialysis, and related services (Prior Authorization required);

7.7.11.5

Pathological and clinical laboratory tests that are required to be sent outside Puerto Rico for processing (Prior Authorization required);

7.7.11.6

Neonatal intensive care unit services, without limit;

7.7.11.7

Radioisotope, chemotherapy, radiotherapy, and cobalt treatments;

7.7.11.8

Treatment of gastrointestinal conditions, treatment of allergies, and nutritional services in autism patients;

7.7.11.9

The following procedures and diagnostic tests, when Medically Necessary (Prior Authorization required):

7.7.11.9.1

Computerized Tomography;

7.7.11.9.2

Magnetic resonance test;

7.7.11.9.3

Cardiac catheters;

7.7.11.9.4

Holter test;

7.7.11.9.5

Doppler test;

7.7.11.9.6

Stress tests;

7.7.11.9.7

Lithotripsy;

7.7.11.9.8

Electromyography;

7.7.11.9.9

Single-photon Emission Computed Topography (“SPECT”) test;

7.7.11.9.10

Orthopantogram (“OPG”) test;

7.7.11.9.11

Impedance Plesthymography;

Page 115 of 324

7.7.11.9.12

Other neurological, cerebrovascular, and cardiovascular procedures, invasive and noninvasive;

7.7.11.9.13

Nuclear imaging;

7.7.11.9.14

Diagnostic endoscopies; and

7.7.11.9.15

Genetic studies;

7.7.11.10

Up to fifteen (15) additional (beyond the services provided under Basic Coverage) physical therapy treatments per Enrollee condition per year when indicated by an orthopedist, physiatrist or chiropractor after Contractor Prior Authorization;

7.7.11.11

General anesthesia, including for dental treatment of special-needs children;

7.7.11.12

Hyperbaric Chamber;

7.7.11.13

Immunosuppressive medicine and clinical laboratories required for the maintenance treatment of post-surgical patients or transplant patients, to ensure the stability of the Enrollee's health, and for emergencies that may occur after said surgery; and

7.7.11.14

Treatment for the following conditions after confirmed laboratory results and established diagnosis:

7.7.11.14.1

HIV Positive factor and/or Acquired Immunodeficiency Syndrome (“AIDS”) (Outpatient and hospitalization services are included; no Referral or Prior Authorization is required for Enrollee visits and treatment at the Health Department's Regional Immunology Clinics or other qualified Providers);

7.7.11.14.2

Aplastic Anemia

7.7.11.14.3

Rheumatoid Arthritis

7.7.11.14.4

Cancer, not limited to Skin Cancer;

7.7.11.14.5

Certain obstetric services, if the Enrollee is active in the Special Coverage Registry.

7.7.11.14.6

Adults with Phenylketonuria (PKU);

7.7.11.14.7

Pulmonary Hypertension

7.7.11.14.8

Tuberculosis;

Page 116 of 324

7.7.11.14.9

Leprosy;

7.7.11.14.10

Systemic Lupus Erythematosus (SLE);

7.7.11.14.11

Cystic Fibrosis;

7.7.11.14.12

Hemophilia;

7.7.11.14.13

Special conditions of children, including the prescribed conditions in the Special Needs Children Diagnostic Manual Codes (see Attachment 13 to this Contract), except:

7.7.11.14.13.1

Psychiatric Disorders; and

7.7.11.14.13.2

Intellectual disabilities;

7.7.11.14.14

Scleroderma;

7.7.11.14.15

Multiple Sclerosis and Amiotrophic Lateral Sclerosis (ALS); and

7.7.11.14.16

Chronic renal disease in levels three (3), four (4) and five (5) (Levels 1 and 2 are included in the Basic Coverage); these levels of renal disease are defined as follows:

7.7.11.14.16.1

Level 3. GFR (Glomerular Filtration – ml/min. per 1.73m² per corporal surface area) between 30 and 59, a moderate decrease in kidney function;

7.7.11.14.16.2

Level 4. GFR between 15 and 29, a severe decrease in kidney function; and

7.7.11.14.16.3

Level 5. GFR under 15, renal failure that will probably require either dialysis or a kidney transplant.

7.7.11.15

Required medication for the outpatient treatment of Tuberculosis and Leprosy is included under Special Coverage. Medication for the outpatient treatment or hospitalization for AIDS-diagnosed Enrollees or HIV-positive Enrollees is also included, with the exception of Protease inhibitors which will be provided by CPTET Centers.

7.7.12

An Enrollee may register for Special Coverage based on one (1) of the conditions listed in Attachment 7 to this Contract. The Contractor must seek ASES Prior Authorization for any other special condition not listed in Attachment 7 to this Contract, which the Enrollee, PCP, or PMG requests to be the basis of Special Coverage for an Enrollee. The request must include sufficient documentation of the Enrollee’s need for services and the cost-effectiveness of the care option. ASES will consult with the Health Department and issue a decision which will be binding between the Parties.

Page 117 of 324

7.7.13

The Contractor must have a mechanism in place to allow Enrollees to directly access a specialist as appropriate for the enrollee’s condition and identified needs, in regards to all services encompassed within the scope of Special Coverage.

7.7.14

Except as expressly noted in this Section 7.7, the exclusions applied to Basic Coverage apply to Special Coverage.

7.8

Administrative Functions and the High Cost High Needs (HCHN) Program

7.8.1

Benefits under the GHP include the Administrative Functions of Care Management and the Wellness Plan (see Section 12.6 of this Contract), which are intended to coordinate care for Enrollees with conditions specified in the HCHN Program or other Enrollees with an identified need for additional coordination.

7.8.2

Care Management

7.8.2.1

The Contractor shall be responsible for the Care Management of Enrollees who demonstrate the greatest need, including those who have conditions specified in the HCHN Program, further described in Section 7.8.3) and/or who require intensive assistance, including during extended hours as required by the Enrollees’ medical conditions, to ensure integration of physical and Behavioral Health needs.

7.8.2.2

Enrollees who present with the following conditions shall be offered Care Management and may elect to opt out of the program:

7.8.2.2.1

Enrollees identified with special health care needs and whom qualify for Special Coverage, the HCHN Program, the High Utilizers Program, or have a Chronic Condition not otherwise covered under Special Coverage or the HCHN Program;

7.8.2.2.2

Enrollees diagnosed with a Serious Mental Illness (SMI) or a Serious Emotional Disturbance (SED); or

7.8.2.2.3

Enrollees who have accessed the emergency room seven (7) or more times within twelve (12) months.

7.8.2.3

The Contractor’s Care Management system shall emphasize prevention, continuity of care, and coordination of care, including between settings of care and appropriate discharge planning for short- and long-term hospital and institutional stays. The system will advocate for, and link Enrollees to, services as necessary across Providers, including community and social support Providers, and settings. Care Management functions include:

Page 118 of 324

7.8.2.3.1

Assignment of a specific Care Manager to each enrollee qualified for Care Management;

7.8.2.3.2

Management of Enrollee to Care Manager ratios that have been reviewed ASES;

7.8.2.3.3

Identification of Enrollees who have or may have chronic or severe Behavioral Health needs, including through use of the screening tools M-CHAT for the detection of Autism, ASQ, ASQ-SE, Conners Scale (ADHD screen), DAST-10, GAD, and PC-PTSD, and other tools available for diagnosis of Behavioral Health disorders;

7.8.2.3.4

Assessment of an Enrollee’s physical and Behavioral Health needs utilizing a standardized needs assessment within thirty (30) Calendar Days of Referral to Care Management that has been reviewed and given written approval by ASES. The Contractor shall also make its best efforts to perform this needs assessment for all new Enrollees within ninety (90) Calendar Days of the Effective Date of Enrollment, and to comply with all other requirements for such assessments set forth in 42 CFR 438.208(b);

7.8.2.3.5

Development of a plan of care within sixty (60) Calendar Days of the needs assessment;

7.8.2.3.6

Referrals and assistance to ensure timely Access to Providers;

7.8.2.3.7

Coordination of care actively linking the Enrollee to Providers, medical services, residential, social, and other support services where deemed necessary;

7.8.2.3.8

Monitoring of the Enrollees needs for assistance and additional services via face-to-face or telephonic contact at least quarterly (based on high- or low-risk);

7.8.2.3.9

Continuity and transition of care; and

7.8.2.3.10

Follow-up and documentation, including the review and/or revision of a plan of care upon reassessment of need, at least every twelve (12) months, or when the Enrollee’s circumstances or needs change significantly, or at the request of the Enrollee.

Page 119 of 324

7.8.2.4

The Contractor shall develop policies and procedures for Care Management that include, at a minimum, the following elements:

7.8.2.4.1

The provision of an individual needs assessment and diagnostic assessment;

7.8.2.4.2

The development of an individual treatment plan, as necessary, based on the needs assessment;

7.8.2.4.3

The establishment of treatment objectives;

7.8.2.4.4

The monitoring of outcomes;

7.8.2.4.5

A process to ensure that treatment plans are revised as necessary;

7.8.2.4.6

A strategy to ensure that all Enrollees or Authorized Representatives, as well as any specialists caring for the Enrollee, are involved in a treatment planning process coordinated by the PCP;

7.8.2.4.7

Procedures and criteria for making Referrals to specialists and subspecialists;

7.8.2.4.8

Procedures and criteria for maintaining care plans and Referral services when the Enrollee changes Providers;

7.8.2.4.9

Capacity to implement, when indicated, Care Management functions such as individual needs assessment, including establishing treatment objectives, treatment follow-up, monitoring of outcomes, or revision of the treatment plan; and

7.8.2.5

These procedures must be designed to include consultation and coordination with Enrollee’s PCP.

7.8.2.6

The Contractor shall submit its Care Management policies and procedures to ASES for review according to the timeframe specified in Attachment 12 to this Contract.

7.8.3

High Cost High Needs (HCHN) Program

7.8.3.1

The HCHN Program is a coordinated model of care focused on conditions that may require intensive use services, monitoring and interventions by a dedicated team of Providers to ensure compliance with plans of care, and specialized care management services (see Section 7.8.2). Outcomes for Enrollees with select conditions in the HCHN Program will be subject to performance metrics and the affiliated Retention Fund as specified in the Health Care Improvement Program (HCIP) Manual (Attachment 19 to this Contract) and Sections 12.5 and 22.4 of the Contract.

Page 120 of 324

7.8.3.2

The Contractor shall design a model of care that assigns Enrollees to an appropriate level of care management and an appropriate team of Providers to treat and manage the health condition. The model of care shall also include transition of care planning when the Enrollee presents at a facility for Emergency Services or post-discharge following an inpatient stay. The model of care shall also include linkages and interventions related to social determinants of health to treat the holistic needs of the Enrollee.

7.8.3.3

The Contractor’s Enrollee Handbook must describe in detail the model of care for treatment of Enrollees with each HCHN condition and the models of care are enforceable and auditable by ASES.

7.8.3.4

Health conditions subject to the Contractor’s HCHN model of care and the process for identifying Enrollees with these specified health conditions is provided in Attachment 28 to this Contract.

7.8.3.5

Contractors will be paid the associated PMPM Payment for Enrollees in the HCHN Program, per specified condition, as provided in Attachment 28 to this Contract.

7.9

Early and Periodic Screening, Diagnosis and Treatment Requirements (“EPSDT”)

7.9.1

The Contractor shall provide EPSDT services to Pediatric Enrollees in compliance with all requirements found below. EPSDT services must be in compliance with Health Department guidelines and the Mothers, Children and Adolescents Program guidelines. ASES may issue additional guidelines to the Contractor in regards to the applicable EPSDT services.

7.9.1.1

The Contractor shall comply with sections 1902(a)(43), 1905(a)(4)(B), and 1905(r) of the Social Security Act, and Part 5 of the State Medicaid Manual, which require EPSDT services to include Outreach and education, screening, tracking, and diagnostic and treatment services.

7.9.1.2

The Contractor shall develop an EPSDT Plan that includes written policies and procedures for conducting Outreach and education, informing, tracking, and organizing follow-up to ensure compliance with the Well Baby Care periodicity schedules.

Page 121 of 324

7.9.1.3

The EPSDT Plan shall emphasize Outreach and compliance monitoring for children and adolescents (young adults), taking into account the multi-lingual, multi-cultural nature of the population, as well as other unique characteristics of this population.

7.9.1.4

The EPSDT Plan shall include procedures for follow-up of missed appointments, including missed Referral appointments for problems identified through EPSDT screens and exams. The plan shall also include procedures for Referral, tracking, and follow-up for annual dental examinations and visits. The Contractor shall submit its EPSDT Plan for review and approval according to the timeframe specified in Attachment 12 to this Contract.

7.9.2

Outreach and Education

7.9.2.1

The Contractor’s EPSDT Outreach and education process for Pediatric Enrollees and their families shall include:

7.9.2.1.1

The importance of preventive care;

7.9.2.1.2

The periodicity schedule and the depth and breadth of services;

7.9.2.1.3

How and where to access services, including necessary transportation and scheduling services; and

7.9.2.1.4

A statement that services are provided without cost.

7.9.2.2

The Contractor shall provide written notification to its families with EPSDT-eligible children when appropriate periodic assessments or needed services are due. The Contractor shall coordinate appointments for care. The Contractor shall follow-up with families with EPSDT-eligible children who have failed to access Well Baby Care services after one hundred and twenty (120) Calendar Days of Enrollment in the GHP.

7.9.2.3

The Contractor shall inform its newly enrolled families with EPSDT-Eligible children about the EPSDT Program upon Enrollment with the Plan. This requirement includes informing pregnant women and new mothers, either before or within fourteen (14) Calendar Days after the birth of their children, that EPSDT services are available.

7.9.2.4

The Contractor shall provide each PCP, on a monthly basis, with a list of the PCP’s EPSDT-eligible children who have not had an appointment during the initial one hundred and twenty (120) Calendar Days of Enrollment, and/or are not in compliance with the EPSDT periodicity schedule. The Contractor and/or the PCP shall subsequently contact the Enrollees’ parents or guardians to schedule an appointment.

Page 122 of 324

7.9.2.5

Outreach and education shall include a combination of written and oral (on the telephone, face-to-face, or films/tapes) methods, and may be done by Contractor personnel or by Providers. All Outreach and education shall be documented and shall be conducted in non-technical language at or below a fourth (4 ^th ) ^- grade reading level. The Contractor shall use accepted methods for informing persons who are blind or deaf, or cannot read or understand the Spanish language.

7.9.2.6

The Contractor may provide nominal, non-cash incentives of fifteen dollars ($15) or less to Enrollees and no more than seventy-five dollars ($75) in the aggregate annually per Enrollee, to motivate compliance with periodicity schedules if prior approved in writing by ASES.

7.9.3

Screening

7.9.3.1

The Contractor is responsible for periodic screens (“EPSDT Checkups”) in accordance with the Puerto Rico Medicaid Program’s periodicity schedule and the American Academy of Pediatrics EPSDT periodicity schedule. Such EPSDT Checkups shall include, but not be limited to, the Well Baby Care checkups described in Section 7.5.3.1.

7.9.3.2

The Contractor shall provide an initial health and screening visit to all newly enrolled CHIP Eligible children within ninety (90) Calendar Days and within twenty-four (24) hours of birth to all newborns; and, after the initial Checkup, annually.

7.9.3.3

The Contractor must advise the Enrollee child, his or her parents, or his or her legal guardian of his or her right to have an EPSDT Checkup.

7.9.3.4

EPSDT Checkups must include all of the following:

7.9.3.4.1

A comprehensive health and developmental history;

7.9.3.4.2

Developmental assessment, including mental, emotional, and Behavioral Health development;

7.9.3.4.3

Measurements (including head circumference for infants);

7.9.3.4.4

An assessment of nutritional status;

7.9.3.4.5

A comprehensive unclothed physical exam;

Page 123 of 324

7.9.3.4.6

Immunizations according to the guidance issued by the Advisory Committee on Immunization Practices (ACIP). All immunizations shall be provided for Pediatric Enrollees, and those necessary according to age, gender, and health condition of the Enrollee, including but not limited to influenza and pneumonia, vaccines for Enrollees over 65 years and vaccines for children and adults with high risk conditions such as pulmonary, renal, diabetes and heart disease, among others.

7.9.3.4.6.1

The Puerto Rico Department of Health shall provide and pay for vaccines to Enrollees ages 0-18 through the Children's Immunization Program. The Contractor shall cover the administration of the vaccines provided by the Puerto Rico Department of Health.

7.9.3.4.6.2

The Contractor shall provide and pay for the immunizations of Enrollees ages 19-20 and those necessary according to age, gender and health condition of the Enrollee, including but not limited to influenza and pneumonia vaccines for beneficiaries over 65 years and adults with high risk conditions such as pulmonary, renal, diabetes, and heart disease, among others.

7.9.3.4.6.3

7.9.3.4.6.4

The Contractor shall administer the immunizations without any charge or deductible.

7.9.3.4.7

Certain laboratory tests;

7.9.3.4.8

Anticipatory guidance and health education;

7.9.3.4.9

Vision screening;

7.9.3.4.10

Tuberculosis;

7.9.3.4.11

Hearing screening; and

7.9.3.4.12

Dental and oral health assessment.

Page 124 of 324

7.9.3.5

Lead screening is a required component of an EPSDT Checkup, and the Contractor shall implement a screening program for the detection of the presence of lead toxicity. The screening program shall consist of two (2) parts: verbal risk assessment (from thirty-six (36) to seventy-two (72) months of age), and blood screening for lead. Regardless of risk, the Contractor shall provide for a blood screening testing for lead for all EPSDT-Eligible children at twelve (12) and twenty-four (24) months of age. Children between twenty-four (24) months of age and seventy-two (72) months of age should receive a blood lead screening testing for lead if there is no record of a previous test.

7.9.3.6

The Contractor shall have procedures for Provider Referral to and follow-up with dental service Providers, including annual dental examinations and services by an oral health Provider.

7.9.3.7

The Contractor shall have procedures for Provider Referral of children for further diagnostic and/or treatment services to correct or ameliorate defects, physical and mental illnesses, and conditions discovered by the EPSDT checkup. Referral to the Provider conducting the screening or to another Provider may be made, as appropriate, as well as any follow-up appointments.

7.9.3.8

The Contractor shall ensure at a minimum fifty percent (50%) compliance during the first Contract year, sixty percent (60%) compliance during the second Contract year, and seventy-five percent (75%) compliance during the third Contract year, with the EPSDT screening requirements, including blood screening for lead and annual dental examinations and services, using the methodology prescribed by CMS to determine the screening rate. ASES may impose penalties, sanctions, and/or fines under Articles 19 and 20 if the Contractor fails to comply with the minimum requirements.

7.9.4

Tracking

7.9.4.1

The Contractor shall establish a tracking system that provides Information on compliance with EPSDT requirements. This system shall have in a place a reminder/notification system and shall track, at a minimum, the following areas:

7.9.4.1.1

Initial newborn Well Baby Care hospital checkups;

7.9.4.1.2

Periodic EPSDT checkups as required by the periodicity schedule;

7.9.4.1.3

Diagnostic and treatment services, including Referrals; and

7.9.4.1.4

Immunizations, lead, tuberculosis, and dental services.

Page 125 of 324

7.9.4.2

All Information generated and maintained in the tracking system shall be consistent with Encounter Data requirements as specified in Section 17.3.3 of this Contract.

7.9.5

Diagnostic and Treatment Services

7.9.5.1

If a suspected problem is detected by a screening examination as described above, the child shall be evaluated as necessary for further diagnosis. This diagnosis is used to determine treatment needs.

7.9.5.2

EPSDT requires coverage for all follow-up diagnostic and treatment services deemed Medically Necessary to ameliorate or correct a problem discovered during an EPSDT checkup. Such Medically Necessary diagnostic and treatment services must be provided regardless of whether such services are covered by the State Medicaid Plan, as long as they are Medicaid-coverable Services as defined in Title XIX of the Social Security Act. The Contractor shall provide Medically Necessary, Medicaid-coverable diagnostic and treatment services.

7.9.6

EPSDT Reporting is addressed in Section 18.2.4 of this Contract.

7.10

Advance Directives

7.10.1

In compliance with 42 CFR 438.3 (j), 42 CFR 422.128(a), 42 CFR 422.128(b), 42 CFR 489.102(a), and Law No. 160 of November 17, 2001, the Contractor shall maintain written policies and procedures for Advance Directives. Such Advance Directives shall be included in each Enrollee’s Medical Record. The Contractor shall provide these policies and procedures written at a fourth (4 ^th ) grade reading level in English and Spanish to all Enrollees eighteen (18) years of age and older and shall advise Enrollees of:

7.10.1.1

Their rights under the laws of Puerto Rico, including the right to accept or refuse medical or surgical treatment and the right to formulate Advance Directives;

7.10.1.2

The Contractor’s written policies respecting the implementation of those rights, including a statement of any limitation that incorporates the requirements set forth under 42 CFR 422.128(b)(1)(ii) regarding the implementation of Advance Directives as a matter of conscience; and

7.10.1.3

The Enrollee’s right to file Complaints concerning noncompliance with Advance Directive requirements directly with ASES or with the Puerto Rico Office of the Patient Advocate.

Page 126 of 324

7.10.2

The Information must include a description of Puerto Rico law and must reflect changes in laws as soon as possible and no later than ninety (90) Calendar Days after the effective change.

7.10.3

The Contractor shall educate its staff about its policies and procedures on Advance Directives, situations in which Advance Directives may be of benefit to Enrollees, and the staff’s responsibility to educate Enrollees about this tool and assist them in making use of it.

7.10.4

The Contractor shall educate Enrollees about their ability to direct their care using Advance Directives and shall specifically designate which staff members or Network Providers are responsible for providing this education.

7.11

Enrollee Cost-Sharing

7.11.1

The Contractor shall ensure that Providers collect the Enrollee’s cost-sharing portion only as specified in Attachment 8 to this Contract, as developed in accordance with 42 CFR 438.108.

7.11.2

The Contractor shall ensure that it accurately differentiates the categories of GHP Enrollees in its Marketing Materials and communications, to clarify the cost-sharing rules that are applied to each group. The Contractor shall ensure that the Enrollee’s eligibility category appears on the Enrollee ID Card, so that cost-sharing is correctly determined.

7.11.3

The Contractor shall ensure that, in keeping with the Co-Payment policies included in Attachment 8 to this Contract, Medicaid and CHIP Eligibles bear no cost-sharing responsibility under the GHP for services provided within the Contractor’s PPN.

7.11.4

As provided in Attachment 8 to this Contract, the Contractor shall impose Co-Payments for services provided in an emergency room outside the Enrollee’s PPN, but only in limited circumstances.

7.11.4.1

For Medicaid and CHIP Eligibles, the Contractor shall not impose any Co-Payment for the treatment of an Emergency Medical Condition or a Psychiatric Emergency. The Contractor shall, however, as provided in Attachment 8 to this Contract, impose Co-Payments for services provided in an emergency room to treat a condition that the attending physician determines, at the time of the visit, does not meet the definition of a Psychiatric Emergency or an Emergency Medical Condition and if the Enrollee does not consult the GHP Service Line Medical Advice Line before visiting the emergency room, and provide his or her call identification number at the emergency room. If the Enrollee presents the call identification number, no Co-Payment shall be imposed.

Page 127 of 324

7.11.4.2

No Co-Payments shall be charged for Medicaid and CHIP children under twenty-one (21) years of age under any circumstances.

7.11.4.3

For Other Eligible Persons, the Contractor shall impose a Co-Payment for any emergency room visit outside the Enrollee’s PPN, if the Enrollee does not consult the GHP Service Line Medical Advice Line before visiting the emergency room, and provide his or her call identification number at the emergency room. If the Enrollee presents the call identification number, no Co-Payment shall be imposed.

7.11.5

As provided in 42 CFR 447.53(e), if a Medicaid or CHIP Eligible expresses his or her inability to pay the established Co-Payment at the time of service, the Contractor (through its contracted Providers) shall not deny the service.

7.11.6

Enrollees of Indian background, as defined in Article 2, are exempt from all Co-Payments.

7.11.7

The Contractor shall ensure that any cost sharing complies with the parity requirements for Financial Requirements in 42 CFR 438.910 addressed in Section 7.5.11.7.

7.12

Dual Eligible Beneficiaries

7.12.1

Dual Eligible Beneficiaries enrolled in the GHP are eligible, with the limitations provided below, for the Covered Services described in this Article 7, with the addition of some coverage of Medicare cost-sharing.

7.12.1.1

Dual Eligible Beneficiaries Who Receive Medicare Part A Only

7.12.1.1.1

The Contractor shall provide regular GHP coverage as provided in this Article 7, excluding services covered under Medicare Part A (hospitalization). However, the GHP shall cover hospitalization services after the Medicare Part A coverage limit has been reached.

7.12.1.1.2

The Contractor shall not cover the Medicare Part A premium or Deductible.

7.12.1.2

Dual Eligible Beneficiaries Who Receive Medicare Part A and Part B

7.12.1.2.1

The Contractor shall provide regular GHP coverage as detailed in this Article 7, excluding services covered under Medicare Part A or Part B. However, the GHP shall cover hospitalization services after the Medicare Part A coverage limit has been reached.

Page 128 of 324

7.12.1.2.2

The Contractor shall not cover the Medicare Part A premium or Deductible.

7.12.1.2.3

The Contractor shall cover Medicare Part B Deductibles and co-insurance in accordance with Section 23.5.1.

7.12.1.3

Dual Eligible Beneficiaries enrolled in a Medicare Part C and/or Platino Plan are not eligible for services under this Contract.

7.12.1.4

Barbiturates and Benzodiazepines for Dual Eligible Beneficiaries with Medicare Part D are covered by Medicare Part D.

7.12.2

Any GHP cost-sharing for Dual Eligible Beneficiaries shall be determined according to Section 7.11 and Attachment 8 to this Contract.

7.12.3

The Contractor must enter into a Coordination of Benefits Agreement with Medicare within sixty (60) Calendar Days from the Effective Date of the Contract and participate in the automated claims crossover process in order to appropriately allocate reimbursement for Dual Eligible Beneficiaries. Any crossover claims not appropriately reimbursed by the applicable Medicare program will be considered an Overpayment and shall be reported and returned in accordance with Section 22.1.19.

7.12.3.1

ASES may extend the sixty (60) Calendar Day time frame set forth in Section 7.12.3 if the Contractor can provide evidence, satisfactory to ASES, that documents the Contractor’s reasonable efforts to enter into a Coordination of Benefits Agreement with Medicare.

7.13

Moral or Religious Objections

7.13.1

If, during the course of the Contract period, pursuant to 42 CFR 438.102, the Contractor elects not to provide, not to reimburse for, or not to provide a Referral or Prior Authorization for a service within the scope of the detailed Covered Services, because of an objection on moral or religious grounds, the Contractor shall notify:

7.13.1.1

ASES within one hundred and twenty (120) Calendar Days before adopting the policy with respect to any service;

7.13.1.2

Enrollees within ninety (90) Calendar Days after adopting the policy with respect to any service; and

7.13.1.3

Enrollees and Potential Enrollees before and during Enrollment.

7.13.2

The Contractor shall furnish information about the services it does not cover based on a moral or religious objection to ASES with its GHP Program application. The Contractor acknowledges that such objections will be factored into the calculation of rates paid to the Contractor and, when made during the course of the Contract period, may serve as grounds for recalculation of the rates paid.

Page 129 of 324

7.13.3

If the Contractor does not cover counseling or referral services because of moral or religious objections and chooses not to furnish information to Enrollees on how and where to obtain such services, ASES must provide that information to Enrollees.

7.14

High Utilizers Program – Collaboration with ASES

7.14.1

Pursuant to Attachment 25 to this Contract, the Contractor shall collaborate with ASES in its implementation and administration of the High Utilizer Program, including but not limited to, providing data related to physical and Behavioral Health services such as:

7.14.1.1

Demographic data.

7.14.1.2

Utilization Data from the population.

7.14.1.3

Real-time data from the hospitals to know every time that one of the patients in the program or patients identified as prospects for the program enters the hospital.

7.14.1.4

Hospital data from the hospitals using the Client contracting relationship with them.

7.14.1.5

Authorization data from fast track process for authorizations within Plans.

7.14.2

The Contractor shall provide expedited authorization processes and contact personnel as needed to help coordinate the High Utilizer Program’s information and services.

ARTICLE 8

INTEGRATION OF PHYSICAL AND BEHAVIORAL HEALTH SERVICES

8.1

General Provisions

8.1.1

The Contractor shall ensure that physical and Behavioral Health Services are fully integrated, to ensure optimal detection, prevention, and treatment of physical and Behavioral Health illness.

8.1.2

The Contractor (through contracted PCPs, PMGs, and other Network Providers) shall be responsible, for identifying Enrollees’ needs and coordinating proper Access to both physical and Behavioral Health Services.

Page 130 of 324

8.1.3

In implementing an integrated model of service delivery, the Contractor shall observe all the protections of the Mental Health Code (Act No. 408) and the Puerto Rico Patient’s Bill of Rights Act, as well as other applicable Federal and Puerto Rico legislation.

8.2

Co-Location of Staff

8.2.1

The Contractor shall require the placement of a psychologist or other type of Behavioral Health Provider as part of the PMG’s PPN. The Behavioral Health Provider shall be present and available to provide assessment, screening, consultation, and Behavioral Health Services to Enrollees. The standard minimum criteria for weekly access will be four (4) hours per week for one thousand (1,000) or fewer Enrollees assigned to the PMG and increments of four (4) hours per every additional one thousand (1,000) Enrollees thereafter as detailed in Attachment 10 to this Contract. Total Behavioral Health Provider hours will be determined by the number of Enrollees assigned to the PMG regardless of the Contractor selected by the Enrollee. The Contractor must ensure that each PMG complies with the ASES Guidelines for Co-location of the Behavioral Health Provider in PMG settings established in Attachment 10 to this Contract.

8.2.2

The Contractor shall ensure that the PMG provides adequate space and resources for the Behavioral Health Provider to provide care and consultations in a confidential setting.

8.2.3

The Behavioral Health Provider housed within the PMG shall conduct screening evaluations (PHQ-9, ASQ, ASQ SE, Conners Scales, DAST-10, GAD, PC-PTSD among others), crisis intervention, and limited psychotherapy (between four (4) and six (6) sessions), according to the needs of the Enrollee). Formal and informal case discussions between the PCP and Behavioral Health Providers are encouraged. Additionally, the Behavioral Health Provider shall evaluate all Enrollees in the HCHN Program, and develop and implement a short term, limited psychotherapy care plan as appropriate. The Contractor shall ensure that the services provided are compliant with Act No. 408.

8.3

Reverse Co-location

8.3.1

The Contractor shall contract with Short-term Intervention Centers (Stabilization Units) based on the needs of the population, and with a geographic distribution approved by ASES. Based on the needs of the population, ASES has the sole discretion of requiring the Contractor to contract additional Behavioral Health Services Facilities.

8.3.2

The Contractor must comply with the ASES Guidelines for Reverse Co-location of the PCP in Behavioral Health Facilities detailed in Attachment 21 of this Contract.

Page 131 of 324

8.3.3

The Contractor shall ensure that a PCP is on site or on call as specified in the Guidelines for Reverse Collocation (see Attachment 21 to this Contract) to monitor the physical health of the Enrollees.

8.3.4

The Contractor shall ensure that the Behavioral Health Facility provides adequate space and resources for the PCP to provide care and consultations in a confidential setting.

8.3.5

In the event that a Behavioral Health Facility does not allow Contractor to place a PCP in the Behavioral Health Facility for the minimum time required, the Contractor shall proceed according to the Guidelines for Reverse Collocation (see Attachment 21 to this Contract).

8.4

Referrals

8.4.1

GHP Enrollees with Behavioral Health conditions requiring more intensive or continuous care than can be provided within the PMG environment as set forth in Section 8.2, shall be referred to a Behavioral Health Provider for on-going services. In the same way, Enrollees who require more intensive or continuous care than can be provided within the Behavioral Health Facility as set forth in Section 8.3 shall be referred to the appropriate physical provider for level of treatment. For any physical urgent care that an Enrollee may have at the Behavioral Health Facility they could be seen by the reverse co-located physician to receive such evaluation. However, Enrollees with SMI shall be assisted by the reverse co-located physician for all acute or chronic physical conditions at the same point of service.

8.4.2

An Enrollee may access Behavioral Health services through the following means:

8.4.2.1

A Referral from the PCP or other PMG physician;

8.4.2.2

Self-referral (walk-in);

8.4.2.3

The GHP Service Line Service;

8.4.2.4

The telephone Call Center provided by ASSMCA, known as “Linea PAS”;

8.4.2.5

Hospitals; and

8.4.2.6

Emergency rooms.

8.5

Information Sharing

8.5.1

To the extent the Contractor utilizes a Subcontractor to provide Behavioral Health services, the Contractor and the Subcontractor shall share documents in their respective possession (including agreements, processes, guidelines and clinical protocols), in order to understand the other’s operations to ensure optimal cooperation and integration of physical and Behavioral Health Services.

Page 132 of 324

8.5.2

The Contractor shall develop forms to facilitate electronic communication between physical health and Behavioral Health Providers, such as:

8.5.2.1

An information sheet for Enrollees on HIPAA requirements;

8.5.2.2

A Referral sheet; and

8.5.2.3

An informed consent form.

8.5.3

The Contractor shall establish a process for monitoring exchange of Information, documenting receipt of Information and following up on Information not submitted in a timely manner.

8.5.4

The Contractor shall require PMG staff to follow-up with Behavioral Health Providers concerning the care of Enrollees referred by the PMG to a Behavioral Health Provider.

8.5.5

The Contractor shall ensure that the Providers implement a certified EHR and a HIE platform with the capacity of centralizing the management of the referred EHR for all the PMG Providers including all Behavioral Health Providers. Also, the Contractor shall provide ASES all the necessary data to assure that the Providers comply with the Medicaid encounters patient volume as required by 42 CFR 495.306. The Contractor must submit to ASES the certification document included as Attachment 24 to this Contract within seven (7) Business Days of ASES’s request of the certification.

8.6

Staff Education

8.6.1

The Contractor shall train PMG and the Behavioral Health Facility staff on the goals and operational details of the integrated model of care, and, as appropriate, the identification of Behavioral Health issues and conditions.

8.6.2

The Contractor shall require PMGs to Immediately refer Enrollees to the Behavioral Health Provider located within the PMG (or, if the Provider is not available, to the emergency room) when an Enrollee displays suicidal behavior.

8.7

Cooperation with Puerto Rico and Federal Government Agencies

8.7.1

The Contractor acknowledges that governmental entities, including ASSMCA and SAMHSA regulate, as applicable, Behavioral Health services under the GHP. The Contractor shall consult such governmental entities where appropriate.

Page 133 of 324

8.8

Integration Plan

8.8.1

The Contractor shall submit to ASES, for its review and approval, an Integration Plan incorporating the elements in this Article 8, according to the timeframe specified in Attachment 12 to this Contract. The Integration Plan shall cover at a minimum:

8.8.1.1

How (1) Reverse Co-location and (2) co-location will be arranged, implemented, and monitored;

8.8.1.2

Target dates for full compliance with reverse co-location and co-location;

8.8.1.3

Contingency plans for PMGs and Behavioral Health Facilities who do not have appropriate space for co-location or reverse co-location or refuse to participate;

8.8.1.4

How Referrals are communicated, implemented, and tracked; and

8.8.1.5

Schedule for staff education and measurement of compliance.

ARTICLE 9

PROVIDER NETWORK

9.1

General Provisions

9.1.1

The Contractor shall comply with the requirements specified in 42 CFR 438.68, 438.206, 438.207, 438.214 and all applicable Puerto Rico requirements regarding Provider Networks. The Contractor shall have policies and procedures that reflect these requirements that are prior approved in writing by ASES in accordance with the timeframes in Attachment 12 to this Contract. The Contractor shall also:

9.1.1.1

Establish and maintain a comprehensive network of Providers capable of serving all Enrollees who enroll in the Contractor’s Plan;

9.1.1.2

Pursuant to Section 1932(b)(7) of the Social Security Act, not discriminate against Providers that serve high-risk populations or specialize in conditions that require costly treatment;

9.1.1.3

Not discriminate with respect to participation, reimbursement, or indemnification of any Provider acting within the scope of that Provider’s license or certification under applicable Puerto Rico law solely on the basis of the Provider’s license or certification;

9.1.1.4

Upon declining to include a Provider or group of Providers that have requested inclusion in the Contractor’s General Network, the Contractor shall give the affected Provider(s) written notice explaining the reason for its decision;

Page 134 of 324

9.1.1.5

Be allowed to negotiate different reimbursement amounts for different specialties or for different practitioners in the same specialty;

9.1.1.6

Be allowed to establish measures that are designed to maintain quality of services and control of costs and are consistent with its responsibility to Enrollees;

9.1.1.7

Not make payment to any Provider who has been barred from participation based on existing Medicare, Medicaid or CHIP sanctions, except for Emergency Services; and

9.1.1.8

Provide Enrollees with special health care needs direct access to a specialist, as appropriate for the Enrollee’s health care condition, as specified in 42 CFR 438.208(c)(4).

9.1.2

The Contractor shall have an adequate network of available Network Providers meeting all Contract requirements in order to (i) ensure timely Access to Covered Services (including complying with all Federal and Puerto Rico requirements concerning timeliness, amount, duration, and scope of services); and (ii) provide sufficient Network Providers to satisfy the demand of Covered Services with adequate capacity and quality service delivery.

9.1.3

When establishing and maintaining an adequate network of Providers, the Contractor shall consider and comply with each of the following criteria, in accordance with 42 CFR 438.206(b)(1):

9.1.3.1

Estimated eligible population and number of Enrollees;

9.1.3.2

Estimated use of services, considering the specific characteristics of the population and special needs for physical and Behavioral Health care;

9.1.3.3

Integration of physical health services and Behavioral Health Services using state facilities, academic medical centers, municipal health services and facilities;

9.1.3.4

Number and type of Providers required to offer services taking experience, training, and specialties into account;

9.1.3.5

Maximum number of patients per Provider;

9.1.3.6

The number of Providers in the PPN and General Network that are not accepting new patients; and

Page 135 of 324

9.1.3.7

Geographic location of Providers and Enrollees, taking into account distance as permitted by law, the duration of trip, the means of transportation commonly used by Enrollees, and whether the facilities provide physical access for Enrollees with physical disabilities or special needs.

9.1.3.8

Sufficient family planning Providers to ensure timely access to family planning Covered Services.

9.1.4

If the Contractor declines to include individual or groups of Providers in its network, it must give the affected Providers written notice of the reason for its decision. 42 CFR 438.12(a) may not be construed to:

9.1.4.1

Require the Contractor to contract with Providers beyond the number necessary to meet the needs of its Enrollees;

9.1.4.2

Preclude the Contractor from using different reimbursement amounts for different specialties or for different practitioners in the same specialty; or

9.1.4.3

Preclude the Contractor from establishing measures that are designed to maintain quality of services and control costs and is consistent with its responsibilities to Enrollees.

9.1.5

The provider’s facilities must comply with Federal and Puerto Rico laws regarding the physical condition of medical facilities, the P rovider’s facilities and must also comply with ASES ’s requirements including, but not limited to, accessibility, cleanliness and proper hygiene. ASES reserves the right to evaluate the appropriateness of such facilities to provide the Covered Services. After receiving a written notice from ASES, the Contractor must timely notify the Provider, propose and enforce a corrective plan to be completed within ninety (90) Calendar Days to make the facilities appropriate to provide the Covered Services.

9.1.5.1

The Contractor shall collaborate with the Providers to provide integrated GHP physical and Behavioral Health Services in order to achieve a fully integrated and holistic approach to providing Enrollee care.

9.1.5.2

The Contractor shall implement procedures in conjunction with the Providers to ensure that each GHP Enrollee has Access to both physical and Behavioral Health outpatient and inpatient services.

9.1.5.3

The Contractor shall develop policies and procedures that ensure timely Access to physical and Behavioral Health Services and integration of care.

Page 136 of 324

9.1.5.4

The Contractor shall submit its policies and procedures to ASES for prior written approval according to the timeframe set forth in Attachment 12 to this Contract

9.1.5.5

The Contractor must sub-contract ASSMCA to be a Behavioral Health Services provider.

9.1.6

The Contractor’s Network shall not include a Provider if the Provider, or any person who has an ownership or controlling interest in the Provider, or is an agent or managing employee of the Provider, is included on the List of Excluded Individuals/Entities (“LEIE”) (which is maintained by HHS-OIG), or who are on the Excluded Parties List System (“EPLS”) or on Puerto Rico’s list of excluded Providers. The Contractor shall check LEIE and EPLS upon the Provider’s Enrollment, Re-Enrollment, and on a monthly basis. Upon enrollment and Re-Enrollment the Contractor must also check the SSA Death Master File to make sure the Provider is not deceased and the National Plan and Provider Enumeration System (“NPPES”) to make sure the Provider has a NPI as required in Section 9.1.7.

9.1.7

The Contractor shall require that each Provider have a unique National Provider Identifier (“NPI”). When the NPI is reported to ASES, the NPI must be in the NPPES standard format.

9.1.8

Ambulatory clinics shall have a sufficient number of Providers to efficiently and promptly provide Behavioral Health Services to Enrollees visiting such clinics, including Vieques and Culebra. Contractor shall provide ASES with a report within the first ten (10) Business Days of each month indicating the number of Enrollees (including walk-ins) receiving Behavioral Health Services therein and the number of Providers providing these services during such period.

9.1.9

ASES shall have the right to previously approve Contractor’s clinical protocols to render behavioral health services and substance abuse to Enrollees in ambulatory care.

9.1.10

In the event that a determined type of Provider cannot be contracted by the Contractor due to lack of such Providers or due to such Provider’s refusal to contract for this GHP Program, the Contractor must carry out all efforts to contract with those Providers. The Contractor must validate and submit all supporting documents evidencing the lack of Providers or refusal to contract to ASES using Form A-102 provided as Attachment 15 to this Contract. ASES will make a determination based on the evidence submitted if any further action is required of the Contractor.

9.1.11

The Contractor is responsible for establishing and monitoring Medical Record guidelines which include documentation of all services provided by the Primary Care Providers as well as any participating Providers in the contracted Provider Network.

Page 137 of 324

9.1.12

Direct Relationship

9.1.12.1

The Contractor shall ensure that all Network Providers have knowingly and willingly agreed to participate in the Contractor’s General Network.

9.1.12.2

The Contractor shall be prohibited from acquiring established networks without contacting each individual Provider to ensure knowledge of the requirements of this Contract and to confirm the Provider’s complete understanding and agreement to fulfill all terms of the Provider Contract.

9.1.12.3

ASES reserves the right to confirm and validate, through collection of information, documentation from the Contractor and on-site visits to Network Providers, the existence of a direct relationship between the Contractor and the Network Providers.

9.1.13

Contractor Documentation of Adequate Capacity and Services

9.1.13.1

Before the Effective Date of this Contract and Immediately upon request by ASES after the Implementation Date of the Contract, the Contractor shall provide documentation demonstrating that it:

9.1.13.1.1

Offers an appropriate range of assessment and treatment, preventive, Primary Care, and specialty services that is adequate for the anticipated number of Enrollees and meets ASES’s Network Adequacy standards in accordance with Section 9.4; and

9.1.13.1.2

Maintains a Provider Network that is sufficient in number, mix, and geographic distribution to meet the needs of the anticipated number of Enrollees and meets ASES’s Network Adequacy Standards in accordance with Section 9.4.

9.1.13.2

The Contractor shall provide documentation of the Network Adequacy Standards stated in this Section 9.4 on an annual basis, and Immediately any time that there has been a significant change in the Contractor’s operations that would affect adequate capacity and services, including:

9.1.13.2.1

When there is a change in Benefits, composition of or payments to its Network Providers; or

9.1.13.2.2

Upon the Enrollment of a new eligibility group in the Contractor’s Plan.

Page 138 of 324

9.2

Provider Qualifications

9.2.1

The following requirements apply to Network Providers in the Contractor’s network:

	FQHC		A Federally Qualified Health Center is an entity that provides outpatient care under Section 330 of the Public Health Service Act (42 U.S.C. 254b) and complies with the standards and regulations established by the Federal Government and is an eligible Provider enrolled in the Medicaid Program.
	PHYSICIAN		A person with a license to practice medicine as an M.D. or a D.O. in Puerto Rico, whether as a PCP or in the area of specialty under which he or she will provide medical services through a contract with the Contractor; and is a Provider enrolled in the Puerto Rico Medicaid Program; and has a valid registration number from the Drug Enforcement Agency and the Certificate of Controlled Substances of Puerto Rico, if required in his or her practice.
	HOSPITAL		An institution licensed as a general or special hospital by the Puerto Rico Health Department under Chapter 241 of the Health and Safety Code of Private Psychiatric Hospitals under Chapter 577 of the Health and Safety Code (or who is a Provider which is a component part of the Puerto Rico or local governmental entity which does not require a license under the laws of Puerto Rico) which is enrolled as a Provider in the Puerto Rico Medicaid Program.
	NON-MEDICAL PRACTICING PROVIDER		A person who possesses a license issued by the licensing agency of Puerto Rico enrolled in the Puerto Rico Medicaid Program or a properly trained person who practices under the direct supervision of a licensed Provider offering support in health care services.
	CLINICAL LABORATORY		An entity that has a valid certificate issued by the Clinical Laboratory Improvement Act (“CLIA”) and which has a license issued by the licensing agency of the Puerto Rico. The Contractor shall ensure that all of the clinical laboratories under contract have a CLIA registration certificate and the registration number or a waiver certificate.

Page 139 of 324

	RURAL HEALTH CLINIC (RHC)		A health facility that the Secretary of Health and Human Services has determined meets the requirements of Section 1861(a)(2) of the Social Security Act; and that has entered into an agreement with the Secretary to provide services in Rural Health Clinics or Centers under Medicare and in accordance with 42 CFR 405.2402.
	LOCAL HEALTH DEPARTMENT		Local Health Department established under Act 81 from March 14, 1912.
	NON-HOSPITAL PROVIDING FACILITY		A Provider which is duly licensed and credentialed to provide services and is enrolled in the Puerto Rico Medicaid Program.
	SCHOOLS OF MEDICINE		Clinics located on the medical campus that provides Primary Care and Preventive Services to children and adolescents.
	MEDICAL PSYCHIATRIST		A person who possesses a license to practice medicine and a psychiatrist specialty license issued by the licensing agency of Puerto Rico and is enrolled in the Puerto Rico Medicaid Program or a properly trained person who practices psychiatry under the direct supervision of a licensed Provider.
	PSYCHOLOGIST		A person who possesses a Doctoral or Master’s Degree in clinical or counseling psychology and a license issued by the licensing agency of Puerto Rico and is enrolled in the Puerto Rico Medicaid Program or a properly trained person who practices psychology under the direct supervision of a licensed Provider.
	SOCIAL WORKER		A person who possesses a Master’s Degree in social work and a current license issued by the licensing agency of Puerto Rico and is enrolled in the Puerto Rico Medicaid Program or a properly trained person who practices social work under the direct supervision of a licensed Provider.
	DETOXIFICATION FACILITY		An entity or health facility that has a valid certificate and license to provide detoxification treatments issued by the licensing agency of Puerto Rico.
	SHORT TERM INTERVENTION CENTER (Stabilization Unit)		An entity or health facility that has a valid certificate and license to provide Behavioral Health Services issued by the licensing agency of Puerto Rico.

Page 140 of 324

9.2.2

The Contractor shall also ensure that Network Providers meet any other qualifications as prescribed by ASES.

9.2.3

Provider Credentialing

9.2.3.1

The Contractor shall be responsible for Credentialing and Re-Credentialing its Network Providers.

9.2.3.2

The Contractor shall ensure that all Network Providers are appropriately credentialed and qualified to provide services under the terms of this Contract, all applicable Federal and Puerto Rico law, and comply with CMS Credentialing requirements included in CMS Chapter VI of the Medicare Managed Care Manual.

9.2.3.3

ASES strongly encourages Contractors to implement a Credentialing Electronic Record System. ASES reserves the right to request access to the Contractor’s Credentialing Electronic Record Systems for monitoring purposes.

9.2.3.4

In the event ASES contracts with or requires Contractors to contract with a single credentialing verification organization to standardize Provider credentialing and re-credentialing processes across the GHP program, the Contractor shall work with ASES on implementing any new processes related to centralized credentialing.

9.2.3.5

Credentialing is required for:

9.2.3.5.1

All physicians who provide services to the Contractor’s Enrollees,

9.2.3.5.2

All other types of Providers who provide services to the Contractor’s Enrollees, and who are permitted to practice independently under Puerto Rico law including but not limited to: hospitals, X-ray facilities, clinical laboratories, and ambulatory service Providers.

9.2.3.6

Credentialing is not required for:

9.2.3.6.1

Providers who are permitted to furnish services only under the direct supervision of another practitioner;

9.2.3.6.2

Hospital-based Providers who provide services to Enrollees Incident to hospital services, unless those Providers are separately identified in Enrollee literature as available to Enrollees; or

9.2.3.6.3

Students, residents, or fellows.

Page 141 of 324

9.2.3.7

Standards for Credentialing and Re-Credentialing

9.2.3.7.1

The Contractor shall document the mechanism for Credentialing and Re-Credentialing of Network Providers or Providers it employs to treat Enrollees outside of the inpatient setting and who fall under its scope of authority and action. This documentation shall include, but not be limited to, defining the scope of Providers covered, the criteria and the primary source verification of Information used to meet the criteria, the process used to make decisions that shall not be discriminatory and the extent of delegated Credentialing and Re-Credentialing arrangements. The Contractor shall:

9.2.3.7.1.1

Have written policies and procedures for the Credentialing and Re-Credentialing process. Such process must permit providers to apply for Credentialing and Re-Credentialing online;

9.2.3.7.1.2

Meet Puerto Rico and Federal regulations for Credentialing and Re-Credentialing, including 42 CFR 455.104, 455.105, 455.106 and 1002.3(b);

9.2.3.7.1.3

Use one (1) standard Credentialing form prescribed by ASES;

9.2.3.7.1.4

Designate a Credentialing committee or other peer review body to make recommendations regarding Credentialing/Re-Credentialing issues;

9.2.3.7.1.5

Complete the Credentialing process within forty-five (45) Calendar Days from receipt of completed application with all required primary source documentation;

9.2.3.7.1.6

Ensure Credentialing/Re-Credentialing forms require ownership and control disclosures, disclosure of business transactions, and criminal conviction information in accordance with Section 9.2.3.7.1.2;

9.2.3.7.1.7

Verify that Network Providers maintain a current and valid license to practice. Verification must show that the license was in effect at the time of the Credentialing decision with a copy of a good standing; or with the Junta de Licenciamiento Médico/Junta de Profesionales de la Salud CD;

Page 142 of 324

9.2.3.7.1.8

Ensure education and training records, including, but not limited to, Internship, Residency, Fellowships, Specialty Boards etc., are validated and current. As per CMS chapter VI, section 60, education verification is required only for the highest level of education or training attained;

9.2.3.7.1.9

Ensure board certification, when applicable, in each clinical specialty area for which the Provider is being credentialed;

9.2.3.7.1.10

Ensure clinical privileges are in good standing at the hospital designated by the Provider, when applicable, as the primary admitting facility. This information may be obtained by contacting the facility, obtaining a copy of the participating facility directory or attestation by the Provider;

9.2.3.7.1.11

Ensure Network Providers maintain current and adequate malpractice insurance. This information may be obtained via the malpractice carrier, a copy of the insurance face sheet or attestation by the Provider;

9.2.3.7.1.12

Obtain Information about sanctions or limitations on licensure from the applicable Puerto Rico licensing agency or board, or from a group such as the Federation of State Medical Boards;

9.2.3.7.1.13

Ensure a valid Drug Enforcement Agency (“DEA") or Controlled Dangerous Substances (“CDS”) certificate in effect at the time of the Credentialing. This information can be obtained through confirmation with CDS, entry into the National Technical Information Service (“NTIS”) database, or by obtaining a copy of the certificate;

9.2.3.7.1.14

Review Network Provider’s history of professional liability claims that resulted in settlements or judgments paid by or on behalf of the Provider: This information can be obtained from the malpractice carrier or from the National Practitioner Data Bank;

9.2.3.7.1.15

Ensure that Behavioral Health Network Providers (as applicable) are trained and certified by the Substance Abuse and Mental Health Services Administration (“SAMHSA”) to provide the opiate addiction treatment certifications stated in Section 7.5.11.3;

Page 143 of 324

9.2.3.7.1.16

Ensure Credentialing of health care facilities shall be governed by, but not limited to, Law 101 of June 26, 1965, as amended, known as "Law of Facilities of Puerto Rico;"

9.2.3.7.1.17

Screen all Providers against the Federal databases specified in 42 CFR 455.436 on a monthly basis to ensure Providers are not employing or contracting with excluded individuals;

9.2.3.7.1.18

Have written policies and procedures, that have been prior approved in writing by ASES, to ensure and verify that providers have appropriate licenses and certifications to perform services outlined in their respective Provider Contracts; and

9.2.3.7.1.19

Maintain records that verify its Credentialing and Re-Credentialing activities, including primary source verification and compliance with Credentialing/Re-Credentialing requirements.

9.2.3.7.2

The Contractor shall perform the following functions:

9.2.3.7.2.1

Credential any Provider who contracts with the Contractor and maintaining complete Credentialing information for these Providers;

9.2.3.7.2.2

Identify potential and actual Network Providers who are enrolled with ASES as Medicaid Providers;

9.2.3.7.2.3

Require any Network Provider to be enrolled with the GHP as a managed care Provider;

9.2.3.7.2.4

Perform Site Visits. The Contractor’s site visit policy will be reviewed pursuant to CMS’ monitoring protocol. At a minimum, the Contractor should consider requiring initial Credentialing site visits of the offices of Primary Care practitioners, obstetrician- gynecologists, or other high-volume Providers, as defined by the organization;

Page 144 of 324

9.2.3.7.2.5

Re-Credential Network Providers every three (3) years;

9.2.3.7.2.6

Ensure all required documents and licenses are current at the time of initial Credentialing or Re-Credentialing;

9.2.3.7.2.7

Maintain a Provider file for all Network Providers. The Provider file shall be updated annually and consist of, at a minimum, the following documents: annual Puerto Rico review, DEA license, malpractice insurance and ASSMCA license.

9.2.3.7.2.8

The Contractor shall ensure, and be able to demonstrate at the request of ASES, that: (i) Out-of-Network Providers have been credentialed by an authoritative entity and that (ii) the Contractor’s internal Credentialing and Re-Credentialing processes are in accordance with 42 CFR 438.214 (Provider Selection).

9.2.3.7.2.9

If the Contractor determines, through the Credentialing or Re-Credentialing process, or otherwise, that a Provider could be excluded pursuant to 42 CFR 1001.1001, or if the Contractor determines that the Provider has failed to make full and accurate disclosures as required in Sections 13.5.13, the Contractor shall deny the Provider’s request to participate in the Provider Network, or, for a current Network Provider, as provided in Section 10.4.1.2, terminate the Provider Contract. The Contractor shall notify ASES of such a decision, and shall provide documentation of the bar on the Provider’s Network participation, within twenty (20) Business Days of communicating the decision to the Provider. The Contractor shall screen its employees, Network Providers, and Subcontractors initially and on an ongoing monthly basis to determine whether any of them have been excluded from participation in Medicare, Medicaid, CHIP, or any other Federal health care program (as defined in Section 1128B(f) of the Social Security Act). ASES or the Puerto Rico Medicaid Program shall, upon receiving notification from a Contractor that the Contractor has denied Credentialing, notify the HHS Office of the Inspector General of the denial with twenty (20) Business Days of the date it receives the Information, in conformance with 42 CFR 1002.4.

Page 145 of 324

9.2.3.7.2.10

The Contractor shall report to ASES on a monthly basis the Credentialing and Re-Credentialing status of Providers. The details of this report are described in Section 18.2.5.3 of this Contract.

9.2.4

Network Provider Enrollment as Medicaid Providers

9.2.4.1

Contractors shall ensure that all Network Providers are Medicaid-enrolled Providers consistent with the Provider disclosure, screening and enrollment requirement of 42 CFR part 455, subparts B and E as incorporated in 42 CFR 438.608(b).

9.2.4.2

Contractors may execute temporary Provider Contracts pending the outcome of the Medicaid provider enrollment process of up to one hundred twenty (120) Calendar Days but must terminate a Network Provider Immediately upon notification from ASES that the Network Provider cannot be enrolled, or the expiration of the one hundred twenty (120) Calendar Day period without enrollment of the Provider, and notify affected Enrollees.

9.2.4.3

Contractors shall assist ASES in facilitating the Medicaid Provider enrollment process, in the manner requested by ASES, including but not limited to the production or certification of Provider Credentialing records, distribution of ASES Provider agreements and all other verbal and/or written communications related to the Medicaid Provider enrollment process.

9.3

Network Description

9.3.1

General Network

9.3.1.1

The General Network shall be comprised of all Providers available to Enrollees including those Providers who are designated as preferred providers and those Providers who are not associated with a PMG.

9.3.1.2

The Contractor shall ensure that its General Network of Providers is adequate to assure Access to all Covered Services, and that all Providers are appropriately credentialed, maintain current licenses, and have appropriate locations to provide the Covered Services.

Page 146 of 324

9.3.1.3

The Contractor shall include and make a part of its General Network any Behavioral Health Provider who is qualified for the GHP (including meeting all Credentialing standards in this Contract) and willing to participate in the Network.

9.3.1.4

If the Contractor’s General Network is unable to provide Medically Necessary Covered Services to an Enrollee within the requirements set forth in Section 9.5, the Contractor shall adequately and timely (as defined in Section 9.5) cover these services using Providers outside of its Network without penalty or additional Co-Payments imposed on the Enrollee.

9.3.1.5

Primary Care Providers (PCPs)

9.3.1.5.1

PCPs will be responsible for providing, managing and coordinating all the services of the Enrollee, including the coordination with Behavioral Health personnel, in a timely manner, and in accordance with the guidelines, protocols, and practices generally accepted in medicine.

9.3.1.5.2

The Contractor shall offer its Enrollees freedom of choice in selecting a PCP. The Contractor shall have policies and procedures describing how Enrollees select their PCPs. The Contractor shall submit these policies and procedures to ASES for review and prior written approval according to the timeframes specified in Attachment 12 to this Contract.

9.3.1.5.3

The PCP is responsible for maintaining each Enrollee’s Medical Record, which includes documentation of all services provided by the PCP as well as any specialty services.

9.3.1.5.4

The following shall be considered PCPs for purposes of contracting with a PMG:

9.3.1.5.4.1

General practitioners;

9.3.1.5.4.2

Internists;

9.3.1.5.4.3

Family practice;

9.3.1.5.4.4

Pediatricians (optional for minors under the age of twenty-one (21)); and

Page 147 of 324

9.3.1.5.4.5

Gynecologists-Obstetricians (obligatory when the woman is pregnant or age twelve (12) or older; this Provider will also be selected for usual gynecological visits).

9.3.1.5.5

No PCP may own any financial control or have a direct or indirect economic interest (as defined in Act 101 of July 26, 1965) in any Ancillary Services facility or any other Provider (including clinical laboratories, pharmacies, etc.) under contract with the PMG.

9.3.1.5.6

Nurse practitioners and physician assistants may not be PCPs.

9.3.1.5.7

The Contractor shall guarantee that women who are pregnant select a gynecologist-obstetrician as their PCP. Additionally, the Contractor will permit female Enrollees to select a gynecologist-obstetrician for their routine gynecological visits at initial Enrollment.

9.3.1.6

Behavioral Health Providers

9.3.1.6.1

The Contractor shall have a sufficient number of Behavioral Health Providers to attend to the Behavioral Health needs of the Enrollees. The Contractor shall make available all specialties specified in this Section 9.3.1.6.

9.3.1.6.2

The Contractor shall have available and under contract a sufficient number of the following types of Network Providers to render services to all Enrollees:

9.3.1.6.2.1

Psychiatrist;

9.3.1.6.2.2

Clinical or Counseling Psychologist;

9.3.1.6.2.3

Social Workers (“MSW”);

9.3.1.6.2.4

Care Managers;

9.3.1.6.2.5

Certified Addiction Counselors; and

9.3.1.6.2.6

Behavioral Health Facilities, as specified in Article 2.

9.3.1.7

Network Provider Types

Page 148 of 324

9.3.1.7.1

For both the General Network and the PPN, the Contractor shall have available the following types of Network Providers:

9.3.1.7.2

Specialists:

9.3.1.7.2.1

Podiatrists, Optometrists, Ophthalmologists, Radiologists, Endocrinologists, Nephrologists, Pneumologists, Otolaryngologists (ENTs), Cardiologists, Urologists, Gastroenterologists, Rheumatologists, Dermatologists, Oncologists, Neurologists, Infectious Disease Specialists, Orthopedists, Physical & Rehabilitative Specialists (Physiatrist), General Surgeons, and Chiropractors.

9.3.1.7.2.2

The Contractor shall offer its Enrollees freedom of choice in selecting a dentist.

9.3.1.7.2.3

The Contractor shall offer its Enrollees freedom of choice in selecting Behavioral Health Providers.

9.3.1.7.3

Facilities

9.3.1.7.3.1

Clinical Laboratories;

9.3.1.7.3.2

X-Ray Facilities;

9.3.1.7.3.3

Hospitals;

9.3.1.7.3.4

Providers and facilities for Behavioral Health (Mental Health and Substance Use Disorder) Services;

9.3.1.7.3.5

Specialized service Providers;

9.3.1.7.3.6

Urgent care centers and emergency rooms; and

9.3.1.7.3.7

Any other Providers or facilities needed to offer Covered Services, except pharmacies, considering the specific health needs of Enrollees.

9.3.1.8

Out-Of-Network Providers

9.3.1.8.1

If the Contractor’s General Network is unable to provide Medically Necessary Covered Services to an Enrollee, the Contractor shall adequately and timely (within the standards in Section 9.5) cover these services using Providers outside of its General Network.

Page 149 of 324

9.3.1.8.2

Except as provided with respect to Emergency Services (see Section 7.5.9), if the Contractor offers the service through a Provider in the General Network but the Enrollee chooses to access the service from an Out-of-Network Provider, the Contractor is not responsible for payment.

9.3.1.8.3

The Contractor must ensure that Out-of-Network Providers are duly credentialed and shall pay them, at a minimum, the same rates the Contractor pays its Network Providers dependent on Provider type. To be considered Duly Credentialed, the Contractor shall demonstrate and evidence that the Out-of-Network Provider is properly licensed for the practice of medicine in Puerto Rico, properly certified for the specialty needed, participating provider of the Medicare Program or have privileges in good standing at a hospital from the Contractor's provider's network and complies with section 13.4 and 13.5.13.5 of this Contract.

9.3.1.9

The Contractor shall not restrict the choice of the Provider from whom an Enrollee may receive family planning services and supplies.

9.3.1.10

The Contractor shall provide female Enrollees with direct access to a women’s health specialist within the General Network for Covered Services necessary to provide women's routine and preventive health care services in addition to the Enrollee's designated source of primary care if that source is not a woman's health specialist.

9.3.2

The Contractor shall ensure, in collecting Co-Payments, that in the event that a Co-Payment is imposed on Enrollees for an Out-of-Network service, the Co-Payment shall not exceed the Co-Payment that would apply if services were provided by a Provider in the General Network.

9.3.3

The Contractor shall also develop, as a subset of its General Network of Providers, a Preferred Provider Network (“PPN”). The objectives of the PPN model are to increase access to Providers and needed services, improve timely receipt of services, improve the quality of Enrollee care, enhance continuity of care, and facilitate effective exchange of Protected Health Information between Providers and the Contractor. The PPN must satisfy the requirements for the General Network described in this section.

9.3.3.1

The PPN is established utilizing a PMG to deliver services to the Enrollees who select a PCP that is a member of an individual PMG.

Page 150 of 324

9.3.3.2

The Contractor shall offer a PPN to all Enrollees. Each provider in the PPN shall be associated with an individual PMG whose group includes PCPs, psychologists or Behavioral Health Providers in compliance with Section 8.2 and Attachment 10 to this Contract, clinical laboratories, x-ray facilities, specialists and other providers that meet network requirements described in this section.

9.3.3.3

Enrollees shall be allowed to receive services from all Providers within their PMG’s PPN without Referral or restriction.

9.3.3.4

Enrollees who receive a prescription from a Network Provider within the PPN/PMG shall be allowed to fill the prescription without the requirement of a Countersignature from their PCP.

9.3.3.5

Additional Preferred Provider Network (“PPN”) Standards

9.3.3.5.1

The Contractor shall establish policies and procedures that, at a minimum, include:

9.3.3.5.1.1

Criteria for participating in the PPN versus the General Network;

9.3.3.5.1.2

Standards for monitoring Provider performance;

9.3.3.5.1.3

Methodologies for monitoring Access to care,

9.3.3.5.1.4

Methodologies for identifying compliance issues; and

9.3.3.5.1.5

Measures to address identified compliance issues.

9.3.3.5.2

The Contractor shall submit its policies and procedures to ASES for review and prior written approval according to the timeframe specified in Attachment 12 to this Contract.

9.4

Network Adequacy Standards

9.4.1

The Contractor must maintain an Island-wide provider network that complies with the Network Adequacy Standards specified in Section 9.4. The Contractor must use Geographical-access and thermomapping to demonstrate that the contracted network is distributed across Puerto Rico such that it meets the needs of Enrollees. The Contractor shall provide adequate Access to Enrollees at all times.

9.4.2

In the event the Contractor cannot meet a Network Adequacy Standard in Section 9.4, an exception must be requested and approved in writing by ASES. The request must provide detailed information justifying the need for an exception and actions underway to meet compliance. The exception does not relieve the Contractor from remedying non-compliance with defined Network Adequacy Standards within a reasonable timeframe, or complying with a Corrective Act Plan established in collaboration with ASES. All approved exceptions must be reported in the annual Provider Network and Evaluation plan described in Section 18.3

Page 151 of 324

9.4.2.1

The standard by which ASES will evaluate the exception request will be based, at a minimum, on the number of Providers in that specialty practicing in Puerto Rico.

9.4.3

The Contractor shall comply with the following Provider-to-Enrollee Ratios, Provider Per Municipality requirements, and Required Network Providers standards for the General Network:

9.4.3.1

PCP Provider-to-Enrollee Ratios

9.4.3.1.1

The following specialties are considered PCPs: Family Practice, Internal Medicine (for Adults), General Medicine, and Pediatrics.

9.4.3.1.2

The Contractor’s provider network must have one (1) PCP per one thousand seven hundred (1,700) Enrollees (excluding Gynecologists);

9.4.3.1.3

The Contractor’s provider network must have one (1) Gynecologist (selected as the Enrollee’s PCP, if the Enrollee is female and twelve (12) years of age or older) per two thousand eight hundred (2,800) Enrollees (1:2,800);

9.4.3.1.4

In the event the Contractor assigns Enrollees to a PCP that exceeds the stated Provider-to-Enrollee Ratio requirement, the Contractor must obtain prior written approval for an exception from ASES to continue to assign Enrollees to the PCP. All approved exceptions must be reported in the annual Provider Network and Evaluation plan described in Section 18.3.

9.4.3.2

Hospital Provider-to-Enrollee Ratios

9.4.3.2.1

The Contractor’s provider network must have one (1) Hospital per fifty thousand (50,000) Enrollees (1:50,000).

9.4.3.3

Provider Per Municipality Requirements

9.4.3.3.1

The Contractor’s provider network must have two (2) Adult PCPs and one (1) Pediatric PCPs, as defined in Sections 9.4.4.1.1 and 9.4.4.2.1, respectively, in each municipality.

Page 152 of 324

9.4.3.3.2

The Contractor’s provider network must have one (1) Psychologist in each municipality.

9.4.3.4

Required Network Providers

9.4.3.4.1

The Contractor’s provider network must have one (1) FQHC.

9.4.3.4.2

The Contractor’s provider network must include all Government Health Care Facilities identified in Section 9.6.

9.4.3.4.3

The Contractor’s provider network must include all available emergency stabilization units, psychiatric hospitals, psychiatric partial hospitals, and certified Buprenorphine providers.

9.4.4

The Contractor shall comply with the minimum Time and Distance Standards for the General Network specified herein. Time and Distance Standards are developed for Urban and Non-Urban Areas as defined in Article 2 of this Contract.

9.4.4.1

Adult Primary Care Providers (PCP)

9.4.4.1.1

Providers classified as Adult PCPs for purposes of Time and Distance Standards are Internal Medicine, Family Practice, and General Practice.

9.4.4.1.2

Enrollees living in Urban Areas and Non-Urban Areas must have a choice of at least two (2) PCPs within fifteen (15) miles/thirty (30) minutes.

9.4.4.2

Pediatric PCPs

9.4.4.2.1

Providers classified as Pediatric PCPs for purposes of Time and Distance Standards are the following: Family Practice, General Practice, and Pediatrics.

9.4.4.2.2

Enrollees living in Urban Areas and Non-Urban Areas must have a choice of at least two (2) PCPs within fifteen (15) miles/thirty (30) minutes.

9.4.4.3

Obstetrics and Gynecology (OB/GYN) Providers

9.4.4.3.1

For female Enrollees age twelve (12) and older, the Contractor must ensure the provider network for OB/GYN Providers meet the following Time and Distance standards:

Page 153 of 324

9.4.4.3.2

Enrollees living in Urban Areas and Non-Urban Areas must have a choice of at least two (2) OB/GYN Providers within fifteen (15) miles/thirty (30) minutes.

9.4.4.4

High Volume Specialty Care Providers

9.4.4.4.1

High Volume Specialty Care Providers are Providers that comprise one (1) percent of utilization for the enrolled population, as identified by ASES. The Contractor must meet the following Time and Distance standards as specified in this section.

9.4.4.4.1.1

Adult High Volume Specialty Care Providers

9.4.4.4.1.1.1

Providers classified as Adult High Volume Specialty Care Providers for purposes of Time and Distances standards are the following: Cardiology, Dermatology, Endocrinology, Gastroenterology, Hematology, Oncology, Nephrology, Neurology, Orthopedic Surgery, Otoloaryngology, Podiatry, Psychiatry, Pulmonology, Rheumatology, Surgery, and Urology.

9.4.4.4.1.1.2

Enrollees living in Urban Areas must have one (1) of each type of Adult High Volume Specialty Care Provider within thirty (30) miles/sixty (60) minutes.

9.4.4.4.1.1.3

Enrollees living in Non-Urban Areas must have one (1) of each type Adult High Volume Specialist within forty-five (45) miles/ninety (90) minutes.

9.4.4.4.1.2

Pediatric High Volume Specialty Care Providers

9.4.4.4.1.2.1

Providers classified as Pediatric High Volume Specialty Care Providers for purposes of Time and Distance standards are the following: Allergy & Immunology, Cardiology, Dermatology, Endocrinology, Gastroenterology, Orthopedic Surgery, Otoloaryngology, Pulmonology, Speech, Language and Hearing, and Surgery.

Page 154 of 324

9.4.4.4.1.2.2

Enrollees living in Urban Areas must have one (1) of each type Pediatric High Volume Specialty Care Provider within thirty (30) miles/sixty (60) minutes.

9.4.4.4.1.2.3

Enrollees living in Non-Urban Areas must have one (1) of each type Pediatric High Volume Specialty Provider within forty-five (45) miles/ninety (90) minutes.

9.4.4.5

Adult and Pediatric Dental Providers

9.4.4.5.1

Enrollees living in Urban Areas must have one (1) Dental Provider within thirty (30) miles/sixty (60) minutes.

9.4.4.5.2

Enrollees living in Non-Urban Areas must have one (1) Dental Provider within forty-five (45) miles/ninety (90) minutes.

9.4.4.6

Adult and Pediatric Mental Health Providers

9.4.4.6.1

Providers classified as Adult and Pediatric Mental Health Providers for purposes of Time and Distance standards are the following: Psychiatrists, Psychologists, Licensed Clinical Social Worker, and Licensed Marriage Counselor.

9.4.4.6.2

Enrollees living in Urban Areas and Non-Urban Areas must have one (1) Psychologist within fifteen (15) miles/thirty (30) minutes.

9.4.4.6.3

Enrollees living in Urban Areas and Non-Urban Areas must have one (1) Psychiatrist within fifteen (15) miles/thirty (30) minutes.

9.4.4.6.4

Enrollees living in Urban Areas and Non-Urban Areas must have one (1) Social Worker or Licensed Marriage Counselor within fifteen (15) miles/thirty (30) minutes.

9.4.4.7

Adult and Pediatric Substance Use Disorder (SUD) Providers

9.4.4.7.1

Providers classified as Adult and Pediatric SUD Providers for purposes of Time and Distance standards are the following: Addiction Medicine, Inpatient Facility, SUD Treatment Programs (including intensive outpatient, inpatient, partial hospitalization, residential and withdrawal management).

Page 155 of 324

9.4.4.7.2

Enrollees living in Urban Areas must have one (1) SUD Provider within thirty (30) miles/sixty (60) minutes.

9.4.4.7.3

Enrollees living in Non-Urban Areas must have one (1) SUD Provider within forty-five (45) miles/ninety (90) minutes.

9.4.4.8

Hospitals

9.4.4.8.1

The Contractor must ensure Enrollees have access to all necessary specialty hospitals as needed based on the needs of the enrolled population.

9.4.4.8.2

Enrollees living in Urban Areas must have one (1) Hospital within thirty (30) miles/sixty (60) minutes.

9.4.4.8.3

Enrollees living in Non-Urban Areas must have one (1) Hospital within forty-five (45) miles/ninety (90) minutes.

9.4.4.9

Emergency Room (Hospital and Freestanding)

9.4.4.9.1

Facilities subject to the Time and Distance standard in this section are emergency rooms, either in a Hospital or a freestanding facility.

9.4.4.9.2

Enrollees living in any area of Puerto Rico must have one (1) Emergency Room within twenty (20) miles/thirty (30) minutes.

9.4.5

Network Adequacy Standards for the Preferred Provider Network (PPN)

9.4.5.1

The Contractor must ensure the PPN complies with the Network Adequacy Standards in Sections 9.4.3 and 9.4.4 for applicable Providers.

9.4.5.2

Each PMG shall be considered a PPN based on the number of Enrollees who have selected a PCP associated with the individual PMG.

9.4.6

The Parties acknowledge that there are shortages of certain Providers. The Contractor will work with the Provider community to address Enrollee Access to Providers to the extent possible. The Contractor will then develop policies and procedures to be prior approved in writing by ASES to ensure Enrollees have Access to services as necessary.

Page 156 of 324

9.4.7

Subject to Section 9.4 of this Contract, the aforementioned Provider-to Enrollee Ratios, Provider Per Municipality, Required Network Provider, and Time and Distance standards must be maintained for Enrollees, regardless of whether the Contractor offers treatment to other private patients.

9.4.8

ASES reserves the right to modify the Network Adequacy requirements herein based on a pattern of complaints from Enrollees or Providers regarding Access.

9.4.9

ASES reserves the right to modify Network Adequacy requirements herein based on a pattern of Access concerns in the Contractor’s Geographical Access and Appointment Availability reports.

9.5

Access

9.5.1

Appointment Standards and Minimum Requirements for Access to Providers

9.5.1.1

The Contractor shall provide adequate Access to Enrollees at all times and are subject to the appointment requirements described in Section 9.5. The Contractor shall provide Access to Covered Services in accordance with the following terms:

9.5.1.1.1

Non-Urgent Conditions

9.5.1.1.1.1

Routine physical exams shall be provided for all Enrollees within thirty (30) Calendar Days of the Enrollee’s request for the service, taking into account both the medical and Behavioral Health need and condition. For Enrollees less than twenty-one (21) years of age, the Contractor shall meet the EPSDT timeframes specified in Section 7.9.3 of this Contract and in accordance with Act No. 408.

9.5.1.1.1.2

Routine evaluations for Primary Care shall be provided within thirty (30) Calendar Days, unless the Enrollee requests a later time;

9.5.1.1.1.3

Covered Services shall be provided within fourteen (14) Calendar Days following the request for service;

9.5.1.1.1.4

Specialist Services shall be provided within thirty (30) Calendar Days of the Enrollee’s original request for service;

9.5.1.1.1.5

Dental services shall be provided within sixty (60) Calendar Days following the request, unless the Enrollee requests a later date;

Page 157 of 324

9.5.1.1.1.6

Behavioral Health Services shall be provided within fourteen (14) Calendar Day following the request, unless the Enrollee requests a later date;

9.5.1.1.1.7

Diagnostic laboratory, diagnostic imaging and other testing appointments shall be provided consistent with the clinical urgency, but no more than fourteen (14) Calendar Days, unless the Enrollee requests a later time;

9.5.1.1.1.8

Diagnostic laboratory, diagnostic imaging and other testing, if a “walk-in” rather than an appointment system is used, the Enrollee wait time shall be consistent with severity of the clinical need; and

9.5.1.1.1.9

ASES highly recommends that the Providers contracted by the Contractor implement an electronic prescribing system;

9.5.1.1.2

Urgent Conditions

9.5.1.1.2.1

Emergency Services shall be provided, including Access to an appropriate level of care as quickly as warranted based on the condition;

9.5.1.1.2.2

Primary medical, dental, and Behavioral Health Care outpatient appointments for urgent conditions shall be available within twenty-four (24) hours;

9.5.1.1.2.3

Urgent outpatient diagnostic laboratory, diagnostic imaging and other testing, appointment availability shall be consistent with the clinical urgency, but no longer than forty-eight (48) hours;

9.5.1.1.2.4

Behavioral Health crisis services, face-to-face appointments shall be available within two (2) hours; and

9.5.1.1.2.5

Detoxification services shall be provided Immediately according to clinical necessity;

9.5.1.1.3

The timing of scheduled follow-up outpatient visits with practitioners shall be consistent with the clinical need; and

Page 158 of 324

9.5.1.1.4

FQHC Services shall be provided in an FQHC setting. The Contractor shall adequately and timely cover these services out-of-network at no cost to Enrollees for as long as the FQHC Services are unavailable in the Contractor’s General Network. All out-of-network services require a Referral from the Enrollee’s PCP.

9.5.2

Access to Services for Enrollees with Special Health Needs

9.5.2.1

The Contractor shall require that its Network Providers evaluate any progressive condition of an Enrollee with special health needs that requires a course of regular monitored care or treatment. This evaluation will include the use of Providers for each identified case.

9.5.2.2

The Contractor shall establish a protocol to screen Enrollees for Special Coverage, Care Management, the High Cost High Needs Program, and the High Utilizer Program in order to facilitate direct access to specialists. The Contractor shall submit its operational protocol to ASES for prior written approval according to the timeframe specified in Attachment 12 to this Contract.

9.5.3

Hours of Service

9.5.3.1

The Contractor shall prohibit its Network Providers from having different hours and schedules for GHP Enrollees than what is offered to commercial Enrollees.

9.5.3.2

The Contractor shall prohibit its Providers from establishing specific days for the delivery of Referrals and requests for Prior Authorization for GHP Enrollees, and the Contractor shall monitor compliance with this rule and take corrective action if there is failure to comply.

9.5.3.3

The Contractor shall require Psychiatric Hospitals (or a unit within a general hospital), Emergency or Stabilization Units to have open service hours covering twenty-four (24) hours a day, seven (7) days a week. The Contractor shall require Partial Hospitalization Facilities to have open service hours covering ten (10) hours per day at least five (5) days per week and shall have available one (l) nurse, one (1) social worker and one (1) psychologist/psychiatrist. The Contractor shall require all other Behavioral Health Facilities to have open service hours covering twelve (12) hours per day, at least (5) days per week and shall have available one (1) nurse, one (1) social worker and one (1) psychologist/psychiatrist.

9.5.4

Preferential Turns

Page 159 of 324

9.5.4.1

The Contractor shall agree to establish a system of Preferential Turns for residents of the island municipalities of Vieques and Culebra. Preferential Turns refers to a policy of requiring Providers to give priority in treating Enrollees from these island municipalities, so that they may be seen by a physician within a reasonable time after arriving in the Provider’s office. This priority treatment is necessary because of the remote locations of these municipalities, and the greater travel time required for the residents to seek medical attention. This requirement was established in Laws No. 86 enacted on August 16, 1997 (Arts. 1 through 4) and Law No. 200 enacted on August 5, 2004 (Arts. 1 through 5). The Contractor shall include this requirement in the Provider Guidelines (see Section 10.2.1.4).

9.5.5

Extended Schedule of PMGs

9.5.5.1

PMGs shall be available to provide primary care services or consultations Monday through Saturday of each Week, from 8:00 a.m. to 6:00 p.m. (Atlantic Time). The following Holidays the PMG will not have to comply with this requirement: January 1 ^st , January 6 ^th , Good Friday, Thanksgiving Day and December 25 ^th . The PMG has the sole discretion to decide whether or not to provide Primary Care services during the previously listed holidays.

9.5.5.2

In addition, each Provider that offers urgent care services, as well as any other qualified Provider willing to provide urgent care services, shall have sufficient personnel to offer urgent care services during extended periods Monday through Friday from 6:00 p.m. to 9:00 p.m. (Atlantic Time), in order to provide Enrollees greater Access to their PCPs and to urgent care services.

9.5.5.3

PMGs may collaborate with each other to establish extended office hours at one (1) or multiple facilities.

9.5.5.4

The Contractor shall submit to ASES its policies and procedures for how it will determine the adequacy and appropriateness of Providers’ available hours, approve such arrangements, and monitor their operation and take corrective action if there is failure to comply. The policies and procedures shall be submitted for prior approval according to the timeframe specified in Attachment 12 to this Contract.

9.5.6

Provider Services Call Center

9.5.6.1

The Contractor shall operate a Provider services call center with a separate toll-free telephone line to respond to Provider questions, comments, inquiries and requests for prior authorizations.

Page 160 of 324

9.5.6.2

The Contractor shall develop Provider service line policies and procedures that address staffing, training, hours of operation, access and response standards, monitoring of calls via recording or other means, and compliance with standards. Such policies and procedures shall be prior approved in writing by ASES.

9.5.6.3

The Contractor shall ensure that the Provider service line is staffed adequately to respond to Providers’ questions at a minimum from 7 a.m. to 7 p.m. (Atlantic Time), Monday through Friday, excluding Puerto Rico holidays.

9.5.6.4

The Contractor shall have an automated system available during non-business hours. This automated system shall include, at a minimum, information on how to obtain after hours UM requests and a voice mailbox for callers to leave messages. The Contractor shall ensure that the automated system has adequate capacity to receive all messages. The Contractor shall return messages on the next Business Day.

9.5.6.5

The Provider service line shall also be adequately staffed to provide appropriate and timely responses regarding authorization requests as described in Article 11.4.2 of this Contract. The Contractor may meet this requirement by having a separate Utilization Management line.

9.5.6.6

The call center staff shall have access to electronic documentation from previous calls made by a Provider.

9.5.6.7

The Contractor shall adequately staff the provider service line to ensure that the line, including the Utilization Management line/queue, meets the following minimum performance standards on a monthly basis:

9.5.6.7.1

Less than five percent (5%) call abandonment rate;

9.5.6.7.2

Eighty percent (80%) of calls are answered by a live voice within thirty (30) seconds;

9.5.6.7.3

Blocked call rate does not exceed three percent (3%); and

9.5.6.7.4

One hundred percent (100%) of voicemails are returned within one (1) Business Day.

9.5.6.8

The Contractor shall submit a Call Center Report in a format prescribed by ASES.

Page 161 of 324

9.6

Government Health Care Facilities

9.6.1

The Contractor shall include and make part of its General Network, health care facilities administered or operated by the Central Government and State Academic Medical Centers providing services to the GHP, including at least the following:

9.6.1.1

Hospital Universitario Ramón Ruiz Arnau (HURRA);

9.6.1.2

Hospital Universitario de Adultos;

9.6.1.3

Hospital Federico Trilla;

9.6.1.4

Hospital Pediátrico Universitario;

9.6.1.5

Centro Cardiovascular de PR y del Caribe;

9.6.1.6

Administración de Servicios Médicos de PR (“ASEM”); and

9.6.1.7

Comprehensive Cancer Center of Puerto Rico (“Centro Comprensivo de Cancer”); and

9.6.1.8

Práctica Intramural del Recinto de Ciencias Médicas

ARTICLE 10

PROVIDER CONTRACTING

10.1

General Provisions

10.1.1

The Contractor shall establish a care model in which the PCP, located within a PMG, manages and coordinates the Enrollee’s care in a timely manner.

10.1.2

The PCP shall provide, manage, and coordinate services to the Enrollee, including coordination with Behavioral Health personnel, in a timely manner, and in accordance with the guidelines, protocols, and practices generally accepted in medicine.

10.1.3

The Contractor and each of its Network Providers shall work to ensure that physical and Behavioral Health Services are delivered in a coordinated manner and conform to the standards as provided in Article 8.

10.1.4

The Contractor shall contract with enough PMGs to serve the Enrollees. As a precondition to executing any Provider Contract, the Contractor shall comply with the requirements stated in Section 10.1.6.1 regarding submitting a model for each type of Provider Contract to ASES.

10.1.5

The Contractor shall not contract with any Provider without confirming and documenting that the Provider meets all of the Credentialing requirements specified in Section 9.2.3 of this Contract. Failure by the Contractor to adequately monitor the Credentialing of Providers may result in sanctions, liquidated damages, and/or fines in accordance with Articles 19 and 20 or termination of this Contract.

Page 162 of 324

10.1.6

Model Provider Contracts

10.1.6.1

The Contractor shall submit a model for each type of Provider Contract to ASES for review and prior written approval, according to the timeframe specified in Attachment 12 to this Contract. The Contractor shall include in such submission, at a minimum, model contracts for PMGs, PCPs, Ancillary Service Providers, Hospitals, Emergency Rooms, and Ambulance Services. The Contractor shall provide ASES with digitized copies of each finalized Provider Contract within thirty (30) Calendar Days of the effective date of the Provider Contract. At the time of submitting the finalized Provider Contract, the Contractor shall disclose to ASES whether the Provider falls under the prohibition stated in Sections 29.1, 29.2, or 29.6 of this Contract.

10.1.6.2

ASES shall review each executed Provider Contract against the approved models of Provider Contracts. ASES reserves the right to cancel Provider Contracts or to impose sanctions or fees against the Contractor for the omission of clauses required in the contracts with Providers.

10.1.6.3

On an ongoing basis, any modifications to models of Provider Contracts shall be submitted to ASES for review and prior written approval, before the amendment may be executed. Similarly, any amendments to Provider Contracts shall be submitted to ASES for review and prior written approval.

10.1.7

The Contractor shall not discriminate against a Provider that is acting within the scope of its license or certification under applicable Puerto Rico law, in decisions concerning contracting, solely on the basis of that license or certification. This Section shall not be construed as precluding the Contractor from using different payment amounts for different specialties, or for different Providers in the same specialty.

10.2

Provider Training

10.2.1

Provider Guidelines

10.2.1.1

The Contractor shall prepare Provider Guidelines, to be distributed to all Network Providers (General Network and PPN), summarizing the GHP program. The Provider Guidelines shall, in accordance with 42 CFR 438.236, (i) be based on valid and reliable clinical evidence or a consensus of Providers in the particular field; (ii) consider the needs of the Contractor’s Enrollees; (iii) be adopted in consultation with Providers; and (iv) be reviewed and updated periodically, as appropriate.

Page 163 of 324

10.2.1.2

The Provider Guidelines shall describe the procedures to be used to comply with the Provider’s duties and obligations pursuant to this Contract, and under the Provider Contract.

10.2.1.3

The Contractor shall submit the Provider Guidelines to ASES for review and prior written approval according to the timeframe specified in Attachment 12 to this Contract.

10.2.1.4

The content of the Provider Guidelines will include, without being limited to, the following topics: the duty to verify eligibility; selection of Providers by the Enrollee; Covered Services; procedures for Access to and provision of services; Preferential Turns, as applicable; coordination of Access to Behavioral Health Services; required service schedule; Medically Necessary Services available twenty-four (24) hours ; report requirements; Utilization Management policies and procedures; Medical Record maintenance requirements; Complaint, Grievance, and Appeal procedures (see Article 14); Co-Payments; HIPAA requirements; the prohibition on denial of Medically Necessary Services; Electronic Health Records and sanctions or fines applicable in cases of non-compliance; and Fraud, Waste and Abuse compliance.

10.2.1.5

The Provider Guidelines shall be delivered to each Network Provider as part of the Provider contracting process, and shall be made available to Enrollees and to Potential Enrollees upon request. The selected Contractor shall maintain evidence of having delivered the Provider Guidelines to all of its Network Providers within fifteen (15) Calendar Days of award of the Provider Contract. The evidence of receipt shall include the legible name of the Network Provider, NPI, date of delivery, and signature of the Network Provider and shall be made available to ASES Immediately upon request.

10.2.1.6

The Contractor shall have policies and procedures (that have been prior approved in writing by ASES in accordance with the timeframes in Attachment 12 to this Contract in place, including both updates to the Provider Guidelines and other communications) to inform its Provider Network, in a timely manner, of programmatic changes such as changes to drug formularies, Covered Services, and protocols.

10.2.2

Provider Education

10.2.2.1

The Contractor shall develop a continuing education curriculum for Providers consisting of twenty (20) hours per year divided into five (5) hours per quarter. The curriculum shall be submitted to ASES for review and prior written approval according to the timeframe specified in Attachment 12 to this Contract. The curriculum shall include a description of how the Contractor will educate Providers on Contract requirements and shall also include, at a minimum:

Page 164 of 324

10.2.2.1.1

Initial and ongoing Provider training and education literacy in Public Health, management of Rheumatoid Arthritis, management of diabetes, and Medicaid with specific emphasis on EPSDT and Behavioral Health Integration, the conditions of participation in the Contractor’s GHP Plan, billing processes, and the Provider’s responsibilities to the Contractor and its Enrollees; and

10.2.2.1.2

Initial and ongoing Provider education and training to address clinical issues and improve the service delivery system, including, but not limited to, assessments, treatment plans, plans of care, discharge plans, evidence-based practices and models of care such as integrated care and trauma-informed care.

10.2.2.2

The Contractor shall coordinate topics with the PBM’s Academic Detailing Program to develop educational activities addressing:

10.2.2.2.1

Management and implications of polypharmacy;

10.2.2.2.2

Condition management;

10.2.2.2.3

Management of prescriptions; and

10.2.2.2.4

Working with patients with conditions of special concern, including autism, ADHD, depression, and diabetes among others.

10.2.2.3

The Contractor shall use various forms of delivery when providing Providers’ training sessions, including web-based sessions, group workshops, face-to-face individualized education, newsletters, communications, and office visits.

10.2.2.4

The Contractor shall make the dates and locations of sessions available to Providers, as soon as possible, but no later than five (5) Business Days prior to the event.

10.2.2.5

Training shall be offered throughout the different geographic regions of Puerto Rico and at different times of the day in order to accommodate participating Providers’ schedules.

Page 165 of 324

10.2.2.6

The Contractor shall have a process to document Provider participation in continuing education, and shall provide ASES with, upon request, documentation that Provider education and training requirements have been met.

10.2.2.7

The Contractor shall provide technical assistance to Providers as determined necessary by the Contractor or by ASES.

10.2.2.8

The Contractor shall maintain a record of its training and technical assistance activities, which it shall make available to ASES upon request.

10.2.2.9

The Contractor shall adopt practice guidelines in accordance with the criteria in 42 CFR 438.236. Practice guidelines shall be disseminated to all affected Providers, and upon request to Enrollees and Potential Enrollees.

10.2.2.9.1

Decisions for utilization management, Enrollee education, coverage of services, and other areas to which the guidelines apply are consistent with the guidelines. This includes consultation and application of USPSTF recommendations when the Contractor is making coverage and utilization management decisions.

10.3

Required Provisions in Provider Contract s

10.3.1

All Provider Contracts shall be labeled with the Provider’s NPI, if applicable. In general, the Contractor’s Provider Contracts shall:

10.3.1.1

Include a section summarizing the Contractor’s obligations under this Contract, as they affect the delivery of health care services under the GHP, and describing Covered Services and populations (or, include the Provider Guidelines as an attachment);

10.3.1.2

Include a signature page that contains the Contractor and Provider names which are typed or legibly written, Provider company with titles, and dated signatures of all appropriate parties;

10.3.1.3

Specify the effective dates of the Provider Contract;

10.3.1.4

Require that the Provider work to advance the integrated model of physical and Behavioral Health Services;

10.3.1.5

Require that the Provider comply with the applicable Federal and Puerto Rico laws listed in Attachment 1 to this Contract, and with all CMS requirements;

Page 166 of 324

10.3.1.6

Require that the Provider verify the Enrollee’s Eligibility before providing services or making a Referral;

10.3.1.7

Prohibit any unreasonable denial, delay, or rationing of Covered Services to Enrollees; and violation of this prohibition shall be subject to the provisions of Article VI, Section 6 of Act 72 and of 42 CFR Part 438, Subpart I (Sanctions);

10.3.1.8

Prohibit the Provider from making claims for any un-allowed administrative expenses, as listed in Section 22.1.15;

10.3.1.9

Prohibit the unauthorized sharing or transfer of ASES Data, as defined in Section 28.1;

10.3.1.10

Notify the Provider that the terms of the contract for services under the GHP program are subject to subsequent changes in legal requirements that are outside of the control of ASES;

10.3.1.11

Require the Provider to comply with all reporting requirements contained in Article 18 of this Contract, as applicable, and particularly with the requirements to submit Encounter Data for all services provided, and to report all instances of suspected Fraud, Waste, or Abuse;

10.3.1.12

Require the Provider to acknowledge that ASES Data (as defined in Section 28.1.1) belongs exclusively to ASES, and that the Provider may not give access to, assign, or sell such Data to Third Parties, without Prior Authorization from ASES. The Contractor shall include penalty clauses in its Provider Contracts to prohibit this practice, and require that the fines be determined by and payable to ASES;

10.3.1.13

Prohibit the Provider from seeking payment from the Enrollee for any Covered Services provided to the Enrollee within the terms of the Contract, and require the Provider to look solely to the Contractor for compensation for services rendered to Enrollees, with the exception of any nominal cost-sharing, as provided in Section 7.11;

10.3.1.14

Require the Provider to cooperate with the Contractor’s quality improvement and Utilization Management activities;

10.3.1.15

Not prohibit a Provider from acting within the lawful scope of practice, from advising or advocating on behalf of an Enrollee for the Enrollee’s health status, medical care, or treatment or non-treatment options per 42 CFR 438.102(a)(1);

Page 167 of 324

10.3.1.16

Not prohibit a Provider from advocating on behalf of the Enrollee in any Grievance and Appeal System or Utilization Management process, or individual authorization process to obtain necessary health care services;

10.3.1.17

Require Providers to meet the timeframes for Access to services pursuant to Section 9.5 of this Contract;

10.3.1.18

Provide for continuity of treatment in the event that a Provider’s participation in the Contractor’s Network terminates during the course of an Enrollee’s treatment by that Provider;

10.3.1.19

Require Providers to monitor and as necessary and appropriate register Enrollee patients to determine whether they have a medical condition that suggests Care Management or inclusion in the High Cost High Needs Program services are warranted;

10.3.1.20

Prohibit Provider discrimination against high-risk populations or Enrollees requiring costly treatments;

10.3.1.21

Prohibit Providers who do not have a pharmacy license from directly dispensing medications, as required by the Puerto Rico Pharmacy Act (with the exception noted in Section 7.5.12.3.2);

10.3.1.22

Specify that ASES, CMS, the Office of Inspector General, the Comptroller General, the Medicaid Fraud Control Unit, and their designees, shall have the right at any time to inspect, evaluate, and audit any pertinent records or documents, including Enrollee records and financial records and transactions, and may inspect the premises, physical facilities, and equipment where activities or work related to the GHP program is conducted. Upon request, the Provider shall assist in such reviews, including the provision of complete copies of medical records. The right to audit exists for ten (10) years from the final date of the contract period or from the date of completion of any audit, whichever is later;

10.3.1.23

Include the definition and standards for Medical Necessity, pursuant to the definition in Section 7.2.1 of this Contract;

10.3.1.24

Require that the Provider attend promptly to requests for Prior Authorizations and Referrals, when Medically Necessary, in compliance with the timeframes set forth in Section 9.5 and in 42 CFR 438.210 and the Puerto Rico Patient’s Bill of Rights;

10.3.1.25

Prohibit the Provider from establishing specific days for the delivery of Referrals or requests for Prior Authorization;

Page 168 of 324

10.3.1.26

Notify the Provider that, in order to participate in the Medicare Platino Program, the Provider shall accept GHP Enrollees;

10.3.1.27

Specify rates of payment, as detailed in Section 10.5, and require that Providers accept such payment as payment in full for Covered Services provided to Enrollees, less any applicable Enrollee Co-Payments pursuant to Section 7.11 of this Contract;

10.3.1.28

Specify acceptable billing and coding requirements including ICD-10;

10.3.1.29

Require that the Provider comply with the Contractor’s Cultural Competency plan;

10.3.1.30

Require that any Marketing Materials developed and distributed by the Provider be submitted to the Contractor for submission to ASES for prior written approval;

10.3.1.31

Specify that the Contractor shall be responsible for any payment owed to Providers for services rendered after the Effective Date of Enrollment, as provided in Section 5.2.2, including during the retroactive period described in Section 5.1.3.1;

10.3.1.32

Require Providers to collect Enrollee Co-Payments as specified in Attachment 8 to this Contract;

10.3.1.33

Require that Providers not employ or subcontract with individuals on the Puerto Rico or Federal LEIE, or with any entity that could be excluded from the Medicaid program under 42 CFR 1001.1001 (ownership or control in sanctioned entities) and 1001.1051 (entities owned or controlled by a sanctioned person);

10.3.1.34

Require that Medically Necessary Services shall be available twenty-four (24) hours per day, seven (7) days per Week, to the extent feasible;

10.3.1.35

Prohibit the Provider from operating on a different schedule for GHP Enrollees than for other patients, and from in any other way discriminating in an adverse manner between GHP Enrollees and other patients;

10.3.1.36

Not require that Providers sign exclusive Provider Contracts with the Contractor if the Provider is an FQHC or RHC;

10.3.1.37

Provide notice that the Contractor’s negotiated rates with Providers shall be adjusted in the event that the Executive Director of ASES directs the Contractor to make such adjustments in order to reflect budgetary changes to the Medical Assistance program;

Page 169 of 324

10.3.1.38

Impose fees or penalties if the Provider breaches the contract or violates Federal or Puerto Rico laws or regulations;

10.3.1.39

Require that the Provider make every effort to cost-avoid claims and identify and communicate to the Contractor available Third Party resources, as required in Section 23.4 of this Contract, and require that the Contractor cover no health care services that are the responsibility of the Medicare Program;

10.3.1.40

Provide that the Contractor shall not pay Claims for services covered under the Medicare Program, and that the Provider may not bill both the GHP and the Medicare Program for a single service to a Dual Eligible Beneficiary;

10.3.1.41

Require the Provider to sign a release giving ASES access to the Provider’s Medicare billing Data for GHP Enrollees who are Dual Eligible Beneficiaries, provided that such access is authorized by CMS and compliant with all HIPAA requirements;

10.3.1.42

Set forth the Provider’s obligations under the Physician Incentive Programs outlined in Section 10.7 of this Contract;

10.3.1.43

Require the Provider to notify the Contractor Immediately if or whether the Provider falls within the prohibitions stated in Sections 29.1, 29.2, or 29.6 of this Contract or has been excluded from the Medicare, Medicaid, or Title XX Services Programs;

10.3.1.44

Include a penalty clause to require the return of public funds paid to a Provider that falls within the prohibitions stated in Section 29.1, 29.2 or 29.6 of this Contract;

10.3.1.45

Require that all reports submitted by the Provider to the Contractor be labeled with the Provider’s NPI, if applicable;

10.3.1.46

Require the Provider to participate in the Provider education activities described in Section 10.2.2;

10.3.1.47

Include Provider dispute process as described in Section 14;

10.3.1.48

Require the Provider to disclose information on ownership and control as specified in Section 54.2;

10.3.1.49

Require the Provider to disclose information as listed in Section 23.7.4; and

10.3.1.50

Require the Provider to comply with any transition of care requirements set forth in 42 CFR 438.62 and as specified in Section 5.5.

Page 170 of 324

10.3.1.51

Require Providers to submit timely, complete and accurate Encounter data. Failure to comply with Encounter data requirements may, at the Contractor’s discretion, subject the Provider to financial penalties.

10.3.1.52

Notify the Provider that Overpayments may be recouped by ASES or the Contractor on behalf of ASES.

10.3.1.53

Include a statement that HIPAA does not bar disclosure of protected health information (PHI) to Federal and State health oversight agencies, including, but not limited to, HHS-OIG, ASES, Medicaid Fraud Control Unit, and CMS, for oversight activities permitted under HIPAA, and provide that any such authorized agency or entity may use these records and information for administrative, civil, or criminal investigations, or other uses as permitted under HIPAA.

10.3.1.54

Specify that in the event that ASES, MFCU, HHS-OIG, or CMS identify that an Overpayment occurred due to suspected or confirmed fraud, the Provider may not claim recoupment by the Contractor or ASES as a defense to any criminal charges brought by a Federal or State entity of competent jurisdiction.

10.3.1.55

Require Providers to fully cooperate with any investigation performed by ASES, OIG, MFCU, or other State or Federal entities with competent jurisdiction, involving the GHP, and in any subsequent actions that may result from such an investigation.

10.3.1.56

Require that PCPs administer the Ages and Stages Questionnaire (“ASQ”) to the parents of child Enrollees as required under Section 7.7.9.3 of this Contract, as applicable.

10.3.1.57

Require that the PCP carry out the Modified Checklist for Autism in Toddlers (“M-CHAT R/F”) pursuant to Section 7.7.9.2 of this Contract, as applicable.

10.3.2

In addition to the required provisions in Section 10.3.1, the following requirements apply to specific categories of Provider contracts.

10.3.2.1

The Contractor’s contracts with PMGs shall:

10.3.2.1.1

Require that the PMG provide services on a regular time schedule, Monday through Saturday, from 8:00 a.m. to 6:00 p.m. (Atlantic Time); PMG will not have to comply with this requirement during the following holidays: January 1 ^st , January 6 ^th , Good Friday, Thanksgiving and December 25 ^th . The PMG has sole discretion to decide whether or not to provide services during the previously listed holidays;

Page 171 of 324

10.3.2.1.2

Require that the PMG employs enough personnel to offer urgent care services between 6:00 p.m. and 9:00 p.m. (Atlantic Time), Monday through Friday;

10.3.2.1.3

Require that the PMG coordinates with Behavioral Health personnel to ensure integrated physical and Behavioral Health Services, as provided in Article 8;

10.3.2.1.4

Require the PMG to work, to the extent possible, within the Contractor’s established PPN, in directing care for Enrollees and coordinating services;

10.3.2.1.5

Authorize the Contractor to adjudicate disputes between the PMG and its Network Providers about the validity of claims by any Network Provider; and

10.3.2.1.6

Require PMGs to provide assurances that the Encounter Data submitted by the PMG to the Contractor encompass all services provided to GHP Enrollees, including clinical laboratories.

10.3.2.2

The Contractor’s Provider Contracts with PCPs shall require the PCP to inform and distribute Information to Enrollee patients about instructions on Advance Directives, and shall require the PCP to notify Enrollees of any changes in Federal or Puerto Rico law relating to Advance Directives, no more than ninety (90) Calendar Days after the effective date of such change.

10.3.2.3

The Contractor’s Provider Contracts with a Network Provider who is a member of the PPN shall prohibit the Provider from collecting Co-Payments from GHP Enrollees, subject only to the exceptions established in Article 9 of this Contract and the Attachment 8 to this Contract (Co-Payment Chart).

10.3.2.4

The Contractor’s Provider Contracts with Hospitals and Emergency Rooms shall prohibit the Hospital or Emergency Room from placing a lower priority on GHP Enrollees than on other patients, and from referring GHP Enrollees to other facilities for reasons of economic convenience. Such contracts shall include sanctions penalizing this practice.

10.4

Termination of Provider Contracts

10.4.1

The Contractor shall comply with all Puerto Rico and Federal laws regarding Provider termination. The Provider Contracts shall:

10.4.1.1

Contain provisions allowing termination of the Provider Contract by the Contractor “for cause.” Termination of the Provider Contract will not be permitted without cause. Cause for termination includes, but is not limited to, gross negligence in complying with contractual requirements or obligations; a pattern of noncompliance with contractual requirements or obligations that the Provider fails to correct after being notified of such noncompliance by the Contractor; insufficiency of funds of ASES or the Contractor, which prevents them from continuing to pay for their obligations; changes in Federal or State law, among others. The Contractor shall not terminate a Provider Contract in retaliation for the Provider exercising his or her Appeal rights, advocating on behalf of the Provider, or for advocating on behalf of an Enrollee.

Page 172 of 324

10.4.1.2

Specify that in addition to any other right to terminate the Provider Contract, and notwithstanding any other provision of this Contract, ASES may demand Provider termination Immediately, or the Contractor may Immediately terminate on its own, a Provider’s participation under the Provider Contract if:

10.4.1.2.1

The Provider fails to abide by the terms and conditions of the Provider Contract, as determined by ASES, or, in the sole discretion of ASES, if the Provider fails to come into compliance within fifteen (15) Calendar Days after a receipt of notice from the Contractor specifying such failure and requesting such Provider to abide by the terms and conditions hereof; or

10.4.1.2.2

The Contractor or ASES learns that the Provider:

10.4.1.2.2.1

Falls within the prohibition stated in Section 29.1 or 29.2, or has a criminal conviction as provided in Section 29.6;

10.4.1.2.2.2

Has been or could be excluded from participation in the Medicare, Medicaid, or CHIP Programs;

10.4.1.2.2.3

Could be excluded from the Medicaid Program under 42 CFR 1001.1001 (ownership or control in sanctioned entities) and 1001.1051 (entities owned or controlled by a sanctioned person); and/or

10.4.1.2.2.4

Fails to comply with the Provider Credentialing process and requirements or is not a Medicaid enrolled Provider.

10.4.1.3

Specify that any Provider whose participation is terminated under the Provider Contract for any reason shall utilize the applicable Appeals procedures outlined in the Provider Contract. No additional or separate right of Appeal to ASES or the Contractor is created as a result of the Contractor’s act of terminating, or decision to terminate any Provider under this Contract. Notwithstanding the termination of the Provider Contract with respect to any particular Provider, this Contract shall remain in full force and effect with respect to all other Providers.

Page 173 of 324

10.4.2

The Contractor shall notify ASES at least forty-five (45) Calendar Days prior to the effective date of the suspension, termination, or withdrawal of a Provider from participation in the Contractor’s General Network. If the cause for termination falls under Section 10.4.1.2, the Contractor shall provide to ASES an explanation of the reasons for termination Immediately.

10.4.2.1

Notices provided to ASES under Section 10.4.2 must be accompanied by an explanation regarding how Network Adequacy will be met regardless of the termination, and a plan to transition Enrollees to a different Provider without interruptions to their care. Contractor shall amend or suspend the transition plan at ASES’s request.

10.4.3

Unless otherwise specified by ASES, the Contractor shall, within fifteen (15) Calendar Days of issuance of a notice of termination to a Provider, provide written notice of the termination to Enrollees who received his or her Primary Care from, or was seen on a regular basis by, the terminated Provider, and shall assist the Enrollee as needed in finding a new Provider.

10.5

Provider Payment

10.5.1

General Provisions

10.5.1.1

The Contractor guarantees payment for all Medically Necessary Services rendered by Providers on a person’s Effective Date of Enrollment, including during the retroactive period described in Section 5.1.3.1.

10.5.1.2

The Contractor shall require, as a condition of payment, that the Provider accept the amount paid by the Contractor or appropriate denial made by the Contractor (or, if applicable, payment by the Contractor that is supplementary to the Enrollee’s Third Party payer) plus any applicable amount of Co-Payment responsibilities due from the Enrollee as payment in full for the service.

10.5.1.3

The Contractor shall ensure that Enrollees are held unaccountable by the Provider for the costs of Medically Necessary Services except for applicable Co-Payment amounts (described in Section 9.3 of this Contract and Attachment 8 to this Contract).

Page 174 of 324

10.5.1.4

The insolvency, liquidation, bankruptcy, or breach of contract of any Provider will not release the Contractor from its obligation to pay for all services rendered as authorized under this Contract.

10.5.1.5

With the exceptions noted below, the Contractor shall negotiate rates with Providers, and such rates shall be specified in the Provider Contract. Payment arrangements may take any form allowed under Federal law and the laws of Puerto Rico, including Capitation payments, Fee-for-Service payment, and salary, if any, subject to Section 10.6 concerning permitted risk arrangements. However, the Contractor must consider the use of a benchmark for provider reimbursement rates equaling eighty percent (80%) of the 2018 Medicare fee schedule for the reimbursement of non-facility professional services related to cardiology and nuclear medicine services, and seventy percent (70%) of the 2018 Medicare fee schedule for the reimbursement of non-facility professional services related to all other specialties except radiation oncology, hematology/oncology, urology, interventional radiology and dialysis services. Any use of the 2018 Medicare fee schedule as a guideline to set maximum provider reimbursement rates shall not obligate the Contractor to increase current provider reimbursement rates that have been previously negotiated. The Contractor shall inform ASES in writing when it enters any Provider payment arrangement.

10.5.1.6

Any Capitation payment made by the Contractor to Providers shall be based on sound actuarial methods in accordance with 42 CFR 438.4. The Contractor shall submit data supporting the actuarial soundness of Capitation Payments to ASES, including the base data generated by the Contractor. All Provider payments by the Contractor shall be reasonable, and the amount paid shall not jeopardize or infringe upon the quality of the services provided.

10.5.1.7

Even if the Contractor does not enter into a capitated payment arrangement with a Provider, the Provider shall nonetheless be required to submit to the Contractor detailed Encounter Data (see Section 16.8 of this Contract).

10.5.1.8

The Contractor shall be responsible for issuing to the forms required by the Department of the Treasury, in accordance with all Puerto Rico laws, regulations, and guidelines.

10.5.1.9

The Contractor shall make timely payments to Providers in accordance with the timeliness standards outlined in Section 16.10 of this Contract.

Page 175 of 324

10.5.2

Payments to FQHCs and RHCs. When the Contractor negotiates a contract with an FQHC and/or an RHC, as defined in Section 1905(a)(2)(B) and 1905(a)(2)(C) of the Social Security Act, the Contractor shall pay to the FQHC or RHC rates that are comparable to rates paid to other similar Providers providing similar services. The Contractor shall cooperate with ASES and the Department of Health in ensuring that payments to FQHCs and RHCs are consistent with Sections 1902(a)(15) and 1902(bb)(5) of the Social Security Act.

10.5.3

Requirement to Verify Eligibility. The Contractor warrants that all of its Network Providers shall verify the eligibility of Enrollees before the Provider provides Covered Services. This verification of eligibility is a condition of receiving payment from the Contractor for Covered Services.

10.5.4

Payments to Providers Owing Funds to ASES. Upon receipt of notice from ASES that ASES is owed funds by a Provider due to an Overpayment or other reasons, the Contractor shall reduce payment to the Provider for all Claims submitted by that Provider by one hundred percent (100%), or such other amount as ASES may elect, until the amount owed to ASES is recovered. The Contractor shall promptly remit any such funds recovered to ASES in the manner specified by ASES. To that end, the Contractor’s Provider Contracts shall contain a provision giving notice of this obligation to the Provider, such that the Provider’s execution of the Contract shall constitute agreement with the Contractor’s obligation to ASES.

10.5.5

Payment Rates Subject to Change. The Contractor shall adjust its negotiated rates with Providers to reflect budgetary changes, as directed by the Executive Director of ASES, to the extent that such adjustments can be made within funds appropriated to ASES and available for payment to the Contractor. The Contractor’s Provider Contracts shall contain a provision giving notice of this obligation to the Provider, such that the Provider’s execution of the Provider Contract shall constitute agreement with the Contractor’s obligation to ASES.

10.5.6

Payments for Hospitalization Services or Services Extending for More than Thirty (30) Calendar Days. In the event of hospitalization or extended services that exceed thirty (30) Calendar Days, the Provider may bill and collect payments for services rendered to the Enrollee at least once per month. These services shall be paid according to the procedures discussed in this Article 10.

10.5.7

Payments for Services to Dual Eligible Beneficiaries. The Contractor shall include in its Provider Contracts a notice that the Contractor shall not pay Claims for services covered under the Medicare Program except as set forth in Section 23.5. No Provider may bill both the GHP and the Medicare Program for a single service rendered to a Dual Eligible Beneficiary. The Contractor shall include in its Provider Contracts a requirement that the Provider shall comply with 42 CFR 447.15 to accept Medicaid payments as payment in full.

Page 176 of 324

10.5.8

Payment for Pharmacy Services. The Contractor shall abide by and comply with the following payment process hereby established:

10.5.8.1

In covering pharmacy services, the Contractor shall adhere to the retail pharmacy reimbursement levels established in Attachment 6 to this Contract.

10.5.8.2

On a bi-monthly payment cycle to be set by the PBM, the PBM will provide the Contractor with the proposed Claims listing. The Contractor shall promptly review the payment listing.

10.5.8.3

The PBM will submit to the Contractor the invoice and summary, which includes the amount of Claims cost to be paid to participating Pharmacies and the amount to switch fees to be paid to the PBM. The Contractor shall electronically transfer funds to the PBM’s bank account within two (2) Business Days after receiving the invoice from the PBM. The Contractor shall certify the listing of medications dispatched and paid bi-weekly to confirm the PBM’s and/or other Contractors’ administrative payment.

10.5.8.4

The Contractor, ASES, and the PBM shall cooperate to identify additional savings opportunities, including special purchasing opportunities, changes in network fees, etc.

10.5.9

Payments to Providers Outside the PPN. The Contractor shall provide for adequate payment in its contracts with Providers outside the PPN.

10.5.10

Payments for Emergency Services and Post-Stabilization Services

10.5.10.1

The Contractor shall not deny a Claim from a Provider for Emergency Services and shall make payment to a Provider for responding to an Enrollee’s Emergency Medical Condition or Psychiatric Emergency by performing medical screening examinations and stabilizing treatment.

10.5.10.2

Pursuant to Section 1932(b)(2)(D) of the Social Security Act, the Contractor shall limit payments to Out-of-Network Providers of Emergency Services to the amount that would have been paid if the service had been provided by a Network Provider.

10.5.11

Payments to State Health Facilities . The Contractor shall establish a payment system, upon request in writing by ASES, to improve cash flow to health care facilities administered or operated by the Central Government identified in Section 9.6.1 that participate in the General Network. Such payment system shall not be structured as a pass-through payment.

Page 177 of 324

10.6

Acceptable Risk Arrangements

10.6.1

The Contractor’s Provider Contracts with PMGs shall establish a financial risk arrangement agreed upon between the Contractor and the PMG which shall be clearly stated in the PMG contract with the Contractor.

10.7

Physician Incentive Programs

10.7.1

General Provisions

10.7.1.1

The Contractor may, upon prior written approval from ASES, design and implement one (1) Physician Incentive Plan, and shall incorporate the requirements of this plan into Provider Contracts. The Contractor shall submit a written request to ASES before implementing any such incentive program by providing a summary of the program for ASES review and approval at least sixty (60) Calendar Days before the projected implementation date for the program. ASES has the absolute right to approve or disapprove the Physician Incentive program, and the program may be implemented only upon receipt of prior written approval from ASES.

10.7.1.2

ASES will approve a Physician Incentive Program only if it, in ASES’s discretion, meets the following requirements:

10.7.1.2.1

The program contains credible medical standards in support of the improvement of quality health services and reduces or eliminates any adverse effects on patients’ care;

10.7.1.2.2

All incentive payments to Providers are related to or made under quality initiatives supported or otherwise approved by CMS;

10.7.1.2.3

The implementation of the program in no way reduces or otherwise limits Enrollee Access to Medically Necessary Services (including a reduction in prescription drugs, diagnostic tests or treatments, hospitalization, and other treatment available regardless of the incentives);

10.7.1.2.4

The Contractor shall employ continuous monitoring by an independent Third Party to confirm that Enrollee care is not adversely affected by the program;

10.7.1.2.5

The intent of the program is to improve the quality of the services to Enrollees. Enrollees shall be informed of the existence of the Physician Incentive program, and the Provider shall be made fully responsible for the proper care to the Enrollee; and

Page 178 of 324

10.7.1.2.6

Incentives are not used to penalize Providers who serve Enrollees whose treatment needs, according to the Provider’s medical judgment, do not fall within the Contractor’s fixed clinical protocols.

10.7.2

Pay for Performance for Hospitals. ASES approves the use of incentive programs targeting hospitals, provided that the incentive programs:

10.7.2.1

Encourage the use of medical standards that support quality improvement and reduce adverse effects in Enrollee care;

10.7.2.2

Advance the quality initiatives supported by CMS;

10.7.2.3

Are not geared toward, and do not have the likely effect of, reducing or limiting services that the Enrollee needs or may need (for example, reduction of diagnostic exams, hospitalization, or treatment);

10.7.2.4

Are not used solely as a mechanism for reducing payments to or recovering payments from Providers;

10.7.2.5

Contain clearly defined objectives, effectively communicated to both Providers and (upon request) Enrollees;

10.7.2.6

Aim to reduce “never events,” such as health care-associated infections and other hospital-acquired conditions (including reaction to foreign substances accidentally left in during procedure, air embolism, blood incompatibility, pressure ulcers, and falls);

10.7.2.7

Address inappropriate admissions and readmissions; and

10.7.2.8

Address over-utilization of caesarian sections.

ARTICLE 11

UTILIZATION MANAGEMENT

11.1

General

11.1.1

The Contractor shall comply with Puerto Rico and Federal requirements for Utilization Management (“UM”) including but not limited to 42 CFR Part 456.

11.1.2

The Contractor shall ensure the involvement of appropriate, knowledgeable, currently practicing Providers in the development of UM procedures.

11.1.3

The Contractor shall manage the use of a limited set of resources and maximize the effectiveness of care by evaluating clinical appropriateness, and authorizing the type and volume of services through fair, consistent, and Culturally Competent decision-making processes while ensuring equitable Access to care and a successful link between care and outcomes.

Page 179 of 324

11.1.4

The Contractor shall submit to ASES on an annual basis existing UM edits in the Contractor’s Claims processing system that control Utilization and prevent payment for Claims that are duplicates, unbundled when they should be bundled, already covered under another charge, etc.

11.1.5

ASES reserves the right require the Contractor to submit any Utilization Management report.

11.2

Utilization Management Policies and Procedures

11.2.1

The Contractor shall provide assistance to Enrollees and Providers to ensure the appropriate Utilization of resources. The Contractor shall have written Utilization Management policies and procedures included in the Provider Guidelines (see Section 10.2.1.4) that:

11.2.1.1

Include protocols and criteria for evaluating Medical Necessity, authorizing services, and detecting and addressing over, under, and inappropriate Utilization. Such protocols and criteria shall comply with Federal and Puerto Rico laws and regulations.

11.2.1.2

Address which services require PCP Referral, which services require Prior Authorization, and how requests for initial and continuing services are processed, and which services will be subject to concurrent, retrospective, or prospective review.

11.2.1.3

Describe mechanisms in place that ensure consistent application of review criteria for Prior Authorization decisions and consult with the requesting Provider when appropriate.

11.2.1.4

Require that all Medical Necessity determinations be made in accordance with ASES’s Medical Necessity definition as stated in Section 7.2. Divergence from standards set forth in clinical protocols and guidelines cannot be the sole reason for denying a Covered Service if the divergence is documented by the treating physician and supported by clinical evidence and generally accepted medical norms; appropriate in type, frequency, grade, setting and duration; and not solely for the convenience of the Enrollee, treating or other Provider, or the Contractor.

11.2.1.5

Facilitate the delivery of high quality, low cost, efficient, and effective care.

11.2.1.6

Ensure that services are based on the history of the problem or illness, its context, and desired outcomes.

Page 180 of 324

11.2.1.7

Emphasize relapse and crisis prevention, not just crisis intervention.

11.2.1.8

Detect over, under, and inappropriate Utilization of services to assess quality and appropriateness of services and to assess quality and appropriateness of care furnished to Enrollees with special health care needs.

11.2.1.9

Ensure that any decision to deny a Service Authorization Request or to authorize a service in an amount, duration, or scope that is less than requested, be made by a Provider who has appropriate clinical expertise to understand the treatment of the Enrollee’s condition or disease, such as the Contractor’s medical director.

11.2.2

The Contractor shall submit its Utilization Management policies and procedures to ASES for review and prior written approval according to the timeframe specified in Attachment 12 to this Contract.

11.2.3

The Contractor’s Utilization Management policies and procedures shall define when a conflict of interest for a Provider involved in Utilization Management activities may exist and shall describe the remedy for such conflict.

11.2.4

The Contractor, and any delegated Utilization Management agent, shall not permit or provide compensation or anything of value to its employees, Agents, or contractors based on:

11.2.4.1

Either a percentage of the amount by which a Claim is reduced for payment or the number of Claims or the cost of services for which the person has denied authorization or payment; or

11.2.4.2

Any other method that encourages a decision to deny, limit, or discontinue a Medically Necessary Covered Service to any Enrollee, as set forth by 42 CFR 438.210(e).

11.2.5

If the Contractor delegates any of its utilization management responsibilities under this Section 11.2 or 11.4 to any delegated Utilization Management agent or Subcontractor, such agent or Subcontractor shall also comply with written policies and procedures for processing requests for authorizations of services in accordance with 42 CFR 438.210(b)(1).

11.3

Utilization Management Guidance to Enrollees

11.3.1

As provided in Section 6.4.5.22, the Contractor shall provide clear guidance in its Enrollee Handbook on Utilization Management policies. Upon request, the Contractor shall provide Utilization Management decision criteria to Providers, Enrollees, their families, and the public.

Page 181 of 324

11.4

Prior Authorization and Referral Policies

11.4.1

Referrals

11.4.1.1

The Contractor shall not require a Referral from a PCP when an Enrollee seeks care from a Provider in the Contractor’s PPN.

11.4.1.2

A written Referral from the PCP shall be required:

11.4.1.2.1

For the Enrollee to access specialty care and services within the Contractor’s General Network but outside the PPN; and

11.4.1.2.2

For the Enrollee to access an Out-of-Network Provider (with the exception of Emergency Services).

11.4.1.3

A Referral for either the General Network or out-of-network services will be provided during the same visit with the PCP but no later than twenty-four (24) hours of the Enrollee’s request.

11.4.1.4

When a Provider does not make the Referral in the required timeframe specified, or refuses to make a Referral, the Contractor shall issue an Administrative Referral.

11.4.1.5

Neither the Contractor nor any Provider or Subcontractor may impose a requirement that Referrals be submitted for the approval of committees, boards, Medical Directors, etc. The Contractor shall strictly enforce this directive and shall issue Administrative Referrals (see Section 11.4.1.4) whenever it deems medically necessary.

11.4.1.6

If the Provider Access requirements of Section 9.5 of this Contract cannot be met within the PPN within thirty (30) Calendar Days of the Enrollee’s request for the Covered Service, the PMG shall refer the Enrollee to a specialist within the General Network, without the imposition of Co-Payments. However, the Enrollee shall return to the PPN specialist once the PPN specialist is available to treat the Enrollee.

11.4.1.7

The Contractor shall ensure that PMGs comply with the rules stated in this Section concerning Referrals, so that Enrollees are not forced to change PMGs in order to obtain needed Referrals.

11.4.1.8

If the Referral system that is developed by the Contractor requires the use of electronic media, such equipment shall be installed in Network Providers’ offices at the Contractor’s expense.

11.4.2

Timeliness of Prior Authorization

Page 182 of 324

11.4.2.1

The Contractor shall ensure that Prior Authorization is provided for the Enrollee in the following timeframes, including on holidays and outside of normal business hours.

11.4.2.1.1

With the exception of Prior Authorization of covered prescription drugs as described in Section 7.5.12.4.2, the decision to grant or deny a Prior Authorization shall not exceed seventy-two (72) hours from the time of the Enrollee’s Service Authorization Request for all Covered Services; except that, where the Contractor or the Enrollee’s Provider determines that the Enrollee’s life or health could be endangered by a delay in accessing services, the Prior Authorization shall be provided as expeditiously as the Enrollee’s health requires, and no later than twenty-four (24) hours from the Service Authorization Request.

11.4.2.1.2

The Contractor may extend the time allowed for Prior Authorization decisions for up to fourteen (14) Calendar Days, where:

11.4.2.1.2.1

The Enrollee, or the Provider, requests the extension; or

11.4.2.1.2.2

The Contractor justifies to ASES a need for the extension in order to collect additional Information, such that the extension is in the Enrollee’s best interest.

11.4.2.1.3

If the timeframe is extended in accordance with 11.4.2.1.2.2, the Contractor shall give the Enrollee written notice of the reason behind granting the extension and inform the Enrollee of the right to file a Grievance if he or she disagrees with that decision. The notice of the determination shall be sent as expeditiously as the Enrollee’s health condition requires and no later than the expiration date of the extension.

11.4.2.2

For services that require Prior Authorization by the Contractor, the Service Authorization Request shall be submitted promptly by the Provider for the Contractor’s approval, so that Prior Authorization may be provided within the timeframe set forth in this Section 11.4.2.

11.4.2.3

The Contractor shall notify the Enrollee and Provider, verbally or in writing, of the approval of a Service Authorization Request Immediately after such determination is made. Notices of Adverse Benefit Determinations must comply with the requirements set forth in Section 14.4.

Page 183 of 324

11.4.3

The Contractor shall submit to ASES Utilization Management clinical criteria to be used for services requiring Prior Authorization. ASES shall prior approve in writing such Utilization Management clinical criteria.

11.4.4

Prohibited Actions

11.4.4.1

Any denial, unreasonable delay, or rationing of Medically Necessary Services to Enrollees is expressly prohibited. The Contractor shall ensure compliance with this prohibition from Network Providers or any other entity related to the provision of Behavioral Health services to GHP Enrollees. Should the Contractor violate this prohibition, the Contractor shall be subject to the provisions of Article VI, Section 6 of Act 72 and 42 CFR 438, Subpart I (Sanctions).

11.4.5

The Contractor shall employ appropriately licensed professionals to supervise all Prior Authorization decisions and shall specify the type of personnel responsible for each type of Prior Authorization in its policies and procedures. Any decision to deny a Service Authorization Request or to authorize a service in an amount, duration, or scope that is less than requested shall be made by a Provider who possesses the appropriate clinical expertise for treating the Enrollee’s condition. For Service Authorization Requests for dental services, only licensed dentists are authorized to make such decisions.

11.4.6

Emergency Services

11.4.6.1

Neither a Referral nor Prior Authorization shall be required for any Emergency Service, no matter whether the Provider is within the PPN, and notwithstanding whether there is ultimately a determination that the condition for which the Enrollee sought treatment from an Emergency Services Provider was not an Emergency Medical Condition or Psychiatric Emergency.

11.4.7

Dental Services

11.4.7.1

The Contractor shall not require a Prior Authorization or a Referral for dental services except for maxillofacial surgery which requires Prior Authorization from a PCP.

11.4.8

Pharmacy Services

11.4.8.1

The Contractor shall require Prior Authorization for filling a drug prescription for certain drugs specified on the FMC, as provided in Section 7.5.12.10.

11.4.8.2

The Contractor shall require a Countersignature from the Enrollee’s PCP in order to fill a prescription written by a Provider who is not in the PPN.

Page 184 of 324

11.4.8.3

Any required Prior Authorization or Countersignature for pharmacy services shall be conducted within the timeframes provided in Sections 7.5.12.4.

11.4.8.4

The Contractor shall comply with the Utilization Management policies and procedures in Section 7.5.12 of this Contract for pharmacy services.

11.4.9

Special Coverage

11.4.9.1

In order to obtain services under Special Coverage, an Enrollee shall be registered in the program, as provided in Section 7.7. Registration is a form of Utilization control, to determine whether the Enrollee’s health condition warrants Access to the expanded services included in Special Coverage.

In addition, as noted in Section 7.7.12, some individual Special Coverage services require Prior Authorization even for Enrollees who have registered under Special Coverage.

11.4.10

Behavioral Health Services. The Contractor shall not require a Prior Authorization or a Referral for Behavioral Health services except for Partial Hospitalizations, Electroconvulsive Therapy and some medications as indicated in the FMC.

11.5

Use of Technology to Promote Utilization Management

11.5.1

ASES strongly encourages the Contractor to develop electronic, web-based Referral processes and systems. In the event that a Referral is made via the telephone, the Contractor shall ensure that Referral Data are maintained in a Data file that can be accessed electronically by the Contractor, the Provider, and ASES.

11.5.2

In conjunction with its other Utilization Management policies, the Contractor shall submit the Referral processes to ASES for review and prior written approval in accordance with Attachment 12 to this Contract.

11.6

Court-Ordered Evaluations and Services

11.6.1

In the event that an Enrollee requires Medicaid-covered services ordered by a court, the Contractor shall fully comply with all court orders while maintaining appropriate Utilization Management practices.

11.7

Second Opinions

11.7.1

The Contractor shall provide a second opinion in any situation when there is a question concerning a diagnosis, the options for surgery, or alternative treatments of a health condition when requested by any Enrollee, or by a parent, guardian, or other person exercising a custodial responsibility over the Enrollee.

Page 185 of 324

11.7.2

The second opinion shall be provided by a qualified Network Provider, or, if a Network Provider is unavailable, the Contractor shall arrange for the Enrollee to obtain a second opinion from an Out-of-Network Provider.

11.7.3

The second opinion shall be provided at no cost to the Enrollee.

ARTICLE 12

QUALITY IMPROVEMENT AND PERFORMANCE PROGRAM

12.1

General Provisions

12.1.1

The Contractor shall provide for the delivery of quality care to all Enrollees with the primary goal of improving health status or, in instances where the Enrollee’s health is not amenable to improvement, maintaining the Enrollee’s current health status by implementing measures to prevent any further deterioration of his or her health status.

12.1.2

The Contractor shall seek input from, and work with, Enrollees, Providers, community resources, and agencies to actively improve the quality of care provided to Enrollees.

12.1.3

The Contractor shall ensure that its Quality Assessment and Performance Improvement Program effectively monitors the program elements listed in 42 CFR 438.66.

12.1.4

ASES, in strict compliance with 42 CFR 438.340 and other Federal and Puerto Rico regulations, shall evaluate the delivery of health care by the Contractor. Such quality monitoring shall include monitoring of all the Contractor’s Quality Management/Quality Improvement (“QM/QI”) programs described in this Article 12 of this Contract.

12.1.5

The Contractor shall cooperate with any Puerto Rico or Federal monitoring of its performance under this Contract, which may include but is not limited to external quality reviews, operational reviews, performance audits and evaluations.

12.1.6

The Contractor shall identify, collect and provide any Data, Medical Records or other Information requested by ASES or its authorized representative or the Federal agency or its authorized representative in the format specified by ASES/Federal agency or its authorized representative. The Contractor shall ensure that the requested Data, Medical Records, and other Information is provided at no charge to ASES, all Federal agencies, or their authorized representative.

Page 186 of 324

12.1.7

If requested, the Contractor shall provide workspace at the Contractor’s local offices for ASES, any Federal agencies, or their authorized representative to review requested Data, Medical Records, or other Information.

12.1.8

Advisory Board

12.1.8.1

The Contractor shall convene and facilitate an advisory board. Advisory board members shall serve to advise the Contractor on issues concerning service delivery and quality of all Covered Services (e.g., Behavioral Health, physical health), Enrollee rights and responsibilities, resolution of Enrollee Grievances and Appeals and the needs of groups represented by advisory board members as they pertain to Medicaid.

12.1.8.2

The advisory board shall consist of representatives from all GHP populations, family members, and Providers. The Contractor shall have an equitable representation of its representatives in terms of race, gender, special populations, and Puerto Rico’s geographic areas.

12.1.8.3

The Contractor’s advisory board shall keep a written record of all attempts to invite and include its representatives in its meetings. The Advisory Board roster and minutes shall be made available to ASES ten (10) Calendar Days following the meeting date. See Article 18 of this Contract for additional reporting requirements.

12.1.8.4

The Contractor shall hold quarterly, centrally located advisory board meetings throughout the Contract Term. The Contractor shall advise ASES ten (10) Calendar Days in advance of meetings to be held. At least two (2) of the quarterly meetings shall focus on Enrollee issues to help ensure that Enrollee issues and concerns are heard and addressed. Attendance rosters and minutes for these two (2) meetings shall be made available to ASES within ten (10) Calendar Days following the meeting date.

12.1.8.5

The Contractor shall ensure that all advisory board representatives actively participate in deliberations and that no one board representative dominates proceedings in order to foster an inclusive meeting environment.

12.2

Quality Assessment Performance Improvement (“QAPI”) Program

12.2.1

The Contractor shall comply with Puerto Rico and Federal standards for Quality Management/Quality Improvement (“QM/QI”).

12.2.1.1

The Contractor shall establish QAPI that specifies the Contractor’s quality measurement and performance improvement activities using clinically sound, nationally developed and accepted criteria.

Page 187 of 324

12.2.2

For Medicaid and CHIP Eligibles, the QAPI program shall be in compliance with Federal requirements specified at 42 CFR 438.330.

12.2.3

The Contractor’s QAPI program shall be based on the latest available research in the area of quality assurance and at a minimum shall include:

12.2.3.1

A method of monitoring, analyzing, evaluating, and improving the delivery, quality and appropriateness of health care furnished to all Enrollees (including over, under, and inappropriate Utilization of services) and including those with special health care needs, as defined by ASES in the quality strategy;

12.2.3.2

Written policies and procedures for quality assessment, Utilization Management, and continuous quality improvement that are periodically assessed for efficacy and reflect Enrollee and Network Provider input;

12.2.3.3

Include an Information System sufficient to support the collection, integration, tracking, analysis, and reporting of Data, in compliance with 42 CFR 438.242;

12.2.3.4

Designated staff with expertise in quality assessment, Utilization Management, and continuous quality improvement;

12.2.3.5

A review of outcome Data at least quarterly for performance improvement recommendations and interventions;

12.2.3.6

A mechanism to detect over, under, and inappropriate Utilization of services;

12.2.3.7

Reports that have been evaluated, indicated recommendations that are implemented, and provided feedback to Providers and Enrollees;

12.2.3.8

A methodology and process for conducting Provider Credentialing and Re-Credentialing;

12.2.3.9

Procedures for validating completeness and quality of Encounter Data;

12.2.3.10

Annual PIPs as specified by ASES;

12.2.3.11

Development of an emergency room (ER) quality initiative program (see Section 12.4);

12.2.3.12

Development of a Health Care Improvement Program (see Section 12.5);

Page 188 of 324

12.2.3.13

Reporting on specified performance measures, including specified performance measures (see Section 12.5.4.1);

12.2.3.14

Conducting Provider and Enrollee satisfaction surveys (see Section 12.6);

12.2.3.15

Quarterly reports on program results, conclusions, recommendations, and implemented system changes, as specified by ASES; and

12.2.3.16

Process for evaluating the impact and effectiveness of the Contractor’s QAPI program at least annually.

12.2.4

The Contractor’s annual QAPI program shall be submitted to ASES for review and prior written approval according to the timeframe specified in Attachment 12 to this Contract and the annual reporting requirements outlined in Article 18.

12.2.5

The Contractor shall submit any changes to its QAPI program to ASES for review and prior written approval sixty (60) Calendar Days prior to implementation of the change.

12.2.6

Upon the request of ASES, the Contractor shall provide any Information and documents related to the implementation of the QAPI program.

12.2.7

As per 42 CFR 438.332(a) and (b), the Contractor shall inform ASES as to whether it has been accredited by a private, independent accrediting entity, and if so, shall provide or authorize the accrediting entity to provide ASES, as applicable, a copy of its most recent accreditation review (including its accreditation status, expiration date of the accreditation, and survey type and level) recommended actions or improvements, corrective action plans, and summaries of findings.

12.3

Performance Improvement Projects (PIPs)

12.3.1

At a minimum, the Contractor shall have a PIPs work plan and activities that are consistent with Federal and Puerto Rico statutes, regulations, and Quality Assessment and Performance Improvement Program requirements for pursuant to 42 C.F.R. 438.330.For more detailed information refer to the “EQR Managed Care Organization Protocol” available at http://www.medicaid.gov/Medicaid-CHIP- Program-Information/By-Topics/Quality-of-Care/Quality-of-Care-External- Quality-Review.html.

12.3.2

PIPs shall be designed to achieve, through ongoing measurements and intervention, significant improvement, sustained over time, in clinical care and administrative areas that are expected to have a favorable effect on health outcomes and Enrollee satisfaction.

12.3.3

The Contractor shall implement PIPs in the following areas:

Page 189 of 324

12.3.3.1

One (1) clinical care project in the area of increasing fistula use for Enrollees at-risk for dialysis;

12.3.3.2

One (1) clinical care project in the area of Behavioral Health;

12.3.3.3

One (1) administrative project in the area of EPSDT screening;

12.3.3.4

One (1) administrative project in the area of reverse co-location and co-location of physical and Behavioral Health and their integration; and

12.3.3.5

The Contractor shall conduct additional PIPs as specified by ASES during the Contract Term.

12.3.4

In designing its PIPs, the Contractor shall:

12.3.4.1

Show that the selected area of study is based on a demonstration of need and is expected to achieve measurable benefit to Enrollee (rationale);

12.3.4.2

Establish clear, defined and measurable goals and objectives that the Contractor shall achieve in each year of the project;

12.3.4.3

Measure performance using quality indicators that are objective, measurable, clearly defined and that allow tracking of performance and improvement over time;

12.3.4.4

Implement interventions designed to achieve quality improvements;

12.3.4.5

Evaluate the effectiveness of the interventions;

12.3.4.6

Establish standardized performance measures (such as HEDIS or another similarly standardized product);

12.3.4.7

Plan and initiate activities for increasing or sustaining improvement; and

12.3.4.8

Document the Data collection methodology used (including sources) and steps taken to assure Data is valid and reliable.

12.3.5

The Contractor shall submit all descriptions of PIPs and program details to ASES annually as part of the QAPI program.

12.3.6

Each PIP shall be evaluated by the EQRO. The Contractor shall provide information to the EQRO on the status and outcomes of the PIP upon request.

12.3.7

When requested, the Contractor shall submit Data to ASES or the EQRO for standardized PIPs. The Contractor shall collect valid and reliable Data, using qualified staff and personnel to collect the Data. Failure of the Contractor to follow Data collection and submission requirements may result in sanctions.

Page 190 of 324

12.4

ER Quality Initiative Program

12.4.1

The Contractor shall develop an emergency room (ER) quality initiative program, implementing efficient and timely monitoring of Enrollees’ use of the emergency room, including whether such use was justified by a legitimate Emergency Medical Condition or Psychiatric Emergency.

12.4.2

The ER quality initiative program shall be designed to identify high users of Emergency Services for non-emergency situations and to allow for early interventions in order to ensure appropriate Utilization of services and resources.

12.4.3

The ER quality initiative program shall specify all strategies to be used by the Contractor to address high users of inappropriate Emergency Services and include, at a minimum, the following components:

12.4.3.1

Description of system(s) for tracking, monitoring, and reporting high users of ER services for non-emergency situations;

12.4.3.2

Criteria for defining non-emergency situations;

12.4.3.3

Educational component to inform (i) Enrollees about the proper use of ER services and how to access ER services and (ii) PCPs about identifying high users or potential high users of ER services and reporting to the Contractor;

12.4.3.4

Protocols for identifying high users of inappropriate ER services and referring them to Care Management for needs assessment and identification of other more appropriate services and resources;

12.4.3.5

Process for ensuring the provision of physical and Behavioral Health Services in an appropriate setting upon identification of the need.

12.4.3.6

Quarterly reporting on ER services Utilization; and

12.4.3.7

Process for monitoring and evaluating program effectiveness, identifying issues, and modifying the ER quality initiative program as necessary to improve service Utilization.

12.4.4

The Contractor shall submit its ER quality initiative program to ASES as part of its QAPI program.

Page 191 of 324

12.5

Health Care Improvement Program (HCIP)

12.5.1

The HCIP consists of four (4) initiatives subject to performance indicators specified in the Health Care Improvement Program Manual (“HCIP Manual”), Attachment 19 to this Contract). The initiatives are further defined in the HCIP Manual and the HCIP Manual will be the authoritative document for specifying the performance indicators and measurement periods for the Contract Term.

12.5.1.1

High Cost Conditions Initiative;

12.5.1.2

Chronic Conditions Initiative;

12.5.1.3

Healthy People Initiative; and

12.5.1.4

Emergency Room High Utilizers Initiative

12.5.2

ASES shall establish a Retention Fund, whereby, per Section 22.4, ASES shall withhold two percent (2%) of PMPM Payments on a monthly basis otherwise payable to the Contractor in order to incent the Contractor to meet performance indicators and targets under Health Care Improvement Program specified in the HCIP Manual. The HCIP Manual will be the authoritative document for specifying the allocation of the overall withhold amount of the PMPM Payments across the initiatives in Section 12.5.1. The Retention Fund shall be reimbursed on a quarterly basis to the Contractor when a determination is made by ASES that the Contractor has complied with the quality standards and criteria established by ASES in accordance with Section 22.4 of this Contract.

12.5.2.1

The Contractor shall submit its quality incentive program as part of its QAPI program. The program description shall include, at a minimum:

12.5.2.1.1

How the Contractor will educate Providers regarding the program requirements; and

12.5.2.1.2

Strategies for ensuring and monitoring program compliance.

12.5.3

When requested, the Contractor shall submit Data to ASES for standardized performance measures, within specified timelines and according to the established procedures Data collection and reporting. The Contractor shall collect valid and reliable Data, using qualified staff and personnel to collect the Data. Failure of the Contractor to follow Data collection and reporting requirements may result in sanctions.

12.6

Wellness Plan

12.6.1

In order to advance the goals of strengthening Preventive Services, providing integrated physical, Behavioral Health, and dental services to all Eligible Persons, and educating Enrollees on health and wellness, the Contractor shall develop a Wellness Plan.

Page 192 of 324

12.6.1.1

The Wellness Plan shall include a strategy for coordination with government agencies of Puerto Rico integral to disease prevention efforts and education efforts, including the Health Department, the Department of the Family, and the Department of Education. The Wellness Plan shall incorporate strategies to reach all Enrollees including those living in remote areas.

12.6.1.2

The Wellness Plan shall present strategies for encouraging Enrollees to:

12.6.1.2.1

Seek an annual health checkup;

12.6.1.2.2

Appropriately use the services of the GHP, including GHP Service Line;

12.6.1.2.3

Seek women’s health screenings including mammograms, pap smears, cervical screenings, and tests for sexually transmitted infections;

12.6.1.2.4

Maintain a healthy body weight, through good nutrition and exercise;

12.6.1.2.5

Seek an annual dental exam;

12.6.1.2.6

Seek Behavioral Health screening;

12.6.1.2.7

Attend to the medical and developmental needs of children and adolescents, including vaccinations; and

12.6.1.2.8

Receive education regarding the diagnosis and treatment of high-risk diagnoses including:

12.6.1.2.8.1

Depression;

12.6.1.2.8.2

Schizophrenia;

12.6.1.2.8.3

Bipolar disorders;

12.6.1.2.8.4

Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder;

12.6.1.2.8.5

Substance abuse; and

12.6.1.2.8.6

Anxiety disorders.

Page 193 of 324

12.6.1.2.9

The Contractor shall ensure that its Wellness Plan reaches, at a minimum, eighty-five percent (85%) of GHP Enrollees. To achieve the eighty-five (85%) goal, the Contractor shall, in compliance with the requirements of HIPAA and the rules and regulations thereunder, utilize wellness advertisements, campaigns and/or seminars, including without limitation, health fairs, educational activities, visits to enrollees, and others. The Contractor shall also ensure that educational activities are offered by duly licensed professionals, within the scope of their clinical career, who are knowledgeable enough in the specific areas to be addressed in the educational activity. These professionals include, but are not limited to: Health Educators, Nutritionists, Nurses, Psychologists and Physicians.

12.6.1.3

The Contractor shall, according to the timeframe specified in Attachment 12 to this Contract, present its Wellness Plan to ASES for review and prior written approval.

12.7

Provider and Enrollee Satisfaction Surveys

12.7.1

The Contractor shall perform an annual satisfaction survey for Providers and Enrollees. The survey for Enrollees shall be the Consumer Assessment of Health Care Providers and Systems (“CAHPS”) and the Experience of Care and Health Outcomes (“ECHO”) survey instruments.

12.7.2

The sample size for both surveys shall equal the number of respondents needed for a statistical confidence level of ninety-five percent (95%) with a margin of error not more than five percent (5%) and shall not have a response rate less than fifty percent (50%).

12.7.3

The results of the surveys shall be submitted to ASES and to the Puerto Rico Medicaid Program.

12.7.4

The Contractor shall have a process for notifying Providers and Enrollees about the availability of survey findings and making survey findings available upon request.

12.7.5

The Contractor shall have a process for utilizing the results of the Provider and Enrollee surveys for monitoring service delivery and quality of services and for making program enhancements.

12.8

External Quality Review

12.8.1

In compliance with Federal requirements at 42 CFR 438.358, ASES will contract with an External Quality Review Organization (“EQRO”) to conduct annual, external, independent reviews of the quality outcomes, timeliness of, and Access to, the services covered in this Contract. The Contractor shall collaborate with ASES’s EQRO to develop studies, surveys, and other analytic activities to assess the quality of care and services provided to Enrollees and to identify opportunities for program improvement. To facilitate this process the Contractor shall supply Data, including but not limited to Claims Data and Medical Records, to the EQRO. Upon the request of ASES, the Contractor shall provide its protocols for providing Information, participating in review activities, and using the results of the reviews to improve the quality of the services and programs provided to Enrollees.

Page 194 of 324

12.8.2

The EQRO shall also audit the Contractor’s Performance Improvement Projects (“PIPs”), performance measure program, and the Contractor’s performance against quality standards based on CMS criteria. The Contractor shall cooperate fully with the EQRO.

12.8.3

The Contractor shall participate with the EQRO in various other tasks and projects identified by ASES to gauge performance in a variety of areas, including the integration of physical and Behavioral Health, care coordination, and treatment of special populations.

12.8.4

The EQRO retained by ASES shall not be a competitor of the Contractor and shall comply with 42 CFR 438.354.

ARTICLE 13

FRAUD, WASTE, AND ABUSE

13.1

General Provisions

13.1.1

The Contractor shall have and implement a comprehensive internal administrative and management controls, policies, and procedures in place designed to prevent, detect, report, investigate, correct, and resolve potential or confirmed cases of Fraud, Waste, and Abuse in the administration and delivery of services detailed in this Contract.

13.1.2

For Medicaid and CHIP Eligibles, the Contractor’s internal controls, policies, and procedures shall comply with all Federal requirements regarding Fraud, Waste, and Abuse and program integrity, including but not limited to Sections 1128, 1128A, 1156, 1842(j)(2), 1902(a)(68), and 1903(i)(2)(C) of the Social Security Act, 42 CFR 438.608, the CMS Medicaid Integrity program, and the Deficit Reduction Act of 2005. The Contractor shall exercise diligent efforts to ensure that no payments are made to any person or entity that has been excluded from participation in Federal health care programs. (See State Medicaid Director Letter #09-001, January 16, 2009.)

13.1.3

The Contractor shall have surveillance and Utilization control programs and procedures (see 42 CFR 456.3, 42 CFR 456.4, 42 CFR 456.23) to safeguard against under-utilization, unnecessary or inappropriate use of Covered Services and against excess payments for Covered Services.

Page 195 of 324

13.1.4

The Contractor shall have adequate staffing and resources to identify and investigate unusual incidents and develop and implement Corrective Action plans to assist the Contractor in preventing and detecting potential Fraud, Waste, and Abuse.

13.1.5

The Contractor shall establish effective lines of communication between the Contractor’s compliance officer and the Contractor’s employees to facilitate the oversight of systems that monitor service Utilization and Encounters for Fraud, Waste, and Abuse.

13.1.6

The Contractor shall submit its Fraud, Waste, and Abuse policies and procedures, its proposed compliance plan, and its program integrity plan to ASES for prior written approval according to the timeframe specified in Attachment 12 to this Contract.

13.1.7

Any changes to the Contractor’s Fraud, Waste, and Abuse policies and procedures shall be submitted to ASES for approval within fifteen (15) Calendar Days of the date the Contractor plans to implement the changes and the changes shall not go into effect until ASES provides prior written approval.

13.1.8

The Contractor shall comply with all program integrity provisions of the PPACA including:

13.1.8.1

Enhanced Provider screening and enrollment, Section 6401;

13.1.8.2

Termination of Provider participation, Section 6501;

13.1.8.3

Provider disclosure of current or previous affiliation with excluded Provider(s), Section 6401; and

13.1.8.4

Provider screening and enrollment, 42 CFR Part 455, Subpart E.

13.1.9

The Contractor shall inform ASES in writing Immediately upon becoming aware of a compliance breach related to the Contractor and/or Network Provider.

13.1.10

The Contractor shall inform the Medicaid Fraud Control Unit and ASES of any meetings it holds with any other GHP MCOs related to compliance and program integrity issues at least forty-eight (48) hours prior to the meeting. The Contractor shall provide a copy of the meeting minutes as well as the results of any follow-up investigations to ASES in writing Immediately.

13.1.11

The Contractor shall have policies and procedures prior approved in writing by ASES to address (i) Immediately notifying ASES of pending Network Provider investigations, suspensions and debarment and (ii) transitioning Enrollees from suspended and debarred Network Providers.

Page 196 of 324

13.2

Compliance Plan

13.2.1

The Contractor shall have a written Fraud, Waste, and Abuse compliance plan with stated program goals and objectives, program scope, and methodology to evaluate program performance. A paper and electronic copy of the compliance plan shall be provided to ASES annually for prior written approval. ASES shall provide notice of approval, denial, or modification to the Contractor within thirty (30) Calendar Days of receipt. The Contractor shall make any necessary changes required by ASES within an additional thirty (30) Calendar Days of the request.

13.2.2

At a minimum, the Contractor’s Fraud, Waste, and Abuse compliance plan shall, in accordance with 42 CFR 438.608:

13.2.2.1

Ensure that all of its officers, directors, managers and employees know and understand the provisions of the Contractor’s Fraud, Waste, and Abuse compliance plan;

13.2.2.2

Require the designation of a compliance officer and a compliance committee that are accountable to the Contractor’s senior management. The compliance officer shall have express authority to provide unfiltered reports directly to the Contractor’s most senior leader and governing body;

13.2.2.3

Ensure and describe effective training and education for the compliance officer and the Contractor’s employees;

13.2.2.4

Ensure that Providers and Enrollees are educated about Fraud, Waste, and Abuse identification and reporting in the materials provided to them;

13.2.2.5

Ensure effective lines of communication between the Contractor’s compliance officer and the Contractor’s employees to ensure that employees understand and comply with the Contractor’s Fraud, Waste, and Abuse program;

13.2.2.6

Ensure enforcement of standards of conduct through well-publicized disciplinary guidelines;

13.2.2.7

Ensure internal monitoring and auditing with provisions for prompt response to potential offenses, and for the development of corrective action initiatives relating to the Contractor’s Fraud, Waste, and Abuse efforts;

13.2.2.8

Describe standards of conduct that articulate the Contractor’s commitment to comply with all applicable Puerto Rico and Federal requirements and standards;

Page 197 of 324

13.2.2.9

Ensure that no individual who reports Provider violations or suspected cases of Fraud, Waste, and Abuse is retaliated against; and

13.2.2.10

Include a monitoring program that is designed to prevent and detect potential or suspected Fraud, Waste, and Abuse. This monitoring program shall include but not be limited to:

13.2.2.10.1

Monitoring the billings of its Providers to ensure Enrollees receive services for which the Contractor is billed;

13.2.2.10.2

Requiring the investigation of all reports of suspected cases of Fraud and over-billings;

13.2.2.10.3

Reviewing Providers for over, under and inappropriate Utilization;

13.2.2.10.4

Verifying with Enrollees the delivery of services as claimed; and

13.2.2.10.5

Reviewing and trending Enrollee Complaints regarding Providers.

13.2.3

The Contractor, and any Subcontractors delegated the responsibility by the Contractor for coverage of services and payment of claims under this Contract, shall include in all employee handbooks a specific discussion of the False Claims Act and its Fraud, Waste, and Abuse policies and procedures, the rights of employees to be protected as whistleblowers, and the Contractor and Subcontractor’s procedures for detecting and preventing Fraud, Waste, and Abuse.

13.2.4

The Contractor shall include in the Enrollee Handbook instructions on how to report Fraud, Waste, and Abuse and the protections for whistleblowers.

13.3

Program Integrity Plan

13.3.1

The Contractor shall develop a program integrity plan that at a minimum:

13.3.1.1

Defines Fraud, Waste, and Abuse;

13.3.1.2

Specifies methods to detect Fraud, Waste, and Abuse;

13.3.1.3

Describes a process to perform investigations on each suspected case of Fraud, Waste, and Abuse;

13.3.1.4

Describes the Contractor’s staff responsible for conducting the investigations and reporting of potential Fraud, Waste, or Abuse, including an organizational chart documenting roles and responsibilities;

Page 198 of 324

13.3.1.5

Includes a variety of methods for identifying, investigating, and referring suspected cases to appropriate entities;

13.3.1.6

Includes a systematic approach to Data analysis;

13.3.1.7

Defines mechanisms to monitor frequency of Encounters and services rendered to Enrollees billed by Providers;

13.3.1.8

Identifies requirements to complete the preliminary investigation of Providers and Enrollees;

13.3.1.9

Include provisions regarding prompt terminations of inactive Providers due to inactivity in the past twelve (12) months;

13.3.1.10

Include a risk assessment of the Contractor’s various Fraud, Waste, and Abuse processes. The risk assessment shall include a listing of the Contractor’s top three (3) vulnerable areas and outline action plans to mitigate risks;

13.3.1.11

Include procedures for the confidential reporting of potential Fraud, Waste, and Abuse, including potential Contractor violations; and

13.3.1.12

Include procedures to ensure that there is no retaliation against an individual who reports Contractor violations or other potential Fraud, Waste, or Abuse to the Contractor or an external entity.

13.3.2

The Contractor’s program integrity plan shall comply in all respects with the ASES Guidelines for the development of a program integrity plan, included as Attachment 14 to this Contract. Upon review of the Contractor’s Program Integrity Plan (see Section 13.3), ASES will promptly (within twenty (20) Business Days) notify the Contractor of any needed revisions in order for the program integrity plan to comply with the guidelines and with Federal law. The Contractor, in turn, shall promptly (within twenty (20) Business Days of receipt of the ASES comments) re-submit its Plan for ASES review and prior written approval.

13.4

Prohibited Affiliations with Individuals Debarred by Federal Agencies

13.4.1

The Contractor shall not knowingly have a relationship with the following:

13.4.1.1

An individual who is debarred, suspended, or otherwise excluded from participating in procurement activities under the Federal Acquisition Regulation or from participating in non-procurement activities under Executive Order No. 12549 or under any guidelines implementing the Executive Order.

Page 199 of 324

13.4.1.2

An individual who is an Affiliate, as defined in the Federal Acquisition Regulation, of a person described in Section 13.4.1.1. The relationship is defined as follows:

13.4.1.2.1

A director, officer, or partner of the Contractor;

13.4.1.2.2

A person with beneficial ownership of five percent (5%) or more of the Contractor’s equity; or

13.4.1.2.3

Any Subcontractor or other person with an employment, consulting, or other arrangement with the Contractor for the provision of items or services that are significant and material the Contractor’s obligations under this Contract.

13.4.1.2.4

A Network Provider or person with an employment, consulting or other arrangement with the Contractor for the provision of items and services that are significant and material to the Contractor’s obligations under the Contract.

13.4.2

The Contractor shall not have a relationship with an individual or entity that is excluded from participation in any Federal health care program under section 1129 or 1128A of the Social Security Act.

13.5

Reporting and Investigations

13.5.1

The Contractor shall cooperate with all duly authorized Federal and Puerto Rico agencies and representatives in reporting, investigating and prosecuting Fraud, Waste, and Abuse.

13.5.2

The Contractor shall have methods for identifying, investigating, and referring suspected Fraud, Waste, and Abuse pursuant to 42 CFR 455.1, 42 CFR 455.13, 42 CFR 455.14 and 42 CFR 455.21 and Immediately notifying ASES. All suspected or confirmed instances of Provider Fraud and Enrollee abuse and neglect shall be referred Immediately by the Contractor to ASES, whom will also notify the Medicaid Fraud Control Unit.

13.5.3

The Contractor shall Immediately report to ASES the identity of any Provider or other person who is debarred, suspended, or otherwise prohibited from participating in procurement activities. ASES shall promptly notify the Secretary of Health and Human Services of the noncompliance, as required by 42 CFR 438.610(d).

13.5.4

The Contractor shall notify ASES within two (2) Business Days of any initiated investigation of a suspected case of Fraud, Waste, or Abuse. The Contractor shall conclude its preliminary investigation within ten (10) Business Days of identifying the potential Fraud, Waste, or Abuse and shall provide the findings of its preliminary investigation in writing to ASES within two (2) Business Days of completing the preliminary investigation.

Page 200 of 324

13.5.5

The Contractor shall subsequently report preliminary results of such investigation activities to ASES and other appropriate State and Federal entities. ASES will provide the Contractor with guidance during the pendency of the investigation and will refer the matter to the US Department of Justice and the Medicaid Fraud Control Unit as appropriate. If directed by ASES and/or the Medicaid Fraud Control Unit, the Contractor shall conduct a full investigation.

13.5.6

The Contractor shall provide the results of its full investigations in writing to ASES within two (2) Business Days of completing the investigation. The Contractor shall consult with ASES, whom shall notify the Medicaid Fraud Control Unit, prior to taking any proposed action regarding an instance of suspected or confirmed fraud or Enrollee abuse.

13.5.7

The Contractor and all Subcontractors shall cooperate fully with Federal and State agencies, including the Medicaid Fraud Control Unit, in Fraud, Waste, and Abuse investigations and subsequent legal actions, whether administrative, civil, or criminal. Such cooperation shall include actively participating in meetings, providing requested Information, access to records, and access to interviews with employees and consultants, including but not limited to those with expertise in the administration of the program and/or medical or pharmaceutical matters or in any matter related to an investigation or prosecution. Such cooperation shall also include providing personnel to testify at any hearings, trials, or other legal proceedings on an as-needed basis.

13.5.8

In accordance with Section 1903(i)(2)(C) of the Social Security Act and 42 CFR 455.23, the Contractor shall have a mechanism in place to suspend payments to any Provider or other Subcontractor when there is a pending investigation of a Credible Allegation of Fraud under the Medicaid program. Suspension of payment shall be approved by ASES following instructions in Attachment 14 to this Contract. In addition, for any cases related to Provider Fraud, which ASES must refer to the Medicaid Fraud Control Unit, the Contractor shall refrain from, or suspend any attempt to, recoup amounts related to the reported instance of Provider Fraud from the referred Provider for a period of thirty (30) Calendar Days while the Medicaid Fraud Control Unit conducts its preliminary evaluation. The Contractor may resume recoupment efforts subsequent to the thirty (30) Calendar Days unless otherwise instructed by the Medicaid Fraud Control Unit or ASES. A determination by the Medicaid Fraud Control Unit not to pursue further action on a referred case of Provider Fraud shall in no way be interpreted to restrict attempts by the Contractor to continue to recoup outstanding amount from the Provider, or to pursue further correction action or penalty otherwise permitted by law or under the Provider Contract.

13.5.9

If a Provider is suspended or terminated from participation in the Puerto Rico Medicaid Program by ASES, the Contractor shall also suspend or terminate the Provider.

Page 201 of 324

13.5.10

If a Provider is terminated from Medicare or another state’s Medicaid or State Children’s Health Insurance Program, the Contractor shall terminate its Provider participation agreement with that Provider (see Section 1902(a)(39) of the Social Security Act and 42 CFR 455.416) and notify ASES Immediately.

13.5.11

The Contractor shall notify ASES at least two (2) Business Days prior to taking any action against a Provider for program integrity reasons, including, but not limited to, denial of a Provider Credentialing/Re-Credentialing application, corrective action or limiting the ability of a Provider to participate in the program (e.g., suspending or terminating a Provider). The notification shall include but not be limited to identification of the Provider and a description of the action, the reason for the action, and documentation to support the reason. The Contractor shall provide additional Information upon ASES’s request.

13.5.12

The Contractor shall submit a risk assessment on an “as needed” basis and Immediately after a program integrity-related action against a Provider. The Contractor shall inform ASES of such action and provide details of such financial action.

13.5.12.1

The Contractor shall Immediately disclose to ASES any and all criminal convictions of its managing employees (see 42 CFR 455.106).

13.5.13

Regarding Provider disclosures, the Contractor shall:

13.5.13.1

Not make payment to a Provider unless the Provider has submitted completed disclosures required by Federal law either to ASES or the Contractor. This includes but is not limited to disclosure regarding ownership and control, business transactions, and criminal convictions (see 42 CFR Part 455, Subpart B).

13.5.13.2

Track information received from ASES identifying Providers from whom ASES has received completed disclosures.

13.5.13.3

For participating Providers for whom ASES has not received completed disclosures, as reported to the Contractor, collect and retain completed Provider disclosures as part of initial Credentialing and then annually, using a disclosure form prior approved by ASES in writing.

13.5.13.4

In accordance with 42 CFR 455.106, Immediately report any criminal conviction disclosures to ASES and explain what action it will take (e.g., terminate the Provider).

13.5.13.5

In accordance with Section 1866(j)(5) of the Social Security Act and implementing regulations, as part of Credentialing and Re-Credentialing, collect disclosures from Out-of-Network Providers regarding any current or previous affiliations with a Provider or supplier that has uncollected debt, has been or is subject to a payment suspension under a Federal health care program (as defined in Section 1128B(f)), has been excluded from participation under Medicare, Medicaid, CHIP, or has had its billing privileges denied or revoked. The Contractor shall notify ASES if the Contractor determines that such affiliation poses an undue risk of Fraud, Waste, or Abuse and denies the application.

Page 202 of 324

13.6

Service Verification with Enrollees

13.6.1

In accordance with 42 CFR 438.608(a)(5), the Contractor shall implement a process for verifying with Enrollees whether services billed by Providers were received.

13.6.2

The Contractor shall employ a methodology and sampling process prior approved by ASES to verify with its Enrollees on a monthly whether services billed to the Contractor by Providers were actually received. The methodology and sampling process shall include criteria for identifying “high-risk” services and Provider types.

13.7

Stark Law Compliance

13.7.1

The Contractor shall have mechanisms in place to ensure that payments are not made in violation of Section 1903(s) of the Social Security Act with respect to certain physician Referrals as defined in Section 1877 of the Social Security Act. The Contractor shall ensure that disclosing Parties provide a financial analysis that includes the total amount actually or potentially due and owed as a result of the disclosed violation, a description of the methodology used to determine the amount due and owing, the total amount of remuneration involved physicians (or an immediate family member of such physicians) received as a result of an actual or potential violation, and a summary of audit activity and documents used in the audit. In accordance with Section 6409 of the PPACA, the Contractor will encourage provider use of the self-referral disclosure protocols, under which providers of services and suppliers may self-disclose actual or potential violations of the physicians’ self-referral statute (Section 1877 of the Social Security Act).

ARTICLE 14

GRIEVANCE AND APPEAL SYSTEM

14.1

General Requirements

14.1.1

In accordance with 42 CFR Part 438, Subpart F, the Contractor shall establish an internal Grievance and Appeal System under which Enrollees, or Providers acting on their behalf, may express dissatisfaction with the Contractor or challenge the denial of coverage of, or payment for, Covered Services.

Page 203 of 324

14.1.2

The Contractor’s Grievance and Appeal System shall include (i) a Complaint process, (ii) Grievance process, (iii) Appeal process, and (iv) access to the Administrative Law Hearing process.

14.1.3

The Contractor shall designate, in writing, an officer who shall have primary responsibility for ensuring that Complaints, Grievances, and Appeals are resolved pursuant to this Contract and for signing all Notices of Adverse Benefit Determination. For such purposes, an officer shall mean a president, vice president, secretary, treasurer, chairperson of the board of directors of the Contractor’s organization, the sole proprietor, the managing general partner of a partnership, or a person having similar executive authority in the organization.

14.1.4

The Contractor shall develop a written Grievance and Appeal System and the policies and procedures that detail the operation of the Grievance System. The Grievance and Appeal System policies and procedures shall be submitted to ASES for review and prior written approval according to the timeframe specified in Attachment 12 to this Contract.

14.1.5

At a minimum, the Contractor’s Grievance and Appeal System policies and procedures shall include the following:

14.1.5.1

Process for filing a Complaint, Grievance, or Appeal, or seeking an Administrative Law Hearing;

14.1.5.2

Process for receiving, recording, tracking, reviewing, reporting, and resolving Grievances filed verbally, in writing, or in-person;

14.1.5.3

Process for receiving, recording, tracking, reviewing, reporting, and resolving Appeals filed verbally or in writing;

14.1.5.4

Process for requesting an expedited review of an Appeal;

14.1.5.5

Process and timeframe for a Provider to file a Complaint, Grievance or Appeal on behalf of an Enrollee;

14.1.5.6

Process for notifying Enrollees of their right to file a Complaint, Grievance, or Appeal with the Patient Advocate Office and how to contact the Patient Advocate Office;

14.1.5.7

Procedures for the exchange of Information with Providers, ASES, and the Enrollees regarding Complaints, Grievances, and Appeals;

14.1.5.8

Process and timeframes for notifying Enrollees in writing regarding receipt of Complaints, Grievances, Appeals, resolution, action, delay of review, and denial of request for expedited review.

Page 204 of 324

14.1.6

The Contractor’s Grievance and Appeal System shall fully comply with the Puerto Rico Patient’s Bill of Rights Act, to the extent that such provisions do not conflict with, or pose an obstacle to Federal regulations.

14.1.7

The Contractor shall process each Complaint, Grievance, or Appeal in accordance with applicable Puerto Rico and Federal statutory and regulatory requirements, this Contract, and the Contractor’s written policies and procedures. Pertinent facts from all Parties shall be collected during the process.

14.1.8

The Contractor shall include educational information in the Enrollee Handbook regarding the Contractor’s Grievance and Appeal System which at a minimum includes:

14.1.8.1

A description of the Contractor’s Grievance and Appeal System;

14.1.8.2

Instructions on how to file Complaints, Grievances and Appeals including the timeframes for filing;

14.1.8.3

The Contractor’s toll-free telephone number and office hours;

14.1.8.4

Information regarding an Enrollee’s right to file a Complaint, Grievance, or Appeal with the Patient Advocate Office and how to file a Complaint, Grievance, or Appeal with the Patient Advocate Office;

14.1.8.5

Information describing the Administrative Law Hearing process and governing rules, including that the Enrollee must first exhaust the Contractor’s Grievance and Appeal System before accessing the Administrative Law Hearing process; and

14.1.8.6

Timelines and limitations associated with filing Grievances or Appeals.

14.1.9

The Contractor shall give Enrollees reasonable assistance in completing forms and taking other procedural steps for Complaints, Grievances and Appeals. This includes, but is not limited to, providing interpreter services and toll-free numbers that have adequate TDD and interpreter capability.

14.1.10

The Contractor shall include information regarding the Grievance and Appeal System in the Provider Guidelines and upon joining the Contractor’s Network, all Providers and Subcontractors, as applicable shall receive training and education regarding the Contractor’s Grievance and Appeal System, which includes but is not limited to:

14.1.10.1

The Enrollee’s right to file Complaints, Grievances and, Appeals and the requirements and timeframes for filing;

Page 205 of 324

14.1.10.2

The Enrollee’s right to file a Complaint, Grievance, or Appeal with the Patient Advocate Office;

14.1.10.3

The Enrollee’s right to an Administrative Law Hearing, how to obtain an Administrative Law Hearing, and representation rules at an Administrative Law Hearing;

14.1.10.4

The availability of assistance in filing a Complaint, Grievance, or Appeal;

14.1.10.5

The toll-free numbers to file oral Complaints, Grievances, and Appeals;

14.1.10.6

The Enrollee’s right to request continuation of Benefits during an Appeal, or an Administrative Law Hearing filing, and that if the Contractor’s Adverse Benefit Determination is upheld in an Administrative Law Hearing, the Enrollee may be liable for the cost of any continued Benefits; and

14.1.10.7

Any Puerto Rico-determined Provider Appeal rights to challenge the failure of the Contractor to cover a service.

14.1.11

The Contractor shall have procedures in place to notify all Enrollees in their primary language of Complaint, Grievance, and Appeal dispositions.

14.1.12

The Contractor shall develop Grievance and Appeal System forms to be submitted for prior written approval by ASES according to the timeframe specified in Attachment 12 to this Contract. The approved forms shall be made available to all Enrollees, shall meet all requirements listed in Sections 6.2 and 6.3 for written materials, and shall, at a minimum:

14.1.12.1

Instruct the Enrollee or Enrollee’s Authorized Representative that documentary evidence should be included, if available; and

14.1.12.2

Include instructions for completion and submission.

14.1.13

All ASES prior approved Complaints, Grievances, and Appeals files and forms shall be made available to ASES for auditing. All Complaint, Grievance, and Appeal documents and related information shall be considered as containing protected health information and shall be treated in accordance with HIPAA regulations and other applicable laws of Puerto Rico.

14.1.14

The Contractor shall ensure that the individuals who make decisions on Grievances and Appeals are individuals:

14.1.14.1

Who were not involved in any previous level of review or decision-making, or who were subordinates of any individual involved in a previous review or decision-making;

Page 206 of 324

14.1.14.2

Who, if deciding any of the following, are Providers who have the appropriate clinical expertise, as determined by ASES, in treating the Enrollee’s condition or disease if deciding any of the following:

14.1.14.2.1

An Appeal of a denial that is based on lack of Medical Necessity;

14.1.14.2.2

A Grievance regarding denial of expedited resolutions of Appeal; and

14.1.14.2.3

Any Grievance or Appeal that involves clinical issues; and

14.1.14.3

Who take into account all comments, documents, records and other information submitted by Enrollee without regard to whether such information was submitted or considered in the initial Adverse Benefit Determination.

14.1.15

The Contractor shall ensure that punitive action is not taken against a Provider who requests a Grievance, Appeal or an Administrative Law Hearing or supports an Enrollee’s Grievance, Appeal or Administrative Law Hearing.

14.1.16

The Contractor and Subcontractors, as applicable, shall have a system in place to collect, analyze, and integrate Data regarding Complaints, Grievances, and Appeals. At a minimum, the record shall be accessible to ASES and available upon request to CMS and include the following information:

14.1.16.1

Date Complaint, Grievance, or Appeal was received;

14.1.16.2

Enrollee’s name;

14.1.16.3

Enrollee’s Medicaid ID number, if applicable;

14.1.16.4

Name of the individual filing the Complaint, Grievance, or Appeal on behalf of the Enrollee;

14.1.16.5

Date of acknowledgement that receipt of Grievance or Appeal was mailed to the Enrollee;

14.1.16.6

Summary of Complaint, Grievance, or Appeal;

14.1.16.7

Date of each review or review meeting and resolution at each level, if applicable;

14.1.16.8

Date Notice of Disposition or Notice of Adverse Benefit Determination was mailed to the Enrollee;

14.1.16.9

Corrective Action required; and

14.1.16.10

Date of resolution.

Page 207 of 324

14.1.17

Contractor shall have sufficient staffing to timely address Grievances, Complaints, Appeals, Provider disputes and to provide attorney representation or the attendance of other required personnel at administrative hearings, when applicable.

14.2

Complaint

14.2.1

The Complaint process is the procedure for addressing Enrollee Complaints, defined as expressions of dissatisfaction about any matter other than an Adverse Benefit Determination that are resolved at the point of contact rather than through filing a formal Grievance.

14.2.2

An Enrollee or Enrollee’s Authorized Representative may file a Complaint either orally or in writing. The Enrollee or Enrollee’s Authorized Representative may follow-up an oral request with a written request. However, the timeframe for resolution begins with the date the Contractor receives the oral request.

14.2.3

An Enrollee or Enrollee’s Authorized Representative shall file a Complaint within fifteen (15) Calendar Days after the date of occurrence that initiated the Complaint. If the Enrollee or Enrollee’s Authorized Representative attempts to file a Complaint beyond the fifteen (15) Calendar Days, the Contractor shall instruct the Enrollee or Enrollee’s Authorized Representative to file a Grievance.

14.2.4

The Contractor shall have procedures in place to provide Notice of Dispositions of Complaints to all Enrollees in their primary language.

14.2.5

The Contractor shall resolve each Complaint within seventy-two (72) hours of the time the Contractor received the initial Complaint, whether orally or in writing. If the Complaint is not resolved within this timeframe, the Complaint shall be treated as a Grievance. The Contractor cannot require the Enrollee to file a separate Grievance before proceeding to Appeal.

14.2.6

The Notice of Disposition shall include the results and date of the resolution of the Complaint and shall include notice of the right to file a Grievance or Appeal and information necessary to allow the Enrollee to request an Administrative Law Hearing, if appropriate, including contact information necessary to pursue an Administrative Law Hearing.

14.3

Grievance Process

14.3.1

An Enrollee or Enrollee’s Authorized Representative may file a Grievance with the Contractor or with the Office of the Patient’s Advocate of Puerto Rico either orally or in writing. A Provider cannot file a Grievance on behalf of an Enrollee unless written consent is granted by the Enrollee.

14.3.2

An Enrollee may file a Grievance at any time.

Page 208 of 324

14.3.3

The Contractor shall acknowledge receipt of each Grievance in writing to the Enrollee (and the Provider, if the Provider filed the Grievance on the Enrollee’s behalf) within ten (10) Business Days of receipt.

14.3.4

The Contractor shall provide written notice of the disposition of the Grievance as expeditiously as the Enrollee’s health condition requires, but in any event, within ninety (90) Calendar Days from the day the Contractor receives the Grievance. If the Grievance originated from a Complaint that was not resolved within the seventy-two (72) hour timeframe set forth in Section 14.2.5, the time already spent by the Contractor to resolve the original Complaint must be deducted from this ninety (90) Calendar Day timeframe.

14.3.5

The Notice of Disposition shall include the following:

14.3.5.1

The resolution of the Grievance,

14.3.5.2

The basis for the resolution, and

14.3.5.3

The date of the resolution.

14.3.6

The Contractor may extend the timeframe to provide a written notice of disposition of a Grievance for up to fourteen (14) Calendar Days if the Enrollee requests the extension or the Contractor demonstrates (to the satisfaction of ASES, upon its request) that there is a need for additional Information and how the delay is in the Enrollee’s interest. If the Contractor extends the timeframe, it shall, for any extension not requested by the Enrollee:

14.3.6.1

Make reasonable efforts to provide Enrollee prompt oral notice of the delay;

14.3.6.2

Give the Enrollee written notice of the reason for the delay within two (2) Calendar Days; and

14.3.6.3

Inform the Enrollee of the right to file a Grievance if the Enrollee disagrees with the decision to extend the timeframe.

14.4

Notice of Adverse Benefit Determination

14.4.1

Pusuant to 42 CFR 438.210(c), the Contractor shall provide written notice to the requesting Provider and the Enrollee of any decision by the Contractor to deny a Service Authorization Request, or to authorize a service in an amount, duration, or scope that is less than requested. The Contractor’s notices shall meet the requirements of 42 CFR 438.404.

14.4.2

The Contractor’s written Notice of Adverse Benefit Determination to Enrollees must meet the language and format requirements in Section 6.2 and 6.3 and be set in accordance with the timeframes described in Section 14.4.4.

Page 209 of 324

14.4.3

The Notice of Adverse Benefit Determination shall contain the following:

14.4.3.1

The Adverse Benefit Determination the Contractor has taken or intends to take;

14.4.3.2

The reasons for the Adverse Benefit Determination;

14.4.3.3

The right of Enrollee to be provided, upon request and at no expense to Enrollee, reasonable access to and copies of all documents, records and other information relevant to the Adverse Benefit Determination.

14.4.3.4

The Enrollee’s right to file an Appeal through the Contractor’s internal Grievance and Appeal System and the procedure for filing an Appeal;

14.4.3.5

The Enrollee’s right to request an Administrative Law Hearing after exhaustion of the Contractor’s Grievance and Appeal System;

14.4.3.6

The Enrollee’s right to allow a Provider to file an Appeal or an Administrative Law Hearing on behalf of the Enrollee, upon written consent;

14.4.3.7

The circumstances under which expedited review is available and how to request it; and

14.4.3.8

The Enrollee’s right to have Benefits continue pending resolution of the Appeal with the Contractor or during the Administrative Law Hearing in accordance with 42 CFR 438.420, how to request that Benefits be continued, and the circumstances under which the Enrollee may be required to pay for the costs of these services.

14.4.4

The Contractor shall mail the Notice of Adverse Benefit Determination within the following timeframes:

14.4.4.1

For termination, suspension, or reduction of previously authorized Covered Services, at least ten (10) Calendar Days before the date of Adverse Benefit Determination. However, notice may be mailed no later than the date of Adverse Benefit Determination, unless otherwise specified, if one of the following exceptions applies:

14.4.4.1.1

The Contractor has factual Information confirming the death of an Enrollee.

14.4.4.1.2

The Contractor receives a clear written statement signed by the Enrollee that he or she no longer wishes to receive services or gives Information that requires termination or reduction of services and indicates that he or she understands that this must be the result of supplying that Information.

Page 210 of 324

14.4.4.1.3

The Enrollee’s whereabouts are unknown and the post office returns the Contractor’s mail directed to the Enrollee indicating no forwarding address (refer to 42 CFR 431.231(d) for procedures if the Enrollee’s whereabouts become known).

14.4.4.1.4

The Enrollee’s Provider prescribes a change in the level of medical care.

14.4.4.1.5

The Contractor may shorten the period of advance notice to five (5) Calendar Days before the date of Adverse Benefit Determination if the Contractor has facts indicating that Adverse Benefit Determination should be taken because of probable Enrollee Fraud and the facts have been verified, if possible, through secondary sources.

14.4.4.2

For denial of payment, at the time of any Adverse Benefit Determination affecting the Claim.

14.4.4.3

For standard authorization decisions that deny or limit Covered Services within the timeframes required in Section 11.4.

14.4.4.4

If the Contractor extends the timeframe for the authorization decision and issuance of Notice of Adverse Benefit Determination according to Section 14.4.3, the Contractor shall give the Enrollee written notice of the reasons for the decision to extend if he or she did not request the extension and the Enrollee’s right to file a Grievance if he or she disagrees with that decision. The Contractor shall issue and carry out its determination as expeditiously as the Enrollee’s health requires and no later than the date the extension expires.

14.4.4.5

For authorization decisions not reached within the timeframes required in Section 11.4 for either standard or expedited authorizations, the Notice of Adverse Benefit Determination shall be mailed on the date the timeframe expires, as this constitutes a denial and is thus an Adverse Benefit Determination.

14.5

Appeal Process

14.5.1

The Enrollee, the Enrollee’s Authorized Representative, or the Provider may file an Appeal either orally or in writing.

14.5.2

Oral inquiries seeking to appeal an Adverse Benefit Determination are treated as Appeals (to establish the earliest possible filing date for the Appeal), but Enrollees must confirm oral requests for Appeals in writing within ten (10) Calendar Days of the oral filing, unless the Enrollee requests expedited resolution, then no additional follow-up is required.

Page 211 of 324

14.5.3

The requirements of the Appeal process shall be binding for all types of Appeals, including expedited Appeals, unless otherwise established for expedited Appeals. Only one (1) level of Appeal is permitted before proceeding to an Administrative Law Hearing.

14.5.4

The Enrollee, the Enrollee’s Authorized Representative, or the Provider acting on behalf of the Enrollee with the Enrollee’s written consent, may file an Appeal to the Contractor within sixty (60) Calendar Days from the date on the Contractor’s Notice of Adverse Benefit Determination.

14.5.5

Appeals shall be filed directly with the Contractor, or its delegated representatives. The Contractor may delegate this authority to an Appeal committee, but the delegation shall be in writing.

14.5.6

The Appeals process shall provide the Enrollee, the Enrollee’s Authorized Representative, or the Provider acting on behalf of the Enrollee with the Enrollee’s written consent, a reasonable opportunity to present evidence and allegations of fact or law, in person, as well as in writing. The Contractor shall inform the Enrollee of the limited time available to provide this in case of expedited review.

14.5.7

The Appeals process shall provide the Enrollee, the Enrollee’s Authorized Representative, or the Provider acting on behalf of the Enrollee with the Enrollee’s written consent, opportunity, before and during the Appeals process, to examine the Enrollee’s case file, including Medical Records, and any other documents and records considered during the Appeals process and provide copies of documents contained therein without charge and sufficiently in advance of the resolution timeframe for the Appeal.

14.5.8

The Appeals process shall include as Parties to the Appeal the Enrollee, the Enrollee’s Authorized Representative, the Provider acting on behalf of the Enrollee with the Enrollee’s written consent, or the legal representative of a deceased Enrollee’s estate.

14.5.9

The Contractor shall resolve each standard Appeal and provide written notice of the disposition, as expeditiously as the Enrollee’s health condition requires but no more than thirty (30) Calendar Days from the date the Contractor receives the Appeal.

14.5.10

The Contractor shall establish and maintain an expedited review process for Appeals, subject to prior written approval by ASES, when the Contractor determines (based on a request from the Enrollee) or the Provider indicates (in making the request on the Enrollee’s behalf) that taking the time for a standard resolution could seriously jeopardize the Enrollee’s life or health or ability to attain, maintain, or regain maximum function. The Enrollee, the Enrollee’s Authorized Representative, or the Provider acting on behalf of the Enrollee with the Enrollee’s written consent, may file an expedited Appeal either orally or in writing.

Page 212 of 324

14.5.11

The Contractor shall resolve each expedited Appeal and provide a written Notice of Disposition, as expeditiously as the Enrollee’s health condition requires, but no longer than seventy-two (72) hours after the Contractor receives the Appeal and make reasonable efforts to provide oral notice.

14.5.12

If the Contractor denies an Enrollee’s request for expedited review, it shall utilize the timeframe for standard Appeals specified herein and shall make reasonable efforts to give the Enrollee prompt oral notice of the denial, and follow-up within two (2) Calendar Days with a written notice. If the Enrollee disagrees with the decision to extend the prescribed timeframe, he or she shall be informed of the right to file a Grievance and the Grievance shall be resolved within twenty-four (24) hours. The Contractor shall also make reasonable efforts to provide oral notice for resolution of an expedited review of an Appeal.

14.5.13

The Contractor may extend the timeframe for standard or expedited resolution of the Appeal by up to fourteen (14) Calendar Days if the Enrollee, Enrollee’s Authorized Representative, or the Provider acting on behalf of the Enrollee with the Enrollee’s written consent, requests the extension or the Contractor demonstrates (to the satisfaction of ASES, upon its request) that there is need for additional information and how the delay is in the Enrollee’s interest. If the Contractor extends the timeframe, it shall, for any extension not requested by the Enrollee:

14.5.13.1

Make reasonable efforts to provide Enrollee prompt oral notice of the delay;

14.5.13.2

Give the Enrollee written notice of the reason for the delay within two (2) Calendar Days;

14.5.13.3

Inform the Enrollee of the right to file a Grievance if the Enrollee disagrees with the decision to extend the timeframe; and

14.5.13.4

Resolve the Appeal as expeditiously as the Enrollee’s health condition requires, and no later than the date the extension expires.

14.5.14

The Contractor shall provide written Notice of Disposition of an Appeal to the Enrollee (and the Provider, if the Provider filed the Appeal on the Enrollee’s behalf) as well as a copy to ASES within two (2) Business Days of the resolution.

14.5.15

The written notice of Disposition shall be in a format and language that, at a minimum, meets applicable notification standards and shall include:

Page 213 of 324

14.5.15.1

The results and date of the Appeal resolution; and

14.5.15.2

For decisions not wholly in the Enrollee’s favor:

14.5.15.3

The right to request an Administrative Law Hearing;

14.5.15.4

How to request an Administrative Law Hearing;

14.5.15.5

The right to continue to receive Benefits pending an Administrative Law Hearing;

14.5.15.6

How to request the continuation of Benefits; and

14.5.15.7

Notification that if the Contractor’s Adverse Benefit Determination is upheld in a hearing, the Enrollee may liable for the cost of any continued Benefits.

14.6

Administrative Law Hearing

14.6.1

The Contractor is responsible for explaining the Enrollee’s right to and the procedures for an Administrative Law Hearing, including that the Enrollee must exhaust the Contractor’s Grievance, Complaints, and Appeals process before requesting an Administrative Law Hearing. However, if the Contractor fails to adhere to all notice and timing requirements set forth in 42 CFR 438.408, the Enrollee is deemed to have exhausted the Contractor’s Appeals process and may proceed with initiating an Administrative Law Hearing.

14.6.2

The parties to the Administrative Law Hearing include the Contractor as well as the Enrollee or his or her Authorized Representative, or the representative of a deceased Enrollee’s estate.

14.6.3

If the Contractor takes an Adverse Benefit Determination, the Enrollee appeals the Adverse Benefit Determination and the resolution of the Appeal is not in the Enrollee’s favor, and the Enrollee requests an Administrative Law Hearing, ASES shall grant the Enrollee such hearing. The right to such Administrative Law Hearing, how to obtain it, and the rules concerning who may represent the Enrollee at such hearing shall be explained to the Enrollee and by the Contractor.

14.6.4

ASES shall permit the Enrollee to request an Administrative Law Hearing within one hundred and twenty (120) Calendar Days of the Notice of Resolution of the Appeal.

14.6.5

Before the Administrative Law Hearing, the Enrollee and the Enrollee’s Authorized Representative, if applicable, can ask to look at and copy the documents and records the Contractor will use at the Administrative Law Hearing or that the Enrollee may otherwise need to prepare his/her case for the hearing. The Contractor shall provide such documents and records at no charge to the Enrollee.

Page 214 of 324

14.6.6

The Administrative Law Hearing resolution shall be:

14.6.6.1

For standard resolution: within ninety (90) Calendar Days of the date the Enrollee filed the appeal with the Contractor (excluding the days the Enrollee took to subsequently file for an Administrative Law Hearing).

14.6.6.2

For an expedited resolution: within three (3) Business Days from agency receipt of an Administrative Law Hearing request for a denial of a service.

14.6.7

The Contractor shall comply with all determinations rendered as a result of Administrative Law Hearings. Nothing in this Section 14.6 shall limit the remedies available to ASES or the Federal government relating to any non-compliance by the Contractor with an Administrative Law Hearing determination or by the Contractor’s refusal to provide disputed services.

14.6.8

The decision issued as a result of the Administrative Law Hearing is subject to review before the Court of Appeals of Puerto Rico.

14.6.9

The Contractor shall comply with all determinations rendered as a result of Administrative Law Hearings. Nothing in this Section 14.6 shall limit the remedies available to Puerto Rico or the Federal government relating to any non-compliance by the Contractor with an Administrative Law Hearing determination or by the Contractor’s refusal to provide disputed services.

14.7

Continuation of Benefits while the Appeal and Administrative Law Hearing are Pending

14.7.1

As used in this Section, “timely” filing means filing on or before the later of the following:

14.7.1.1

Within ten (10) Calendar Days of the Contractor mailing the Notice of Adverse Benefit Determination; or

14.7.1.2

The intended effective date of the Contractor’s proposed Adverse Benefit Determination.

14.7.2

The Contractor shall continue the Enrollee’s Benefits if the Enrollee or the Enrollee’s Authorized Representative files the Appeal within sixty (60) Calendar Days following the date on the Adverse Benefit Determination notice; the Appeal involves the termination, suspension, or reduction of a previously authorized course of treatment; the services were ordered by an authorized Provider; the period covered by the original authorization has not expired; and the Enrollee timely files for continuation of the Benefits.

Page 215 of 324

14.7.3

If, at the Enrollee’s request, the Contractor continues or reinstates the Enrollee’s Benefits while the Appeal or Administrative Law Hearing is pending, the Benefits shall be continued until one of the following occurs:

14.7.3.1

The Enrollee withdraws the Appeal or request for the Administrative Law Hearing.

14.7.3.2

Ten (10) Calendar Day pass after the Contractor mails the Notice of Adverse Benefit Determination, unless the Enrollee, within the ten (10) Calendar Day timeframe, has requested an Administrative Law Hearing with continuation of Benefits until an Administrative Law Hearing decision is reached.

14.7.3.3

An administrative law judge issues an Administrative Law Hearing decision adverse to the Enrollee.

14.7.3.4

The time period or service limits of a previously authorized service has been met.

14.7.4

If the final resolution of Appeal or Administrative Law Hearing is adverse to the Enrollee, that is, upholds the Contractor’s Adverse Benefit Determination, the Contractor may recover from the Enrollee the cost of the services furnished to the Enrollee while the Appeal/Administrative Law Hearing was pending, to the extent that they were furnished solely because of the requirements of this Section.

14.7.5

If the Contractor or ASES reverses a decision to deny, limit, or delay services that were not furnished while the Appeal/Administrative Law Hearing was pending, the Contractor shall authorize or provide the disputed services promptly and as expeditiously as the Enrollee’s health condition requires but no later than seventy-two (72) hours from the date the Contractor receives notice reversing the determination.

14.7.6

If the Contractor or ASES reverses a decision to deny authorization of services, and the Enrollee received the disputed services while the Appeal/Administrative Law Hearing was pending, the Contractor shall pay for those services. The Contractor shall submit evidence of compliance.

14.8

Reporting Requirements

14.8.1

The Contractor shall log and track all Complaints, Grievances, Notices of Adverse Benefit Determination, Appeals, including extensions of time granted by the Contractor for these items, as well as Administrative Law Hearing requests (see Section 14.1.16 for details regarding Information collected).

14.8.2

ASES may publicly disclose summary Information regarding the nature of Complaints, Grievances, and Appeals and related dispositions or resolutions in consumer Information materials.

Page 216 of 324

14.8.3

The Contractor shall submit quarterly Grievance and Appeal System reports to ASES using a format prescribed by ASES and incorporate the findings of these reports into its Quality Strategy.

14.9

Remedy for Contractor Non-Compliance with Advance Directive Requirements.

In addition to the Complaint, Grievance, and Appeal rights described in this Article, an Enrollee may lodge with ASES a Complaint concerning the Contractor’s non-compliance with the Advance Directive requirements stated in Section 7.10 of this Contract.

ARTICLE 15

ADMINISTRATION AND MANAGEMENT

15.1

General Provisions

15.1.1

The Contractor shall be responsible for the administration and management of all requirements of this Contract, and consistent with the Medicaid Managed Care regulations of 42 CFR Part 438.

15.1.2

All costs and expenses related to the administration and management of this Contract shall be the responsibility of the Contractor.

15.2

Place of Business and Hours of Operation

15.2.1

Given that Enrollment occurs chiefly on site in the Contractor’s administrative offices, the Contractor shall ensure that its administrative offices are physically accessible to all Enrollees and fully equipped to perform all functions related to carrying out this Contract.

15.2.2

The Contractor shall maintain a number and geographic distribution of administrative offices to provide reasonable physical accessibility for Enrollees. The plan for administrative offices must be approved in writing by ASES.

15.2.3

The Contractor shall accommodate any request by ASES to visit the Contractor’s administrative offices to ensure that the offices are compliant with the Americans with Disabilities Act’s (“ADA”) requirements for public buildings, and with all other applicable Federal and Puerto Rico rules and regulations.

15.2.4

The Contractor must maintain one (1) central administrative office and additional administrative offices as described in section 15.2.2 of this Contract.

15.2.5

The Contractor’s office shall be centrally located and in a location accessible by foot and by vehicle traffic.

15.2.6

Contractor’s written communications to Enrollees must contain the address of the location identified as the legal, duly-licensed, central administrative office. This administrative office must be open at least between the hours of 9:00 a.m. and 5:00 p.m. (Atlantic Time) during Business Days; In addition, pursuant to the Contractor’s Enrollment Outreach plan (see Section 6.12), the Contractor’s administrative office must have extended open hours (until 7:00 p.m. (Atlantic Time) at least one (1) Business Day per Week; and must be open (to the extent necessary to permit Enrollment activities) one Saturday per month, from 9:00 a.m. to 5:00 p.m. (Atlantic Time)).

Page 217 of 324

15.2.7

The Contractor shall ensure that the office(s) are adequately staffed, throughout the Contract Term, to ensure that Potential Enrollees may visit the office to enroll at any time during Contractor’s hours of operation. This provision will ensure that Enrollees and Providers receive prompt and accurate responses to inquiries.

15.2.8

The Contractor shall provide access to Information to Enrollees through GHP Service Line, during the hours provided in Section 6.8.3 of this Contract.

15.2.9

The Contractor shall provide access twenty-four (24) hours a day, seven (7) days per Week to its website.

15.3

Training and Staffing

15.3.1

The Contractor shall conduct ongoing training for all of its staff, in all departments, to ensure appropriate functioning in all areas and to ensure that staff:

15.3.1.1

Understand the GHP program and the Medicaid Managed Care requirements;

15.3.1.2

Are aware of all programmatic changes; and

15.3.1.3

Are trained in the Contractor’s Cultural Competency plan.

15.3.2

The Contractor shall submit a staff training plan and a current organizational chart to ASES for review and prior written approval according to the timeframe specified in Attachment 12 to this Contract.

15.4

Data Certification

15.4.1

The Contractor shall certify all Data pursuant to 42 CFR 438.606. The Data that must be certified include, but are not limited to, Enrollment Information, Encounter Data, and other Information required by ASES and contained in Contracts, the Contractor’s Proposal, and related documents. The Data must be certified by one of the following: the Contractor’s Chief Executive Officer (“CEO”), the Contractor’s Chief Financial Officer (“CFO”), or an individual who has delegated authority to sign for, and who reports directly to the Contractor’s CEO or CFO. The certification must attest, based on best knowledge, Information, and belief, as follows:

Page 218 of 324

15.4.1.1

To the accuracy, completeness and truthfulness of the Data; and

15.4.1.2

To the accuracy, completeness, and truthfulness of the documents specified by ASES.

15.4.2

The Contractor shall submit the certification concurrently with the certified Data.

15.4.3

Contractor shall sign the Trading Partner Agreement included as Attachment 30 to this Contract.

15.5

Implementation Plan and Submission of Initial Deliverables

15.5.1

The Contractor shall develop an Implementation Plan that verifies that the Contractor will submit the Deliverables listed in the chart in Attachment 12 to this Contract, and that details any additional procedures and activities that will be accomplished during the period between the Effective Date of this Contract and November 1, 2018, which is the Implementation Date of this Contract. The Implementation Plan shall include coordination and cooperation with ASES and its representatives during all phases.

15.5.2

The Contractor shall submit its implementation plan to ASES for ASES’s review and written approval according to the timeframe specified in Attachment 12 to this Contract. Implementation of the Contract shall not commence prior to ASES written approval.

15.5.3

The Contractor will not receive any additional payment to cover start up or implementation costs.

ARTICLE 16

PROVIDER PAYMENT MANAGEMENT

16.1

General Provisions

16.1.1

The The Contractor shall administer an effective, accurate and efficient Provider payment management function that (i) under this Contract’s risk arrangement adjudicates and settles Provider Claims for Covered Services that are filed within the timeframes specified by this Article 16 and in compliance with all applicable Puerto Rico and Federal laws, rules, and regulations; (ii) processes PMPM Payments to applicable Providers within the timeframes specified by this Article; and (iii) performs Claims payment administrative functions for all Providers as specified by this Article 16.

16.1.2

The Contractor shall maintain a Claims management system that can accurately identify the date of receipt (the date the Contractor receives the Claim as indicated by the date-stamp), real-time-accurate history of actions taken on each Provider Claim (i.e. paid, denied, suspended, appealed, etc.), and the date of payment (the date of the check or other form of payment).

Page 219 of 324

16.1.3

To the extent feasible, the Contractor shall implement an Automated Clearinghouse (“ACH”) mechanism that allows Providers to request and receive Electronic Funds Transfer (“EFT”) of Claims payments. The Contractor shall encourage its Providers, as an alternative to the filing of paper-based Claims, to submit and receive Claims Information through Electronic Data Interchange (“EDI”), i.e., electronic Claims. Electronic Claims must be processed in adherence to Information exchange and Data management requirements specified in Article 17. As part of this electronic Claims management (“ECM”) function, the Contractor shall also provide on-line and phone-based capabilities to obtain Claims processing status Information.

16.1.4

If the Contractor does not receive Claims through an EDI system, the Contractor shall either provide a central address to which Providers must submit Claims; or provide to each Network Provider a complete list, including names, addresses, electronic mail and phone number, of entities to which the Providers must submit Claims.

16.1.5

The Contractor shall notify Network Providers in writing of any changes in the policies and procedures, subject to prior written approval of ASES, for filing Claims at least thirty (30) Calendar Days before the effective date of the change. If the Contractor is unable to provide thirty (30) Calendar Days of notice, it must give Providers a thirty (30) Calendar Day extension on their Claims filing deadline to ensure Claims are routed to the correct processing center.

16.1.6

To be processed, all Claims submitted for payment shall comply with the Clean Claim standards as established by Federal regulation (42 CFR 447.46), and with the standards described in Section 16.10.2 of this Contract.

16.1.7

The Contractor shall generate explanations of benefits and remittance advices in accordance with ASES standards for formatting, content, and timeliness.

16.1.8

The Contractor shall not pay any Claim submitted by a Provider during the period of time when such Provider is excluded or suspended from the Medicare, Medicaid, CHIP or Title V Maternal and Child Health Services Block Grant programs for Fraud, Waste, or Abuse or otherwise included on the Department of Health and Human Services Office of the Inspector General exclusions list, or employs someone on this list, and when the Contractor knew, or had reason to know, of that exclusion, after a reasonable time period after reasonable notice has been furnished to the Contractor. The Contractor shall not pay any Claim submitted by a Provider that is on Payment Hold.

16.1.9

The Contractor is prohibited from paying for an item or service with respect to any amount expended for which funds may not be used under the Assisted Suicide Funding Restriction Act of 1997.

16.1.10

Network Providers may not receive payment other than by the Contractor for services covered under this Agreement, except when such payments are specifically required to be made by ASES under Title XIX of the Social Security Act, or its implementing regulations, or when ASES makes direct payments to Network Providers for graduate medical education costs approved under the Medicaid State Plan. The Contractor is prohibited from making payment on any amount expended for any item or service not covered under the Medicaid State Plan.

Page 220 of 324

16.1.11

Pursuant to Section 1903(i) of the Social Security Act the Contractor is prohibited from paying for organ transplants unless the State Plan provides, and the Contractor follows, written standards that provide for similarly situated individuals to be treated alike and for any restriction on facilities or practitioners to be consistent with the accessibility of high quality of care to Enrollees.

16.2

Payment Schedule

16.2.1

At a minimum, the Contractor shall run one (1) Provider payment cycle per Week, on the same day each Week, as determined by the Contractor. The Contractor shall develop a payment schedule to be submitted to ASES for review and its prior written approval according to the timeframe specified in Attachment 12 to this Contract.

16.2.2

Other than for cause explicitly stated in the Provider Contract, payment to Providers made in the form of a Capitation payment shall be issued not later than the fifteenth (15 ^th ) Calendar Day of the month. Any Provider Capitation payment retained by the Contractor past the 15 ^th Calendar Day of each month shall accrue interest at the prevailing highest legal interest rate for personal loans as such rate is determined by the Board of the Office of the Commissioner of Financial Institutions, and interest shall be paid along with the Capitation payment to the Provider for that month. The Contractor shall make such payment regardless of receiving the PMPM Payment under Section 22.1.1 of the Contract.

16.3

Required Claims Processing Reports

16.3.1

The Contractor shall submit to ASES a monthly report not later than the fifth (5 ^th ) Calendar Day after the last day of the month listing all paid, pending, and denied Claims during that month. The report shall be made available in an electronic format and shall detail all paid, pending, and denied Claims for all Providers.

16.3.2

The report shall list, by Provider, Claims paid from the preceding month, and those that are pending payment and the reason for the payment delay or the reason for the Contractor’s decision to deny the Claim.

16.3.3

In the event that Providers associated with a PMG consent to the disbursement of payment directly to the PMG, the Contractor shall so specify in its report.

Page 221 of 324

16.4

Submission of Encounter Data

16.4.1

Providers shall furnish Encounter Data to the Contractor per Section 17.3.3 and Attachment 26 to this Contract on a monthly basis. The Data shall be submitted regardless of the payment arrangement, capitated or otherwise, agreed upon between the Contractor and the Provider. Encounter Data for all items and services provided by Network Providers, even if the Network Provider is reimbursed on a Capitated basis, must be submitted with the paid field indicating the allowed amount, even if the amount is zero (0) dollars.

16.4.2

Encounter Data must comply with HIPAA security and privacy standards and be submitted in the format and timeframe required by the Medicaid Statistical Information System (MMIS) or format required by any successor system in accordance with 42 CFR 438.818.

16.4.3

ASES will perform quarterly Encounter Data validation to evaluate level of accuracy, which will be used to determine if liquidated damages should be assessed on the Contractor.

16.5

Relationship with Pharmacy Benefit Manager (PBM)

16.5.1

The Contractor shall work with the PBM engaged by ASES to facilitate the processing of pharmacy services Claims submitted by the PBM, as provided in Section 7.5.12.11.

16.5.2

To facilitate Claims processing, the Contractor shall send to the PBM, on a Daily Basis, the Enrollee Data described in Section 5.3.8.

16.6

Timely Payment of Claims

16.6.1

The Contractor shall comply with the timely processing of Claims standards contained in Section 1902(a)(37) of the Social Security Act and Federal regulations at 42 CFR 447.46.

16.6.2

Provider Contracts shall include the following provisions for timely payment of Clean Claims.

16.6.2.1

A Clean Claim under 42 CFR 447.46(b), as defined in 42 CFR 447.45(b), is a Claim received by the Contractor for adjudication, which can be processed without obtaining additional Information from the Provider of the service or from a Third Party. It includes a Claim with errors originating in the Contractor’s Claims system. It does not include a Claim from a Provider who is under investigation for Fraud, Waste, or Abuse, or a Claim under review for Medical Necessity.

16.6.2.2

Provider Contracts shall provide that ninety-five percent (95%) of all Clean Claims must be paid by the Contractor not later than thirty (30) Calendar Days from the date of receipt of the Claim (including Claims billed by paper and electronically), and one hundred percent (100%) of all Clean Claims must be paid by the Contractor not later than fifty (50) Calendar Days from the date of receipt of the Claim.

Page 222 of 324

16.6.2.3

Any Clean Claims not paid within thirty (30) Calendar Days shall bear interest in favor of the Provider on the total unpaid amount of such Claim, according to the prevailing highest legal interest rate fixed by the Puerto Rico Commissioner of Financial Institutions. Such interest shall be considered payable on the day following the terms of this Section, and interest shall be paid together with the claim.

16.6.3

An Unclean Claim is any Claim that falls outside the definition of Clean Claim in Section 16.10.2.1. The Contractor shall include the following provisions in its Provider Contracts for timely resolution of Unclean Claims.

16.6.3.1

Ninety percent (90%) of Unclean Claims must be resolved and processed with payment by the Contractor, if applicable, not later than ninety (90) Calendar Days from the date of initial receipt of the Claim. This includes Claims billed on paper or electronically.

16.6.3.2

Of the remaining ten percent (10%) of total Unclean Claims that may remain outstanding after ninety (90) Calendar Days,

16.6.3.2.1

Nine percent (9%) of the Unclean Claims must be resolved and processed with payment by the Contractor, if applicable, not later than six (6) calendar months from the date of initial receipt (including Claims billed on paper and those billed electronically); and

16.6.3.2.2

One percent (1%) of the Unclean Claims must be resolved and processed with payment by the Contractor, if applicable, not later than one year (twelve (12) months) from the date of initial receipt of the Claim (including Claims billed on paper and those billed electronically).

16.6.4

The Contractor shall not establish any administrative procedures, such as administrative audits, authorization number, or other formalities under the control of the Contractor, which could prevent the Provider from submitting a Clean Claim.

16.6.5

The foregoing timely payment standards are more stringent than those required in the Federal regulations, at 42 CFR 447.46. The Contractor shall include the foregoing standards in each Provider Contract and, per 42 CFR 447.46(c).

16.6.6

The Contractor shall deliver to Providers, within fifteen (15) Calendar Days of award of the Provider Contract (along with the Provider Guidelines described in Section 10.2.1), Claims coding and processing guidelines for the applicable Provider type, and the definition of a Clean Claim, as requested in this Article 16, to be applied.

Page 223 of 324

16.6.7

The Contractor shall give Providers ninety (90) Calendar Days’ notice in advance of the effective date of any change in Claims coding and processing deadlines.

16.7

Contractor Denial of Claims and Resolution of Contractual and Claims Disputes

16.7.1

Not later than the fifth (5th) Business Day after the receipt of a Provider Claim that the Contractor has deemed not to meet the Clean Claim requirements, the Contractor shall suspend the Claim and request in writing (notification via e-mail, the Contractor’s website, or an interim remittance advice satisfies this requirement) all outstanding Information such that the Claim can be deemed clean. Upon receipt of all the requested Information from the Provider, the Contractor shall complete processing of the Claim in accordance with the standards outlined in this Section..

16.7.2

Claims suspended for additional Information must be closed (paid or denied) such that compliance with the timely payment rules outlined in Section 16.10 is achieved.

16.7.3

The Contractor must process, and finalize, all appealed Claims to a paid or denied status within thirty (30) Calendar Days of receipt of the appealed Claim; for Claims for which the Contractor has requested further information, per Section 16.7.1, the Contractor shall pay or deny the Claim within thirty (30) Calendar Days of receipt of the requested Information.

16.7.4

The Contractor shall send Providers written notice (notification via e-mail, surface mail, the Contractor’s website, or a remittance advice satisfies this requirement) for each Claim that is denied, including an explanation of the reason(s) for the denial, the date the Contractor received the Claim, and a reiteration of the outstanding Information required from the Provider to adjudicate the Claim.

16.7.5

Provider Dispute Resolution System

16.7.5.1

The Contractor shall establish and use a procedure to resolve billing, payment, and other administrative disputes between Providers and the Contractor arising under Provider Contracts including a Provider Complaint resolution process implemented by the Contractor to address, among others, lost or incomplete Claims forms or electronic submissions; Contractor requests for additional explanation as to services or treatment rendered by a Provider; and inappropriate or unapproved Referrals issued by Providers. This dispute resolution system shall exclude Grievances filed by Providers on behalf of Enrollees pursuant to Section 14.3 of this Contract.

Page 224 of 324

16.7.5.2

For any dispute between the Provider and Contractor arising under the Provider Contract, the Contractor shall implement an internal dispute resolution system, which shall include the opportunity for an aggrieved Provider to submit a timely written complaint to the Contractor. The Contractor shall issue a written decision on the Provider’s complaint within fifteen (15) Calendar Days of receipt of the Provider’s written complaint. A Contractor’s written decision that is in any way adverse to the Provider shall include an explanation of the grounds for the decision and a notice of the Provider’s right to and procedures for an Administrative Law Hearing within ASES.

16.7.5.2.1

Providers disputing the denial of payment for a submitted Claim, or the payment of an amount that is less than the amount for which the Claim was submitted, shall be afforded a term of one hundred twenty (120) Calendar Days to submit a written Complaint. Contractor shall issue a determination regarding such Claims within one hundred twenty (120) Calendar Days.

16.7.5.3

If the Provider is not satisfied with the decision on its complaint within the Contractor’s dispute resolution system, the Provider may pursue an Administrative Law Hearing. The parties to the Administrative Law Hearing shall be the Contractor and the Provider. ASES shall grant a Provider request for an Administrative Law Hearing, provided that the Provider submits a written appeal, accompanied by supporting documentation, not more than thirty (30) Calendar Days following the Provider’s receipt of the Contractor’s written decision.

16.7.5.4

Judicial Review. A decision issued as a result of the Administrative Law Hearing provided for in Section 16.11.6.3 shall be subject to review before the Court of Appeals of Puerto Rico.

16.8

Contractor Recovery from Providers

16.8.1

When the Contractor determines after the fact that it has paid a Claim incorrectly the Contractor may request applicable reimbursement from the Provider through written notice, stating the basis for the request. The notice shall list the Claims and the amounts to be recovered.

16.8.2

The Provider will have a period of sixty (60) Calendar Days to make the requested payment, to agree to Contractor retention of said payment, or to dispute the recovery action.

Page 225 of 324

16.9

ASES Review of Contractor, Subcontractor, and Provider Use of Puerto Rico and Federal Funds

16.9.1

The Contractor shall cooperate fully and diligently with ASES and/or its auditors in their review of the use of Puerto Rico and Federal funds provided to the Contractor under the GHP Program. The Contractor, its Subcontractors, and Network Providers shall, upon request, make available to ASES and/or its auditors any and all administrative, financial, and Medical Records relating to the administration of and the delivery of items or services for which Puerto Rico and Federal monies are expended. In addition, the Contractor and its Subcontractors including Network Providers shall provide ASES and/or its auditors with access during normal business hours to its respective place of business and records.

16.10

ASES Recovery from Contractor

16.10.1

ASES and the Contractor shall diligently work in good faith together to resolve any audit findings identified through audits by ASES. All audit findings shall be resolved or a Corrective Action Plan shall be implemented within ninety (90) Calendar Days of issuance of a final audit report. Any Overpayment remittance due to ASES from the Contractor will be offset from future payments to the Contractor, or invoiced by ASES to the Contractor.

ARTICLE 17

INFORMATION MANAGEMENT AND SYSTEMS

17.1

General Provisions

17.1.1

The Contractor shall have Information management processes and Information Systems (hereafter referred to as Systems) that enable it to meet GHP requirements, ASES and Federal reporting requirements, all other Contract requirements, and any other applicable Puerto Rico and Federal laws, rules and regulations including but not limited to the standards and operating rules in Section 1104 of the PPACA and associated regulations, the Health Insurance Portability and Accountability Act of 1996 (“HIPAA ”), Health Information Technology for Economic and Clinical Health Act (HITECH) and associated regulations and 42 CFR 438.242.

17.1.2

The Contractor’s Data and Systems shall comply with the standards and operating rules for EFT, eligibility, Claim status and health care payment/remittance advice transactions, in accordance with 45 C.F.R. parts 160 and 162..

17.1.3

The Contractor’s Systems shall possess capacity sufficient to handle the workload projected for the start of the program and will be scalable and flexible so they can be adapted as needed, within negotiated timeframes, in response to program or Enrollment changes.

Page 226 of 324

17.1.4

The Contractor’s Systems shall have the capability of adapting to any future changes necessary as a result of modifications to the service delivery system and its requirements, including Data collection, records and reporting based upon unique Enrollee and Provider identifiers to track services and expenditures across funding streams. The Systems shall be scalable and flexible so they can be adapted as needed, within negotiated timeframes, in response to changes in Contract requirements, increases in Enrollment estimates, etc. The System architecture shall facilitate rapid application of the more common changes that can occur in the Contractor’s operation, including but not limited to:

17.1.4.1

Changes in pricing methodology;

17.1.4.2

Rate changes;

17.1.4.3

Eligibility criteria changes;

17.1.4.4

Changes in Utilization Management criteria;

17.1.4.5

Additions and deletions of Provider types; and

17.1.4.6

Additions and deletions of procedure, diagnosis and other service codes.

17.1.4.7

Changes in the Enrollment methodology.

17.1.5

The Contractor shall provide secure, online access to select system functionality to at least three (3) ASES personnel to facilitate resolution of Enrollee inquiries and to research Enrollee-related issues as needed.

17.1.6

The Contractor shall participate in systems work groups organized by ASES. The Systems work groups will meet on a designated schedule as agreed to by ASES and the Contractors.

17.1.7

The Contractor shall provide a continuously available electronic mail communication link (E-mail system) with ASES. This system shall be:

17.1.7.1

Available from the workstations of the designated Contractor contacts; and

17.1.7.2

Capable of attaching and sending documents created using software products other than Contractor systems, including Puerto Rico’s currently installed version of Microsoft Office and any subsequent upgrades as adopted.

17.2

Global System Architecture and Design Requirements

17.2.1

The Contractor shall comply with Federal and Puerto Rico policies, standards and regulations in the design, development and/or modification of the Systems it will employ to meet the aforementioned requirements and in the management of information contained in those Systems. Additionally, the Contractor shall adhere to ASES and Puerto Rico-specific system and Data architecture standards and/or guidelines.

Page 227 of 324

17.2.2

The Contractor’s Systems shall meet Federal and industry standards of architecture, including but not limited to the following requirements:

17.2.2.1

Conform to HIPAA standards for Data and document management;

17.2.2.2

Contain controls to maintain information integrity. These controls shall be in place at all appropriate points of processing. The controls shall be tested in periodic and spot audits following a methodology to be developed jointly by and mutually agreed upon by the Contractor and ASES; and

17.2.2.3

Partner with ASES in the development of transaction/event code set, Data exchange and reporting standards not specific to HIPAA or other Federal efforts and will conform to such standards as stipulated in the plan to implement the standards.

17.2.3

Where web services are used in the engineering of applications, the Contractor’s Systems shall conform to World Wide Web Consortium (W3C) standards such as XML, UDDI, WSDL and SOAP so as to facilitate integration of these Systems with ASES and other Puerto Rico systems that adhere to a service-oriented architecture.

17.2.4

Audit trails shall be incorporated into all Systems to allow information on source Data files and documents to be traced through the processing stages to the point where the information is finally recorded. The audit trails shall:

17.2.4.1

Contain a unique log-on or terminal ID, the date, and time of any create/modify/delete action and, if applicable, the ID of the system job that effected the action;

17.2.4.2

Have the date and identification “stamp” displayed on any on-line inquiry;

17.2.4.3

Have the ability to trace Data from the final place of recording back to its source Data file and/or document shall also exist;

17.2.4.4

Be supported by listings, transaction reports, update reports, transaction logs, or error logs;

17.2.4.5

Facilitate auditing of individual Claim records as well as batch audits; and

Page 228 of 324

17.2.4.6

Be maintained for ten (10) years in either live and/or archival systems. The duration of the retention period may be extended at the discretion of and as indicated to the Contractor by ASES as needed for ongoing audits or other purposes.

17.2.5

The Contractor shall house indexed images of documents used by Enrollees and Providers to transact with the Contractor in the appropriate database(s) and document management systems so as to maintain the logical relationships between certain documents and certain Data. The Contractor shall follow all applicable requirements for the management of Data in the management of documents.

17.2.6

The Contractor shall institute processes to insure the validity and completeness of the Data it submits to ASES. At its discretion, ASES will conduct general Data validity and completeness audits using industry-accepted statistical sampling methods. Data elements that will be audited include but are not limited to: Enrollee ID, date of service, Provider ID, category and sub category (if applicable) of service, diagnosis codes, procedure codes, revenue codes, date of Claim processing, and date of Claim payment.

17.2.6.1

Where a System is herein required to, or otherwise supports, the applicable batch or on-line transaction type, the system shall comply with HIPAA-standard transaction code sets.

17.2.6.2

The Contractor shall assure that all Contractor staff is trained in all HIPAA requirements, as applicable.

17.2.7

The layout and other applicable characteristics of the pages of Contractor websites shall be compliant with Federal “Section 508 standards” and Web Content Accessibility Guidelines developed and published by the Web Accessibility Initiative.

17.3

System and Data Integration Requirements

17.3.1

The Contractor’s systems shall be able to transmit, receive and process Data in HIPAA-compliant formats that are in use as of the Contract Implementation Date.

17.3.2

Data and Report Validity and Completeness. The Contractor shall institute processes to ensure the validity and completeness of the data, including reports, it submits to ASES. At its discretion, ASES will conduct general data validity and completeness audits using industry-accepted statistical sampling methods. Data elements that will be audited include, but are not limited to: enrollee ID, date of service, assigned Medicaid provider ID, category and subcategory (if applicable) of service, diagnosis codes, procedure codes, revenue codes, date of claim processing, and (if and when applicable) date of claim payment. Control totals shall also be reviewed and verified

Page 229 of 324

17.3.3

The Contractor’s applications shall be able to interface with ASES’s systems for purposes of Data exchange and will conform to standards and specifications set by ASES. These standards and specifications are subject to change. Current standards and specifications are detailed in Attachment 26 to this Contract.

17.3.4

The Contractor’s System(s) shall be able to transmit and receive transaction Data to and from ASES’s systems as required for the appropriate processing of Claims.

17.3.4.1

The Contractor will be required to perform any necessary changes to update interfaces to ASES’s systems, including those required by the Medicaid Management Information System (MMIS) as well as new Eligibility and Enrollment processes. These interface changes may require changes in the Contractors core systems.

17.3.5

Each month the Contractor shall generate Encounter Data files from its Claims management system(s) and/or other sources. Such files must be submitted in standardized Accredited Standards Committee (ASC) X12N 837 and National Council for Prescription Drug Programs (NCPDP) formats, and the ASC X12N 835 format as appropriate. The files will contain settled Claims and Claim adjustments and Encounter Data from Providers for the most recent month for which all such transactions were completed. The Contractor shall provide these files electronically to ASES and/or its Agent at a frequency and level of detail to be specified by CMS and ASES based on program administration, oversight, and program integrity needs, and in adherence to the procedure, content standards and format indicated in Attachment 26 to this Contract. The Contractor shall make changes or corrections to any systems, processes or Data transmission formats as needed to comply with Encounter Data quality standards as originally defined or subsequently amended.

17.3.6

The Contractor’s System(s) shall be capable of generating files in the prescribed formats for upload into ASES Systems used specifically for program integrity and compliance purposes.

17.3.7

The Contractor’s System(s) shall possess mailing address standardization functionality in accordance with US Postal Service conventions.

17.3.8

To comply with MAGI requirements, the Contractor must update its Information Systems in accordance with the procedures and timelines set forth in Attachment 26 to this Contract and any other subsequent guidance issued by ASES.

17.4

System Access Management and Information Accessibility Requirements

17.4.1

The Contractor’s System shall employ an access management function that restricts access to varying hierarchical levels of system functionality and Information. The access management function shall:

Page 230 of 324

17.4.1.1

Restrict access to information on a "need-to-know" basis, e.g. users permitted inquiry privileges only will not be permitted to modify information;

17.4.1.2

Restrict access to specific System functions and Information based on an individual user profile, including inquiry only capabilities; global access to all functions will be restricted to specified staff jointly agreed to by ASES and the Contractor; and

17.4.1.3

Restrict attempts to access system functions to three (3), with a system function that automatically prevents further access attempts and records these occurrences.

17.4.2

The Contractor shall make System information available to duly Authorized Representatives of ASES and other Puerto Rico and Federal agencies to evaluate, through inspections or other means, the quality, appropriateness and timeliness of services performed.

17.4.3

The Contractor shall have procedures to provide for prompt transfer of System Information upon request to other Network or Out-of-Network Providers for the medical management of the Enrollee in adherence to HIPAA and other applicable requirements.

17.4.4

All Information, whether Data or documents, and reports that contain or make references to said Information, involving or arising out of this Contract, are owned by ASES. The Contractor is expressly prohibited from sharing or publishing ASES Information and reports without the prior written consent of ASES. In the event of a dispute regarding the sharing or publishing of Information and reports, ASES’s decision on this matter shall be final and not subject to appeal.

17.5

Systems Availability and Performance Requirements

17.5.1

The Contractor shall ensure that critical systems, including but not limited to the Enrollee and Provider portal and/or phone-based functions and information, such as confirmation of Contractor Enrollment (“CCE”) and electronic Claims management (ECM), Enrollee services and Provider services, are available to the applicable System users twenty-four (24) hours a day, seven (7) Calendar Days a Week, except during periods of scheduled System Unavailability agreed upon by ASES and the Contractor. Unavailability caused by events outside of a Contractor’s Span of Control is outside of the scope of this requirement.

17.5.2

The Contractor shall ensure that at a minimum all non-critical system functions and information is available to the applicable system users between the hours of 7:00 a.m. and 7:00 p.m. Monday through Friday (Atlantic Time).

Page 231 of 324

17.5.3

The Contractor shall develop an automated method of monitoring critical systems on at least a thirty (30) minute basis twenty-four (24) hours a day, seven (7) days per Week.

17.5.4

Upon discovery of any problem within its Span of Control that may jeopardize System availability and performance as defined in this Section of the Contract, the Contractor shall notify the applicable ASES staff in person, via phone, and/or electronic mail. The Contractor shall deliver notification as soon as possible but no later than 7:00 pm (Atlantic Time) if the problem occurs during the Business Day and no later than 9:00 am (Atlantic Time) the following Business Day if the problem occurs after 7:00 pm (Atlantic Time).

17.5.5

Where the operational problem results in delays in report distribution or problems in on-line access during the Business Day, the Contractor shall notify the applicable ASES staff within fifteen (15) minutes of discovery of the problem, in order for the applicable work activities to be rescheduled or be handled based on System Unavailability protocols.

17.5.6

The Contractor shall provide to appropriate ASES staff information on System Unavailability events, as well as status updates on problem resolution. These up-dates shall be provided on an hourly basis and made available via electronic mail, telephone and, if applicable, the Contractor’s website.

17.5.7

The following rules govern unscheduled System Unavailability.

17.5.7.1

CCE Functions

17.5.7.1.1

Unscheduled System Unavailability of CCE functions caused by the failure of systems and telecommunications technologies within the Contractor’s Span of Control will be resolved, and the restoration of services implemented, within thirty (30) minutes of the official declaration of System Unavailability.

17.5.7.1.2

Throughout the Contract Term, the Contractor shall have in place a method to validate eligibility manually twenty-four (24) hours per day, seven (7) days a Week as a contingency to any unscheduled Systems Unavailability for CCE functions.

17.5.7.2

ECM Functions. Unscheduled System Unavailability of ECM functions caused by the failure of systems and technologies within the Contractor’s Span of Control will be resolved, and the restoration of services implemented, within sixty (60) minutes of the official declaration of System Unavailability, if unavailability occurs during normal business hours; or within sixty (60) minutes of the start of the next Business Day, if unavailability occurs outside business hours.

Page 232 of 324

17.5.7.3

All Other Contractor System Functions. Unscheduled System Unavailability of all other Contractor System functions caused by systems and telecommunications technologies within the Contractor’s Span of Control shall be resolved, and the restoration of services implemented:

17.5.7.3.1

Within four (4) hours of the official declaration of Unscheduled System Unavailability, when unavailability occurs during business hours, and

17.5.7.3.2

Within two (2) hours of the start of the next Business Day, when unavailability occurs during non-business hours.

17.5.8

Cumulative System Unavailability caused by systems and telecommunications technologies within the Contractor’s Span of Control shall not exceed one (1) hour during any continuous five (5) Calendar Day period for functions that affect GHP Enrollees and services. For functions that do not affect GHP Enrollees, cumulative System Unavailability caused by systems and telecommunications technologies within the Contractor’s Span of Control shall not exceed four (4) hours during any continuous five (5) Business Day periods.

17.5.9

The Contractor shall not be responsible for the availability and performance of systems and telecommunications technologies outside of the Contractor’s Span of Control.

17.5.10

For any System outage that is not corrected within the required time limits, the Contractor shall provide full written documentation that includes a Corrective Action Plan, describing how the problem will be prevented from occurring again, within five (5) Business Days of the problem’s occurrence.

17.5.11

Regardless of the architecture of its Systems, the Contractor shall develop and be continually ready to invoke a Business Continuity and Disaster Recovery (“BC-DR”) plan that at a minimum addresses the following scenarios: (i) the central computer installation and resident software are destroyed or damaged; (ii) System interruption or failure resulting from network, operating hardware, software, or operational errors that compromises the integrity of transactions that are active in a live system at the time of the outage; (iii) System interruption or failure resulting from network, operating hardware, software or operational errors that compromises the integrity of Data maintained in a live or archival system; and (iv) System interruption or failure resulting from network, operating hardware, software or operational errors that does not compromise the integrity of transactions or Data maintained in a live or archival system but does prevent access to the System, i.e. causes unscheduled System Unavailability. This BC-DR plan must be prior approved by ASES.

17.5.12

The Contractor shall on an annual basis test its BC-DR plan through simulated disasters and lower level failures in order to demonstrate to ASES that it can restore System functions per the standards outlined elsewhere in this Section 17.5 of the Contract. The results of these tests shall be reported to ASES within thirty (30) Calendar Days of completion of said tests.

Page 233 of 324

17.5.13

In the event that the Contractor fails to demonstrate in the tests of its BC-DR plan that it can restore system functions per the standards outlined in this Contract, the Contractor shall be required to submit to ASES a Corrective Action Plan that describes how the failure will be resolved. The Corrective Action Plan will be delivered within five (5) Business Days of the conclusion of the test.

17.5.14

The Contractor shall submit a monthly Systems Availability and Performance Report to ASES as further described in Section18.2.8 of this Contract.

17.6

System Testing and Change Management Requirements

17.6.1

The Contractor shall absorb the cost of routine maintenance, inclusive of defect correction, System changes required to effect changes in Puerto Rico and Federal statute and regulations, and production control activities, of all Systems within its Span of Control.

17.6.2

The Contractor shall respond to ASES reports of System problems not resulting in System Unavailability according to the following timeframes:

17.6.2.1

Within five (5) Calendar Days of receipt, the Contractor shall respond in writing to notices of System problems.

17.6.2.2

Within fifteen (15) Calendar Days, the correction will be made or a requirements analysis and specifications document will be due.

17.6.3

The Contractor shall correct the deficiency by an effective date to be determined by ASES.

17.6.4

The Contractor’s Systems will have a system-inherent mechanism for recording any change to a software module or subsystem.

17.6.5

The Contractor shall put in place procedures and measures for safeguarding ASES from unauthorized modifications to the Contractor’s Systems.

17.6.6

Unless otherwise agreed to in advance by ASES, scheduled System Unavailability to perform System maintenance, repair and/or upgrade activities to Contractor’s CCE systems shall take place between 11 p.m. on a Saturday and 6 a.m. on the following Sunday (Atlantic Time).

17.6.7

The Contractor shall work with ASES pertaining to any testing initiative as required by ASES.

Page 234 of 324

17.6.8

The Contractor shall provide sufficient System access to allow verification of System functionality, availability and performance by ASES during the times required by ASES prior to April 1, 2015 which is the Implementation Date of the Contract, and as subsequently required during the Contract Term .

17.7

System Security and Information Confidentiality and Privacy Requirements

17.7.1

The Contractor shall provide for the physical safeguarding of its Data processing facilities and the Systems and Information housed therein. The Contractor shall provide ASES with access to Data facilities upon ASES’s request. The physical security provisions shall be in effect for the life of this Contract.

17.7.2

The Contractor shall restrict perimeter access to equipment sites, processing areas, and storage areas through a card key or other comparable system, as well as provide accountability control to record access attempts, including attempts of unauthorized access.

17.7.3

The Contractor shall include physical security features designed to safeguard processor site(s) through required provision of fire retardant capabilities, as well as smoke and electrical alarms, monitored by security personnel.

17.7.4

The Contractor shall ensure that the operation of all of its Systems is performed in accordance with Puerto Rico and Federal regulations and guidelines related to security and confidentiality of the protected information managed by the Contractor, and shall strictly comply with HIPAA Privacy and Security Rules, as amended, and with the Breach Notification Rules under the HITECH Act.

17.7.5

The Contractor will put in place procedures, measures and technical security to prohibit unauthorized access to the regions of the Data communications network inside of a Contractor’s Span of Control.

17.7.6

The Contractor shall ensure compliance with:

17.7.6.1

42 CFR Part 431 Subpart F (confidentiality of information concerning applicants and enrollees of public medical assistance programs);

17.7.6.2

42 CFR Part 2 (confidentiality of alcohol and drug abuse records); and

17.7.6.3

Special confidentiality provisions in Puerto Rico or Federal law related to people with HIV/AIDS and mental illness.

17.7.7

The Contractor shall provide its Enrollees with its HIPAA Notice of Privacy Practices that conforms to all applicable Federal and State laws. The Contractor shall provide ASES with a copy of this Notice.

Page 235 of 324

17.8

Information Management Process and Information Systems Documentation Requirements

17.8.1

The Contractor shall ensure that written System Process and Procedure Manuals document and describe all manual and automated system procedures for its information management processes and Information Systems. These manuals shall be provided to ASES Immediately upon request.

17.8.2

The System User Manuals shall contain information about, and instructions for, using applicable System functions and accessing applicable system Data.

17.8.3

When a System change that would alter the conditions and services agreed upon in this Contract is subject to ASES sign off, the Contractor shall draft revisions to the appropriate manuals prior to ASES sign off of the change.

17.8.4

Updates to the electronic version of these manuals shall occur in real time; updates to the printed version of these manuals shall occur within ten (10) Business Days of the update taking effect.

17.8.5

ASES reserves the right to audit the Contractor’s policies and procedures manuals and protocols compliance related to its Information Systems.

17.9

Reporting Functionality Requirements

17.9.1

The Contractor’s Systems shall have the capability of producing a wide variety of reports that support program management, policymaking, quality improvement, program evaluation, analysis of fund sources and uses, funding decisions and assessment of compliance with Federal and Puerto Rico requirements.

17.9.2

The Contractor shall support a mechanism for obtaining service and expenditure reports by funding source, Provider, Provider type or other characteristic; and Enrollee, Enrollee group/category or other characteristic.

17.9.3

The Contractor shall extend access to this mechanism to select ASES personnel in a secure manner to access Data, including program and fiscal information regarding Enrollees served, services rendered, etc. and the ability for said personnel to develop and/or retrieve reports. This requirement could be met by the provision of access to a decision support system/Data warehouse. The Contractor shall provide training in and documentation on the use of this mechanism.

17.9.4

Within five (5) Calendar Days upon ASES’s request, the Contractor will deliver a copy of the then current ASES’s System information to ASES in a mutually acceptable form and format.

Page 236 of 324

17.10

Disaster Recovery, Disaster Declaration, Data Content Delivery to ASES

17.10.1

The Contractor shall maintain a disaster recovery and business recovery plan in effect throughout the term of the Contract. The disaster recovery plan shall be subject to ASES review upon reasonable notice to the Contractor. The Contractor shall maintain reasonable safeguards against the destruction, loss, intrusion and unauthorized alteration of printed materials and data in its possession. At a minimum, the Contractor shall perform (i) incremental daily back-ups, (ii) weekly full backups, and (iii) such additional back-ups as the Contractor may determine to be necessary to maintain such reasonable safeguards.

17.10.2

Both Parties recognize that a failure by the Contractor’s Network may adversely impact ASES business and operations, as the responsible party for the GHP. Therefore, in the event that the Contractor’s Network designed to deliver the services herein contemplated becomes unable, or is anticipated to become unable, to deliver such services on a timely basis, Contractor shall Immediately notify ASES by telephone, and shall work closely with ASES to fix the problem. In the event that Contractor fails to provide such required notice to ASES and such delay in the notification has a material and adverse effect upon ASES and/or Enrollees, ASES may terminate this Contract for cause as provided in Article 35 of this Contract.

17.10.3

Within five (5) Calendar Days upon ASES’s request, the Contractor will deliver a copy of the then current ASES’s Data Content to ASES in a mutually acceptable form and format which is useable and readable and understandable by ASES.

17.11

Health Information Organization (HIO) and Health Information Exchange (HIE) Requirements

17.11.1

The Contractor shall initiate the active participation in any Health Information Organization (HIO) that offers Health Information Exchange (HIE) services, in order to integrate the Enrollees’ Protected Health Information, facilitate access to and retrieval of their clinical Data to provide safer and more timely, efficient, effective, and equitable patient-centered care. The HIO participation is also required to support the analysis of the health of the population. As required by ASES, the Contractor shall be active in a HIO and cooperate with this effort.

17.11.2

ASES shall retain the right to request from the Contractor the active participation in the Puerto Rico Health Information Exchange Corporation (PRHIEC), the Puerto Rico HIO State Designated Entity, in order to achieve the effective alignment of activities across Medicaid and Puerto Rico public health programs, to avoid duplicate efforts and to ensure integration and support of a unified approach to information exchange for the GHP Program .

Page 237 of 324

17.11.3

The Contractor shall verify that the HIO complies with all Information System standards and requirements for interoperability and security capabilities dictated by ONCHIT, and other Federal and Puerto Rico regulations.

17.11.4

The Contractor shall work with Network Providers and staff to encourage active participation in an HIO, as specified in the strategic plan found in Attachment 17 to this Contract.

ARTICLE 18

REPORTING

18.1

General Requirements

18.1.1

ASES may, at its discretion, require the Contractor to submit additional reports or any other data, documentation or information relating to the performance of the Contractor’s obligations both on an ad hoc and recurring basis as required by ASES or CMS. If ASES requests any revisions to the reports already submitted, the Contractor shall make the changes and re-submit the reports, according to the time period and format specified by ASES.

18.1.2

The Contractor shall submit all reports to ASES in the manner and format prescribed by ASES and as prescribed in the reporting guide.

18.1.3

The Contractor shall submit all reports, including but not limited to those required by Law 72, Article 7, Section 2, in a manner and format prescribed by ASES.

18.1.4

All reports submitted to ASES containing information about a Provider must include the Provider’s National Provider Identifier (NPI), if applicable.

18.1.5

All quantitative reports shall include a summary table that presents Data over time including monthly, quarterly and/or year-to-date summaries as directed by ASES.

18.1.6

ASES’s requirements regarding reports, report content, and frequency of submission are subject to change at any time during the term of the Contract. A list of required reports is provided in Attachment 16 to this Contract. ASES shall notify the Contractor, in writing, of changes to existing required report content, format or schedule at least fourteen (14) Calendar Days prior to implementing the reporting change. ASES shall notify the Contractor, in writing, of new reports at least forty-five (45) Calendar Days prior to implementing the new report. The Contractor shall be held harmless if ASES fails to meet this requirement for any changes for existing reports. However, the Contractor is not otherwise relieved of any responsibility for the submission of late, inaccurate or otherwise incomplete reports. The first submission of a report revised by ASES to include a change in Data requirements or definition will not be subject to penalty for accuracy.

Page 238 of 324

18.1.7

The Contractor shall submit reports timely and in proper format. The submission of late, inaccurate, or otherwise incomplete reports constitutes failure to report. “Timely submission” shall mean that the report was submitted on or before the date it was due. “Accuracy” shall mean the report was prepared according to the specific written guidance, including report template, provided by ASES to the Contractor. All elements must be met for each required report submission. Therefore, the report must be timely, accurate and contain an analysis. If any portion of the report element is not met, the report is deemed in “error” and the Contractor will be considered to not be in compliance with the Contract and will be subject to intermediate sanctions and or liquidated damages and/or fines in accordance with Articles 19 and 20 of this Contract. The Contractor shall not be penalized if an error in a previously submitted report is identified by the Contractor and reported to ASES prior to ASES’s identification of the error. Corrected reports in this type of situation will be submitted to ASES in a timeframe determined by ASES after consulting with the Contractor. Failure to comply with the agreed upon timeframes for correction and resubmission shall be subject to intermediate sanctions and or liquidated damages and/or fines in accordance with Articles 19 and 20 of this Contract.

18.1.8

Each report must include an analysis, which shall include, at a minimum: (i) identification of any changes compared to previous reporting periods as well as trending over time; (ii) an explanation of said changes (positive or negative); (iii) an action plan or performance improvement activities addressing any negative changes; and (iv) any other additional information pertinent to the reporting period. ASES may assess intermediate sanctions, liquidated damages and/or fines in accordance with Articles 19 and 20 of this Contract for failure to address any of these requirements. The above Data requirements may be represented in charts, graphs, tables and any other Data illustrations to demonstrate findings.

18.1.9

The Contractor shall review, as part of its continuous improvement activities, timeliness and accuracy of reports submitted to ASES to identify instances and patterns of non-compliance. The Contractor shall perform an analysis identifying any patterns or issues of non-compliance and shall implement quality improvement activities to improve overall performance and compliance.

18.1.10

The Contractor shall submit all reports to ASES, unless indicated otherwise in this Contract, according to the schedule below. Failure to report timely may result in intermediate sanctions, liquidated damages and/or fines in accordance with Articles 19 and 20. Reports or other required Data shall be received on or before scheduled due dates.

18.1.11

The Contractor shall submit all reports to ASES, unless indicated otherwise in this Contract, according to the schedule below:

Page 239 of 324

		DELIVERABLES			DUE DATE
		Weekly Reports			Friday of the following Week
		Monthly Reports			Fifteenth (15th) Calendar Day of the following month
		Quarterly Reports			Thirtieth (30th) Calendar Day of the following month
		Semi-Annual Reports			March 31 and September 30 of the Contract year
		Annual Reports			Ninety (90) Calendar Days after the end of the Contract Year

18.1.12

If a report due date falls on a weekend or a Puerto Rico holiday, receipt of the report the next Business Day is acceptable.

18.1.13

Extensions to report submission dates will be considered by ASES after the Contractor has contacted the ASES designated point of contact via email at least twenty-four (24) hours in advance of the report due date. Extension for submission of reports should be under rare and unusual circumstances. If ASES grants an extension, and the report is submitted before the extended deadline, the report(s) will be considered timely and not subject to penalty for timeliness. Not requesting an extension within at least twenty-four (24) hours of the report due date is considered failure to report timely.

18.1.14

Anytime a report is rejected for any reason, the Contractor shall resubmit the report within ten (10) Business Days from notification of the rejection or as directed by ASES.

18.1.15

The Contractor shall submit all reports electronically to ASES’s FTP site unless directed otherwise by ASES. ASES shall provide the Contractor with access to the FTP site. The email generated by the FTP upload will be used as the time stamp for the submission of the report(s).

18.1.16

ASES shall provide feedback, as necessary, to the Contractor regarding format and timeliness of reports within forty-five (45) Calendar Days from the due date of the report.

18.1.17

All reports in the reporting templates provided to the Contract require Contractor certification. The Authorized Certifier or an equivalent position as delegated by the Contractor and approved by ASES, shall review the accuracy of language, analysis, and Data in each report prior to submitting the report to ASES. The Authorized Certifier shall include a signed attestation each time the report is submitted. The attestation must include a certification, based on best knowledge, information, and belief, as to the accuracy, completeness and truthfulness of the Data in the report. Reports will be deemed incomplete if an attestation is not included.

Page 240 of 324

18.1.18

The Contractor Data transfers shall occur in standard format as prescribed by ASES and will be compliant with HIPAA and Federal regulations. The Contractor shall submit in formats as prescribed by ASES so long as ASES’s direction does not conflict with any Federal law.

18.2

Specific Report Requirements

18.2.1

The following section provides an overview and description of all reports required by this Contract. The details and requirements of the reports are subject to change at the discretion of ASES.

18.2.2

Administrative Reports

18.2.2.1

The Contractor shall submit a monthly Call Center Report that provides information about the Enrollee services, Provider services, and nurse advice lines. The report shall, at a minimum, include by language queue: (i) number of calls received; (ii) number of calls answered; (iii) abandonment rate; (iv) number of calls answered within thirty (30) seconds; and (v) call topics.

18.2.2.2

The Contractor shall submit a quarterly Enrollee Enrollment Materials Report regarding the mailing of initial and replacement Enrollee Enrollment materials including Enrollee ID cards, Enrollee handbooks, and Provider directories. The Data in the report shall be reported separately for initial mailings to new Enrollees and requests for replacement materials for current Enrollees. The report shall include, at a minimum, the following: (i) number of ID cards, handbooks and Provider directories mailed during the month regardless of whether the request was made by phone, online or in person; (ii) number of ID cards, handbooks and Provider directories mailed within Contract standards; and (iii) number of ID cards, handbooks and Provider directories not mailed within Contract standards.

18.2.2.3

The Contractor shall submit a quarterly Fraud, Waste, and Abuse Report . The report contains three subsections:

18.2.2.3.1

Information regarding suspicious activity, Fraud, Waste, and Abuse cases, recoupments, Cost Avoidance, Referrals, and other information as directed by ASES. At a minimum, the report shall include: (i) Enrollee name and ID number; (ii) Provider name, Provider type and NPI; (iii) source and date of Complaint; (iv) nature of Complaint (including alleged persons or entities involved, category of services, factual explanation of the allegation and dates of contact); (v) all communications between the Contractor and the Provider about the Complaint; (vi) approximate dollars involved or amount paid to the Provider during the past three (3) years (whichever is greater); (vii) amount recouped; (viii) disciplinary measures imposed, if any; and (ix) legal disposition of the case.

Page 241 of 324

18.2.2.3.2

List by name all Network Provider suspensions or terminations, at a minimum, (i) each Network Provider’s name; (ii) the Network Provider’s specialty; (iii) the Network Provider’s NPI; (iv) the Network Provider’s primary city; (v) reason(s) for the action taken; and (vi) the effective date of the suspension or termination. If the Contractor has taken no action against Providers during the quarter this should be documented in the report.

18.2.2.3.3

Include information pertaining to employees and Contractors that have been suspended or debarred from participating in the program.

18.2.2.4

The Contractor shall submit a monthly Privacy and Confidentiality Report. The report shall provide information on any Incidents that involve the loss, theft or unauthorized use or access of Enrollee PHI. The report shall include at a minimum: (i) the date of the Incident; (ii) the date of notification to ASES; (iii) the nature and scope of the Incident; (iv) the Contractor’s response to the Incident; (v) the number of Enrolles actually or potentially impacted; (vi) any mitigating measures taken by the Contractor to prevent similar incidents.

18.2.2.5

The Contractor shall submit a monthly Systems Incident Report . The report shall provide information on any Incidents that involve unauthorized access to the Contractor’s systems, databases or servers. This report shall be provided at least annually, but the Contractor shall provide the report ten (10) Business Days following an Incident. The report shall include, at a minimum, the date of the Incident, the date of notification to ASES, the nature and scope of the Incident, the Contractor’s response to the Incident, and the mitigating measures taken by the Contractor to prevent similar Incidents in the future. “Port scans” or other unsuccessful queries to the Contractor’s Information System shall not be considered a privacy/security Incident for purposes of this report.

18.2.2.6

The Contractor shall submit a quarterly Federally Qualified Health Center (FQHC) Report as required by ASES and the Puerto Rico Medicaid Program. The report contains the following subsections:

18.2.2.6.1

Fee for Services Payment Report and Attestation includes all FFS payments by PMG.

Page 242 of 324

18.2.2.6.2

Visits Data Support and Attestation includes information on face-to-face visits by type of Provider, population category, and other criteria.

18.2.2.6.3

PMG Population Detail and Attestation includes Enrollees by category (Federal, State, CHIP and Other) by PMG.

18.2.2.6.4

Capitation Settlement and Attestation includes a reconciliation of payments per capita.

18.2.2.7

The Contractor shall submit a monthly Special Coverage Registry Report. The report shall provide information on all registered Enrollees, PMG, PCP NPI, type of registry, Special Coverage category, diagnosis code, start and end dates, identify new cases, case status, reason(s) for closing the case. For the Obstetric category, the expected date of delivery, last menstrual period and Obstetric Specialist NPI.

18.2.2.8

The Contractor shall submit a monthly HCHN Registry Report for ASES to process monthly PMPM Payments. The report shall provide information on all HCHN Enrollees that are identified by the Contractor following the procedures established in Attachment 28 to this Contract. ASES will perform a retroactive review of the conditions identified by Enrollee utilizing the monthly claims data submitted by the Contractor to ASES. If the data does not support the identified condition(s), ASES may retroactively recoup the difference in PMPM Payment.

18.2.2.9

The Contractor shall submit an annual Disclosure of Information on Annual Business Transactions as described in Section 23.7.4 of the Contract.

18.2.2.10

Within forty-five (45) days of the end of the Puerto Rico Government’s fiscal year, Contractor shall submit the statistical report required under Section 2, Article VII of Law 72-1993 in the layout specified by ASES.

18.2.3

Claims

18.2.3.1

The Contractor shall submit a monthly Claims Activity Report . At a minimum, this report shall identify: (i) the number of Claims received; (ii) number of Claims denied (by reason); (iii) number of Claims paid; (iv) number of Claims pending (by reason); (v) and the total amount paid for all Providers (by Provider category) specified by ASES in accordance with Section 16.2 of this Contract.

18.2.3.2

The Contractor shall submit Encounter Data in a standardized format as specified by ASES (see Section 16.3 of this Contract and Attachment 26) transmitted electronically to ASES on a monthly basis. The Contractor shall provide any information and/or Data requested in a format to be specified by ASES as required to support the validation, testing or auditing of the completeness and accuracy of Encounter Data submitted by the Contractor.

Page 243 of 324

18.2.4

Covered Services

18.2.4.1

The Contractor shall submit an annual CMS 416 Report that measures and documents EPSDT screening and participation rates. In addition to the requirements in the CMS 416 Report, the Contractor shall report on any additional Data that ASES determines is necessary for monitoring and compliance purposes.

18.2.4.2

The Contractor shall submit a quarterly Executive Director and Utilization Data Report that provides information on selected GHP populations and Providers. The report shall include, at a minimum:

18.2.4.2.1

Enrollee, Special Conditions and Child: Information regarding (i) GHP Enrollees; (ii) Enrollees in special programs (including Enrollees with Special Coverage); (iii) PPN and Network Providers; (iv) services for children; (v) dental services; (vi) hospitalizations, and statistical data on the top ten (10) most prevalent diagnosis as specified by ASES.

18.2.4.2.2

Preventable Conditions. Information as defined in Sections 7.1.1.1.1 and 7.1.1.1.2 of this Contract. The report shall include but not be limited to, a description of each identified instance of a Provider Preventable Condition, the name of the applicable Provider, and a summary of corrective actions taken by the Contractor or Provider to address any underlying causes of the Provider Preventable Condition.

18.2.4.2.3

Dental, Hospital, Emergency Room

18.2.4.2.3.1

Dental. The total number of dental services and the cost on a quarterly basis.

18.2.4.2.3.2

Hospital Services. Total number of bed days and cost quarterly for Physical Health and Behavioral health, separately.

18.2.4.2.3.3

Emergency Room. On a quarterly basis, the total number of ER visits and costs; the top conditions for Physical Health admissions; and the top conditions for Behavioral Health admissions.

Page 244 of 324

18.2.4.2.4

Outpatient/Ambulatory Services. The total number of Outpatient services by type on a quarterly basis. Types of services include: Office visits, PCP encounters, imaging Laboratory, Pathology, OP Surgery, Other Medical Procedures and Services and Other Ancillary Services. Behavioral Health OP services by type on a quarterly basis. Types of BH services include: Psychiatrist, Psychologist, BH treatment by a General Practitioner, Other, Partial Hospitalization, Clinical Labs and all Other Ancillary BH Services. Behavioral Ambulatory Clinics: the number of Enrollees (including walk-ins) receiving Behavioral Health Services therein and the number of Providers rendering these services during such period.

18.2.4.2.5

Admissions and Re-admissions. The number of discharges and re-admissions within thirty (30) Calendar Days of a previous discharge, distributed by Physical Health and Behavioral Health; the top three (3) diagnosis codes for Physical Health and Behavioral Health; and the top five (5) re-admission facilities by Physical Health and Behavioral Health.

18.2.4.2.6

Prior Authorization (PA). PA information by service, specifying (i) total PA requests received; (ii) total process by type of determination; (iii) denials by reason and type of service; and (iv) HCHN PA processed and denied by condition.

18.2.5

Provider Reports

18.2.5.1

The Contractor shall submit a monthly Network Provider List Report that provides information on the number of Providers with and without assigned lives in the Contractor’s General and PPN network. At a minimum, the report shall include information on the Network Provider’s: (i) name; (ii) specialty; (iii) NPI; (iv) specialty code; (v) license number; (vi) primary office location; (vii) office hours; (viii) Credentialing status; (ix) PMG affiliation; (x) ratio to Enrollees (including PCPs, Behavioral Health Providers); and (xi) the number of assigned lives (if applicable); and (xii) credentialing and re-credentialing information. For facilities, the report shall include: (i) EIN; (ii) name of the entity; (iii) municipality code; (iv) Provider type code; and (v) the NPI.

18.2.5.2

The Contractor shall submit quarterly Geographical Access reports using geographic Information Systems software that allows ASES to analyze, at a minimum, the following: (i) description of geographic systems software utilized to generate geographic access reports; (ii) description of monitoring activities to ensure Access standards are met and that Enrollees have Access to services; (iii) description of gaps in geographic Access and methodologies used to identify them; (iv) Data on all service locations for PCP and all specialty Providers; and (v) number of Enrollees that are currently assigned to the Network Provider (PCPs only).

Page 245 of 324

18.2.5.3

The Contractor shall submit a quarterly Appointment Availability Report that provides network assurance reviews and outreach to individual Providers. The report should include a 25% review of the Contractor’s provider network. The report shall (i) verify appointment availability and timeliness; (ii) verify contact information, address, phone, email and fax numbers; (iii) verify open/closed panel status and identify Providers accepting new patients; (iv) verify disability access, equipment or limitations; (v) verify languages spoken and cultural specific training; and (vi) verification of co-location hours based on assigned Enrollees.

18.2.5.4

The Contractor shall submit an annual Provider Satisfaction Report that encompasses Physical and Behavioral Health Network Providers. The report shall include but not be limited to, a summary of the Provider survey methods and findings for Physical and Behavioral Health Network Providers separately and an analysis of opportunities for improvement. See Section 12.6 for additional information regarding Provider Satisfaction Surveys.

18.2.5.5

The Contractor shall submit a quarterly Provider Training and Outreach Evaluation Report to evaluate the initiatives in the plan and present findings and lessons learned. The report shall specify the training topic(s), the targeted Providers, the content of the training, the training schedule (including dates/times and locations), training methods, funds expended, and number and types of attendees.

18.2.5.6

The Contractor shall submit an annual Physician Incentive Program Report in a narrative format including the information specified by regulation in order for ASES to adequately monitor the Contractor’s program under the criteria in 42 CFR 422.208 and 422.210.

18.2.6

Quality

18.2.6.1

The Contractor shall submit a quarterly Grievances and Appeals Report. The Contractor shall submit reports of all Provider and Enrollee Grievances (informal and formal), Appeals, Notices of Adverse Benefit Determinations and Administrative Law Hearings utilizing the ASES-provided reporting templates and codes. The report will also capture Enrollee comments and inquiries made through the Contractor’s website.

Page 246 of 324

18.2.6.2

The Contractor shall submit a quarterly Health Care Improvement Program (HCIP) Report. The Contractor shall use measurements and performance guidelines outlined in the HCIP Manual, Attachment 19 to this Contract.

18.2.6.3

The Contractor shall submit an annual Enrollee Satisfaction Survey Report that includes, but is not limited to, a summary of the Enrollee survey methods, findings, analysis and evaluation. The report shall present information separately for CAHPS and ECHO. The survey and findings shall be presented by populations as determined by ASES (e.g., Adults, children, Behavioral Health and Chronic Conditions). The report must provide an action plan addressing areas for improvement of the Contractor as identified in the survey results. Refer to Section 12.6 of this Contract for additional information regarding the survey.

18.2.6.4

The Contractor shall submit an annual Audited HEDIS Results Report . The Contractor shall use only NCQA published HEDIS standardized measures that specify how MCOs collect, audit, calculate and report performance information.

18.2.6.4.1

Each HEDIS submission must require the following information:

18.2.6.4.1.1

A signed attestation that will provided by ASES;

18.2.6.4.1.2

Quantitative Data and Qualitative Data collected according to HEDIS technical specifications. This Data shall be reported to ASES in an excel workbook and as a searchable .PDF document; and

18.2.6.4.1.3

A final HEDIS Compliance Audit Report and supporting documentation according to HEDIS Compliance Audit standards, policies and procedures. The Contractor shall contract with a certified HEDIS auditor to validate the processes of the Contractor. For Medicaid and CHIP Eligibles, the validation procedures shall be consistent with Federal requirements specified at 42 CFR 438.358(b)(2).

18.2.6.4.2

As specified in Section 12.3.4.6 of this Contract, the Contractor shall submit the standardized HEDIS measures in the format required by ASES. On January each year, ASES will notify Contractors on the HEDIS measures to be reported.

Page 247 of 324

18.2.6.4.3

ASES may add, change, or remove HEDIS reporting requirements with notice sixty (60) Calendar Days in advance of the effective date of the addition, change, or removal.

18.2.6.4.4

18.2.7

Utilization Management

18.2.7.1

The Contractor shall submit a quarterly Integration Model Report that includes information on Physical and Behavioral Health Services.

The report shall, at a minimum, include the following data as specified by ASES:

18.2.7.1.1

Co-location Services. By Provider, the total membership, BHP quarterly required hours and actual quarterly hours, the number of unique Enrollees, the total number of hours served by col-location, the number of initial assessments, the number of Enrollees receiving short intervention and the number of Enrollees where case discussion took place with any Provider.

18.2.7.1.2

Reverse Co-location Services. By facility or clinic; the number of BHP quarterly required hours and actual quarterly hours; the total number of patients seen for Physical Health issues (by number of visits, not by unique Enrollees); number of services; number of Enrollees in the Serious Mental Illness (SMI) registry, and of those Enrollees seen for Physical Health, how many were in the SMI registry.

18.2.7.1.3

Beneficiary Educational Activities. By facility, the Enrollment number, the total number of Enrollees seen, the program name, date, duration, and number of attendees.

Page 248 of 324

18.2.7.1.4

Provider Educational Activities. By date, the total number of education hours, the clinic name, the total number of staff members, and total number that attended the activity.

18.2.7.1.5

Care Management. Care management data by program category, HCHN and Chronic Conditions data by diagnosis category, screenings by category, and referrals.

18.2.7.1.6

Pregnancy data on the pregnant population and Prenatal and Maternal Program.

18.2.7.1.7

Number of Enrollees in each category as registered in the quarter: Smoking cessation, autism, ADD, and Buprenorphine.

18.2.8

Systems

18.2.8.1

The Contractor shall submit a monthly Systems Availability and Performance Report that provides information on availability and unavailability by major system as well as response times for the Contractor’s confirmation of Contractor’s Enrollment and electronic Claims management functions, as measured within the Contractor’s Span of Control. The report shall meet the requirements of Section 17.5.

18.2.8.2

The Contractor shall submit an annual Business Continuity and Disaster Recovery (“BC-DR”) Test Report for review and written approval as specified by ASES in accordance with Section 17.5. The Contractor shall conduct annual tests of the BC-DR system and report the findings of the test results with the system generated log report within thirty (30) Calendar Days of the date of the test.

18.2.9

Financial Management

18.2.9.1

The Contractor shall submit a quarterly Unaudited Financial Statement Report in a format and level of detail as specified by ASES.

18.2.9.2

The Contractor shall submit an annual Report on Controls Placed in Operation and Tests of Operating Effectiveness. The report must meet all standards and requirements of the AICPA’s SSAE 18 for the Contractor’s operations performed for ASES under this Contract.

18.2.9.3

The Contractor shall submit an annual Audited Financial Statements . The Contractor shall provide ASES with copies of its audited financial statements following general accepted accounting principles and generally accepted auditing standards in the US, at its own cost and charge, for the duration of the Contract, and as of the end of each Contract Year during the Contract Term, regarding the financial operations related to the GHP Program. These reports shall be submitted to ASES no later the ninety (90) Calendar Days after the close of the Contract Year.

Page 249 of 324

18.2.9.4

The Contractor shall submit a quarterly Cost Avoidance Report. The report shall describe, as specified by ASES, the Contractor’s findings regarding routine audits of Network Providers to evaluate cost-avoidance performance.

18.2.9.5

The Contractor shall submit an annual Report to Puerto Rico Insurance Commissioner’s Office in the format agreed upon by the National Association of Insurance Commissioners (NAIC).

18.2.9.6

The Contractor shall submit an Annual Corporate Report at the close of the Contractor’s fiscal/calendar year.

18.2.9.7

The Contractor shall, in the format specified by ASES, submit a duly signed Pharmacy Certification every two weeks, including the amount of pharmacy claims paid, rejected, denied, reversed and adjusted.

18.2.9.8

The Contractor shall submit a quarterly Incurred But Not Paid Report (IBNR) in the format required by ASES.

18.2.9.9

The Contractor shall, in the format specified by ASES, submit a Medical Loss Ratio Report in accordance with Section 22.2 by July 31 following the end of the Contract Year.

18.3

Annual Plans

18.3.1

Departmental annual plans are required as follows:

18.3.1.1

The Contractor shall submit an annual Maternal and Prenatal Plan in accordance with Section 7.5.8.

18.3.1.2

The Contractor shall submit an annual EPSDT Plan as described in Section 7.9.

18.3.1.3

The Contractor shall submit an annual Wellness Plan in accordance with Section 12.6.

18.3.1.4

The Contractor shall submit an annual Compliance Plan that meets the requirements outlined in Section 13.2.

18.3.1.5

The Contractor shall submit an annual Program Integrity Plan that meets the requirements outlined in Section 13.3.

Page 250 of 324

18.3.1.6

The Contractor shall submit an annual Provider Training and Outreach Plan describing Provider training initiatives including, but not limited to, the following: (i) Prior Authorizations; (ii) Claims/Encounter Data submissions; (iii) how to access Ancillary Service Providers; (iv) Enrollee rights and responsibilities; (v) quality improvement program/initiatives; (vi) Provider and Enrollee Appeals and Grievances; (vii) recoupment of funds processes and procedures; (viii) EPSDT benefit requirements, including Preventive Services guidelines; and (ix) Fraud, Waste and Abuse.

18.3.1.7

The Contractor shall submit an annual Provider Network Development and Management Plan that at a minimum, shall include: (i) summary of Network Providers, by type and geographic location in Puerto Rico; (ii) demonstration of monitoring activities to ensure that access standards are met and Enrollees have timely access to services, per the requirements of this Contract; (iii) a summary of Network Provider capacity issues by service and municipality, the Contractor’s remediation and quality management/quality improvement activities and the targeted and actual completion dates for those activities; (iv) network deficiencies by service and by geographical area and interventions to address the deficiencies; and (v) ongoing activities for Provider network development and expansion taking into consideration identified participating provider capacity, network deficiencies, service delivery issues and future needs, and (vi) if an exception has been granted, an update on recruiting initiatives.

18.3.1.8

The Contractor shall submit an annual UM Program Description/Work Plan . The program description shall include a description of the structure and accountability mechanisms. At a minimum, the description shall include: (i) scope of the UM program, (ii) goals and objective of the UM program, (iii) program structure including organizational structure, authority and accountability and committee structure; (iv) description of UM networking and support; and (v) a description of the following UM processes: pre-service review, concurrent review, post service review, discharge planning and emergency department services. The UM Work Plan shall include: (i) planned UM improvement activities that will address quality of service delivery; (ii) specific mechanism for periodic Data tracking and trending of UM performance indicators; and (iii) periodic evaluations of the effectiveness of UM interventions.

18.3.1.9

The Contractor shall submit an annual BC-DR Plan in accordance with Section 17.5.

Page 251 of 324

18.3.1.10

The Contractor shall submit an annual Physician Incentive Plan in accordance with Section 23.6.

ARTICLE 19

ENFORCEMENT – INTERMEDIATE SANCTIONS

19.1

General Provisions

19.1.1

In monitoring Contractor’s compliance with the terms of the Contract, ASES may impose intermediate sanctions, and/or liquidated damages, and/or fines pursuant to Puerto Rico Act No. 72-1993 and ASES Regulation No. 8446, for Contractor’s failure to comply with the terms and conditions of this Contract (as further specified in Articles 19 and 20 of this Contract).

19.1.2

In the event the Contractor incurs any proscribed conduct or otherwise is in default as to any applicable term, condition, or requirement of this Contract, and in accordance with any applicable provision of 42 CFR 438.700 and Section 4707 of the Balanced Budget Act of 1997, at any time following the Effective Date of the Contract, the Contractor agrees that, in addition to the terms of Section 35.1.1 of this Contract, ASES may impose intermediate sanctions against the Contractor for any such default in accordance with this Article 19. ASES may impose both intermediate sanctions and fines pursuant to Puerto Rico Act No. 72-1993 and ASES Regulation 8446. The assessment or non-assessment of intermediate sanctions under this Contract cannot and will not limit the power or authority of ASES to impose any other fines, civil money penalties, sanctions, or other remedies recognized by Puerto Rico or Federal laws or regulations, including, but not limited to, Puerto Rico Act No. 72-1993 and ASES Regulation No. 8446.

19.1.3

Notwithstanding any intermediate sanctions imposed upon the Contractor under this Article 19, other than Contract termination, the Contractor shall continue to provide all Covered Services and other Benefits under this Contract.

19.1.4

ASES shall have the right impose the following intermediate sanctions:

19.1.4.1

Civil Money Penalty. ASES may impose a civil money penalty for the following categories of events.

19.1.4.1.1

Category 1. A civil money penalty in accordance with any applicable provision of 42 CFR 438.700 up to one-hundred thousand dollars ($100,000) per determination shall be imposed for this category. The following constitute Category 1 events:

19.1.4.1.1.1

Acts that discriminate among Enrollees on the basis of their health status or need for health care services. This includes termination of Enrollment or refusal to reenroll a Potential Enrollee, except as permitted under the Medicaid program, or any practice that would reasonably be expected to discourage Enrollment by beneficiaries whose medical or Behavioral Health condition or history indicates probable need for substantial future medical or Behavioral Health Services. Notwithstanding the foregoing, ASES may impose a civil money penalty in the amount of fifteen thousand dollars ($15,000) per each (i) Potential Enrollee that was not enrolled because of discriminatory practices as described above and/or (ii) discriminatory practices imposed on Enrollees, subject to the overall limit of one-hundred thousand dollars ($100,000) per each determination.

Page 252 of 324

19.1.4.1.1.2

The misrepresentation or falsification of information submitted to ASES and/or CMS.

19.1.4.1.2

Category 2. A civil money penalty in accordance with any applicable provision of 42 CFR 438.700 up to twenty-five thousand dollars ($25,000) per determination shall be imposed for this category. The following constitute Category 2 events:

19.1.4.1.2.1

Failure by the Contractor to substantially provide Medically Necessary Services that the Contractor is required to provide, under applicable law or under this Contract, to an Enrollee under this Contract.

19.1.4.1.2.2

Misrepresentation or falsification by the Contractor of information that it furnishes to an Enrollee, Potential Enrollee, or Provider.

19.1.4.1.2.3

Failure by the Contractor to comply with the requirements for Physician Incentive Plans, as set forth in 42 CFR 422.208 and 422.210.

19.1.4.1.2.4

The distribution by the Contractor, directly or indirectly through any Agent or independent contractor, of Marketing Materials that have not been prior approved by ASES or that contain false or materially misleading information.

19.1.4.1.3

Category 3. Pursuant to 42 CFR 438.704(c), ASES may impose a civil money penalty for the Contractor’s imposition of premiums or charges in excess of the amounts permitted under the Medicaid program. The maximum amount of the penalty is the greater of twenty-five thousand dollars ($25,000) or double the amount of the excess charges. ASES will deduct from the penalty the amount of overcharge and return it to the affected Enrollees.

Page 253 of 324

19.1.4.2

Temporary Management. ASES may appoint temporary management for the Contractor’s GHP operations, as provided in 42 C.F.R. 438.702 and 42 C.F.R. 438.706 as a result of Contractor’s:

19.1.4.2.1

Continued egregious behavior, including but not limited to behavior described in Categories 1 through 3 of this Article 19;

19.1.4.2.2

Behavior that is contrary to, or is non-compliant with, Sections 1903(m) or 1932 of the Social Security Act, as amended, found at 42 U.S.C. §§ 1396b (m) and 1396u-2;

19.1.4.2.3

Actions which have caused substantial risk to an Enrollee’s health; and/or

19.1.4.2.4

Behavior which has led ASES to determine that temporary management is necessary to ensure the health of Contractor’s Enrollees while improvements to remedy Category 1 through 3 violations are being made, or until the Contractor’s orderly termination or reorganization.

19.1.4.2.5

If temporary management is appointed for any reason specified in Sections 19.1.4.2 above, such temporary management will cease once ASES has, in its discretion, determined that the sanctioned behavior will not re-occur.

19.1.4.3

Enrollment Termination. ASES may grant Enrollees the right to terminate Enrollment without cause, and notify the affected Enrollees of their right to disenroll when:

19.1.4.3.1

The Contractor has engaged in continued egregious behavior, including but not limited to behavior described in Categories 1 through 3 of this Article 19;

19.1.4.3.2

The Contractor has engaged in behavior that is contrary to, or is non-compliant with, Sections 1903(m) or 1932 of the Social Security Act, as amended, found at 42 U.S.C. §§ 1396b (m) and 1396u-2;

19.1.4.3.3

The Contractor has taken actions that have caused substantial risk to Enrollees’ health;

Page 254 of 324

19.1.4.3.4

ASES determines that temporary management is necessary or convenient to ensure the health of the Contractor’s Enrollees; or

19.1.4.3.5

ASES determines that such Enrollment termination is necessary or appropriate to remedy Category 1 through 3 violations.

19.1.4.4

Enrollment Suspension. ASES may suspend all new Enrollments, including default Enrollment, after the effective date of the intermediate sanction and until the intermediate sanction is no longer in effect.

19.1.4.5

Payment Suspension. ASES may suspend payment of the PMPM Payment for Enrollees enrolled after the effective date of the intermediate sanction and until CMS or ASES is satisfied that the reason for imposition of the intermediate sanction no longer exists and is not likely to re-occur or upon the Termination Date of the Contract.

19.1.4.6

Mandatory Imposition of Certain Intermediate Sanctions. ASES shall impose the temporary management and Enrollment suspension intermediate sanctions described in Sections 19.1.4.2 and 19.1.4.3 above, if ASES finds that the Contractor has repeatedly failed to meet substantive requirements in Sections 1903(m) or 1932 of the Social Security Act, as amended, found at 42 U.S.C. §§ 1396b (m) and 1396u-2.

19.1.4.7

Subject to Article 35 of this Contract, in lieu of imposing a sanction allowed under this Article 19, ASES may terminate this Contract, without any liability whatsoever (but subject to making any payments due under this Contract through any such date of termination), if the terms of a Corrective Action Plan implemented pursuant to this Article 19 to address a failure specified in Category 1 or Category 2 of this Article 19 are not implemented to ASES’s approval or if such failure continues or is not corrected, to ASES’s satisfaction.

19.2

Notice of Administrative Inquiry

19.2.1

ASES may issue the Contractor a notice of imposition of sanctions in lieu of a notice of administrative inquiry if ASES determines, in its sole discretion, that the Contractor’s non-compliance will not be cured with a Corrective Action Plan. In all other cases, ASES shall issue a notice of administrative inquiry informing Contractor about ASES’s compliance, monitoring, and auditing activities regarding potential non-compliance as described in this Article 19. This notice of administrative inquiry shall include the following:

Page 255 of 324

19.2.1.1

A brief description of the facts;

19.2.1.2

Citations to Puerto Rico and Federal laws and regulations, or Contract provisions that the Contractor has breached;

19.2.1.3

The Contractor’s non-compliance with Puerto Rico and Federal laws and regulations or Contract provisions as referenced in the Contract;

19.2.1.4

The Contractor’s breach of applicable intermediate sanction Contract provisions;

19.2.1.5

ASES’s authority to determine and impose intermediate sanctions under this Article 19;

19.2.1.6

The amount of potential, or Contractor’s exposure to intermediate sanctions, when they will be imposed and how they were computed; and

19.2.1.7

If applicable, a statement requiring the Contractor to submit a Corrective Action Plan within fifteen (15) Calendar Days of receipt of the notice of administrative inquiry under this Article 19.

19.2.2

The Contractor shall submit a Corrective Action Plan within fifteen (15) Calendar Days of receipt of the notice of administrative inquiry. However, the submission of a Corrective Action Plan shall not limit ASES’s power and authority to impose intermediate sanctions, fines, liquidated damages, or any other remedy allowed under this Contract or under Federal or Puerto Rico laws and regulations.

19.2.3

A notice of administrative inquiry shall not be deemed to constitute and is not ASES’s final or partial determination of intermediate sanctions. Thus, any administrative inquiries issued by ASES are not subject to administrative review under Section 19.5, and would be considered premature rendering any administrative examiner without jurisdiction to review the matter.

19.2.4

If the Contractor fails to comply with any material provision under a Corrective Action Plan submitted to ASES pursuant to Section 19.2.2 above, ASES may impose:

19.2.4.1

A daily $5,000 civil money penalty, up to a maximum total of $100,000, for Contractor’s ongoing failure to comply with any material provision of the Corrective Action Plan; or

19.2.4.2

The applicable intermediate sanction for any or all behavior that resulted in the Contractor’s submission of the Corrective Action Plan pursuant to Section 19.2 above.

Page 256 of 324

19.3

Notice of Imposition of Intermediate Sanctions

19.3.1

Prior to the imposition of intermediate sanctions, ASES will issue a notification, delivered thorough US Postal Service Certified Mail, to the Contractor that includes the following:

19.3.1.1

A brief description of the facts;

19.3.1.2

Citations to Puerto Rico and Federal laws and regulations, or Contract provision(s) that the Contractor has breached;

19.3.1.3

ASES’s determination to impose intermediate sanctions;

19.3.1.4

Intermediate sanctions imposed and their effective date;

19.3.1.5

Methodology for the civil money penalty calculation or determination of the intermediate sanctions; and

19.3.1.6

A statement that the Contractor has a right to object and request an administrative review of the imposition of intermediate sanctions pursuant to the procedures in ASES Regulation 8446.

19.3.2

ASES shall notify CMS in writing of the imposition of intermediate sanctions within thirty (30) Calendar Days of imposing sanctions and concurrently provide the Contractor with a copy of such notice

19.4

Administrative Review. Contractor has the right to object and seek administrative review of the imposition of intermediate sanctions, including but not limited to civil money penalties, by ASES, pursuant to the procedures in ASES Regulation No. 8446.

19.4.1

The Contractor has the right within fifteen (15) Calendar Days following receipt of the notice of imposition of intermediate sanctions to seek administrative review in writing of ASES’s determination and any such immediate sanctions, pursuant to Act 72 or under any other applicable law or regulation. This time period can be extended for an additional fifteen (15) Calendar Days if the Contractor submits a written request that includes a credible explanation of why it needs additional time, the request is receipted by ASES before the end of the initial period, and ASES has determined that the Contractor’s conduct does not pose a threat to an Enrollee’s health or safety.

19.4.2

As part of the administrative review, the Parties shall cooperate with the examining officer, and follow all applicable procedures for the administrative review.

19.4.3

Upon completion of the administrative review, the examining officer may recommend to:

19.4.3.1

Confirm the intermediate sanctions;

Page 257 of 324

19.4.3.2

Modify or amend the intermediate sanctions pursuant to applicable law or regulation; or

19.4.3.3

Eliminate the imposed intermediate sanctions.

19.4.4

Once the sanction becomes final ASES shall deduct the amount of the sanction from the PMPM Payment or the Retention Fund.

19.4.5

In addition to the actions described under Section 19.4.3, the examining officer may recommend the delivery and implementation of a Corrective Action Plan with respect to the Contractor’s failure to comply with the terms of this Contract as set forth in ASES’ notice of intermediate sanctions.

19.4.6

ASES shall notify CMS in writing of any modification in the imposition of intermediate sanctions through the administrative review process within thirty (30) Calendar Days of receipt of the examining officer’s determination, and concurrently provide the Contractor with a copy of such notice.

19.5

Judicial Review. To the extent administrative review is sought by the Contractor pursuant to Section 19.4, the Contractor has the right to seek judicial review of ASES’s actions by the Puerto Rico Court of Appeals, San Juan Panel, within thirty (30) Calendar Days of the notice of final determination issued by ASES.

19.6

Federal Sanctions. Payments provided for under this Contract will be denied for new Enrollees when, and for so long as, payment for those Enrollees is denied by CMS in accordance with the requirements in 42 C.F.R. 438.730.

ARTICLE 20

ENFORCEMENT – LIQUIDATED DAMAGES AND OTHER REMEDIES

20.1

General Provisions

20.1.1

ASES may impose intermediate sanctions, liquidated damages, and/or fines pursuant to Puerto Rico Act No. 72-1993 and ASES Regulation No. 8446 (as indicated in Articles 19 and 20 of this Contract).

20.1.2

In the event the Contractor is in default as to any applicable term, condition, or requirement of this Contract, and in accordance with any applicable provision of 42 CFR 438.700 and Section 4707 of the Balanced Budget Act of 1997, at any time following the Effective Date of this Contract, the Contractor agrees that, in addition to the terms of Section 35.1.1 of this Contract, ASES may assess liquidated damages against the Contractor for any such default, in accordance with this Article 20. The Parties further acknowledge and agree that the specified liquidated damages are reasonable and the result of a good faith effort by the Parties to estimate the anticipated or actual harm caused by the Contractor’s breach and are in lieu of any other financial remedies to which ASES may otherwise have been entitled. The assessment or non-assessment of liquidated damages under the Contract cannot and will not limit the power or authority of ASES to impose fines, civil money penalties, sanctions, or other remedies under Article 19 of this Contract or otherwise under Puerto Rico or Federal laws or regulations, including but not limited to Puerto Rico Act No. 72-1993 and ASES Regulation No. 8446.

Page 258 of 324

20.1.3

Notwithstanding any sanction, including liquidated damages, imposed upon the Contractor, other than Contract termination, the Contractor shall continue to provide all Covered Services and other Benefits under this Contract.

20.1.4

The Contractor’s breach or failure to comply with the terms and conditions of this Contract for which liquidated damages may be assessed under this Article 20 shall be divided into four (4) categories of events. ASES retains the discretion to impose liquidated damages or other sanctions for Contractor’s non-compliance with an obligation of the Contractor under this Contract or Puerto Rico Law that is not specified under the categories in Sections 20.2, 20.3, 20.4 or 20.5.

20.2

Category 1

20.2.1

Liquidated damages in accordance with any applicable provision of this Contract of up to one-hundred thousand dollars ($100,000) per violation, Incident or occurrence may be imposed for Category 1 events. The following constitute Category 1 events:

20.2.1.1

Material non-compliance with an ASES or CMS directive, determination or notice to cease and desist not otherwise described in Article 19 or other provision of this Article 20, provided that the Contractor has received prior written notice with respect to such specific material non-compliance, and afforded an opportunity to cure within a reasonable period to be determined by ASES in its sole discretion.

20.3

Category 2

20.3.1

Liquidated damages in accordance with any applicable provision of this Contract of up to twenty-five thousand dollars ($25,000) per violation, Incident, or occurrence may be imposed for Category 2 events. The following constitute Category 2 events:

20.3.1.1

Subject to ASES compliance with its obligations under Article 22 of this Contract, repeated noncompliance by the Contractor with any material obligation that adversely affects the services that the Contractor is required to provide under Article 7 of this Contract;

20.3.1.2

Failure of the Contractor to assume its duties and obligations under this Contract in accordance with the transition timeframes specified herein;

Page 259 of 324

20.3.1.3

Failure of the Contractor to terminate a Provider that imposes Co-Payments or other cost-sharing on Enrollees that are in excess of the fees permitted by ASES, as listed on Attachment 8 to this Contract (ASES will deduct the amount of the overcharge and return it to the affected Enrollees);

20.3.1.4

Failure of the Contractor to address Enrollees’ Complaints, Appeals, and Grievances, and Provider disputes, within the timeframes specified in this Contract;

20.3.1.5

Failure of the Contractor to comply with the confidentiality provisions in accordance with 45 CFR 160 and 164; and

20.3.1.6

Failure of the Contractor to comply with a subcontracting requirement in the Contract.

20.4

Category 3

20.4.1

Liquidated damages in accordance with any applicable provision this Contract of five-thousand dollars ($5,000) per day may be imposed for Category 3 events. The following constitute Category 3 events:

20.4.1.1

Failure to submit required reports in the timeframes prescribed in Article 18;

20.4.1.2

Submission of incorrect or deficient Deliverables or reports in accordance with Article 18 of this Contract;

20.4.1.3

Failure to comply with the Claims processing standards as follows:

20.4.1.3.1

Failure to process and finalize to a paid or denied status ninety-five percent (95%) of all Clean Claims within thirty (30) Calendar Days of receipt;

20.4.1.3.2

Failure to process and finalize to a paid or denied status one hundred percent (100%) of all Clean Claims within fifty (50) Calendar Days of receipt; and

20.4.1.3.3

Failure to process Unclean Claims as specified in Section 16.6.3 of this Contract;

20.4.1.4

Failure to pay Providers interest at the rate identified in and otherwise in accordance with Section 16.6.2 of this Contract when a Clean Claim is not adjudicated within the Claims processing deadlines;

Page 260 of 324

20.4.1.5

Failure to comply with the quarterly submission of EPSDT reports to ASES according to the guidelines to be issued by ASES under Section 7.9.1;

20.4.1.6

Failure to notify PCPs of the gaps in care analysis in accordance with the EPSDT guidelines to be issued by ASES under Section 7.9.1;

20.4.1.7

Failure to provide the Claims Payment Disbursement Illustration and Actuarial Report Information required in Section 18 of this Contract;

20.4.1.8

Failure to seek, collect and/or report Third Party Liability information as provided in Section 23.4 of this Contract; and

20.4.1.9

Failure of Contractor to issue written notice to Enrollees upon Provider’s termination of a Provider as described in Section 10.4.3 of this Contract.

20.5

Category 4

20.5.1

Liquidated damages as specified below may be imposed for Category 4 events. The following constitute Category 4 events:

20.5.1.1

Failure to implement the BC-DR plan as follows:

20.5.1.1.1

Implementation of the (BC-DR) plan exceeds the proposed time by two (2) or less Calendar Days: five thousand dollars ($5,000) per day up to day 2;

20.5.1.1.2

Implementation of the (BC-DR) plan exceeds the proposed time by more than two (2) and up to five (5) Calendar Days: ten thousand dollars ($10,000) per each day beginning with day 3 and up to day 5;

20.5.1.1.3

Implementation of the (BC-DR) plan exceeds the proposed time by more than five (5) and up to ten (10) Calendar Days, twenty-five thousand dollars ($25,000) per day beginning with day 6 and up to day 10;

20.5.1.1.4

Implementation of the (BC-DR) plan exceeds the proposed time by more than ten (10) Calendar Days: fifty thousand dollars ($50,000) per each day beginning with day 11;

20.5.1.2

Unscheduled System Unavailability in violation of Article 17, in ASES’s discretion, two hundred fifty dollars ($250) for each thirty (30) minute period or portions thereof;

Page 261 of 324

20.5.1.3

Failure to make available to ASES or its Agent, valid extracts of Encounter Information for a specific month within fifteen (15) Calendar Days of the close of the month: five hundred dollars ($500) per day. After thirty (30) Calendar Days of the close of the month: two thousand dollars ($2,000) per Calendar Day;

20.5.1.4

Failure to correct a system problem not resulting in System Unavailability within the allowed timeframe, where failure to complete was not due to the action or inaction on the part of ASES as documented in writing by the Contractor:

20.5.1.4.1

One (1) to fifteen (15) Calendar Days late: two hundred and fifty dollars ($250) per Calendar Day for days 1 through 15;

20.5.1.4.2

Sixteen (16) to thirty (30) Calendar Days late: five hundred dollars ($500) per Calendar Day for days 16 through 30; and

20.5.1.4.3

More than thirty (30) Calendar Days late: one thousand dollars ($1,000) per Calendar Day for days 31 and beyond; and

20.5.1.5

Failure to meet the GHP Service Line performance standards:

20.5.1.5.1

One-thousand dollars ($1,000) for each percentage point that is below the target answer rate of eighty percent (80%) in thirty (30) seconds;

20.5.1.5.2

One-thousand dollars ($1,000) for each percentage point that is above the target of a three percent (3%) Blocked Call rate; and

20.5.1.5.3

One-thousand dollars ($1,000) for each percentage point that is above the target of a five percent (5%) Abandoned Call rate.

20.6

Other Remedies

20.6.1

Subject to Article 35 of this Contract, in lieu of imposing a Remedy allowed under this Article 20, ASES may elect to terminate this Contract, without any liability whatsoever (but subject to making any payments due, if any, under this Contract through any such date of termination), if the terms of a Corrective Action Plan implemented pursuant to this Article 20 to address a failure specified in Category 1 or Category 2 of this Article 20 are not implemented to ASES’s satisfaction or if such failure continues or is not corrected, to ASES’s sole satisfaction.

20.6.2

In the event of non-compliance by the Contractor with Article 18 of this Contract, ASES shall have the right to Withhold, with respect to Article 18, a sum not to exceed ten percent (10%) of the Per Member Per Month Payment for the following month and for continuous consecutive months thereafter until such noncompliance is cured and corrected to ASES’ satisfaction in lieu of imposing any liquidated damages, penalties or sanctions against the Contractor hereunder. ASES shall release the Withhold of the PMPM Payment to the Contractor within two (2) Business Days after the corresponding event of noncompliance is cured to ASES’s sole satisfaction.

Page 262 of 324

20.7

Notice of Administrative Inquiry regarding Liquidated Damages and/or Other Article 20 Remedies

20.7.1

Administrative Inquiry. ASES may issue the Contractor a notice of imposition of liquidated damages and/or other Article 20 remedies in lieu of a notice of administrative inquiry regarding liquidated damages and/or other Article 20 remedies if ASES determines, in its sole discretion, that the Contractor’s non-compliance will not be cured with a Corrective Action Plan. In all other cases, ASES shall issue a notice of administrative inquiry informing the Contractor about ASES’s compliance, monitoring, and auditing activities regarding potential non-compliance as described in this Article 20. This notice of administrative inquiry shall include the following:

20.7.1.1

A brief description of the facts;

20.7.1.2

Citations to Puerto Rico and Federal laws and regulations, or Contract provision(s) the Contractor has breached;

20.7.1.3

The Contractor’s non-compliance with Puerto Rico and Federal laws and regulations or Contract provisions;

20.7.1.4

The Contractor’s breach of applicable Contract provisions and event categories that could result in remedies or liquidated damages pursuant to this Article 20;

20.7.1.5

ASES’s authority to determine and seek liquidated damages or other remedies against the Contractor under this Article 20;

20.7.1.6

The amount of potential, or Contractor’s exposure to liquidated damages, or other Article 20 remedies, when they will be imposed and how they were computed; and

20.7.1.7

If applicable, a statement requiring the Contractor to submit a Corrective Action Plan within fifteen (15) Calendar Days of receipt of the notice of administrative inquiry under this Article 20.

20.7.2

The Contractor shall submit a Corrective Action Plan within fifteen (15) Calendar Days of receipt of the notice of administrative inquiry issued pursuant to this Article 20.

Page 263 of 324

20.7.3

A notice of administrative inquiry shall not constitute ASES’s final or partial determination of liquidated damages. Thus, any administrative inquiries made are not subject to administrative review under Section 20.7.6 and would be construed to be premature rendering any administrative examiner without jurisdiction to review the matter.

20.7.4

If the Contractor fails to comply with any material provision under a Corrective Action Plan submitted to ASES pursuant to Section 20.7.2 above, ASES may impose:

20.7.4.1

A daily amount of $5,000 in liquidated damages, up to a maximum total amount of $100,000, for the Contractor’s failure to comply with any material provision part or condition of the Corrective Action Plan; and/or

20.7.4.2

The applicable Article 20 Remedy for any or all behavior that resulted in the submission of Corrective Action Plan pursuant to Section 20.7.2 above.

20.7.5

Notice of Imposition of Liquidated Damages and/or Other Remedies

20.7.5.1

Prior to the imposition of liquidated damages and/or any other remedies under this Article 20, ASES will issue a notification, delivered thorough US Postal Service Certified Mail, to the Contractor that includes the following:

20.7.5.1.1

A brief description of the facts;

20.7.5.1.2

Citations to Puerto Rico and Federal laws and regulations, or Contract provision(s) the Contractor has breached;

20.7.5.1.3

ASES’s determination to assess and impose liquidated damages and/or any other Article 20 Remedy;

20.7.5.1.4

Liquidated damages and/or any other Article 20 Remedy imposed and their effective date;

20.7.5.1.5

Methodology for the liquidated damages and/or any other Article 20 Remedy calculation; and

20.7.5.1.6

A statement that the Contractor has a right to object and request an administrative review of the imposition of liquidated damages and other Article 20 remedies pursuant to the procedures in ASES Regulation 8446 and Puerto Rico Act No. 38-2017, as amended.

Page 264 of 324

20.7.5.2

The Contractor shall submit a Corrective Action Plan to ASES within thirty (30) Calendar Days of receipt of a notice of liquidated damages or other remedies pursuant to this Article 20.

20.7.6

Administrative Review. The Contractor has the right to object and seek administrative review of the imposition of liquidated damages and/or any other Remedy under this Article 20.7, pursuant to the procedures in ASES Regulation No. 8446.

20.7.6.1

As part of the administrative review, the Parties shall cooperate with the examining officer, and follow all applicable procedures for the administrative review.

20.7.6.2

Once the sanction becomes final ASES shall deduct the amount of the sanction from the PMPM Payment or the Retention Fund.

20.8

Judicial Review. The Contractor has the right to seek reconsideration and judicial review of ASES’s determination pursuant to the procedures in ASES Regulation No. 8446 and Puerto Rico Act No. 389-2017, as amended.

ARTICLE 21

CONTRACT TERM

21.1

Subject to and upon the terms and conditions herein, this Contract shall be in full force and effect on November 1, 2018 and shall terminate on September 30, 2021. The Contractor shall begin providing Covered Services to Enrollees on November 1, 2018, which shall be deemed to be the Implementation Date of the Contract. The foregoing notwithstanding, ASES, subject to Article 35 reserves the right, prior written notice of ninety (90) Calendar Days, to amend or partially terminate the Contract at any time to implement a demonstrative plan to incorporate the new public health policies and/or strategies of the Government. Upon written notice of amendment or partial termination of this Contract pursuant to this Article 21, ASES will evaluate in good faith a renegotiation of PMPM Payments payable under this Contract.

21.2

The Contract Term shall begin at 12:01 a.m., Puerto Rico Time, Effective Date of the Contract and shall continue until 11:59 p.m., Puerto Rico time, on September 30, 2021.

21.3

The provision of Covered Services and Benefits to Enrollees by the Contractor under this Contract shall begin on November 1, 2018, which is the Implementation Date of the Contract.

21.4

The PMPM Payments shall be negotiated for every rating period covered by the Contract (namely from November 1, 2018 to October 31, 2019, from November 1, 2019 to October 31, 2020, and November 1, 2020 to September 30, 2021). Any increase in the PMPM Payment shall be subject to ASES’s determination that the proposed new amount is actuarially sound.

Page 265 of 324

21.5

The Contract shall expire at the close of the Contract Term unless earlier terminated under Article 35.

21.6

ASES is hereby granted the option to renew this Contract for an additional term of up to one (1) fiscal year, which shall begin on October 1, 2021 and end at midnight on September 30, 2022. The terms of the renewal shall be negotiated, but any increase in PMPM Payment shall be subject to ASES’s determination that the proposed new amount is actuarially sound. The option to renew the Contract shall be exercisable solely and exclusively by ASES.

ARTICLE 22

PAYMENT FOR SERVICES

22.1

General Provisions

22.1.1

The actual PMPM Payment will be equal to the number of Enrollees as of the last day of the month proceeding the month in which payment is made, multiplied by the negotiated PMPM Payment agreed to between the Contractor and ASES. The rates are specified in Attachment 11 to this Contract. The due date for the PMPM Payment to the Contractor shall be the fifth (5 ^th ) day of each month. However, ASES shall have the right to make partial payments throughout the month, provided that payment in full will be made on or before the last day of each month. The PMPM Payment made based upon the number of Enrollees as of the last day of the preceding month will be reconciled to the actual number of Enrollees for that month when that information is available and appropriate PMPM Payment adjustments will be made.

22.1.2

ASES shall provide PMPM Payments only for those Enrollees for whom ASES has received adequate notification of Enrollment from the Contractor as of the date specified by ASES, per Section 5.2.2. ASES will work with the Contractor to establish the amount of any PMPM Payments that are due to the Contractor for any Enrollee that has retroactive coverage per Section 5.1.3.1.

22.1.3

Risk Adjustment. PMPM Payments for the rate cells specified in Section 22.1.7.1 shall be risk adjusted, using publicly available risk adjustment software, on a semi-annual basis by rate cell against all other Contractors to the same population category.

22.1.3.1

The rate cells that will be risk adjusted are Federal Adult, Federal Children, State Adult, State Children, CHIP, and Federal HCHN (Pulmonary, Diabetes, High Cardio, Renal and Cancer), State HCHN (Pulmonary, Diabetes, High Cardio, Renal, and Cancer), and CHIP HCHN (Pulmonary and Diabetes).

22.1.3.2

The risk scores shall be established for each Contractor across all rate cells. As necessary, the risk scores will be established using a credibility formula for each Contractor. The credibility formula will be determined by ASES’ actuary.

Page 266 of 324

22.1.3.2.1

For an Enrollee’s individual Claims data to be the basis for a risk adjustment score hereunder, such Enrollee must have been enrolled in the GHP for at least six (6) full months during the time period from which Claims data are used to calculate the adjustment. In the event an Enrollee has not been enrolled in the GHP for at least six (6) full months, such Enrollee shall receive a risk score equal to the Contractor’s average risk score.

22.1.3.2.2

All diagnosis codes submitted by the Contractor shall be included in calculations of risk scoring irrespective of placement of such diagnosis codes in the Encounter Data records.

22.1.3.2.3

Diagnosis codes from Claims or Encounters that included a lab and radiology procedure or revenue code on any line, with the exception of those associated with an inpatient hospital claim, will not be collected for the risk adjustment analysis. It is assumed that these diagnosis codes could be for testing purposes and may not definitively indicate an Enrollee’s disease condition.

22.1.3.2.4

Encounter records may not be supplemented by medical record data. Diagnosis codes may only be recorded by the Provider at the time of the creation of the medical record and may not be retroactively adjusted except to correct errors.

22.1.3.2.5

A significant change in risk scores by a Contractor may warrant an audit of the diagnosis collection and submission methods. To the extent that ASES’ actuary believes the Encounter Data limitations are resulting in risk score variances among Contractors, ASES reserves the right to request diagnosis codes and other information to perform risk adjustment.

22.1.3.3

Initial Risk Adjustment Period. The initial risk adjustment period shall be the first six (6) month period during which the Contractor receives its initial enrollment under this Contract. The risk scores for the initial risk adjustment period will be calculated using the Contractor’s enrollment as of the first month following the month in which Enrollment is completed and will be based on a weighted average of the number of months each Enrollee is enrolled with the specific Contractor.

22.1.3.3.1

The Claims data to be used for such calculations shall be the Claims data for Claims with dates of services from the most recent twelve (12) month period that ASES determines to be reasonably complete. To the extent an Enrollee was enrolled with another Contractor during the most recent twelve (12) month period that ASES has determined to be reasonably complete, the Encounters accepted by ASES during that period shall be used in addition to the aforementioned Claims data.

Page 267 of 324

22.1.3.3.1.1

ASES shall provide written notification to the Contractor of the initial risk adjustment factor, along with sufficient detail supporting the calculations. Contractors shall have thirty (30) Calendar Days after the date ASES sent such notice to review the calculations and detail provided and to submit questions, if any, to ASES regarding the same. No modification to the Contractor’s PMPM Payment may be made during such thirty (30) Calendar Day review period.

22.1.3.3.1.2

If the Contractor disputes the risk adjustment factor during the review period, ASES shall meet with the Contractor within a reasonable timeframe to achieve a good faith resolution of the disputed matter.

22.1.3.3.2

Modifications to the Contractor’s PMPM Payment resulting from the application of the risk adjustment factor, if any, shall be effective retroactively to the first month of the initial enrollment and prospectively to the end of the initial risk adjustment period.

22.1.3.3.3

All risk scores shall be budget neutral to ASES or normalized to a 1.0000 value among the Contractors.

22.1.3.4

Ongoing Risk Adjustment Periods. For every six (6) month period thereafter, Enrollee risk scores shall be recalculated using Enrollee Claims or Encounter Data, as applicable, from a prior twelve (12) month period.

22.1.3.4.1

ASES shall provide written notification to the Contractor of the risk adjustment factor, along with sufficient detail supporting the calculations. Contractors shall have thirty (30) Calendar Days after the date ASES sent such notice to review the calculations and detail provided and to submit questions, if any, to ASES regarding the same. No modification to the Contractor’s PMPM Payment may be made during such thirty (30) Calendar Day review period.

Page 268 of 324

22.1.3.4.2

If the Contractor disputes the risk adjustment factor during the review period, ASES shall meet with the contractor within a reasonable timeframe to achieve a good faith resolution of the disputed matter.

22.1.3.4.3

Modifications to the Contractor’s PMPM Payment resulting from the application of the applicable risk adjustment factor, if any, shall be effective for the duration of the applicable adjustment period, effective as of the first day thereof.

22.1.3.4.4

All risk scores shall be budget neutral to ASES or normalized to a 1.0000 value among the Contractors.

22.1.3.5

In the event the application of the risk adjustment factor for a retroactive period results in a reduction or increase to a Contractor’s PMPM Payment, such reduction or increase will be applied on a prospective basis to the PMPM Payments.

22.1.4

ASES will have the discretion to recoup payments made to the Contractor for ineligible Enrollees, including, but not limited to, the following:

22.1.4.1

Enrollees incorrectly enrolled with more than one Contractor;

22.1.4.2

Enrollees who die prior to the Enrollment month for which the payment was made;

22.1.4.3

Enrollees whom ASES later determines were not eligible for Medicaid during the Enrollment month for which payment was made.

22.1.4.4

Enrollees whom were not domiciled in Puerto Rico during the Enrollment month for which payment was made;

22.1.4.5

Enrollees whom were incarcerated during the Enrollment month for which payment was made.

22.1.5

Any payments due to ASES from the Contractor will be offset from future payments to the Contractor, or may be invoiced by ASES to the Contractor, at ASES’s discretion.

22.1.6

The Contractor shall have the right to recoup from Providers or other persons to whom the Contractor has made payment for any payments made for which ASES has recouped the PMPM Payment.

22.1.7

The PMPM Payment for Enrollees not enrolled for the full month shall be determined on a pro rata basis by dividing the monthly Capitation amount by the number of days in the month and multiplying the result by the number of days including and following the Effective Date of Enrollment or the number of days prior to and including the Effective Date of Disenrollment, as applicable. The Contractor is entitled to a PMPM Payment for each Enrollee as of the Effective Date of Enrollment, including the period referred to in Section 5.2.2. The Contractor is entitled to a PMPM Payment for each Enrollee up to the Effective Date of Disenrollment, including the period referred to in Section 5.3.

Page 269 of 324

22.1.8

Payment for services under this Contract will not commence before Implementation Date of the Contract.

22.1.9

Payments for the first month of program operations under this Contract will be made only upon a determination by ASES that the Contractor has complied with all of its obligations for the implementation of this Contract, including a finding by ASES that the Contractor has satisfied the readiness review, and the Contractor’s submission of initial Deliverables as specified in Attachment 12 to this Contract.

22.1.10

In order to receive payments from ASES, the Contractor shall provide to ASES, and keep current, its tax identification number, billing address, and other contact information, as required by ASES.

22.1.11

The Contractor acknowledges that the payments agreed to under the terms of this Contract in addition to any applicable cost-sharing as provided in Attachment 8 to this Contract constitute full payment for Covered Services and Benefits under GHP. ASES will have no responsibility for payment for Covered Services and Benefits beyond that amount unless the Contractor has obtained prior written approval, in the form of a Contract amendment, authorizing an increase in the total payment.

22.1.12

Fee-for-Service amounts paid by the Contractor for Claims, or Capitation payments made by the Contractor derived or otherwise based on Encounter Data submitted by Providers, resulting from services determined not to be Medically Necessary by the Contractor, will not be considered in the Contract's experience for purposes of prospective rate adjustments.

22.1.13

Pursuant to the terms of this Contract, should ASES assess liquidated damages or other Remedies for the Contractor’s noncompliance or deficiency with the terms of this Contract, such amount may be withheld from the PMPM Payment for the following month, and for continuous consecutive months thereafter until such noncompliance or deficiency is corrected at ASES’s satisfaction.

22.1.14

The Contractor shall maintain all the Utilization and financial Data related to this Contract duly segregated from its regular accounting system including, but not limited to, the general ledger.

22.1.15

Administrative expenses to be included in determining the experience of the program are those directly related to this Contract. Separate allocations of expenses from the Contractor’s insurance plans, other than GHP, from the Contractor’s related companies, from the Contractor’s parent company, or from other entities will be reflected or made a part of the financial Data described in the preceding section. Any pooling of operating expenses with other of the Contractor's groups, cost-shifting, financial consolidation or the implementation of other combined financial measures is expressly forbidden.

Page 270 of 324

22.1.16

The following administrative expenses are unallowable for purposes of reporting program expenditures and prospective rate setting:

22.1.16.1

Costs of entertainment, festivities and other activities for the recreation of the personnel of the insurer, including employees, managers, directors, officers or Third Parties, such as: expenses for parties, dinners, food, alcoholic beverages, gifts, etc.;

22.1.16.2

Costs of advertising, public relations and marketing, except as provided in Section 6.15 of this Contract;

22.1.16.3

Costs of recruiting office, managerial and executive personnel;

22.1.16.4

Payroll costs related to corporate officers and employees exceeding the equivalent time dedicated to work related to the GHP program if these same officers and employees also perform duties in support of other lines of business. Payroll expenses to be charged to GHP shall be reasonable according to industry standards and the only time that may be charged is when they perform work specific to the GHP program;

22.1.16.5

Any payment related to the liquidation of payroll or marginal benefits due to termination (severance) and restructuring of the company (downsizing), including “parachute” clauses, for board of directors, corporate officers or executives of the Contractor;

22.1.16.6

The Contractor’s employer contributions to savings plans for employees, directors, officers or executives of the Contractor;

22.1.16.7

Costs related to the awarding and exercise of stock options of employees, directors, officers or executives of the Contractor;

22.1.16.8

Payment of productivity bonuses, or bonuses of another nature, to directors, officers, executives and employees, excluding the Christmas bonus as required by the law;

22.1.16.9

Costs of trips to the US or to foreign countries, whether for business, continued education or pleasure;

22.1.16.10

Expenses or payments related to vacations, including, but not limited to, stay expenses, hotel, air, land or sea transportation, food, gratuity, etc.;

Page 271 of 324

22.1.16.11

First class fees for air tickets, and travel expenses including charter flights or in commercial lines, within or outside of Puerto Rico;

22.1.16.12

Payments related to attendance and stay at conventions, seminars, workshops, or continued education, for executives, directors, officers or employees of the Contractor, whether within or outside of Puerto Rico;

22.1.16.13

Payments related to educational expenses such as: training, retraining, studies, scholarships, memberships, dues, employee licenses, etc., except for, and limited to, the cost of professional licenses required for personnel directly providing health-related services to Enrollees;

22.1.16.14

Payments related to automobile expenses, including rent, lease, purchase and depreciation, car allowance, maintenance expenses, gasoline, repairs, etc., except for, and limited to, mileage costs incurred by nurses, doctors or care managers during the provision of Disease Management and/or Care Management services to Enrollees;

22.1.16.15

Costs of transportation, including taxi service, airplanes, charters, urban train, automobiles, and gasoline or diesel for motor vehicles;

22.1.16.16

Payment of cellular phone expenses, including Internet access;

22.1.16.17

Monies used for gifts, gratuity, contests, prizes, donations, charity, etc.;

22.1.16.18

Any commissions, management fees or similar charges from related parties without express approval from ASES;

22.1.16.19

Categorizing expenses under a general category such as overhead, other, miscellaneous, is expressly forbidden; and

22.1.16.20

Any other expense not allowed by ASES.

22.1.17

The Contractor shall provide ASES every month with a PMPM Payment Disbursement Report. This document shall present the distribution of the Capitation or other service payments to Providers, Claim expenses by coverage, reserves, and administrative expenses. Failure to comply with the requirements contained herein may be cause for the imposition of liquidated damages as outlined in Section 20 of this Contract.

22.1.18

The Contractor shall provide to ASES, on a monthly basis, actuarial Data in a format specified in the Actuarial Report provided by ASES. Failure to comply with the requirements contained herein may be cause for the imposition of liquidated damages as outlined in Section 20 of this Contract.

Page 272 of 324

22.1.19

The Contractor shall report all of the profit of its partially- or wholly-owned subsidiaries or Affiliates realized from services rendered in relation to this Contract (the “Affiliated Profit”), unless the Contractor demonstrates and ASES agrees that the Affiliated Profit did not result from preferential contractual terms included in the Contractor’s contracts or arrangements with its partially- or wholly-owned subsidiaries and Affiliates.

22.1.19.1

Preferential contract terms are those that result in a cost or expense that exceeds fair market value, or those that exceed other terms for the provisioning of same or similar goods and services as would be agreed to by a reasonable person under the same or similar circumstances prevailing at the time the decision was made for the same or similar good or service. In determining whether preferential contract terms exist, consideration must be given to factors including “sound business practices,” “arm’s length bargaining” and “market prices for comparable goods and services for the geographical area.” Contractual terms shall also be deemed preferential if the Contractor’s partially- or wholly-owned subsidiaries of Affiliates charge the Contractor a higher price for the same or similar goods or services than the lowest price charged by the Contractor’s partially- or wholly-owned subsidiaries or Affiliates to any and all other clients.

22.1.19.2

Notwithstanding the above, if a Contractor’s subsidiary or Affiliate charges the Contractor for goods or services provided under or associated with the GHP program and such charges exceed sixty percent (60%) of the total revenue of the subsidiary or Affiliate, such charges must be at cost.

22.1.19.3

The Contractor shall report to ASES’s Office of Finance all related-party transactions within thirty (30) Calendar Days and provide a copy of the contract for each transaction detailing the amounts paid or to be paid, charged or transferred and goods or services to be provided under the contract. A certification under penalty from criminal perjury from the Contractor’s President, Vice-President, Chief Financial Officer, or Treasurer specifying what are the “at cost” and/or “fair market value” amounts of the contract, as applicable, shall be included with each submission.

22.1.20

To comply with 42 CFR 438.608(d) and 42 CFR 433.312, the Contractor shall, consistent with the procedures set forth in Attachment 23 to this Contract, refund (i) the share of the Overpayment due to ASES within eleven (11) months of the discovery and (ii) the share of an Overpayment due to ASES within fifteen (15) Calendar Days from a final judgment on a Fraud, Waste, or Abuse Action. The Contractor must also require and have a mechanism for a Provider to report to the Contractor when it has received an Overpayment, to return that Overpayment to the Contractor with a written reason for the Overpayment within sixty (60) Calendar Days after the date on which the Overpayment was identified. The Contractor shall report annually to ASES on their recoveries of all Overpayments.

Page 273 of 324

22.2

Medical Loss Ratio

22.2.1

The Contractor shall report a Medical Loss Ratio (MLR) and related data, including the data on the basis of which ASES will determine the compliance of the Contractor with the Medical Loss Ratio Requirement, as required under 42 CFR 438.8(k) for each MLR reporting year, which aligns with the rating period. Such reporting shall be provided to ASES no later than July 31 of the following year.

22.2.2

The Contractor shall calculate its MLR and related data based on the methodology set forth in 42 CFR 438.8 and any other instructions issued by CMS or ASES. Effective November 1, 2018, the Contractor shall achieve a minimum MLR, as calculated per 42 CFR 438.8, of at least ninety-two percent (92%) for the MLR reporting year.

22.2.3

If the Contractor’s MLR is below ninety-two percent (92%), the Contractor must pay a remittance to ASES within thirty (30) Calendar Days of notification from ASES that a remittance is owed. The amount of the remittance owed is the difference between the Contractor’s Medical Loss Ratio for the MLR reporting year and target Medical Loss Ratio of ninety-two percent (92%). The requirement to pay the remittance survives the termination of this Contract.

22.3

Contractor Objections to Payment

22.3.1

If the Contractor wishes to contest the amount of payments made by ASES in accordance with the terms outlined in Section 22.1 for services provided under the terms of this Contract, the Contractor shall submit to ASES all relevant documentation supporting the Contractor’s objection no later than thirty (30) Calendar Days after payment is made. Once this term has ended, the Contractor forfeits its right to claim any additional amounts.

22.3.2

After the Contractor’s submission of all relevant information, the Contractor and ASES will meet to discuss the matter. If after discussing the matter and analyzing all relevant Data it is subsequently determined that an error in payment was made, the Contractor and ASES will develop a plan to remedy the situation, which must include a timeframe for resolution agreed to by both Parties, within a time period mutually agreed upon by both Parties.

22.4

Retention Fund for Health Care Improvement Program

22.4.1

ASES shall maintain a Retention Fund of the PMPM Payment each month as part of the Health Care Improvement Program (HCIP) described in Section 12.5 and Attachment 19 to this Contract. The overall Retention Fund Percentage is two percent (2%) of the PMPM Payment according Attachment 19 to this Contract.

Page 274 of 324

22.4.2

With respect to each HCIP initiative, ASES, as indicated herein, shall upon expiration of each quarter during the Contract Term conduct a review to determine if the Contractor has met the applicable performance targets for that period according to the following process:

22.4.2.1

The Contractor shall submit a quarterly report no later than ninety (90) Calendar Days after the end of each quarter regarding each of the performance indicators to be evaluated, as determined by ASES (from those listed in Attachment 19 to this Contract);

22.4.2.2

No later than thirty (30) Calendar Days after receipt of the Contractor’s quarterly reports, ASES shall determine if the Contractor has met the applicable performance objectives for each measure for that period;

22.4.2.3

If the Contractor is in full compliance with the applicable performance targets for said period, ASES shall disburse to the Contractor, no later than thirty (30) Calendar Days after ASES determines compliance with the performance objectives, the portion of the PMPM Payment associated with each initiative for such period.

22.4.3

The Retention Fund for the HCIP and any other withhold arrangements between ASES and the Contractor must comply the requirements set forth in 42 CFR 438.6(b)(3).

22.5

Maternity Kick Payment

22.5.1

ASES will perform a review as described in Attachment 29 to this Contract to determine any applicable Maternity Kick Payments by utilizing claims and encounter data submitted by the Contractor to ASES. The Contractor shall receive $4,641.59 for each delivery reported and validated by ASES. If the data or an audit process does not validate the reported delivery(ies), ASES may retroactively recoup the Maternity Kick Payment.

ARTICLE 23

FINANCIAL MANAGEMENT

23.1

General Provisions

23.1.1

The Contractor shall be responsible for the sound financial management of Puerto Rico and Federal funds provided to the Contractor under the GHP Program.

Page 275 of 324

23.1.2

The Contractor shall notify ASES in writing of any loans or other special financial arrangements made between the Contractor and any PMG or any other Provider. Any such loans shall strictly conform to the legal requirements of Federal and Puerto Rico anti-Fraud and anti-kickback laws and regulations.

23.1.3

The Contractor shall provide ASES with copies of its audited financial statements following Generally Accepted Accounting Principles (“GAAP”), at its own cost and expense, within ninety (90) Calendar Days following the end of each Contract Year during the Contract Term as specified in Section 18.2.9.3. The statements shall be provided in a format specified by ASES.

23.1.4

The Contractor shall provide to ASES a copy of its Annual Report required to be filed with the Puerto Rico Office of the Insurance Commissioner (OIC Report), as applicable, in the format agreed upon by the National Association of Insurance Commissioners (NAIC), for the year ended on December 31, 2017, and subsequently thereafter, during the Contract Term and any renewals, not later than March 31 of each year. The Contractor shall submit to ASES a reconciliation of the OIC Report with its annual audited financial statements filed pursuant to Section 23.1.3 and Section 18.2.9.8.

23.1.5

The Contractor shall provide to ASES unaudited financial statements for each quarter during the Contract Term, not later thirty (30) Calendar Days after the close of each quarter in a format specified by ASES.

23.1.6

The Contractor shall provide to ASES a copy of the annual corporate report of its parent company at the close of the calendar year.

23.1.7

The Contractor shall maintain adequate procedures and controls to ensure that any payments pursuant to this Contract are properly made. In establishing and maintaining such procedures, the Contractor shall provide for separation of the functions of certification and disbursement.

23.1.8

The Contractor acknowledges, and shall incorporate in contracts with Subcontractors, that the GHP is a government-funded program. As such, the administrative costs that are deemed allowable shall be in accordance with cost principles permissible, and with Federal and Puerto Rico applicable guidelines, including Office of Management and Budget Circulars, primarily recognizing that: (1) a cost shall be reasonable if it is of the type generally recognized as ordinary and necessary, and if in its nature and amount, and taking into consideration the purpose for which it was disbursed, it does not exceed that which would be incurred by a prudent person in the ordinary course of business under the circumstances prevailing at the time the decision was made to incur the cost; and (2) a cost shall be reasonable if it is allocable to or related to the cost objective that compels cost association. The Contractor will not allow administrative costs as specified in Section 22.1.15 above.

Page 276 of 324

23.1.9

The Contractor shall maintain an accounting system for GHP separate from the rest of its commercial activities. This system will only include GHP Data.

23.1.10

The Contractor shall provide, throughout the Contract Term, any other necessary and related information that is deemed necessary by ASES in order to evaluate the Contractor’s financial capacity and stability.

23.2

Solvency and Financial Requirements

23.2.1

The Contractor shall establish and maintain adequate net worth, working capital, and financial reserves to carry out its obligations under this Contract. An indemnity agreement containing terms and conditions acceptable to ASES between the Contractor and its parent company may satisfy the requirements set forth in Sections 23.2.2 and 23.2.3.

23.2.2

The Contractor shall maintain at all times during the Contract Term a minimum two hundred percent (200%) of risk-based capital. ASES reserves the right to require additional capital guarantees as ASES deems reasonably necessary. The Contractor shall comply, as applicable, with Article 3.151 and Article 19.140 of the Puerto Rico Insurance Code relating to insolvency protection.

23.2.3

The Contractor shall provide assurances to ASES that its provision against the risk of insolvency is adequate, in compliance with the Federal standards set forth in 42 CFR 438.116, and shall submit data on the basis of which ASES will determine that the Contractor has made adequate provision against the risk of insolvency. In particular, the Contractor shall, according to the timeframe specified in Attachment 12 to this Contract, furnish documentation, certified by a Certified Public Accountant, of:

23.2.3.1

The relationship between PMPM Payments and capital, with the optimal relationship being 10:1, in order to prove capacity to assume risk;

23.2.3.2

A debt level of less than seventy-five percent (75%).and

23.2.3.3

Relationship of current assets to total liabilities shall be at least eighty percent (80%).

23.2.4

As part of its accounting and budgeting function, and in accordance with the Insurance Code of Puerto Rico, the Contractor shall establish an actuarially sound process for estimating and tracking potential liability associated with IBNR Claims. As part of its reserving process the Contractor shall conduct annual reviews to assess its IBNR reserving methodology and make adjustments as necessary.

23.2.5

The Contractor shall establish a reserve fund for IBNR Claims that under no circumstances may exceed ten percent (10%) of Capitation to PMGs. The reserve shall be reconciled and adjusted every ninety (90) Calendar Days and, if necessary, any excess will be liquidated. Once the PMG has the reserve necessary as determined by the Contractor, the monthly retention may not exceed three percent (3%) of Capitation. Any increase must be justified in information from the PMG file. One hundred and eighty (180) Calendar Days after the end of the Contract Term, the Contractor shall reconcile the IBNR reserve. Any remainder of the IBNR funds shall be returned to the PMGs within sixty (60) Calendar Days from the date that the Contractor conducts the reconciliation. This period may not be extended.

Page 277 of 324

23.2.6

The Contractor agrees to provide any additional guarantees that ASES may require as a result of the periodical evaluation performed by the Office of the Commissioner of Insurance of the financial health of the Contractor.

23.3

Reinsurance and Stop Loss

23.3.1

ASES will not administer a Reinsurance program.

23.3.2

The Contractor shall have and maintain a minimum of one million dollars ($1,000,000.00) in Reinsurance protection against financial loss due to outlier (catastrophic) cases or otherwise maintain self-insurance acceptable to ASES. The Contractor shall submit to ASES such documentation as is necessary to prove the existence of this protection, which may include policies and procedures of Reinsurance. The Contractor may request that ASES waive this requirement by providing sufficient documentation to ASES that the Contractor has adequate protection against financial loss due to outlier (catastrophic) cases. ASES shall review such documentation and, at its discretion, deem this requirement to be met.

23.3.3

The Contractor shall establish a stop-loss limit amount that is in compliance with the limits specified in 42 CFR 422.208(f). The limit shall be activated when the expense of providing Covered Services to an Enrollee, including all outpatient and inpatient expenses, reaches this sum. The Contractor shall have mechanisms in place to identify the stop loss once it is reached for an Enrollee, and shall establish monthly reports to inform PMGs of Enrollees who have reached the stop-loss limit. The Contractor shall assume all losses exceeding the limit.

23.3.4

The Contractor’s stop-loss responsibility shall not be transferred to a PMG unless the PMG and the Contractor expressly agree in writing to the PMG’s assuming this risk and the associated risk distribution arrangement has been previously approved in writing by ASES.

23.4

Third Party Liability and Cost Avoidance

23.4.1

General Provisions

23.4.1.1

The GHP shall be the payer of last resort for all Covered Services rendered on behalf of Medicaid and CHIP Enrollees in accordance with Federal regulations at 42 CFR 433 Subpart D; ASES will enforce this rule with respect to all GHP Enrollees.

Page 278 of 324

23.4.1.2

The Contractor shall exercise full assignment rights as applicable and shall be responsible for making every reasonable effort to determine the legal liability of Third Parties to pay for services rendered to Enrollees under this Contract and to cost avoid or recover any such liability from the Third Party. “Third Party,” for purposes of this Section, shall mean any person or entity that is or may be liable to pay for the care and services rendered to a GHP Enrollee. Examples of a Third Party include, but are not limited to, an Enrollee’s health insurer, casualty insurer, a managed care organization, and Medicare.

23.4.1.3

The Contractor, and by extension its Providers and Subcontractors, hereby agree to utilize for Claims Cost Avoidance purposes, within thirty (30) Calendar Days of learning of such sources, other available public or private sources of payment for services rendered to Enrollees in the Contractor’s Plan. If Third Party Liability (TPL) exists for part or all of the services provided directly by the Contractor to an Enrollee, the Contractor shall make reasonable efforts to recover from TPL sources the value of services rendered. If TPL exists for part or all of the services provided to an Enrollee by a Subcontractor or a Provider, and the Third Party will make payment within a reasonable time, the Contractor may pay the Subcontractor or Provider only the amount, if any, by which the Subcontractor’s or Provider’s allowable Claim exceeds the amount of TPL.

23.4.1.4

The Contractor shall deny payment on a Claim that has been denied by a Third Party payer when the reason for denial is the Provider’s failure to follow prescribed procedures, including, but not limited to, failure to obtain Prior Authorization, failure to file Claims timely, etc.

23.4.1.5

The Contractor shall, within five (5) Business Days of issuing a denial of any Claim based on TPL, provide TPL Data to the Provider.

23.4.1.6

The Contractor shall treat funds recovered from Third Parties as offsets to Claims payments. The Contractor shall report all Cost Avoidance values to ASES in accordance with Federal guidelines and as provided for in this Section.

23.4.1.7

The Contractor shall post all Third Party payments or recoveries to Claim-level detail by Enrollee.

Page 279 of 324

23.4.1.8

If the Contractor operates or administers a non-GHP program or other lines of business, the Contractor shall access the resources of those entities to assist ASES with the identification of Enrollees with access to other insurance or sources of payment.

23.4.1.9

The Contractor shall audit and review its Providers’ Claims, using monthly the reports submitted pursuant to Section 16.7 of this Contract or other pertinent Data, to ensure that Providers are not receiving duplicate payment for services billable to Third Parties. The Contractor shall report to ASES on a quarterly basis its findings regarding Claims, invoices, or duplicate or inappropriate payments. According to the timeframe specified in Attachment 12 to this Contract, the Contractor shall submit to ASES for its review and prior written approval a plan for such routine audits.

23.4.1.10

The Contractor shall demonstrate, upon request, to ASES that reasonable effort has been made to seek, including through collaboration with Providers, to collect and report Third Party recoveries. ASES shall have the sole responsibility for determining whether or not reasonable efforts have been demonstrated. Said determination shall take into account reasonable industry standards and practices.

23.4.1.11

The Contractor shall comply with 42 CFR 433 Subpart D – Third Party Liability and 42 CFR 447.20 Provider Restrictions: State Plan Requirements, and work cooperatively with ASES to assure compliance with the requirements therein, as it relates to the Medicaid and CHIP populations served by the Contractor’s plan and its Third Party Liability and Cost Avoidance responsibilities.

23.4.2

Legal Causes of Action for Damages. ASES or its designee will have the sole and exclusive right to pursue and collect payments made by the Contractor when a legal cause of action for damages is instituted on behalf of a GHP Enrollee against a Third Party, or when ASES receives notices that legal counsel has been retained by or on behalf of any Enrollee. The Contractor shall cooperate with ASES in all collection efforts, and shall also direct its Providers to cooperate with ASES in these efforts.

23.4.3

Estate Recoveries. ASES (or another agency of the Government) will have the sole and exclusive right to pursue and recover correctly paid benefits from the estate of a deceased Enrollee who was Medicaid Eligible in accordance with Federal and Puerto Rico law. Such recoveries will be retained by ASES.

23.4.4

Subrogation

23.4.4.1

Third Party resources shall include subrogation recoveries. The Contractor shall be required to seek subrogation amounts regardless of the amount believed to be available as required by Federal Medicaid guidelines and Puerto Rico law.

Page 280 of 324

23.4.4.2

The amount of any subrogation recoveries collected by the Contractor outside of the Claims processing system shall be treated by the Contractor as offsets to medical expenses for the purposes of reporting.

23.4.4.3

The Contractor shall conduct diagnosis and trauma code editing to identify potential subrogation Claims. This editing should, at minimum, identify Claims with a diagnosis of 900.00 through 999.99 (excluding 994.6) or Claims submitted with an accident trauma indicator of ‘Y.’

23.4.5

Cost Avoidance

23.4.5.1

When the Contractor is aware of health or casualty insurance coverage before paying for a Covered Service, the Contractor shall avoid payment by promptly (within fifteen (15) Business Days of receipt) rejecting the Provider’s Claim and directing that the Claim be submitted first to the appropriate Third Party.

23.4.5.2

Exceptions to the Cost Avoidance Rule. In the following situations, the Contractor shall first pay its Providers and then coordinate with the liable Third Party, unless prior approval to take other action is obtained from ASES:

23.4.5.2.1

The coverage is derived from a parent whose obligation to pay support is being enforced by a government agency.

23.4.5.2.2

The Claim is for maternal and prenatal services to a pregnant woman or for EPSDT services that are covered by the Medicaid program.

23.4.5.2.3

The Claim is for labor, delivery, and post-partum care and does not involve hospital costs associated with an inpatient stay.

23.4.5.2.4

The Claim is for a child who is in the custody of ADFAN.

23.4.5.2.5

The Claim involves coverage or services mentioned in this Section in combination with another service.

23.4.5.3

If the Contractor knows that the Third Party will neither pay for nor provide the Covered Service, and the service is Medically Necessary, the Contractor shall neither deny payment for the service nor require a written denial from the Third Party.

Page 281 of 324

23.4.5.4

If the Contractor does not know whether a particular service is covered by the Third Party, and the service is Medically Necessary, the Contractor shall promptly (within ten (10) Business Days of receipt of the Claim) contact the Third Party and determine whether or not such service is covered rather than requiring the Enrollee to do so. Further, the Contractor shall require the Provider to bill the Third Party if coverage is available.

23.4.6

Sharing of TPL Information by ASES

23.4.6.1

By the fifth (5 ^th ) Calendar Day after the close of the month during which ASES learns of such information, ASES will provide the Contractor with a list of all known health insurance information on Enrollees for the purpose of updating the Contractor’s files.

23.4.6.2

Additionally, by the fifteenth (15 ^th ) Calendar Day after the close of the calendar quarter, ASES will provide to the Contractor a copy of a report containing all of the health insurers licensed by Puerto Rico as of the close of the previous quarter, and any other related information that is needed to file TPL Claims.

23.4.7

Sharing of TPL Information by the Contractor

23.4.7.1

The Contractor shall submit a monthly report to ASES (following ASES file content, format and transmission specifications) by the fifth (5 ^th ) Calendar Day after the close of the month during which the Contractor learns that an Enrollee has new health insurance coverage, or casualty insurance coverage, or of any change in an Enrollee’s health insurance coverage. The Contractor shall impose a corresponding requirement on its Providers to notify the Contractor of any newly discovered coverage.

23.4.7.2

When the Contractor becomes aware that an Enrollee has retained counsel, who either may institute or has instituted a legal cause of action for damages against a Third Party, the Contractor shall notify ASES in writing, including the Enrollee’s name and GHP Enrollee identification number, the date of the accident/incident, the nature of the injury, the name and address of the Enrollee’s legal representative, copies of the pleadings, and any other documents related to the action in the Contractor’s possession or control. This shall include, but not be limited to, the name of the Provider, the Enrollee’s diagnosis, the Covered Service provided to the Enrollee, and the amount paid to the Provider for each service.

23.4.7.3

The Contractor shall notify ASES within thirty (30) Calendar Days of the date it becomes aware of the death of one of its Medicaid Eligible Enrollees age fifty-five (55) or older, giving the Enrollee’s full name, Social Security number, and date of death. ASES will then determine whether it can recover correctly paid Medicaid benefits from the Enrollee’s estate.

Page 282 of 324

23.4.7.4

The Contractor agrees to share with ASES instances of Enrollee non-cooperation with the Contractor’s and with Network Providers’ efforts to determine sources of Third Party Liability.

23.4.7.5

The Contractor agrees to cooperate with ASES in its oversight and monitoring reviews of all Third Party Liability activities.

23.4.8

Historic Cost Avoidance due to the existence of liable Third Parties is embedded in the cost of health services delivery and is reflected in the rates upon which ASES will base PMPM Payments to the Contractor. The PMPM Payment does not include any reductions due to tort recoveries.

23.5

GHP as Secondary Payer to Medicare

23.5.1

In general, as provided in Section 7.12, except for services offered by Medicare Platino plans which operate independently of this Contract, the GHP does not duplicate coverage provided by Medicare to Dual Eligible Beneficiaries and the Contractor shall not be a secondary payer for services for which Medicare is liable.

23.5.1.1

However, in a situation in which a Covered Service is covered in whole or part by both Medicare and GHP (for example, hospitalization services for a Dual Eligible Beneficiary who is enrolled in Medicare Part A only and whose hospitalization costs exceed the Medicare limit, per Section 7.12. of this Contract), the Contractor shall determine liability as a secondary payer as follows:

23.5.1.1.1

If the total amount of Medicare’s established liability for the services (Medicare paid amount) is equal to or greater than the negotiated contract rate between the Contractor and the Provider for the services, minus any GHP cost-sharing requirements, then the Provider is not entitled to, and the Contractor shall not pay, any additional amounts for the services.

23.5.1.1.2

If the total amount of Medicare’s established liability (Medicare paid amount) is less than the negotiated contract rate between the Contractor and the Provider for the services, minus any GHP cost-sharing requirements, the Provider is entitled to, and the Contractor shall pay, the lesser of:

23.5.1.1.2.1

The Medicaid cost-sharing (Deductibles and coinsurance) payment amount for which the Dual Eligible Beneficiary is responsible under Medicare, and

Page 283 of 324

23.5.1.1.2.2

An amount which represents the difference between (1) the negotiated contract rate between the Contractor and the Provider for the service minus any GHP cost-sharing requirements, and (2) the established Medicare liability for the services.

23.5.2

Enrollment Exclusions and Contractor Liability for the Cost of Care. Any Dual Eligible Beneficiary who is already enrolled in a Medicare Platino Plan may not be enrolled by the Contractor. However, if the Contractor operates its own Medicare Platino plan, the Contractor may enroll a Dual Eligible Beneficiary in the Platino plan, which furnishes GHP Benefits, per separate contract with ASES.

23.5.3

Protections for Medicaid Enrollees

23.5.3.1

The Contractor shall neither impose, nor allow Providers to impose, any cost-sharing charges of any kind upon Medicaid Eligibles enrolled in GHP, other than as authorized in this Contract.

23.5.3.2

Unless otherwise permitted by Federal or Puerto Rico law, Covered Services may not be denied to a Medicaid Enrollee because of a Third Party’s potential liability to pay for the services, and the Contractor shall ensure that its Cost Avoidance efforts do not prevent Enrollees from receiving Medically Necessary Services.

23.6

Physician Incentive Plans

23.6.1

Any Physician Incentive Plans established by the Contractor shall comply with Federal and Puerto Rico regulations, including 42 CFR 422.208 and 422.210, and 42 CFR 438.3(i), and with the requirements in Section 10.7 of this Contract.

23.6.2

The Contractor shall obtain prior written approval from ASES before implementing any Physician Incentive Plan arrangements, as provided in Section 10.7, and shall provide information about such arrangements to Enrollees upon request, as required in Section 6.4.5 of the Contract. Such disclosure shall include:

23.6.2.1

Whether services not furnished by the Provider or PMG are covered by the incentive plan;

23.6.2.2

The type of incentive arrangement;

23.6.2.3

The percentage of Withhold or bonus;

Page 284 of 324

23.6.2.4

The panel size and if patients are pooled, the method used; and

23.6.2.5

If the Provider or PMG is at substantial financial risk proof that the Provider or PMG has adequate stop loss coverage, including amount and type of stop loss.

23.6.3

Annually, the Contractor shall report the information specified by the regulations to ASES in order that ASES can adequately monitor the Contractor’s plan, under the criteria set forth in 42 CFR 422.208 and 422.210.

23.6.4

Such Physician Incentive Plans may not provide for payment, either directly or indirectly, to a Provider or PMG as an inducement to reduce or limit Medically Necessary Services furnished to an Enrollee.

23.7

Financial Reporting Requirements

23.7.1

The Contractor shall submit to ASES all of the reports as indicated in Section 18.1.

23.7.2

Failure to submit the reports within the established timeframes, or failure to submit complete, accurate reports, may result in the imposition of liquidated damages and/or fines as outlined in Article 20 of this Contract.

23.7.3

The Contractor, at its sole expense, shall submit by May 15 (or a later date if approved by ASES) of each year a “Report on Controls Placed in Operation and Tests of Operating Effectiveness,” meeting all standards and requirements of the SSAE 18 for the Contractor’s operations performed for ASES under the GHP Contract.

23.7.3.1

The audit shall be conducted by an independent auditing firm, with prior audit experience using AICPA “Statements on Auditing Standards”. The auditor shall meet all AICPA standards for independence. The selection of, and contract with the independent auditor shall be subject to the prior written approval of ASES. ASES reserves the right to, at the Contractor’s expense; designate other auditors or reviewers to examine the Contractor’s operations and records for monitoring and/or stewardship purposes.

23.7.3.2

The Contractor will deliver to ASES, along with the Report on Controls Placed in Operation and Tests of Operating Effectiveness, the findings and recommendations of the independent audit firm encountered in the preparation of such a report. The audit shall be conducted and the report shall be prepared in accordance with generally accepted auditing standards for such audits as defined in the publications of the AICPA, entitled “Statements on Auditing Standards” (SAS). In particular, SSAE 18 is to be used.

Page 285 of 324

23.7.3.3

The Contractor shall respond to the audit findings and recommendations within thirty (30) Calendar Days of receipt of the final audit report. Also the Contractor must submit a Corrective Action Plan to ASES which will be subject to ASES’ prior review and written approval within twenty (20) Calendars Days of the notification of the audit. The Contractor must implement the Corrective Action Plan, as a maximum, within fifteen (15) Calendar Days of its approval by ASES. The entity should request an extension by formal written request addressed to the Office of Compliance of ASES who will evaluate the request and provide the specific timeframe for the extension.

23.7.4

The Contractor shall submit to ASES a “Disclosure of Information on Annual Business Transactions.” This report shall include:

23.7.4.1

Definition of A Party in Interest. As defined in Section 1318(b) of the Public Health Service Act, a party in interest is:

23.7.4.1.1

(i) Any director, officer, partner, or employee responsible for management or administration of the Contractor; (ii) any person or legal entity that is directly or indirectly the beneficial owner of more than five percent (5%) of the equity of the Contractor; (iii) any person or legal entity that is the beneficial owner of a mortgage, deed of trust, note, or other interest secured by, and valuing more than five percent (5%) of the Contractor; or, (iv) in the case of a Contractor organized as a nonprofit corporation, an incorporator or enrollee of such corporation under applicable Puerto Rico corporation law;

23.7.4.1.2

Any organization in which a person or a legal entity described in Section 23.7.4.1.1 is director, officer or partner; has directly or indirectly a beneficial interest of more than five percent (5%) of the equity of the Contractor; or has a mortgage, deed of trust, note, or other interest valuing more than five percent (5%) of the assets of the Contractor;

23.7.4.1.3

Any person directly or indirectly controlling, controlled by, or under common control with the Contractor; or

23.7.4.1.4

Any spouse, child, or parent of an individual described in Sections 23.7.4.1.1-23.7.4.1.3.

23.7.4.2

Types of Transactions Which Must Be Disclosed. Business transactions which must be disclosed include:

23.7.4.2.1

Any sale, exchange or lease of any property between the Contractor and a party in interest;

Page 286 of 324

23.7.4.2.2

Any lending of money or other extension of credit between the Contractor and a party in interest; and

23.7.4.2.3

Any furnishing for consideration of goods, services (including management services) or facilities between the Contractor and the party in interest. This does not include salaries paid to employees for services provided in the normal course of their employment.

23.7.4.3

The information which must be disclosed in the transactions listed in this Section 23.7.4 between the Contractor and a party of interest includes:

23.7.4.3.1

The name of the party in interest for each transaction;

23.7.4.3.2

A description of each transaction and the quantity or units involved;

23.7.4.3.3

The accrued dollar value of each transaction during the fiscal year; and

23.7.4.3.4

Justification of the reasonableness of each transaction.

23.7.4.4

As per 42 CFR 455.105 the Contractor, within thirty-five (35) Calendar Days of the date of request by the HHS Secretary, ASES or the Puerto Rico Medicaid agency, and on an annual basis to ASES and the Puerto Rico Medicaid agency, shall report full and complete information about:

23.7.4.4.1

The ownership of any subcontractor with whom the provider has had business transactions totaling more than $25,000 during the twelve (12) month period ending on the day of the request; and

23.7.4.4.2

Any significant business transactions between the provider and any wholly owned supplier, or between the provider and any subcontractor, during the five (5) year period ending on the date of the request.

23.7.4.5

Disclosures of Information on Annual Business Transactions or other reports of transactions between the Contractor and parties in interest provided to ASES or other agencies must be made available to Enrollees upon reasonable request.

Page 287 of 324

ARTICLE 24

PAYMENT OF TAXES

24.1

The Contractor certifies and guarantees that at the time of execution of this Contract:

24.1.1

It is an entity duly authorized to conduct business in Puerto Rico and has filed income tax returns for the previous five (5) years;

24.1.2

It complied with and paid unemployment insurance tax, disability insurance tax (Law 139), social security for drivers (“seguro social choferil”), if applicable;

24.1.3

It filed State Department reports for the five (5) previous years; and

24.1.4

It does not owe any kind of taxes to Puerto Rico.

24.2

The Contractor will forthwith pay all taxes lawfully imposed upon it with respect to this Contract or any product delivered in accordance herewith. ASES makes no representation whatsoever as to the liability or exemption from liability of Contractor to any tax imposed by any governmental entity.

24.3

Notwithstanding the above, if, as a result of the enactment of any Federal, state, local or municipal legal provision, administrative regulation, or government directive, the Contractor is burdened with a requirement to pay a fee, tax, imposition, levy, or duty with regards to any of the proceeds of this Contract, including but not limited to the imposition of any fees pertaining to the existence of any government contracts, or any sales and use tax (IVU, for its Spanish acronym), ASES will evaluate, in good faith, an adjustment to the PMPM Payment under this Contract, among other possible alternatives.

ARTICLE 25

RELATIONSHIP OF PARTIES

25.1

Neither Party is an Agent, employee, or servant of the other. It is expressly agreed that the Contractor and any Subcontractors and Agents, officers, and employees of the Contractor or any Subcontractor in the performance of this Contract shall act as independent contractors and not as officers or employees of ASES. The Parties acknowledge, and agree, that the Contractor, its Agent, employees, and servants shall in no way hold themselves out as Agent, employees, or servants of ASES. It is further expressly agreed that this Contract shall not be construed as a partnership or joint venture between the Contractor or any Subcontractor and ASES.

ARTICLE 26

INSPECTION OF WORK

26.1

ASES, the Puerto Rico Medicaid Program, other agencies of the Government, the US Department of Health and Human Services, the General Accounting Office, the US Comptroller General, the Comptroller General of Puerto Rico, if applicable, or their Authorized Representatives, shall have the right to enter into the premises of the Contractor or all Subcontractors, or such other places where duties under this Contract are being performed for ASES, to inspect, monitor or otherwise evaluate the services or any work performed pursuant to this Contract. All inspections and evaluations of work being performed shall be conducted with prior notice and during normal business hours. All inspections and evaluations shall be performed in such a manner that will not unduly delay work.

Page 288 of 324

ARTICLE 27

GOVERNMENT PROPERTY

27.1

The Contractor agrees that any papers, materials and other documents that are produced or that result, directly or indirectly, from, under or in connection with the Contractor’s provision of the services under this Contract shall be the property of ASES upon creation of such documents, for whatever use that ASES deems appropriate, and the Contractor further agrees to prepare any and all documents, including the Deliverables listed in Attachment 12 to this Contract, or to take any additional actions that may be necessary in the future to effectuate this provision fully. In particular, if the work product or services include the taking of photographs or videotapes of individuals, the Contractor shall obtain the consent from such individuals authorizing the use by ASES of such photographs, videotapes, and names in conjunction with such use. The Contractor shall also obtain necessary releases from such individuals, releasing ASES from any and all claims or demands arising from such use.

27.2

The Contractor shall be responsible for the proper custody and care of any ASES-owned property furnished for the Contractor’s use in connection with the performance of this Contract. The Contractor will reimburse ASES for its loss or damage, normal wear and tear excepted, while such property is in the Contractor’s custody or use.

ARTICLE 28

OWNERSHIP AND USE OF DATA AND SOFTWARE

28.1

Ownership and Use of Data

28.1.1

All Information created from Data, documents, messages (verbal or electronic), reports, or meetings involving or arising out of or in connection with this Contract is owned by ASES (the information will be hereinafter referred to as “ASES Data and Information”). The Contractor shall make all Data and Information available to ASES, which will also provide the Data to CMS or other pertinent government agencies and authorities upon request. The Contractor is expressly prohibited from sharing, distributing, disseminating, or publishing ASES Data and Information without the express prior written consent of ASES. In the event of a dispute regarding what is or is not ASES Data and Information, ASES’s decision on this matter shall be final and not subject to appeal.

28.1.2

ASES acknowledges that before executing this Contract and in contemplation of the same, the Contractor has developed and designed certain programs and systems such as standard operating procedures, programs, business plans, policies and procedures, which ASES acknowledges are the exclusive property of the Contractor. Nevertheless, in case of default by the Contractor, ASES is hereby authorized to use to the extent allowable by any applicable commercial software and hardware licensing that exists at that moment or with which agreement can be reached at that moment with the vendor to modify such licensing to permit its use by ASES, at no cost to ASES, such properties for a period of one hundred and twenty (120) Calendar Days to effect an orderly transition to any new Contractor or service provider. In any cases where the use of such systems from an operational perspective would also impact other lines of the Contractor’s business or where licensing restrictions cannot be remedied, the Contractor shall operate such systems on behalf of ASES. Such operation by the Contractor on behalf of ASES can occur at ASES’ discretion under the full supervision of their employees or appointed third party personnel. Under such a scenario, ASES’ access to Data will be restricted through the most efficient means possible to the Contractor’s Data segment. If the Contractor fails to operate such systems on ASES’ behalf in a timely manner per normal previous operating schedule, ASES may claim ownership of such systems and operate them for its own purposes.

Page 289 of 324

28.1.3

The Contractor shall not deny access to ASES’s Data under any case or circumstances, nor retain ASES’s Data while controversies between ASES and the Contractor are resolved and finally adjudicated

28.2

Responsibility for Information Technology Investments

28.2.1

The Parties understand and agree that the cost of any newly acquired or developed software programs or upgrades or enhancements to existing software programs, hardware, or other related information technology equipment or infrastructure component, made in order to comply with the requirements of this Contract shall be borne in its entirety by the Contractor.

ARTICLE 29

CRIMINAL BACKGROUND CHECKS

29.1

ASES is prohibited by law from entering into contracts with any person or entity that has been, or whose affiliated subsidiary companies, or any of its shareholders, partners, officers, principals, managing employees, subsidiaries, parent companies, officers, directors, board members, or ruling bodies have been, under investigation for, accused of, convicted of, or sentenced to imprisonment, in Puerto Rico, the other USA jurisdictions, or any other jurisdiction, for any crime involving corruption, fraud, embezzlement, or unlawful appropriation of public funds, pursuant to Act 458, as amended, and Act 84 of 2002 .

29.2

Before the Effective Date of this Contract, and in order for the Contract to take effect, the Contractor shall provide to ASES a certification that neither the Contractor nor the affiliated persons/entities listed in Section 29.1 falls under the prohibition stated in Section 29.1. In addition, the Contractor shall provide to ASES a certification as to whether, to the best of its knowledge after inquiry, any Network Provider, or any shareholder, partner, officer, principal, managing employee, subsidiary, parent company, officer, director, board member, or ruling body of a Network Provider, falls under the prohibition stated in Section 29.1.

Page 290 of 324

29.3

ASES may terminate this Contract if ASES determines that the Contractor, or any of the natural persons listed in Section 29.1, falls within the prohibition stated in Section 29.1, or failed to provide an accurate certification as required in Section 29.2. In addition, the Contractor shall terminate a Provider Contract if it determines that a Provider, or any of the natural persons listed in Section 29.1, falls within the prohibition stated in Section 29.1.

29.4

During the Contract Term, the Contractor shall promptly (within twenty (20) Business Days of the date it receives the information) report any significant fact or event related to the rule stated in this Article.

29.5

In cases in which none of the events listed in Section 29.1 has occurred, but statements or admissions of crimes have been made by or against the Contractor or one of its shareholders, partners, officers, principals, subsidiaries, or parent companies, ASES shall provide all pertinent information about the matter, within twenty (20) Business Days from the date it receives the information, to the Secretary of Justice of Puerto Rico, who will make the pertinent findings and recommendations concerning the Contract.

29.6

In addition, as provided in 42 CFR 455.106(c), ASES may refuse to enter into or renew an agreement with any entity if any person who has an ownership or control interest in the entity, or is an Agent or managing employee of the entity, has ever been convicted of a criminal offense related to the person’s involvement in any program established under Medicare, Medicaid, or the Title XX services programs. Before the Effective Date of this Contract, pursuant to 42 CFR 455.106(a), the Contractor shall disclose to ASES the identity of any person who has ever been convicted of a criminal offense related to the Medicare, Medicaid, or Title XX services programs. The Contractor shall collect the same information on criminal conviction for Providers during the Credentialing process, as provided in Section 9.2.3 and shall, immediately upon receipt of such information relating to a Provider, disclose the information to ASES. ASES will notify the HHS Inspector General of any disclosures related to criminal convictions within twenty (20) Business Days from the date that ASES receives the information, as required by 42 CFR 455.106.

ARTICLE 30

SUBCONTRACTS

30.1

Use of Subcontractors

30.1.1

In carrying out the terms of this Contract, the Contractor, with the prior written approval of ASES, may enter into written Subcontract(s) with other entities for the provision of administrative services or a combination of Covered Services and administrative services, under terms and conditions acceptable to ASES in its sole discretion.

Page 291 of 324

30.1.2

The Contractor shall assume sole responsibility for all functions performed by a Subcontractor(s), as well as any payments to a Subcontractor(s) for services related to this Contract. In the event that a Subcontractor is incapable of performing the service contracted for by the Contractor, the Contractor shall (i) notify ASES within two (2) Business Days and (ii) assume responsibility for providing the services that the Subcontractor is incapable of performing. The Contractor shall remain obligated to provide any services that the Subcontractor is incapable of performing.

30.1.3

If the Contractor becomes aware of a Subcontractor’s failure to comply with this Contract, the Contractor shall correct the failure within thirty (30) Calendar Days of becoming aware of the failure.

30.1.4

All Subcontracts between the Contractor and Subcontractors must be in writing, must comply with all applicable Medicaid laws and regulations, including subregulatory guidance and provisions set forth in this Contract, as applicable, and must specify the activities and responsibilities delegated to the Subcontractor containing terms and conditions consistent with this Contract and 42 CFR 438.230(c). The Subcontracts must also include provisions for revoking delegation or imposing other sanctions if the Subcontractor’s performance is inadequate. The Contractor and the Subcontractors must also make reference to a business associates agreement between the Parties.

30.1.5

All Subcontracts between the Contractor and Subcontractors must ensure that the Contractor evaluates the prospective Subcontractor’s ability to perform the activities to be delegated; monitors the Subcontractor’s performance on an ongoing basis and subjects it to formal review according to a periodic schedule established by ASES and consistent with industry standards or Puerto Rico laws and regulations; and identifies deficiencies or areas for improvement, ensuring that corrective action is taken as appropriate or required. The Contractor must provide to ASES, on behalf of the Subcontractor, any and all materials required under Puerto Rico law to enter into a contract with the Government of Puerto Rico, in accordance with Puerto Rico Department of Treasury Circular Letter Number 1300-16-16.

30.1.6

The Contractor shall not Subcontract or permit anyone other than Contractor personnel to perform any of the work, services, or other performances required of the Contractor under this Contract relating to functions associated with the provision of Benefits to Enrollees or assign any of its rights or obligations hereunder, without the prior written consent of ASES. Prior to hiring or entering into a Subcontract with any Subcontractor, any and all Subcontractors shall be previously approved in writing by ASES. ASES reserves the right to review all Subcontract agreements at any time during the Contract Term. Upon request from ASES, the Contractor shall provide in writing the names of all proposed or actual Subcontractors.

Page 292 of 324

30.1.7

The Contractor shall not engage nor contract with a person or entity that is debarred or suspended or otherwise excluded from participating in procurement activities under the Federal Acquisition Regulation (FAR) or from participating in non-procurement activities under regulations issued under Executive Order No. 12549 or under guidelines implementing Executive Order No. 12549, or a person or entity that is an Affiliate, as defined in FAR, of a such a person or entity (see 42 CFR 438.610).

30.1.8

ASES shall have the right to review all financial or business transactions between the Contractor and a Subcontractor at any time upon request. ASES, CMS, or Office of Inspector General may inspect, evaluate and audit the Subcontractor at any time if ASES, CMS or Office of Inspector General determines there is a reasonable possibility of fraud or similar risk. ASES shall also retain the right to review all criminal background checks for all employees of the Subcontractor, as referenced in Article 29, as well as any past exclusion from Federal programs.

30.1.9

The Contractor shall provide ASES Immediate notice by certified mail, of any action or suit filed and of any claim made against the Contractor by the Subcontractor or against a Subcontractor(s) that, in the opinion of the Contractor, may result in litigation related in any way to this Contract. The Contractor shall provide notification in writing as to how this action or suit may affect the overall provision of services to Enrollees and the Contractor’s plan to mitigate such affect.

30.1.10

When a Subcontract related to the provision of Covered Services or that includes Claims processing services is being terminated other than for cause, the Contractor shall give at least one hundred twenty (120) Calendar Days prior written notice of the termination to ASES. If the termination is for cause, the Contractor shall Immediately notify ASES.

30.1.11

The Contractor shall give ASES Immediate notice in writing by registered mail or certified mail of any action or suit filed by any Subcontractor and prompt notice of any claim made against the Contractor by any Subcontractor or vendor that, in the opinion of Contractor, may result in litigation related in any way to this Contract.

30.1.12

Pursuant to the requirements of 42 CFR 438.230(c)(3)(i) and 42 CFR 438.3(k), ASES, CMS, the Office of Inspector General, the Comptroller General, and their respective designees shall have the right at any time to inspect, evaluate, and audit any books, records, contractors, computer or other electronic systems of the Subcontractor, or of the Subcontractor’s contractor, that pertain to any aspect of services and activities performed or determination of amounts payable under this Agreement.

Page 293 of 324

30.1.13

All Subcontractors must fulfill the requirements of 42 CFR 438.3, 438.6 and 438.230 as appropriate. Subcontractors shall also retain, as applicable, Enrollee grievance and appeal records as per 42 CFR 438.416, base data for setting actuarially sound capitation rates as per 42 CFR 438.5(c), Medical Loss Ratio reports as per 42 CFR 438.8(k), and the data, information and documentation specified in 42 CFR 438.604, 438.606, 438.608, and 438.610 for a period of no less than ten (10) years, as set forth in Section 33.1.1.

30.1.14

All Subcontracts entered into by the Contractor must comply with the applicable 42 CFR part 438 requirements that pertain to the service or activity performed by the Subcontractor.

30.2

Cost or Pricing by Subcontractors

30.2.1

The Contractor shall submit to ASES, and shall require any Subcontractors hereunder to submit to ASES, cost or pricing Data for any Subcontract to this Contract prior to award. The Contractor shall also certify that the information submitted by the Subcontractor is, to the best of the Contractor’s knowledge and belief, accurate, complete and current as of the date of agreement, or the date of the negotiated price of the Subcontract or amendment to the Contract. The Contractor shall insert the substance of this Section in each Subcontract hereunder.

30.2.2

If ASES determines that any price, including profit or fee negotiated in connection with this Contract, or any cost reimbursable under this Contract was increased by any significant sum because of the inaccurate cost or pricing Data, then such price and cost shall be reduced accordingly and this Contract and the Subcontract shall be modified in writing to reflect such reduction.

ARTICLE 31

REQUIREMENT OF INSURANCE LICENSE

31.1

In order for this Contract to take effect, the Contractor must be licensed to underwrite health insurance by the Puerto Rico Insurance Commissioner. The Contractor must submit a copy of its insurance license according to the timeframe specified in Attachment 12 to this Contract.

31.2

The Contractor shall renew the license as required, and shall submit evidence of the renewal to ASES within thirty (30) Calendar Days of the expiration date of the license.

ARTICLE 32

CERTIFICATIONS

32.1

The Contractor shall provide to ASES within fifteen (15) Calendar Days of the Effective Date of this Contract, and thereafter by January 10 of each calendar year during the Contract Term, the certifications and other documents set forth below, according to the timeframe specified below. If any certification, document, acknowledgment, or other representation or assurance on the Contractor’s part under this Article, or elsewhere in this Contract, is determined to be false or misleading, ASES shall have cause for termination of this Contract or to withhold the amount of any existing debt owed to the Government of Puerto Rico in order to make a payment on behalf of the Contractor. In the event that the Contract is terminated based upon this Article, the Contractor shall reimburse ASES all sums of monies received under the Contract; provided, however, that the amount reimbursed shall not exceed the amount of outstanding debt, less any payments made by the Contractor in satisfaction of such debt.

Page 294 of 324

32.2

The Contractor shall submit the following certifications:

32.2.1

Certification issued by the Treasury Department of Puerto Rico (Model SC-2888) with evidence that that the Contractor has filed income tax returns in the past five (5) years or has non-profit status;

32.2.2

Certification from the Treasury Department of Puerto Rico that Contractor has no outstanding debt with the Department or, if such a debt exists, it is subject to a payment plan or pending administrative review under applicable law or regulation (Model SC-3537);

32.2.3

Certification from the Center for the Collection of Municipal Revenues certifying that there is no outstanding debt or, if a debt exists, that such debt is subject to payment plan or pending administrative review under applicable law or regulations;

32.2.4

Certification from the Department of Labor and Human Resources certifying compliance with unemployment insurance, temporary disability insurance and/or chauffeur’s social security, if applicable;

32.2.5

Evidence of Incorporation and of Good Standing issued by the Department of State of Puerto Rico;

32.2.6

Certification of current municipal license tax (“Patentes Municipales”), if applicable;

32.2.7

Certification issued by the Minor Children Support Administration (“ASUME”, by its Spanish acronym) of no outstanding alimony or child support debts, if applicable;

32.2.8

A sworn statement certifying that it has no debt with the Government, or with any State agencies, corporations or instrumentalities that provide or are related to the provision of health services; or that such debt is subject to a payment plan with which the Contractor is in compliance, a work plan to reconcile amounts in controversy with which the Contractor is in compliance, or pending administrative review under applicable law or regulations; and

32.2.9

Certification from the Puerto Rico Administration of Medical Services (“ASEM”, its Spanish acronym) certifying that there is no outstanding debt or, if a debt exists, that such debt is subject to a payment plan with which the Contractor is in compliance, a work plan to reconcile amounts in controversy with which the Contractor is in compliance, or pending administrative review under applicable law or regulations.

Page 295 of 324

32.3

The Contractor shall, in addition, provide the following documents:

32.3.1

A list of all contracts the Contractor has with government agencies, public corporations or municipalities, including those contracts in the process of being executed;

32.3.2

A letter indicating if any of its directors serves as member of any governmental board of directors or commission;

32.3.3

A certificate of the Corporate Resolution, or appropriate resolution, authorizing the person signing this Contract to appear on behalf of the Contractor;

32.3.4

Evidence of compliance with the Compensation System for Work-Related Accidents Act (“Fondo del Seguro del Estado de Puerto Rico”); and

32.3.5

A copy of the Insurance Coverage Certificate as required in Article 37.

32.4

If the Contractor fails to meet the obligations of Sections 32.2 and 32.3 within the required timeframe, ASES shall cease payment to the Contractor until the documents have been delivered to the ASES’s satisfaction, or adequate evidence is provided to ASES that reasonable efforts have been made to obtain the documents.

ARTICLE 33

RECORDS REQUIREMENTS

33.1

General Provisions

33.1.1

The Contractor and its Subcontractors, if any, shall preserve and make available all of its records pertaining to the performance under this Contract for inspection or audit, as provided below, throughout the Contract Term, for a period of ten (10) years from the date of final payment under this Contract, and for such period, if any, as is required by applicable statute or by any other section of this Contract. If the Contract is completely or partially terminated, the records relating to the work terminated shall be preserved and made available for period of ten (10) years from the Termination Date of the Contract or of any resulting final settlement. The Contractor is responsible to preserve all records pertaining to its performance under this Contract, and to have them available and accessible in a timely manner, and in a reasonable format that assures their integrity. Records that relate to Appeals, litigation, or the settlements of Claims arising out of the performance of this Contract, or costs and expenses of any such agreements as to which exception has been taken by the Contractor or any of its duly Authorized Representatives, shall be retained by Contractor until such Appeals, litigation, Claims or exceptions have been disposed of.

Page 296 of 324

33.2

Records Retention and Audit Requirements

33.2.1

Since funds from the Puerto Rico Plans under Title XIX and Title XXI of the Social Security Act Medical Assistance Programs (Medicaid and CHIP) are used to finance this project in part, the Contractor shall agree to comply with the requirements and conditions of the Centers for Medicare and Medicaid Services (CMS), the US Comptroller General, the Comptroller of Puerto Rico and ASES, as to the maintenance of records related to this Contract.

33.2.2

Puerto Rico and Federal standards for audits of ASES Agents, contractors, and programs are applicable to this section and are incorporated by reference into this Contract as though fully set out herein.

33.2.3

Pursuant to the requirements of 42 CFR 434.6(a)(5) and 42 CFR 434.38, ASES, CMS, the Office of Inspector General, the Comptroller General, the Medicaid Fraud Control Unit, and their respective designees shall have the right at any time to inspect, evaluate, and audit any pertinent records or documents of the Contractor and Subcontractors, and may inspect the premises, physical facilities, equipment, computers or other electronic systems where activities or work related to the GHP program is conducted. The right to audit exists for ten (10) years from the final date of the contract period or from the date of completion of any audit, whichever is later. Any records requested hereunder shall be produced Immediately for on-site review or sent to the requesting authority by mail within fourteen (14) Calendar Days following a request. All records shall be provided at the sole cost and expense of the Contractor. ASES shall have unlimited rights to use, disclose, and duplicate all Information and Data in any way relating to this Contract in accordance with applicable Puerto Rico and Federal laws and regulations.

33.2.4

In certain circumstances, as follows, the authorities listed in Section 33.2.3 shall have the right to inspect and audit records in a timeframe that exceeds the timeframe set forth in Section 33.1.1.

33.2.4.1

ASES determines that there is a special need to retain a particular record or group of records for a longer period and notifies the Contractor at least thirty (30) Calendar Days before the expiration of the timeframe set forth in Section 33.1.1.

33.2.4.2

There has been a Contract termination, dispute, fraud, or similar fault by the Contractor, resulting in a final judgment or settlement against the Contractor, in which case the retention may be extended to three (3) years from the date of the final judgment or settlement.

33.2.4.3

ASES determines that there is a reasonable possibility of Fraud, and gives the Contractor notice, before the expiration of the timeframe set forth in Section 33.1.1, that it wishes to extend the time period for retention of records.

Page 297 of 324

33.2.4.4

There has been, during the time period set forth in Section 33.1.1, an audit initiated by CMS, the Comptroller of Puerto Rico, the US Comptroller General, and/or ASES, in which case the timeframe for retention of records shall extend until the conclusion of the audit and publication of the final report.

33.2.5

All records retention requirements set forth in this Article or in any other Article shall be subject at all times and to the extent mandated by law and regulation, to the HIPAA regulations described elsewhere in this Contract.

33.3

Medical Record Requests

33.3.1

The Contractor shall ensure that a copy of each Enrollee’s Medical Record is made available, without charge, upon the written request of the Enrollee or Authorized Representative within fourteen (14) Calendar Days of the receipt of the written request.

33.3.2

The Contractor shall ensure that Medical Records are furnished at no cost to a Provider, upon the Enrollee’s request, no later than fourteen (14) Calendar Days following the written request.

ARTICLE 34

CONFIDENTIALITY

34.1

General Confidentiality Requirements

34.1.1

The Contractor shall protect all information, records, and Data collected in connection with the Contract from unauthorized disclosures. In addition, the Contractor shall agree to guard the confidentiality of Enrollee information. Access to all individually identifiable information relating to Medicaid Enrollees that is obtained by the Contractor shall be limited by the Contractor to Subcontractors, consultants, advisors or agencies that require the information in order to perform their duties in accordance with this Contract, and to such others as may be authorized by ASES in accordance with applicable law, including individuals seeking access to their own Protected Health Information, as defined by HIPAA (PHI).

34.1.2

The Contractor is responsible for understanding the degree to which information obtained through the performance of this Contract is confidential under Puerto Rico and Federal law, rules, and regulations.

34.1.3

Any other individual or entity shall be granted access to confidential Information only after complying with the requirements of Puerto Rico and Federal law pertaining to such access and the terms of this Contract. ASES shall have absolute authority to determine if and when any other individual or entity has properly obtained the right to have access to this confidential information. Contractor is permitted to de-identify PHI or create limited data sets, but such de-identification and use of de-identified data and limited data sets must be in full compliance with 45 CFR 164.514. Nothing herein shall prohibit the disclosure of information in summary, statistical, or other form that does not identify particular individuals if the information is de-identified in accordance with applicable laws and regulations. The Contractor shall retain the right to use information for its quality and Utilization Management and research purposes subject to the Data ownership and publicity requirements defined within the Contract. Notwithstanding the foregoing, Contractor may not use or disclose PHI for research unless such use or disclosure is in full compliance with applicable law, including HIPAA.

Page 298 of 324

34.1.4

The Contractor, its employees, Agents, Subcontractors, consultants or advisors must treat all information that is obtained through Providers’ performance of the services under this Contract, including, but not limited to, information relating to Enrollees, Potential Enrollees, as confidential Information to the extent that confidential treatment is provided under Puerto Rico and Federal law, rules, and regulations.

34.1.5

Any disclosure or transfer of confidential information by the Contractor, including information required by ASES, will be encrypted or otherwise secured in accordance with applicable law. If the Contractor receives a request for information deemed confidential under this Contract, the Contractor will Immediately notify ASES of such request, and will make reasonable efforts to protect the information from public disclosure.

34.1.6

In accordance with the timeframes outlined in Attachment 12 to this Contract, the Contractor shall develop and provide to ASES for review and approval written policies and procedures for the protection of all records and all other documents deemed confidential under this Contract including Medical Records/Enrollee information and adolescent/sexually transmitted disease appointment records. All Enrollee information, Medical Records, Data and Data elements collected, maintained, disclosed, transmitted, disposed or used in the administration of this Contract shall be protected by the Contractor from unauthorized disclosure per the HIPAA Privacy and Security standards codified at 45 CFR Part 160 and 45 CFR Part 164, Subparts A, C and E, and in accordance with Law 111 of September 7, 2005. The Contractor must provide safeguards that restrict the use, access, management, transmittal, disposal or disclosure of PHI concerning Enrollees to purposes directly connected with the administration of this Contract and as permitted by the HIPAA Business Associate Agreement.

34.1.7

The Contractor must comply with HIPAA notification requirements, including those set forth in HITECH. The Contractor must notify ASES’s Privacy Officer and Director of Compliance by secure email of all Breaches or suspected Breaches of unspecified PHI, as defined by HITECH and Law 111 of September 7, 2005, without unreasonable delay and in no event later than twenty-four (24) hours, if so directed by ASES or required by law, must also notify individuals and the federal Department of Health and Human Services and provide any other notices required by law. If, in ASES’s determination, the Contractor has not provided notice in the manner or format prescribed by HITECH, then ASES may require the Contractor to provide such notice or be subject to sanctions for non-compliance.

Page 299 of 324

34.1.8

Assurance of Confidentiality

34.1.8.1

The Contractor shall take reasonable steps to ensure the physical security of Data under its control, including, but not limited to: fire protection; protection against smoke and water damage; alarm systems; locked files, guards, or other devices reasonably expected to prevent loss or unauthorized removal of manually held Data; passwords, access logs, badges, or other methods reasonably expected to prevent loss or unauthorized access to electronically or mechanically held Data; limited terminal access; limited access to input documents and output documents; and design provisions to limit use of Enrollee names.

34.1.8.2

The Contractor shall inform and provide quarterly trainings to each of its employees having any involvement with personal Data or other confidential information, whether with regard to design, development, operation, or maintenance, of the Puerto Rico and Federal law relating to confidentiality. The Contractor shall also set forth training requirements for its Agents, Subcontractors, consultants, advisors and Providers.

34.1.9

Return of Confidential Data

34.1.9.1

The Contractor shall return all Data, PHI, and other confidential information furnished pursuant to this Contract promptly at the request of ASES in whatever form it is maintained by the Contractor. Upon the termination or completion of the Contract, the Contractor may not use any such Data or any material derived from the Data for any purpose not permitted by Puerto Rico or Federal law or regulation and where so instructed by ASES shall destroy such Data or material if permitted and required by Puerto Rico or Federal law or regulation.

34.1.10

Publicizing Safeguarding Requirements

34.1.10.1

The Contractor shall comply with 42 CFR 431.304. The Contractor agrees to publicize provisions governing the confidential nature of information about Enrollees, including the legal sanctions imposed for improper disclosure and use. The Contractor must include these provisions in the Enrollee handbook and provide copies of these provisions to Enrollees and to other persons and agencies to which information is disclosed.

Page 300 of 324

34.1.10.2

In addition to the requirements expressly stated in this Article, the Contractor must comply with any policy, rule, or reasonable requirement of ASES that relates to the safeguarding or disclosure of information relating to Enrollees, the Contractor’s operations, or the Contractor’s performance of this Contract.

34.1.10.3

In the event of the expiration of this Contract or termination thereof for any reason, all confidential information disclosed to and all copies thereof made by the Contractor and its Agents, Subcontractors, consultants, and advisors must be returned promptly to ASES at its request or, at ASES’s option, erased or destroyed in the presence of ASES employees or representatives in compliance with applicable laws and regulations. The Contractor must provide ASES certificates evidencing such destruction.

34.1.10.4

The Contractor’s contracts with practitioners and other Providers shall explicitly state expectations about the confidentiality of ASES’s confidential information and Enrollee records.

34.1.10.5

The Contractor shall afford Enrollees and/or their Authorized Representatives the opportunity to approve or deny the release of identifiable personal information by the Contractor to a person or entity outside of the Contractor, except to duly authorized Subcontractors, Providers or review organizations, or when such release is required by law, regulation, or quality standards or as otherwise permitted in the HIPAA Business Associate Agreement.

34.1.10.6

This Article 34 does not restrict the Contractor from making any disclosure pursuant to any applicable law, or under any court or government agency, provided that the Contractor, prior to the disclosure, Immediately provides notice to ASES of such order.

34.1.11

Disclosure of ASES’s Confidential Information

34.1.11.1

The Contractor shall Immediately report to ASES any and all suspected and actual unauthorized disclosures (breaches) or uses of confidential information of which it or its Subcontractors, consultants, or Agents are aware or have knowledge of. The Contractor acknowledges that any publication or disclosure of confidential information to unauthorized persons may cause immediate and irreparable harm to ASES and may constitute a violation of Puerto Rico or Federal statutes. If the Contractor, its Subcontractors, consultants, or Agents should publish or disclose Confidential Information to others without authorization, ASES will immediately be entitled to injunctive relief or any other remedies to which it is entitled under law or equity. ASES will have the right to recover from the Contractor all damages and liabilities caused by or arising from the Contractor’s, its Subcontractors’, Network Providers’, representatives’, consultants’, or Agents’ failure to protect confidential Information. The Contractor will defend with counsel approved by ASES, indemnify and hold harmless ASES from all damages, costs, liabilities, and expenses caused by or arising from the Contractor’s, or its Subcontractors’, Providers’, representatives’, consultants’ or Agents’ failure to protect confidential Information. ASES will not unreasonably withhold approval of counsel selected by the Contractor.

Page 301 of 324

34.1.12

The Contractor shall remove any person from performance of services hereunder upon notice that ASES reasonably believes that such person has failed to comply with the confidentiality obligations of this Contract. The Contractor shall replace such removed personnel in accordance with the staffing requirements of this Contract.

34.1.13

ASES, the Government, Federal officials as authorized by Federal law or regulations, or the Authorized Representatives of these Parties shall have access to all confidential information in accordance with the requirements of Puerto Rico and Federal laws and regulations.

34.1.14

The confidentiality provisions contained in this Contract survive the termination of this contract and shall bind the Contractor, and its PMGs and Network Providers, so long as they maintain any PHI relating to Enrollees.

34.2

HIPAA Compliance

34.2.1

The Contractor shall assist ASES in its efforts to comply with HIPAA and its amendments, rules, procedures, and regulations. To that end, the Contractor shall cooperate with and abide by any data privacy, security or other requirements mandated by HIPAA or any other applicable laws. The Contractor acknowledges that HIPAA requires the Contractor and ASES to sign documents for compliance purposes, including but not limited to a business associate agreement. The parties agree to the terms of the HIPAA Business Associate Agreement included as Attachment 18 to this Contract, which is incorporated by reference. The Contractor shall cooperate with ASES on these matters and sign whatever documents may be required for HIPAA compliance and abide by their terms and conditions. This Agreement, including the HIPAA Business Associate Agreement, shall be construed in a manner that allows ASES to comply with applicable law. Contractor shall be responsible for ensuring that individuals have the right to access and amendment of PHI and accounting of disclosures, with respect to PHI created, received, maintained or transmitted by Contractor. Contractor shall ensure that Enrollees receive a Notice of Privacy Practices as required by HIPAA.

Page 302 of 324

34.3

Privacy of Information in Enrollment Database

34.3.1

Any individually identifiable health information held in the Enrollment Database described in Section 5.3.8 of this Contract shall be kept confidential and shall be used and disclosed by the Contractor or its Network Providers only for purposes directly connected with performance of all obligations contained in this Contract and as permitted by the HIPAA Business Associate Agreement, and in strict compliance with HIPAA’s privacy and security requirements and any applicable laws of Puerto Rico.

34.4

Data Breach

34.4.1

The Contractor shall Immediately report to ASES, as required in Section 13402 of the HITECH Act, of any actual or suspected event where ASES’s Data could be exposed in a non-authorized or illegal circumstance, and/or when any Data Breach occurs. The Contractor must take all reasonable steps to mitigate the Breach, notify actual or potentially impacted Enrollees, and provide appropriate notice to the applicable State and Federal regulatory agencies as required by law.

34.4.2

The Contractor agrees that without unreasonable delay, but no later than twenty-four (24) hours after it suspects or has determined that a Data Breach occurred, the Contractor shall notify ASES of such Breach. The notification shall include sufficient information for ASES to understand the nature of the Breach. For instance, such notification must include, at a minimum, and to the extent available at the time of the notification, the following information:

34.4.2.1

One or two sentence description of the event;

34.4.2.2

Description of the roles of the people involved in the Breach (e.g., employees, participant users, service Providers, unauthorized persons, etc.)

34.4.2.3

The type of Data/Information as well as Protected Health Information that was breached;

34.4.2.4

Enrollees likely impacted by the Breach;

34.4.2.5

Number of individuals or records impacted/estimated to be impacted by the Breach;

34.4.2.6

Actions taken by the Contractor to mitigate the Breach;

34.4.2.7

Current status of the Breach (under investigation or resolved);

Page 303 of 324

34.4.2.8

Corrective action taken and steps planned to be taken to prevent a similar Breach.

34.4.3

The Contractor shall have a duty to supplement the information contained in the notification as it becomes available and to cooperate with ASES.

ARTICLE 35

TERMINATION OF CONTRACT

35.1

General Procedures

35.1.1

In addition to any other non-financial remedy set forth in this Contract or available by law, or in lieu of any financial Remedy contained in Articles 19 and 20 of this Contract or available by law, and subject to compliance with the termination procedures set forth in Section 35.8 below, ASES may terminate this Contract for any or all of the following reasons:

35.1.1.1

Default by the Contractor, upon thirty (30) Calendar Days’ notice, unless ASES, in its reasonable discretion, determines that the Contractor has cured the default to ASES’s satisfaction within the notice period;

35.1.1.2

Immediately, in the event of insolvency or declaration of bankruptcy by the Contractor;

35.1.1.3

Immediately, when sufficient appropriated funds no longer exist for the payment of ASES's obligation under this Contract; or

35.1.1.4

In the event that the Contractor or any of its shareholders, director, officers, or employees fall under the prohibition stated in Section 29.1 or 29.6 of this Contract.

35.1.2

A decision by ASES not to renew this Contract, per Article 21, shall not constitute a Termination of the Contract.

35.1.3

The Contractor shall have a limited right of termination of this Contract only in the events described in Section 35.10 of this Contract.

35.1.4

Each Party shall have the opportunity to cure any default alleged in a termination notice sent pursuant to this Article 35, upon receiving a written termination notice the other Party. With respect to termination by ASES, the Contractor shall have the right to submit to ASES a written Corrective Action Plan containing terms and conditions acceptable to ASES in its sole discretion to cure such default or an explanation of non-default in the thirty (30) Calendar Day period from the date of receipt of ASES’ written termination notice and such plan or explanation of non-default is accepted by ASES, in ASES’ sole discretion, which acceptance shall not be unreasonably withheld, conditioned or delayed.

Page 304 of 324

35.1.5

Notwithstanding the termination of this Contract pursuant to this Article 35 for any reason, the Contractor shall remain obligated to provide the Administrative Functions as described in Article 36, including but not limited to the payment of Claims for Covered Services provided to Enrollees prior to the Termination Date and as specified in the Patient’s Bill of Rights Act through the Runoff Period.

35.1.6

Continuing Obligations of ASES. Notwithstanding the termination of this Contract for pursuant to this Article 35 for any reason, ASES shall remain obligated to pay to the Contractor the PMPM through the Termination Date (inclusive of the Transition Period).

35.1.7

Termination Procedures to be Strictly Followed. No termination of this Contract shall be effective unless the termination procedures under Section 35 of this Contract have been strictly followed or waived by the Parties.

35.2

Termination by Default

35.2.1

In the event ASES determines that the Contractor has defaulted by failing to carry out the terms or conditions of this Contract or by failing to meet the applicable requirements in sections 1932 and 1903(m) of the Social Security Act, or in the event that ASES determines that the Contractor falls within the prohibitions stated in Section 29.1 or 29.6, ASES may terminate the Contract in addition to or in lieu of any other remedies set out in this Contract or available by law.

35.2.2

Before terminating this Contract, ASES will:

35.2.2.1

Provide written notice of the intent to terminate at least thirty (30) Calendar Days prior to the Termination Date, stating the reason for the termination and the time and place of a hearing, to take place at least fifteen (15) Calendar Days after the date of mailing of the notice of intent to terminate, to give the Contractor an opportunity to appeal the determination or cure the default;

35.2.2.2

Provide written notice of the decision affirming or reversing the proposed termination of the Contract, and for an affirming decision, the effective date of the termination; and

35.2.2.3

For an affirming decision, give Enrollees of the Contractor notice of the termination and information consistent with 42 CFR 438.10 on their options for receiving services following the Termination Date of the Contract.

35.3

Termination for Convenience

35.3.1

ASES may terminate this Contract for convenience and without cause upon thirty (30) Calendar Days written notice. Termination for convenience shall not be a breach of the Contract by ASES. The Contractor shall be entitled to receive, and shall be limited to just and equitable compensation for any satisfactory authorized work performed as of the Termination Date of the Contract.

Page 305 of 324

35.4

Termination for Insolvency or Bankruptcy

35.4.1

The Contractor’s insolvency, or the Contractor’s filing of a petition in bankruptcy, shall constitute grounds for termination for cause. In the event of the filing of a petition in bankruptcy, the Contractor shall immediately advise ASES. If ASES reasonably determines that the Contractor's financial condition is not sufficient to allow the Contractor to provide the services as described herein in the manner required by ASES, ASES may terminate this Contract in whole or in part, Immediately or in stages. The Contractor's financial condition shall be presumed not sufficient to allow the Contractor to provide the services described herein, in the manner required by ASES if the Contractor cannot demonstrate to ASES's satisfaction that the Contractor has risk reserves and a minimum net worth sufficient to meet the statutory standards for licensed health care plans, as required under this Contract. The Contractor shall cover continuation of services to Enrollees for the duration of period for which payment has been made, as well as for inpatient admissions up to discharge.

35.4.2

In the event that this Contract is terminated because of the Contractor’s insolvency, the Contractor shall guarantee that Enrollees shall not be liable for:

35.4.2.1

The Contractor’s debts;

35.4.2.2

The Covered Services provided to the Enrollee, for which ASES does not pay the Contractor or its Network Providers;

35.4.2.3

The Covered Services provided to the Enrollee, for which ASES or the Contractor does not pay a Provider who furnishes the services under a contractual, Referral, or other arrangement; or

35.4.2.4

Payment for Covered Services furnished under a contractual, Referral, or other arrangement, to the extent that those payments are in excess of the amount that the Enrollee would owe if the Contractor provided the services directly.

35.4.3

The Contractor shall cover continuation of services to Enrollees for the duration of the period for which payment has been made by ASES, as well as for inpatient admissions up to discharge.

35.5

Termination for Insufficient Funding

35.5.1

In the event that Federal and/or Puerto Rico funds to finance this Contract become unavailable or insufficient, ASES may terminate the Contract in writing, unless both Parties agree, through a written amendment, to a modification of the obligations under this Contract.

Page 306 of 324

35.5.2

The Termination Date of the Contract when the Contract is terminated due to insufficient funding shall be ninety (90) Calendar Days after ASES delivers written notice to the Contractor, unless available funds are insufficient to continue payments in full during the ninety (90) Calendar Day period, in which case ASES shall give the Contractor written notice of an earlier date at which the Contract shall terminate.

35.5.3

Upon termination, the Contractor shall comply with the phase-out obligations established in Article 36 of this Contract.

35.5.4

In the event of termination for insufficient funding, the Contractor shall be entitled to receive, and shall be limited to, just and equitable compensation for any satisfactory authorized work performed as of the Termination Date of the Contract.

35.5.5

Availability of funds shall be determined solely by ASES.

35.6

Termination Under Section 29.3

35.6.1

If any of the events specified in Section 29.3 of this Contract occur, ASES may terminate this Contract as required under Act 458 and Act 84.

35.6.2

Upon Termination, the Contractor shall comply with the phase-out obligations established in Article 36 of this Contract.

35.7

ASES may terminate this Contract for any other just reason upon thirty (30) Calendar Days written notice.

35.8

Termination Procedures

35.8.1

ASES will issue a written notice of termination to the Contractor by certified mail, return receipt requested, or in person with evidence of delivery. The notice of termination shall cite the provision of this Contract giving the right to terminate, the circumstances giving rise to termination, and the Termination Date of the Contract. Termination shall be effective at 11:59 p.m. EST on the Termination Date of the Contract.

35.8.2

Upon receipt of notice of termination or on the date specified in the notice of termination and as directed by ASES, the Contractor shall:

35.8.2.1

Stop work under the Contract on the date and to the extent specified in the notice of termination;

35.8.2.2

Place no further orders or subcontract for materials, services, or facilities, except as may be necessary for completion of such portion of the work under the Contract prior to termination that is already in process;

Page 307 of 324

35.8.2.3

Terminate all orders and subcontracts to the extent that they relate to the performance of work terminated by the notice of termination;

35.8.2.4

Assign to ASES, in the manner and to the extent directed by ASES, all of the right, title, and interest of Contractor under the orders or subcontracts so terminated, in which case ASES will have the right, at its discretion, to settle or pay any or all Claims arising out of the termination of such orders and subcontracts;

35.8.2.5

With the prior written approval of ASES, settle all outstanding liabilities and all Claims arising out of such termination or orders and subcontracts, the cost of which would be reimbursable in whole or in part, in accordance with the provisions of this Contract;

35.8.2.6

Complete the performance of such part of the work that was not terminated by the notice of termination;

35.8.2.7

Take such action as may be necessary, or as ASES may direct, for the protection and preservation of any and all property or information related to the Contract that is in the possession of the Contractor and in which ASES has or may acquire an interest;

35.8.2.8

Promptly make available to ASES, or to another MCO acting on behalf of ASES, any and all records, whether medical or financial, related to the Contractor's activities undertaken pursuant to this Contract. Such records shall be provided at no expense to ASES;

35.8.2.9

Promptly supply all information necessary to ASES, or another ASES plan acting on behalf of ASES, for reimbursement of any outstanding Claims at the time of termination; and

35.8.2.10

Submit a termination/transition plan to ASES for review and prior written approval that includes commitments to carry out at minimum the following obligations:

35.8.2.10.1

Provide Enrollees continuation of all the Covered Services and Benefits during a defined transition period, such transition period to be determined by ASES;

35.8.2.10.2

Comply with all duties and/or obligations incurred prior to the actual Termination Date of the Contract, including but not limited to, the Grievance and Appeal process as described in Article 14;

35.8.2.10.3

Maintain Claims processing functions as necessary for ten (10) consecutive months from the Termination Date of the Contract in order to complete adjudication of all Claims;

Page 308 of 324

35.8.2.10.4

Create a task force to reconcile and certify any pending and outstanding balances in connection with services rendered by the Contractor under the Contract and previous contracts between ASES and the Contractor.

35.8.2.10.5

File all reports concerning the Contractor’s operations during the term of the Contract in the manner described in this Contract;

35.8.2.10.6

Assist ASES in making all necessary notices to Enrollees and Providers at least thirty (30) Calendar Days prior to the effective date of change and as may be required under the Contract, or otherwise required under applicable law, regarding notices to Enrollees;

35.8.2.10.7

Ensure the efficient and orderly transition of Enrollees from coverage under this Contract to coverage under any new arrangement developed or agreed to by ASES, including cooperation with another contractor, as provided in Article 35;

35.8.2.10.8

Ensure the proper identification of the Enrollees requiring the authorization for either prescription medications or DME to avoid any interruptions in services by providing such Data to ASES as contemplated in the transition plan;

35.8.2.10.9

Submit to ASES all scripts used at Call Centers to communicate with Enrollees during the transition period;

35.8.2.10.10

Maintain the financial requirements and insurance set forth in this Contract until ASES provides the Contractor written notice that all continuing obligations of this Contract have been fulfilled;

35.8.2.10.11

Submit reports to ASES as directed but no less frequently than every thirty (30) Calendar Days, detailing the Contractor’s progress in completing its continuing obligations under this Contract, until completion; and

35.8.2.10.12

Meet with ASES personnel, as requested, to ensure satisfactory completion of all obligations under the Termination Plan.

35.8.3

This Termination Plan shall be subject to review and approval by CMS.

35.8.4

Upon completion of these continuing obligations, the Contractor shall submit a final report to ASES describing how the Contractor has completed its continuing obligations. ASES will advise, within twenty (20) Calendar Days of receipt of this report, if all of the Contractor’s obligations are discharged. If ASES finds that the final report does not evidence that the Contractor has fulfilled its continuing obligations, then ASES will require the Contractor to submit a revised final report to ASES for approval, and take any other action necessary to discharge all of its duties under this Contract, as directed by ASES.

Page 309 of 324

35.8.5

Except as provided in this Article 35, a notification that ASES intends to terminate this Contract shall not release the Contractor from its obligations to pay for Covered Services rendered or otherwise to perform under this Contract.

35.9

Termination Claims

35.9.1

After receipt of a notice of termination, the Contractor shall submit to ASES any termination claim in the form, and with the certification prescribed by, ASES. Such claim shall be submitted promptly but in no event later than ten (10) months from the Termination Date of the Contract. Upon failure of the Contractor to submit its termination claim within the time allowed, ASES may determine, on the basis of information available, the amount, if any, due to the Contractor by reason of the termination and shall thereupon cause to be paid to the Contractor the amount so determined.

35.9.2

Upon receipt of notice of termination, the Contractor shall have no entitlement to receive any amount for lost revenues or anticipated profits or for expenditures associated with this Contract or any other contract. Upon termination the Contractor shall be paid in accordance with the following:

35.9.2.1

At the Contract price(s) for services delivered to and accepted by ASES; and/or

35.9.2.2

At a price mutually agreed upon by the Contractor and ASES for partially completed services.

35.9.3

In the event the Contractor and ASES fail to agree in whole or in part as to the amounts with respect to costs to be paid to the Contractor in connection with the total or partial termination of work pursuant to this article, ASES will determine, on the basis of information available, the amount, if any, due to the Contractor by reason of termination and shall pay to the Contractor the amount so determined.

35.10

Limited Right of Termination by the Contractor

35.10.1

Subject to compliance with the termination procedures set forth in Section 35.8, the Contractor may terminate this Contract under the following circumstances:

35.10.1.1

Termination Due to ASES’s Financial Breach. Upon fifteen (15) Calendar Days written notice, in the event ASES defaults in making payment of three (3) consecutive monthly PMPM Payments and fails to cure such breach within the notice period. For purposes of this Section, a default in making payment does not include instances where ASES has made any Withhold payments pursuant to the terms of this Contract, provided that ASES has given the Contractor advance written notice of any such Withhold.

Page 310 of 324

35.10.1.2

Termination Due to Insufficient Funding. Immediately, upon receipt from ASES of a written notice pursuant to Section 35.5 that appropriated federal and/or Puerto Rico funds become unavailable or that such funds will be insufficient for the payment of ASES's obligation under this Contract when due, unless both Parties agree, through a written amendment, to a modification of the obligations under this Contract.

35.10.1.3

If forty-five (45) Calendar Days before the last day of each fiscal year covered under the Contract, the Contractor and ASES have not (as provided in Section 21.4 agreed to PMPM for the succeeding fiscal year, the Contractor may exercise an option to terminate the Contract by giving ASES written notice of the Contractor’s intent not to continue to provide services under the Contract no later than forty-five (45) Calendar Days prior to the termination of the corresponding fiscal year. Once the Contractor has given ASES such written notice, the Contractor shall fully discharge the termination phase-out obligations listed in Section 35.8. At any time before the end of the fiscal year, the Contractor may rescind its notice of termination, if the Parties reach an agreement on rates for the following fiscal year.

ARTICLE 36

PHASE-OUT AND COOPERATION WITH OTHER CONTRACTORS

36.1

If, in the best interest of Enrollees of GHP, ASES terminates any GHP contract, the Contractor shall, upon the request of ASES, assume responsibility for Enrollees previously managed by any MCO or other Contractor whose contractual arrangement with ASES was terminated, in accordance with the contracted PMPM Payment, pursuant to the written amendment of the Contract, if required.

36.2

If in the best interest of Enrollees of GHP, ASES develops and implements new projects that impact the scope of services, the Contractor shall assist in the transition process, after receiving at least ninety (90) Calendar Days written notice from ASES of such change, and pursuant to written amendment of the Contract, if required. PMPM Payments shall be adjusted accordingly.

36.3

In the event that ASES has entered into, or enters into, agreements with other contractors for additional work related to the Benefits rendered hereunder, the Contractor agrees to cooperate fully with such other contractors. The Contractor shall not commit any act or omission that will interfere with the performance of work by any other contractor, or actions taken by ASES to facilitate the work.

Page 311 of 324

36.4

If ASES chooses not to renew this Contract, pursuant to Article 21, the Contractor agrees that it will not engage in any behavior or inaction that prevents or hinders the work of another contractor or ASES, as the case may be. Upon receiving ASES’s notice that it does not intend to renew the Contract, the Contractor agrees to submit a written termination/transition plan to ASES within thirty (30) Calendar Days of receiving the notice. The turn-over plan shall include all the elements listed in Section 35.8.2.9.1. The Parties agree that the Contractor has not successfully met this obligation until ASES accepts its turn-over plan and/or transition plan, required under this Article 36.

ARTICLE 37

INSURANCE

37.1

The Contractor shall, at a minimum, prior to the commencement of work, procure the insurance policies identified below at the Contractor’s own cost and expense and shall furnish ASES with proof of coverage at least in the amounts indicated. It shall be the responsibility of the Contractor to require any Subcontractor to secure the same insurance coverage as prescribed herein for the Contractor, and to obtain a certificate evidencing that such insurance is in effect. In the event that any such insurance is proposed to be reduced, terminated or cancelled for any reason, the Contractor shall provide to ASES at least thirty (30) Calendar Days prior written notice. Prior to the reduction, expiration and/or cancellation of any insurance policy required hereunder, the Contractor shall secure replacement coverage upon the same terms and provisions to ensure no lapse in coverage, and shall furnish, at the request of ASES, a certificate of insurance indicating the required coverage. The Contractor shall maintain insurance coverage sufficient to insure against claims arising at any time during the term of the Contract. The provisions of this Section shall survive the expiration or termination of this Contract for any reason. In addition, the Contractor shall indemnify and hold harmless ASES and the Government from any liability arising out of the Contractor’s or its Subcontractor’s untimely failure in securing adequate insurance coverage as prescribed herein:

37.2

Workers’ Compensation Insurance, the policy(ies) to insure the statutory limits established by law of Puerto Rico. The Workers’ Compensation Policy must include Coverage B – Employer’s Liability Limits of:

37.2.1

Bodily Injury by Accident. Five hundred thousand dollars ($500,000) each accident;

37.2.2

Bodily Injury by Disease. Five hundred thousand dollars ($500,000) each employee; and

37.2.3

One million dollars ($1,000,000) policy limits.

37.3

The Contractor shall require all Subcontractors performing work under this Contract to obtain an insurance certificate showing proof of Worker’s Compensation Coverage.

37.3.1

The Contractor shall have commercial general liability policy(ies) as follows:

Page 312 of 324

37.3.1.1

Combined single limits of one million dollars ($1,000,000) per person and three million dollars ($3,000,000) per occurrence;

37.3.1.2

On an “occurrence” basis; and

37.3.1.3

Liability for property damage in the amount of three million dollars ($3,000,000) including contents coverage for all records maintained pursuant to this Contract.

ARTICLE 38

COMPLIANCE WITH ALL LAWS

38.1

Nondiscrimination

38.1.1

The Contractor shall comply with applicable Federal and Puerto Rico laws, rules, and regulations, and the Puerto Rico policy relative to nondiscrimination in employment practices because of political affiliation, religion, race, color, sex, physical handicap, age, or national origin. Applicable Federal nondiscrimination law includes, but is not limited to, Title VI of the Civil Rights Act of 1964, as amended; Title IX of the Education Amendments of 1972, as amended; the Age Discrimination Act of 1975, as amended; Equal Employment Opportunity and its implementing regulations (45 CFR 74 Appendix A (1), Executive Order 11246 and 11375); the Rehabilitation Act of 1973; and the Americans with Disabilities Act of 1993 and its implementing regulations (including but not limited to 28 CFR § 35.100 et seq.). Nondiscrimination in employment practices is applicable to employees for employment, promotions, dismissal and other elements affecting employment.

38.1.2

The Contractor shall comply with all provisions of the Puerto Rico Patient’s Bill of Rights and the implementing regulation, which prohibits discrimination against any patient.

38.2

Compliance with All Laws in the Delivery of Service

38.2.1

The Contractor agrees that all work done under this Contract will comply fully with and abide by all applicable Federal and Puerto Rico laws, rules, regulations, statutes, policies, or procedures that may govern the Contract, including but not limited to those listed in Attachment 1 to this Contract.

38.2.2

All applicable Puerto Rico and Federal laws, rules, and regulations, consent decrees, court orders, policy letters and normative letters, and policies and procedures, including but not limited to those described in Attachment 1 to this Contract, are hereby incorporated by reference into this Contract. Any change in those applicable laws and requirements, including any new law, regulations, policy guidance, or normative letter, shall be automatically incorporated into this Contract by reference as soon as it becomes effective.

38.2.3

At the request of either party, ASES will evaluate any enacted Federal, state or local legislative or regulatory changes with applicability to the GHIP program that materially impact the PMPM Payment. If after a process of actuarial evaluation, using credible data, ASES determines that the enacted legislative and/or regulatory changes materially impact the PMPM Payment, ASES will adjust the PMPM rates to reflect the above-referenced changes after the adjusted rates are approved by CMS. Any revisions to the PMPM Payments under this Section would be applicable from November 1, 2018 until October 31, 2019, or from the effective date of any new law or regulation, whichever is later. “Materially impact” shall mean that a recalculation of current PMPM Payments is required in order to remain actuarially sound.

Page 313 of 324

38.2.4

To the extent that applicable laws, rules, regulations, statutes, policies, or procedures require the Contractor to take action or inaction, any costs, expenses, or fees associated with that action or inaction shall be borne and paid by the Contractor solely. Such compliance-associated costs include, but are not limited to, attorneys’ fees, accounting fees, research costs, or consultant costs, where these costs are related to, arise from, or are caused by compliance with any and all laws. In the event of a disagreement on this matter, ASES’s determination on this matter shall be conclusive and not subject to appeal.

38.2.5

The Contractor shall include notice of grantor agency requirements and regulations pertaining to reporting and patient rights under any contracts involving research, developmental, experimental or demonstration work with respect to any discovery or invention which arises or is developed in the course of or under such contract, and of grantor agency requirements and regulations pertaining to copyrights and rights in Data.

38.2.6

The Contractor certifies and warrants to ASES that at the time of execution of this Contract: (i) it is a corporation or entity duly authorized to conduct business in Puerto Rico, and has filed all the required income tax returns for the preceding five years; and (ii) it filed its report due with the Office of the Commissioner of Insurance during the five (5) years preceding the Execution Date of this Contract.

ARTICLE 39

CONFLICT OF INTEREST AND CONTRACTOR INDEPENDENCE

39.1

The duty to provide information about interests and conflicting relations is continuous and extends throughout the Contract Term.

39.2

The Contractor covenants that it presently has no interest and shall not acquire any interest, direct or indirect, that would conflict in any material manner or degree with, or have a material adverse effect on the performance of its services hereunder. The Contractor further covenants that in the performance of the Contract no person having any such interest shall be employed. The Contractor shall submit a conflict of interest form, attesting to these same facts, by January 10 of each calendar year; and at any time, within fifteen (15) Calendar Days of request by ASES.

Page 314 of 324

39.3

It shall be the responsibility of the Contractor to maintain independence and to establish necessary policies and procedures to assist the Contractor in determining if the actual individuals performing work under this Contract have any impairment to their independence.

39.4

The Contractor further agrees to take all necessary actions to eliminate threats to impartiality and independence, including but not limited to reassigning, removing, or terminating Providers or Subcontractors.

ARTICLE 40

CHOICE OF LAW OR VENUE

40.1

This Contract shall be governed in all respects by the laws of Puerto Rico. Any lawsuit or other action brought against ASES or the Government based upon or arising from this Contract shall be brought in a court of competent jurisdiction in Puerto Rico. Nothing in this Section shall be construed as a restriction on the ability of the Contractor to discuss matters relating to this Contract in ASES’s administrative forum.

ARTICLE 41

ATTORNEY’S FEES

41.1

In the event that either Party deems it necessary to take legal action to enforce any provision of this Contract, and in the event ASES prevails, the Contractor agrees to pay all expenses of such an action including reasonable attorney’s fees and costs at all stages of litigation as awarded by the court, a lawful tribunal, a hearing officer, or an administrative law judge. The term legal action shall be deemed to include administrative proceedings of all kinds, as well as all actions regarding the law or equity.

ARTICLE 42

SURVIVABILITY

42.1

The terms, provisions, representations, and warranties contained in this Contract shall survive the delivery or provision of all services hereunder.

ARTICLE 43

PROHIBITED AFFILIATIONS WITH INDIVIDUALS DEBARRED AND SUSPENDED

43.1

The Contractor certifies that it is not presently debarred, suspended, proposed for debarment, or declared ineligible for award of contracts by any Federal or Puerto Rico agency, as provided in Section 13.4. In addition, the Contractor certifies that it does not employ or subcontract with any person or entity that could be excluded from participation in the Medicaid Program under 42 CFR 1001.1001 (exclusion of entities owned or controlled by a sanctioned person) or 1001.1051 (exclusion of individuals with ownership or control interest in sanctioned entities), and that Contractor screens for such exclusions on a monthly basis. Any violation of this Article shall be grounds for termination of the Contract.

Page 315 of 324

ARTICLE 44

WAIVER

44.1

No covenant, condition, duty, obligation, or undertaking contained in or made a part of the Contract shall be waived except by the written agreement of the Parties. Forbearance or indulgence in any form or manner by either Party in any regard whatsoever shall not constitute a waiver of the covenant, conditions, duties, obligations, and undertakings to be kept, performed, or discharged by the Party to which the same may apply. Notwithstanding any such forbearance or indulgence, the other Party shall have the right to invoke any Remedy available under law or equity until complete performance or satisfaction of all such covenants, conditions, duties, obligations, and undertakings.

44.2

The waiver by ASES of any breach of any provision contained in this Contract shall not be deemed to be a waiver of such provision or any subsequent breach of the same or any other provision contained in this Contract and shall not establish a course of performance between the Parties contradictory to the terms hereof. No term or condition of the Contract shall be held to be waived, modified, or deleted except by an instrument, in writing, signed by the Parties thereto.

ARTICLE 45

FORCE MAJEURE

45.1

Neither Party of this Contract shall be held responsible for delays or failures in performance resulting from acts beyond the control of each Party. Such acts shall include, but not be limited to, acts of God, strikes, riots, lockouts, acts of war, epidemics, fire, earthquakes, or other disasters.

ARTICLE 46

BINDING

46.1

This Contract and all of its terms, conditions, requirements, and amendments shall be binding on ASES and the Contractor and for their respective successors and permitted assigns.

ARTICLE 47

TIME IS OF THE ESSENCE

47.1

Time is of the essence in this Contract. Any reference to “days” shall be deemed Calendar Days unless otherwise specifically stated.

Page 316 of 324

ARTICLE 48

AUTHORITY

48.1

ASES has full power and authority to enter into this Contract as does the person acting on behalf of and signing for the Contractor. Additionally, the person signing on behalf of the Contractor has been properly authorized and empowered to enter into this Contract on behalf of the Contractor and to bind the Contractor to the terms of this Contract. Each Party further acknowledges that it has had the opportunity to consult with and/or retain legal counsel of its choice and read this Contract. Each party acknowledges that it understands this Contract and agrees to be bound by it.

ARTICLE 49

ETHICS IN PUBLIC CONTRACTING

49.1

The Contractor understands, states, and certifies that it made its Proposal without collusion or Fraud and that it did not offer or receive any kickbacks or other inducements from any other Contractor, supplier, manufacturer, or Subcontractor in connection with its Proposal.

49.2

The Contractor understands, states, and certifies that it will comply with the requirements of the Code of Ethics for Contractors, Suppliers and Applicants of Economic Incentives of the Government of Puerto Rico, as described in Title III of Act 2 of January 4, 2018, known as the “Anticorruption Code for the New Puerto Rico.”

ARTICLE 50

CONTRACT LANGUAGE INTERPRETATION

50.1

The Contractor and ASES agree that in the event of a disagreement regarding, arising out of, or related to, Contract language interpretation, ASES’s interpretation of the Contract language in dispute shall control and govern.

ARTICLE 51

ARTICLE AND SECTION TITLES NOT CONTROLLING

51.1

The Article and Section titles used in this Contract are for reference purposes only and shall not be deemed to be a part of this Contract.

ARTICLE 52

LIMITATION OF LIABILITY/EXCEPTIONS

52.1

Nothing in this Contract shall limit the Contractor’s indemnification liability or civil liability arising from, based on, or related to claims brought by ASES or any Third Party or any claims brought against ASES or the Government by a Third Party or the Contractor.

Page 317 of 324

ARTICLE 53

COOPERATION WITH AUDITS

53.1

The Contractor shall assist and cooperate with ASES in any and all matters and activities related to or arising out of any audit or review, whether Federal, private, or internal in nature, at no cost to ASES.

53.2

The Parties also agree that the Contractor shall be solely responsible for any costs it incurs for any audit related inquiries or matters. Moreover, the Contractor may not charge or collect any fees or compensation from ASES for any matter, activity, or inquiry related to, arising out of, or based on an audit or review.

53.3

ASES reserves the right to audit the Contractor and/or its Subcontractors at any time during the term of the Contract. The Contractor and/or its Subcontractors shall be solely responsible for the cost of such audits.

ARTICLE 54

OWNERSHIP AND FINANCIAL DISCLOSURE

54.1

The Contractor and Subcontractors shall disclose, and ASES shall review, financial statements for each person or corporation with an ownership or control interest of five percent (5%) or more of its entity. For the purposes of this Section, a person or corporation with an ownership or control interest shall mean a person or corporation:

54.1.1

That owns directly or indirectly five percent (5%) or more of the Contractor’s/Subcontractor’s capital or stock or received five percent (5%) or more of its profits;

54.1.2

That has an interest in any mortgage, deed of trust, note, or other obligation secured in whole or in part by the Contractor/Subcontractor or by its property or assets, and that interest is equal to or exceeds five percent (5%) of the total property and assets of the Contractor/Subcontractor; and

54.1.3

That is an officer or director of the Contractor/Subcontractor (if it is organized as a corporation) or is a partner in the Contractor’s/Subcontractor’s organization (if it is organized as a partnership).

54.2

As per 42 CFR 455.104, disclosure by the Contractor will include the following information on ownership and control:

54.2.1

The name and address of any person (individual or corporation) with an ownership or control interest in the disclosing entity, fiscal agent, or Contractor. The address for corporate entities must include as applicable primary business address, every business location, and P.O. Box address.

54.2.2

Date of birth and Social Security Number (in the case of an individual).

54.2.3

Other tax identification number (in the case of a corporation) with an ownership or control interest in the disclosing entity (or fiscal agent or managed care entity) or in any Subcontractor in which the disclosing entity (or fiscal agent or managed care entity) has a five percent (5%) or more interest.

Page 318 of 324

54.2.4

Whether the person (individual or corporation) with an ownership or control interest in the disclosing entity (or fiscal agent or MCO) is related to another person with ownership or control interest in the disclosing entity as a spouse, parent, child, or sibling; or whether the person (individual or corporation) with an ownership or control interest in any Subcontractor in which the disclosing entity (or fiscal agent or managed care entity) has a five percent (5%) or more interest is related to another person with ownership or control interest in the disclosing entity as a spouse, parent, child, or sibling.

54.2.5

The name of any other disclosing entity (or fiscal agent or MCO) in which an owner of the disclosing entity (or fiscal agent or managed care entity) has an ownership or control interest.

54.2.6

The name, address, date of birth, and Social Security Number of any managing employee of the disclosing entity (or fiscal agent or managed care entity).

54.2.7

Disclosures from Providers or Disclosing Entities. Providers or disclosing entities shall comply with the information disclosure required by Section 54.2. Disclosure from any provider or disclosing entity is due at any of the following times:

54.2.7.1

Upon the provider or disclosing entity submitting the provider application.

54.2.7.2

Upon the provider or disclosing entity executing the provider agreement.

54.2.7.3

Upon request of ASES during the re-validation of provider enrollment process under 42 CFR 455.414.

54.2.7.4

Within 35 Calendar Days after any change in ownership of the disclosing entity.

54.2.8

Disclosures from Fiscal Agents. Fiscal agents shall comply with the information disclosure required by Section 54.2. Disclosures from fiscal agents are due at any of the following times:

54.2.8.1

Upon the fiscal agent submitting the proposal in accordance with the Government's procurement process.

54.2.8.2

Upon the fiscal agent executing the contract with the Government.

54.2.8.3

Upon renewal or extension of the Contract.

Page 319 of 324

54.2.8.4

Within thirty-five (35) Calendar Days after any change in ownership of the fiscal agent.

54.2.9

Disclosures from the Contractor. The Contractor shall comply with the information disclosure required by Section 54.2. Disclosures from Contractors are due at any of the following times:

54.2.9.1

Upon the managed care entity submitting the proposal in accordance with the Government's procurement process.

54.2.9.2

Upon the MCO executing the contract with the Government.

54.2.9.3

Upon renewal or extension of the Contract.

54.2.9.4

Within thirty-five (35) Calendar Days after any change in ownership of the Contractor.

ARTICLE 55

AMENDMENT IN WRITING

55.1

No amendment, waiver, termination, or discharge of this Contract, or any of the terms or provisions hereof, shall be binding upon either Party unless confirmed in writing by ASES and any other appropriate governmental agency. Additionally, CMS approval shall be required before any such amendment is effective. Any agreement of the Parties to amend, modify, eliminate, or otherwise change any part of this Contract shall not affect any other part of this Contract, and the remainder of this Contract shall continue to be in full force and effect as set out herein.

55.2

ASES reserves the authority to seek an amendment to this Contract at any time if such an amendment is necessary in order for the terms of this Contract to comply with Federal law, the laws of Puerto Rico or the Government of Puerto Rico Fiscal Plan as certified by the Financial Oversight and Management Board for Puerto Rico pursuant to the Puerto Rico Oversight, Management and Economic Stability Act of 2016. The Contractor shall consent to any such amendment.

ARTICLE 56

CONTRACT ASSIGNMENT

56.1

The Contractor shall not assign this Contract, in whole or in part, without the prior written consent of ASES, and any attempted assignment not in accordance herewith shall be null and void and of no force or effect.

ARTICLE 57

SEVERABILITY

57.1

If any Article, Section, paragraph, term, condition, provision, or other part of this Contract (including items incorporated by reference) is judged, held, declared, or found to be voidable, illegal, unenforceable, invalid or void, then both ASES and the Contractor shall be relieved of all obligations arising under such provision. However, if the remainder of the Contract is capable of being performed, it shall not be affected by such declaration or finding and those duties and tasks shall be fully performed. To this end, the provisions of the Contract are declared to be severable.

Page 320 of 324

ARTICLE 58

ENTIRE AGREEMENT

58.1

This Contract constitutes the entire agreement between the Parties with respect to the subject matter herein and supersedes all prior negotiations, representations, or contracts. No written or oral agreements, representatives, statements, negotiations, understandings, or discussions that are not set out, referenced, or specifically incorporated in this Contract shall in any way be binding or of effect between the Parties.

58.2

The terms of the Request for Proposals and of the Contractor’s Proposal are incorporated by reference, except as otherwise provided in this Contract. However, in the event of a conflict between the terms of this Contract and the terms of the Request for Proposals or the terms of the Contractor’s Proposal, the terms of this Contract shall prevail.

58.3

All applicable laws are incorporated by reference into this Contract, as provided in Article 38.

58.4

Subject to Section 55, the Contractor acknowledges that it may be necessary or convenient during the Contract Term to clarify or supplement certain terms and conditions of this Contract so that it conforms to the terms of the Request for Proposals or otherwise in order to incorporate CMS requirements. In any of these events, the Contractor agrees that ASES shall have the right to issue from time to time normative letters which shall be then incorporated into the Contract. Such normative letters are advisory in nature, and shall not, absent an amendment to the Contract, effect a change in the Contractor’s substantive obligations under this Contract.

ARTICLE 59

INDEMNIFICATION

59.1

The Contractor hereby releases and agrees to indemnify and hold ASES, the Government, and its departments, agencies, and instrumentalities harmless from and against any and all claims, demands, liabilities, losses, costs or expenses, and attorneys' fees, caused by, growing out of, or arising from this Contract, due to any act or omission on the part of the Contractor, its Agents, employees, customers, invitees, licensees, or others working at the direction of the Contractor or on its behalf, or due to any breach of this Contract by the Contractor, or due to the application or violation of any pertinent Federal, Puerto Rico or local law, rule or regulation. This indemnification extends to the successors and assigns of the Contractor and survives the termination of the Contract and the dissolution or, to the extent allowed by the law, the bankruptcy of the Contractor.

Page 321 of 324

ARTICLE 60

NOTICES

60.1

All notices, consents, approvals, and requests required or permitted shall be given in writing and shall be effective for all purposes if hand delivered or sent by (i) personal delivery, (ii) expedited prepaid delivery service, either commercial or US Postal Service, with proof of attempted delivery, (iii) telecopies, or (iv) electronic mail. In each case of (c) and (d), with answer back acknowledged, addressed as follows:

60.1.1

If to ASES at:

Mailing Address: Administración de Seguros de Salud P.O. Box 195661 San Juan, PR 00919-5661	Physical Address: Administración de Seguros de Salud Urb. Caribe 1549 Ave. Ponce de León, Sec. El Cinco San Juan, PR 00926-2706
Attention: Executive Director

60.1.2

If to Contractor at:

Mailing Address: Triple-S Salud, Inc. P.O. Box 363628 San Juan, PR 00919-1580	Physical Address: Triple-S Salud, Inc. 1441 Ave. Roosevelt, 6 ^th Floor San Juan, PR 00920
Attention: President

60.1.3

All notices, elections, requests, and demands under this Contract shall be effective and deemed received upon the earliest of (i) the actual receipt of the item by personal delivery or otherwise, (ii) two (2) Business Days after being deposited with a nationally recognized overnight courier service as required above, (iii) three (3) Business Days after being deposited in the US mail as required above or (iv) on the day sent if sent by facsimile with voice confirmation on or before 4:00 p.m. Atlantic Time on any Business Day or on the next Business Day if so delivered after 4:00 p.m. Atlantic Time or on any day other than a Business Day. Rejection or other refusal to accept or the inability to deliver because of changed address of which no notice was given as herein required shall be deemed to be receipt of the notice, election, request, or demand sent.

Page 322 of 324

ARTICLE 61

OFFICE OF THE COMPTROLLER

61.1

ASES will file this Contract in the Office of the Comptroller of Puerto Rico within fifteen (15) Calendar Days from the Effective Date of the Contract.

(Signatures on following page)

Page 323 of 324

SIGNATURE PAGE

IN WITNESS WHEREOF, the Parties state and affirm that they are duly authorized to bind the respected entities designated below as of the day and year indicated.

ADMINISTRACIÓN DE SEGUROS DE SALUD DE PUERTO RICO (ASES)

/s/ Angela M. Avila Marrero		September 21, 2018
Angela M. Avila Marrero		Date
Executive Director
EIN: 66-0500678

TRIPLE-S SALUD, INC.

/s/ Madeline Hernández Urquiza		September 21, 2018
Madeline Hernández Urquiza		Date
President
EIN: 66-0555677

Page 324 of 324

Attachment 5

GOVERNMENT HEALTHCARE PLAN

List of Drugs by Exception (LME)

2017

Therapeutic Category [Categoría Terapéutica]	Therapeutic Class [Clase Terapéutica]	Drug Description [Descripción de la Droga]	Preautorization [Preautorización] Y=Yes
ADHD/ANTI- NARCOLEPSY/ANTIOBESITY/ANOREXIANTS	Stimulants - Misc.	Modafinil Oral Tablet 100 MG	Y
ADHD/ANTI- NARCOLEPSY/ANTIOBESITY/ANOREXIANTS	Stimulants - Misc.	Modafinil Oral Tablet 200 MG	Y
ADHD/ANTI- NARCOLEPSY/ANTIOBESITY/ANOREXIANTS	Stimulants - Misc.	Provigil Oral Tablet 100 MG	Y
ADHD/ANTI- NARCOLEPSY/ANTIOBESITY/ANOREXIANTS	Stimulants - Misc.	Provigil Oral Tablet 200 MG	Y
ANALGESICS - ANTIINFLAMMATORY	Interleukin-1 Receptor Antagonist (IL-1Ra)	Kineret Subcutaneous Solution Prefilled Syringe 100 MG/0.67ML	Y
ANTHELMINTICS	ANTHELMINTICS	Albenza Oral Tablet 200 MG	Y
ANTHELMINTICS	ANTHELMINTICS	Ivermectin Oral Tablet 3 MG	Y
ANTHELMINTICS	ANTHELMINTICS	Stromectol Oral Tablet 3 MG	Y
ANTIDOTES AND SPECIFIC ANTAGONISTS	Antidotes - Chelating Agents	Exjade Oral Tablet Soluble 125 MG	Y
ANTIDOTES AND SPECIFIC ANTAGONISTS	Antidotes - Chelating Agents	Exjade Oral Tablet Soluble 250 MG	Y
ANTIDOTES AND SPECIFIC ANTAGONISTS	Antidotes - Chelating Agents	Exjade Oral Tablet Soluble 500 MG	Y
ANTIDOTES AND SPECIFIC ANTAGONISTS	Antidotes - Chelating Agents	Jadenu Oral Tablet 90 MG	Y
ANTIDOTES AND SPECIFIC ANTAGONISTS	Antidotes - Chelating Agents	Jadenu Oral Tablet 180 MG	Y
ANTIDOTES AND SPECIFIC ANTAGONISTS	Antidotes - Chelating Agents	Jadenu Oral Tablet 360 MG	Y
ANTIEMETICS	Substance P/Neurokinin 1 (NK1) Receptor Antagonists	Aprepitant Oral Capsule 80 MG	Y

Therapeutic Category [Categoría Terapéutica]	Therapeutic Class [Clase Terapéutica]	Drug Description [Descripción de la Droga]	Preautorization [Preautorización] Y=Yes
ANTIEMETICS	Substance P/Neurokinin 1 (NK1) Receptor Antagonists	Aprepitant Oral Capsule 125 MG	Y
ANTIEMETICS	Substance P/Neurokinin 1 (NK1) Receptor Antagonists	Emend Oral Capsule 80 MG	Y
ANTIEMETICS	Substance P/Neurokinin 1 (NK1) Receptor Antagonists	Emend Oral Capsule 125 MG	Y
ANTIEMETICS	Substance P/Neurokinin 1 (NK1) Receptor Antagonists	Aprepitant Oral Capsule 40 MG	Y
ANTIEMETICS	Substance P/Neurokinin 1 (NK1) Receptor Antagonists	Emend Oral Capsule 40 MG	Y
ANTIEMETICS	Substance P/Neurokinin 1 (NK1) Receptor Antagonists	Emend Oral Capsule 80 & 125 MG	Y
ANTIEMETICS	Substance P/Neurokinin 1 (NK1) Receptor Antagonists	Emend Oral Suspension Reconstituted 125 MG	Y
ANTIEMETICS	Substance P/Neurokinin 1 (NK1) Receptor Antagonists	Aprepitant Oral Capsule 80 & 125 MG	Y
ANTI-INFECTIVE AGENTS - MISC.	Antiprotozoal Agents	Mepron Oral Suspension 750 MG/5ML	Y
ANTI-INFECTIVE AGENTS - MISC.	Antiprotozoal Agents	Atovaquone Oral Suspension 750 MG/5ML	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Alkylating Agents	Cyclophosphamide Oral Capsule 25 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Alkylating Agents	Cyclophosphamide Oral Capsule 50 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Antibiotics	Novantrone Intravenous Concentrate 20 MG/10ML	Y

Therapeutic Category [Categoría Terapéutica]	Therapeutic Class [Clase Terapéutica]	Drug Description [Descripción de la Droga]	Preautorization [Preautorización] Y=Yes
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Antibiotics	Mitoxantrone HCl Intravenous Concentrate 25 MG/12.5ML	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Antibiotics	Mitoxantrone HCl Intravenous Concentrate 20 MG/10ML	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Antibiotics	Mitoxantrone HCl Intravenous Concentrate 30 MG/15ML	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antimetabolites	Tabloid Oral Tablet 40 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic - Antibodies	Rituxan Intravenous Solution 100 MG/10ML	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic - Antibodies	Rituxan Intravenous Solution 500 MG/50ML	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic - Hedgehog Pathway Inhibitors	Erivedge Oral Capsule 150 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic - Hormonal and Related Agents	Xtandi Oral Capsule 40 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic - Hormonal and Related Agents	Lysodren Oral Tablet 500 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic - Hormonal and Related Agents	Fareston Oral Tablet 60 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Sutent Oral Capsule 37.5 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Votrient Oral Tablet 200 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Tykerb Oral Tablet 250 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Sutent Oral Capsule 12.5 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Sutent Oral Capsule 50 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Sutent Oral Capsule 25 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Tarceva Oral Tablet 25 MG	Y

Therapeutic Category [Categoría Terapéutica]	Therapeutic Class [Clase Terapéutica]	Drug Description [Descripción de la Droga]	Preautorization [Preautorización] Y=Yes
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Tarceva Oral Tablet 100 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Tarceva Oral Tablet 150 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Bosulif Oral Tablet 500 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Bosulif Oral Tablet 100 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Afinitor Disperz Oral Tablet Soluble 2 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Afinitor Disperz Oral Tablet Soluble 3 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Afinitor Disperz Oral Tablet Soluble 5 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Tafinlar Oral Capsule 50 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Tafinlar Oral Capsule 75 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Mekinist Oral Tablet 0.5 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Mekinist Oral Tablet 2 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Imbruvica Oral Capsule 140 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Zelboraf Oral Tablet 240 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Ibrance Oral Capsule 75 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Ibrance Oral Capsule 100 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Ibrance Oral Capsule 125 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Cotellic Oral Tablet 20 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Ninlaro Oral Capsule 2.3 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Ninlaro Oral Capsule 3 MG	Y
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	Antineoplastic Enzyme Inhibitors	Ninlaro Oral Capsule 4 MG	Y

Therapeutic Category [Categoría Terapéutica]	Therapeutic Class [Clase Terapéutica]	Drug Description [Descripción de la Droga]	Preautorization Preautorización] Y=Yes
ANTIPSYCHOTICS/ANTIMANIC AGENTS	Benzisoxazoles	Risperdal Consta Intramuscular Suspension Reconstituted 12.5 MG	Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS	Benzisoxazoles	Risperdal Consta Intramuscular Suspension Reconstituted 37.5 MG	Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS	Benzisoxazoles	Risperdal Consta Intramuscular Suspension Reconstituted 50 MG	Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS	Benzisoxazoles	Risperdal Consta Intramuscular Suspension Reconstituted 25 MG	Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS	Dibenzapines	Quetiapine Fumarate ER Oral Tablet Extended Release 24 Hour 200 MG	Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS	Dibenzapines	Quetiapine Fumarate ER Oral Tablet Extended Release 24 Hour 300 MG	Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS	Dibenzapines	Quetiapine Fumarate ER Oral Tablet Extended Release 24 Hour 400 MG	Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS	Dibenzapines	Quetiapine Fumarate ER Oral Tablet Extended Release 24 Hour 50 MG	Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS	Dibenzapines	Quetiapine Fumarate ER Oral Tablet Extended Release 24 Hour 150 MG	Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS	Dibenzapines	Clozaril Oral Tablet 100 MG	Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS	Dibenzapines	Clozaril Oral Tablet 25 MG	Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS	Dibenzapines	Clozapine Oral Tablet 100 MG	Y
ANTIPSYCHOTICS/ANTIMANIC AGENTS	Dibenzapines	Clozapine Oral Tablet 25 MG	Y
ANTIVIRALS	Hepatitis Agents	Hepsera Oral Tablet 10 MG	Y
ANTIVIRALS	Hepatitis Agents	Adefovir Dipivoxil Oral Tablet 10 MG	Y
ANTIVIRALS	Hepatitis Agents	Entecavir Oral Tablet 0.5 MG	Y

Therapeutic Category	Therapeutic Class	Drug Description	Preauthorization Y=Yes
ANTIVIRALS	Hepatitis Agents	Entecavir Oral Tablet 1 MG	Y
ANTIVIRALS	Hepatitis Agents	Baraclude Oral Tablet 0.5 MG	Y
ANTIVIRALS	Hepatitis Agents	Baraclude Oral Tablet 1 MG	Y
CORTICOSTEROIDS	Glucocorticosteroids	Entocort EC Oral Capsule Delayed Release Particles 3 MG	Y
CORTICOSTEROIDS	Glucocorticosteroids	Budesonide Oral Capsule Delayed Release Particles 3 MG	Y
DERMATOLOGICALS	Antipsoriatics	Tazorac External Gel 0.05 %	Y
DERMATOLOGICALS	Antipsoriatics	Tazorac External Gel 0.1 %	Y
DERMATOLOGICALS	Antipsoriatics	Tazorac External Cream 0.05 %	Y
DERMATOLOGICALS	Antipsoriatics	Tazorac External Cream 0.1 %	Y
ENDOCRINE AND METABOLIC AGENTS - MISC.	Bone Density Regulators	Forteo Subcutaneous Solution 600 MCG/2.4ML	Y
ENDOCRINE AND METABOLIC AGENTS - MISC.	Bone Density Regulators	Reclast Intravenous Solution 5 MG/100ML	Y
ENDOCRINE AND METABOLIC AGENTS - MISC.	Bone Density Regulators	Zoledronic Acid Intravenous Solution 5 MG/100ML	Y
ENDOCRINE AND METABOLIC AGENTS - MISC.	Bone Density Regulators	Pamidronate Disodium Intravenous Solution 30 MG/10ML	Y
ENDOCRINE AND METABOLIC AGENTS - MISC.	Bone Density Regulators	Pamidronate Disodium Intravenous Solution 90 MG/10ML	Y
ENDOCRINE AND METABOLIC AGENTS - MISC.	Bone Density Regulators	Pamidronate Disodium Intravenous Solution 6 MG/ML	Y
ENDOCRINE AND METABOLIC AGENTS - MISC.	Bone Density Regulators	Alendronate Sodium Oral Tablet 40 MG	Y
ENDOCRINE AND METABOLIC AGENTS - MISC.	Bone Density Regulators	Fosamax Oral Tablet 40 MG	Y
ENDOCRINE AND METABOLIC AGENTS - MISC.	Bone Density Regulators	Prolia Subcutaneous Solution 60 MG/ML	Y

Therapeutic Category [Categoría Terapéutica]	Therapeutic Class [Clase Terapéutica]	Drug Description [Descripción de la Droga]	Preautorization [Preautorización] Y=Yes
ENDOCRINE AND METABOLIC AGENTS - MISC.	Hormone Receptor Modulators	Raloxifene HCl Oral Tablet 60 MG	Y
ENDOCRINE AND METABOLIC AGENTS - MISC.	Hormone Receptor Modulators	Evista Oral Tablet 60 MG	Y
ENDOCRINE AND METABOLIC AGENTS - MISC.	Growth Hormone Receptor Antagonists	Somavert Subcutaneous Solution Reconstituted 10 MG	Y
ENDOCRINE AND METABOLIC AGENTS - MISC.	Growth Hormone Receptor Antagonists	Somavert Subcutaneous Solution Reconstituted 15 MG	Y
ENDOCRINE AND METABOLIC AGENTS - MISC.	Growth Hormone Receptor Antagonists	Somavert Subcutaneous Solution Reconstituted 20 MG	Y
ENDOCRINE AND METABOLIC AGENTS - MISC.	Growth Hormone Receptor Antagonists	Somavert Subcutaneous Solution Reconstituted 25 MG	Y
ENDOCRINE AND METABOLIC AGENTS - MISC.	Growth Hormone Receptor Antagonists	Somavert Subcutaneous Solution Reconstituted 30 MG	Y
HEMATOLOGICAL AGENTS - MISC.	Antihemophilic Products	Feiba NF Intravenous Solution Reconstituted	Y
HEMATOLOGICAL AGENTS - MISC.	Antihemophilic Products	Feiba VH Immuno Intravenous Solution Reconstituted	Y
HEMATOLOGICAL AGENTS - MISC.	Antihemophilic Products	Feiba Intravenous Solution Reconstituted	Y
HEMATOLOGICAL AGENTS - MISC.	Antihemophilic Products	Eloctate Intravenous Solution Reconstituted 250 UNIT	Y
HEMATOLOGICAL AGENTS - MISC.	Antihemophilic Products	Eloctate Intravenous Solution Reconstituted 500 UNIT	Y
HEMATOLOGICAL AGENTS - MISC.	Antihemophilic Products	Eloctate Intravenous Solution Reconstituted 750 UNIT	Y
HEMATOLOGICAL AGENTS - MISC.	Antihemophilic Products	Eloctate Intravenous Solution Reconstituted 1000 UNIT	Y
HEMATOLOGICAL AGENTS - MISC.	Antihemophilic Products	Eloctate Intravenous Solution Reconstituted 1500 UNIT	Y

Therapeutic Category	Therapeutic Class	Drug Description	Preautorization Y=Yes
HEMATOLOGICAL AGENTS - MISC.	Antihemophilic Products	Eloctate Intravenous Solution Reconstituted 2000 UNIT	Y
HEMATOLOGICAL AGENTS - MISC.	Antihemophilic Products	Eloctate Intravenous Solution Reconstituted 3000 UNIT	Y
HEMATOLOGICAL AGENTS - MISC.	Platelet Aggregation Inhibitors	Effient Oral Tablet 5 MG	Y
HEMATOLOGICAL AGENTS - MISC.	Platelet Aggregation Inhibitors	Effient Oral Tablet 10 MG	Y
MISCELLANEOUS THERAPEUTIC CLASSES	Immunosuppressive Agents	Zortress Oral Tablet 0.25 MG	Y
MISCELLANEOUS THERAPEUTIC CLASSES	Immunosuppressive Agents	Zortress Oral Tablet 0.75 MG	Y
MISCELLANEOUS THERAPEUTIC CLASSES	Immunosuppressive Agents	Zortress Oral Tablet 0.5 MG	Y
MISCELLANEOUS THERAPEUTIC CLASSES	Systemic Lupus Erythematosus Agents	Benlysta Intravenous Solution Reconstituted 120 MG	Y
MISCELLANEOUS THERAPEUTIC CLASSES	Systemic Lupus Erythematosus Agents	Benlysta Intravenous Solution Reconstituted 400 MG	Y
NEUROMUSCULAR AGENTS	Neuromuscular Blocking Agent - Neurotoxins	Botox Injection Solution Reconstituted 200 UNIT	Y
NEUROMUSCULAR AGENTS	Neuromuscular Blocking Agent - Neurotoxins	Botox Injection Solution Reconstituted 100 UNIT	Y
OPHTHALMIC AGENTS	Ophthalmic Steroids	Tobradex Ophthalmic Suspension 0.3-0.1 %	Y
OPHTHALMIC AGENTS	Ophthalmic Steroids	Tobramycin- Dexamethasone Ophthalmic Suspension 0.3-0.1 %	Y
OPHTHALMIC AGENTS	Prostaglandins - Ophthalmic	Travatan Z Ophthalmic Solution 0.004 %	Y
OPHTHALMIC AGENTS	Prostaglandins - Ophthalmic	Lumigan Ophthalmic Solution 0.01 %	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gammagard S/D Intravenous Solution Reconstituted 5 GM	Y

Therapeutic Category	Therapeutic Class	Drug Description	Preautorization Y=Yes
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gammagard S/D Intravenous Solution Reconstituted 10 GM	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gammagard S/D Less IgA Intravenous Solution Reconstituted 5 GM	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gammagard S/D Less IgA Intravenous Solution Reconstituted 10 GM	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gamunex-C Injection Solution 1 GM/10ML	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gamunex-C Injection Solution 2.5 GM/25ML	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gamunex-C Injection Solution 5 GM/50ML	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gamunex-C Injection Solution 20 GM/200ML	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gamunex-C Injection Solution 10 GM/100ML	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gammaked Injection Solution 1 GM/10ML	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gammaked Injection Solution 2.5 GM/25ML	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gammaked Injection Solution 5 GM/50ML	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gammaked Injection Solution 10 GM/100ML	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gammaked Injection Solution 20 GM/200ML	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gammagard Injection Solution 1 GM/10ML	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gammagard Injection Solution 2.5 GM/25ML	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gammagard Injection Solution 5 GM/50ML	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gammagard Injection Solution 10 GM/100ML	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gammagard Injection Solution 20 GM/200ML	Y
PASSIVE IMMUNIZING AND TREATMENT AGENTS	Immune Serums	Gammagard Injection Solution 30 GM/300ML	Y

Therapeutic Category [Categoría Terapéutica]	Therapeutic Class [Clase Terapéutica]	Drug Description [Descripción de la Droga]	Preautorization [Preautorización] Y=Yes
RESPIRATORY AGENTS - MISC.	Cystic Fibrosis Agents	Pulmozyme Inhalation Solution 1 MG/ML	Y
TETRACYCLINES	TETRACYCLINES	Tetracycline HCl Oral Capsule 250 MG	Y
TETRACYCLINES	TETRACYCLINES	Tetracycline HCl Oral Capsule 500 MG	Y
TETRACYCLINES	TETRACYCLINES	Demeclocycline HCl Oral Tablet 150 MG	Y
TETRACYCLINES	TETRACYCLINES	Demeclocycline HCl Oral Tablet 300 MG	Y
TETRACYCLINES	TETRACYCLINES	Declomycin Oral Tablet 300 MG	Y
VASOPRESSORS	Anaphylaxis Therapy Agents	Epinephrine Injection Solution Auto-injector 0.15 MG/0.3ML	Y
VASOPRESSORS	Anaphylaxis Therapy Agents	Epinephrine Injection Solution Auto-injector 0.15 MG/0.15ML	Y
VASOPRESSORS	Anaphylaxis Therapy Agents	Epinephrine Injection Solution Auto-injector 0.3 MG/0.3ML	Y

ASES

Puerto Rico Healthcare Insurance Administration

Integrated Emergency

Formulary (IEF)

2017

Formulary of Drugs Covered by

the Government Healthcare Plan (GHP)

Authorized by the P.R. Elections Commission CEE-SA-16-2732

	GOVERNMENT OF PUERTO RICO	Hon. Ricardo A. Rosselló Nevares
	Healthcare Insurance Administration	Governor
		Ms. Ángela M. Ávila Marrero Executive Director

May 1, 2017

TO ALL GOVERNMENT HEALTHCARE PLAN (GHP) PROVIDERS

Dear provider:

I am pleased to submit to you the Formulary of Drugs Covered by the GHP (FDC) for Physical and Mental Health, as well as its corresponding sub-formularies. The FDC supports healthcare under the new integrated services model of the Government Healthcare Plan, which has been in effect since April 1, 2015.

The Physical Health FDC includes: Dental, Nephrology, Ob-gyn, Oncology, Integrated Emergency Formulary, HIV-AIDS, and Sub-physical. Moreover, the Mental Health FDC also has a Sub-formulary. The Mental Health FDC will be used by contracted psychiatrists and by physicians contracted by facilities devoted to Mental Health treatment. The Mental Health Sub-formulary will be used by participating primary care physicians (PCPs) in Primary Care Medical Groups.

The drugs included in the FDC have been evaluated and approved by the Pharmacy and Therapeutics Committee of the Healthcare Insurance Administration (ASES, Spanish acronym) constituted by primary care physicians and clinical pharmacists. This committee meets periodically to evaluate the therapeutic classes and make recommendations based on clinical aspects. The FDC is a dynamic document that can undergo changes, of which you will be informed periodically by means of Regulatory Letters.

I urge you to keep this guide for future reference. It is also available on our webpage, www.asespr.org .

Cordially,

[signed]

Ángela M. Ávila Marrero

Executive Director


PO Box 195661, San Juan, PR 00919-5661 · Tel.: 787.474.3300 · Fax: 787.474.3348 · www.ases.pr.gov

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE

OF THE GOVERNMENT HEALTHCARE PLAN (GHP)

1.	Drug Formulary

The Healthcare Insurance Administration (ASES, Spanish acronym) is the agency responsible for establishing and reviewing the Formulary of Drugs Covered by the GHP (FDC) for Physical and Mental Health. For these purposes, ASES has established a Pharmacy and Therapeutics Committee that evaluates physical and mental health drugs. The Committee is constituted by healthcare professionals, including primary care physicians, psychiatrists, and licensed pharmacists. The Committee meets periodically to evaluate the various therapeutic classes and make recommendations to ASES for the drug formulary based on scientific evidence, clinical aspects, and a cost-effectiveness analysis.

The Formulary of Drugs Covered by the GHP (FDC) will serve as a guide in the provision of drugs under the prescription drug coverage. The purpose of the FDC is to improve, update, and procure a cost-effective use of drugs under the GHP coverage.

ASES designs and updates the Formulary of Drugs Covered by the GHP through its Pharmacy Program Administrator or PPA based on the most recent clinical evidence. Said formulary is the official formulary of the program from which drugs must be prescribed to GHP beneficiaries.

Non-formulary drugs may only be used in exceptional cases through the Exception Process that we will explain in point number 2.

2.	Exception Process

In the case of patients who need a drug that is not included in the FDC, healthcare service providers and, as applicable, insurance companies must use the process described below to obtain approval of the drug by exception. This procedure will consider the particular merits of each case, which may include:

Contraindication to the drug(s) included in the FDC;

History of a clinically significant adverse reaction to the drug(s) included in the FDC;

Evidence of therapeutic failure of all alternatives available in the FDC; and/or

Lack of a therapeutic alternative in the FDC.

This exception process requires a clinical justification that is duly documented by the service provider with the clinical reasons justifying the use of a non-formulary drug, which will be evaluated on a case-by-case basis by a clinical team at the insurance company(ies) contracted by ASES.

3.	Other Aspects of the Prescription Drug Coverage

The prescription drug coverage of the GHP establishes that using generic bioequivalent products as the first option is mandatory.

Insurance companies or the TPA (Third Party Administrator) and healthcare service providers will only process their prescription drug claims through the Pharmacy Benefit Manager or PBM contracted by ASES.

Page 13 of 38

ASES has an active process to continually review the prescription drug coverage in accordance with changes or advances in medical practice standards in relation to an illness or treatment area. It also evaluates new drugs to decide if they should be included. Because of the dynamic nature of this process, ASES may require that drugs be included in or excluded from the FDC at any time, taking the necessary measures to inform beneficiaries and medical providers about the changes to guarantee a transition process that will safeguard adequate access to services and maintain continuity of care.

No entity contracted by ASES or by healthcare companies or organizations (for example, primary care medical groups, independent providers, specialists, among others) may use a formulary other than the FDC or create an internal drug formulary different than the formularies established by ASES. Furthermore, they may not limit the drugs included in the ASES FDC in any way contrary to the provisions in the contract between ASES and the contracted entities or in this coverage. Insurance companies will be responsible for supervising their providers and employees with regard to their compliance with these provisions.

The maximum supply dispensed for acute conditions will cover a fifteen (15) day therapy. The treatment period may be extended, as applicable, when medically necessary.

The maximum supply dispensed for chronic conditions (maintenance drugs) will cover a thirty (30) day therapy with three refills or ninety (90) days, except at the start of the therapy when, at the physician’s discretion, a minimum of fifteen (15) days may be prescribed with the purpose of reevaluating adherence and tolerance. The Government Healthcare Plan has decided that one prescription and a maximum of five (5) refills will be covered. Drug prescriptions will be valid for twelve (12) months, except in the case of narcotics, which will be dispensed only one (1) time, without refills. Drugs requiring preauthorization (PA) will be approved for a maximum of six (6) months. Physicians must reevaluate the pharmacotherapy in terms of adherence, tolerance, and dosage within ninety (90) days after the maintenance drug has been prescribed. Changes in dosage will not require preauthorization. Changes in the drug(s) used may require preauthorization.

ASES requires the use of generic bioequivalent drugs approved by the Food and Drug Administration (FDA) coded as “AB” and those authorized under applicable local regulations in Puerto Rico.

The lack of appropriate bioequivalent drug inventories does not exempt providers from dispensing the prescribed drug or entail any additional payment by the beneficiary. As a general rule, generic bioequivalent drugs must be dispensed only as long as there is a generic bioequivalent for the corresponding brand-name drug, unless, in spite of the fact that there is a generic bioequivalent, ASES decides to cover the brand-name drug or both, in which case it will usually be managed by means of the exception mechanism.

Drug prescriptions will be filled by a pharmacy contracted by the PBM that is duly authorized under the law of the Commonwealth of Puerto Rico and has been freely chosen by the beneficiary.

The right to freedom of choice requires the availability of a pharmacy that is reasonably accessible to each insured. The PBM is the entity in charge of contracting the pharmacy network according to the terms specified by ASES.

Page 14 of 38

Prescription drugs must be delivered after the date and time when the beneficiary presents the prescription or when an electronic prescription is received at the pharmacy. Drugs must be dispensed within no more than 72 hours. Drugs requiring a PA must be approved within 72 hours, except for expedited PAs, which must be processed within 24 hours. If a drug is not available at the pharmacy, the insured must have the option of requesting the prescription to have it filled at another pharmacy; in the case of electronic prescriptions, the insured must contact his or her physician to have the prescription sent to another pharmacy of his or her choice.

4.	Emergency Rule

The products that appear in the Integrated Emergency Formulary (IEF) will be dispensed for five (5) business days, except as otherwise specified.

The same thing applies to analgesics, narcotics, combination drugs, and nonsteroidal anti-inflammatory drugs, which will also be dispensed in amounts sufficient for five (5) business days.

Beneficiaries who have not been admitted into a hospital institution must visit their primary care physician for continuity of treatment, including pharmacotherapy. We would like to remind you that the GHP model is a coordinated care plan. We also recommend that you verify that the products prescribed in an emergency room are included in the IEF.

If you have any questions about the prescription drug coverage, you may contact the insurance company contracted by ASES in your region and/or the Pharmacy Benefit Manager (PBM) contracted by ASES.

Page 15 of 38

INTEGRATED EMERGENCY FORMULARY

GOVERNMENT HEALTHCARE PLAN

FORMULARY OF DRUGS COVERED BY THE GHP (FDC)

2017

TABLE OF CONTENTS

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE OF THE GOVERNMENT HEALTHCARE PLAN		3
DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES		11
	MONTHLY NET COST RANGE	11
	GENERIC DRUGS	12
THERAPEUTIC CATEGORY		13
ANALGESICS		13
	Nonsteroidal Anti-Inflammatory Agents (NSAIDs)	13
	Short-Acting Opioid Analgesics	13
ANESTHETICS		14
	Local Anesthetics	14
ANTIANXIETY AGENTS		14
	Benzodiazepines	14
	Miscellaneous Anxiolytics	14
ANTIBACTERIALS		14
	First Generation Cephalosporins	14
	Macrolides	14
	Miscellaneous Antibacterials	15
	Penicillins	15
	Quinolones	16
	Second Generation Cephalosporins	16
	Sulfonamides	16
	Third Generation Cephalosporins	17
ANTICONVULSANTS		17
	Anticonvulsants	17

Page 16 of 38

INTEGRATED EMERGENCY FORMULARY

ANTIDEMENTIA AGENTS		18
	Cholinesterase Inhibitors	18
ANTIDEPRESSANTS		19
	Miscellaneous Antidepressants	19
ANTIDIABETIC AGENTS		19
	Alpha-Glucosidase Inhibitors	19
	Biguanides	19
	Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors	19
	Insulin Mixtures	19
	Insulin Sensitizing Agents	19
	Intermediate-Acting Insulins	19
	Short-Acting Insulins	19
	Sulfonylureas	20
ANTIEMETICS		20
	Miscellaneous Antiemetics	20
	Phenothiazines	20
ANTIGOUT AGENTS		20
	Antigout Agents	20
	Uricosurics	20
ANTIHYPERTENSIVES		20
	Alpha-Adrenergic Agonists	20
	Alpha-Adrenergic Blocking Agents	21
	Angiotensin II Receptor Blockers (ARB)	21
	Angiotensin-Converting Enzyme (ACE) Inhibitors	21
	Calcium Channel Blocking Agents	21
	Carbonic Anhydrase Inhibitors Diuretics	21
	Cardioselective Beta Blocking Agents	21
	Cardioselective Beta-Adrenergic Blocking Agents	22
	Loop Diuretics	22
	Nonselective Beta Blocking Agents	22
	Potassium-Sparing Diuretics	22

Page 17 of 38

INTEGRATED EMERGENCY FORMULARY

	Thiazide Diuretics	23
	Vasodilator Beta Blockers	23
	Vasodilators	23
ANTIMIGRAINE AGENTS		23
	Beta-Adrenergic Blocking Agents	23
ANTIMYASTHENIC AGENTS		23
	Parasympathomimetics	23
ANTIMYCOBACTERIALS		24
	Antituberculars	24
ANTIPARASITICS		24
	Antimalarials	24
ANTIPARKINSON AGENTS		24
	Anticholinergics	24
	Antiparkinson Dopaminergics	24
	Dopamine Precursors	25
ANTIPSYCHOTICS		25
	Atypical - Second Generation	25
	Typical - First Generation	26
ANTIVIRALS		26
	Anti-Cytomegalovirus (Cmv) Agents	26
	Antiherpetic Agents	26
	Anti-Influenza Agents	26
BENIGN PROSTATIC HYPERTROPHY AGENTS		26
	Alpha-Adrenergic Blocking Agents	26
BLOOD MODIFIERS		26
	Anticoagulants	26
	Colony Stimulating Factors	27
	Platelet Modifying Agents	27
CARDIOVASCULAR AGENTS		27
	Antiarrhythmics Class Ii	27
	Antiarrhythmics Type I-A	27

Page 18 of 38

INTEGRATED EMERGENCY FORMULARY

	Antiarrhythmics Type I-B	28
	Antiarrhythmics Type I-C	28
	Antiarrhythmics Type Iii	28
	Miscellaneous Cardiovascular Agents	28
	Vasodilators	28
DENTAL AND ORAL AGENTS		28
	Antifungals	28
DERMATOLOGICAL AGENTS		29
	Pediculicides and Scabicides	29
	Topical Antibiotics	29
DYSLIPIDEMICS		29
	Bile Acid Sequestrants	29
	Fibric Acid Derivatives	29
	Hmg-Coa Reductase Inhibitors	29
GASTROINTESTINAL AGENTS		29
	Histamine2 (H2) Receptor Antagonists	29
	Miscellaneous Gastrointestinal Agents	29
	Proton Pump Inhibitors	30
GENITOURINARY AGENTS		30
	Miscellaneous Genitourinary Agents	30
HORMONAL AGENTS		30
	Antithyroid Agents	30
	Calcimimetic Agents	30
	Dopamine Agonists	30
	Thyroid Hormones	30
IMMUNOSUPPRESSANTS		31
	Glucocorticosteroids	31
	Immune Globulins	31
INFLAMMATORY BOWEL DISEASE		31
	Aminosalicylates	31
	Sulfonamides	31

Page 19 of 38

INTEGRATED EMERGENCY FORMULARY

MINERALS & ELECTROLYTES		31
	Calcium Regulating Agents	31
MUSCLE RELAXANTS		31
	Antispasticity Agents	31
	Skeletal Muscle Relaxants	32
OPHTHALMIC AGENTS		32
	Antiglaucoma Agents	32
	Ophthalmic Antibiotics	32
	Ophthalmic Prostaglandins	32
	Ophthalmic Steroids	33
OTIC AGENTS		33
	Miscellaneous Otic Agents	33
	Otic Antibiotics	33
RESPIRATORY AGENTS		33
	Anticholinergic Bronchodilators	33
	Antileukotrienes	33
	Antitussive-Expectorant	33
	Inhaled Corticosteroids	33
	Sedating Histamine1 Blocking Agents	34
	Sympathomimetic Bronchodilators	34

Page 20 of 38

INTEGRATED EMERGENCY FORMULARY

DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES

The drugs that appear on the FDC are the drugs covered under the Government Healthcare Plan. These drugs are selected based on their safety profile, proven efficacy (cost-effectiveness), the existence of bioequivalent drugs, and cost of treatment. We suggest that physicians prescribe and pharmacists dispense only the drugs that appear in the FDC.

The example below illustrates the information provided for the drugs included in the FDC.

Drug Name	Net Cost	Tier	Reference Name	Requirements/ Limits
THERAPEUTIC CATEGORY
Therapeutic Class
ANALGESICS
Nonsteroidal Anti-Inflammatory Agents (NSAIDs)
ibuprofen 400 mg tab, 600 mg tab, 800 mg tab	1	Preferred	MOTRIN	QL = 5 days
indomethacin 25 mg cap, 50 mg cap	1	Non-preferred	INDOCIN	QL = 5 days
nabumetone 500 mg tab, 750 mg tab	1	Preferred	RELAFEN	QL = 5 days
naproxen 250 mg tab, 375 mg tab, 500 mg tab	1	Preferred	NAPROSYN	QL = 5 days
naproxen sodium 275 mg tab, 550 mg tab	1	Preferred	ANAPROX	QL = 5 days
salsalate 500 mg tab, 750 mg tab	1	Preferred	DISALCID	QL = 5 days
indomethacin er 75 mg cap er	2	Non- preferred	INDOCIN	QL = 5 days

For each drug included in the FDC, the First Column shows the name of the generic bioequivalent drug in lower-case letters if the drug is available in a generic version. If the drug is only available in its brand-name version, the brand name will appear in the First Column in upper-case letters.

The Second Column shows the Monthly Net Cost Range per Average Beneficiary (“Net Cost”). The Third Column shows the drug classification (tier): Preferred or Non-preferred. The Fourth Column shows the brand name only for reference, since the generic equivalent drug will always be dispensed if there is one. The Fifth Column shows the Reference Guides or Limits, as applicable.

MONTHLY NET COST RANGE

The monthly net cost range per average beneficiary (“Net Cost”) is included in the second column of the FDC to estimate the monthly net cost of the therapy to be prescribed, including any negotiated discount and comparing the product with other therapeutic alternatives available as per the indication. Said exercise compares the average cost of monthly therapy for thirty (30) days. The cost comparison is made based on all the products included in a therapeutic class (for example, the class of cardiovascular drugs). The net cost ranges next to each drug identify its average monthly cost and must be interpreted as follows:

Page 21 of 38

INTEGRATED EMERGENCY FORMULARY

1	less than $20	Least costly per month
2	$20 - $49
3	$50 - $99
4	$100 - $199
5	$200 - $349
6	$350 - $549
7	$550 - $799
8	$800 - $1,099
9	$1,100 - $1,499
10	$1,500 - $1,999
11	$2,000 - $2,499
12	$2,500 - $2,999
13	$3,000 - $3,499
14	$3,500 - $3,999
15	$4,000 - $4,499
16	$4,500 - $4,999
17	$5,000 - $5,499
18	$5,500 - $5,999
19	$6,000 - $6,499
20	$6,500 - $6,999
21	$7,000 - $7,499
22	$7,500 - $7,999
23	$8,000 - $8,499
24	$8,500 - $9,000
25	more than $9,000	Most costly per month

We recommend that you consider prescribing the drug with the lowest monthly net cost within each therapeutic category (the one with the lowest number in the scale from 1 to 25) when medically appropriate and when there are several clinically feasible alternatives for the beneficiary.

The net cost analysis is an ongoing exercise subject to constant changes. Net costs as published here are current as of the date of this edition of the FDC.

GENERIC DRUGS

Generic bioequivalent drugs are identified with lower-case letters. Certain generic bioequivalent drugs have a Maximum Allowable Cost (MAC List) to reimburse the pharmacies contracted in the network. Usually, this price covers the cost of acquiring the generic product, but not the brand-name product. The products selected for inclusion in the MAC List are those that are more frequently prescribed and have been approved by the Food and Drug Administration (FDA) for marketing.

Page 22 of 38

INTEGRATED EMERGENCY FORMULARY

Page 23 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Terapéutica]
ANALGESICS [ANALG ÉSICOS]
Nonsteroidal Anti-Inflammatory Agents (Nsaids) [ Anti-Inflamatorios No Esteroidales]
ibuprofen 400 mg tab, 600 mg tab, 800 mg tab	1	Preferred	MOTRIN	QL = 5 días
indomethacin 25 mg cap, 50 mg cap	1	Non-Preferred	INDOCIN	QL = 5 días
nabumetone 500 mg tab, 750 mg tab	1	Preferred	RELAFEN	QL = 5 días
naproxen 250 mg tab, 375 mg tab, 500 mg tab	1	Preferred	NAPROSYN	QL = 5 días
naproxen sodium 275 mg tab, 550 mg tab	1	Preferred	ANAPROX	QL = 5 días
salsalate 500 mg tab, 750 mg tab	1	Preferred	DISALCID	QL = 5 días
Short-Acting Opioid Analgesics [Analgésicos Opiodes De Corta Duración]
acetaminophen -codeine 120-12 mg/5ml soln, 300-15 mg tab, 300-30 mg tab, 300-60 mg tab	1	Preferred	TYLENOL- CODEINE	QL = 5 días
acetaminophen-codeine #2 300-15 mg tab	1	Preferred	TYLENOL- CODEINE	QL = 5 días
acetaminophen-codeine #3 300-30 mg tab	1	Preferred	TYLENOL- CODEINE	QL = 5 días
acetaminophen-codeine #4 300-60 mg tab	1	Preferred	TYLENOL- CODEINE	QL = 5 días
butalbital-apap-caffeine 50-325-40 mg tab	1	Preferred	FIORICET	QL = 5 días
tramadol hcl 50 mg tab	1	Preferred	ULTRAM	QL = 5 días
butalbital-apap-caffeine 50-325-40 mg cap	2	Preferred	FIORICET	QL = 5 días

• PA - Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL - Quantity Limit [Límite de Cantidad] • ST - Step Therapy [Terapia Escalonada] • AL - Age Limit [Límite de Edad] • Net Cost [Costo Neto] - Please refer to page #12 for monthly net cost range [Ver página #12 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]

Page 24 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
ANESTHETICS [ANESTÉSICOS]
Local Anesthetics [Anestésicos Locales]
lidocaine viscous 2 % mouth/throat soln	1	Preferred	XYLOCAINE	QL = 5 días
ANTIANXIETY AGENTS [AGENTES PARA LA ANXIEDAD]
Benzodiazepines [Benzodiazepinas]
clonazepam 0.5 mg tab, 1 mg tab, 2mg tab	1	Preferred	KLONOPIN	QL = 5 días
diazepam 10 mg tab, 2 mg tab, 5 mg tab	1	Preferred	VALIUM	QL = 5 días
lorazepam 0.5 mg tab, 1 mg tab	1	Preferred	ATIVAN	QL = 5 días
temazepam 15 mg cap, 30 mg cap	1	Preferred	RESTORIL	QL = 5 días
Miscellaneous Anxiolytics [Ansiolíticos Misceláneos]
hydroxyzine pamoate 100 mg cap, 25 mg cap, 50 mg cap	1	Preferred	VISTARIL	QL = 5 días
ANTIBACTERIALS [ANTIBACTERIANOS]
First Generation Cephalosporins [Cefalosporinas De Primera Generación]
cephalexin 125 mg/5ml susp, 250 mg cap, 500 mg cap	1	Preferred	KEFLEX	QL = 5 días
cefadroxil 250 mg/5ml susp	2	Non-Preferred	DURICEF	QL = 5 días, AL ≤ 12
cephalexin 250 mg/5ml susp	2	Preferred	KEFLEX	QL = 5 días
cefadroxil 500 mg/5ml susp	3	Non-Preferred	DURICEF	QL = 5 días, AL ≤ 12
Macrolides [Macrólidos]
azithromycin 250 mg tab, 500 mg tab	1	Preferred	ZITHROMAX	QL = 5 días
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab	2	Preferred	ZITHROMAX	QL = 5 días

Page 25 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
clarithromycin 125 mg/5ml susp, 250 mg tab, 500 mg tab	2	Preferred	BIAXIN	QL = 5 días
clarithromycin 250 mg/5ml susp	3	Preferred	BIAXIN	QL = 5 días
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab	3	Preferred	ERY-TAB	QL = 5 días
erythromycin ethylsuccinate 400 mg tab	3	Preferred	E.E.S.	QL = 5 días
ERYTHROCIN STEARATE 250 mg tab	4	Non-Preferred		QL = 5 días
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
clindamycin hcl 150 mg cap, 300 mg cap, 75 mg cap	1	Preferred	CLEOCIN	QL = 5 días
MACRODANTIN 25 mg cap	1	Preferred		QL = 5 días
metronidazole 250 mg tab, 500 mg tab	1	Preferred	FLAGYL	QL = 5 días
nitrofurantoin macrocrystal 50 mg cap	1	Preferred	MACRODANTIN	QL = 5 días
nitrofurantoin macrocrystal 100 mg cap	2	Preferred	MACRODANTIN	QL = 5 días
nitrofurantoin oral suspension 25 MG/5ML	6	Non-Preferred	FURADANTIN
nitrofurantoin monohyd macro 100 mg cap	2	Preferred	MACROBID	QL = 5 días
Penicillins [Penicilinas]
amoxicillin 125 mg/5ml susp, 200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab	1	Preferred	AMOXIL	QL = 5 días

Page 26 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 600-42.9 mg/5ml susp, 875-125 mg tab	1	Preferred	AUGMENTIN	QL = 5 días
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap	1	Preferred	PRINCIPEN	QL = 5 días
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab	1	Preferred	VEETIDS	QL = 5 días
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp	3	Preferred	AUGMENTIN	QL = 5 días
Quinolones [Quinolonas]
ciprofloxacin hcl 250 mg tab, 500 mg tab, 750 mg tab	1	Preferred	CIPRO	QL = 5 días
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab	1	Preferred	LEVAQUIN	QL = 5 días
ciprofloxacin 500 mg/5ml (10%) susp	3	Preferred	CIPRO	QL = 5 días
ciprofloxacin 250 mg/5ml (5%) susp	4	Preferred	CIPRO	QL = 5 días
Second Generation Cephalosporins [Cefalosporinas De Segunda Generación]
cefaclor 250 mg cap, 500 mg cap	2	Preferred	CECLOR	QL = 5 días
cefprozil 125 mg/5ml susp, 250 mg tab, 250 mg/5ml susp, 500 mg tab	2	Preferred	CEFZIL	QL = 5 días
Sulfonamides [Sulfonamidas]
sulfamethoxazole -tmp ds 800-160 mg tab	1	Preferred	SEPTRA	QL = 5 días

Page 27 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab	1	Preferred	SEPTRA	QL = 5 días
Third Generation Cephalosporins [Cefalosporinas De Tercera Generación]
cefdinir 125 mg/5ml susp, 300 mg cap	2	Preferred	OMNICEF	QL = 5 días
cefdinir 250 mg/5ml susp	3	Preferred	OMNICEF	QL = 5 días
ANTICONVULSANTS [ANTICONVULSIVANTES]
Anticonvulsants [Anticonvulsivantes]
carbamazepine 100 mg tab chew, 200 mg tab	1	Preferred	TEGRETOL	QL = 5 días
clonazepam 0.5 mg tab, 1 mg tab, 2mg tab	1	Preferred	KLONOPIN	QL = 5 días
divalproex sodium 125 mg tab dr, 250 mg tab dr, 500 mg tab dr	1	Preferred	DEPAKOTE	QL = 5 días
gabapentin 100 mg cap, 300 mg cap, 400 mg cap, 600 mg tab, 800 mg tab	1	Preferred	NEURONTIN	QL = 5 días
lamotrigine 100 mg tab, 150 mg tab, 200 mg tab, 25 mg tab	1	Preferred	LAMICTAL	QL = 5 días
lamotrigine chew tab 5 mg, 25 mg	3	Non-Preferred	LAMICTAL
levetiracetam 250 mg tab, 500 mg tab	1	Preferred	KEPPRA	QL = 5 días
levetiracetam er 24 hrs 500 mg tab, 750 mg	3	Non-Preferred	KEPPRA XR
oxcarbazepine 150 mg tab	1	Preferred	TRILEPTAL	QL = 5 días
phenobarbital 100 mg tab, 15 mg tab, 16.2 mg tab, 30 mg tab, 32.4 mg tab, 60 mg tab, 64.8 mg tab, 97.2 mg tab	1	Preferred	PHENOBARBITAL	QL = 5 días

Page 28 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
primidone 250 mg tab, 50 mg tab	1	Preferred	MYSOLINE	QL = 5 días
topiramate 100 mg tab, 200 mg tab, 25 mg tab, 50 mg tab	1	Preferred	TOPAMAX	QL = 5 días
valproic acid 250 mg cap, 250 mg/5ml soln, 250 mg/5ml syr	1	Preferred	DEPAKENE	QL = 5 días
zonisamide 50 mg cap	1	Preferred	ZONEGRAN	QL = 5 días
DILANTIN 30 mg cap	2	Preferred		QL = 5 días
levetiracetam 1000 mg tab, 750 mg tab	2	Preferred	KEPPRA	QL = 5 días
oxcarbazepine 300 mg tab, 600 mg tab	2	Preferred	TRILEPTAL	QL = 5 días
phenytoin 125 mg/5ml susp, 50 mg tab chew	2	Preferred	DILANTIN	QL = 5 días
phenytoin sodium extended 100 mg cap, 200 mg cap, 300 mg cap	2	Preferred	DILANTIN	QL = 5 días
zonisamide 100 mg cap, 25 mg cap	2	Preferred	ZONEGRAN	QL = 5 días
ethosuximide 250 mg cap, 250 mg/5ml soln	3	Preferred	ZARONTIN	QL = 5 días
phenobarbital 20 mg/5ml oral elix, 20 mg/5ml soln	3	Preferred	PHENOBARBITAL	QL = 5 días
ANTIDEMENTIA AGENTS [AGENTES ANTIDEMENCIA]
Cholinesterase Inhibitors [Inhibidores De Colinesterasa				]
donepezil hcl 10 mg tab, 5 mg tab	1	Preferred	ARICEPT	QL = 5 días
rivastigmine tartrate 1.5 mg cap, 3 mg cap, 4.5 mg cap, 6 mg cap	3	Preferred	EXELON	QL = 5 días

Page 29 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
ANTIDEPRESSANTS [ANTIDEPRESIVOS]
Miscellaneous Antidepressants [Antidepresivos Misceláneos]
trazodone hcl 100 mg tab, 150 mg tab, 50 mg tab	1	Preferred	DESYREL	QL = 5 días
Monoamine Oxidase (Mao) Inhibitors [Inhibidores De Mao]
selegiline hcl 5 mg tab	3	Non-Preferred	CARBEX	QL = 5 días
ANTIDIABETIC AGENTS [AGENTES ANTIDIABÉTICOS]
Alpha-Glucosidase Inhibitors [Inhibidores De Alfa Glucosidasa]
acarbose 100 mg tab, 25 mg tab, 50 mg tab	2	Preferred	PRECOSE	QL = 5 días
Biguanides [Biguanidas]
metformin hcl 1000 mg tab, 500 mg tab, 850 mg tab	1	Preferred	GLUCOPHAGE	QL = 5 días
Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors [Inhibidores De Dpp-4]
KOMBIGLYZE XR 2.5 -1000 mg tab er 24 hr, 5-1000 mg tab er 24 hr, 5-500 mg tab er 24 hr	3	Preferred		QL = 5 días, ST, P
ONGLYZA 2.5 mg tab, 5 mg tab	3	Preferred		QL = 5 días, ST, P
Insulin Mixtures [Mezclas De Insulinas]
HUMULIN 70/30 (70 -30) 100 unit/ml sc susp	2	Preferred		QL = 1 Vial 10 ML/30 días, P
Insulin Sensitizing Agents [Agentes Sensibilizantes De Insulin]
pioglitazone hcl 15 mg tab, 30 mg tab, 45 mg tab	1	Preferred	ACTOS	QL = 5 días
Intermediate-Acting Insulins [Insulinas De Duración Intermedia]
HUMULIN N 100 unit/ml sc susp	2	Preferred		QL = 1 Vial 10 ML/30 días, P
Short-Acting Insulins [Insulinas De Corta Duración]
HUMULIN R 100 unit/ml inj soln	2	Preferred		QL = 1 Vial 10 ML/30 días, P

Page 30 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Sulfonylureas [Sulfonilureas]
glimepiride 1 mg tab, 2 mg tab, 4 mg tab	1	Preferred	AMARYL		QL = 5 días
glipizide 10 mg tab, 5 mg tab	1	Preferred	GLUCOTROL		QL = 5 días
ANTIEMETICS [ANTIEMÉTICOS]
Miscellaneous Antiemetics [Antieméticos Misceláneos]
metoclopramide hcl 10 mg tab, 5 mg tab, 5 mg/ml inj soln	1	Preferred	REGLAN		QL = 5 días
ormir 50 mg cap	1	Preferred	BENADRYL		QL = 5 días
pharbedryl 50 mg cap	1	Preferred	BENADRYL		QL = 5 días
trimethobenzamide hcl 300 mg cap	1	Preferred	TIGAN		QL = 5 días
Phenothiazines [Fenotiazinas]
prochlorperazine maleate 10 mg tab, 5 mg tab	1	Preferred	COMPAZINE		QL = 5 días
prochlorperazine 25 mg rect supp	4	Non-Preferred	COMPAZINE		QL = 5 días
ANTIGOUT AGENTS [AGENTES ANTIGOTA]
Antigout Agents [Agentes Antigota]
allopurinol 100 mg tab, 300 mg tab	1	Preferred	ZYLOPRIM		QL = 5 días
colchicine 0.6 mg cap	3	Preferred	MITIGARE		PA
COLCRYS 0.6 mg tab	4	Non-Preferred			QL= 3 tab, 15días
Uricosurics [Uricosúricos]
probenecid 500 mg tab	1	Preferred	BENEMID		QL = 5 días
ANTIHYPERTENSIVES [ANTIHIPERTENSIVOS]
Alpha-Adrenergic Agonists [Agonistas Alfa Adrenérgico				s]
clonidine hcl 0.1 mg tab, 0.2 mg tab, 0.3 mg tab	1	Preferred	CATAPRESS		QL = 5 días
methyldopa 250 mg tab, 500 mg tab	1	Preferred	ALDOMET		QL = 5 días

Page 31 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
terazosin hcl 1 mg cap, 10 mg cap, 2 mg cap, 5 mg cap	1	Preferred	HYTRIN	QL = 5 días
Angiotensin II Receptor Blockers (ARB) [Antagonistas Del Receptor Angiotensina II]
losartan potassium 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	COZAAR	QL = 5 días
losartan potassium-hctz 100-12.5 mg tab, 100-25 mg tab, 50-12.5 mg tab	1	Preferred	HYZAAR	QL = 5 días
Angiotensin-Converting Enzyme (ACE) Inhibitors [Inhibidores De La Enzima Convertidora De Angiotensina]
lisinopril 10 mg tab, 2.5 mg tab, 20 mg tab, 30 mg tab, 40 mg tab, 5 mg tab	1	Preferred	ZESTRIL	QL = 5 días
lisinopril-hydrochlorothiazide 10-12.5 mg tab, 20-12.5 mg tab, 20-25 mg tab	1	Preferred	ZESTORETIC	QL = 5 días
Calcium Channel Blocking Agents [Bloqueadores De Canales De Calcio]
amlodipine besylate 10 mg tab, 2.5 mg tab, 5 mg tab	1	Preferred	NORVASC	QL = 5 días
diltiazem hcl 120 mg tab, 30 mg tab, 60 mg tab, 90 mg tab	1	Preferred	CARDIZEM	QL = 5 días
verapamil hcl 120 mg tab, 40 mg tab, 80 mg tab	1	Preferred	CALAN	QL = 5 días
Carbonic Anhydrase Inhibitors Diuretics [Diuréticos Inhibidores De Anhidrasa Carbónica]
acetazolamide 125 mg tab, 250 mg tab	3	Preferred	DIAMOX	QL = 5 días
Cardioselective Beta Blocking Agents [Bloqueadores Beta Cardioselectivos]
atenolol 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	TENORMIN	QL = 5 días

Page 32 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
metoprolol succinate er 25 mg tab er 24 hr, 50 mg tab er 24 hr	1	Preferred	LOPRESSOR	QL = 5 días
metoprolol tartrate 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	LOPRESSOR	QL = 5 días
metoprolol succinate er 100 mg tab er 24 hr, 200 mg tab er 24 hr	2	Preferred	LOPRESSOR	QL = 5 días
Cardioselective Beta-Adrenergic Blocking Agents [Bloqueadores Beta-Adrenérgicos Cardioselectivos]
atenolol -chlorthalidone 10025 mg tab, 50-25 mg tab	1	Preferred	TENORETIC	QL = 5 días
metoprolol- hydrochlorothiazide 50-25 mg tab	2	Non-Preferred	LOPRESSOR HCT	QL = 5 días
metoprololhydrochlorothiazide 100-25 mg tab, 100-50 mg tab	3	Non-Preferred	LOPRESSOR HCT	QL = 5 días
Loop Diuretics [Diuréticos Del Asa]
furosemide 10 mg/ml soln, 20 mg tab, 40 mg tab, 80 mg tab	1	Preferred	LASIX	QL = 5 días
Nonselective Beta Blocking Agents [Bloqueadores Beta No-Selectivos]
propranolol hcl 10 mg tab, 20 mg tab, 40 mg tab, 80 mg tab	1	Preferred	INDERAL	QL = 5 días
propranolol hcl 60 mg tab	2	Preferred	INDERAL	QL = 5 días
Potassium-Sparing Diuretics [Diuréticos Conservadores De Potasio]
spironolactone 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	ALDACTONE	QL = 5 días
triamterene-hctz 37.5-25 mg cap, 37.5-25 mg tab, 75-50 mg tab	1	Preferred	MAXZIDE	QL = 5 días

Page 33 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Thiazide Diuretics [Diuréticos Tiazidas]
chlorothiazide 250 mg tab, 500 mg tab	1	Preferred	DIURIL	QL = 5 días
chlorthalidone 25 mg tab, 50 mg tab	1	Non-Preferred	HYGROTON	QL = 5 días
DIURIL 250 mg/5ml susp	1	Preferred		QL = 5 días
hydrochlorothiazide 12.5 mg tab, 25 mg tab, 50 mg tab	1	Preferred	MICROZIDE	QL = 5 días
indapamide 1.25 mg tab, 2.5 mg tab	1	Preferred	LOZOL	QL = 5 días
metolazone 2.5 mg tab, 5 mg tab	1	Non-Preferred	ZAROXOLYN	QL = 5 días
chlorthalidone 100 mg tab	2	Non-Preferred	HYGROTON	QL = 5 días
metolazone 10 mg tab	2	Non-Preferred	ZAROXOLYN	QL = 5 días
Vasodilator Beta Blockers [Bloqueadores Beta Vasodilatadores]
carvedilol 12.5 mg tab, 25 mg tab, 3.125 mg tab, 6.25 mg tab	1	Preferred	COREG	QL = 5 días
Vasodilators [Vasodilatadores]
hydralazine hcl 10 mg tab, 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	APRESOLINE	QL = 5 días
ANTIMIGRAINE AGENTS [AGENTES ANTIMIGRAÑA]
Beta-Adrenergic Blocking Agents [Bloqueadores Beta Adrenérgicos]
divalproex sodium 125 mg tab dr, 250 mg tab dr, 500 mg tab dr	1	Preferred	DEPAKOTE	QL = 5 días
topiramate 100 mg tab, 200 mg tab, 25 mg tab, 50 mg tab	1	Preferred	TOPAMAX	QL = 5 días, ST
ANTIMYASTHENIC AGENTS [AGENTES ANTIMIASTÉNICOS]
Parasympathomimetics [Parasimpatomiméticos]
pyridostigmine bromide 60 mg tab	2	Preferred	MESTINON	QL = 5 días

Page 34 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name	Net Cost	Tier	Reference Name	Requirements/ Limits
MESTINON 60 mg/5ml syr	4	Non-Preferred		QL = 5 días
pyridostigmine bromide 180 mg tab er	6	Non-Preferred	MESTINON	QL = 5 días
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
Antituberculars [Antituberculosos]
CAPASTAT SULFATE 1 gm inj soln				QL = 5 días Puerto Rico Department Tuberculosis Control Program
cycloserine 250 mg cap			SEROMYCIN
RIFAMATE 150-300 mg cap
TRECATOR 250 mg tab
rifabutin 150 mg cap	7		MYCOBUTIN
isoniazid 100 mg tab, 300 mg tab	1	Preferred	ISONIAZID	QL = 5 días
rifampin 150 mg cap	1	Preferred	RIFADIN	QL = 5 días
ethambutol hcl 100 mg tab	2	Non-Preferred	MYAMBUTOL	QL = 5 días
pyrazinamide 500 mg tab	2	Non-Preferred	PYRAZINAMIDE	QL = 5 días
rifampin 300 mg cap	2	Preferred	RIFADIN	QL = 5 días
ethambutol hcl 400 mg tab	3	Non-Preferred	MYAMBUTOL	QL = 5 días
isoniazid 50 mg/5ml syr	5	Non-Preferred	ISONIAZID	QL = 5 días
ANTIPARASITICS [ANTIPARASITARIOS]
Antimalarials [Antimaláricos]
chloroquine phosphate 250 mg tab, 500 mg tab	1	Preferred	ARALEN	QL = 5 días
hydroxychloroquine sulfate 200 mg tab	1	Preferred	PLAQUENIL	QL = 5 días
quinine sulfate 324 mg cap	4	Preferred	QUININE	QL = 5 días
DARAPRIM 25 mg tab	7	Non-Preferred		PA, QL = 5 días
ANTIPARKINSON AGENTS [AGENTES ANTIPARKINSON]
Anticholinergics [Anticolinérgicos]
benztropine mesylate 0.5 mg tab, 1 mg tab, 2 mg tab	1	Preferred	COGENTIN	QL = 5 días
Antiparkinson Dopaminergics [Dopaminérgicos Antiparkinson]
amantadine hcl 50 mg/5ml syr	1	Preferred	SYMMETREL	QL = 5 días

Page 35 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name	Net Cost	Tier	Reference Name	Requirements/ Limits
pramipexole dihydrochloride 0.125 mg tab, 0.25 mg tab, 0.5 mg tab, 0.75 mg tab, 1 mg tab, 1.5 mg tab	1	Preferred	MIRAPEX	QL = 5 días
ropinirole hcl 0.25 mg tab, 0.5 mg tab, 1 mg tab, 3 mg tab, 4 mg tab, 5 mg tab	1	Preferred	REQUIP	QL = 5 días
ropinirole hcl 2 mg tab	2	Preferred	REQUIP	QL = 5 días
amantadine hcl 100 mg cap	3	Preferred	SYMMETREL	QL = 5 días
bromocriptine mesylate 2.5 mg tab	3	Preferred	PARLODEL	QL = 5 días
carbidopa-levodopaentacapone 18.75-75-200 mg tab	4	Non-Preferred	STALEVO	QL = 5 días
carbidopa-levodopaentacapone 12.5-50-200 mg tab, 25-100-200 mg tab, 31.25-125-200 mg tab, 37.5150-200 mg tab, 50-200-200 mg tab	5	Non-Preferred	STALEVO	QL = 5 días
Dopamine Precursors [Precursores De Dopamina]
carbidopa -levodopa 10-100 mg tab, 25-100 mg tab	1	Preferred	SINEMET	QL = 5 días
carbidopa-levodopa 25-250 mg tab	2	Preferred	SINEMET	QL = 5 días
carbidopa-levodopa er 25100 mg tab er, 50-200 mg tab er	2	Preferred	SINEMET CR	QL = 5 días
ANTIPSYCHOTICS [ANTIPSICÓTICOS]
Atypical - Second Generation [Atípicos - Segunda Generación]
risperidone 0.25 mg tab, 0.5 mg tab, 1 mg tab, 2 mg tab, 3 mg tab, 4 mg tab	1	Preferred	RISPERDAL	QL = 5 días

Page 36 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Typical - First Generation [Típicos - Primera Generación]
haloperidol 0.5 mg tab, 1 mg tab, 2 mg tab	1	Preferred	HALDOL	QL = 5 días
haloperidol 5 mg tab	2	Preferred	HALDOL	QL = 5 días
haloperidol 10 mg tab	3	Preferred	HALDOL	QL = 5 días
haloperidol 20 mg tab	4	Preferred	HALDOL	QL = 5 días
ANTIVIRALS [ANTIVIRALES]
Anti-Cytomegalovirus (Cmv) Agents [Agentes Anti-Citomegalovirus]
valganciclovir hcl 450 mg tab	13	Non-Preferred	VALCYTE	PA, QL = 5 días
Antiherpetic Agents [Agentes Antiherpéticos]
acyclovir 200 mg cap, 400 mg tab, 800 mg tab	1	Preferred	ZOVIRAX	QL = 5 días
acyclovir 200 mg/5ml susp	2	Preferred	ZOVIRAX	QL = 5 días
Anti-Influenza Agents [Agentes Antiinfluenza]
amantadine hcl 50 mg/5ml syr	1	Preferred	SYMMETREL	QL = 5 días
amantadine hcl 100 mg cap	3	Preferred	SYMMETREL	QL = 5 días
oseltamivir phosphate 30 mg cap, 45 mg cap, 75 mg	4	Preferred	TAMIFLU
TAMIFLU 6 mg/ ml susp	5	Non-Preferred
BENIGN PROSTATIC HYPERTROPHY AGENTS [AGENTES PARA HIPERTROFIA PROSTÁTICA BENIGNA]
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
terazosin hcl 1 mg cap, 10 mg cap, 2 mg cap, 5 mg cap	1	Preferred	HYTRIN	QL = 5 días
BLOOD MODIFIERS [MODIFICADORES DE LA SANGRE]
Anticoagulants [Anticoagulantes]
warfarin sodium 1 mg tab, 10 mg tab, 2 mg tab, 2.5 mg tab, 3 mg tab, 4 mg tab, 5 mg tab, 6 mg tab, 7.5 mg tab	1	Preferred	COUMADIN	QL = 5 días
heparin sodium (porcine) 1000 unit/ml inj soln	2	Preferred	HEPARIN	QL = 5 días

Page 37 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name	Net Cost	Tier	Reference Name	Requirements/ Limits
heparin sodium (porcine) 10000 unit/ml inj soln, 5000 unit/ml inj soln	3	Preferred	HEPARIN	QL = 5 días
heparin sodium (porcine) pf 5000 unit/0.5ml inj soln	3	Preferred	HEPARIN	QL = 5 días
heparin sodium (porcine) 2000 unit/ml iv soln	8	Preferred	HEPARIN	QL = 5 días
Colony Stimulating Factors [Estimulantes Mieloides]
NEULASTA 6 mg/0.6ml sc soln	12	Preferred		PA, QL = 5 días, P
NEULASTA DELIVERY KIT 6 mg/0.6ml sc soln	12	Preferred		PA, QL = 5 días, P
Platelet Modifying Agents [Modificadores De Plaquetas]
cilostazol 100 mg tab, 50 mg tab	1	Preferred	PLETAL	QL = 5 días
clopidogrel bisulfate 75 mg tab	1	Preferred	PLAVIX	QL = 5 días
CARDIOVASCULAR AGENTS [AGENTES CARDIOVASCULARES]
Antiarrhythmics Class Ii [Antiar rítmicos Clase Ii]
propranolol hcl 10 mg tab, 20 mg tab, 40 mg tab, 80 mg tab	1	Preferred	INDERAL	QL = 5 días
sotalol hcl 120 mg tab, 160 mg tab, 240 mg tab, 80 mg tab	1	Preferred	BETAPACE	QL = 5 días
sotalol hcl (af) 120 mg tab, 160 mg tab, 80 mg tab	1	Preferred	BETAPACE	QL = 5 días
propranolol hcl 60 mg tab	2	Preferred	INDERAL	QL = 5 días
Antiarrhythmics Type I-A [Antiarrítmicos Tipo I-A]
quinidine sulfate 200 mg tab, 300 mg tab	1	Preferred	QUINIDINE SULFATE	QL = 5 días
quinidine gluconate er 324 mg tab er	2	Preferred	QUINAGLUTE	QL = 5 días
quinidine sulfate er 300 mg tab er	2	Preferred	QUINIDINE SULFATE	QL = 5 días

Page 38 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Antiarrhythmics Type I-B [Antiarrítmicos Tipo I-B]
mexiletine hcl 150 mg cap	2	Preferred	MEXITIL	QL = 5 días
mexiletine hcl 200 mg cap	3	Preferred	MEXITIL	QL = 5 días
Antiarrhythmics Type I-C [Antiarrítmicos Tipo I-C]
flecainide acetate 100 mg tab, 50 mg tab	1	Preferred	TAMBOCOR	QL = 5 días
propafenone hcl 150 mg tab, 225 mg tab	1	Preferred	RYTHMOL	QL = 5 días
flecainide acetate 150 mg tab	2	Preferred	TAMBOCOR	QL = 5 días
propafenone hcl 300 mg tab	3	Preferred	RYTHMOL	QL = 5 días
Antiarrhythmics Type Iii [Antiarrítmicos Tipo Iii]
amiodarone hcl 200 mg tab	1	Preferred	CORDARONE	QL = 5 días
Miscellaneous Cardiovascular Agents [Agentes Cardiovasculares Misceláneos]
digoxin 125 mcg tab, 250 mcg tab	2	Preferred	LANOXIN	QL = 5 días
Vasodilators [Vasodilatadores]
isosorbide mononitrate 10 mg tab, 20 mg tab	1	Preferred	ISORDIL	QL = 5 días
isosorbide mononitrate er 120 mg tab er 24 hr, 30 mg tab er 24 hr, 60 mg tab er 24 hr	1	Preferred	IMDUR	QL = 5 días
NITROSTAT 0.3 mg tab subl, 0.4 mg tab subl, 0.6 mg tab subl	1	Preferred		QL = 5 días
DENTAL AND ORAL AGENTS [AGENTES DENTALES Y ORALES]
Antifungals [Antifungales]
clotrimazole 10 mg mouth/throat lozenge, 10 mg mouth/throat troche	1	Preferred	MYCELEX	QL = 5 días
nystatin 100000 unit/ml mouth/throat susp, 100000 unit/ml crm	1	Preferred	NYSTATIN	QL = 5 días

Page 39 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
DERMATOLOGICAL AGENTS [AGENTES DERMATOLÓGICOS]
Pediculicides And Scabicides [Pediculicidas Y Escabicidas]
permethrin 5 % crm	3	Preferred	ELIMITE	QL = 5 días
Topical Antibiotics [Antibióticos Tópicos]
mupirocin 2 % oint	1	Preferred	BACTROBAN	QL = 5 días
silver sulfadiazine 1 % crm	1	Preferred	SILVADENE	QL = 5 días
terbinafine 1% crm	1	Preferred	LAMISIL	OTC, QL = 5días
DYSLIPIDEMICS [DISLIPIDÉMICOS]
Bile Acid Sequestrants [Secuestradores De Ácidos Biliares]
cholestyramine 4 gm pckt, 4 gm/dose oral pwdr	3	Preferred	QUESTRAN	QL = 5 días
cholestyramine light 4 gm pckt, 4 gm/dose oral pwdr	3	Preferred	QUESTRAN	QL = 5 días
Fibric Acid Derivatives [Derivados De Ácido Fíbrico]
gemfibrozil 600 mg tab	1	Preferred	LOPID	QL = 5 días
Hmg-Coa Reductase Inhibitors [Inhibidores De La Hmg-Coa Reductasa]
atorvastatin calcium 10 mg tab, 20 mg tab, 40 mg tab, 80 mg tab	1	Preferred	LIPITOR	QL = 5 días
simvastatin 10 mg tab, 20 mg tab, 40 mg tab, 5 mg tab	1	Preferred	ZOCOR	QL = 5 días
GASTROINTESTINAL AGENTS [AGENTES GASTROINTESTINALES]
Histamine2 (H2) Receptor Antagonists [Antagonistas Del Receptor De H2]
famotidine 20 mg tab, 40 mg tab	1	Preferred	PEPCID	QL = 5 días
ranitidine hcl 15 mg/ml syr, 150 mg/10ml syr, 300 mg tab, 75 mg/5ml syr	1	Preferred	ZANTAC	QL = 5 días
Miscellaneous Gastrointestinal Agents [Agentes Gastrointestinales Misceláneos]
ursodiol 300 mg cap	2	Preferred	ACTIGALL	PA, QL = 5 días

Page 40 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Proton Pump Inhibitors [Inhibidores De La Bomba De Protones]
omeprazole 10 mg cap dr, 20 mg cap dr, 40 mg cap dr	1	Preferred	PRILOSEC	QL=180 caps/ 365 días
GENITOURINARY AGENTS [AGENTES GENITOURINARIOS]
Miscellaneous Genitourinary Agents [Agentes Genitourinarios Misceláneos]
phenazopyridine hcl 100 mg tab, 200 mg tab	1	Preferred	PYRIDIUM	QL = 3 días
HORMONAL AGENTS [AGENTES HORMONALES]
Antithyroid Agents [Agentes Antitiroide]
methimazole 10 mg tab, 5 mg tab	1	Preferred	TAPAZOLE	QL = 5 días
propylthiouracil 50 mg tab	2	Preferred	PROPYLTHIOURA CIL	QL = 5 días
Calcimimetic Agents [Agentes Calcimiméticos]
SENSIPAR 30 mg tab	7	Preferred		PA, QL = 5 días
SENSIPAR 60 mg tab	9	Preferred		PA, QL = 5 días
SENSIPAR 90 mg tab	10	Preferred		PA, QL = 5 días
Dopamine Agonists [Agonistas De Dopamina]
bromocriptine mesylate 2.5 mg tab	3	Preferred	PARLODEL	QL = 5 días
Thyroid Hormones [Hormona Tiroidea]
SYNTHROID 100 mcg tab, 112 mcg tab, 125 mcg tab, 137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab	1	Preferred		QL = 5 días, P

Page 41 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
Glucocorticosteroids [Glucocorticoides]
dexamethasone 0.5 mg tab, 0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab	1	Preferred	DECADRON	QL = 5 días
methylprednisolone 32 mg tab, 4 mg tab	1	Preferred	MEDROL	QL = 5 días
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab	1	Preferred	DELTASONE	QL = 5 días
prednisone (pak) 10 mg tab, 5 mg tab	1	Preferred	DELTASONE	QL = 5 días
methylprednisolone 16 mg tab, 8 mg tab	2	Preferred	MEDROL	QL = 5 días
Immune Globulins [Immunoglobulinas]
RHOGAM ultra-filtered plus im soln 1500 unit	4	Preferred
INFLAMMATORY BOWEL DISEASE [ENFERMEDAD INFLAMATORIA INTESTINAL]
Aminosalicylates [Aminosalicilatos]
DELZICOL 400 mg cap dr	5	Preferred		QL = 5 días, P
ASACOL HD 800 mg tab dr	6	Preferred		QL = 5 días, P
Sulfonamides [Sulfonamidas]
sulfasalazine 500 mg tab, 500 mg tab dr	1	Preferred	AZULFIDINE	QL = 5 días
MINERALS & ELECTROLYTES [MINERALES Y ELECTROLITOS]
Calcium Regulating Agents [Agentes Reguladores De Calcio]
vitamin d 400 unit cap	1	Preferred	VITAMIN D	QL = 5 días
MUSCLE RELAXANTS [RELAJANTES MUSCULARES]
Antispasticity Agents [Agentes Antiespasticidad]
baclofen 10 mg tab, 20 mg tab	1	Preferred	LIORESAL	QL = 5 días

Page 42 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
dantrolene sodium 25 mg cap, 50 mg cap	2	Preferred	DANTRIUM	QL = 5 días
dantrolene sodium 100 mg cap	3	Preferred	DANTRIUM	QL = 5 días
Skeletal Muscle Relaxants [Relajantes Musculoesqueletales]
cyclobenzaprine hcl 10 mg tab	1	Preferred	FLEXERIL	QL = 5 días
OPHTHALMIC AGENTS [AGENTES OFTÁLMICOS]
Antiglaucoma Agents [Agentes Antiglaucoma]
brimonidine tartrate 0.2 % ophth soln	1	Preferred	ALPHAGAN	QL = 1 Frasco 5 ML/15 días
dorzolamide hcl 2 % ophth soln	1	Preferred	TRUSOPT	QL = Frasco 10 ML/30 días
levobunolol hcl 0.5 % ophth soln	1	Preferred	BETAGAN	QL = 1 Frasco 5 ML/25 días
levobunolol hcl 0.25 % ophth soln	1	Preferred	BETAGAN	QL = 1 Frasco 5 ML/15 días
timolol maleate 0.5 % ophth soln	1	Preferred	TIMOPTIC	QL = 1 Frasco 5 ML/30 días
dorzolamide hcl-timolol mal ophth sol 22.3-6.8 mg/ml	1	Preferred	COSOPT	QL = 1 Frasco 5 ML/30 días
timolol maleate 0.25 % ophth soln	1	Preferred	TIMOPTIC	QL = 1 Frasco 5 ML/25 días
betaxolol hcl 0.5 % ophth soln	2	Non-Preferred	BETOPTIC	QL = 1 Frasco 5 ML/15 días
Ophthalmic Antibiotics [Antibióticos Oftálmicos]
gentamicin sulfate 0.3 % ophth oint	1	Preferred	GARAMYCIN	QL = 1 Tubo 3.5 GM/5 días
gentamicin sulfate 0.3 % ophth soln	1	Preferred	GARAMYCIN	QL = 1 Frasco 5 ML/5 días
tobramycin 0.3 % ophth soln	1	Preferred	TOBREX	QL = 1 Frasco 5 ML/5 días
Ophthalmic Prostaglandins [Prostaglandinas Oftálmicas]
latanoprost 0.005 % ophth soln	1	Preferred	XALATAN	QL = 1 Frasco/25 días

Page 43 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Ophthalmic Steroids [Esteroides Oftálmicos]
neomycin -polymyxindexamethasone 3.5-100000.1 ophth oint, 3.5-100000.1 ophth susp	1	Preferred	MAXITROL	QL = 1 Frasco 5 ML/5 días
prednisolone acetate 1 % ophth susp	2	Preferred	PRED FORTE	QL = 1 Frasco 5 ML/5 días
OTIC AGENTS [AGENTES OTICOS]
Miscellaneous Otic Agents [Agentes Oticos Misceláneos]
acetic acid 2 % otic soln	2	Preferred	VOSOL	QL = 1 Frasco 15 ML/10 días
Otic Antibiotics [Antibióticos Oticos]
neomycin -polymyxin-hc 1 % otic soln, 3.5-10000-1 otic soln, 3.5-10000-1 otic susp	2	Preferred	CORTISPORIN	QL = 1 Frasco 10 ML/10 días
RESPIRATORY AGENTS [AGENTES RESPIRATORIOS]
Anticholinergic Bronchodilators [Broncodilatadores Anticolinérgicos]
ipratropium bromide 0.02 % inh soln	1	Non-Preferred	ATROVENT	QL = 5 días
Antileukotrienes [Antileukotrienos]
montelukast sodium 10 mg tab, 4 mg tab chew, 5 mg tab chew 1 Preferred SINGULAIR QL = 5 días
Antitussive-Expectorant [Expectorantes Antitusivos]
benzonatate 100 mg cap	1	Preferred	TESSALON	QL = 5 días
guaifenesin-codeine 100-10 mg/5ml soln	1	Preferred	CHERATUSSIN	QL = 5 días
Inhaled Corticosteroids [Corticosteroides Inhalados]
FLOVENT DISKUS 100 mcg/blist inh aer pwdr, 250 mcg/blist inh aer pwdr, 50 mcg/blist inh aer pwdr	3	Preferred		QL = 1 Inh 60 EA/30 días, P

Page 44 of 38

INTEGRATED EMERGENCY FORMULARY

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
FLOVENT HFA 110 mcg/act inh aer	3	Preferred		QL = 1 Inh 12 EA/30 días, P
FLOVENT HFA 44 mcg/act inh aer	3	Preferred		QL = 1 Inh 10.6 EA/30 días, P
budesonide 0.25 mg/2ml inh susp, 0.5 mg/2ml inh susp, 1mg/2ml inh susp	4	Non-Preferred	PULMICORT	AL </=12
budesonide 1mg/2ml inh susp	8	Non-Preferred	PULMICORT	AL </=12
FLOVENT HFA 220 mcg/act inh aer	4	Preferred		QL = 1 Inh 12 EA/30 días, P
Sedating Histamine1 Blocking Agents [Sedantes Bloqueadores Histamine1]
promethazine hcl 12.5 mg tab, 25 mg tab, 50 mg tab, 6.25 mg/5ml soln, 6.25 mg/5ml syr	1	Preferred	PHENERGAN	QL = 5 días
Sympathomimetic Bronchodilators [Broncodilatadores Simpatomiméticos]
albuterol sulfate (2.5 mg/3ml) 0.083% inh neb soln, (5 mg/ml) 0.5% inh neb soln, 2 mg/5ml syr	1	Dl	ALBUTEROL	QL = 5 días
terbutaline sulfate 2.5 mg tab, 5 mg tab	1	Preferred	BRETHINE	QL = 5 días
VENTOLIN HFA 108 (90 base) mcg/act inh aer	1	Preferred		QL = 1 Inh 18 EA/30 días, P

Page 45 of 38

A
acarbose	19
acetaminophen-codeine	13
acetaminophen-codeine #2	13
acetaminophen-codeine #3	13
acetaminophen-codeine #4	13
acetazolamide	21
acetic acid	33
acyclovir	26
albuterol sulfate	34
allopurinol .	20
amantadine hcl	24, 25, 26
amiodarone hcl	28
amlodipine besylate	21
amoxicillin	15
amoxicillin-pot clavulanate	16
ampicillin	16
ASACOL HD	31
atenolol	21
atenolol-chlorthalidone	22
atorvastatin calcium	29
azithromycin	14
B
baclofen	31
benzonatate	33
benztropine mesylate	24
betaxolol hcl	32
brimonidine tartrate	32
bromocriptine mesylate	25, 30
budesonide	34
butalbital-apap-caffeine	13
C
CAPASTAT SULFATE	24
carbamazepine	17
carbidopa-levodopa	25
carbidopa-levodopa er	25
carbidopa-levodopa-entacapone	25
carvedilol	23
cefaclor	16
cefadroxil	14
cefdinir	17
cefprozil	16

cephalexin	14
chloroquine phosphate	24
chlorothiazide	23
chlorthalidone	23
cholestyramine	29
cholestyramine light	29
cilostazol	27
ciprofloxacin	16
ciprofloxacin hcl	16
clarithromycin	15
clindamycin hcl	15
clonazepam	14, 17
clonidine hcl	20
clopidogrel bisulfate	27
clotrimazole	28
colchicine	20
COLCRYS	20
cyclobenzaprine hcl	32
cycloserine	24
D
dantrolene sodium	32
DARAPRIM	24
DELZICOL	31
dexamethasone	31
diazepam	14
digoxin	28
DILANTIN	18
diltiazem hcl	21
DIURIL	23
divalproex sodium	17, 23
donepezil hcl	18
dorzolamide hcl	32
E
ERYTHROCIN STEARATE	15
erythromycin base	15
erythromycin ethylsuccinate	15
ethambutol hcl	24
ethosuximide	18 F
famotidine	29
flecainide acetate	28
FLOVENT DISKUS	33
FLOVENT HFA	34

Page 46 of 38

furosemide	22
G
gabapentin	17
gemfibrozil	29
gentamicin sulfate	32
glimepiride	20
glipizide	20
guaifenesin-codeine	33
H
haloperidol	26
heparin sodium (porcine)	26, 27
heparin sodium (porcine) pf	27
HUMULIN 70/30	19
HUMULIN N	19
HUMULIN R	19
hydralazine hcl	23
hydrochlorothiazide	23
hydroxychloroquine sulfate	24
hydroxyzine pamoate	14
I
ibuprofen	13
indapamide	23
indomethacin	13
ipratropium bromide	33
isoniazid	24
isosorbide mononitrate	28
isosorbide mononitrate er	. 28
K
KOMBIGLYZE XR	19
L
lamotrigine	17
lamotrigine chew tab	17
latanoprost	32
levetiracetam	17, 18
levetiracetam er 24 hrs	17
levobunolol hcl	32
levofloxacin	16
lidocaine viscous	14
lisinopril	21
lisinopril-hydrochlorothiazide	21
lorazepam	14
losartan potassium	21
losartan potassium-hctz	21

M
MACRODANTIN	15
MESTINON	24
metformin hcl	19
methimazole	30
methyldopa	20
methylprednisolone	31
metoclopramide hcl	20
metolazone	23
metoprolol succinate er	22
metoprolol tartrate	22
metoprolol-hydrochlorothiazide	22
metronidazole	15
mexiletine hcl	28
montelukast sodium	33
mupirocin	29
N
nabumetone	13
naproxen	13
naproxen sodium	13
neomycin-polymyxin-dexamethasone	33
neomycin-polymyxin-hc	33
NEULASTA	27
NEULASTA DELIVERY KIT	27
nitrofurantoin macrocrystal	15
nitrofurantoin monohyd macro	15
nitrofurantoin oral suspension	15
NITROSTAT	28
nystatin	28
O
omeprazole	30
ONGLYZA	19
ormir	20
oseltamivir phosphate	26
oxcarbazepine	17, 18
P
penicillin v potassium	16
permethrin	29
pharbedryl	20
phenazopyridine hcl	30
phenobarbital	17, 18
phenytoin	18
phenytoin sodium extended	18

Page 47 of 38

pioglitazone hcl	19
pramipexole dihydrochloride	25
prednisolone acetate	33
prednisone	31
prednisone (pak)	31
primidone	18
probenecid	20
prochlorperazine	20
prochlorperazine maleate	20
promethazine hcl	34
propafenone hcl	28
propranolol hcl	22, 27
propylthiouracil	30
pyrazinamide	24
pyridostigmine	24
pyridostigmine bromide	23
Q
quinidine gluconate er	27
quinidine sulfate	27
quinidine sulfate er	27
quinine sulfate	24
R
ranitidine hcl	29
RHOGAM	31
RHOGAM ultra-filtered plus im soln 1500 unit	31
rifabutin	24
RIFAMATE	24
rifampin	24
risperidone	25
rivastigmine tartrate	18
ropinirole hcl	25
S
salsalate	13
selegiline hcl	19
SENSIPAR	30
silver sulfadiazine	29
simvastatin	29
sotalol hcl	27
sotalol hcl (af)	27
spironolactone	22

sulfamethoxazole-tmp ds	16
sulfamethoxazole-trimethoprim	17
sulfasalazine	31
SYNTHROID	30
T
TAMIFLU	26
temazepam	14
terazosin hcl	21, 26
terbutaline sulfate	34
timolol maleate	32
tobramycin	32
topiramate	18, 23
tramadol hcl	13
trazodone hcl	19
TRECATOR	24
triamterene-hctz	22
trimethobenzamide hcl	20
U
ursodiol	29
V
valganciclovir hcl	26
valproic acid	18
VENTOLIN HFA	34
verapamil hcl	21
vitamin d	31
W
warfarin sodium	26
Z
zonisamide	18

Page 48 of 38

ASES

Puerto Rico Healthcare Insurance Administration

Dental

2017

Formulary of Drugs Covered by

the Government Healthcare Plan (GHP)

Authorized by the P.R. Elections Commission CEE-SA-16-2732

Page 49 of 38

		GOVERNMENT OF PUERTO RICO	Hon. Ricardo A. Rosselló Nevares
		Healthcare Insurance Administration	Governor
			Ms. Ángela M. Ávila Marrero Executive Director

May 1, 2017

TO ALL GOVERNMENT HEALTHCARE PLAN (GHP) PROVIDERS

Dear provider:

I urge you to keep this guide for future reference. It is also available on our webpage, www.asespr.org .

Cordially,

[signed]

Ángela M. Ávila Marrero

Executive Director


PO Box 195661, San Juan, PR 00919-5661 · Tel.: 787.474.3300 · Fax: 787.474.3348 · www.ases.pr.gov

Page 50 of 38

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE

OF THE GOVERNMENT HEALTHCARE PLAN (GHP)

1.	Drug Formulary

Non-formulary drugs may only be used in exceptional cases through the Exception Process that we will explain in point number 2.

2.	Exception Process

Contraindication to the drug(s) included in the FDC;

History of a clinically significant adverse reaction to the drug(s) included in the FDC;

Evidence of therapeutic failure of all alternatives available in the FDC; and/or

Lack of a therapeutic alternative in the FDC.

3.	Other Aspects of the Prescription Drug Coverage

The prescription drug coverage of the GHP establishes that using generic bioequivalent products as the first option is mandatory.

Page 51 of 12

The maximum supply dispensed for acute conditions will cover a fifteen (15) day therapy. The treatment period may be extended, as applicable, when medically necessary.

ASES requires the use of generic bioequivalent drugs approved by the Food and Drug Administration (FDA) coded as “AB” and those authorized under applicable local regulations in Puerto Rico.

Drug prescriptions will be filled by a pharmacy contracted by the PBM that is duly authorized under the law of the Commonwealth of Puerto Rico and has been freely chosen by the beneficiary.

Page 52 of 12

4.	Emergency Rule

The products that appear in the Integrated Emergency Formulary (IEF) will be dispensed for five (5) business days, except as otherwise specified.

The same thing applies to analgesics, narcotics, combination drugs, and nonsteroidal anti-inflammatory drugs, which will also be dispensed in amounts sufficient for five (5) business days.

If you have any questions about the prescription drug coverage, you may contact the insurance company contracted by ASES in your region and/or the Pharmacy Benefit Manager (PBM) contracted by ASES.

Page 53 of 12

DENTAL

GOVERNMENT HEALTHCARE PLAN

FORMULARY OF DRUGS COVERED BY THE GHP (FDC)

2017

TABLE OF CONTENTS

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE OF THE GOVERNMENT HEALTHCARE PLAN		3
DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES		7
	MONTHLY NET COST RANGE	7
	GENERIC DRUGS	8
ANALGESICS		9
	Nonsteroidal Anti-Inflammatory Agents (Nsaids)	9
	Short-Acting Opioid Analgesics	9
ANTIBACTERIALS		9
	First Generation Cephalosporins	9
	Macrolides	9
	Miscellaneous Antibacterials	10
	Penicillins	10

Page 54 of 12

DENTAL

DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES

The example below illustrates the information provided for the drugs included in the FDC.

Drug Name	Net Cost	Tier	Reference Name	Requirements/ Limits
THERAPEUTIC CATEGORY
Therapeutic Class
ANALGESICS
Nonsteroidal Anti-Inflammatory Agents (Nsaids)
ibuprofen 400 mg tab, 600 mg tab, 800 mg tab	1	Preferred	MOTRIN
naproxen 250 mg tab, 375 mg tab, 500 mg tab	1	Preferred	NAPROSYN
naproxen dr 375 mg tab dr, 500 mg tab dr	1	Preferred	NAPROSYN
naproxen sodium 275 mg tab, 550 mg tab	1	Preferred	ANAPROX

MONTHLY NET COST RANGE

Page 55 of 12

DENTAL

1	less than $20	Least costly per month
2	$20 - $49
3	$50 - $99
4	$100 - $199
5	$200 - $349
6	$350 - $549
7	$550 - $799
8	$800 - $1,099
9	$1,100 - $1,499
10	$1,500 - $1,999
11	$2,000 - $2,499
12	$2,500 - $2,999
13	$3,000 - $3,499
14	$3,500 - $3,999
15	$4,000 - $4,499
16	$4,500 - $4,999
17	$5,000 - $5,499
18	$5,500 - $5,999
19	$6,000 - $6,499
20	$6,500 - $6,999
21	$7,000 - $7,499
22	$7,500 - $7,999
23	$8,000 - $8,499
24	$8,500 - $9,000
25	more than $9,000	Most costly per month

The net cost analysis is an ongoing exercise subject to constant changes. Net costs as published here are current as of the date of this edition of the FDC.

GENERIC DRUGS

Page 56 of 12

DENTAL

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Terapéutica]
ANALGESICS [ANALGÉSICOS]
Nonsteroidal Anti-Inflammatory Agents (Nsaids) [Anti-Inflamatorios No Esteroidales]
ibuprofen 400 mg tab, 600 mg tab, 800 mg tab	1	Preferred	MOTRIN	QL=7 días
naproxen 250 mg tab, 375 mg tab, 500 mg tab	1	Preferred	NAPROSYN	QL=7 días
naproxen dr 375 mg tab dr, 500 mg tab dr	1	Preferred	NAPROSYN	QL=7 días
Short-Acting Opioid Analgesics [Analgésicos Opiodes De Corta Duración]
acetaminophen -codeine 120-12 mg/5ml soln, 300-15 mg tab, 300-30 mg tab, 300- 60 mg tab	1	Preferred	TYLENOL- CODEINE	QL=7 días
acetaminophen-codeine #2 300-15 mg tab	1	Preferred	TYLENOL- CODEINE	QL=7 días
acetaminophen-codeine #3 300-30 mg tab	1	Preferred	TYLENOL- CODEINE	QL=7 días
acetaminophen-codeine #4 300-60 mg tab	1	Preferred	TYLENOL- CODEINE	QL=7 días
hydrocodone- acetaminophen 10-325 mg tab, 5-325 mg tab, 7.5-325 mg tab	1	Preferred	VICODIN	QL=7 días
ANTIBACTERIALS [ANTIBACTERIANOS]
First Generation Cephalosporins [Cefalosporinas De Primera Generación]
cephalexin 125 mg/5ml susp, 250 mg cap, 500 mg cap	1	Preferred	KEFLEX
cefadroxil 250 mg/5ml susp	2	Non-Preferred	DURICEF	AL ≤ 12 años
cephalexin 250 mg/5ml susp	2	Preferred	KEFLEX
cefadroxil 500 mg/5ml susp	3	Non-Preferred	DURICEF	AL ≤ 12 años
Macrolides [Macrólidos]
ERY -TAB 500 mg tab dr	3	Preferred

•

PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 7 for monthly net cost range [Ver página 7 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Página 9 de 12

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab	3	Preferred	ERY-TAB
erythromycin ethylsuccinate 400 mg tab	3	Preferred	E.E.S.
ERYTHROCIN STEARATE 250 mg tab	4	Non-Preferred
E.E.S. GRANULES 200 mg/5ml susp	5	Preferred
ERYPED 200 200 mg/5ml susp	5	Preferred
ERYPED 400 400 mg/5ml susp	6	Preferred
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
clindamycin hcl 150 mg cap, 300 mg cap, 75 mg cap	1	Preferred	CLEOCIN
Penicillins [Penicilinas]
amoxicillin 125 mg/5ml susp, 200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab	1	Preferred	AMOXIL
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap	1	Preferred	PRINCIPEN
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab	1	Preferred	VEETIDS
			naproxen d Página 10 de 12 Revisado 5/12/2017

ASES

Puerto Rico Healthcare Insurance Administration

Nephrology

2017

Formulary of Drugs Covered by

the Government Healthcare Plan (GHP)

Authorized by the P.R. Elections Commission CEE-SA-16-2732

		GOVERNMENT OF PUERTO RICO		Hon. Ricardo A. Rosselló Nevares Governor Ms. Ángela M. Ávila Marrero Executive Director
		Healthcare Insurance Administration

May 1, 2017

TO ALL GOVERNMENT HEALTHCARE PLAN (GHP) PROVIDERS

Dear provider:

I urge you to keep this guide for future reference. It is also available on our webpage, www.asespr.org .

Cordially,

[signed]

Ángela M. Ávila Marrero

Executive Director




PO Box 195661, San Juan, PR 00919-5661 · Tel.: 787.474.3300 · Fax: 787.474.3348 · www.ases.pr.gov

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE

OF THE GOVERNMENT HEALTHCARE PLAN (GHP)

1.	Drug Formulary

Non-formulary drugs may only be used in exceptional cases through the Exception Process that we will explain in point number 2.

2.	Exception Process

Contraindication to the drug(s) included in the FDC;

History of a clinically significant adverse reaction to the drug(s) included in the FDC;

Evidence of therapeutic failure of all alternatives available in the FDC; and/or

Lack of a therapeutic alternative in the FDC.

3.	Other Aspects of the Prescription Drug Coverage

The prescription drug coverage of the GHP establishes that using generic bioequivalent products as the first option is mandatory.

Page 61 of 25

The maximum supply dispensed for acute conditions will cover a fifteen (15) day therapy. The treatment period may be extended, as applicable, when medically necessary.

ASES requires the use of generic bioequivalent drugs approved by the Food and Drug Administration (FDA) coded as “AB” and those authorized under applicable local regulations in Puerto Rico.

Page 62 of 25

Drug prescriptions will be filled by a pharmacy contracted by the PBM that is duly authorized under the law of the Commonwealth of Puerto Rico and has been freely chosen by the beneficiary.

4.	Emergency Rule

The products that appear in the Integrated Emergency Formulary (IEF) will be dispensed for five (5) business days, except as otherwise specified.

The same thing applies to analgesics, narcotics, combination drugs, and nonsteroidal anti-inflammatory drugs, which will also be dispensed in amounts sufficient for five (5) business days.

If you have any questions about the prescription drug coverage, you may contact the insurance company contracted by ASES in your region and/or the Pharmacy Benefit Manager (PBM) contracted by ASES.

Page 63 of 25

GOVERNMENT HEALTHCARE PLAN

FORMULARY OF DRUGS COVERED BY THE GHP (FDC)

2017

TABLE OF CONTENTS

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE OF THE GOVERNMENT HEALTHCARE PLAN		3
DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES		9
	MONTHLY NET COST RANGE	9
	GENERIC DRUGS	10
ANALGESICS		11
	Nonsteroidal Anti-Inflammatory Agents (Nsaids)	11
ANTIBACTERIALS		11
	First Generation Cephalosporins	11
	Macrolides	11
	Penicillins	12
	Quinolones	12
	Second Generation Cephalosporins	13
	Sulfonamides	13
	Third Generation Cephalosporins	13
ANTIDIABETIC AGENTS		13
	Alpha-Glucosidase Inhibitors	13
	Biguanides	13
	Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors	13
	Insulin Mixtures	13
	Insulin Sensitizing Agents	14
	Intermediate-Acting Insulins	14
	Long-Acting Insulins	14
	Rapid-Acting Insulins	14
	Short-Acting Insulins	14
	Sulfonylureas	14

Page 64 of 25

ANTIEMETICS		14
	Miscellaneous Antiemetics	14
ANTIHYPERTENSIVES		15
	Alpha-Adrenergic Blocking Agents	15
	Angiotensin-Converting Enzyme (Ace) Inhibitors	15
	Calcium Channel Blocking Agents	15
	Cardioselective Beta Blocking Agents	16
	Cardioselective Beta-Adrenergic Blocking Agents	16
	Loop Diuretics	17
	Nonselective Beta Blocking Agents	17
	Nonselective Beta-Adrenergic Blocking Agents	17
	Thiazide Diuretics	17
	Vasodilator Beta Blockers	17
BENIGN PROSTATIC HYPERTROPHY AGENTS		17
	Alpha 1-Adrenoceptor Antagonists	17
BLOOD MODIFIERS		18
	Cobalamins	18
	Erythropoiesis-Stimulating Agents	18
	Folates	18
	Iron	19
CHEMOTHERAPIES		19
	Antineoplastic Progestins	19
DIABETES SUPPLIES		19
	Needles & Syringes	19
DYSLIPIDEMICS		19
	Bile Acid Sequestrants	19
	Fibric Acid Derivatives	19
	Hmg Coa Reductase Inhibitors	19

Page 65 of 25

GASTROINTESTINAL AGENTS		19
	Histamine2 (H2) Receptor Antagonists	19
GENITOURINARY AGENTS		20
	Phosphate Binder Agents	20

HORMONAL AGENTS		20
	Calcimimetics	20
	Mineralocorticoids	20
	Vasopressin Analogs	20
IMMUNOSUPPRESSANTS		20
	Cyclosporine Analogs	20
	Glucocorticosteroids	21
	Organ Transplant Agents	21
MINERALS & ELECTROLYTES		22
	Calcium Regulating Agents	22
	Electrolytes/Minerals Replacement	22
	Potassium Removing Resins	22

Page 66 of 25

DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES

The example below illustrates the information provided for the drugs included in the FDC.

Drug Name	Net Cost	Tier	Reference Name	Requirements/ Limits
THERAPEUTIC CATEGORY
Therapeutic Class
ANALGESICS
Nonsteroidal Anti-Inflammatory Agents (NSAIDs)
indomethacin 25 mg cap, 50 mg cap	1	Non-preferred	INDOCIN
indomethacin er 75 mg cap er	2	Non- preferred	INDOCIN
ANTIBACTERIALS
First Generation Cephalosporins
cephalexin 125 mg/5 ml susp, 250 mg cap, 500 mg cap	1	Preferred	KEFLEX
cefadroxil 250 mg/5 ml susp	2	Non-preferred	DURICEF	AL ≤ 12 years
cephalexin 250 mg/5 ml susp	2		KEFLEX
cefadroxil 500 mg/5 ml susp	3	Non-preferred	DURICEF	AL ≤ 12 years

MONTHLY NET COST RANGE

Page 67 of 25

1	less than $20	Least costly per month
2	$20 - $49
3	$50 - $99
4	$100 - $199
5	$200 - $349
6	$350 - $549
7	$550 - $799
8	$800 - $1,099
9	$1,100 - $1,499
10	$1,500 - $1,999
11	$2,000 - $2,499
12	$2,500 - $2,999
13	$3,000 - $3,499
14	$3,500 - $3,999
15	$4,000 - $4,499
16	$4,500 - $4,999
17	$5,000 - $5,499
18	$5,500 - $5,999
19	$6,000 - $6,499
20	$6,500 - $6,999
21	$7,000 - $7,499
22	$7,500 - $7,999
23	$8,000 - $8,499
24	$8,500 - $9,000
25	more than $9,000	Most costly per month

The net cost analysis is an ongoing exercise subject to constant changes. Net costs as published here are current as of the date of this edition of the FDC.

GENERIC DRUGS

Page 68 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Te rapéutica]
ANALGESICS [ANALGÉ SICOS]
Nonsteroidal Anti-Inflammatory Agents (Nsaids) [Anti-Inflamatorios No Esteroidales]
indomethacin 25 mg cap, 50 mg cap	1	Non-Preferred	INDOCIN
ANTIBACTERIALS [ANTIBACTERIANOS]
First Generation Cephalosporins [Cefalosporinas De Primera Generación]
cephalexin 125 mg/5ml susp, 250 mg cap, 500 mg cap	1	Preferred	KEFLEX
cefadroxil 250 mg/5ml susp	2	Non-Preferred	DURICEF	AL ≤ 12 años
cephalexin 250 mg/5ml susp	2		KEFLEX
cefadroxil 500 mg/5ml susp	3	Non-Preferred	DURICEF	AL≤ 12 años
Macrolides [Macrólidos]
azithromycin 250 mg tab, 500 mg tab	1	Preferred	ZITHROMAX
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab	2	Preferred	ZITHROMAX
clarithromycin 125 mg/5ml susp, 250 mg tab, 500 mg tab	2	Preferred	BIAXIN
clarithromycin 250 mg/5ml susp	3	Preferred	BIAXIN
ERY-TAB 500 mg tab dr	3	Preferred
XI ycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab	3	Preferred	ERY-TAB
erythromycin ethylsuccinate 400 mg tab	3	Preferred	E.E.S.
ERYTHROCIN STEARATE 250 mg tab	4	Non-Preferred
E.E.S. GRANULES 200 mg/5ml susp	5	Preferred
ERYPED 200 200 mg/5ml susp	5	Preferred

Page 69 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
ERYPED 400 400 mg/5ml susp	6	Preferred
Penicillins [Penicilinas]
amoxicillin 125 mg/5ml susp, 200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab	1	Preferred	AMOXIL
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 875-125 mg tab	1	Preferred	AUGMENTIN
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap	1	Preferred	PRINCIPEN
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab	1	Preferred	VEETIDS
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp	3	Preferred	AUGMENTIN
BICILLIN L-A 600000 unit/ml im susp	3	Non-Preferred
penicillin g procaine 600000 unit/ml im susp	3	Non-Preferred	BICILLIN LA
BICILLIN L-A 1200000 unit/2ml im susp	4	Non-Preferred
BICILLIN L-A 2400000 unit/4ml im susp	5	Non-Preferred
Quinolones [Quinolonas]
ciprofloxacin hcl 250 mg tab, 500 mg tab, 750 mg tab	1	Preferred	CIPRO
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab	1	Preferred	LEVAQUIN
ciprofloxacin 500 mg/5ml (10%) susp	3	Preferred	CIPRO

Page 70 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
ciprofloxacin 250 mg/5ml (5%) susp	4	Preferred	CIPRO
Second Generation Cephalosporins [Cefalosporinas De Segunda Generación]
cefaclor 250 mg cap, 500 mg cap	2	Preferred	CECLOR
cefprozil 125 mg/5ml susp, 250 mg tab, 250 mg/5ml susp, 500 mg tab	2	Preferred	CEFZIL
Sulfonamides [Sulfonamidas]
sulfamethoxazole -tmp ds 800-160 mg tab	1	Preferred	SEPTRA
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab	1	Preferred	SEPTRA
Third Generation Cephalosporins [Cefalosporinas De Tercera Generación]
cefdinir 125 mg/5ml susp, 300 mg cap	2	Preferred	OMNICEF
cefdinir 250 mg/5ml susp	3	Preferred	OMNICEF
ANTIDIABETIC AGENTS [AGENTES ANTIDIABÉTICOS]
Alpha-Glucosidase Inhibitors [Inhibidores De Alfa Glucosidasa]
acarbose 100 mg tab, 25 mg tab, 50 mg tab	2	Preferred	PRECOSE
Biguanides [Biguanidas]
metformin hcl 1000 mg tab, 500 mg tab, 850 mg tab	1	Preferred	GLUCOPHAGE
metformin hcl er 500 mg tab er 24 hr, 750 mg tab er 24 hr	1	Preferred	GLUCOPHAGE XR
Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors [Inhibidores De Dpp-4]
KOMBIGLYZE XR 2.5 -1000 mg tab er 24 hr, 5-1000 mg tab er 24 hr, 5-500 mg tab er 24 hr	3	Preferred		ST, P
ONGLYZA 2.5 mg tab, 5 mg tab	3	Preferred		ST, P
Insulin Mixtures [Mezclas De Insulinas]
HUMULIN 70/30 (70 -30) 100 unit/ml sc susp	2	Preferred		P

Page 71 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
HUMALOG MIX 75/25 (7525) 100 unit/ml sc susp	3	Preferred		P
HUMALOG MIX 50/50 (5050) 100 unit/ml sc susp	4	Preferred		P
Insulin Sensitizing Agents [Agentes Sensibilizantes De Insulin]
pioglitazone hcl 15 mg tab, 30 mg tab, 45 mg tab	1	Preferred	ACTOS
Intermediate-Acting Insulins [Insulinas De Duración Intermedia]
HUMULIN N 100 unit/ml sc susp	2	Preferred		P
Long-Acting Insulins [Insulinas De Larga Duración]
LANTUS SOLOSTAR 100 unit/ml subcutaneous solution pen-injector	2	Preferred		P
LANTUS 100 unit/ml sc soln	3	Preferred		P
Rapid-Acting Insulins [Insulinas De Rápida Duración]
HUMALOG 100 unit/ml subcutaneous solution cartridge	2	Preferred		P
HUMALOG 100 unit/ml sc soln	3	Preferred		P
Short-Acting Insulins [Insulinas De Corta Duración]
HUMULIN R 100 unit/ml inj soln	2	Preferred		P
Sulfonylureas [Sulfonilureas]
glimepiride 1 mg tab, 2 mg tab, 4 mg tab	1	Preferred	AMARYL
glipizide 10 mg tab, 5 mg tab	1	Preferred	GLUCOTROL
ANTIEMETICS [ANTIEMÉTICOS]
Miscellaneous Antiemetics [Antieméticos Misceláneos]
metoclopramide hcl 10 mg tab, 10 mg/10ml soln, 5 mg tab, 5 mg/5ml soln, 5 mg/ml inj soln	1	Preferred	REGLAN

Page 72 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
ANTIHYPERTENSIVES [ANTIHIPERTENSIVOS]
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
terazosin hcl 1 mg cap, 10 mg cap, 2 mg cap, 5 mg cap	1	Preferred	HYTRIN
Angiotensin II Receptor Blockers (Arb) [Antagonistas Del Receptor Angiotensina II]
losartan potassium 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	COZAAR
losartan potassium-hctz 100-12.5 mg tab, 100-25 mg tab, 50-12.5 mg tab	1	Preferred	HYZAAR
Angiotensin-Converting Enzyme (Ace) Inhibitors [Inhibidores De La Enzima Convertidora De Angiotensin]
fosinopril sodium 10 mg tab, 20 mg tab, 40 mg tab	1	Preferred	MONOPRIL
lisinopril 10 mg tab, 2.5 mg tab, 20 mg tab, 30 mg tab, 40 mg tab, 5 mg tab	1	Preferred	ZESTRIL
lisinopril-hydrochlorothiazide 10-12.5 mg tab, 20-12.5 mg tab, 20-25 mg tab	1	Preferred	ZESTORETIC
Calcium Channel Blocking Agents [Bloqueadores De Canales De Calcio]
amlodipine besylate 10 mg tab, 2.5 mg tab, 5 mg tab	1	Preferred	NORVASC
diltiazem hcl 120 mg tab, 30 mg tab, 60 mg tab, 90 mg tab	1	Preferred	CARDIZEM
diltiazem hcl er 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr	1	Preferred	DILACOR XR
diltiazem hcl er beads 120 mg cap er 24 hr	1	Preferred	TIAZAC
diltiazem hcl er coated beads 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr	1	Preferred	CARDIZEM CD
dilt-xr 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr	1	Preferred	DILACOR XR

Page 73 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
nifedipine er osmotic 30 mg tab er 24 hr	1	Preferred	PROCARDIA XL
verapamil hcl 120 mg tab, 40 mg tab, 80 mg tab	1	Preferred	CALAN
verapamil hcl er 120 mg tab er, 180 mg tab er, 240 mg tab er	1	Preferred	CALAN SR
diltiazem hcl er beads 180 mg cap er 24 hr, 240 mg cap er 24 hr, 300 mg cap er 24 hr, 360 mg cap er 24 hr	2	Preferred	TIAZAC
diltiazem hcl er coated beads 300 mg cap er 24 hr	2	Preferred	CARDIZEM CD
nifedipine er osmotic 60 mg tab er 24 hr, 90 mg tab er 24 hr	2	Preferred	PROCARDIA XL
Cardioselective Beta Blocking Agents [Bloqueadores Beta Cardioselectivos]
atenolol 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	TENORMIN
metoprolol succinate er 25 mg tab er 24 hr, 50 mg tab er 24 hr	1	Preferred	LOPRESSOR
metoprolol tartrate 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	LOPRESSOR
metoprolol succinate er 100 mg tab er 24 hr, 200 mg tab er 24 hr	2	Preferred	LOPRESSOR
Cardioselective Beta-Adrenergic Blocking Agents [Bloqueadores Beta-Adrenérgicos Cardioselectivos]
atenolol -chlorthalidone 10025 mg tab, 50-25 mg tab	1	Preferred	TENORETIC
metoprolol- hydrochlorothiazide 50-25 mg tab	2	Non-Preferred	LOPRESSOR HCT
metoprololhydrochlorothiazide 100-25 mg tab, 100-50 mg tab	3	Non-Preferred	LOPRESSOR HCT

Page 74 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
Loop Diuretics [Diuréticos Del Asa]
bumetanide 0.5 mg tab, 1 mg tab, 2 mg tab	1	Non-Preferred	BUMEX
furosemide 10 mg/ml soln, 20 mg tab, 40 mg tab, 80 mg tab	1	Preferred	LASIX
Nonselective Beta Blocking Agents [Bloqueadores Beta No-Selectivos]
propranolol hcl 10 mg tab, 20 mg tab, 20 mg/5ml soln, 40 mg tab, 40 mg/5ml soln, 80 mg tab	1	Preferred	INDERAL
propranolol hcl 60 mg tab	2	Preferred	INDERAL
Nonselective Beta-Adrenergic Blocking Agents [Bloqueadores Beta-Adrenérgicos No- Selectivos]
Thiazide Diuretics [Diuréticos Tiazidas]
chlorothiazide 250 mg tab, 500 mg tab	1	Preferred	DIURIL
chlorthalidone 25 mg tab, 50 mg tab	1	Non-Preferred	HYGROTON
DIURIL 250 mg/5ml susp	1	Preferred
hydrochlorothiazide 25 mg tab, 50 mg tab	1	Preferred	MICROZIDE
metolazone 2.5 mg tab, 5 mg tab	1	Non-Preferred	ZAROXOLYN
chlorthalidone 100 mg tab	2	Non-Preferred	HYGROTON
metolazone 10 mg tab	2	Non-Preferred	ZAROXOLYN
Vasodilator Beta Blockers [Bloqueadores Beta Vasodilatadores]
carvedilol 12.5 mg tab, 25 mg tab, 3.125 mg tab, 6.25 mg tab	1	Preferred	COREG
BENIGN PROSTATIC HYPERTROPHY AGENTS [AGENTES PARA HIPERTROFIA PROSTÁTICA BENIGNA]
Alpha 1-Adrenoceptor Antagonists [Bloqueadores Alfa1-Adrenérgicos]
tamsulosin hcl 0.4 mg cap	1	Preferred	FLOMAX

Page 75 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
BLOOD MODIFIERS [MODIFICADORES DE LA SANGRE]
Cobalamins [Cobalaminas]
cyanocobalamin 1000 mcg/ml inj soln	1	Preferred	VIT B-12
Erythropoiesis-Stimulating Agents [Agentes Estimulantes De Eritropoiesis]
ARANESP (ALBUMIN FREE) 100 mcg/0.5ml inj soln	1	Preferred		PA, P
PROCRIT 2000 unit/ml inj soln, 3000 unit/ml inj soln, 4000 unit/ml inj soln	5	Preferred		PA, P
ARANESP (ALBUMIN FREE) 25 mcg/0.42ml inj soln, 25 mcg/ml inj soln	6	Preferred		PA, P
PROCRIT 10000 unit/ml inj soln	6	Preferred		PA, P
ARANESP (ALBUMIN FREE) 40 mcg/0.4ml inj soln	7	Preferred		PA, P
ARANESP (ALBUMIN FREE) 40 mcg/ml inj soln, 60 mcg/ml inj soln	8	Preferred		PA, P
ARANESP (ALBUMIN FREE) 150 mcg/0.75ml inj soln, 200 mcg/0.4ml inj soln, 200 mcg/ml inj soln, 300 mcg/0.6ml inj soln, 300 mcg/ml inj soln, 500 mcg/ml inj soln, 60 mcg/0.3ml inj soln	9	Preferred		PA, P
PROCRIT 20000 unit/ml inj soln	9	Preferred		PA, P
ARANESP (ALBUMIN FREE) 100 mcg/ml inj soln	11	Preferred		PA, P
PROCRIT 40000 unit/ml inj soln	11	Preferred		PA, P
Folates [Folatos]
folic acid 1 mg tab, 400 mcg tab, 800 mcg tab	1	Preferred	FOLIC ACID	OTC

Page 76 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
Iron [Hierro]
iron 325 (65 fe) mg tab	1	Preferred	IRON
DEXFERRUM 50 mg/ml inj soln	5	Non-Preferred
INFED 50 mg/ml inj soln	5
CHEMOTHERAPIES [QUIMIOTERAPIAS]
Antineoplastic Progestins [Antineoplásicos De Progestina]
megestrol acetate 20 mg tab, 40 mg tab	1	Preferred	MEGACE
megestrol acetate 40 mg/ml susp, 400 mg/10ml susp	2	Preferred	MEGACE
DIABETES SUPPLIES [SUMINISTROS PARA DIABETES]
Needles & Syringes [Agujas Y Jeringuillas]
insulin syringe/needle	1	Preferred	.
DYSLIPIDEMICS [DISLIPIDÉMICOS]
Bile Acid Sequestrants [Secuestradores De Acidos Biliares]
cholestyramine 4 gm pckt, 4 gm/dose oral pwdr	3	Preferred	QUESTRAN
Fibric Acid Derivatives [Derivados De Ácido Fíbrico]
gemfibrozil 600 mg tab	1	Preferred	LOPID
Hmg Coa Reductase Inhibitors [Inhibidores De La Reductasa De Hmg Coa]
atorvastatin calcium 10 mg tab, 20 mg tab, 40 mg tab, 80 mg tab	1	Preferred	LIPITOR
pravastatin sodium 10 mg tab, 20 mg tab, 80 mg tab	1	Non-Preferred	PRAVACHOL
simvastatin 10 mg tab, 20 mg tab, 40 mg tab, 5 mg tab, 80 mg tab	1	Preferred	ZOCOR
pravastatin sodium 40 mg tab	2	Non-Preferred	PRAVACHOL
GASTROINTESTINAL AGENTS [AGENTES GASTROINTESTINALES]
Histamine2 (H2) Receptor Antagonists [Antagonistas Del Receptor De H2]
famotidine 20 mg tab, 40 mg tab	1	Preferred	PEPCID

Page 77 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
ranitidine hcl 15 mg/ml syr, 150 mg/10ml syr, 300 mg tab, 75 mg/5ml syr	1	Preferred	ZANTAC
GENITOURINARY AGENTS [AGENTES GENITOURINARIOS]
Phosphate Binder Agents [Enlazadores De Fosfato]
RENVELA 0.8 gm pckt	6	Preferred		PA, P
RENVELA 2.4 gm pckt, 800 mg tab	7	Preferred		PA, P
calcium acetate 667 mg cap.	3	Non-Preferred	PHOSLO
HORMONAL AGENTS [AGENTES HORMONALES]
Calcimimetics [Calcimiméticos]
SENSIPAR 30 mg tab	7	Preferred		PA
SENSIPAR 60 mg tab	9	Preferred		PA
SENSIPAR 90 mg tab	10	Preferred		PA
Mineralocorticoids [Mineralocorticoides]
fludrocortisone acetate 0.1 mg tab	1	Preferred	FLORINEF
Vasopressin Analogs [Análogos De Vasopresina]
desmopressin acetate 4 mcg/ml inj soln	2	Non-Preferred	DDAVP
desmopressin acetate 0.2 mg tab	3	Non-Preferred	DDAVP
desmopressin ace spray refrig 0.01 % nasal soln	4	Non-Preferred	DDAVP
desmopressin acetate 0.1 mg tab	4	Non-Preferred	DDAVP
desmopressin acetate spray 0.01 % nasal soln	4	Non-Preferred	DDAVP
STIMATE 1.5 mg/ml nasal soln	7	Non-Preferred		PA
IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
Cyclosporine Analogs [Análogos De Ciclosporina]
cyclosporine modified 25 mg cap, 50 mg cap	3	Preferred	NEORAL	PA, P
cyclosporine modified 25 mg cap, 50 mg cap	3	Preferred	NEORAL	PA
NEORAL 25 mg cap	3	Preferred		PA, P

Page 78 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
cyclosporine 25 mg cap	4	Preferred	SANDIMMUNE	PA
cyclosporine modified 100 mg cap, 100 mg/ml soln	4	Preferred	NEORAL	PA
cyclosporine 100 mg cap	5	Preferred	SANDIMMUNE	PA
cyclosporine modified 100 mg cap	5	Preferred	NEORAL	PA, P
NEORAL 100 mg cap	5	Preferred		PA, P
cyclosporine 100 mg cap, 25 mg cap	6	Preferred	SANDIMMUNE	PA, P
SANDIMMUNE 100 mg cap, 100 mg/ml soln, 25 mg cap	6	Preferred		PA, P
cyclosporine modified 100 mg/ml soln	7	Preferred	NEORAL	PA, P
NEORAL 100 mg/ml soln	7	Preferred		PA, P
Glucocorticosteroids [Glucocorticoides]
dexamethasone 0.5 mg tab , 0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab	1	Preferred	DECADRON
MEDROL 2 mg tab	1	Preferred
methylprednisolone 32 mg tab, 4 mg tab	1	Preferred	MEDROL
methylprednisolone (pak) 4 mg tab	1	Preferred	MEDROL
prednisolone 15 mg/5ml soln, 15 mg/5ml syr	1	Preferred	PRELONE
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab	1	Preferred	DELTASONE
prednisone (pak) 10 mg tab, 5 mg tab	1	Preferred	DELTASONE
hydrocortisone 10 mg tab, 20 mg tab, 5 mg tab	2	Preferred	CORTEF
methylprednisolone 16 mg tab, 8 mg tab	2	Preferred	MEDROL
Organ Transplant Agents [Agentes Para Trasplantes]
azathioprine 50 mg tab	1	Preferred	IMURAN

Page 79 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
mycophenolate mofetil 250 mg cap, 500 mg tab	2	Preferred	CELLCEPT	PA
tacrolimus 0.5 mg cap	3	Non-Preferred	PROGRAF	PA
MYFORTIC 180 mg tab dr	4	Preferred		PA, P
tacrolimus 1 mg cap	4	Non-Preferred	PROGRAF	PA
mycophenolic acid 180 mg tab dr	5	Preferred	MYFORTIC	PA
sirolimus 0.5 mg tab, 1 mg tab, 2 mg tab	5	Non-Preferred	RAPAMUNE	PA
MYFORTIC 360 mg tab dr	6			PA, P
tacrolimus 5 mg cap	6	Non-Preferred	PROGRAF	PA
mycophenolic acid 360 mg tab dr	7	Preferred	MYFORTIC	PA
RAPAMUNE 1 mg/ml soln	8	Non-Preferred		PA
MINERALS & ELECTROLYTES [MINERALES Y ELECTROLITOS]
Calcium Regulating Agents [Agentes Reguladores De Calcio]
calcitriol 0.25 mcg cap	1	Preferred	ROCALTROL
calcitriol 0.5 mcg cap	2	Preferred	ROCALTROL
calcitriol 1 mcg/ml soln	5	Preferred	ROCALTROL
Electrolytes/Minerals Replacement [Reemplazo De Electrolitos/Minerales]
potassium chloride 20 meq/15ml (10%) oral liquid, 20 meq/15ml (10%) soln	1	Preferred	KAY-CIEL
potassium chloride crys er 10 meq tab er, 20 meq tab er	1	Preferred	KLOR-CON
potassium chloride er 10 meq tab er, 8 meq tab er	1	Preferred	KLOR-CON
potassium chloride er 10 meq cap er, 8 meq cap er	2	Preferred	MICRO-K
potassium chloride 40 meq/15ml (20%) oral liquid	4	Preferred	KAON CL
Potassium Removing Resins [Resinas Removedoras De Potasio]
kalexate oral pwdr	3	Preferred	KAYEXALATE
sodium polystyrene sulfonate oral pwdr, 15 gm/60ml susp	3	Preferred	KAYEXALATE

Page 80 of 25

A
acarbose	13
amlodipine besylate	15
amoxicillin	12
amoxicillin-pot clavulanate	12
ampicillin	12
ARANESP (ALBUMIN FREE)	18
atenolol	16
atenolol-chlorthalidone	16
atorvastatin calcium	19
azathioprine	21
azithromycin	11
B
BICILLIN L-A	12
bumetanide	17
C
calcitriol	22
calcium acetate	20
carvedilol	17
cefaclor	13
cefadroxil	11
cefdinir	13
cefprozil	13
cephalexin	11
chlorothiazide	17
chlorthalidone	17
cholestyramine	.19
ciprofloxacin	12, 13
ciprofloxacin hcl	12
clarithromycin	11
cyanocobalamin	18
cyclosporine	21
cyclosporine modified	20, 21
D
desmopressin ace spray refrig	20
desmopressin acetate	20
desmopressin acetate spray	20
dexamethasone	21
DEXFERRUM	19
diltiazem hcl	15
diltiazem hcl er	15

diltiazem hcl er beads	15, 16
diltiazem hcl er coated beads	15, 16
dilt-xr	15
DIURIL	17
E
E.E.S. GRANULES	11
ERYPED 200	11
ERYPED 400	12
ERY-TAB	11
ERYTHROCIN STEARATE	11
erythromycin base	11
erythromycin ethylsuccinate	11
F
famotidine	19
fludrocortisone acetate	20
folic acid	18
fosinopril sodium	15
furosemide	17
G
gemfibrozil	19
glimepiride	14
glipizide	14
H
HUMALOG	14
HUMALOG MIX 50/50	14
HUMALOG MIX 50/50 (50-50) 100 unit/ml sc susp	14
HUMALOG MIX 75/25	14
HUMALOG MIX 75/25 (75-25) 100 unit/ml sc susp	14
HUMULIN 70/30	13
HUMULIN N	14
HUMULIN R	14
hydrochlorothiazide	17
hydrocortisone	21
I
indomethacin	11
INFED	19
insulin syringe/needle	19
iron	19

Page 81 of 25

K
kalexate	22
KOMBIGLYZE XR	13
L
LANTUS	14
LANTUS SOLOSTAR	14
levofloxacin	12
lisinopril	15
lisinopril-hydrochlorothiazide	15
losartan potassium	15
losartan potassium-hctz	15
M
MEDROL	21
megestrol acetate	. 19
metformin hcl	13
metformin hcl er	13
methylprednisolone	21
methylprednisolone (pak)	21
metoclopramide hcl	14
metolazone	17
metoprolol succinate er	16
metoprolol tartrate	16
metoprolol-hydrochlorothiazide	16
mycophenolate mofetil	22
mycophenolic acid	22
N
NEORAL	20, 21
nifedipine er osmotic	16
O
ONGLYZA	13
P
penicillin g procaine	12
penicillin v potassium	12

pioglitazone hcl	14
potassium chloride	22
potassium chloride crys er	22
potassium chloride er	22
pravastatin sodium	19
prednisolone	21
prednisone	21
prednisone (pak)	21
PROCRIT	18
propranolol hcl	17
R
ranitidine hcl	20
RAPAMUNE	22
RENVELA	20
S
SANDIMMUNE	21
SENSIPAR	20
simvastatin	19
sirolimus	22
sodium polystyrene sulfonate	22
STIMATE	20
sulfamethoxazole-tmp ds	13
sulfamethoxazole-trimethoprim	13
T
tacrolimus	22
tamsulosin hcl	17
terazosin hcl	15
V
verapamil hcl	16
verapamil hcl er	16

Page 82 of 25

Puerto Rico Healthcare Insurance Administration

Ob-Gyn

2017

Formulary of Drugs Covered by

the Government Healthcare Plan (GHP)

Authorized by the P.R. Elections Commission CEE-SA-16-2732

Page 83 of 25

		GOVERNMENT OF PUERTO RICO		Hon. Ricardo A. Rosselló Nevares Governor Ms. Ángela M. Ávila Marrero Executive Director
		Healthcare Insurance Administration

May 1, 2017

TO ALL GOVERNMENT HEALTHCARE PLAN (GHP) PROVIDERS

Dear provider:

I urge you to keep this guide for future reference. It is also available on our webpage, www.asespr.org .

Cordially,

[signed]

Ángela M. Ávila Marrero

Executive Director




PO Box 195661, San Juan, PR 00919-5661 · Tel.: 787.474.3300 · Fax: 787.474.3348 · www.ases.pr.gov

Page 84 of 25

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE

OF THE GOVERNMENT HEALTHCARE PLAN (GHP)

1.	Drug Formulary

Non-formulary drugs may only be used in exceptional cases through the Exception Process that we will explain in point number 2.

2.	Exception Process

Contraindication to the drug(s) included in the FDC;

History of a clinically significant adverse reaction to the drug(s) included in the FDC;

Evidence of therapeutic failure of all alternatives available in the FDC; and/or

Lack of a therapeutic alternative in the FDC.

3.	Other Aspects of the Prescription Drug Coverage

The prescription drug coverage of the GHP establishes that using generic bioequivalent products as the first option is mandatory.

Page 85 of 25

The maximum supply dispensed for acute conditions will cover a fifteen (15) day therapy. The treatment period may be extended, as applicable, when medically necessary.

ASES requires the use of generic bioequivalent drugs approved by the Food and Drug Administration (FDA) coded as “AB” and those authorized under applicable local regulations in Puerto Rico.

Page 86 of 25

Drug prescriptions will be filled by a pharmacy contracted by the PBM that is duly authorized under the law of the Commonwealth of Puerto Rico and has been freely chosen by the beneficiary.

4.	Emergency Rule

The products that appear in the Integrated Emergency Formulary (IEF) will be dispensed for five (5) business days, except as otherwise specified.

The same thing applies to analgesics, narcotics, combination drugs, and nonsteroidal anti-inflammatory drugs, which will also be dispensed in amounts sufficient for five (5) business days.

If you have any questions about the prescription drug coverage, you may contact the insurance company contracted by ASES in your region and/or the Pharmacy Benefit Manager (PBM) contracted by ASES.

Page 87 of 25

GOVERNMENT HEALTHCARE PLAN

FORMULARY OF DRUGS COVERED BY THE GHP (FDC)

2017

TABLE OF CONTENTS

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE OF THE GOVERNMENT HEALTHCARE PLAN		3
DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES		9
	MONTHLY NET COST RANGE	9
	GENERIC DRUGS	10
THERAPEUTIC CATEGORY		11
ANALGESICS		11
	Short-Acting Opioid Analgesics	11
ANTIANXIETY AGENTS		11
	Miscellaneous Anxiolytics	11
ANTIBACTERIALS		11
	First Generation Cephalosporins	11
	Macrolides	11
	Miscellaneous Antibacterials	12
	Penicillins	12
	Second Generation Cephalosporins	13
	Sulfonamides	13
	Third Generation Cephalosporins	13
	Vaginal Antibiotics	13
ANTIDIABETIC AGENTS		14
	Insulin Mixtures	14
	Intermediate-Acting Insulins	14
	Long-Acting Insulins	14
	Rapid-Acting Insulins	14
	Short-Acting Insulins	14

Page 88 of 25

ANTIEMETICS		14
	Miscellaneous Antiemetics	14
	Phenothiazines	15
ANTIHYPERTENSIVES		15
	Alpha-Adrenergic Agonists	15
	Cardioselective Beta Blocking Agents	15
	Cardioselective Beta-Adrenergic Blocking Agents	15
	Nonselective Beta Blocking Agents	16
	Vasodilator Beta Blockers	16
	Vasodilators	16
ANTIMYCOBACTERIALS		16
	Antituberculars	16
	Miscellaneous Antimycobacterials	16
ANTIMYCOTIC AGENTS		16
	Vaginal Antifungals	16
ANTIPARASITICS		17
	Antiprotozoals - Non-Antimalarials	17
ANTIVIRALS		17
	Antiherpetic Agents	17
	Anti-Influenza Agents	17
	Nucleoside/Nucleotide Reverse Transcriptase Inhibitors	17
BLOOD MODIFIERS		17
	Anticoagulants	17
	Cobalamins	17
	Folates	18
	Iron	18
BONE DENSITY REGULATORS		18
	Bisphosphonates	18
	CHEMOTHERAPIES	18
	Folic Acid Antagonists Rescue Agents	18
	Luteinizing Hormone-Releasing (Lhrh) Analogs	18

Page 89 of 25

DERMATOLOGICAL AGENTS		18
	Antihistamines	18
	Topical Antifungals	19
DIABETES SUPPLIES		19
	Needles & Syringes	19
GASTROINTESTINAL AGENTS		19
	Anti-Ulcer Agents	19
	Histamine2 (H2) Receptor Antagonists	19
	Rectal Anti-Inflammatories	19
HORMONAL AGENTS		19
	Dysmenorrhea Agents	19
	Estrogens	20
	Estrogens and Progestins	20
	Glucocorticosteroids	20
	Mineralocorticoids	20
	Thyroid Hormones	20
	Vaginal Estrogens	20
IMMUNOSUPPRESSANTS		21
	Glucocorticosteroids	21
	Immune Globulins	21
MINERALS & ELECTROLYTES		22
	Prenatal Vitamins	22
RESPIRATORY AGENTS		22
	Anticholinergic Bronchodilators	22
	Inhaled Corticosteroids	22
	Nonsedating Histamine1 Blocking Agents	22
	Sedating Histamine1 Blocking Agents	23
	Sympathomimetic Bronchodilators	23

Page 90 of 25

DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES

The example below illustrates the information provided for the drugs included in the FDC.

Drug Name	Net Cost	Tier	Reference Name	Requirements/ Limits
THERAPEUTIC CATEGORY
Therapeutic Class
ANALGESICS
Short-Acting Opioid Analgesics
oxycodone-acetaminophen 5-325 mg tab	1	Preferred	PERCOCET
oxycodone-acetaminophen 10-325 mg tab, 7.5-325 mg tab	3	Preferred	PERCOCET
ANTIANXIETY AGENTS
Miscellaneous Anxiolytics
hydroxyzine pamoate 100 mg cap, 25 mg cap, 50 mg cap	1	Preferred	VISTARIL

MONTHLY NET COST RANGE

Page 91 of 25

1	less than $20	Least costly per month
2	$20 - $49
3	$50 - $99
4	$100 - $199
5	$200 - $349
6	$350 - $549
7	$550 - $799
8	$800 - $1,099
9	$1,100 - $1,499
10	$1,500 - $1,999
11	$2,000 - $2,499
12	$2,500 - $2,999
13	$3,000 - $3,499
14	$3,500 - $3,999
15	$4,000 - $4,499
16	$4,500 - $4,999
17	$5,000 - $5,499
18	$5,500 - $5,999
19	$6,000 - $6,499
20	$6,500 - $6,999
21	$7,000 - $7,499
22	$7,500 - $7,999
23	$8,000 - $8,499
24	$8,500 - $9,000
25	more than $9,000	Most costly per month

The net cost analysis is an ongoing exercise subject to constant changes. Net costs as published here are current as of the date of this edition of the FDC.

GENERIC DRUGS

Page 92 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Terapéutica]
ANALGESICS [ANALGÉSICOS]
Short-Acting Opioid Analgesics [Analgésicos Opiodes De Corta Duración]
oxycodone -acetaminophen 5-325 mg tab	1	Preferred	PERCOCET	QL=15 días No refills
oxycodone-acetaminophen 10-325 mg tab, 7.5-325 mg tab	3	Preferred	PERCOCET	QL=15 días No refills
ANTIANXIETY AGENTS [AGENTES PARA LA ANXIEDAD]
Miscellaneous Anxiolytics [Ansiolíticos Misceláneos]
hydroxyzine pamoate 100 mg cap, 25 mg cap, 50 mg cap	1	Preferred	VISTARIL
ANTIBACTERIALS [ANTIBACTERIANOS]
First Generation Cephalosporins [Cefalosporinas De Primera Generación]
cephalexin 125 mg/5ml susp, 250 mg cap, 500 mg cap	1	Preferred	KEFLEX
cephalexin 250 mg/5ml susp	2	Preferred	KEFLEX
Macrolides [Macrólidos]
azithromycin 250 mg tab, 500 mg tab	1	Preferred	ZITHROMAX
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab	2	Preferred	ZITHROMAX
ERY-TAB 500 mg tab dr	3	Preferred
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab	3	Preferred	ERY-TAB
erythromycin ethylsuccinate 400 mg tab	3	Preferred	E.E.S.
ERYTHROCIN STEARATE 250 mg tab	4	Non-Preferred

Page 93 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
E.E.S. GRANULES 200 mg/5ml susp	5	Preferred
ERYPED 200 200 mg/5ml susp	5	Preferred
ERYPED 400 400 mg/5ml susp	6	Preferred
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
clindamycin hcl 150 mg cap, 300 mg cap, 75 mg cap	1	Preferred	CLEOCIN
MACRODANTIN 25 mg cap	1	Preferred
metronidazole 250 mg tab, 500 mg tab	1	Preferred	FLAGYL
nitrofurantoin macrocrystal 50 mg cap	1	Preferred	MACRODANTIN
nitrofurantoin macrocrystal 100 mg cap	2	Preferred	MACRODANTIN
nitrofurantoin monohyd macro 100 mg cap	2	Preferred	MACROBID
nitrofurantoin oral suspension 25 MG/5ML	6	Non-Preferred	FURADANTIN
Penicillins [Penicilinas]
amoxicillin 125 mg/5ml susp , 200 mg/5ml susp, 250 mg cap, , 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab	1	Preferred	AMOXIL
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 875-125 mg tab	1	Preferred	AUGMENTIN
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap	1	Preferred	PRINCIPEN

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 9 for monthly net cost range [Ver página 9 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido]

Page 94 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab	1	Preferred	VEETIDS
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp	3	Preferred	AUGMENTIN
BICILLIN L-A 600000 unit/ml im susp	3	Non-Preferred
penicillin g procaine 600000 unit/ml im susp	3	Non-Preferred	BICILLIN LA
BICILLIN L-A 1200000 unit/2ml im susp	4	Non-Preferred
BICILLIN L-A 2400000 unit/4ml im susp	5	Non-Preferred
Second Generation Cephalosporins [Cefalosporinas De Segunda Generación]
cefaclor 250 mg cap, 500 mg cap	2	Preferred	CECLOR
cefprozil 125 mg/5ml susp, 250 mg tab, 250 mg/5ml susp, 500 mg tab	2	Preferred	CEFZIL
Sulfonamides [Sulfonamidas]
sulfamethoxazole -tmp ds 800-160 mg tab	1	Preferred	SEPTRA
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab	1	Preferred	SEPTRA
Third Generation Cephalosporins [Cefalosporinas De Tercera Generación]
cefdinir 125 mg/5ml susp, 300 mg cap	2	Preferred	OMNICEF
cefdinir 250 mg/5ml susp	3	Preferred	OMNICEF
Vaginal Antibiotics [Antibióticos Vaginales]
metronidazole 0.75 % vag gel	2	Preferred	VANDAZOLE

Page 95 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
clindamycin phosphate 2 % vag crm	3	Preferred	CLEOCIN
ANTIDIABETIC AGENTS [AGENTES ANTIDIABÉTICOS]
Insulin Mixtures [Mezclas De Insulinas]
HUMULIN 70/30 (70 -30) 100 unit/ml sc susp	3	Preferred		P
HUMALOG MIX 75/25 (7525) 100 unit/ml sc susp	4	Preferred		P
HUMALOG MIX 50/50 (5050) 100 unit/ml sc susp	4	Preferred		P
Intermediate-Acting Insulins [Insulinas De Duración Intermedia]
HUMULIN N 100 unit/ml sc susp	2	Preferred		P
Long-Acting Insulins [Insulinas De Larga Duración]
LANTUS SOLOSTAR 100 unit/ml subcutaneous solution pen-injector	3	Preferred		P
LANTUS 100 unit/ml sc soln	3	Preferred		P
Rapid-Acting Insulins [Insulinas De Rápida Duración]
HUMALOG 100 unit/ml sc soln	4	Preferred		P
Short-Acting Insulins [Insulinas De Corta Duración]
HUMULIN R 100 unit/ml inj soln	2	Preferred		P
ANTIEMETICS [ANTIEMÉTICOS]
Miscellaneous Antiemetics [Antieméticos Misceláneos]
metoclopramide hcl 10 mg tab, 10 mg/10ml soln, 5 mg tab, 5 mg/5ml soln, 5 mg/ml inj soln	1	Preferred	REGLAN
trimethobenzamide hcl 300 mg cap	1	Preferred	TIGAN

Page 96 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
Phenothiazines [Fenotiazinas]
prochlorperazine edisylate 5 mg/ml inj soln	1	Preferred	COMPAZINE
prochlorperazine maleate 10 mg tab, 5 mg tab	1	Preferred	COMPAZINE
prochlorperazine 25 mg rect supp	4	Non-Preferred	COMPAZINE
ANTIHYPERTENSIVES [ANTIHIPERTENSIVOS]
Alpha-Adrenergic Agonists [Agonistas Alfa Adrenérgicos]
methyldopa 250 mg tab, 500 mg tab	1	Preferred	ALDOMET
Cardioselective Beta Blocking Agents [Bloqueadores Beta Cardioselectivos]
atenolol 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	TENORMIN
metoprolol succinate er 25 mg tab er 24 hr, 50 mg tab er 24 hr	1	Preferred	LOPRESSOR
metoprolol tartrate 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	LOPRESSOR
metoprolol succinate er 100 mg tab er 24 hr, 200 mg tab er 24 hr	2	Preferred	LOPRESSOR
Cardioselective Beta-Adrenergic Blocking Agents [Bloqueadores Beta-Adrenérgicos Cardioselectivos]
atenolol -chlorthalidone 10025 mg tab, 50-25 mg tab	1	Preferred	TENORETIC
metoprolol- hydrochlorothiazide 50-25 mg tab	2	Non-Preferred	LOPRESSOR HCT
metoprololhydrochlorothiazide 100-25 mg tab, 100-50 mg tab	3	Non-Preferred	LOPRESSOR HCT

Page 97 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
Nonselective Beta Blocking Agents [Bloqueadores Beta No-Selectivos]
propranolol hcl 10 mg tab , 20 mg tab, 40 mg tab, 80 mg tab	1	Preferred	INDERAL
propranolol hcl 60 mg tab	2	Preferred	INDERAL
Vasodilator Beta Blockers [Bloqueadores Beta Vasodilatadores]
carvedilol 12.5 mg tab, 25 mg tab, 3.125 mg tab, 6.25 mg tab 1 Preferred COREG
Vasodilators [Vasodilatadores]
hydralazine hcl 10 mg tab, 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	APRESOLINE
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
Antituberculars [Antituberculosos]
isoniazid 100 mg tab, 300 mg tab	1	Preferred	ISONIAZID
rifampin 150 mg cap	1	Preferred	RIFADIN
ethambutol hcl 100 mg tab	2	Non-Preferred	MYAMBUTOL
rifampin 300 mg cap	2	Preferred	RIFADIN
ethambutol hcl 400 mg tab	3	Non-Preferred	MYAMBUTOL
isoniazid 50 mg/5ml syr	5	Non-Preferred	ISONIAZID
rifabutin 150 mg cap	6	Preferred	MYCOBUTIN	Puerto Rico Health Department Tuberculosis Control Program
RIFAMATE 50-300 mg cap
TRECATOR 250 mg tab
Miscellaneous Antimycobacterials [Antimicobacterianos Misceláneos]
dapsone 100 mg tab, 25 mg tab	2	Preferred	DAPSONE
ANTIMYCOTIC AGENTS [ANTIMICÓTICOS]
Vaginal Antifungals [Antifungales Vaginales]
terconazole 0.4 % vag crm, 0.8 % vag crm	2	Preferred	TERAZOL

Page 98 of 25

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
ANTIPARASITICS [ANTIPARASITARIOS]
Antiprotozoals - Non-Antimalarials [Antiprotozoarios No-Antimalaráricos]
NEBUPENT 300 mg inh soln	4	Preferred		PA
ANTIVIRALS [ANTIVIRALES]
Antiherpetic Agents [Agentes Antiherpéticos]
acyclovir 200 mg cap, 400 mg tab, 800 mg tab	1	Preferred	ZOVIRAX
acyclovir 200 mg/5ml susp	2	Preferred	ZOVIRAX
Anti-Influenza Agents [Agentes Antiinfluenza]
RELENZA DISKHALER 5 mg/blister inh aer pwdr	3	Preferred
oseltamivir phosphate 30 mg cap, 45 mg cap, 75 mg cap	4	Preferred	TAMIFLU
TAMIFLU 6 mg/ ml susp	5	Non-Preferred
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors [Inhibidores Nucleósidos/Nucleótidos De La Transcriptasa Reversa]
zidovudine 300 mg tab	2	Non-Preferred	RETROVIR
zidovudine 100 mg cap, 50 mg/5ml syr	4	Non-Preferred	RETROVIR
BLOOD MODIFIERS [MODIFICADORES DE LA SANGRE]
Anticoagulants [Anticoagulantes]
heparin sodium (porcine) 1000 unit/ml inj soln	2	Preferred	HEPARIN
heparin sodium (porcine) 10000 unit/ml inj soln, 5000 unit/ml inj soln	3	Preferred	HEPARIN
heparin sodium (porcine) pf 5000 unit/0.5ml inj soln	3	Preferred	HEPARIN
heparin sodium (porcine) 2000 unit/ml iv soln	8	Preferred	HEPARIN
Cobalamins [Cobalaminas]
cyanocobalamin 1000 mcg/ml inj soln	1	Preferred	VIT B-12

Page 99 of 25

Revisado: 1 de mayo de 2017

OB-GYN

Drug Name [Nombre del

Medicamento]

Net

Cost

[Costo

Neto]

Tier [Tier]

Reference Name

[Nombre de

Referencia]

Requirements/

Limits

[Requerimientos/

Límites]

Folates [Folatos]
folic acid 1 mg tab, 400 mcg tab, 800 mcg tab	1	Preferred	FOLIC ACID	OTC
Iron [Hierro]
iron 325 (65 fe) mg tab	1	Preferred	IRON
DEXFERRUM 50 mg/ml inj soln	5	Non-Preferred
INFED 50 mg/ml inj soln	5	Preferred
BONE DENSITY REGULATORS [REGULADORES DE DENSIDAD ÓSEA]
Bisphosphonates [Bifosfonatos]
alendronate sodium 10 mg tab, 35 mg tab, 5 mg tab, 70 mg tab	1	Preferred	FOSAMAX
CHEMOTHERAPIES [QUIMIOTERAPIAS]
Folic Acid Antagonists Rescue Agents [Antagonistas De Ácido Fólico]
leucovorin calcium 5 mg tab	3	Preferred	LEUCOVORIN
leucovorin calcium 10 mg tab, 15 mg tab	4	Preferred	LEUCOVORIN
leucovorin calcium 25 mg tab	9	Preferred	LEUCOVORIN
leucovorin calcium 50 mg inj, 100 mg inj, 200 mg inj, 350 mg inj, 500 mg inj	9	Non-Preferred	LEUCOVORIN
Luteinizing Hormone-Releasing (Lhrh) Analogs [Análogos De Lhrh]
LUPRON DEPOT 11.25 mg im kit, 3.75 mg im kit	6	Preferred		PA, P
ZOLADEX 3.6 mg, 10.8 mg subcutaneous implant	7	Non-preferred		PA
DERMATOLOGICAL AGENTS [AGENTES DERMATOLÓGICOS]
Antihistamines [Antihistamínicos]
hydroxyzine hcl 10 mg tab, 10 mg/5ml soln, 10 mg/5ml syr, 25 mg tab, 50 mg tab	1	Preferred	ATARAX

Page 100 of 25

Revisado: 1 de mayo de 2017

OB-GYN

Drug Name [Nombre del

Medicamento]

Net

Cost

[Costo

Neto]

Tier [Tier]

Reference Name

[Nombre de

Referencia]

Requirements/

Limits

[Requerimientos/

Límites]

Topical Antifungals [Antifungales Tópicos]
clotrimazole 1 % crm	1	Preferred	LOTRIMIN	OTC ( crm )
nystatin 100000 unit/gm oint	1	Preferred	MYCOSTATIN
DIABETES SUPPLIES [SUMINISTROS PARA DIABETES]
Needles & Syringes [Agujas Y Jeringuillas]
insulin syringe/needle	1	Preferred	.
GASTROINTESTINAL AGENTS [AGENTES GASTROINTESTINALES]
Anti-Ulcer Agents [Agentes Anti-Ulceras]
sucralfate 1 gm tab	1	Preferred	CARAFATE
CARAFATE 1 gm/10ml susp	3	Non-Preferred
Histamine2 (H2) Receptor Antagonists [Antagonistas Del Receptor De H2]
famotidine 20 mg tab, 40 mg tab	1	Preferred	PEPCID
ranitidine hcl 15 mg/ml syr, 150 mg/10ml syr, 300 mg tab, 75 mg/5ml syr	1	Preferred	ZANTAC
Rectal Anti-Inflammatories [Anti-Inflamatorios Rectales]
hydrocortisone ace pramoxine 1-1 % rect crm, 2.5-1 % rect crm	2	Preferred	ANALPRAM-HC
pramcort 1-1 % rect crm	2	Preferred	ANALPRAM-HC
HORMONAL AGENTS [AGENTES HORMONALES]
Dysmenorrhea Agents [Agentes Para La Dismenorrea]
medroxyprogesterone acetate 10 mg tab, 2.5 mg tab, 5 mg tab	1	Preferred	PROVERA
alyacen 1/35 1-35 mg-mcg tab	2	Preferred	ARANELLE	PA
CRYSELLE-28 0.3-30 mgmcg tab	2	Preferred		PA
ELINEST 0.3-30 mg-mcg tab	2	Preferred		PA
LOW-OGESTREL 0.3-30 mg-mcg tab	2	Preferred		PA

Page 101 of 25

Revisado: 1 de mayo de 2017

OB-GYN

Drug Name [Nombre del

Medicamento]

Net

Cost

[Costo

Neto]

Tier [Tier]

Reference Name

[Nombre de

Referencia]

Requirements/

Limits

[Requerimientos/

Límites]

Estrogens [Estrógenos]
estradiol 1 mg tab, 2 mg tab	1	Preferred	ESTRACE
estropipate 0.75 mg tab, 1.5 mg tab	1	Preferred	ESTROPIPATE
estropipate 3 mg tab	2	Preferred	ESTROPIPATE
Estrogens and Progestins [Estrógenos y Progestinas]
estradiol -norethindrone acet 1-0.5 mg tab	4	Non-Preferred	ACTIVELLA
Glucocorticosteroids [Glucocorticoides]
betamethasone sod phos & acet 6 (3-3) mg/ml inj susp	2	Preferred	CELESTONE
Mineralocorticoids [Mineralocorticoides]
fludrocortisone acetate 0.1 mg tab	1	Preferred	FLORINEF
Thyroid Hormones [Hormona Tiroidea]
levothyroxine sodium 100 mcg tab, 112 mcg tab, 125 mcg tab, 137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab	1	Preferred	SYNTHROID
SYNTHROID 100 mcg tab, 112 mcg tab, 125 mcg tab, 137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab	1	Preferred		P
Vaginal Estrogens [Estrógenos Vaginal]
VAGIFEM 10 mcg vag tab	3	Non-Preferred

Page 102 of 25

Revisado: 1 de mayo de 2017

OB-GYN

Drug Name [Nombre del

Medicamento]

Net

Cost

[Costo

Neto]

Tier [Tier]

Reference Name

[Nombre de

Referencia]

Requirements/

Limits

[Requerimientos/

Límites]

IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
Glucocorticosteroids [Glucocorticoides]
dexamethasone 0.5 mg tab, 0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab	1	Preferred	DECADRON
dexamethasone sodium phosphate 120 mg/30ml inj soln, 20 mg/5ml inj soln, 4 mg/ml inj soln	1	Preferred	DECADRON
KENALOG 10 mg/ml inj susp	1	Non-Preferred
MEDROL 2 mg tab	1	Preferred
methylprednisolone 32 mg tab, 4 mg tab	1	Preferred	MEDROL
methylprednisolone (pak) 4 mg tab	1	Preferred	MEDROL
prednisolone 15 mg/5ml soln, 15 mg/5ml syr	1	Preferred	PRELONE
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab	1	Preferred	DELTASONE
prednisone (pak) 10 mg tab, 5 mg tab	1	Preferred	DELTASONE
hydrocortisone 10 mg tab, 20 mg tab, 5 mg tab	2	Preferred	CORTEF
methylprednisolone 16 mg tab, 8 mg tab	2	Preferred	MEDROL
KENALOG 40 mg/ml inj susp	5	Non-Preferred
Immune Globulins [Immunoglobulinas]
RHOGAM ultra-filtered plus im soln 1500 unit	4	Preferred

Page 103 of 25

Revisado: 1 de mayo de 2017

OB-GYN

Drug Name [Nombre del

Medicamento]

Net

Cost

[Costo

Neto]

Tier [Tier]

Reference Name

[Nombre de

Referencia]

Requirements/

Limits

[Requerimientos/

Límites]

MINERALS & ELECTROLYTES [MINERALES Y ELECTROLITOS]
Prenatal Vitamins [Vitaminas Prenatales]
prenatal tab	1	Preferred	PRENATAL VITAMINS
RESPIRATORY AGENTS [AGENTES RESPIRATORIOS]
Anticholinergic Bronchodilators [Broncodilatadores Anticolinérgicos]
ipratropium bromide 0.02 % inh soln	1	Non-Preferred	ATROVENT
Inhaled Corticosteroids [Corticosteroides Inhalados]
FLOVENT DISKUS 100 mcg/blist inh aer pwdr, 250 mcg/blist inh aer pwdr, 50 mcg/blist inh aer pwdr	3	Preferred		QL = 1 pompa / 30 días, P
FLOVENT HFA 110 mcg/act inh aer, 44 mcg/act inh aer	3	Preferred		QL = 1 pompa / 30 días, P
ADVAIR DISKUS 100-50 mcg/dose inh aer pwdr, 25050 mcg/dose inh aer pwdr	4	Preferred		QL = 1 pompa / 30 días, ST, P
ADVAIR HFA 115-21 mcg/act inh aer, 45-21 mcg/act inh aer	4	Preferred		QL = 1 pompa / 30 días, ST, P
budesonide 0.25 mg/2ml inh susp, 0.5 mg/2ml inh susp,	4	Non-Preferred	PULMICORT	AL ≤ 12 años
budesonide 1mg/2ml inh susp	8	Non-Preferred	PULMICORT	AL ≤ 12 años
FLOVENT HFA 220 mcg/act inh aer	4	Preferred		QL = 1 pompa / 30 días, P
ADVAIR DISKUS 500-50 mcg/dose inh aer pwdr	5	Preferred		QL = 1 pompa / 30 días, ST, P
ADVAIR HFA 230-21 mcg/act inh aer	5	Preferred		QL = 1 pompa / 30 días, ST, P
Nonsedating Histamine1 Blocking Agents [Bloqueadores De Histamina1 No-Sedantes]
loratadine 10 mg tab	1	Preferred	CLARITIN	OTC

Page 104 of 25

Revisado: 1 de mayo de 2017

OB-GYN

Drug Name [Nombre del

Medicamento]

Net

Cost

[Costo

Neto]

Tier [Tier]

Reference Name
[Nombre de

Referencia]

Requirements/

Limits

[Requerimientos/
Límites]

Sedating Histamine1 Blocking Agents [Sedantes Bloqueadores Histamine1]
promethazine hcl 12.5 mg tab, 25 mg tab, 50 mg tab, 6.25 mg/5ml soln, 6.25 mg/5ml syr	1	Preferred	PHENERGAN
Sympathomimetic Bronchodilators [Broncodilatadores Simpatomiméticos]
albuterol sulfate (2.5 mg/3ml) 0.083% inh neb soln, (5 mg/ml) 0.5% inh neb soln	1	Preferred	ALBUTEROL
terbutaline sulfate 2.5 mg tab, 5 mg tab	1	Preferred	BRETHINE
VENTOLIN HFA 108 (90 base) mcg/act inh aer	1	Preferred		QL = 1 pompa / 30 días, P

Page 105 of 25

OB-GYN

A

acyclovir	17
ADVAIR DISKUS	25, 26
ADVAIR HFA	25, 26
albuterol sulfate	26
alendronate sodium	19
alyacen 1/35	21
amoxicillin	12
amoxicillin-pot clavulanate	12, 13
ampicillin	12
atenolol	15
atenolol-chlorthalidone	15
azithromycin	11

B

betamethasone sod phos & acet	22
BICILLIN L-A	13
budesonide	25

C

CARAFATE	20
carvedilol	16
cefaclor	13
cefdinir	13
cefprozil	13
cephalexin	11
clindamycin hcl	12
clindamycin phosphate	14
clotrimazole	20
CRYSELLE-28	21
cyanocobalamin	18

D

dapsone	17
dexamethasone	23
dexamethasone sodium phosphate	23
DEXFERRUM	19

E

E.E.S. GRANULES	12
ELINEST	21
ERYPED 200	12
ERYPED 400	12
ERY-TAB	11
ERYTHROCIN STEARATE	11
erythromycin base	11
erythromycin ethylsuccinate	11
estradiol	21
estradiol-norethindrone acet	22
estropipate	21, 22
ethambutol hcl	16

F

famotidine	20
FLOVENT DISKUS	25
FLOVENT HFA	25
fludrocortisone acetate	22
folic acid	18

H

heparin sodium (porcine)	18
heparin sodium (porcine) pf	18
HUMALOG	14
HUMALOG MIX 50/50	14
HUMALOG MIX 75/25	14
HUMULIN 70/30	14
HUMULIN N	14
HUMULIN R	14
hydralazine hcl	16
hydrocortisone	24
hydrocortisone ace-pramoxine	21
hydroxyzine hcl	20
hydroxyzine pamoate	11

I

INFED	19
insulin syringe/needle	20
ipratropium bromide	25

Page 106 of 25

iron	19
isoniazid	16

K

KENALOG	23, 24

L

LANTUS	14
LANTUS SOLOSTAR	14
leucovorin calcium	19
levothyroxine sodium	22
loratadine	26
LOW-OGESTREL	21
LUPRON DEPOT	19

M

MACRODANTIN	12
MEDROL	23
medroxyprogesterone acetate	21
methyldopa	15
methylprednisolone	23, 24
methylprednisolone (pak)	24
metoclopramide hcl	14
metoprolol succinate er	15
metoprolol tartrate	15
metoprolol-hydrochlorothiazide	15
metronidazole	12, 13

N

NEBUPENT	17
nitrofurantoin macrocrystal	12
nitrofurantoin monohyd macro	12
nitrofurantoin oral suspension	12
nystatin	20

O

oseltamivir phosphate	17
oxycodone-acetaminophen	11

P

penicillin g procaine	13
penicillin v potassium	13
pramcort	21
prednisolone	24
prednisone	24
prednisone (pak)	24
pre-natal formula	24
prochlorperazine	15
prochlorperazine edisylate	15
prochlorperazine maleate	15
promethazine hcl	26
propranolol hcl	16

R

ranitidine hcl	21
RELENZA DISKHALER	17
RHOGAM ultra-filtered plus im soln 1500 unit	24
rifabutin	16
RIFAMATE	17
rifampin	16

S
sucralfate	20
sulfamethoxazole-tmp ds	13
sulfamethoxazole-trimethoprim	13
SYNTHROID	23

T

TAMIFLU	18
terbutaline sulfate	26
terconazole	17
TRECATOR	17
trimethobenzamide hcl	14

V

VAGIFEM	23
VENTOLIN HFA	26

Page 107 of 25

OB-GYN

Z
zidovudine	18

ZOLADEX

Page 108 of 25

ASES

Puerto Rico Healthcare Insurance Administration

Oncology

2017

Formulary of Drugs Covered by

the Government Healthcare Plan (GHP)

Authorized by the P.R. Elections Commission CEE-SA-16-2732

Page 109 of 25

		GOVERNMENT OF PUERTO RICO	Hon. Ricardo A. Rosselló Nevares
		Healthcare Insurance Administration	Governor
			Ms. Ángela M. Ávila Marrero Executive Director

May 1, 2017

TO ALL GOVERNMENT HEALTHCARE PLAN (GHP) PROVIDERS

Dear provider:

I urge you to keep this guide for future reference. It is also available on our webpage, www.asespr.org .

Cordially,

[signed]

Ángela M. Ávila Marrero

Executive Director

PO Box 195661, San Juan, PR 00919-5661 · Tel.: 787.474.3300 · Fax: 787.474.3348 · www.ases.pr.gov

Page 110 of 25

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE

OF THE GOVERNMENT HEALTHCARE PLAN (GHP)

1.	Drug Formulary

Non-formulary drugs may only be used in exceptional cases through the Exception Process that we will explain in point number 2.

2.	Exception Process

Contraindication to the drug(s) included in the FDC;

History of a clinically significant adverse reaction to the drug(s) included in the FDC;

Evidence of therapeutic failure of all alternatives available in the FDC; and/or

Lack of a therapeutic alternative in the FDC.

3.	Other Aspects of the Prescription Drug Coverage

The prescription drug coverage of the GHP establishes that using generic bioequivalent products as the first option is mandatory.

Page 111 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

The maximum supply dispensed for acute conditions will cover a fifteen (15) day therapy. The treatment period may be extended, as applicable, when medically necessary.

ASES requires the use of generic bioequivalent drugs approved by the Food and Drug Administration (FDA) coded as “AB” and those authorized under applicable local regulations in Puerto Rico.

Page 112 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

Drug prescriptions will be filled by a pharmacy contracted by the PBM that is duly authorized under the law of the Commonwealth of Puerto Rico and has been freely chosen by the beneficiary.

4.	Emergency Rule

The products that appear in the Integrated Emergency Formulary (IEF) will be dispensed for five (5) business days, except as otherwise specified.

The same thing applies to analgesics, narcotics, combination drugs, and nonsteroidal anti-inflammatory drugs, which will also be dispensed in amounts sufficient for five (5) business days.

If you have any questions about the prescription drug coverage, you may contact the insurance company contracted by ASES in your region and/or the Pharmacy Benefit Manager (PBM) contracted by ASES.

Page 113 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

GOVERNMENT HEALTHCARE PLAN

FORMULARY OF DRUGS COVERED BY THE GHP (FDC)

2017

TABLE OF CONTENTS

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE OF THE GOVERNMENT HEALTHCARE PLAN		3

DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES		9

	MONTHLY NET COST RANGE	9

	GENERIC DRUGS	10

THERAPEUTIC CATEGORY		11
ANALGESICS		11
	Nonsteroidal Anti-Inflammatory Agents (NSAIDs)	11
	Opioid Analgesics, Long-Acting	11
	Short-Acting Opioid Analgesics	12
ANESTHETICS		13
	Local Anesthetics	13
ANTIBACTERIALS		13
	Macrolides	13
	Penicillins	14
	Quinolones	15
	Sulfonamides	15
ANTICONVULSANTS		15
	Anticonvulsants	15
ANTIEMETICS		16
	5-Hydroxytryptamine 3 (5-HT3) Antagonists	16
	Miscellaneous Antiemetics	16
	Phenothiazines	16
ANTIMYCOBACTERIALS		16

Page 114 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

	Miscellaneous Antimycobacterials	16
ANTIMYCOTIC AGENTS		17
	Antifungals	17
ANTIVIRALS		17
	Antiherpetic Agents	17
BLOOD MODIFIERS		17
	Cobalamins	17
	Colony Stimulating Factors	17
	Erythropoiesis-Stimulating Agents	17
	Folates	18
	Iron	18
CHEMOTHERAPIES		19
	Alkylating Agents	19
	Angiogenesis Inhibitors	19
	Antiandrogens	19
	Antiestrogens	19
	Antimetabolites	19
	Antineoplastic Enzyme Inhibitors	19
	Antineoplastic Progestins	20
	Aromatase Inhibitors	20
	Folic Acid Antagonists Rescue Agents	20
	Luteinizing Hormone-Releasing (Lhrh) Analogs	20
	Miscellaneous Antineoplastics	21
	Mitotic Inhibitors	21
DENTAL AND ORAL AGENTS		21
	Antifungals	21
DERMATOLOGICAL AGENTS		21
	Dermatological Skin Cancer Agents	21
GASTROINTESTINAL AGENTS		21

Page 115 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

	Anti-Ulcer Agents	21
	Histamine2 (H2) Receptor Antagonists	21
	Proton Pump Inhibitors	22
HORMONAL AGENTS		22
	Mineralocorticoids	22
IMMUNOSUPPRESSANTS		22
	Cyclosporine Analogs	22
	Glucocorticosteroids	23
	Organ Transplant Agents	23
MINERALS & ELECTROLYTES		24
	Calcium Regulating Agents	24

Page 116 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES

The example below illustrates the information provided for the drugs included in the FDC.

Drug Name	Net Cost	Tier	Reference Name	Requirements/ Limits
THERAPEUTIC CATEGORY
Therapeutic Class
ANALGESICS
Nonsteroidal Anti-Inflammatory Agents (NSAIDs)
ibuprofen 400 mg tab, 600 mg tab, 800 mg tab	1	Preferred	MOTRIN
indomethacin 25 mg cap, 50 mg cap	1	Non-preferred	INDOCIN
nabumetone 500 mg tab, 750 mg tab	1	Preferred	RELAFEN
naproxen 250 mg tab, 375 mg tab, 500 mg tab	1	Preferred	NAPROSYN
naproxen dr 375 mg tab dr, 5 0 0 mg tab dr	1	Preferred	NAPROSYN
naproxen sodium 275 mg tab, 550 mg tab	1	Preferred	ANAPROX
sulindac 150 mg tab, 200 mg tab	1	Preferred	CLINORIL
celecoxib 50 mg cap	2	Non- preferred	CELEBREX	ST

Page 117 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

MONTHLY NET COST RANGE

1	less than $20	Least costly per month
2	$20 - $49
3	$50 - $99
4	$100 - $199
5	$200 - $349
6	$350 - $549
7	$550 - $799
8	$800 - $1,099
9	$1,100 - $1,499
10	$1,500 - $1,999
11	$2,000 - $2,499
12	$2,500 - $2,999
13	$3,000 - $3,499
14	$3,500 - $3,999
15	$4,000 - $4,499
16	$4,500 - $4,999
17	$5,000 - $5,499
18	$5,500 - $5,999
19	$6,000 - $6,499
20	$6,500 - $6,999
21	$7,000 - $7,499
22	$7,500 - $7,999
23	$8,000 - $8,499
24	$8,500 - $9,000
25	more than $9,000	Most costly per month

The net cost analysis is an ongoing exercise subject to constant changes. Net costs as published here are current as of the date of this edition of the FDC.

GENERIC DRUGS

Page 118 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

Drug Name [Nombre del

Medicamento]

Net

Cost

[Costo

Neto]

Tier [Tier]

Reference Name [Nombre de

Referencia]

Requirements/

Limits

[Requerimientos/ Límites]

THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Terapéutica]
ANALGESICS [ANALG ÉSICOS]
Nonsteroidal Anti-Inflammatory Agents (NSAIDS) [Anti-Inflamatorios No Esteroidales]
ibuprofen 400 mg tab, 600 mg tab, 800 mg tab	1	Preferred	MOTRIN	QL=15 días No refills
nabumetone 500 mg tab, 750 mg tab	1	Preferred	RELAFEN
naproxen 250 mg tab, 375 mg tab, 500 mg tab	1	Preferred	NAPROSYN	QL=15 días No refills
naproxen dr 375 mg tab dr, 500 mg tab dr	1	Preferred	NAPROSYN	QL=15 días No refills
sulindac 150 mg tab, 200 mg tab	1	Preferred	CLINORIL
meloxicam7.5 mg tab, 15 mg tab	1	Preferred	MOBIC	QL=15 días No refills
indomethacin 25 mg cap, 50 mg cap	1	Non-Preferred	INDOCIN
Opioid Analgesics, Long-Acting [Analgésicos Opiodes, Larga Duración]
fentanyl 25 mcg/hr td patch 72 hr	2	Preferred	DURAGESIC
oxycodone hcl 10 mg tab	2	Preferred	DAZIDOX	QL=15 días No refills
fentanyl 50 mcg/hr td patch 72 hr, 75 mcg/hr td patch 72 hr	3	Preferred	DURAGESIC
morphine sulfate er 15 mg tab er	3	Preferred	MORPHINE
oxycodone hcl 20 mg tab	3	Preferred	DAZIDOX	QL=15 días No refills
fentanyl 100 mcg/hr td patch 72 hr	4	Preferred	DURAGESIC

Page 119 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

Drug Name [Nombre del

Medicamento]

Net

Cost

[Costo

Neto]

Tier [Tier]

Reference Name

[Nombre de

Referencia]

Requirements/

Limits

[Requerimientos/

Límites]

morphine sulfate er 30 mg tab er	4	Preferred	MORPHINE
morphine sulfate er 60 mg tab er	5	Preferred	MORPHINE
morphine sulfate er 100 mg tab er	6	Preferred	MORPHINE
Short-Acting Opioid Analgesics [Analgésicos Opiodes De Corta Duración]
acetaminophen -codeine 120-12 mg/5ml soln, 300-15 mg tab, 300-30 mg tab, 300- 60 mg tab	1	Preferred	TYLENOL- CODEINE	QL=15 días No refills
acetaminophen-codeine #2 300-15 mg tab	1	Preferred	TYLENOL- CODEINE	QL=15 días No refills
acetaminophen-codeine #3 300-30 mg tab	1	Preferred	TYLENOL- CODEINE	QL=15 días No refills
acetaminophen-codeine #4 300-60 mg tab	1	Preferred	TYLENOL- CODEINE	QL=15 días No refills
hydrocodoneacetaminophen 10-325 mg tab, 5-325 mg tab, 7.5-325 mg tab, 7.5-500 mg/15ml soln	1	Preferred	VICODIN	QL=15 días No refills
hydromorphone hcl 2 mg tab, 4 mg tab	1	Preferred	DILAUDID
meperidine hcl 50 mg/ml inj soln	1	Preferred	DEMEROL
morphine sulfate 15 mg tab, 30 mg tab	1	Preferred	MORPHINE
oxycodone-acetaminophen 5-325 mg tab	1	Preferred	PERCOCET	QL=15 días No refills
tramadol hcl 50 mg tab	1	Preferred	ULTRAM
codeine sulfate 15 mg tab, 30 mg tab, 60 mg tab	2	Preferred	CODEINE

Page 120 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
meperidine hcl 100 mg/ml inj soln	2	Preferred	DEMEROL
morphine sulfate 10 mg/5ml soln	2	Preferred	MORPHINE
morphine sulfate (concentrate) 100 mg/5ml soln, 20 mg/ml soln	2	Preferred	MORPHINE
hydromorphone hcl 8 mg tab	3	Preferred	DILAUDID
oxycodone-acetaminophen 10-325 mg tab, 7.5-325 mg tab	3	Preferred	PERCOCET	QL=15 días No refills
hydromorphone hcl 1 mg/ml oral liquid	4	Preferred	DILAUDID
ANESTHETICS [ANESTÉSICOS]
Local Anesthetics [Anestésicos Locales]
lidocaine viscous 2 % mouth/throat soln 1		Preferred	XYLOCAINE
ANTIBACTERIALS [ANTIBACTERIANOS]
Macrolides [Macrólidos]
azithromycin 250 mg tab, 500 mg tab	1	Preferred	ZITHROMAX
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab	2	Preferred	ZITHROMAX
clarithromycin 125 mg/5ml susp, 250 mg tab, 500 mg tab	2	Preferred	BIAXIN
clarithromycin 250 mg/5ml susp	3	Preferred	BIAXIN
ERY-TAB 500 mg tab dr	3	Preferred
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab	3	Preferred	ERY-TAB

Page 121 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
erythromycin ethylsuccinate 400 mg tab	3	Preferred	E.E.S.
ERYTHROCIN STEARATE 250 mg tab	4	Non-Preferred
E.E.S. GRANULES 200 mg/5ml susp	5	Preferred
ERYPED 200 200 mg/5ml susp	5	Preferred
ERYPED 400 400 mg/5ml susp	6	Preferred
Penicillins [Penicilinas]
amoxicillin 125 mg/5ml susp, 200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab	1	Preferred	AMOXIL
amoxicillin-pot clavulanate, 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 875-125 mg tab	1	Preferred	AUGMENTIN
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap	1	Preferred	PRINCIPEN
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab	1	Preferred	VEETIDS
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp	3	Preferred	AUGMENTIN
BICILLIN L-A 600000 unit/ml im susp	3	Non-Preferred
penicillin g procaine 600000 unit/ml im susp	3	Non-Preferred	BICILLIN LA

Page 122 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

Drug Name [Nombre del

Medicamento]

Net

Cost

[Costo

Neto]

Tier [Tier]

Reference Name

[Nombre de

Referencia]

Requirements/

Limits

[Requerimientos/

Límites]

BICILLIN L-A 1200000 unit/2ml im susp	4	Non-Preferred
BICILLIN L-A 2400000 unit/4ml im susp	5	Non-Preferred
Quinolones [Quinolonas]
ciprofloxacin hcl 250 mg tab, 500 mg tab, 750 mg tab	1	Preferred	CIPRO
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab	1	Preferred	LEVAQUIN
ciprofloxacin 500 mg/5ml (10%) susp	3	Preferred	CIPRO
ciprofloxacin 250 mg/5ml (5%) susp	4	Preferred	CIPRO
Sulfonamides [Sulfonamidas]
sulfamethoxazole -tmp ds 800-160 mg tab	1	Preferred	SEPTRA
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab	1	Preferred	SEPTRA
sulfadiazine 500 mg tab	4	Preferred	SULFADIAZINE
ANTICONVULSANTS [ANTICONVULSIVANTES]
Anticonvulsants [Anticonvulsivantes]
gabapentin 100 mg cap, 300 mg cap, 400 mg cap, 600 mg tab, 800 mg tab	1	Preferred	NEURONTIN
DILANTIN 30 mg cap	2	Preferred
gabapentin 250 mg/5ml soln	2	Preferred	NEURONTIN
phenytoin 125 mg/5ml susp, 50 mg tab chew	2	Preferred	DILANTIN
phenytoin sodium extended 100 mg cap	2	Preferred	DILANTIN

Page 123 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

Drug Name [Nombre del

Medicamento]

Net

Cost

[Costo

Neto]

Tier [Tier]

Reference Name

[Nombre de

Referencia]

Requirements/

Limits

[Requerimientos/

Límites]

ANTIEMETICS [ANTIEMÉTICOS]
5-Hydroxytryptamine 3 (5-HT3) Antagonists [Antagonistas De 5-HT3]
ondansetron 4 mg odt, 8 mg odt	1	Preferred	ZOFRAN ODT
ondansetron hcl 24 mg tab, 4 mg tab, 8 mg tab	1	Preferred	ZOFRAN
Miscellaneous Antiemetics [Antieméticos Misceláneos]
metoclopramide hcl 10 mg tab, 10 mg/10ml soln, 5 mg tab, 5 mg/5ml soln, 5 mg/ml inj soln	1	Preferred	REGLAN
promethazine hcl 25 mg/ml inj soln, 50 mg/ml inj soln	1	Preferred	PHENERGAN
promethazine hcl 12.5 mg tab, 25 mg tab, 50 mg tab, 6.25 mg/5ml soln, 6.25 mg/5ml syr	1	Preferred	PHENERGAN
trimethobenzamide hcl 300 mg cap	1	Preferred	TIGAN
Phenothiazines [Fenotiazinas]
prochlorperazine edisylate 5 mg/ml inj soln	1	Preferred	COMPAZINE
prochlorperazine maleate 10 mg tab, 5 mg tab	1	Preferred	COMPAZINE
prochlorperazine 25 mg rect supp	4	Non-Preferred	COMPAZINE
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
Miscellaneous Antimycobacterials [Antimicobacterianos Misceláneos]
dapsone 100 mg tab, 25 mg tab	2	Preferred	DAPSONE

Page 124 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

Drug Name [Nombre del

Medicamento]

Net

Cost

[Costo

Neto]

Tier [Tier]

Reference Name

[Nombre de

Referencia]

Requirements/

Limits

[Requerimientos/

Límites]

ANTIMYCOTIC AGENTS [ANTIMICÓTICOS]
Antifungals [Antifungales]
fluconazole 10 mg/ml susp, 100 mg tab, 150 mg tab, 200 mg tab, 50 mg tab	1	Preferred	DIFLUCAN
ketoconazole 200 mg tab	1	Preferred	NIZORAL
terbinafine hcl 250 mg tab	1	Preferred	LAMISIL
fluconazole 40 mg/ml susp	2	Preferred	DIFLUCAN
ANTIVIRALS [ANTIVIRALES]
Antiherpetic Agents [Agentes Antiherpéticos]
acyclovir 200 mg cap, 400 mg tab, 800 mg tab	1	Preferred	ZOVIRAX
acyclovir 200 mg/5ml susp	2	Preferred	ZOVIRAX
BLOOD MODIFIERS [MODIFICADORES DE LA SANGRE]
Cobalamins [Cobalaminas]
cyanocobalamin 1000 mcg/ml inj soln	1	Preferred	VIT B-12
Colony Stimulating Factors [Estimulantes Mieloides]
NEUPOGEN 300 mcg/0.5ml inj soln, 300 mcg/ml inj soln, 480 mcg/1.6ml inj soln	10	Preferred		PA, P
NEULASTA 6 mg/0.6ml sc soln	12	Preferred		PA, P
NEUPOGEN 480 mcg/0.8ml inj soln	12	Preferred		PA, P
Erythropoiesis-Stimulating Agents [Agentes Estimulantes De Eritropoiesis]
ARANESP (ALBUMIN FREE) 100 mcg/0.5ml inj soln	1	Preferred		PA, P
PROCRIT 2000 unit/ml inj soln, 3000 unit/ml inj soln, 4000 unit/ml inj soln	5	Preferred		PA, P

Page 125 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

Drug Name [Nombre del

Medicamento]

Net

Cost

[Cost o

Neto]

Tier [Tier]

Reference Name

[Nombre de

Referencia]

Requirements/

Limits

[Requerimientos/

Límites]

ARANESP (ALBUMIN FREE) 25 mcg/0.42ml inj soln, 25 mcg/ml inj soln	6	Preferred		PA, P
PROCRIT 10000 unit/ml inj soln	6	Preferred		PA, P
ARANESP (ALBUMIN FREE) 40 mcg/0.4ml inj soln	7	Preferred		PA, P
ARANESP (ALBUMIN FREE) 40 mcg/ml inj soln, 60 mcg/ml inj soln	8	Preferred		PA, P
ARANESP (ALBUMIN FREE) 150 mcg/0.3ml inj soln, 150 mcg/0.75ml inj soln, 200 mcg/0.4ml inj soln, 200 mcg/ml inj soln, 300 mcg/0.6ml inj soln, 300 mcg/ml inj soln, 500 mcg/ml inj soln, 60 mcg/0.3ml inj soln	9	Preferred		PA, P
PROCRIT 20000 unit/ml inj soln	9	Preferred		PA, P
ARANESP (ALBUMIN FREE) 100 mcg/ml inj soln	11	Preferred		PA, P
PROCRIT 40000 unit/ml inj soln	11	Preferred		PA, P
Folates [Folatos]
folic acid 1 mg tab, 400 mcg tab, 800 mcg tab	1	Preferred	FOLIC ACID	OTC
Iron [Hierro]
iron 325 (65 fe) mg tab	1	Preferred	IRON
DEXFERRUM 50 mg/ml inj soln	5	Non-Preferred
INFED 50 mg/ml inj soln	5	Preferred

Page 126 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

Drug Name [Nombre del

Medicamento]

Net

Cost

[Costo

Neto]

Tier [Tier]

Reference Name [Nombre de

Referencia]

Requirements/

Limits

[Requerimientos/

Límites]

CHEMOTHERAPIES [QUIMIOTERAPIAS]
Alkylating Agents [Agentes Alquilantes]
lomustine 10 mg cap	3	Non-Preferred	CEENU
ALKERAN 2 mg tab	4	Non-Preferred
temozolomide 5 mg cap	4	Non-Preferred	TEMODAR	PA
lomustine 40 mg cap	5	Non-Preferred	CEENU
LEUKERAN 2 mg tab	6	Non-Preferred
lomustine 100 mg cap	6	Non-Preferred	CEENU
MYLERAN 2 mg tab	7	Preferred
temozolomide 20 mg cap	9	Non-Preferred	TEMODAR	PA
temozolomide 250 mg cap	11	Non-Preferred	TEMODAR	PA
temozolomide 140 mg cap	13	Non-Preferred	TEMODAR	PA
temozolomide 100 mg cap, 180 mg cap	14	Non-Preferred	TEMODAR	PA
Angiogenesis Inhibitors [Inhibidores de Angiogénesis]
STIVARGA 40 mg tab	21	Preferred		PA, P
Antiandrogens [Antiandrógenos]
bicalutamide 50 mg tab	2	Preferred	CASODEX
flutamide 125 mg cap	4	Non-Preferred	EULEXIN	PA
Antiestrogens [Antiestrógenos]
tamoxifen citrate 10 mg tab, 20 mg tab	1	Preferred	NOLVADEX
Antimetabolites [Antimetabolitos]
hydroxyurea 500 mg cap	2	Preferred	HYDREA
mercaptopurine 50 mg tab	2	Preferred	PURINETHOL
methotrexate 2.5 mg tab	2	Preferred	METHOTREXATE
capecitabine 150 mg tab	7	Preferred	XELODA	PA
capecitabine 500 mg tab	11	Preferred	XELODA	PA
Antineoplastic Enzyme Inhibitors [Antineoplásicos Inhibidores De Enzimas]
SPRYCEL 20 mg tab	10	Preferred		PA, P
SPRYCEL 50 mg tab	13	Preferred		PA, P
imatinib 100 mg tab	13	Non-Preferred	GLEEVEC	PA

Page 127 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
SPRYCEL 70 mg tab	14	Preferred		PA, P
TASIGNA 200 mg cap	15	Preferred		PA, P
SPRYCEL 80 mg tab	17	Preferred		PA, P
TASIGNA 150 mg cap	18	Preferred		PA, P
SPRYCEL 100 mg tab	19	Preferred		PA, P
AFINITOR 2.5 mg tab	20	Preferred		PA, P
NEXAVAR 200 mg tab	20	Preferred		PA, P
SPRYCEL 140 mg tab	20	Preferred		PA, P
AFINITOR 10 mg tab, 5 mg tab, 7.5 mg tab	21	Preferred		PA, P
imatinib 400 mg tab	23	Non-Preferred	GLEEVEC	PA
Antineoplastic Progestins [Antineoplásicos De Progestina]
megestrol acetate 20 mg tab, 40 mg tab	1	Preferred	MEGACE
megestrol acetate 40 mg/ml susp, 400 mg/10ml susp	2	Preferred	MEGACE
Aromatase Inhibitors [Inhibidores De La Aromatasa]
anastrozole 1 mg tab	1	Preferred	ARIMIDEX
Folic Acid Antagonists Rescue Agents [Antagonistas De Ácido Fólico]
leucovorin calcium 5 mg tab	3	Preferred	LEUCOVORIN
leucovorin calcium 10 mg tab, 15 mg tab	4	Preferred	LEUCOVORIN
leucovorin calcium 25 mg tab	9	Preferred	LEUCOVORIN
Luteinizing Hormone-Releasing (Lhrh) Analogs [Análogos De Lhrh]
LUPRON DEPOT 11.25 mg im kit, 3.75 mg im kit	6	Preferred		PA, P
LUPRON DEPOT-PED 11.25 mg im kit, 15 mg im kit, 7.5 mg im kit	8	Preferred		PA, P
LUPRON DEPOT 22.5 mg im kit, 30 mg im kit	9	Preferred		PA, P

Page 128 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
leuprolide acetate 1 mg/ 0.2 ml inj kit		Non-preferred		PA
ZOLADEX 3.6 mg, 10.8 mg subcutaneous implant	7	Non-preferred		PA
Miscellaneous Antineoplastics [Antineoplásicos Misceláneos]
MATULANE 50 mg cap	10	Non-Preferred		PA
ACTIMMUNE 2000000 unit/0.5ml sc soln	25	Non-Preferred		PA
Mitotic Inhibitors [Inhibidores Mitóticos]
etoposide 50 mg cap	4	Non-Preferred	VEPESID
DENTAL AND ORAL AGENTS [AGENTES DENTALES Y ORALES]
Antifungals [Antifungales]
clotrimazole 10 mg mouth/throat lozenge, 10 mg mouth/throat troche	1	Preferred	MYCELEX	OTC
nystatin 100000 unit/ml mouth/throat susp	1	Preferred	MYCOSTATIN
DERMATOLOGICAL AGENTS [AGENTES DERMATOLÓGICOS]
Dermatological Skin Cancer Agents [Dermatológicos Para Cáncer De La Piel]
fluorouracil 2 % soln, 5 % soln	3	Preferred	EFUDEX
fluorouracil 5 % crm	4	Non-Preferred	EFUDEX
GASTROINTESTINAL AGENTS [AGENTES GASTROINTESTINALES]
Anti-Ulcer Agents [Agentes Anti-Ulceras]
misoprostol 100 mcg tab, 200 mcg tab	1	Preferred	CYTOTEC
sucralfate 1 gm tab	1	Preferred	CARAFATE
CARAFATE 1 gm/10ml susp	3	Non-Preferred
Histamine2 (H2) Receptor Antagonists [Antagonistas Del Receptor De H2]
famotidine 20 mg tab, 40 mg tab	1	Preferred	PEPCID

Page 129 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
ranitidine hcl 15 mg/ml syr, 150 mg/10ml syr, 300 mg tab, 75 mg/5ml syr	1	Preferred	ZANTAC
Proton Pump Inhibitors [Inhibidores De La Bomba De Protones]
omeprazole 10 mg cap dr, 20 mg cap dr	1	Preferred	PRILOSEC	QL=180 caps/ 365 días
omeprazole 40 mg cap dr	1	Preferred	PRILOSEC	QL=180 caps/ 365 días
HORMONAL AGENTS [AGENTES HORMONALES]
Mineralocorticoids [Mineralocorticoides]
fludrocortisone acetate 0.1 mg tab	1	Preferred	FLORINEF
IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
Cyclosporine Analogs [Análogos De Ciclosporina]
NEORAL 25 mg cap	3	Preferred		PA, P
cyclosporine modified 25 mg cap, 50 mg cap	3	Preferred	NEORAL	PA
cyclosporine 25 mg cap	4	Preferred	SANDIMMUNE	PA
cyclosporine modified 100 mg cap, 100 mg/ml soln	4	Preferred	NEORAL	PA
cyclosporine 100 mg cap	5	Preferred	SANDIMMUNE	PA
NEORAL 100 mg cap	5	Preferred		PA, P
cyclosporine 100 mg cap, 25 mg cap	6	Preferred	SANDIMMUNE	PA
SANDIMMUNE 100 mg cap, 100 mg/ml soln, 25 mg cap	6	Preferred		PA, P
NEORAL 100 mg/ml soln	7	Preferred		PA, P

Page 130 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
Glucocorticosteroids [Glucocorticoides]
dexamethasone 0.5 mg tab, 0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab	1	Preferred	DECADRON
MEDROL 2 mg tab	1	Preferred
methylprednisolone 32 mg tab, 4 mg tab	1	Preferred	MEDROL
methylprednisolone (pak) 4 mg tab	1	Preferred	MEDROL
prednisolone 15 mg/5ml soln, 15 mg/5ml syr	1	Preferred	PRELONE
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab	1	Preferred	DELTASONE
prednisone (pak) 10 mg tab, 5 mg tab	1	Preferred	DELTASONE
hydrocortisone 10 mg tab, 20 mg tab, 5 mg tab	2	Preferred	CORTEF
methylprednisolone 16 mg tab, 8 mg tab	2	Preferred	MEDROL
Organ Transplant Agents [Agentes Para Trasplantes]
azathioprine 50 mg tab	1	Preferred	IMURAN
mycophenolate mofetil 200 mg/ml susp, 250 mg cap, 500 mg tab	2	Preferred	CELLCEPT	PA
tacrolimus 0.5 mg cap	3	Non-Preferred	PROGRAF	PA
MYFORTIC 180 mg tab dr	4	Preferred		PA, P
tacrolimus 1 mg cap	4	Non-Preferred	PROGRAF	PA
sirolimus 0.5 mg tab, 1 mg tab, 2 mg tab	5	Non-Preferred	RAPAMUNE	PA
MYFORTIC 360 mg tab dr	6	Preferred		PA, P

Page 131 of 25

Revisado: 5 de mayo de 2017

ONCOLOGIA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
tacrolimus 5 mg cap	6	Non-Preferred	PROGRAF	PA
RAPAMUNE 1 mg/ml soln	8	Non-Preferred		PA
MINERALS & ELECTROLYTES [MINERALES Y ELECTROLITOS]
Calcium Regulating Agents [Agentes Reguladores De Calcio]
calcitriol 0.25 mcg cap	1	Preferred	ROCALTROL
calcitriol 0.5 mcg cap	2	Preferred	ROCALTROL

Page 132 of 25

A

acetaminophen-codeine	12
acetaminophen-codeine #2	12
acetaminophen-codeine #3	12
acetaminophen-codeine #4	13
ACTIMMUNE	27
acyclovir	20
AFINITOR	25
ALKERAN	23
amoxicillin	16
amoxicillin-pot clavulanate	16
ampicillin	16
anastrozole	26
ARANESP (ALBUMIN FREE)	21, 22
azathioprine	31
azithromycin	14

B

bicalutamide	24
BICILLIN L-A	16, 17

C

calcitriol	31, 32
capecitabine	24
CARAFATE	28
ciprofloxacin	17
ciprofloxacin hcl	17
clarithromycin	15
clotrimazole	27
codeine sulfate	13
cyanocobalamin	20
cyclosporine	29
cyclosporine modified	29

D

dapsone	19
dexamethasone	30
DEXFERRUM	22
DILANTIN	18

E

E.E.S. GRANULES	15
ERYPED 200	15
ERYPED 400	15

ERY-TAB	15
ERYTHROCIN STEARATE	15
erythromycin base	15
erythromycin ethylsuccinate	15
etoposide	27

F

famotidine	28
fentanyl	11, 12
fluconazole	19, 20
fludrocortisone acetate	28
fluorouracil	27
flutamide	24
folic acid	22

G

gabapentin	18
GLEEVEC	25

H

hydrocodone-acetaminophen	13
hydrocortisone	30
hydromorphone hcl	13, 14
hydroxyurea	24

I

ibuprofen	11
imatinib	25
indomethacin	11
INFED	22
iron	22

K

ketoconazole	20

L

leucovorin calcium	26
LEUKERAN	23
leuprolide acetate	26
levofloxacin	17
lidocaine viscous	14
lomustine	23
LUPRON DEPOT	26
LUPRON DEPOT-PED	26

Page 133 of 25

M

MATULANE	27
MEDROL	30
megestrol acetate	25, 26
meloxicam	11
meperidine hcl	13
mercaptopurine	24
methotrexate	24
methylprednisolone	30, 31
methylprednisolone (pak)	30
metoclopramide hcl	18
misoprostol	28
morphine sulfate	13, 14
morphine sulfate (concentrate)	14
morphine sulfate er	12
mycophenolate mofetil	31
mycophenolic acid	31
MYLERAN	23

N

nabumetone	11
naproxen	11
naproxen dr	11
NEORAL	29
NEULASTA	20
NEUPOGEN	20
NEXAVAR	25
nystatin	27

O

omeprazole	28
ondansetron	18
ondansetron hcl	18
oxycodone hcl	11, 12
oxycodone-acetaminophen	13, 14

P

penicillin g procaine	16
penicillin v potassium	16

phenytoin	18
phenytoin sodium extended	18
prednisolone	30
prednisone	30
prednisone (pak)	30
prochlorperazine	19
prochlorperazine edisylate	19
prochlorperazine maleate	19
PROCRIT	21, 22
promethazine hcl	19

R

ranitidine hcl	28
RAPAMUNE	31

S

SANDIMMUNE	29
sirolimus	31
SPRYCEL	25
STIVARGA	24
sucralfate	28
sulfadiazine	17
sulfamethoxazole-tmp ds	17
sulfamethoxazole-trimethoprim	17
sulindac	11

T

tacrolimus	31
tamoxifen citrate	24
TASIGNA	25
temozolomide	23
terbinafine hcl	20
tramadol hcl	13
trimethobenzamide hcl	19

Z

ZOLADEX	27

Page 134 of 25

ASES

Puerto Rico Healthcare Insurance Administration

Physical Health

2017

Formulary of Drugs Covered by

the Government Healthcare Plan (GHP)

Authorized by the P.R. Elections Commission CEE-SA-16-2732

Page 135 of 25

		GOVERNMENT OF PUERTO RICO	Hon. Ricardo A. Rosselló Nevares
		Healthcare Insurance Administration	Governor
			Ms. Ángela M. Ávila Marrero Executive Director

May 1, 2017

TO ALL GOVERNMENT HEALTHCARE PLAN (GHP) PROVIDERS

Dear provider:

I urge you to keep this guide for future reference. It is also available on our webpage, www.asespr.org .

Cordially,

[signed]

Ángela M. Ávila Marrero

Executive Director

PO Box 195661, San Juan, PR 00919-5661 · Tel.: 787.474.3300 · Fax: 787.474.3348 · www.ases.pr.gov

Page 136 of 25

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE

OF THE GOVERNMENT HEALTHCARE PLAN (GHP)

1.	Drug Formulary

Non-formulary drugs may only be used in exceptional cases through the Exception Process that we will explain in point number 2.

2.	Exception Process

Contraindication to the drug(s) included in the FDC;

History of a clinically significant adverse reaction to the drug(s) included in the FDC;

Evidence of therapeutic failure of all alternatives available in the FDC; and/or

Lack of a therapeutic alternative in the FDC.

3.	Other Aspects of the Prescription Drug Coverage

The prescription drug coverage of the GHP establishes that using generic bioequivalent products as the first option is mandatory.

Page 137 of 25

The maximum supply dispensed for acute conditions will cover a fifteen (15) day therapy. The treatment period may be extended, as applicable, when medically necessary.

ASES requires the use of generic bioequivalent drugs approved by the Food and Drug Administration (FDA) coded as “AB” and those authorized under applicable local regulations in Puerto Rico.

Drug prescriptions will be filled by a pharmacy contracted by the PBM that is duly authorized under the law of the Commonwealth of Puerto Rico and has been freely chosen by the beneficiary.

Page 138 of 25

4.	Emergency Rule

The products that appear in the Integrated Emergency Formulary (IEF) will be dispensed for five (5) business days, except as otherwise specified. The same thing applies to analgesics, narcotics, combination drugs, and nonsteroidal anti-inflammatory drugs, which will also be dispensed in amounts sufficient for five (5) business days.

If you have any questions about the prescription drug coverage, you may contact the insurance company contracted by ASES in your region and/or the Pharmacy Benefit Manager (PBM) contracted by ASES.

Page 139 of 25

PHYSICAL HEALTH

ASES

Puerto Rico Healthcare Insurance Administration

Physical Health

2017

Formulary of Drugs Covered by

the Government Healthcare Plan (GHP)

Page 140 of 25

SALUD FÍSICA

GOVERNMENT HEALTHCARE PLAN

FORMULARY OF DRUGS COVERED BY THE GHP (FDC)

2017

TABLE OF CONTENTS

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE OF THE GOVERNMENT HEALTHCARE PLAN		3
DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES		15
THERAPEUTIC CATEGORY		17
ANALGESICS		17
	Nonsteroidal Anti-Inflammatory Agents (NSAIDs)	17
	Long-Acting Opioid Analgesics	17
	Short-Acting Opioid Analgesics	18
	test	18
ANESTHETICS		19
	Local Anesthetics	19
ANTIANXIETY AGENTS		19
	Benzodiazepines	19
	Miscellaneous Anxiolytics	19
ANTIBACTERIALS		19
	Aminoglycosides	19
	First Generation Cephalosporins	20
	Macrolides	20
	Miscellaneous Antibacterials	20
	Quinolones	22
	Second Generation Cephalosporins	22
	Sulfonamides	22
	Tetracyclines	22
	Third Generation Cephalosporins	22

Page 141 of 25

SALUD FÍSICA

	Vaginal Antibiotics	23
ANTICONVULSANTS		23
	Anticonvulsants	23
ANTIDEMENTIA AGENTS		25
	Antidementia Agents	25
	Cholinesterase Inhibitors	25
	NMDA Receptor Antagonists	25
ANTIDEPRESSANTS		25
	Antidepressants	25
ANTIDIABETIC AGENTS		26
	Alpha-Glucosidase Inhibitors	26
	Biguanides	26
	Dipeptidyl Peptidase-4 (DPP-4) Inhibitors	26
	Glycemic Agents	26
	Insulin Mixtures	26
	Insulin Sensitizing Agents	26
	Intermediate-Acting Insulins	26
	Long-Acting Insulins	26
	Rapid-Acting Insulins	27
	Short-Acting Insulins	27
	Sulfonylureas	27
DIABETES SUPPLIES		27
	Needles & Syringes	27
ANTIEMETICS		27
	5-Hydroxytryptamine 3 (5-HT3) Antagonists	27

Page 142 of 25

SALUD FÍSICA

	Miscellaneous Antiemetics	27
	Phenothiazines	27
ANTIGOUT AGENTS		28
	Antigout Agents	28
	Uricosurics	28
ANTIHYPERTENSIVES		28
	Alpha-Adrenergic Agonists	28
	Alpha-Adrenergic Blocking Agents	28
	Angiotensin II Receptor Blockers (ARB)	28
	Angiotensin-Converting Enzyme (ACE) Inhibitors	28
	Calcium Channel Blocking Agents	29
	Carbonic Anhydrase Inhibitors Diuretics	30
	Cardioselective Beta Blocking Agents	30
	Cardioselective Beta-Adrenergic Blocking Agents	30
	Loop Diuretics	30
	Nonselective Beta Blocking Agents	31
	Potassium-Sparing Diuretics	31
	Thiazide Diuretics	31
	Vasodilator Beta Blockers	31
	Vasodilators	31
ANTIMIGRAINE AGENTS		32
	Beta-Adrenergic Blocking Agents	32
	Serotonin (5-HT) Receptor Agonists	32
ANTIMYASTHENIC AGENTS		32
	Parasympathomimetics	32

Page 143 of 25

SALUD FÍSICA

ANTIMYCOBACTERIALS		32
	Antituberculars	32
	Miscellaneous Antimycobacterials	32
ANTIMYCOTIC AGENTS		33
	Antifungals	33
	Vaginal Antifungals	33
	Antimalarials	33
	Antiprotozoals - Non-Antimalarials	33
ANTIPARASITICS		33
	Anthelmintics	33
ANTIPARKINSON AGENTS		33
	Anticholinergics	33
	Antiparkinson Dopaminergics	33
	Dopamine Precursors	34
	Monoamine Oxidase B (MAO-B) Inhibitors	34
	Anti-Influenza Agents	34
	Anti-Cytomegalovirus (CMV) Agents	35
	Antiherpetic Agents	35
	Antiretroviral Combinations	35
	Integrase Inhibitors	35
	Miscellaneous Anti-HIV Agents	35
	Non-Nucleoside Reverse Transcriptase Inhibitors	35
	Nucleoside/Nucleotide Reverse Transcriptase Inhibitors	36
BENIGN PROSTATIC HYPERTROPHY AGENTS		36
	5-Alpha Reductase Inhibitors	36

Page 144 of 25

SALUD FÍSICA

	Alpha-Adrenergic Blocking Agents	37
BLOOD MODIFIERS		37
	Anticoagulants	37
	Cobalamins	37
	Colony Stimulating Factors	37
	Erythropoiesis-Stimulating Agents	38
	Factor Xa Inhibitors	38
	Folates	39
	Iron	39
	Low Molecular Weight Heparins	39
	Platelet Modifying Agents	39
BONE DENSITY REGULATORS		39
	Bisphosphonates	39
CARDIOVASCULAR AGENTS		40
	Antiarrhythmics Class II	40
	Antiarrhythmics Type I-A	40
	Antiarrhythmics Type I-B	40
	Antiarrhythmics Type I-C	40
	Antiarrhythmics Type III	40
	Intermittent Claudication Agents	40
	Miscellaneous Cardiovascular Agents	40
	Pulmonary Hypertension Agents	41
	Vasodilators	41
CENTRAL NERVOUS SYSTEM AGENTS		41
	Multiple Sclerosis Agents	41

Page 145 of 25

SALUD FÍSICA

CHEMOTHERAPIES		42
	Alkylating Agents	42
	Angiogenesis Inhibitors	42
	Antiandrogens	42
	Antiestrogens	42
	Vaginal Estrogens	42
	Antimetabolites	42
	Antineoplastic Enzyme Inhibitors	43
	Appetite Stimulants	43
	Aromatase Inhibitors	43
	Folic Acid Antagonists Rescue Agents	43
	Luteinizing Hormone-Releasing (LHRH) Analogs	43
	Miscellaneous Antineoplastics	44
	Mitotic Inhibitors	44
DENTAL AND ORAL AGENTS		44
	Antifungals	44
	Oral Antiseptics	44
	Xerostomia	44
DERMATOLOGICAL AGENTS		45
	Acne Antibiotics	45
	Acne Products	45
	Antihistamines	45
	Antiseborrheic Products	45
	Dermatological Skin Cancer Agents	45
	Very High Potency Topical Glucocorticoids	45

Page 146 of 25

SALUD FÍSICA

	High Potency Topical Glucocorticoids	45
	Medium Potency Topical Glucocorticoids	46
	Low Potency Topical Glucocorticoids	46
	Pediculicides and Scabicides	46
	Topical Skin Antibiotics	46
	Topical Antifungals	46
	Topical Antipsoriatics	46
DYSLIPIDEMICS		46
	Bile Acid Sequestrants	46
	Fibric Acid Derivatives	46
	HMG-CoA Reductase Inhibitors	46
GASTROINTESTINAL AGENTS		47
	Antispasmodics	47
	Anti-Ulcer Agents	47
	Digestive Enzymes	47
	Histamine2 (H2) Receptor Antagonists	47
	Miscellaneous Gastrointestinal Agents	47
	Proton Pump Inhibitors	48
	Rectal Anti-Inflammatories	48
GENITOURINARY AGENTS		48
	Miscellaneous Genitourinary Agents	48
	Phosphate Binder Agents	48
	Urinary Antibiotics	48
	Urinary Antispasmodics	48
HEMATOLOGICAL AGENTS		48

Page 147 of 25

SALUD FÍSICA

	Antihemophilic Products	48
	Hemostatics	49
HORMONAL AGENTS		50
	Androgens	50
	Antithyroid Agents	50
	Calcimimetics	50
	Dopamine Agonists	50
	Dysmenorrhea Agents	50
	Estrogens	50
	Estrogens and Progestins	51
	Growth Hormones Analogs	51
	Mineralocorticoids	51
	Prostaglandins	51
	Somatostatic Analogs	51
	Thyroid Hormones	52
	Vasopressin Analogs	52
IMMUNOLOGICAL AGENTS		52
	Immunomodulators (TNF and Non-TNF)	52
IMMUNOSUPPRESSANTS		53
	Glucocorticosteroids	53
	Organ Transplant Agents	54
INFLAMMATORY BOWEL DISEASE		55
	Aminosalicylates	55
	Immunomodulators (TNF and Non-TNF)	55
	Intrarectal Low Potency Glucocorticoids	55

Page 148 of 25

SALUD FÍSICA

	Sulfonamides	55
MINERALS & ELECTROLYTES		55
	Calcium Regulating Agents	55
	Carnitine Deficiency	56
	Chelating Agents	56
	Electrolytes/Minerals Replacement	56
	Potassium Removing Resins	56
	Prenatal Vitamins	56
	Vitamin K	57
MUSCLE RELAXANTS		57
	Antispasticity Agents	57
	Skeletal Muscle Relaxants	57
NASAL AGENTS		57
	Nasal Anticholinergics	57
	Nasal Mast Cell Stabilizers	57
	Nasal Steroids	57
OPHTHALMIC AGENTS		57
	Antiglaucoma Agents	57
	Miotics	58
	Mydriatics	58
	Nonsteroidal Anti-Inflammatory Agents (NSAIDs)	58
	Ophthalmic Antibiotics	58
	Ophthalmic Antivirals	58
	Ophthalmic Prostaglandins	58
	Ophthalmic Steroids	59

Page 149 of 25

SALUD FÍSICA

OTIC AGENTS		59
	Miscellaneous Otic Agents	59
	Otic Antibiotics	59
RESPIRATORY AGENTS		59
	Anticholinergic Bronchodilators	59
	Antileukotrienes	59
	Antitussive-Expectorant	59
	Bronchiolitis Agents	59
	Inhaled Corticosteroids	60
	Nonsedating Histamine1 Blocking Agents	60
	Phosphodiesterase Inhibitors	60
	Sympathomimetic Bronchodilators	61
RHEUMATOID ARTHRITIS AGENTS		61
	Immunomodulators (TNF and Non-TNF)	61
	Non-Biologic Agents	61

Page 150 of 25

SALUD FÍSICA

DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES

The example below illustrates the information provided for the drugs included in the FDC.

Drug Name	Net Cost	Tier	Reference Name	Requirements/ Limits
THERAPEUTIC CATEGORY
Therapeutic Class
ANALGESICS
Nonsteroidal Anti-Inflammatory Agents (NSAIDs)
ibuprofen 400 mg tab, 600 mg tab, 800 mg tab	1	Preferred	MOTRIN
indomethacin 25 mg cap, 50 mg cap	1	Preferred	INDOCIN
nabumetone 500 mg tab, 750 mg tab	1	Preferred	RELAFEN
naproxen 250 mg tab, 375 mg tab, 500 mg tab	1	Preferred	NAPROSYN
naproxen dr 375 mg tab dr, 5 0 0 mg tab dr	1	Preferred	NAPROSYN
naproxen sodium 275 mg tab, 550 mg tab	1	Preferred	ANAPROX
salsalate 500 mg tab, 750 mg tab	1	Preferred	DISALCID
sulindac 150 mg tab, 200 mg tab	1	Preferred	CLINORIL
celecoxib 50 mg cap	2	Non- preferred	CELEBREX	ST

Page 151 of 25

SALUD FÍSICA

MONTHLY NET COST RANGE

1	less than $20	Least costly per month
2	$20 - $49
3	$50 - $99
4	$100 - $199
5	$200 - $349
6	$350 - $549
7	$550 - $799
8	$800 - $1,099
9	$1,100 - $1,499
10	$1,500 - $1,999
11	$2,000 - $2,499
12	$2,500 - $2,999
13	$3,000 - $3,499
14	$3,500 - $3,999
15	$4,000 - $4,499
16	$4,500 - $4,999
17	$5,000 - $5,499
18	$5,500 - $5,999
19	$6,000 - $6,499
20	$6,500 - $6,999
21	$7,000 - $7,499
22	$7,500 - $7,999
23	$8,000 - $8,499
24	$8,500 - $9,000
25	more than $9,000	Most costly per month

Page 152 of 25

SALUD FÍSICA

The net cost analysis is an ongoing exercise subject to constant changes. Net costs as published here are current as of the date of this edition of the FDC.

Page 153 of 25

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Terapéutica]
ANALGESICS [ANA LGÉSICOS]
Nonsteroidal Anti-Inflammatory Agents (NSAIDs) [Anti-Inflamatorios No Esteroidales]
ibuprofen 400 mg tab, 600 mg tab, 800 mg tab	1	Preferred	MOTRIN	QL=15 días No refills
indomethacin 25 mg cap, 50 mg cap	1	Non-Preferred	INDOCIN
nabumetone 500 mg tab, 750 mg tab	1	Preferred	RELAFEN
naproxen 250 mg tab, 375 mg tab, 500 mg tab	1	Preferred	NAPROSYN	QL=15 días No refills
naproxen dr 375 mg tab dr, 500 mg tab dr	1	Preferred	NAPROSYN	QL=15 días No refills
salsalate 500 mg tab, 750 mg tab	1	Preferred	DISALCID
sulindac 150 mg tab, 200 mg tab	1	Preferred	CLINORIL
meloxicam7.5 mg tab, 15 mg tab	1	Preferred	MOBIC	QL=15 días No refills
Long-Acting Opioid Analgesics [Analgésicos Opiodes de Larga Duración]
fentanyl 25 mcg/hr td patch 72 hr	2	Preferred	DURAGESIC
fentanyl 50 mcg/hr td patch 72 hr, 75 mcg/hr td patch 72 hr	3	Preferred	DURAGESIC
morphine sulfate er 15 mg tab er	3	Preferred	MORPHINE
fentanyl 100 mcg/hr td patch 72 hr	4	Preferred	DURAGESIC
morphine sulfate er 30 mg tab er	4	Preferred	MORPHINE
morphine sulfate er 60 mg tab er	5	Preferred	MORPHINE
morphine sulfate er 100 mg tab er	6	Preferred	MORPHINE

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
methadone hcl oral tablet 10 mg		Preferred	METHADONE	ASSMCA
methadone hcl oral solution 10 mg/ 5ml		Preferred	METHADONE	ASSMCA
Short-Acting Opioid Analgesics [Analgésicos Opiodes de Corta Duración]
test
acetaminophen-codeine 120-12 mg/5ml soln, 30015 mg tab, 300-30 mg tab, 300-60 mg tab	1	Preferred	TYLENOL-CODEINE	QL=15 días No refills
hydrocodoneacetaminophen 10-325 mg tab, 5-325 mg tab, 7.5-325 mg tab, 7.5-500 mg/15ml soln	1	Preferred	VICODIN	QL=15 días No refills
hydromorphone hcl 2 mg tab, 4 mg tab	1	Preferred	DILAUDID
meperidine hcl 50 mg/ml inj soln	1	Preferred	DEMEROL
morphine sulfate 15 mg tab, 30 mg tab	1	Preferred	MORPHINE
oxycodone-acetaminophen 5-325 mg tab	1	Preferred	OXYCODONE APAP	QL=15 días No refills
tramadol hcl 50 mg tab	1	Preferred	ULTRAM
butalbital-apap-caffeine 50325-40 mg cap, 50-325-40 mg tab	2	Preferred	FIORICET	QL=15 días No refills
codeine sulfate 15 mg tab, 30 mg tab, 60 mg tab	2	Preferred	CODEINE
meperidine hcl 100 mg/ml inj soln	2	Preferred	DEMEROL
morphine sulfate 10 mg/5ml soln	2	Preferred	MORPHINE
morphine sulfate (concentrate) 100 mg/5ml soln, 20 mg/ml soln	2	Preferred	MORPHINE
hydromorphone hcl 8 mg tab	3	Preferred	DILAUDID

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
oxycodone-acetaminophen 10-325 mg tab, 7.5-325 mg tab	3	Preferred	OXYCODONE APAP	QL=15 días No refills
hydromorphone hcl 1 mg/ml oral liquid	4	Preferred	DILAUDID
ANESTHETICS [ANESTÉSICOS]
Local Anesthetics [Anestésicos Locales]
lidocaine viscous 2 % mouth/throat soln	1	Preferred	XYLOCAINE
ANTIANXIETY AGENTS [AGENTES PARA LA ANSIEDAD]
Benzodiazepines [Ben zodiazepinas]
clonazepam 0.5 mg tab, 1 mg tab, 2mg tab	1	Preferred	KLONOPIN
diazepam 1 mg/ml soln, 10 mg tab, 2 mg tab, 5 mg tab, 5 mg/ml oral conc	1	Preferred	VALIUM	MENTAL/ SUB MENTAL QL= 5días
flurazepam hcl 15 mg cap, 30 mg cap	1	Preferred	DALMANE	MENTAL/ SUB MENTAL QL= 5días
lorazepam 0.5 mg tab, 1 mg tab	1	Preferred	ATIVAN	MENTAL/ SUB MENTAL QL= 5días
midazolam hcl 10 mg/10ml inj soln, 2 mg/2ml inj soln, 5 mg/5ml inj soln, 5 mg/ml inj soln	1	Preferred	VERSED	QL 5ml / 30días
Miscellaneous Anxiolytics [Ansiolíticos Misceláneos]
hydroxyzine pamoate 100 mg cap, 25 mg cap, 50 mg cap	1	Preferred	VISTARIL
ANTIBACTERIALS [ANTIBACTERIANOS]
Aminoglycosides [Aminoglucósidos]
tobramycin 300 mg/5ml inh neb soln	18	Non-Preferred	TOBI	PA

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 57 de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
First Generation Cephalosporins [Cefalosporinas de Primera Generación]
cephalexin 125 mg/5ml susp, 250 mg cap, 500 mg cap	1	Preferred	KEFLEX
cefadroxil 250 mg/5ml susp	2	Non-Preferred	DURICEF	AL ≤ 12 años
cephalexin 250 mg/5ml susp	2	Preferred	KEFLEX
cefadroxil 500 mg/5ml susp	3	Non-Preferred	DURICEF	AL ≤ 12 años
Macrolides [Macrólidos]
azithromycin 250 mg tab, 500 mg tab	1	Preferred	ZITHROMAX
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab	2	Preferred	ZITHROMAX
clarithromycin 125 mg/5ml susp, 250 mg tab, 500 mg tab	2	Preferred	BIAXIN
clarithromycin 250 mg/5ml susp	3	Preferred	BIAXIN
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab	3	Preferred	ERY-TAB
erythromycin ethylsuccinate 400 mg tab	3	Preferred	E.E.S.
ERYTHROCIN STEARATE 250 mg tab	4	Non-Preferred
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
clindamycin hcl 150 mg cap, 300 mg cap, 75 mg cap	1	Preferred	CLEOCIN
MACRODANTIN 25 mg cap	1	Preferred
metronidazole 250 mg tab, 500 mg tab	1	Preferred	FLAGYL
nitrofurantoin macrocrystal 50 mg cap	1	Preferred	MACRODANTIN

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
nitrofurantoin macrocrystal 100 mg cap	2	Preferred	MACRODANTIN
nitrofurantoin monohyd macro 100 mg cap	2	Preferred	MACROBID
nitrofurantoin oral suspension 25 MG/5ML	6	Non-Preferred	FURADANTIN
vancomycin hcl 125 mg cap	9	Non-Preferred	VANCOCIN
vancomycin hcl 250 mg cap	10	Non-Preferred	VANCOCIN
Penincillinis [Penicilinas]
amoxicillin 125 mg/5ml susp, 200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab	1	Preferred	AMOXIL
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 400-57 mg/5ml susp, 500125 mg tab, 600-42.9 mg/5ml susp, 875-125 mg tab	1	Preferred	AUGMENTIN
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap	1	Preferred	PRINCIPEN
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab	1	Preferred	VEETIDS
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp	3	Preferred	AUGMENTIN
BICILLIN L-A 600000 unit/ml im susp	3	Non-Preferred
penicillin g procaine 600000 unit/ml im susp	3	Non-Preferred	BICILLIN LA

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
BICILLIN L-A 1200000 unit/2ml im susp	4	Non-Preferred
BICILLIN L-A 2400000 unit/4ml im susp	5	Non-Preferred
Quinolones [Quinolonas]
ciprofloxacin hcl 250 mg tab, 500 mg tab, 750 mg tab	1	Preferred	CIPRO
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab	1	Preferred	LEVAQUIN
ciprofloxacin 500 mg/5ml (10%) susp	3	Preferred	CIPRO
ciprofloxacin 250 mg/5ml (5%) susp	4	Preferred	CIPRO
Second Generation Cephalosporins [Cefalosporinas de Segunda Generación]
cefaclor 250 mg cap, 500 mg cap	2	Preferred	CECLOR
cefprozil 125 mg/5ml susp, 250 mg tab, 250 mg/5ml susp, 500 mg tab	2	Preferred	CEFZIL
Sulfonamides [Sulfonamidas]
sulfamethoxazole -tmp ds 800-160 mg tab	1	Preferred	SEPTRA
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab	1	Preferred	SEPTRA
sulfadiazine 500 mg tab	4	Preferred	SULFADIAZINE
Tetracyclines [Tetraciclinas]
minocycline hcl 100 mg cap, 50 mg cap, 75 mg cap	1	Preferred	MINOCIN
doxycycline monohydrate 50 mg cap, 100 mg cap	2	Non-Preferred	MONODOX
Third Generation Cephalosporins [Cefalosporinas de Tercera Generación]
cefdinir 125 mg/5ml susp, 300 mg cap	2	Preferred	OMNICEF
cefdinir 250 mg/5ml susp	3	Preferred	OMNICEF

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Vaginal Antibiotics [Antibióticos Vaginales]
metronidazole 0.75 % vag gel	2	Preferred	VANDAZOLE
clindamycin phosphate 2 % vag crm	3	Non-Preferred	CLEOCIN
ANTICONVULSANTS [ANTICONVULSIVANTES]
Anticonvulsants [Anticonvulsivantes]
carbamazepine 100 mg tab chew, 200 mg tab	1	Preferred	TEGRETOL
clonazepam 0.5 mg tab, 1 mg tab, 2 mg tab	1	Preferred	KLONOPIN
divalproex sodium 125 mg tab dr, 250 mg tab dr, 500 mg tab dr	1	Preferred	DEPAKOTE
gabapentin 100 mg cap, 300 mg cap, 400 mg cap, 600 mg tab, 800 mg tab	1	Preferred	NEURONTIN
lamotrigine 100 mg tab, 150 mg tab, 200 mg tab, 25 mg tab	1	Preferred	LAMICTAL
lamotrigine chew tab 5 mg, 25 mg	3	Non-Preferred	LAMICTAL
levetiracetam 250 mg tab, 500 mg tab	1	Preferred	KEPPRA
levetiracetam er 24 hrs 500 mg tab, 750 mg	3	Non-Preferred	KEPPRA XR
oxcarbazepine 150 mg tab	1	Preferred	TRILEPTAL
phenobarbital 100 mg tab, 15 mg tab, 16.2 mg tab, 30 mg tab, 32.4 mg tab, 60 mg tab, 64.8 mg tab, 97.2 mg tab	1	Preferred	PHENOBARBITAL
primidone 250 mg tab, 50 mg tab	1	Preferred	MYSOLINE
topiramate 100 mg tab, 200 mg tab, 25 mg tab, 50 mg tab	1	Preferred	TOPAMAX

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
valproic acid 250 mg cap, 250 mg/5ml syr	1	Preferred	DEPAKENE
zonisamide 50 mg cap	1	Preferred	ZONEGRAN
DILANTIN 30 mg cap	2	Preferred
gabapentin 250 mg/5ml soln	2	Preferred	NEURONTIN
levetiracetam 100 mg/ml soln, 1000 mg tab, 750 mg tab	2	Preferred	KEPPRA
oxcarbazepine 300 mg tab, 600 mg tab	2	Preferred	TRILEPTAL
phenytoin 125 mg/5ml susp, 50 mg tab chew	2	Preferred	DILANTIN
phenytoin sodium extended 100 mg cap, 200 mg cap, 300 mg cap	2	Preferred	DILANTIN
zonisamide 100 mg cap, 25 mg cap	2	Preferred	ZONEGRAN
carbamazepine er 200 mg tab er 12 hr	3	Preferred	TEGRETOL
ethosuximide 250 mg cap, 250 mg/5ml soln	3	Preferred	ZARONTIN
phenobarbital 20 mg/5ml oral elix, 20 mg/5ml soln	3	Preferred	PHENOBARBITAL
carbamazepine 100 mg/5ml susp	4	Preferred	TEGRETOL
carbamazepine er 400 mg tab er 12 hr	4	Preferred	TEGRETOL
oxcarbazepine 300 mg/5ml susp	4	Preferred	TRILEPTAL
VIMPAT 10 mg/ml soln, 100 mg tab, 150 mg tab, 50 mg tab	5	Preferred		PA, C
VIMPAT 200 mg tab, 200 mg/20ml iv soln	6	Preferred		PA, C

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
ANTIDEMENTIA AGENTS [AGENTES ANTIDEMENCIA]
Antidementia Agents [Agen tes Antidemencia]
ergoloid mesylates 1 mg tab	6	Non-Preferred	HYDERGINE
Cholinesterase Inhibitors [Inhibidores de Colinesterasa]
donepezil hcl 10 mg tab, 10 mg odt, 5 mg tab, 5 mg odt	1	Preferred	ARICEPT
rivastigmine tartrate 1.5 mg cap, 3 mg cap, 4.5 mg cap, 6 mg cap	3	Preferred	EXELON
NMDA Receptor Antagonists [Antagonista del Receptor NMDA]
memantine 10 mg tab, 5 mg tab	1	Preferred	NAMENDA
memantine TITRATION PAK 5 (28)-10 (21) mg tab	1	Preferred	NAMENDA
ANTIDEPRESSANTS [ANTIDEPRESIVOS]
Antidepressants [Antidepresivos]
amitriptyline hcl 10 mg tab, 100 mg tab, 150 mg tab, 25 mg tab, 50 mg tab, 75 mg tab	1	Preferred	ELAVIL	MENTAL, SUB MENTAL
doxepin hcl 10 mg cap, 10 mg/ml oral conc, 25 mg cap, 50 mg cap, 75 mg cap	1	Preferred	SINEQUAN	MENTAL, SUB MENTAL
imipramine hcl 10 mg tab, 25 mg tab, 50 mg tab	1	Preferred	TOFRANIL	MENTAL, SUB MENTAL
nortriptyline hcl 10 mg cap, 10 mg/5ml soln, 25 mg cap, 50 mg cap, 75 mg cap	1	Preferred	PAMELOR	MENTAL, SUB MENTAL
doxepin hcl 100 mg cap, 150 mg cap	2	Preferred	SINEQUAN	MENTAL, SUB MENTAL
duloxetine 20 mg cap, 30 mg cap, 60 mg cap	2	Non-Preferred	CYMBALTA

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
ANTIDIABETIC AGENTS [AGENTES ANTIDIABÉTICOS]
Alpha-Glucosidase Inhibitors [Inhibidores de Alfa Glucosidasa]
acarbose 100 mg tab, 25 mg tab, 50 mg tab	2	Preferred	PRECOSE
Biguanides [Biguanidas]
metformin hcl 1000 mg tab, 500 mg tab, 850 mg tab	1	Preferred	GLUCOPHAGE
metformin hcl er 500 mg tab er 24 hr, 750 mg tab er 24 hr	1	Preferred	GLUCOPHAGE XR
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors [Inhibidores de DPP-4]
KOMBIGL YZE XR 2.51000 mg tab er 24 hr, 5- 1000 mg tab er 24 hr, 5-500 mg tab er 24 hr	3	Preferred		ST, C
ONGLYZA 2.5 mg tab, 5 mg tab	3	Preferred		ST, C
Glycemic Agents [Agentes Glicémicos]
GLUCAGON EMERGENCY 1 mg inj kit	4	Preferred
Insulin Mixtures [Mezclas de Insulinas]
HUMULIN 70/30 (70 -30) 100 unit/ml sc susp	3	Preferred		C
HUMALOG MIX 75/25 (7525) 100 unit/ml sc susp	4	Preferred		C
HUMALOG MIX 50/50 (5050) 100 unit/ml sc susp	4	Preferred		C
Insulin Sensitizing Agents [Agentes Sensibilizantes de Insulin]
pioglitazone hcl 15 mg tab, 30 mg tab, 45 mg tab	1	Preferred	ACTOS
Intermediate-Acting Insulins [Insulinas de Duración Intermedia]
HUMULIN N 100 unit/ml sc susp	2	Preferred		C
Long-Acting Insulins [Insulinas de Larga Duración]
LANTUS SOLOSTAR 100 unit/ml subcutaneous solution pen-injector	2	Preferred		C

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
LANTUS 100 unit/ml sc soln	3	Preferred		C
Rapid-Acting Insulins [Insulinas de Rápida Duración]
HUMALOG 100 unit/ml sc soln	3	Preferred		C
Short-Acting Insulins [Insulinas de Corta Duración]
HUMULIN R 100 unit/ml inj soln	2	Preferred		C
Sulfonylureas [Sulfonilureas]
glimepiride 1 mg tab, 2 mg tab, 4 mg tab	1	Preferred	AMARYL
glipizide 10 mg tab, 5 mg tab	1	Preferred	GLUCOTROL
DIABETES SUPPLIES [SUMINISTROS PARA DIABETES]
Needles & Syringes [Agujas y Jeringuillas]
insulin syringe/needle	1	Preferred
ANTIEMETICS [ANTIEMÉTICOS]
5-Hydroxytryptamine 3 (5-HT3) Antagonists [Antagonistas de 5-HT3]
ondansetron 4 mg odt, 8 mg odt	1	Preferred	ZOFRAN ODT
ondansetron hcl 24 mg tab, 4 mg tab, 8 mg tab	1	Preferred	ZOFRAN
Miscellaneous Antiemetics [Antieméticos Misceláneos]
metoclopramide hcl 10 mg tab, 10 mg/10ml soln, 5 mg tab, 5 mg/5ml soln, 5 mg/ml inj soln	1	Preferred	REGLAN
promethazine hcl 12.5 mg tab, 25 mg tab, 50 mg tab, 6.25 mg/5ml soln, 6.25 mg/5ml syr, 25 mg/ml inj soln, 50 mg/ml inj soln	1	Preferred	PHENERGAN
trimethobenzamide hcl 300 mg cap	1	Preferred	TIGAN
Phenothiazines [Fenotiazinas]
prochlorperazine edisylate 5 mg/ml inj soln	1	Preferred	COMPAZINE

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
prochlorperazine maleate 10 mg tab, 5 mg tab	1	Preferred	COMPAZINE
prochlorperazine 25 mg rect supp	4	Non-Preferred	COMPAZINE
ANTIGOUT AGENTS [AGENTES ANTIGOTA]
Antigout Agents [Agentes Antigota]
allopurinol 100 mg tab, 300 mg tab	1	Preferred	ZYLOPRIM
colchicine 0.6 mg cap	3	Preferred	MITIGARE	PA
colchicine 0.6 mg tab	3	Non-Preferred	COLCRYS	QL= 3 tab, 15días
Uricosurics [Uricosúricos]
probenecid 500 mg tab	1	Preferred	BENEMID
ANTIHYPERTENSIVES [ANTIHIPERTENSIVOS]
Alpha-Adrenergic Agonists [Agonistas Alfa Adrenérgicos]
clonidine hcl 0.1 mg tab, 0.2 mg tab, 0.3 mg tab	1	Preferred	CATAPRESS
methyldopa 250 mg tab, 500 mg tab	1	Preferred	ALDOMET
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
terazosin hcl 1 mg cap, 10 mg cap, 2 mg cap, 5 mg cap	1	Preferred	HYTRIN
Angiotensin II Receptor Blockers (ARB) [Antagonistas Del Receptor Angiotensina II]
losartan potassium 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	COZAAR
losartan potassium-hctz 100-12.5 mg tab, 100-25 mg tab, 50-12.5 mg tab	1	Preferred	HYZAAR
Angiotensin-Converting Enzyme (ACE) Inhibitors [Inhibidores de la Enzima Convertidora de Angiotensin]
fosinopril sodium 10 mg tab, 20 mg tab, 40 mg tab	1	Preferred	MONOPRIL
lisinopril 10 mg tab, 2.5 mg tab, 20 mg tab, 30 mg tab, 40 mg tab, 5 mg tab	1	Preferred	ZESTRIL

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
lisinopril- hydrochlorothiazide 1012.5 mg tab, 20-12.5 mg tab, 20-25 mg tab	1	Preferred	ZESTORETIC
Calcium Channel Blocking Agents [Bloqueadores de Canales de Calcio]
amlodipine besylate 10 mg tab, 2.5 mg tab, 5 mg tab	1	Preferred	NORVASC
diltiazem hcl 120 mg tab, 30 mg tab, 60 mg tab, 90 mg tab	1	Preferred	CARDIZEM
diltiazem hcl er 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr	1	Preferred	DILACOR XR
diltiazem hcl er beads 120 mg cap er 24 hr	1	Preferred	TIAZAC
diltiazem hcl er coated beads 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr	1	Preferred	CARDIZEM CD
dilt-xr 120 mg cap er 24 hr, 180 mg cap er 24 hr, 240 mg cap er 24 hr	1	Preferred	DILACOR XR
nifedipine er osmotic 30 mg tab er 24 hr	1	Preferred	PROCARDIA XL
verapamil hcl 120 mg tab, 40 mg tab, 80 mg tab	1	Preferred	CALAN
verapamil hcl er 120 mg tab er, 180 mg tab er, 240 mg tab er	1	Preferred	CALAN SR
diltiazem hcl er beads 180 mg cap er 24 hr, 240 mg cap er 24 hr, 300 mg cap er 24 hr, 360 mg er 24 hr	2	Preferred	TIAZAC
diltiazem hcl er coated beads 300 mg cap er 24 hr	2	Preferred	CARDIZEM CD

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
nifedipine er osmotic 60 mg tab er 24 hr, 90 mg tab er 24 hr	2	Preferred	PROCARDIA XL
Carbonic Anhydrase Inhibitors Diuretics [Diuréticos Inhibidores de Anhidrasa Carbónica]
acetazolamide 125 mg tab, 250 mg tab	3	Preferred	DIAMOX
Cardioselective Beta Blocking Agents [Bloqueadores Beta Cardioselectivos]
atenolol 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	TENORMIN
metoprolol succinate er 25 mg tab er 24 hr, 50 mg tab er 24 hr	1	Preferred	TOPROL XL
metoprolol tartrate 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	LOPRESSOR
metoprolol succinate er 100 mg tab er 24 hr, 200 mg tab er 24 hr	2	Non-Preferred	TOPROL XL
Cardioselective Beta-Adrenergic Blocking Agents [Bloqueadores Beta-Adrenérgicos Cardioselectivos]
atenolol -chlorthalidone 100-25 mg tab, 50-25 mg tab	1	Preferred	TENORETIC
metoprolol- hydrochlorothiazide 50-25 mg tab	2	Non-Preferred	LOPRESSOR HCT
metoprolol- hydrochlorothiazide 100-25 mg tab, 100-50 mg tab	3	Non-Preferred	LOPRESSOR HCT
Loop Diuretics [Diuréticos del Asa]
bumetanide 0.5 mg tab, 1 mg tab, 2 mg tab	1	Non-Preferred	BUMEX
furosemide 10 mg/ml soln, 20 mg tab, 40 mg tab, 80 mg tab	1	Preferred	LASIX

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Nonselective Beta Blocking Agents [Bloqueadores Beta No-Selectivos]
propranolol hcl 10 mg tab, 20 mg tab, 20 mg/5ml soln, 40 mg tab, 40 mg/5ml soln, 80 mg tab	1	Preferred	INDERAL
propranolol hcl 60 mg tab	2	Non-Preferred	INDERAL
Potassium-Sparing Diuretics [Diuréticos Conservadores de Potasio]
spironolactone 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	ALDACTONE
triamterene-hctz 37.5-25 mg cap, 37.5-25 mg tab, 75-50 mg tab	1	Preferred	MAXZIDE
Thiazide Diuretics [Diuréticos Tiazidas]
chlorothiazide 250 mg tab, 500 mg tab	1	Preferred	DIURIL
chlorthalidone 25 mg tab, 50 mg tab	1	Non-Preferred	HYGROTON
DIURIL 250 mg/5ml susp	1	Preferred
hydrochlorothiazide 12.5 mg tab, 25 mg tab, 50 mg tab	1	Preferred	MICROZIDE
indapamide 1.25 mg tab, 2.5 mg tab	1	Preferred	LOZOL
metolazone 2.5 mg tab, 5 mg tab	1	Non-Preferred	ZAROXOLYN
chlorthalidone 100 mg tab	2	Non-Preferred	HYGROTON
metolazone 10 mg tab	2	Non-Preferred	ZAROXOLYN
Vasodilator Beta Blockers [Bloqueadores Beta Vasodilatadores]
carvedilol 12.5 mg tab, 25 mg tab, 3.125 mg tab, 6.25 mg tab	1	Preferred	COREG
Vasodilators [Vasodilatadores]
hydralazine hcl 10 mg tab, 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	APRESOLINE
minoxidil 10 mg tab, 2.5 mg tab	1	Preferred	LONITEN

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
ANTIMIGRAINE AGENTS [AGENTES ANTIMIGRAÑA]
Beta-Adrenergic Blocking Agents [Bloqueadores Beta Adrenérgicos]
divalproex sodium 125 mg tab dr, 250 mg tab dr, 500 mg tab dr	1	Preferred	DEPAKOTE
topiramate 100 mg tab, 200 mg tab, 25 mg tab, 50 mg tab	1	Preferred	TOPAMAX
Serotonin (5-HT) Receptor Agonists [Agonistas Del Receptor De Serotonina]
sumatriptan succinate 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	IMITREX	QL= 6 tab
ANTIMYASTHENIC AGENTS [AGENTES ANTIMIASTÉNICOS]
Parasympathomimetics [Parasimpatomiméticos]
pyridostigmine bromide 60 mg tab	2	Preferred	MESTINON
MESTINON 60 mg/5ml syr	4	Non-Preferred
pyridostigmine bromide 180 mg tab er	6	Non-Preferred	MESTINON
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
Antituberculars [Antituberculosos]
isoniazid 100 mg tab, 300 mg tab	1	Preferred	ISONIAZID
rifampin 150 mg cap	1	Preferred	RIFADIN
ethambutol hcl 100 mg tab	2	Non-Preferred	MYAMBUTOL
pyrazinamide 500 mg tab	2	Non-Preferred	PYRAZINAMIDE
rifampin 300 mg cap	2	Preferred	RIFADIN
ethambutol hcl 400 mg tab	3	Non-Preferred	MYAMBUTOL
isoniazid 50 mg/5ml syr	5	Non-Preferred	ISONIAZID
rifabutin 150 mg cap			MYCOBUTIN	Puerto Rico Health Department Tuberculosis Control Program
cycloserine 250 mg cap			SEROMYCIN
RIFAMATE 50-300 mg cap
TRECATOR 250 mg tab
CAPASTAT 1 gm inj
Miscellaneous Antimycobacterials [Antimicobacterianos Misceláneos]
dapsone 100 mg tab, 25 mg tab	2	Preferred	DAPSONE

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
ANTIMYCOTIC AGENTS [ANTIMICÓTICOS]
Antifungals [Antifungales]
fluconazole 10 mg/ml susp, 100 mg tab, 150 mg tab, 200 mg tab, 50 mg tab	1	Preferred	DIFLUCAN
ketoconazole 200 mg tab	1	Preferred	NIZORAL
nystatin 100000 unit/gm crm	1	Preferred	MYCOSTATIN
terbinafine hcl 250 mg tab	1	Preferred	LAMISIL
fluconazole 40 mg/ml susp	2	Preferred	DIFLUCAN
itraconazole 100 mg cap		Preferred	SPORANOX	SIDA
Vaginal Antifungals [Antifungales Vaginales]
terconazole 0.4 % vag crm, 0.8 % vag crm	2	Preferred	TERAZOL
Antimalarials [Antimaláricos]
chloroquine phosphate 250 mg tab, 500 mg tab	1	Preferred	ARALEN
hydroxychloroquine sulfate 200 mg tab	1	Preferred	PLAQUENIL
DARAPRIM 25 mg tab	19	Non-Preferred		PA
Antiprotozoals - Non-Antimalarials [Antiprotozoarios No-Antimalaráricos]
NEBUPENT 300 mg inh soln	4	Non-Preferred		PA
ANTIPARASITICS [ANTIPARASITARIOS]
Anthelmintics [Antihelmínticos]
PIN-X 720.5 mg chew tab	1	Preferred		OTC
REESES PINWORM MEDICINE 144 mg/ml Susp	1	Preferred		OTC
BILTRICIDE 600 mg tab	7	Non-Preferred		PA
ANTIPARKINSON AGENTS [AGENTES ANTIPARKINSON]
Anticholinergics [Anticolinérgicos]
benztropine mesylate 0.5 mg tab, 1 mg tab, 2 mg tab	1	Preferred	COGENTIN
Antiparkinson Dopaminergics [Dopaminérgicos Antiparkinson]
amantadine hcl 50 mg/5ml syr	1	Preferred	SYMMETREL

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
pramipexole dihydrochloride 0.125 mg tab, 0.25 mg tab, 0.5 mg tab, 0.75 mg tab, 1 mg tab, 1.5 mg tab	1	Preferred	MIRAPEX
ropinirole hcl 0.25 mg tab, 0.5 mg tab, 1 mg tab, 3 mg tab, 4 mg tab, 5 mg tab	1	Preferred	REQUIP
ropinirole hcl 2 mg tab	2	Preferred	REQUIP
amantadine hcl 100 mg cap	3	Preferred	SYMMETREL
bromocriptine mesylate 2.5 mg tab	3	Preferred	PARLODEL
carbidopa-levodopaentacapone 18.75-75-200 mg tab	4	Non-Preferred	STALEVO
carbidopa-levodopaentacapone 12.5-50-200 mg tab, 25-100-200 mg tab, 31.25-125-200 mg tab, 37.5-150-200 mg tab, 50200-200 mg tab	5	Non-Preferred	STALEVO
Dopamine Precursors [Precursores de Dopamina]
carbidopa -levodopa 10- 100 mg tab, 25-100 mg tab	1	Preferred	SINEMET
carbidopa-levodopa 25250 mg tab	2	Preferred	SINEMET
carbidopa-levodopa er 25100 mg tab er, 50-200 mg tab er	2	Preferred	SINEMET CR
Monoamine Oxidase B (MAO-B) Inhibitors [Inhibidores de MAO-B]
selegiline hcl 5 mg tab	3	Non-Preferred	CARBEX
ANTIVIRALS [ANTIVIRALES]
Anti-Influenza Agents [Age ntes Anti-Infuenza]
oseltamivir phosphate 30 mg cap, 45 mg cap, 75 mg cap	4	Preferred	TAMIFLU
TAMIFLU 6 mg/ ml susp	13	Non-Preferred

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Anti-Cytomegalovirus (CMV) Agents [Agentes Anti-Citomegalovirus]
valganciclovir hcl 450 mg tab	13	Non-Preferred	VALCYTE	PA
Antiherpetic Agents [Agentes Antiherpéticos]
acyclovir 200 mg cap, 400 mg tab, 800 mg tab	1	Preferred	ZOVIRAX
acyclovir 200 mg/5ml susp	2	Preferred	ZOVIRAX
Antiretroviral Combinations [Combinaciones Antiretrovirales]
EPZICOM 600-300 mg tab				CENTROS DE PREVENCIÓN Y TRATAMIENTO - CLÍNICAS DE IMMUNOLOGÍA
ATRIPLA 600-200-300 mg tab
Integrase Inhibitors [Inhibidores de la Integrasa]
ISENTRESS potassium 400 mg tab				CENTROS DE PREVENCIÓN Y TRATAMIENTO - CLÍNICAS DE IMMUNOLOGÍA
Miscellaneous Anti-HIV Agents [Agentes Anti-VIH Misceláneos]
SELZENTRY 300 mg tab				CENTROS DE PREVENCIÓN Y TRATAMIENTO - CLÍNICAS DE IMMUNOLOGÍA
FUZEON subcutaneous kit 90 mg
Non-Nucleoside Reverse Transcriptase Inhibitors [Inhibidores No Nucleósidos de la Transciptasa Reversa]
nevirapine 200 mg tab	1	Preferred	VIRAMUNE
nevirapine 50 mg/5ml susp	5	Non-Preferred	VIRAMUNE
RESCRIPTOR 200 mg tab	6	Non-Preferred
SUSTIVA 50 mg cap, 200 mg cap	6	Preferred		C
nevirapine er, 100 mg tab er 24 hr, 400 mg tab er 24 hr	7	Non-Preferred	VIRAMUNE XR
SUSTIVA 600 mg tab	7	Preferred		C

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
INTELENCE 200 mg tab				CENTROS DE PREVENCIÓN Y TRATAMIENTO - CLÍNICAS DE IMMUNOLOGÍA
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors [Inhibidores Nucleósidos/Nucleótidos de la Transcriptasa Reversa]
zidovudine 300 mg tab	2	Non-Preferred	RETROVIR
stavudine 1 mg/ml soln, 15 mg cap, 20 mg cap, 30 mg cap, 40 mg cap	3	Preferred	ZERIT
didanosine 125 mg cap dr, 200 mg cap dr, 250 mg cap dr	4	Non-Preferred	ZIAGEN
lamivudine 10 mg/ml soln	5	Preferred	EPIVIR
lamivudine 150 mg tab	4	Preferred	EPIVIR
zidovudine 100 mg cap, 50 mg/5ml syr	4	Non-Preferred	RETROVIR
abacavir sulfate 300 mg tab	5	Preferred	ZIAGEN
didanosine 400 mg cap dr	5	Non-Preferred	ZIAGEN
lamivudine 300 mg tab	5	Preferred	EPIVIR
VIDEX 2 gm soln	5	Non-Preferred
lamivudine 100 mg tab	6	Preferred	EPIVIR	PA
lamivudine-zidovudine 150-300 mg tab	6	Preferred	COMBIVIR
abacavir-lamivudinezidovudine 300-150-300 mg tab	10	Non-Preferred	TRIZIVIR
EMTRIVA 200 mg cap				CENTROS DE PREVENCIÓN Y TRATAMIENTO - CLÍNICAS DE IMMUNOLOGÍA
VIREAD 300 mg tab
TRUVADA 200-300 mg tab			TRUVADA
BENIGN PROSTATIC HYPERTROPHY AGENTS [AGENTES PARA HIPERTROFIA PROSTÁTICA BENIGNA]
5-Alpha Reductase Inhibitors [Inhibidores de 5-Alfa Reductasa]
finasteride 5 mg tab	1	Preferred	PROSCAR

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
tamsulosin hcl 0.4 mg cap	1	Preferred	FLOMAX
terazosin hcl 1 mg cap, 10 mg cap, 2 mg cap, 5 mg cap	1	Preferred	HYTRIN
BLOOD MODIFIERS [MODIFICADORES DE LA SANGRE]
Anticoagulants [Anticoagulantes]
warfarin sodium 1 mg tab, 10 mg tab, 2 mg tab, 2.5 mg tab, 3 mg tab, 4 mg tab, 5 mg tab, 6 mg tab, 7.5 mg tab	1	Preferred	COUMADIN
heparin sodium (porcine) 1000 unit/ml inj soln	2	Preferred	HEPARIN
heparin sodium (porcine) 10000 unit/ml inj soln, 5000 unit/ml inj soln	3	Preferred	HEPARIN
heparin sodium (porcine) pf 5000 unit/0.5ml inj soln	3	Preferred	HEPARIN
heparin sodium (porcine) 2000 unit/ml iv soln	8	Preferred	HEPARIN
Cobalamins [Cobalaminas]
cyanocobalamin 1000 mcg/ml inj soln	1	Preferred	VIT B-12
Colony Stimulating Factors [Estimulantes Mieloides]
NEUPOGEN 300 mcg/0.5ml inj soln, 300 mcg/ml inj soln, 480 mcg/1.6ml inj soln	10	Preferred		PA, C
NEULASTA 6 mg/0.6ml sc soln	15	Preferred		PA, C
NEULASTA DELIVERY KIT 6 mg/0.6ml sc soln	15	Preferred		PA, C
NEUPOGEN 480 mcg/0.8ml inj soln	12	Preferred		PA, C

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Erythropoiesis-Stimulating Agents [Agentes Estimulantes de Eritropoiesis]
ARANESP (ALBUMIN FREE) 100 mcg/0.5ml inj soln	1	Preferred		PA, C
PROCRIT 2000 unit/ml inj soln, 3000 unit/ml inj soln, 4000 unit/ml inj soln	6	Preferred		PA, C
ARANESP (ALBUMIN FREE) 25 mcg/0.42ml inj soln, 25 mcg/ml inj soln	6	Preferred		PA, C
PROCRIT 10000 unit/ml inj soln	7	Preferred		PA, C
ARANESP (ALBUMIN FREE) 40 mcg/0.4ml inj soln	7	Preferred		PA, C
ARANESP (ALBUMIN FREE) 40 mcg/ml inj soln, 60 mcg/ml inj soln	8	Preferred		PA, C
ARANESP (ALBUMIN FREE) 150 mcg/0.3ml inj soln, 150 mcg/0.75ml inj soln, 200 mcg/0.4ml inj soln, 200 mcg/ml inj soln, 300 mcg/0.6ml inj soln, 300 mcg/ml inj soln, 500 mcg/ml inj soln, 60 mcg/0.3ml inj soln	9	Preferred		PA, C
PROCRIT 20000 unit/ml inj soln	9	Preferred		PA, C
ARANESP (ALBUMIN FREE) 100 mcg/ml inj soln	11	Preferred		PA, C
PROCRIT 40000 unit/ml inj soln	10	Preferred		PA, C
Factor Xa Inhibitors [Inhibidores Del Factor Xa]
ELIQUIS 2.5 mg tab	4	Preferred		PA, C
ELIQUIS 5 mg tab	4	Preferred		PA, C

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Folates [Folatos]
folic acid 1 mg tab, 400 mcg tab, 800 mcg tab	1	Preferred	FOLIC ACID	OTC
Iron [Hierro]
ferrous sulfate 325 (65 fe) mg tab	1	Preferred	IRON	OTC
INFED 50 mg/ml inj soln	5	Non-Preferred
Low Molecular Weight Heparins [Heparinas de Bajo Peso Molecular]
enoxaparin sodium 30 mg/0.3ml sc soln, 40 mg/0.4ml sc soln	5	Non-Preferred	LOVENOX	PA
enoxaparin sodium 300 mg/3ml inj soln, 60 mg/0.6ml sc soln, 80 mg/0.8ml sc soln	7	Non-Preferred	LOVENOX	PA
enoxaparin sodium 100 mg/ml sc soln	9	Non-Preferred	LOVENOX	PA
enoxaparin sodium 120 mg/0.8ml sc soln	10	Non-Preferred	LOVENOX	PA
enoxaparin sodium 150 mg/ml sc soln	14	Non-Preferred	LOVENOX	PA
Platelet Modifying Agents [Modificadores de Plaquetas]
aspirin 325 mg tab, 325 mg tab dr, 81 mg tab dr	1	Preferred	ASPIRIN	OTC
aspirin low dose 81 mg tab, 81 mg tab dr	1	Preferred	ASPIRIN	OTC
cilostazol 100 mg tab, 50 mg tab	1	Preferred	PLETAL
clopidogrel bisulfate 75 mg tab	1	Preferred	PLAVIX
BONE DENSITY REGULATORS [REGULADORES DE DENSIDAD ÓSEA]
Bisphosphonates [Bifosfonatos]
alendronate sodium 10 mg tab, 35 mg tab, 5 mg tab, 70 mg tab	1	Preferred	FOSAMAX

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
CARDIOVASCULAR AGENTS [AGENTES CARDIOVASCULARES]
Antiarrhythmics Class II [Antiarrítmicos Clase II]
propranolol hcl 10 mg tab, 20 mg tab, 40 mg tab, 80 mg tab	1	Preferred	INDERAL
sotalol hcl 120 mg tab, 160 mg tab, 240 mg tab, 80 mg tab	1	Preferred	BETAPACE
propranolol hcl 60 mg tab	2	Preferred	INDERAL
Antiarrhythmics Type I-A [Antiarrítmicos Tipo I-A]
quinidine sulfate 200 mg tab, 300 mg tab	1	Preferred	QUINIDINE SULFATE
quinidine gluconate er 324 mg tab er	2	Preferred	QUINAGLUTE
quinidine sulfate er 300 mg tab er	2	Preferred	QUINIDINE SULFATE
Antiarrhythmics Type I-B [Antiarrítmicos Tipo I-B]
mexiletine hcl 150 mg cap	2	Preferred	MEXITIL
mexiletine hcl 200 mg cap	3	Preferred	MEXITIL
Antiarrhythmics Type I-C [Antiarrítmicos Tipo I-C]
flecainide acetate 100 mg tab, 50 mg tab	1	Preferred	TAMBOCOR
propafenone hcl 150 mg tab, 225 mg tab	1	Preferred	RYTHMOL
flecainide acetate 150 mg tab	2	Preferred	TAMBOCOR
propafenone hcl 300 mg tab	3	Preferred	RYTHMOL
Antiarrhythmics Type III [Antiarrítmicos Tipo III]
amiodarone hcl 200 mg tab	1	Preferred	CORDARONE
Intermittent Claudication Agents [Agentes Para La Claudicación Intermitente]
pentoxifylline er 400 mg tab er	1	Preferred	TRENTAL
Miscellaneous Cardiovascular Agents [Agentes Cardiovasculares Misceláneos]
digox 125 mcg tab, 250 mcg tab	2	Preferred	LANOXIN

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
digoxin 0.05 mg/ml soln, 125 mcg tab, 250 mcg tab	2	Preferred	LANOXIN
Pulmonary Hypertension Agents [Agentes Para Hipertensión Pulmonar]
sildenafil citrate 20 mg tab	3	Preferred	REVATIO	PA
ADEMPAS 0.5 mg tab	15	Preferred		PA, C
ADEMPAS 1 mg tab, 1.5 mg tab, 2 mg tab	18	Preferred		PA, C
ADEMPAS 2.5 mg tab	20	Preferred		PA, C
Vasodilators [Vasodilatadores]
isosorbide mononitrate 10 mg tab, 20 mg tab	1	Preferred	IMDUR
isosorbide mononitrate er 120 mg tab er 24 hr, 30 mg tab er 24 hr, 60 mg tab er 24 hr	1	Preferred	IMDUR
nitroglycerin 0.2 mg/hr td patch 24hr	1	Preferred	NITRODUR
NITROSTAT 0.3 mg tab subl, 0.4 mg tab subl, 0.6 mg tab subl	1	Preferred
nitroglycerin 0.1 mg/hr td patch 24hr, 0.4 mg/hr td patch 24hr, 0.6 mg/hr td patch 24hr	2	Non-Preferred	NITRODUR
CENTRAL NERVOUS SYSTEM AGENTS [AGENTES SISTEMA NERVIOSO CENTRAL]
Multiple Sclerosis Agents [Agentes para Esclerosis Múltiple]
AMPYRA 10 tab er 12hr	9	Preferred		PA, C
COPAXONE 20 mg/ml sc kit	17	Preferred		PA, C
COPAXONE 40 mg/ml subcutaneous solution prefilled syringe	14	Preferred		PA, C
AVONEX 30 mcg im kit	13	Preferred		PA, C
AVONEX PEN 30 mcg/0.5ml im kit	13	Preferred		PA, C
AVONEX PREFILLED 30 mcg/0.5ml im kit	13	Preferred		PA, C
GILENYA 0.5 mg cap	15	Preferred		PA, C

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
TYSABRI intravenous concentrate 300 mg/15ml	15	Preferred		PA, C
TECFIDERA 120 mg cap dr	14	Preferred		PA, C
TECFIDERA 240 mg cap dr	14	Preferred		PA, C
TECFIDERA 120-240 MG misc	14	Preferred		PA, C
BETASERON 0.3 mg sc kit	13	Preferred		PA, C
CHEMOTHERAPIES [QUIMIOTERAPIAS]
Alkylating Agents [Agentes Alquilantes]
lomustine 10 mg cap	3	Non-Preferred	CEENU
ALKERAN 2 mg tab	4	Non-Preferred
temozolomide 5 mg cap	4	Non-Preferred	TEMODAR	PA
lomustine 40 mg cap	5	Non-Preferred	CEENU
LEUKERAN 2 mg tab	6	Non-Preferred
lomustine 100 mg cap	6	Non-Preferred	CEENU
MYLERAN 2 mg tab	7	Non-Preferred
temozolomide 20 mg cap	9	Non-Preferred	TEMODAR	PA
temozolomide 250 mg cap	11	Non-Preferred	TEMODAR	PA
temozolomide 140 mg cap	13	Non-Preferred	TEMODAR	PA
temozolomide 100 mg cap, 180 mg cap	14	Non-Preferred	TEMODAR	PA
Angiogenesis Inhibitors [Inhibidores de Angiogénesis]
STIVARGA 40 mg tab	15	Preferred		PA, C
Antiandrogens [Antiandrógenos]
bicalutamide 50 mg tab	2	Preferred	CASODEX
flutamide 125 mg cap	4	Non-Preferred	EULEXIN
Antiestrogens [Antiestrógenos]
tamoxifen citrate 10 mg tab, 20 mg tab	1	Preferred	NOLVADEX
Vaginal Estrogens [Estrógenos Vaginal]
VAGIFEM 10 mcg vag tab	3	Non-Preferred
Antimetabolites [Antimetabolitos]
hydroxyurea 500 mg cap	2	Preferred	HYDREA
mercaptopurine 50 mg tab	2	Preferred	PURINETHOL
methotrexate 2.5 mg tab	2	Preferred	METHOTREXATE

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
capecitabine 150 mg tab	7	Non-Preferred	XELODA	PA
capecitabine 500 mg tab	11	Non-Preferred	XELODA	PA
Antineoplastic Enzyme Inhibitors [Antineoplásicos Inhibidores de Enzimas]
SPRYCEL 20 mg tab	14	Preferred		PA, C
SPRYCEL 50 mg tab	21	Preferred		PA, C
imatinib 100 mg tab	18	Non-Preferred	GLEEVEC	PA
SPRYCEL 70 mg tab	17	Preferred		PA, C
SPRYCEL 80 mg tab	25	Preferred		PA, C
TASIGNA 150 mg cap	22	Preferred		PA, C
SPRYCEL 100 mg tab	25	Preferred		PA, C
AFINITOR 2.5 mg tab	25	Preferred		PA, C
NEXAVAR 200 mg tab	25	Preferred		PA, C
SPRYCEL 140 mg tab	25	Preferred		PA, C
AFINITOR 10 mg tab, 5 mg tab, 7.5 mg tab	23	Preferred		PA, C
TASIGNA 200 mg cap	19	Preferred		PA, C
imatinib 400 mg tab	25	Non-Preferred	GLEEVEC	PA
Apetite Stimulants [Estimulantes de Apetito]
megestrol acetate 20 mg tab, 40 mg tab	1	Preferred	MEGACE
megestrol acetate 40 mg/ml susp, 400 mg/10ml susp	2	Preferred	MEGACE
Aromatase Inhibitors [Inhibidores de la Aromatasa]
anastrozole 1 mg tab	1	Preferred	ARIMIDEX
Folic Acid Antagonists Rescue Agents [Antagonistas de Ácido Fólico]
leucovorin calcium 5 mg tab	3	Preferred	LEUCOVORIN
leucovorin calcium 10 mg tab, 15 mg tab	4	Preferred	LEUCOVORIN
leucovorin calcium 25 mg tab	9	Preferred	LEUCOVORIN
Luteinizing Hormone-Releasing (LHRH) Analogs [Análogos De LHRH]
LUPRON DEPOT 45 mg im kit	2	Preferred		PA, C
LUPRON DEPOT 11.25 mg im kit, 3.75 mg im kit	6	Preferred		PA, C

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
LUPRON DEPOT-PED 11.25 mg im kit, 15 mg im kit, 7.5 mg im kit	8	Preferred		PA, C
LUPRON DEPOT 22.5 mg im kit, 30 mg im kit	9	Preferred		PA, C
LUPRON DEPOT-PED 11.25 mg (ped) im kit	9	Preferred		PA, C
LUPRON DEPOT-PED 30 mg (ped) im kit	10	Preferred		PA, C
leuprolide acetate 1 mg/ 0.2 ml inj kit	7	Non-preferred		PA
ZOLADEX 3.6 mg, 10.8 mg subcutaneous implant	7	Non-preferred		PA
Miscellaneous Antineoplastics [Antineoplásicos Misceláneos]
MATULANE 50 mg cap	10	Non-Preferred		PA
ACTIMMUNE 2000000 unit/0.5ml sc soln	25	Non-Preferred		PA
INTRON A 6000000 unit/ml, 10000000 unit, 18000000 unit, 50000000 unit		Non-Preferred		PA
Mitotic Inhibitors [Inhibidores Mitóticos]
etoposide 50 mg cap	4	Non-Preferred	VEPESID
DENTAL AND ORAL AGENTS [AGENTES DENTALES Y ORALES]
Antifungals [Antifungales]
clotrimazole 10 mg mouth/throat lozenge, 10 mg mouth/throat troche	1	Preferred	MYCELEX
nystatin 100000 unit/ml mouth/throat susp	1	Preferred	MYCOSTATIN
Oral Antiseptics [Antisépticos Orales]
chlorhexidine gluconate 0.12 % mouth/throat soln 1 Preferred PERIDEX
Xerostomia [Xerostomía]
pilocarpine 5 mg tab	3	Preferred	SALAGEN

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
DERMATOLOGICAL AGENTS [AGENTES DERMATOLÓGICOS]
Acne Antibiotics [Antibióticos para Acné]
sulfacetamide sodium sulfur 10-5 % external emulsion	1	Preferred	SULFACET R
clindamycin phosphate 1 % soln	2	Preferred	CLEOCIN T
erythromycin 2 % gel, 2 % soln	2	Preferred	ERYGEL
Acne Products [Productos para el Acné]
tretinoin 0.05 % crm,	2	Preferred	RETIN A	AL < 21 años
isotretinoin 10 mg cap, 20 mg cap, 30 mg cap	6	Preferred	Zenatane
Antihistamines [Antihistamínicos]
hydroxyzine hcl 10 mg tab, 10 mg/5ml soln, 10 mg/5ml syr, 25 mg tab, 50 mg tab	1	Preferred	ATARAX
Antipsoriatics [Antipsoriáticos]
methoxsalen 10 m cap		Preferred	Oxsoralen
Antiseborrheic Products [Productos Antiseborrea]
selenium sulfide 2.5 % lot	1	Preferred	SELSUN
nystatin 100000 unit/gm oint, crm	1	Preferred	MYCOSTATIN
Dermatological Skin Cancer Agents [Dermatológicos para Cáncer de la Piel]
fluorouracil 2 % soln, 5 % soln	3	Preferred	EFUDEX
fluorouracil 5 % crm	4	Non-Preferred	EFUDEX
Very High Potency Topical Glucocorticoids [Glucocorticoides Tópicos de Muy Alta Potencia]
betamethasone dipropionate aug 0.05 % crm	3	Non-Preferred	DIPROLENE
betamethasone dipropionate aug 0.05 % oint	4	Non-Preferred	DIPROLENE
High Potency Topical Glucocorticoids [Glucocorticoides Tópicos de Alta Potencia]
mometasone furoate 0.1 % oint, 0.1% crm, 0.1% soln	1	Preferred	ELOCON

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Medium Potency Topical Glucocorticoids [Glucocorticoides Tópicos de Mediana Potencia]
triamcinolone acetonide 0.1 % crm, 0.1 % oint, 0.5 % crm, 0.5 % oint	1	Preferred	KENALOG
betamethasone valerate 0.1 % crm, 0.1 % lot, 0.1 % oint	1	Preferred	DIPROLENE
Low Potency Topical Glucocorticoids [Glucocorticoides Tópicos de Baja Potencia]
hydrocortisone 2.5 % crm, 2.5 % lot, 2.5 % oint	1	Preferred	HYDROCORTISONE
Pediculicides and Scabicides [Pediculicidas y Escabicidas]
permethrin 5 % crm	3	Preferred	ELIMITE	QL= 60 gm.
lindane 1 % lot	4	Non-Preferred	LINDANE	QL = 60 cc, 30días, ST
Topical Skin Antibiotics [Antibióticos Tópicos para la piel]
mupirocin 2 % oint	1	Preferred	BACTROBAN
silver sulfadiazine 1 % crm	1	Preferred	SILVADENE
metronidazole 0.75 % crm, 0.75 % gel, 0.75 % lot	4	Non-Preferred	METROLOTION
Topical Antifungals [Antifungales Tópicos]
clotrimazole 1 % crm	1	Preferred	LOTRIMIN	OTC ( crm )
nystatin 100000 unit/gm oint, crm	1	Preferred	MYCOSTATIN
Topical Antipsoriatics [Antipsoriáticos Tópicos]
calcipotriene 0.005 % crm	6	Non-Preferred	DOVONEX
acitretin 10 mg cap, 17.5 mg cap, 25 mg cap	7	Non-Preferred	SORIATANE
DYSLIPIDEMICS [DISLIPIDÉMICOS]
Bile Acid Sequestrants [Secuestradores de Acidos Biliares]
cholestyramine 4 gm pckt, 4 gm/dose oral pwdr	3	Preferred	QUESTRAN
Fibric Acid Derivatives [Derivados de Ácido Fíbrico]
gemfibrozil 600 mg tab	1	Preferred	LOPID
HMG-CoA Reductase Inhibitors [Inhibidores de la Reductasa De HMG-CoA]
atorvastatin calcium 10 mg tab, 20 mg tab, 40 mg tab, 80 mg tab	1	Preferred	LIPITOR

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
pravastatin sodium 10 mg tab, 20 mg tab, 80 mg tab	1	Non-Preferred	PRAVACHOL
simvastatin 10 mg tab, 20 mg tab, 40 mg tab, 5 mg tab, 80 mg tab	1	Preferred	ZOCOR
pravastatin sodium 40 mg tab	2	Non-Preferred	PRAVACHOL
GASTROINTESTINAL AGENTS [AGENTESGASTROINTESTINALES]
Antispasmodics [Antiespasmódicos]
dicyclomine hcl 10 mg cap, 20 mg tab	1	Preferred	BENTYL
dicyclomine hcl 10 mg/5ml soln	2	Preferred	BENTYL
Anti-Ulcer Agents [Agentes Anti-Ulceras]
misoprostol 100 mcg tab, 200 mcg tab	1	Preferred	CYTOTEC
sucralfate 1 gm tab	1	Preferred	CARAFATE
1 gm/10ml susp	3	Non-Preferred
Digestive Enzymes [Enzimas Digestivas]
CREON 12000 unit cap dr prt, 6000 unit cap dr prt	3	Preferred		C
CREON 24000 unit cap dr prt, 36000 unit cap dr prt, 3000-9500 unit cap dr prt	5	Preferred		C
Histamine2 (H2) Receptor Antagonists [Antagonistas del Receptor de H2]
famotidine 20 mg tab, 40 mg tab	1	Preferred	PEPCID
ranitidine hcl 15 mg/ml syr, 150 mg/10ml syr, 300 mg tab, 75 mg/5ml syr	1	Preferred	ZANTAC
Miscellaneous Gastrointestinal Agents [Agentes Gastrointestinales Misceláneos]
ursodiol 300 mg cap	4	Preferred	ACTIGALL	PA
cromolyn sodium 100 mg/5ml oral conc	6	Non-Preferred	GASTROCROM	PA

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Proton Pump Inhibitors [Inhibidores de la Bomba de Protones]
omeprazole 10 mg cap dr, 20 mg cap dr,40 mg cap dr	1	Preferred	PRILOSEC	QL=180 caps/ 365 días
Rectal Anti-Inflammatories [Anti-Inflamatorios Rectales]
hydrocortisone ace pramoxine 1-1 % rect crm, 2.5-1 % rect crm	2	Preferred	ANALPRAM-HC
GENITOURINARY AGENTS [AGENTES GENITOURINARIOS]
Miscellaneous Genitourinary Agents [Agentes Genitourinarios Misceláneos]
phenazopyridine hcl 100 mg tab, 200 mg tab	1	Preferred	PYRIDIUM	QL= 6 tab.
Phosphate Binder Agents [Enlazadores de Fosfato]
RENVELA 0.8 gm pckt	8	Preferred		PA, C
RENVELA 2.4 gm pckt, 800 mg tab	8	Preferred		PA, C
calcium acetate 667 mg cap.	3	Non-Preferred	PHOSLO
Urinary Antibiotics [Antibióticos Urinarios]
ur n -c 81.6 mg tab	1	Preferred	URIN D/S
URETRON D/S tab	1	Preferred
URIMAR-T 120 mg tab	1	Preferred
urin ds tab	1	Preferred	URIN D/S
Urinary Antispasmodics [Antiespasmódicos Urinarios]
oxybutynin chloride 5 mg tab, 5 mg/5ml syr	1	Preferred	DITROPAN
HEMATOLOGICAL AGENTS [AGENTES HEMATOLÓGICOS]
Antihemophilic Products [Productos Antithemofílicos]
ADVATE 250 unit iv soln, 500 unit iv soln, 1000 unit iv soln, 1500 unit iv soln, 2000 unit iv soln, 3000 unit iv soln, 4000 unit iv soln	25	Preferred		PA, C

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
ALPHANATE/VWF COMPLEX/HUMAN 250 unit iv soln, 500 unit iv soln, 1000 unit iv soln, 1500 unit iv soln, 2000 unit iv soln	25	Non-Preferred		PA
KOGENATE FS 1000 unit intravenous kit, 2000 unit intravenous kit, 250 unit intravenous kit, 3000 unit intravenous kit, 500 unit intravenous kit	25	Preferred		PA, C
KOGENATE FS BIO-SET 1000 unit intravenous kit, 2000 unit intravenous kit, 250 unit intravenous kit, 3000 unit intravenous kit, 500 unit intravenous kit	25	Preferred		PA, C
BENEFIX 250 unit intravenous kit, 500 unit intravenous kit, 1000 unit intravenous kit, 2000 unit intravenous kit, 3000 unit intravenous kit	25	Preferred		PA, C
ANTIINHIBITOR COAGULANT COMPLEX for inj	25	Non-Preferred		PA
ANTIHEMOPHILIC FACTOR VIII for inj.	25	Non-Preferred		PA
Hemostatics [Hemostáticos]
tranexamic acid 650 mg tab, 1000 mg/ ml IV soln	4	Non-Preferred	LYSTEDA	PA
AMICAR 500 mg tab, 0.25 gm/ml oral soln	5	Non-Preferred		PA
AMICAR 0.25 gm/ml oral soln	8	Non-Preferred		PA
tranexamic acid 100 mg/ml IV soln		Non-Preferred	CYKLOKAPRON	PA

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
HORMONAL AGENTS [AGENTES HORMONALES]
Androgens [Andrógenos]
testosterone cypionate 100 mg/ml im soln, 200 mg/ml im soln	2	Preferred	DEPO- TESTOSTERONE
Antithyroid Agents [Agentes Antitiroide]
methimazole 10 mg tab, 5 mg tab	1	Preferred	TAPAZOLE
propylthiouracil 50 mg tab	2	Preferred	PROPYLTHIOURACIL
Calcimimetics [Calcimiméticos]
SENSIPAR 30 mg tab	7	Preferred		PA, C
SENSIPAR 60 mg tab	9	Preferred		PA, C
SENSIPAR 90 mg tab	10	Preferred		PA, C
Dopamine Agonists [Agonistas de Dopamina]
bromocriptine mesylate 2.5 mg tab	3	Preferred	PARLODEL
cabergoline 0.5 mg tab	3	Preferred	DOSTINEX
Dysmenorrhea Agents [Agentes para la Dismenorrea]
medroxyprogesterone acetate 10 mg tab, 2.5 mg tab, 5 mg tab	1	Preferred	PROVERA
alyacen 1/35 1-35 mg-mcg tab	2	Preferred	ARANELLE	PA
CRYSELLE-28 0.3-30 mgmcg tab	2	Preferred		PA
LOW-OGESTREL 0.3-30 mg-mcg tab	2	Preferred		PA
medroxyprogesterone acetate 150mg/ml susp	5	Preferred	DEPO-PROVERA	PA
Estrogens [Estrógenos]
estradiol 0.5 mg tab, 1 mg tab, 2 mg tab	1	Preferred	ESTRACE
estropipate 0.75 mg tab, 1.5 mg tab	1	Preferred	ESTROPIPATE
estropipate 3 mg tab	2	Preferred	ESTROPIPATE

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Estrogens and Progestins [Estrógenos y Progestinas]
estradiol -norethindrone acet 1-0.5 mg tab	4	Non-Preferred	ACTIVELLA
Growth Hormones Analogs [Análogos de Hormona de Crecimiento]
NORDITROPIN FLEXPRO 5 mg/1.5ml sc soln	5	Preferred		PA, C
NORDITROPIN FLEXPRO 30 mg/3ml sc soln	8	Preferred		PA, C
NORDITROPIN NORDIFLEX 30 mg/3ml sc soln	9	Preferred		PA, C
NORDITROPIN FLEXPRO 10 mg/1.5ml sc soln, 15 mg/1.5ml sc soln	8	Preferred		PA, C
Mineralocorticoids [Mineralocorticoides]
fludrocortisone acetate 0.1 mg tab	1	Preferred	FLORINEF
Prostaglandins [Prostaglandinas]
misoprostol 100 mcg tab, 200 mcg tab	1	Preferred	CYTOTEC
Somatostatic Analogs [Análogos de Somastatina]
octreotide acetate 50 mcg/ml inj soln	3	Preferred	SANDOSTATIN	PA
octreotide acetate 100 mcg/ml inj soln, 1000 mcg/5ml inj soln, 200 mcg/ml inj soln, 500 mcg/ml inj soln	6	Preferred	SANDOSTATIN	PA
octreotide acetate 1000 mcg/ml inj soln	8	Preferred	SANDOSTATIN	PA
SANDOSTATIN LAR DEPOT 10 mg im kit	11	Non-Preferred		PA
SANDOSTATIN LAR DEPOT 30 mg im kit	14	Non-Preferred		PA
SANDOSTATIN LAR DEPOT 20 mg im kit	16	Non-Preferred		PA

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Thyroid Hormones [Hormona Tiroidea]
levothyroxine sodium 100 mcg tab, 112 mcg tab, 125 mcg tab, 137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab	1	Preferred	SYNTHROID
SYNTHROID 100 mcg tab, 112 mcg tab, 125 mcg tab, 137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab	1	Preferred		C
Vasopressin Analogs [Análogos de Vasopresina]
desmopressin acetate 4 mcg/ml inj soln	2	Non-Preferred	DDAVP
desmopressin acetate 0.2 mg tab	3	Non-Preferred	DDAVP
desmopressin ace rhinal tube 0.01 % nasal soln	4	Non-Preferred	DDAVP
desmopressin ace spray refrig 0.01 % nasal soln	4	Non-Preferred	DDAVP
desmopressin acetate 0.1 mg tab	4	Non-Preferred	DDAVP
desmopressin acetate spray 0.01 % nasal soln	4	Non-Preferred	DDAVP
STIMATE 1.5 mg/ml nasal soln	7	Non-Preferred
IMMUNOLOGICAL AGENTS [AGENTES INMUNOLÓGICOS]
Immunomodulators (TNF and Non-TNF) [Inmunomoduladores (TNF y No-TNF)]
ENBREL 25 mg sc kit, 25mg/0.5ml sc sol	9	Preferred		PA, C
ENBREL 50mg/ml sc soldermat	9	Preferred		PA, C

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
HUMIRA 10 mg/0.2ml sc kit, 20 mg/0.4ml sc kit, 40 mg/0.8ml sc kit	9	Preferred		PA, C
REMICADE 100 mg iv soln	16	Preferred		PA, C
IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
Organ Transplant Agents
cyclosporine modified 25 mg cap, 50 mg cap	3	Preferred	NEORAL	a PA
cyclosporine modified 25 mg cap, 50 mg cap	3	Preferred	NEORAL	aPA
NEORAL 25 mg cap	4	Preferred		aPA, C
cyclosporine 25 mg cap	4	Preferred	SANDIMMUNE	aPA
cyclosporine modified 100 mg cap, 100 mg/ml soln	4	Preferred	NEORAL	aPA
cyclosporine 100 mg cap	5	Preferred	SANDIMMUNE	aPA
cyclosporine modified 100 mg cap	5	Preferred	NEORAL	aPA
NEORAL 100 mg cap	5	Preferred		aPA, C
cyclosporine 100 mg cap, 25 mg cap	6	Preferred	SANDIMMUNE	aPA
SANDIMMUNE 100 mg cap, 100 mg/ml soln, 25 mg cap	6	Preferred		aPA, C
cyclosporine modified 100 mg/ml soln	7	Preferred	NEORAL	aPA
NEORAL 100 mg/ml soln	8	Preferred		aPA, C
Glucocorticosteroids [Glucocorticoides]
dexamethasone 0.5 mg tab, 0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab	1	Preferred	DECADRON
dexamethasone sodium phosphate 120 mg/30ml inj soln, 20 mg/5ml inj soln, 4 mg/ml inj soln	1	Preferred	DECADRON	OB-GYN

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página 1 de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
KENALOG 10 mg/ml inj susp	1	Preferred
MEDROL 2 mg tab	1	Preferred
methylprednisolone 32 mg tab, 4 mg tab	1	Preferred	MEDROL
methylprednisolone (pak) 4 mg tab	1	Preferred	MEDROL
prednisolone 15 mg/5ml soln, 15 mg/5ml syr	1	Preferred	PRELONE
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab	1	Preferred	DELTASONE
prednisone (pak) 10 mg tab, 5 mg tab	1	Preferred	DELTASONE
hydrocortisone 10 mg tab, 20 mg tab, 5 mg tab	2	Preferred	CORTEF
methylprednisolone 16 mg tab, 8 mg tab	2	Preferred	MEDROL
cortisone acetate 25 mg tab	3	Non-Preferred	CORTISONE
KENALOG 40 mg/ml inj susp	5	Non-Preferred
betamethasone sod phos & acet 6 mg/ml inj susp	2	Preferred	CELESTONE SOLUSPAN	OB-GYN
Organ Transplant Agents [Agentes para Trasplantes]
azathioprine 50 mg tab	1	Preferred	IMURAN
AZASAN 75 mg, 100 mg		Non-Preferred
mycophenolate mofetil 200 mg/ml susp, 250 mg cap, 500 mg tab	2	Preferred	CELLCEPT	aPA
tacrolimus 0.5 mg cap	3	Non-Preferred	PROGRAF	aPA
MYFORTIC 180 mg tab dr	4	Preferred		aPA, C
tacrolimus 1 mg cap	4	Non-Preferred	PROGRAF	aPA
sirolimus 0.5 mg tab, 1 mg tab, 2 mg tab	5	Non-Preferred	RAPAMUNE	aPA
MYFORTIC 360 mg tab dr	6	Preferred		aPA, C
tacrolimus 5 mg cap	6	Non-Preferred	PROGRAF	aPA
RAPAMUNE 1 mg/ml soln	8	Non-Preferred		aPA

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
INFLAMMATORY BOWEL DISEASE [ENFERMEDAD INFLAMATORIA INTESTINAL]
Aminosalicylates [Aminosalicilatos]
mesalamine rectal enema 4 gm	4	Preferred	ROWASA
DELZICOL 400 mg cap dr	5	Preferred		C
ASACOL HD 800 mg tab dr	6	Preferred		C
Immunomodulators (TNF and Non-TNF) [Inmunomoduladores (TNF y No-TNF)]
ENBREL 25 mg sc kit, 25mg/0.5ml sc sol	8	Preferred		PA, C
ENBREL 50mg/ml sc sol	9	Preferred		PA, C
HUMIRA 10 mg/0.2 ml sc kit, 20 mg/0.4ml sc kit, 40 mg/0.8ml sc kit	11	Preferred		PA, C
HUMIRA PEDIATRIC CROHNS START 40 mg/0.8ml sc kit	11	Preferred		PA, C
HUMIRA PEN 40 mg/0.8ml sc kit	11	Preferred		PA, C
HUMIRA PEN-CROHNS STARTER 40 mg/0.8ml sc kit	11	Preferred		PA, C
HUMIRA PEN-PSORIASIS STARTER 40 mg/0.8ml sc kit	11	Preferred		PA, C
REMICADE 100 mg iv soln	13	Preferred		PA, C
Intrarectal Low Potency Glucocorticoids [Glucocorticoides Intrarectales de Baja Potencia]
hydrocortisone 100 mg/60ml rect enema	2	Preferred	COLOCORT
Sulfonamides [Sulfonamidas]
sulfasalazine 500 mg tab, 500 mg tab dr	1	Preferred	AZULFIDINE
MINERALS & ELECTROLYTES [MINERALES Y ELECTROLITOS]
Calcium Regulating Agents [Agentes Reguladores de Calcio]
calcitriol 0.25 mcg cap	1	Preferred	ROCALTROL
calcitriol 0.5 mcg cap	2	Preferred	ROCALTROL

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Carnitine Deficiency [Deficiencia de Carnitina]
levocarnitine 1 gm/10ml soln, 330 mg tab	3	Preferred	CARNITOR
Chelating Agents [Agentes Quelantes]
DEPEN TITRATABS 250 mg tab	25	Preferred		PA
Electrolytes/Minerals Replacement [Reemplazo de Electrolitos/Minerales]
potassium chloride 20 meq/15ml (10%) oral liquid, 20 meq/15ml (10%) soln	1	Preferred	KAY-CIEL
potassium chloride crys er 10 meq tab er, 20 meq tab er	1	Preferred	KLOR-CON
potassium chloride er 10 meq cap er, 8 meq cap er	2	Preferred	MICRO-K
potassium chloride 40 meq/15ml (20%) oral solution	4	Preferred	KAON CL
Potassium Removing Resins [Resinas Removedoras de Potasio]
sodium polystyrene sulfonate 15 gm/60ml susp	3	Preferred	KAYEXALATE
Prenatal Vitamins [Vitaminas Prenatales]
classic prenatal 28-0.8 mg tab	1	Preferred	PRENATAL VITAMINS	OB-GYN
prenatal 27-0.8 mg tab, 271 mg tab, 28-0.8 mg tab	1	Preferred	PREPLUS	OB-GYN
prenatal 19 tab chew, tab, 29-1 mg tab chew, 29-1 mg tab	1	Preferred	PRENATAL VITAMINS	OB-GYN
prenatal formula 28-0.8 mg tab	1	Preferred	PRENATAL VITAMINS	OB-GYN
prenatal low iron 27-0.8 mg tab, 27-1 mg tab	1	Preferred	PREPLUS	OB-GYN
prenatal plus iron 29-1 mg tab	1	Preferred	PRENATABS	OB-GYN
prenatal vitamins 0.8 mg tab, 28-0.8 mg tab	1	Preferred	PRENATAL VITAMINS	OB-GYN

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Vitamin K [Vitamina K]
MEPHYTOIN 5 mg tab	6	Non-Preferred
MUSCLE RELAXANTS [RELAJANTES MUSCULARES]
Antispasticity Agents [Agentes Antiespasticidad]
baclofen 10 mg tab, 20 mg tab	1	Preferred	LIORESAL
dantrolene sodium 25 mg cap, 50 mg cap	2	Preferred	DANTRIUM
dantrolene sodium 100 mg cap	3	Preferred	DANTRIUM
Skeletal Muscle Relaxants [Relajantes Musculoesqueletales]
cyclobenzaprine hcl 10 mg tab	1	Preferred	FLEXERIL
NASAL AGENTS [AGENTES NASALES]
Nasal Anticholinergics [Anticolinérgicos Nasales]
ipratropium bromide 0.03 % nasal soln	2	Non-Preferred	ATROVENT
Nasal Mast Cell Stabilizers [Estabilizadores Nasales de Mastocitos]
cromolyn sodium 5.2 mg/act nasal aerosol sol	1	Preferred	NASALCROM
Nasal Steroids [Esteroides Nasales]
fluticasone propionate 50 mcg/act nasal susp	1	Preferred	FLONASE	QL = 1 pompa / 30 días
OPHTHALMIC AGENTS [AGENTES OFTÁLMICOS]
Antiglaucoma Agents [Agentes Antiglaucoma]
brimonidine tartrate 0.2 % ophth soln	1	Preferred	ALPHAGAN
dorzolamide hcl 2 % ophth soln	1	Preferred	TRUSOPT
levobunolol hcl 0.25 % ophth soln, 0.5 % ophth soln	1	Preferred	BETAGAN
timolol maleate 0.25 % ophth soln, 0.5 % ophth soln	1	Preferred	TIMOPTIC
dorzolamide hcl-timolol mal ophth sol 22.3-6.8 mg/ml	1	Preferred	COSOPT

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
betaxolol hcl 0.5 % ophth soln	2	Non-Preferred	BETOPTIC
Miotics [Mióticos]
pilocarpine hcl 1 % ophth soln, 2 % ophth soln, 4 % ophth soln	3	Preferred	ISOPTOCARPINE
Mydriatics [Midriáticos]
atropine sulfate 1 % ophth oint, 1 % ophth soln	1	Preferred	ISO-ATROPINE
Nonsteroidal Anti-Inflammatory Agents (NSAIDs) [Anti-Inflamatorios No Esteroidales]
diclofenac sodium 0.1 % ophth soln	1	Preferred	VOLTAREN	QL = max 30 días / 365 días
ketorolac tromethamine 0.5 % ophth soln	1	Preferred	ACULAR	QL = max 30 días / 365 días
Ophthalmic Antibiotics [Antibióticos Oftálmicos]
ciprofloxacin hcl 0.3 % ophth soln	1	Preferred	CILOXAN
gentamicin sulfate 0.3 % ophth oint, 0.3 % ophth soln	1	Preferred	GARAMYCIN
ofloxacin 0.3 % ophth soln	1	Preferred	OCUFLOX
polymyxin b-trimethoprim 10000-0.1 unit/ml-% ophth soln	1	Preferred	POLYTRIM
tobramycin 0.3 % ophth soln	1	Preferred	TOBREX
bacitracin 500 unit/gm ophth oint	3	Non-Preferred	BACITRACIN
Ophthalmic Antivirals [Antivirales Oftálmicos]
trifluridine 1 % ophth soln	4	Non-Preferred	VIROPTIC	PA
Ophthalmic Prostaglandins [Prostaglandinas Oftálmicas]
latanoprost 0.005 % ophth soln	1	Preferred	XALATAN

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Ophthalmic Steroids [Esteroides Oftálmicos]
neomycin -polymyxindexamethasone 3.5- 10000-0.1 ophth oint, 3.5- 10000-0.1 ophth susp	1	Preferred	MAXITROL
prednisolone acetate 1 % ophth susp	2	Preferred	PRED FORTE
prednisolone sodium phosphate 1 % ophth soln	2	Preferred	INFLAMASE
fluorometholone 0.1 % ophth susp	3	Preferred	FML LIQUIFILM
OTIC AGENTS [AGENTES OTICOS]
Miscellaneous Otic Agents [Agentes Oticos Misceláneos]
acetic acid 2 % otic soln	2	Preferred	VOSOL
Otic Antibiotics [Antibióticos Oticos]
neomycin -polymyxin-hc 1 % otic soln, 3.5-10000-1 otic soln, 3.5-10000-1 otic susp	2	Preferred	CORTISPORIN
cipro hc 0.2-1 % otic susp	1	Preferred
RESPIRATORY AGENTS [AGENTES RESPIRATORIOS]
Anticholinergic Bronchodilators [Broncodilatadores Anticolinérgicos]
ipratropium bromide 0.02 % inh soln	1	Preferred	ATROVENT
Antileukotrienes [Antileukotrienos]
montelukast sodium 10 mg tab, 4 mg tab chew, 5 mg tab chew	1	Preferred	SINGULAIR
Antitussive-Expectorant [Expectorantes Antitusivos]
benzonatate 100 mg cap	1	Preferred	TESSALON
guaifenesin-codeine 10010 mg/5ml soln	1	Preferred	CHERATUSSIN
Bronchiolitis Agents [Agentes para Bronquiolitis]
SYNAGIS 50 mg/0.5ml im soln	9	Preferred		PA, C
SYNAGIS 100 mg/ml im soln	11	Preferred		PA, C

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Inhaled Corticosteroids [Corticosteroides Inhalados]
FLOVENT DISKUS 100 mcg/blist inh aer pwdr, 250 mcg/blist inh aer pwdr, 50 mcg/blist inh aer pwdr	3	Preferred		QL = 1 pompa / 30 días, C
FLOVENT HFA 110 mcg/act inh aer, 44 mcg/act inh aer	3	Preferred		QL = 1 pompa / 30 días, C
ADVAIR DISKUS 100-50 mcg/dose inh aer pwdr, 250-50 mcg/dose inh aer pwdr	4	Preferred		QL= 1 pompa / 30 días, ST, C
ADVAIR HFA 115-21 mcg/act inh aer, 45-21 mcg/act inh aer	4	Preferred		QL= 1 pompa / 30 días, ST, C
budesonide 0.25 mg/2ml inh susp, 0.5 mg/2ml inh susp	4	Non-Preferred	PULMICORT	AL ≤ 12 años
budesonide 1mg/2ml inh susp	8	Non-Preferred	PULMICORT	AL ≤ 12 años
FLOVENT HFA 220 mcg/act inh aer	4	Preferred		QL= 1 pompa / 30 días, C
ADVAIR DISKUS 500-50 mcg/dose inh aer pwdr	5	Preferred		QL= 1 pompa / 30 días, ST, C
ADVAIR HFA 230-21 mcg/act inh aer	5	Preferred		QL= 1 pompa / 30 días, ST, C
Nonsedating Histamine1 Blocking Agents [Bloqueadores de Histamina1 No-Sedantes]
cetirizine HCl oral soln 1 MG/ML (5 MG/5ML)	1	Preferred	ZYRTEC	OTC
loratadine 5 mg/5ml soln, 5 mg/5ml syr	1	Preferred	CLARITIN	OTC
loratadine 10 mg tab	1	Preferred	CLARITIN	OTC
Phosphodiesterase Inhibitors [Inhibidores de la Fosfodiesterasa]
theophylline er 100 mg tab er 12 hr, 200 mg tab er 12 hr, 300 mg tab er 12 hr, 450 mg tab er 12 hr	1	Preferred	THEO-DUR

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

SALUD FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos /Límites]
Sympathomimetic Bronchodilators [Broncodilatadores Simpatomiméticos]
albuterol sulfate (2.5 mg/3ml) 0.083% inh neb soln, (5 mg/ml) 0.5% inh neb soln, 2 mg/5ml syr	1	Preferred	ALBUTEROL
terbutaline sulfate 2.5 mg tab, 5 mg tab	1	Preferred	BRETHINE
VENTOLIN HFA 108 (90 base) mcg/act inh aer	2	Preferred		QL = 1 pompa / 30 días, C
RHEUMATOID ARTHRITIS AGENTS [AGENTES PARA ARTRITIS REUMATOIDE]
Immunomodulators (TNF And Non-TNF) [Inmunomoduladores (TNF Y No-TNF)]
ENBREL 25 mg sc kit, 25mg/0.5ml sc sol	8	Preferred		PA, C
ENBREL 50mg/ml sc sol	9	Preferred		PA, C
ORENCIA 125 mg/ml subcutaneous solution prefilled syringe, 125 mg/ml ClickJect sc sol Autoinjector	10	Preferred		PA, C
HUMIRA 10 mg/ 0.2ml sc kit, 20 mg/0.4ml sc kit, 40 mg/0.8ml sc kit	11	Preferred		PA, C
REMICADE 100 mg iv soln	13	Preferred		PA, C
Non-Biologic Agents [Agentes No-Biológicos]
methotrexate 2.5 mg tab	2	Preferred	METHOTREXATE
leflunomide 10 mg tab, 20 mg tab	4	Non-Preferred	ARAVA	PA
DEPEN TITRATABS 250 mg tab	25	Preferred		PA

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL – Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 16 for monthly net cost range [Ver página 16 Página de 67 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/18/2017

ASES

Puerto Rico Healthcare Insurance Administration

Mental Health

2017

Formulary of Drugs Covered by

the Government Healthcare Plan (GHP)

Authorized by the P.R. Elections Commission CEE-SA-16-2732

		GOVERNMENT OF PUERTO RICO		Hon. Ricardo A. Rosselló Nevares Governor Ms. Ángela M. Ávila Marrero Executive Director
		Healthcare Insurance Administration

May 1, 2017

TO ALL GOVERNMENT HEALTHCARE PLAN (GHP) PROVIDERS

Dear provider:

I urge you to keep this guide for future reference. It is also available on our webpage, www.asespr.org .

Cordially,

[signed]

Ángela M. Ávila Marrero

Executive Director

PO Box 195661, San Juan, PR 00919-5661 · Tel.: 787.474.3300 · Fax: 787.474.3348 · www.ases.pr.gov

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE OF THE GOVERNMENT HEALTHCARE PLAN (GHP)

1.	Drug Formulary

Non-formulary drugs may only be used in exceptional cases through the Exception Process that we will explain in point number 2.

2.	Exception Process

Contraindication to the drug(s) included in the FDC;

History of a clinically significant adverse reaction to the drug(s) included in the FDC;

Evidence of therapeutic failure of all alternatives available in the FDC; and/or

Lack of a therapeutic alternative in the FDC.

3.	Other Aspects of the Prescription Drug Coverage

The prescription drug coverage of the GHP establishes that using generic bioequivalent products as the first option is mandatory.

The maximum supply dispensed for acute conditions will cover a fifteen (15) day therapy. The treatment period may be extended, as applicable, when medically necessary.

ASES requires the use of generic bioequivalent drugs approved by the Food and Drug Administration (FDA) coded as “AB” and those authorized under applicable local regulations in Puerto Rico.

Drug prescriptions will be filled by a pharmacy contracted by the PBM that is duly authorized under the law of the Commonwealth of Puerto Rico and has been freely chosen by the beneficiary.

4.	Emergency Rule

The products that appear in the Integrated Emergency Formulary (IEF) will be dispensed for five (5) business days, except as otherwise specified.

The same thing applies to analgesics, narcotics, combination drugs, and nonsteroidal anti-inflammatory drugs, which will also be dispensed in amounts sufficient for five (5) business days.

If you have any questions about the prescription drug coverage, you may contact the insurance company contracted by ASES in your region and/or the Pharmacy Benefit Manager (PBM) contracted by ASES.

Page 3 of 83

SALUD MENTAL

GOVERNMENT HEALTHCARE PLAN

FORMULARY OF DRUGS COVERED BY THE GHP (FDC)

2017

TABLE OF CONTENTS

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE OF THE GOVERNMENT HEALTHCARE PLAN	3

DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES	5

MONTHLY NET COST RANGE	5

GENERIC DRUGS	6

ANTI-ADDICTION AGENTS	8

Opioid Antagonist	8

Detox Treatment	8

ANTIANXIETY AGENTS	8

Benzodiazepines	8

Sedating Histamine 1 Blocking Agents	8

ANTIDEPRESSANTS	9

Miscellaneous Antidepressants	9

Serotonin and/or Norepinephrine Modulators	9

Tricyclic Agents	10

ANTIPARKINSON AGENTS	10

ANTIPSYCHOTICS	10

Atypical - Second Generation	10

Typical - First Generation	11

MOOD STABILIZERS	12

Bipolar Agents	12

PSYCHOSTIMULANTS	13

ADHD Amphetamines	13

ADHD Non-Amphetamines	14

SLEEP DISORDER AGENTS	14

Benzodiazepines	14

Miscellaneous Sleep Disorder Agents	14

Page 4 of 83

SALUD MENTAL

DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES

The example below illustrates the information provided for the drugs included in the FDC.

Drug Name	Net Cost	Tier	Reference Name	Requirements/ Limits
THERAPEUTIC CATEGORY
Therapeutic Class
ANTI-ADDICTION AGENTS
Opioid Antagonist
buprenorphine hcl 2 mg tab subl, 8 mg tab subl	3	Preferred	SUBUTEX	PA
SUBOXONE subl film 2-0.5 mg, 8-2 mg, 4-1 mg, 12-3 mg	4	Preferred		PA, C
Detox Treatment
b-1 100 mg tab	1	Preferred	THIAMINE	QL
clonidine hcl 0.1 mg tab	1	Preferred	CATAPRESS
folic acid 1 mg tab, 400 mcg tab, 800 mcg tab	1	Preferred	FOLIC ACID	QL, OTC
ibuprofen 800 mg tab	1	Preferred	MOTRIN	QL
loperamide hcl 2 mg cap	1	Preferred	IMODIUM	QL

Page 5 of 83

SALUD MENTAL

MONTHLY NET COST RANGE

1	less than $20	Least costly per month
2	$20 - $49
3	$50 - $99
4	$100 - $199
5	$200 - $349
6	$350 - $549
7	$550 - $799
8	$800 - $1,099
9	$1,100 - $1,499
10	$1,500 - $1,999
11	$2,000 - $2,499
12	$2,500 - $2,999
13	$3,000 - $3,499
14	$3,500 - $3,999
15	$4,000 - $4,499
16	$4,500 - $4,999
17	$5,000 - $5,499
18	$5,500 - $5,999
19	$6,000 - $6,499
20	$6,500 - $6,999
21	$7,000 - $7,499
22	$7,500 - $7,999
23	$8,000 - $8,499
24	$8,500 - $9,000
25	more than $9,000	Most costly per month

The net cost analysis is an ongoing exercise subject to constant changes. Net costs as published here are current as of the date of this edition of the FDC.

GENERIC DRUGS

Page 6 of 83

SALUD MENTAL

Page 7 of 83

Revisado: 1 de mayo de 2017

SALUD MENTAL

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Terapéutica]
ANTI-ADDICTION AGENTS [AGENTES CONTRA LA ADDICIÓN]
Opioid Antagonist [Antagonistas De Opioides]
buprenorphine hcl 2 mg tab subl, 8 mg tab subl	3	Preferred	SUBUTEX	PA
SUBOXONE subl film 2-0.5 mg, 8-2 mg, 4-1 mg, 12-3 mg	4	Preferred		PA, C
Detox Treatment [Tratamiento De Detox]
b-1 100 mg tab	1	Preferred	THIAMINE	QL
clonidine hcl 0.1 mg tab	1	Preferred	CATAPRESS
folic acid 1 mg tab	1	Preferred	FOLIC ACID	QL
ibuprofen 800 mg tab	1	Preferred	MOTRIN	QL
loperamide hcl 2 mg cap	1	Preferred	IMODIUM	QL
ANTIANXIETY AGENTS [AGENTES PARA LA ANXIEDAD]
Benzodiazepines [Benzodiazepinas]
clonazepam 0.5 mg tab, 1 mg tab, 2mg tab	1	Preferred	KLONOPIN
diazepam 10 mg tab, 2 mg tab, 5 mg tab	1	Preferred	VALIUM
lorazepam 0.5 mg tab, 1 mg tab	1	Preferred	ATIVAN
diazepam 1 mg/ml soln	2	Non-Preferred	VALIUM
DIAZEPAM INTENSOL 5 mg/ml oral conc	2	Non-Preferred
lorazepam 2 mg/ml oral conc	2	Non-Preferred	ATIVAN
Sedating Histamine 1 Blocking Agents [Sedantes Bloqueadores Histamine 1]
hydroxyzine pamoate 100 mg cap, 25 mg cap, 50 mg cap	1	Preferred	VISTARIL

Page 8 of 83

Revisado: 1 de mayo de 2017

SALUD MENTAL

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
ANTIDEPRESSANTS [ANTIDEPRESIVOS]
		Miscellaneous Antidepressants
[Antidepresivos Misceláneos]
bupropion hcl 75 mg tab	1	Preferred	WELLBUTRIN
bupropion hcl er (sr) 100 mg tab er 12 hr, 150 mg tab er 12 hr, 200 mg tab er 12 hr	1	Preferred	WELLBUTRIN SR
escitalopram oxalate 5mg tab, 10 mg tab, 20 mg tab	1	Preferred	LEXAPRO
mirtazapine 15 mg tab, 30 mg tab, 45 mg tab, 7.5 mg tab	1	Preferred	REMERON
trazodone hcl 100 mg tab, 150 mg tab, 50 mg tab	1	Preferred	DESYREL
bupropion hcl 100 mg tab	2	Non-Preferred	WELLBUTRIN
bupropion hcl er (xl) 150 mg tab er 24 hr, 300 mg tab er 24 hr	2	Non-Preferred	WELLBUTRIN XL
mirtazapine 15 mg odt, 30 mg odt, 45 mg odt	3	Non-Preferred	REMERON
Serotonin and/or Norepinephrine Modulators [Moduladores De Serotonina y/o Norepinefrina]

citalopram hydrobromide 10 mg tab, 20 mg tab, 40 mg tab	1	Preferred	CELEXA
fluoxetine hcl 10 mg cap, 20 mg cap	1	Preferred	PROZAC
paroxetine hcl 10 mg tab, 20 mg tab, 30 mg tab, 40 mg tab	1	Preferred	PAXIL
sertraline hcl 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	ZOLOFT
sertraline hcl oral concentrate 20 mg/ml	2	Non-Preferred	ZOLOFT

Page 9 of 83

Revisado: 1 de mayo de 2017

SALUD MENTAL

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
venlafaxine hcl 100mg tab, 25mg tab, 37.5mg tab, 50mg tab, 75mg tab	1	Preferred	EFFEXOR
venlafaxine hcl er 150 mg cap er 24 hr, 37.5 mg cap er 24 hr, 75 mg cap er 24 hr	1	Preferred	EFFEXOR XR
duloxetine 20 mg cap, 30 mg cap, 60 mg cap	2	Non-Preferred	CYMBALTA
Tricyclic Agents [Tricíclicos]
amitriptyline hcl 10 mg tab, 100 mg tab, 150 mg tab, 25 mg tab, 50 mg tab, 75 mg tab	1	Preferred	ELAVIL
doxepin hcl 10 mg cap, 10 mg/ml oral conc, 25 mg cap, 50 mg cap, 75 mg cap	1	Preferred	SINEQUAN
imipramine hcl 10 mg tab, 25 mg tab, 50 mg tab	1	Preferred	TOFRANIL
nortriptyline hcl 10 mg cap, 10 mg/5ml soln, 25 mg cap, 50 mg cap, 75 mg cap	1	Preferred	PAMELOR
doxepin hcl 100 mg cap, 150 mg cap	2	Preferred	SINEQUAN
ANTIPARKINSON AGENTS [AGENTES ANTIPARKINSON]
Anticholinergics [Anticolinérgicos]
benztropine mesylate 0.5 mg tab, 1 mg tab, 2 mg tab	1	Preferred	COGENTIN
ANTIPSYCHOTICS [ANTIPSICÓTICOS]
Atypical - Second Generation [Atípicos - Segunda Generación]

olanzapine 10 mg tab, 15 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 7.5 mg tab	1	Preferred	ZYPREXA
quetiapine fumarate 25 mg tab	1	Preferred	SEROQUEL

Page 10 of 83

Revisado: 1 de mayo de 2017

SALUD MENTAL

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
risperidone 0.25 mg tab, 0.5 mg tab, 1 mg tab, 2 mg tab, 3 mg tab, 4 mg tab	1	Preferred	RISPERDAL
quetiapine fumarate 50 mg tab	2	Preferred	SEROQUEL
risperidone 1 mg/ml soln	2	Preferred	RISPERDAL
quetiapine fumarate 100 mg tab	3	Preferred	SEROQUEL
LATUDA 120 mg tab, 20 mg tab, 40 mg tab, 60 mg tab, 80 mg tab	4	Preferred	PA	PA, P
quetiapine fumarate 200 mg tab	4	Preferred	SEROQUEL
quetiapine fumarate 300 mg tab	5	Preferred	SEROQUEL
quetiapine fumarate 400 mg tab	6	Preferred	SEROQUEL
aripriprazole 2 mg tab, 5 mg tab, 10 mg tab, 15 mg tab, 20 mg tab, 30 mg tab	7	Non-Preferred	ABILIFY	PA
aripiprazole 1 mg/ml soln	10	Non-Preferred	ABILIFY	PA
Typical - First Generation [Típicos - Primera Generación]
fluphenazine hcl 1 mg tab, 10 mg tab, 2.5 mg tab, 5 mg tab	1	Preferred	PROLIXIN
haloperidol 0.5 mg tab, 1 mg tab, 2 mg tab, 2 mg/ml oral conc	1	Preferred	HALDOL
thioridazine hcl 10 mg tab, 25 mg tab, 50 mg tab	1	Preferred	MELLARIL
thiothixene 1 mg cap, 2 mg cap, 5 mg cap	1	Preferred	NAVANE
trifluoperazine hcl mg tab, 2 mg tab, 5 mg tab, 10 mg tab	2	Preferred	STELAZINE

Page 11 of 83

Revisado: 1 de mayo de 2017

SALUD MENTAL

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
chlorpromazine hcl 25 mg tab	2	Preferred	THORAZINE
haloperidol 5 mg tab	2	Preferred	HALDOL
haloperidol decanoate 50 mg/ml im soln	2	Preferred	HALDOL DECANOATE
thioridazine hcl 100 mg tab	2	Preferred	MELLARIL
thiothixene 10 mg cap	2	Preferred	NAVANE
chlorpromazine hcl 100 mg tab, 50 mg tab	3	Preferred	THORAZINE
haloperidol 10 mg tab	3	Preferred	HALDOL
haloperidol decanoate 100 mg/ml im soln	3	Preferred	HALDOL DECANOATE
chlorpromazine hcl 200 mg tab	4	Preferred	THORAZINE
haloperidol 20 mg tab	4	Preferred	HALDOL
MOOD STABILIZERS [ESTABILIZADORES DEL ÁNIMO]
Bipolar Agents [Agentes Para Bipolaridad]
divalproex sodium 125 mg tab dr, 250 mg tab dr, 500 mg tab dr	1	Preferred	DEPAKOTE
lamotrigine 100 mg tab, 150 mg tab, 200 mg tab, 25 mg tab	1	Preferred	LAMICTAL
lamotrigine chew tab 5 mg, 25 mg	3	Non-Preferred	LAMICTAL
lithium carbonate 150 mg cap, 300 mg cap, 300 mg tab, 600 mg cap	1	Preferred	LITHIUM
lithium carbonate er 300 mg tab er, 450 mg tab er	1	Preferred	LITHIUM
olanzapine 10 mg tab, 15 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 7.5 mg tab	1	Preferred	ZYPREXA
quetiapine fumarate 25 mg tab	1	Preferred	SEROQUEL

Page 12 of 83

Revisado: 1 de mayo de 2017

SALUD MENTAL

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
risperidone 0.25 mg tab, 0.5 mg tab, 1 mg tab, 2 mg tab, 3 mg tab, 4 mg tab	1	Preferred	RISPERDAL
valproic acid 250 mg cap, 250 mg/5ml soln, 250 mg/5ml syr	1	Preferred	DEPAKENE
quetiapine fumarate 50 mg tab	2	Preferred	SEROQUEL
risperidone 1 mg/ml soln	2	Preferred	RISPERDAL
quetiapine fumarate 100 mg tab	3	Preferred	SEROQUEL
quetiapine fumarate 200 mg tab	4	Preferred	SEROQUEL
quetiapine fumarate 300 mg tab	5	Preferred	SEROQUEL
quetiapine fumarate 400 mg tab	6	Preferred	SEROQUEL
aripriprazole 10 mg tab, 15 mg tab, 2 mg tab, 5 mg tab, 20 mg tab, 30 mg tab	7	Non-Preferred	ABILIFY	PA
aripiprazole 1 mg/ml soln	10	Non-Preferred	ABILIFY	PA
PSYCHOSTIMULANTS [PSICOESTIMULANTES]
ADHD Amphetamines [Anfetaminas ADHD]
amphetamine - dextroamphetamine 15 mg tab, 30 mg tab	2	Preferred	ADDERALL	AL 4-20años
amphetamine- dextroamphetamine 10 mg tab, 12.5 mg tab, 20 mg tab, 5 mg tab, 7.5 mg tab	3	Preferred	ADDERALL	AL 4-20 años
dextroamphetamine sulfate 10 mg tab, 5 mg tab	3	Preferred	DEXEDRINE	AL 4-20 años
dextroamphetamine sulfate er 5 mg cap er 24 hr, 10 mg cap er 24 hr	4	Non-Preferred	DEXEDRINE SR	AL 4-20 años

Page 13 of 83

Revisado: 1 de mayo de 2017

SALUD MENTAL

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
dextroamphetamine sulfate er 15 mg cap er 24 hr	5	Non-Preferred	DEXEDRINE SR	AL 4-20 años
DYANAVEL XR oral susp. er 2.5 mg/ mL	4	Non-Preferred	DYANAVEL XR	PA, AL 6-20 años
ADHD Non-Amphetamines [No-Anfetaminas ADHD]
clonidine hcl 0.1 mg tab	1	Preferred	CATAPRESS
dexmethylphenidate hcl 2.5 mg tab, 5 mg tab	2	Preferred	FOCALIN	AL 6-20 años
methylphenidate hcl 5 mg tab	2	Preferred	RITALIN	AL 6-20 años
dexmethylphenidate hcl 10 mg tab	3	Preferred	FOCALIN	AL 6-20 años
methylphenidate hcl 10 mg tab, 20 mg tab	3	Preferred	RITALIN	AL 6-20 años
methylphenidate soln 5mg/5ml, 10 mg/5ml		Non-Preferred	METHYLIN
STRATTERA 10 mg cap, 100 mg cap, 18 mg cap, 25 mg cap, 40 mg cap, 60 mg cap, 80 mg cap	4	Preferred		PA, AL 6-20 años, P
SLEEP DISORDER AGENTS [DESORDENES DEL SUEÑO]
		Benzodiazepines [Benzodiazepinas]
flurazepam hcl 15 mg cap, 30 mg cap	1	Preferred	DALMANE
temazepam 15 mg cap, 30 mg cap	1	Preferred	RESTORIL
Miscellaneous Sleep Disorder Agents [Agentes Misceláneos Desordenes Del Sueño]
doxepin hcl 10 mg cap, 10 mg/ml oral conc, 25 mg cap, 50 mg cap, 75 mg cap	1	Preferred	SINEQUAN
zolpidem tartrate 10 mg tab, 5 mg tab	1	Preferred	AMBIEN

Page 14 of 83

A
ABILIFY	14, 17
amitriptyline hcl	12
amphetamine-dextroamphetamine	17

B
b-1	9
benztropine mesylate	13
buprenorphine hcl	9
bupropion hcl	10, 11
bupropion hcl er (sr)	10
bupropion hcl er (xl)	11

C
chlorpromazine hcl	14, 15
citalopram hydrobromide	11
clonazepam	9
clonidine hcl	9, 18

D
dexmethylphenidate hcl	18
dextroamphetamine sulfate	18
dextroamphetamine sulfate er	18
diazepam	9, 10
DIAZEPAM INTENSOL	10
divalproex sodium	15
doxepin hcl .	12, 19
DYANAVEL XR	18

E
escitalopram	10

F
fluoxetine hcl	11
fluphenazine hcl	14
flurazepam hcl	19
folic acid	9

H
haloperidol	14, 15
haloperidol decanoate	15
hydroxyzine pamoate	10

I
Ibuprofen	9
imipramine hcl	12

L
lamotrigine	16
lamotrigine chew tab	16
LATUDA	13
lithium carbonate	16
lithium carbonate er	16
loperamide hcl	9
lorazepam	10

M
methylphenidate hcl	18
methylphenidate soln	18
mirtazapine	10, 11

N

nortriptyline hcl	12

O
olanzapine	13, 16

P
paroxetine hcl	11

Q
quetiapine fumarate	13, 14, 16, 17

R
risperidone	13, 16, 17

S
sertraline hcl	11
sertraline hcl oral concentrate .	11
STRATTERA	19
SUBOXONE	9

Page 15 of 83

T
temazepam	19
thioridazine hcl	14, 15
thiothixene	14, 15
trazodone hcl	11

V
valproic acid	16
venlafaxine hcl	12
venlafaxine hcl er	12

Z
zolpidem tartrate	19

Page 16 of 83

ASES

Puerto Rico Healthcare Insurance Administration

Sub-formulary of

Physical Health

2017

Formulary of Drugs Covered by

the Government Healthcare Plan (GHP)

Authorized by the P.R. Elections Commission CEE-SA-16-2732

		GOVERNMENT OF PUERTO RICO		Hon. Ricardo A. Rosselló Nevares Governor Ms. Ángela M. Ávila Marrero Executive Director
		Healthcare Insurance Administration

May 1, 2017

TO ALL GOVERNMENT HEALTHCARE PLAN (GHP) PROVIDERS

Dear provider:

I urge you to keep this guide for future reference. It is also available on our webpage, www.asespr.org .

Cordially,

[signed]

Ángela M. Ávila Marrero

Executive Director

PO Box 195661, San Juan, PR 00919-5661 · Tel.: 787.474.3300 · Fax: 787.474.3348 · www.ases.pr.gov

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE

OF THE GOVERNMENT HEALTHCARE PLAN (GHP)

1.	Drug Formulary

Non-formulary drugs may only be used in exceptional cases through the Exception Process that we will explain in point number 2.

2.	Exception Process

Contraindication to the drug(s) included in the FDC;

History of a clinically significant adverse reaction to the drug(s) included in the FDC;

Evidence of therapeutic failure of all alternatives available in the FDC; and/or

Lack of a therapeutic alternative in the FDC.

3.	Other Aspects of the Prescription Drug Coverage

The prescription drug coverage of the GHP establishes that using generic bioequivalent products as the first option is mandatory.

Page 3 of 83

ASES has an active process to continually review the prescription drug coverage in accordnce with changes or advances in medical practice standards in relation to an illness or treatment area. It also evaluates new drugs to decide if they should be included. Because of the dynamic nature of this process, ASES may require that drugs be included in or excluded from the FDC at any time, taking the necessary measures to inform beneficiaries and medical providers about the changes to guarantee a transition process that will safeguard adequate access to services and maintain continuity of care.

The maximum supply dispensed for acute conditions will cover a fifteen (15) day therapy. The treatment period may be extended, as applicable, when medically necessary.

ASES requires the use of generic bioequivalent drugs approved by the Food and Drug Adminitration (FDA) coded as “AB” and those authorized under applicable local regulations in Puerto Rico.

Drug prescriptions will be filled by a pharmacy contracted by the PBM that is duly authorized under the law of the Commonwealth of Puerto Rico and has been freely chosen by the beneficiary.

Page 4 of 83

K.	Emergency Rule

The products that appear in the Integrated Emergency Formulary (IEF) will be dispensed for five (5) business days, except as otherwise specified.

The same thing applies to analgesics, narcotics, combination drugs, and nonsteroidal anti-inflammatory drugs, which will also be dispensed in amounts sufficient for five (5) business days.

If you have any questions about the prescription drug coverage, you may contact the insurance company contracted by ASES in your region and/or the Pharmacy Benefit Manager (PBM) contracted by ASES.

Page 5 of 83

SUB FÍSICA

GOVERNMENT HEALTHCARE PLAN

FORMULARY OF DRUGS COVERED BY THE GHP (FDC)

2017

TABLE OF CONTENTS

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE OF THE GOVERNMENT HEALTHCARE PLAN	3
DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES	11
MONTHLY NET COST RANGE	12
GENERIC DRUGS	12
ANALGESICS	13
Nonsteroidal Anti-Inflammatory Agents (NSAIDs)	13
Short-Acting Opioid Analgesics	13
ANESTHETICS	14
Local Anesthetics	14
ANTIBACTERIALS	14
First Generation Cephalosporins	14
Macrolides	14
Miscellaneous Antibacterials	14
Penicillins	15
Quinolones	15
Second Generation Cephalosporins	16
Sulfonamides	16
Third Generation Cephalosporins	16
ANTICONVULSANTS	16

Page 6 of 83

SUB FÍSICA

Anticonvulsants	16
ANTIDEMENTIA AGENTS	17
Cholinesterase Inhibitors	17
ANTIDEPRESSANTS	17
Monoamine Oxidase (Mao) Inhibitors	17
ANTIDIABETIC AGENTS	17
Alpha-Glucosidase Inhibitors	17
Biguanides	17
Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors	18
Insulin Mixtures	18
Insulin Sensitizing Agents	18
Intermediate-Acting Insulins	18
Short-Acting Insulins	18
Sulfonylureas	18
ANTIEMETICS	18
Miscellaneous Antiemetics	18
Phenothiazines	18
ANTIGOUT AGENTS	19
Antigout Agents	19
Uricosurics	19
ANTIHYPERTENSIVES	19
Alpha-Adrenergic Agonists	19
Alpha-Adrenergic Blocking Agents	19
Angiotensin II Receptor Blockers (Arb)	19
Angiotensin-Converting Enzyme (Ace) Inhibitors	19
Calcium Channel Blocking Agents	19
Carbonic Anhydrase Inhibitors Diuretics	20
Cardioselective Beta Blocking Agents	20
Cardioselective Beta-Adrenergic Blocking Agents	20
Loop Diuretics	20
Nonselective Beta Blocking Agents	20

Page 7 of 83

SUB FÍSICA

Potassium-Sparing Diuretics	21
Thiazide Diuretics	21
Vasodilator Beta Blockers	21
Vasodilators	21
ANTIMIGRAINE AGENTS	21
Beta-Adrenergic Blocking Agents	21
ANTIMYASTHENIC AGENTS	21
Parasympathomimetics	21
ANTIMYCOBACTERIALS	22
Antituberculars	22
ANTIPARASITICS	22
Antimalarials	22
ANTIPARKINSON AGENTS	22
Antiparkinson Dopaminergics	22
Dopamine Precursors	23
Monoamine Oxidase B (Mao-B) Inhibitors	23
ANTIVIRALS	23
Anti-Cytomegalovirus (Cmv) Agents	23
Antiherpetic Agents	23
Anti-Influenza Agents	23
BENIGN PROSTATIC HYPERTROPHY AGENTS	24
Alpha-Adrenergic Blocking Agents	24
BLOOD MODIFIERS	24
Anticoagulants	24
Colony Stimulating Factors	24
Platelet Modifying Agents	24
CARDIOVASCULAR AGENTS	24
Antiarrhythmics Class II	24
Antiarrhythmics Type I-A	25
Antiarrhythmics Type I-B	25
Antiarrhythmics Type I-C	25

Page 8 of 83

SUB FÍSICA

Antiarrhythmics Type III	25
Miscellaneous Cardiovascular Agents	25
Vasodilators	25
DENTAL AND ORAL AGENTS	26
Antifungals	26
DERMATOLOGICAL AGENTS	26
Topical Antibiotics	26
DYSLIPIDEMICS	26
Bile Acid Sequestrants	26
Fibric Acid Derivatives	26
Hmg-Coa Reductase Inhibitors	26
GASTROINTESTINAL AGENTS	27
Histamine2 (H2) Receptor Antagonists	27
Miscellaneous Gastrointestinal Agents	27
Proton Pump Inhibitors	27
GENITOURINARY AGENTS	27
Miscellaneous Genitourinary Agents	27
HORMONAL AGENTS	27
Antithyroid Agents	27
Calcimimetic Agents	27
Dopamine Agonists	27
Thyroid Hormones	27
IMMUNOSUPPRESSANTS	28
Glucocorticosteroids	28
INFLAMMATORY BOWEL DISEASE	28
Aminosalicylates	28
Sulfonamides	28
MINERALS & ELECTROLYTES	28
MUSCLE RELAXANTS	28
Antispasticity Agents	28
Skeletal Muscle Relaxants	29

Page 9 of 83

SUB FÍSICA

OPHTHALMIC AGENTS	29
Antiglaucoma Agents	29
Ophthalmic Antibiotics	29
Ophthalmic Prostaglandins	29
Ophthalmic Steroids	29
OTIC AGENTS	30
Miscellaneous Otic Agents	30
Otic Antibiotics	30
RESPIRATORY AGENTS	30
Anticholinergic Bronchodilators	30
Antileukotrienes	30
Antitussive-Expectorant	30
Inhaled Corticosteroids	30
Sedating Histamine1 Blocking Agents	31
Sympathomimetic Bronchodilators	31

Page 10 of 83

SUB FÍSICA

DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES

The example below illustrates the information provided for the drugs included in the FDC.

Drug Name	Net Cost	Tier	Reference Name	Requirements/ Limits
THERAPEUTIC CATEGORY
Therapeutic Class
ANALGESICS
Nonsteroidal Anti-Inflammatory Agents (NSAIDs)
ibuprofen 400 mg tab, 600 mg tab	1	Preferred	MOTRIN	QL = 5 days
indomethacin 25 mg cap, 50 mg cap	1	Non-preferred	INDOCIN	QL = 5 days
nabumetone 500 mg tab, 750 mg tab	1	Preferred	RELAFEN	QL = 5 days
naproxen 250 mg tab, 375 mg tab, 500 mg tab	1	Preferred	NAPROSYN	QL = 5 days
naproxen sodium 275 mg tab, 550 mg tab	1	Preferred	ANAPROX	QL = 5 days
salsalate 500 mg tab, 750 mg tab	1	Preferred	DISALCID	QL = 5 days
indomethacin er 75 mg cap er	2	Non- preferred	INDOCIN	QL = 5 days

Page 11 of 83

SUB FÍSICA

MONTHLY NET COST RANGE

1	less than $20	Least costly per month
2	$20 - $49
3	$50 - $99
4	$100 - $199
5	$200 - $349
6	$350 - $549
7	$550 - $799
8	$800 - $1,099
9	$1,100 - $1,499
10	$1,500 - $1,999
11	$2,000 - $2,499
12	$2,500 - $2,999
13	$3,000 - $3,499
14	$3,500 - $3,999
15	$4,000 - $4,499
16	$4,500 - $4,999
17	$5,000 - $5,499
18	$5,500 - $5,999
19	$6,000 - $6,499
20	$6,500 - $6,999
21	$7,000 - $7,499
22	$7,500 - $7,999
23	$8,000 - $8,499
24	$8,500 - $9,000
25	more than $9,000	Most costly per month

The net cost analysis is an ongoing exercise subject to constant changes. Net costs as published here are current as of the date of this edition of the FDC.

GENERIC DRUGS

Page 12 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Terapéutica]
ANALGESICS [ANALG ÉSICOS]
Nonsteroidal Anti-Inflammatory Agents (NSAIDs) [Anti-Inflamatorios No Esteroidales]
ibuprofen 400 mg tab, 600 mg tab	1	Preferred	MOTRIN	QL=5 días
nabumetone 500 mg tab, 750 mg tab	1	Preferred	RELAFEN	QL=5 días
naproxen 250 mg tab, 375 mg tab, 500 mg tab	1	Preferred	NAPROSYN	QL=15 días No repeticiones
salsalate 500 mg tab, 750 mg tab	1	Preferred	DISALCID	QL=5 días
indomethacin 25 mg cap, 50 mg cap	1	Non-Preferred	INDOCIN
Short-Acting Opioid Analgesics [Analgésicos Opiodes De Corta Duración]
acetaminophen -codeine 120-12 mg/5ml soln, 300-15 mg tab, 300-30 mg tab, 300- 60 mg tab	1	Preferred	TYLENOL- CODEINE	QL=5 días
acetaminophen-codeine #2 300-15 mg tab	1	Preferred	TYLENOL- CODEINE	QL=5 días
acetaminophen-codeine #3 300-30 mg tab	1	Preferred	TYLENOL- CODEINE	QL=5 días
acetaminophen-codeine #4 300-60 mg tab	1	Preferred	TYLENOL- CODEINE	QL=5 días
butalbital-apap-caffeine 50325-40 mg tab	1	Preferred	FIORICET	QL=5 días
tramadol hcl 50 mg tab	1	Preferred	ULTRAM	QL=5 días
butalbital-apap-caffeine 50325-40 mg cap	2	Preferred	FIORICET	QL=5 días
margesic 50-325-40 mg cap	2	Preferred	FIORICET	QL=5 días

Page 13 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
ANESTHETICS [ANESTÉSICOS]
Local Anesthetics [Anestésicos Locales]
lidocaine viscous 2 % mouth/throat soln	1	Preferred	XYLOCAINE	QL=5 días
ANTIBACTERIALS [ANTIBACTERIANOS]
First Generation Cephalosporins [Cefalosporinas De Primera Generación]
cephalexin 125 mg/5ml susp, 250 mg cap, 500 mg cap	1	Preferred	KEFLEX	QL=5 días
cefadroxil 250 mg/5ml susp	2	Non-Preferred	DURICEF	QL=5 días, AL 012 años
cephalexin 250 mg/5ml susp	2	Preferred	KEFLEX	QL=5 días
cefadroxil 500 mg/5ml susp	3	Non-Preferred	DURICEF	QL=5 días, AL 0-12 años
Macrolides [Macrólidos]
azithromycin 250 mg tab, 500 mg tab	1	Preferred	ZITHROMAX	QL=5 días
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab	2	Preferred	ZITHROMAX	QL=5 días
clarithromycin 125 mg/5ml susp, 250 mg tab, 500 mg tab	2	Preferred	BIAXIN	QL=5 días
clarithromycin 250 mg/5ml susp	3	Preferred	BIAXIN	QL=5 días
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab	3	Preferred	ERY-TAB	QL=5 días
erythromycin ethylsuccinate 400 mg tab	3	Preferred	E.E.S.	QL=5 días
ERYTHROCIN STEARATE 250 mg tab	4	Non-Preferred		QL=5 días
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
clindamycin hcl 150 mg cap, 300 mg cap, 75 mg cap	1	Preferred	CLEOCIN	QL=5 días
MACRODANTIN 25 mg cap	1	Preferred		QL=5 días

Page 14 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Cost Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
metronidazole 250 mg tab, 500 mg tab	1	Preferred	FLAGYL	QL=5 días
nitrofurantoin macrocrystal 50 mg cap	1	Preferred	MACRODANTIN	QL=5 días
nitrofurantoin macrocrystal 100 mg cap	2	Preferred	MACRODANTIN	QL=5 días
nitrofurantoin monohyd macro 100 mg cap	2	Preferred	MACROBID	QL=5 días
		Penicillins [Penicilinas]
amoxicillin 125 mg/5ml susp, 200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab	1	Preferred	AMOXIL	QL=5 días
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 600-42.9 mg/5ml susp, 875-125 mg tab	1	Preferred	AUGMENTIN	QL=5 días
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap	1	Preferred	PRINCIPEN	QL=5 días
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab	1	Preferred	VEETIDS	QL=5 días
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp	3	Preferred	AUGMENTIN	QL=5 días
		Quinolones [Quinolonas]
ciprofloxacin hcl 250 mg tab, 500 mg tab, 750 mg tab	1	Preferred	CIPRO	QL=5 días
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab	1	Preferred	LEVAQUIN	QL=5 días
ciprofloxacin 500 mg/5ml (10%) susp	3	Preferred	CIPRO	QL=5 días
ciprofloxacin 250 mg/5ml (5%) susp	4	Preferred	CIPRO	QL=5 días

Page 15 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
Second Generation Cephalosporins [Cefalosporinas De Segunda Generación]
cefaclor 250 mg cap, 500 mg cap	2	Preferred	CECLOR	QL=5 días
cefprozil 125 mg/5ml susp, 250 mg tab, 250 mg/5ml susp, 500 mg tab	2	Preferred	CEFZIL	QL=5 días
Sulfonamides [Sulfonamidas]
sulfamethoxazole-tmp ds 800-160 mg tab	1	Preferred	SEPTRA	QL=5 días
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab	1	Preferred	SEPTRA	QL=5 días
Third Generation Cephalosporins [Cefalosporinas De Tercera Generación]
cefdinir 125 mg/5ml susp, 300 mg cap	2	Preferred	OMNICEF	QL=5 días
cefdinir 250 mg/5ml susp	3	Preferred	OMNICEF	QL=5 días
ANTICONVULSANTS [ANTICONVULSIVANTES]
Anticonvulsants [Anticonvulsivantes]
carbamazepine 100 mg tab chew, 200 mg tab	1	Preferred	TEGRETOL	QL=5 días
gabapentin 100 mg cap, 300 mg cap, 400 mg cap, 600 mg tab, 800 mg tab	1	Preferred	NEURONTIN	QL=5 días
levetiracetam 250 mg tab, 500 mg tab	1	Preferred	KEPPRA	QL=5 días
oxcarbazepine 150 mg tab	1	Preferred	TRILEPTAL	QL=5 días
phenobarbital 100 mg tab, 15 mg tab, 16.2 mg tab, 30 mg tab, 32.4 mg tab, 60 mg tab, 64.8 mg tab, 97.2 mg tab	1	Preferred	PHENOBARBITAL	QL=5 días
primidone 250 mg tab, 50 mg tab	1	Preferred	MYSOLINE	QL=5 días
topiramate 100 mg tab, 200 mg tab, 25 mg tab, 50 mg tab	1	Preferred	TOPAMAX	QL=5 días
DILANTIN 30 mg cap	2	Preferred		QL=5 días

Page 16 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
levetiracetam 1000 mg tab, 750 mg tab	2	Preferred	KEPPRA	QL=5 días
oxcarbazepine 300 mg tab, 600 mg tab	2	Preferred	TRILEPTAL	QL=5 días
phenytoin 125 mg/5ml susp, 50 mg tab chew	2	Preferred	DILANTIN	QL=5 días
phenytoin sodium extended 100 mg cap, 200 mg cap, 300 mg cap	2	Preferred	DILANTIN	QL=5 días
phenytoin sodium extended 100 mg cap, 200 mg cap, 300 mg cap	2	Preferred	DILANTIN	QL=5 días
ethosuximide 250 mg cap, 250 mg/5ml soln	3	Preferred	ZARONTIN	QL=5 días
phenobarbital 20 mg/5ml oral elix, 20 mg/5ml soln	3	Preferred	PHENOBARBITAL	QL=5 días
ANTIDEMENTIA AGENTS [AGENTES ANTIDEMENCIA]
Cholinesterase Inhibitors [Inhibidores De Colinesterasa]
donepezil hcl 10 mg tab, 5 mg tab	1	Preferred	ARICEPT	QL=5 días
rivastigmine tartrate 1.5 mg cap, 3 mg cap, 4.5 mg cap, 6 mg cap	3	Preferred	EXELON	QL=5 días
ANTIDEPRESSANTS [ANTIDEPRESIVOS]
Monoamine Oxidase (Mao) Inhibitors [Inhibidores De Mao]
selegiline hcl 5 mg tab	3	Non-Preferred	CARBEX	QL=5 días
ANTIDIABETIC AGENTS [AGENTES ANTIDIABÉTICOS]
Alpha-Glucosidase Inhibitors [Inhibidores De Alfa Glucosidasa]
acarbose 100 mg tab, 25 mg tab, 50 mg tab	2	Preferred	PRECOSE	QL=5 días
Biguanides [Biguanidas]
metformin hcl 1000 mg tab, 500 mg tab, 850 mg tab	1	Preferred	GLUCOPHAGE	QL=5 días

Page 17 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors [Inhibidores De Dpp-4]
KOMBIGLYZE XR 2.5 -1000 mg tab er 24 hr, 5-1000 mg tab er 24 hr, 5-500 mg tab er 24 hr	3	Preferred		QL=5 días, ST, P
ONGLYZA 2.5 mg tab, 5 mg tab	3	Preferred		QL=5 días, ST, P
Insulin Mixtures [Mezclas De Insulinas]
HUMULIN 70/30 (70 -30) 100 unit/ml sc susp	2	Preferred		QL= 1 vial / 30 días, P
Insulin Sensitizing Agents [Agentes Sensibilizantes De Insulin]
pioglitazone hcl 15 mg tab, 30 mg tab, 45 mg tab	1	Preferred	ACTOS	QL=5 días
Intermediate-Acting Insulins [Insulinas De Duración Intermedia]
HUMULIN N 100 unit/ml sc QL= 1 vial / susp 2 Preferred 30 días, P
Short-Acting Insulins [Insulinas De Corta Duración]
HUMULIN R 100 unit/ml inj soln	2	Preferred		QL= 1 vial / 30 días, P
Sulfonylureas [Sulfonilureas]
glimepiride 1 mg tab, 2 mg tab, 4 mg tab	1	Preferred	AMARYL	QL=5 días
glipizide 10 mg tab, 5 mg tab	1	Preferred	GLUCOTROL	QL=5 días
ANTIEMETICS [ANTIEMÉTICOS]
Miscellaneous Antiemetics [Antieméticos Misceláneos]
metoclopramide hcl 10 mg tab, 5 mg tab, 5 mg/ml inj soln	1	Preferred	REGLAN	QL=5 días
trimethobenzamide hcl 300 mg cap	1	Preferred	TIGAN	QL=5 días
Phenothiazines [Fenotiazinas]
prochlorperazine maleate 10 mg tab, 5 mg tab	1	Preferred	COMPAZINE	QL=5 días
prochlorperazine 25 mg rect supp	4	Non-Preferred	COMPAZINE	QL=5 días

Page 18 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
ANTIGOUT AGENTS [AGENTES ANTIGOTA]
Antigout Agents [Agentes Antigota]
allopurinol 100 mg tab, 300 mg tab	1	Preferred	ZYLOPRIM	QL=5 días
colchicine 0.6 mg cap	3	Preferred	MITIGARE	PA
colchicine 0.6 mg tab	3	Non-Preferred	COLCRYS	QL= 3 tab, 15días
Uricosurics [Uricosúricos]
probenecid 500 mg tab	1	Preferred	BENEMID	QL=5 días
ANTIHYPERTENSIVES [ANTIHIPERTENSIVOS]
Alpha-Adrenergic Agonists [Agonistas Alfa Adrenérgicos]
clonidine hcl 0.2 mg tab, 0.3 mg tab	1	Preferred	CATAPRESS	QL=5 días
methyldopa 250 mg tab, 500 mg tab	1	Preferred	ALDOMET	QL=5 días
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
terazosin hcl 1 mg cap, 10 mg cap, 2 mg cap, 5 mg cap	1	Preferred	HYTRIN	QL=5 días
Angiotensin II Receptor Blockers (Arb) [Antagonistas Del Receptor Angiotensina II]
losartan potassium 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	COZAAR	QL=5 días
losartan potassium-hctz 100-12.5 mg tab, 100-25 mg tab, 50-12.5 mg tab	1	Preferred	HYZAAR	QL=5 días
Angiotensin-Converting Enzyme (Ace) Inhibitors [Inhibidores De La Enzima Convertidora De Angiotensin]
lisinopril 10 mg tab, 2.5 mg tab, 20 mg tab, 30 mg tab, 40 mg tab, 5 mg tab	1	Preferred	ZESTRIL	QL=5 días
lisinopril-hydrochlorothiazide 10-12.5 mg tab, 20-12.5 mg tab, 20-25 mg tab	1	Preferred	ZESTORETIC	QL=5 días
Calcium Channel Blocking Agents [Bloqueadores De Canales De Calcio]
amlodipine besylate 10 mg tab, 2.5 mg tab, 5 mg tab	1	Preferred	NORVASC	QL=5 días

Page 19 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
diltiazem hcl 120 mg tab, 30 mg tab, 60 mg tab, 90 mg tab	1	Preferred	CARDIZEM	QL=5 días
verapamil hcl 120 mg tab, 40 mg tab, 80 mg tab	1	Preferred	CALAN	QL=5 días
Carbonic Anhydrase Inhibitors Diuretics [Diuréticos Inhibidores De Anhidrasa Carbónica]
acetazolamide 125 mg tab, 250 mg tab	3	Preferred	DIAMOX	QL=5 días
Cardioselective Beta Blocking Agents [Bloqueadores Beta Cardioselectivos]
atenolol 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	TENORMIN	QL=5 días
metoprolol succinate er 25 mg tab er 24 hr, 50 mg tab er 24 hr	1	Preferred	LOPRESSOR	QL=5 días
metoprolol tartrate 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	LOPRESSOR	QL=5 días
metoprolol succinate er 100 mg tab er 24 hr, 200 mg tab er 24 hr	2	Preferred	LOPRESSOR	QL=5 días
Cardioselective Beta-Adrenergic Blocking Agents [Bloqueadores Beta-Adrenérgicos Cardioselectivos]
atenolol -chlorthalidone 10025 mg tab, 50-25 mg tab	1	Preferred	TENORETIC	QL=5 días
metoprolol- hydrochlorothiazide 50-25 mg tab	2	Non-Preferred	LOPRESSOR HCT	QL=5 días
metoprolol- hydrochlorothiazide 100-25 mg tab, 100-50 mg tab	3	Non-Preferred	LOPRESSOR HCT	QL=5 días
Loop Diuretics [Diuréticos Del Asa]
furosemide 10 mg/ml soln, 20 mg tab, 40 mg tab, 80 mg tab	1	Preferred	LASIX	QL=5 días
Nonselective Beta Blocking Agents [Bloqueadores Beta No-Selectivos]
propranolol hcl 10 mg tab, 20 mg tab, 40 mg tab, 80 mg tab	1	Preferred	INDERAL	QL=5 días
propranolol hcl 60 mg tab	2	Preferred	INDERAL	QL=5 días

Page 20 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
Potassium-Sparing Diuretics [Diuréticos Conservadores De Potasio]
spironolactone 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	ALDACTONE	QL=5 días
triamterene-hctz 37.5-25 mg cap, 37.5-25 mg tab, 75-50 mg tab	1	Preferred	MAXZIDE	QL=5 días
Thiazide Diuretics [Diuréticos Tiazidas]
chlorothiazide 250 mg tab, 500 mg tab	1	Preferred	DIURIL	QL=5 días
chlorthalidone 25 mg tab, 50 mg tab	1	Preferred	HYGROTON	QL=5 días
DIURIL 250 mg/5ml susp	1	Preferred		QL=5 días
hydrochlorothiazide 12.5 mg tab, 25 mg tab, 50 mg tab	1	Preferred	MICROZIDE	QL=5 días
indapamide 1.25 mg tab, 2.5 mg tab	1	Preferred	LOZOL	QL=5 días
metolazone 2.5 mg tab, 5 mg tab	1	Non-Preferred	ZAROXOLYN	QL=5 días
chlorthalidone 100 mg tab	2	Preferred	HYGROTON	QL=5 días
metolazone 10 mg tab	2	Non-Preferred	ZAROXOLYN	QL=5 días
Vasodilator Beta Blockers [Bloqueadores Beta Vasodilatadores]
carvedilol 12.5 mg tab, 25 mg tab, 3.125 mg tab, 6.25 mg tab	1	Preferred	COREG	QL=5 días
Vasodilators [Vasodilatadores]
hydralazine hcl 10 mg tab, 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	APRESOLINE	QL=5 días
ANTIMIGRAINE AGENTS [AGENTES ANTIMIGRAÑA]
Beta-Adrenergic Blocking Agents [Bloqueadores Beta Adrenérgicos]
topiramate 100 mg tab, 200 mg tab, 25 mg tab, 50 mg tab 1 Preferred TOPAMAX QL=5 días
ANTIMYASTHENIC AGENTS [AGENTES ANTIMIASTÉNICOS]
Parasympathomimetics [Parasimpatomiméticos]
pyridostigmine bromide 60 mg tab	2	Preferred	MESTINON	QL=5 días

Page 21 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
pyridostigmine bromide 180 mg tab er	6	Non-Preferred	MESTINON
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
Antituberculars [Antituberculosos]
isoniazid 100 mg tab, 300 mg tab	1	Preferred	ISONIAZID	QL=5 días
rifampin 150 mg cap	1	Preferred	RIFADIN	QL=5 días
pyrazinamide 500 mg tab	2	Non-Preferred	PYRAZINAMIDE	QL=5 días
rifampin 300 mg cap	2	Preferred	RIFADIN	QL=5 días
isoniazid 50 mg/5ml syr	5	Non-Preferred	ISONIAZID	QL=5 días
rifabutin 150 mg cap			MYCOBUTIN	Puerto Rico Health Department Tuberculosis Program
cycloserine 250 mg cap			SEROMYCIN
CAPASTAT SULFATE 1 gm inj
RIFAMATE 150-300 mg cap
TRECATOR 250 mg tab
ANTIPARASITICS [ANTIPARASITARIOS]
Antimalarials [Antimaláricos]
chloroquine phosphate 250 mg tab, 500 mg tab	1	Preferred	ARALEN	QL=5 días
hydroxychloroquine sulfate 200 mg tab	1	Preferred	PLAQUENIL	QL=5 días
DARAPRIM 25 mg tab	7	Non-Preferred		QL=5 días
ANTIPARKINSON AGENTS [AGENTES ANTIPARKINSON]
Antiparkinson Dopaminergics [Dopaminérgicos Antiparkinson]
amantadine hcl 50 mg/5ml syr	1	Preferred	SYMMETREL	QL=5 días
pramipexole dihydrochloride 0.125 mg tab, 0.25 mg tab, 0.5 mg tab, 0.75 mg tab, 1 mg tab, 1.5 mg tab	1	Preferred	MIRAPEX	QL=5 días
ropinirole hcl 0.25 mg tab, 0.5 mg tab, 1 mg tab, 3 mg tab, 4 mg tab, 5 mg tab	1	Preferred	REQUIP	QL=5 días
ropinirole hcl 2 mg tab	2	Preferred	REQUIP	QL=5 días
amantadine hcl 100 mg cap	3	Preferred	SYMMETREL	QL=5 días

Page 22 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Re ference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
bromocriptine mesylate 2.5 mg tab	3	Preferred	PARLODEL	QL=5 días
carbidopa-levodopaentacapone 18.75-75-200 mg tab	4	Non-Preferred	STALEVO	QL=5 días
carbidopa-levodopaentacapone 12.5-50-200 mg tab, 25-100-200 mg tab, 31.25-125-200 mg tab, 37.5150-200 mg tab, 50-200-200 mg tab	5	Non-Preferred	STALEVO	QL=5 días
Dopamine Precursors [Precursores De Dopamina]
carbidopa -levodopa 10-100 mg tab, 25-100 mg tab	1	Preferred	SINEMET	QL=5 días
carbidopa-levodopa 25-250 mg tab	2	Preferred	SINEMET	QL=5 días
carbidopa-levodopa er 25100 mg tab er, 50-200 mg tab er	2	Preferred	SINEMET CR	QL=5 días
Monoamine Oxidase B (Mao-B) Inhibitors [Inhibidores De Mao-B]
selegiline hcl 5 mg tab	3	Preferred	CARBEX	QL=5 días
ANTIVIRALS [ANTIVIRALES]
Anti-Cytomegalovirus (Cmv) Agents [Agentes Anti-Citomegalovirus]
valganciclovir hcl 450 mg tab	13	Non-Preferred	VALCYTE	PA, QL=5 días
Antiherpetic Agents [Agentes Antiherpéticos]
acyclovir 200 mg cap, 400 mg tab, 800 mg tab	1	Preferred	ZOVIRAX	QL=5 días
acyclovir 200 mg/5ml susp	2	Preferred	ZOVIRAX	QL=5 días
Anti-Influenza Agents [Agentes Antiinfluenza]
amantadine hcl 50 mg/5ml syr	1	Preferred	SYMMETREL	QL=5 días
amantadine hcl 100 mg cap	3	Preferred	SYMMETREL	QL=5 días

Page 23 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
BENIGN PROSTATIC HYPERTROPHY AGENTS [AGENTES PARA HIPERTROFIA PROSTÁTICA BENIGNA]
Alpha-Adrenergic Blocking Agents [Bloqueadores Alfa Adrenérgicos]
terazosin hcl 1 mg cap, 10 mg cap, 2 mg cap, 5 mg cap	1	Preferred	HYTRIN	QL=5 días
BLOOD MODIFIERS [MODIFICADORES DE LA SANGRE]
Anticoagulants [Anticoagulantes]
warfarin sodium 1 mg tab, 10 mg tab, 2 mg tab, 2.5 mg tab, 3 mg tab, 4 mg tab, 5 mg tab, 6 mg tab, 7.5 mg tab	1	Preferred	COUMADIN	QL=5 días
heparin sodium (porcine) 1000 unit/ml inj soln	2	Preferred	HEPARIN	QL=5 días
heparin sodium (porcine) 10000 unit/ml inj soln, 5000 unit/ml inj soln	3	Preferred	HEPARIN	QL=5 días
heparin sodium (porcine) pf 5000 unit/0.5ml inj soln	3	Preferred	HEPARIN	QL=5 días
heparin sodium (porcine) 2000 unit/ml iv soln	8	Preferred	HEPARIN	QL=5 días
Colony Stimulating Factors [Estimulantes Mieloides]
NEULASTA 6 mg/0.6ml sc soln	12	Preferred		PA, QL=5 días, P
NEULASTA DELIVERY KIT 6 mg/0.6ml sc soln	12	Preferred		PA, QL=5 días, P
Platelet Modifying Agents [Modificadores De Plaquetas]
cilostazol 100 mg tab, 50 mg tab	1	Preferred	PLETAL	QL=5 días
clopidogrel bisulfate 75 mg tab	1	Preferred	PLAVIX	QL=5 días
CARDIOVASCULAR AGENTS [AGENTES CARDIOVASCULARES]
Antiarrhythmics Class II [Antiarrítmicos Clase II]
propranolol hcl 10 mg tab, 20 mg tab, 40 mg tab, 80 mg tab	1	Preferred	INDERAL	QL=5 días

Page 24 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
sotalol hcl 120 mg tab, 160 mg tab, 240 mg tab, 80 mg tab	1	Preferred	BETAPACE	QL=5 días
sotalol hcl (af) 120 mg tab, 160 mg tab, 80 mg tab	1	Preferred	BETAPACE	QL=5 días
propranolol hcl 60 mg tab	2	Preferred	INDERAL	QL=5 días
Antiarrhythmics Type I-A [Antiarrítmicos Tipo I-A]
quinidine sulfate 200 mg tab, 300 mg tab	1	Preferred	QUINIDINE SULFATE	QL=5 días
quinidine gluconate er 324 mg tab er	2	Preferred	QUINAGLUTE	QL=5 días
quinidine sulfate er 300 mg tab er	2	Preferred	QUINIDINE SULFATE	QL=5 días
Antiarrhythmics Type I-B [Antiarrítmicos Tipo I-B]
mexiletine hcl 150 mg cap	2	Preferred	MEXITIL	QL=5 días
mexiletine hcl 200 mg cap	3	Preferred	MEXITIL	QL=5 días
Antiarrhythmics Type I-C [Antiarrítmicos Tipo I-C]
flecainide acetate 100 mg tab, 50 mg tab	1	Preferred	TAMBOCOR	QL=5 días
propafenone hcl 150 mg tab, 225 mg tab	1	Preferred	RYTHMOL	QL=5 días
flecainide acetate 150 mg tab	2	Preferred	TAMBOCOR	QL=5 días
propafenone hcl 300 mg tab	3	Preferred	RYTHMOL	QL=5 días
Antiarrhythmics Type III [Antiarrítmicos Tipo III]
amiodarone hcl 200 mg tab	1	Preferred	CORDARONE	QL=5 días
Miscellaneous Cardiovascular Agents [Agentes Cardiovasculares Misceláneos]
digox 125 mcg tab, 250 mcg tab	2	Preferred	LANOXIN	QL=5 días
digoxin 125 mcg tab, 250 mcg tab	2	Preferred	LANOXIN	QL=5 días
Vasodilators [Vasodilatadores]
isosorbide mononitrate 10 mg tab, 20 mg tab	1	Preferred	ISORDIL	QL=5 días

Page 25 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
isosorbide mononitrate er 120 mg tab er 24 hr, 30 mg tab er 24 hr, 60 mg tab er 24 hr	1	Preferred	IMDUR	QL=5 días
NITROSTAT 0.3 mg tab subl, 0.4 mg tab subl, 0.6 mg tab subl	1	Preferred		QL=5 días
DENTAL AND ORAL AGENTS [AGENTES DENTALES Y ORALES]
Antifungals [Antifungales]
clotrimazole 10 mg mouth/throat lozenge, 10 mg mouth/throat troche	1	Preferred	MYCELEX	QL=5 días, OTC
nystatin 100000 unit/ml mouth/throat susp, 100000 unit/ml crm	1	Preferred	NYSTATIN	QL=5 días
DERMATOLOGICAL AGENTS [AGENTES DERMATOLÓGICOS]
Topical Antibiotics [Antibióticos Tópicos]
mupirocin 2 % oint	1	Preferred	BACTROBAN	QL=5 días
silver sulfadiazine 1 % crm	1	Preferred	SILVADENE	QL=5 días
gentamicin sulfate 0.1 % crm	2	Preferred	GARAMYCIN	QL=1 frasco / 5 días
gentamicin sulfate 0.1 % oint	2	Preferred	GARAMYCIN	QL=1 tubo / 5 días
DYSLIPIDEMICS [DISLIPIDÉMICOS]
Bile Acid Sequestrants [Secuestradores De Acidos Biliares]
cholestyramine 4 gm pckt, 4 gm/dose oral pwdr	3	Preferred	QUESTRAN	QL=5 días
cholestyramine light 4 gm pckt, 4 gm/dose oral pwdr	3	Preferred	QUESTRAN	QL=5 días
Fibric Acid Derivatives [Derivados De Ácido Fíbrico]
gemfibrozil 600 mg tab	1	Preferred	LOPID	QL=5 días
Hmg-Coa Reductase Inhibitors [Inhibidores De La Hmg-Coa Reductasa]
atorvastatin calcium 10 mg tab, 20 mg tab, 40 mg tab, 80 mg tab	1	Preferred	LIPITOR	QL=5 días
simvastatin 10 mg tab, 20 mg tab, 40 mg tab, 5 mg tab	1	Preferred	ZOCOR	QL=5 días

Page 26 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
GASTROINTESTINAL AGENTS [AGENTES GASTROINTESTINALES]
Histamine2 (H2) Receptor Antagonists [Antagonistas Del Receptor De H2]
famotidine 20 mg tab, 40 mg tab	1	Preferred	PEPCID	QL=5 días
ranitidine hcl 15 mg/ml syr, 150 mg/10ml syr, 300 mg tab, 75 mg/5ml syr	1	Preferred	ZANTAC	QL=5 días
Miscellaneous Gastrointestinal Agents [Agentes Gastrointestinales Misceláneos]
ursodiol 300 mg cap	2	Preferred	ACTIGALL	PA, QL=5 días
Proton Pump Inhibitors [Inhibidores De La Bomba De Protones]
omeprazole 10 mg cap dr, 20 mg cap dr	1	Preferred	PRILOSEC	QL=5 días
GENITOURINARY AGENTS [AGENTES GENITOURINARIOS]
Miscellaneous Genitourinary Agents [Agentes Genitourinarios Misceláneos]
phenazopyridine hcl 100 mg tab, 200 mg tab	1	Preferred	PYRIDIUM	QL=3 días
HORMONAL AGENTS [AGENTES HORMONALES]
Antithyroid Agents [Agentes Antitiroide]
methimazole 10 mg tab, 5 mg tab	1	Preferred	TAPAZOLE	QL=5 días
propylthiouracil 50 mg tab	2	Preferred	PROPYLTHIOURA CIL	QL=5 días
Calcimimetic Agents [Agentes Calcimiméticos]
SENSIPAR 30 mg tab	7			PA, QL=5 días
SENSIPAR 60 mg tab	9			PA, QL=5 días
SENSIPAR 90 mg tab	10			PA, QL=5 días
Dopamine Agonists [Agonistas De Dopamina]
bromocriptine mesylate 2.5 mg tab	3	Preferred	PARLODEL	QL=5 días
Thyroid Hormones [Hormona Tiroidea]
levothyroxine sodium 100 mcg tab, 112 mcg tab, 125 mcg tab, 137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab	1	Preferred	SYNTHROID	QL=5 días

Page 27 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
SYNTHROID 100 mcg tab, 112 mcg tab, 125 mcg tab, 137 mcg tab, 150 mcg tab, 175 mcg tab, 200 mcg tab, 25 mcg tab, 300 mcg tab, 50 mcg tab, 75 mcg tab, 88 mcg tab	1	Preferred		QL=5 días
IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
Glucocorticosteroids [Glucocorticoides]
dexamethasone 0.5 mg tab, 0.5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab	1	Preferred	DECADRON	QL=5 días
methylprednisolone 32 mg tab, 4 mg tab	1	Preferred	MEDROL	QL=5 días
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab	1	Preferred	DELTASONE	QL=5 días
prednisone (pak) 10 mg tab, 5 mg tab	1	Preferred	DELTASONE	QL=5 días
methylprednisolone 16 mg tab, 8 mg tab	2	Preferred	MEDROL	QL=5 días
INFLAMMATORY BOWEL DISEASE [ENFERMEDAD INFLAMATORIA INTESTINAL]
Aminosalicylates [Aminosalicilatos]
DELZICOL 400 mg cap dr	5	Preferred		QL=5 días, P
ASACOL HD 800 mg tab dr	6	Preferred		QL=5 días, P
Sulfonamides [Sulfonamidas]
sulfasalazine 500 mg tab, 500 mg tab dr	1	Preferred	AZULFIDINE	QL=5 días
MINERALS & ELECTROLYTES [MINERALES Y ELECTROLITOS]
MUSCLE RELAXANTS [RELAJANTES MUSCULARES]
Antispasticity Agents [Agentes Antiespasticidad]
baclofen 10 mg tab, 20 mg tab	1	Preferred	LIORESAL	QL=5 días
dantrolene sodium 25 mg cap, 50 mg cap	2	Preferred	DANTRIUM	QL=5 días

Page 28 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
dantrolene sodium 100 mg cap	3	Preferred	DANTRIUM	QL=5 días
Skeletal Muscle Relaxants [Relajantes Musculoesqueletales]
cyclobenzaprine hcl 10 mg tab	1	Preferred	FLEXERIL	QL=5 días
OPHTHALMIC AGENTS [AGENTES OFTÁLMICOS]
Antiglaucoma Agents [Agentes Antiglaucoma]
brimonidine tartrate 0.2 % ophth soln	1	Preferred	ALPHAGAN	QL=1 frasco 5 ml / 15 días
dorzolamide hcl 2 % ophth soln	1	Preferred	TRUSOPT	QL=1 frasco / 30 días
levobunolol hcl 0.5 % ophth soln	1	Preferred	BETAGAN	QL=1 frasco / 15 días
levobunolol hcl 0.25 % ophth soln	1	Preferred	BETAGAN	QL=1 frasco / 15 días
timolol maleate 0.5 % ophth soln	1	Preferred	TIMOPTIC	QL=1 frasco / 30 días
timolol maleate 0.25 % ophth soln	1	Preferred	TIMOPTIC	QL=1 frasco / 25 días
dorzolamide hcl-timolol mal ophth sol 22.3-6.8 mg/ml	1	Preferred	COSOPT	QL=1 frasco / 30 días
betaxolol hcl 0.5 % ophth soln	2	Non-Preferred	BETOPTIC	QL=1 frasco / 15 días
Ophthalmic Antibiotics [Antibióticos Oftálmicos]
gentamicin sulfate 0.3 % ophth oint	1	Preferred	GARAMYCIN	QL=5 días
gentamicin sulfate 0.3 % ophth soln	1	Preferred	GARAMYCIN	QL=5 días
tobramycin 0.3 % ophth soln	1	Preferred	TOBREX	QL=1 frasco / 5 días
Ophthalmic Prostaglandins [Prostaglandinas Oftálmicas]
latanoprost 0.005 % ophth soln	1	Preferred	XALATAN	QL=1 frasco / 25 días
Ophthalmic Steroids [Esteroides Oftálmicos]
neomycin -polymyxindexamethasone 3.5-100000.1 ophth oint, 3.5-100000.1 ophth susp	1	Preferred	MAXITROL

Page 29 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
prednisolone acetate 1 % ophth susp	2	Preferred	PRED FORTE	QL=1 frasco 5ml / 25 días
OTIC AGENTS [AGENTES OTICOS]
Miscellaneous Otic Agents [Agentes Oticos Misceláneos]
acetic acid 2 % otic soln	2	Preferred	VOSOL	QL= 1 frasco / 10 días
Otic Antibiotics [Antibióticos Oticos]
neomycin -polymyxin-hc 1 % otic soln, 3.5-10000-1 otic soln, 3.5-10000-1 otic susp	2	Preferred	CORTISPORIN	QL=1 frasco / 10 días
RESPIRATORY AGENTS [AGENTES RESPIRATORIOS]
Anticholinergic Bronchodilators [Broncodilatadores Anticolinérgicos]
ipratropium bromide 0.02 % inh soln	1	Non-Preferred	ATROVENT	QL=5 días
Antileukotrienes [Antileukotrienos]
montelukast sodium 10 mg tab, 4 mg tab chew, 5 mg tab chew	1	Preferred	SINGULAIR	QL=5 días
Antitussive-Expectorant [Expectorantes Antitusivos]
guaifenesin -codeine 100-10 mg/5ml soln	1	Preferred	CHERATUSSIN	QL=5 días
Inhaled Corticosteroids [Corticosteroides Inhalados]
FLOVENT DISKUS 100 mcg/blist inh aer pwdr, 250 mcg/blist inh aer pwdr, 50 mcg/blist inh aer pwdr	3	Preferred		QL=1 pompa / 30 días, P
FLOVENT HFA 110 mcg/act inh aer	3	Preferred		QL=1 pompa / 30 días, P
FLOVENT HFA 44 mcg/act inh aer	3	Preferred		QL=1 pompa / 30 días, P
budesonide 0.25 mg/2ml inh susp, 0.5 mg/2ml inh susp,	4	Non-Preferred	PULMICORT	QL=5 días, AL 012 años
budesonide 1mg/2ml inh susp	8	Non-Preferred	PULMICORT	AL 0-12 años
FLOVENT HFA 220 mcg/act inh aer	4	Preferred		QL=1 pompa / 30 días, P

Page 30 of 83

SUB FÍSICA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
Sedating Histamine1 Blocking Agents [Sedantes Bloqueadores Histamine1]
promethazine hcl 12.5 mg tab, 25 mg tab, 50 mg tab, 6.25 mg/5ml soln, 6.25 mg/5ml syr	1	Preferred	PHENERGAN	QL=5 días
Sympathomimetic Bronchodilators [Broncodilatadores Simpatomiméticos]
albuterol sulfate (2.5 mg/3ml) 0.083% inh neb soln, (5 mg/ml) 0.5% inh neb soln, 2 mg/5ml syr	1	Preferred	PROVENTIL	QL=5 días
terbutaline sulfate 2.5 mg tab, 5 mg tab	1	Preferred	BRETHINE	QL=5 días
VENTOLIN HFA 108 (90 base) mcg/act inh aer	1	Preferred		QL=1 frasco / 30 días, P

Page 31 of 83

A
acarbose	19
acetaminophen-codeine	13
acetaminophen-codeine #2	13
acetaminophen-codeine #3	13
acetaminophen-codeine #4	13
acetazolamide	22
acetic acid	37
acyclovir	28
albuterol sulfate	38
allopurinol	21
amantadine hcl	26, 27, 28
amiodarone hcl	30
amlodipine besylate	22
amoxicillin	16
amoxicillin-pot clavulanate	16
ampicillin	16
ASACOL HD	35
atenolol .	22
atenolol-chlorthalidone	23
atorvastatin calcium	32
azithromycin	14

B
baclofen	35
betaxolol hcl	36
brimonidine tartrate	35
bromocriptine mesylate	27, 33
budesonide	38
butalbital-apap-caffeine	14

C
CAPASTAT SULFATE	26
carbamazepine ..	17
carbidopa-levodopa	27
carbidopa-levodopa er	27
carbidopa-levodopa-entacapone	27
carvedilol	24
cefaclor	17
cefadroxil	14
cefdinir	17
cefprozil	17

cephalexin	14
chloroquine phosphate	26
chlorothiazide	24
chlorthalidone	24
cholestyramine	32
cholestyramine light	32
cilostazol	29
ciprofloxacin	16, 17
ciprofloxacin hcl	16
clarithromycin	15
clindamycin hcl	15
clonidine hcl	21
clopidogrel bisulfate	29
clotrimazole	31
colchicine	21
COLCRYS	.21
cyclobenzaprine hcl	35
cycloserine	25

D
dantrolene sodium	35
DARAPRIM	26
DELZICOL	34
dexamethasone .	34
digox	30
digoxin	31
DILANTIN	18
diltiazem hcl	22
DIURIL	4
donepezil hcl	19
dorzolamide hcl	35

E
ERYTHROCIN STEARATE	15
erythromycin base	15
erythromycin ethylsuccinate .	15
ethosuximide	18

F
famotidine	32
flecainide acetate	30
FLOVENT DISKUS	37

Page 32 of 83

FLOVENT HFA	37, 38
furosemide	23

G
gabapentin	17
gemfibrozil	32
gentamicin sulfate .	31, 36
glimepiride	20
glipizide	20
guaifenesin-codeine	37

H
heparin sodium (porcine)	28, 29
heparin sodium (porcine) pf	29
HUMULIN 70/30	20
HUMULIN N	20
HUMULIN R	20
hydralazine hcl	25
hydrochlorothiazide	24
hydroxychloroquine sulfate	26

I
ibuprofen	13
indapamide	24
indomethacin	13
ipratropium bromide	37
isoniazid	25
isosorbide mononitrate	31
isosorbide mononitrate er	31

K
KOMBIGLYZE XR	19

L
latanoprost	36
levetiracetam	17, 18
levobunolol hcl	35
levofloxacin	16
levothyroxine sodium .	33
lidocaine viscous	14
lisinopril	22
lisinopril-hydrochlorothiazide	22

losartan potassium	21
losartan potassium-hctz	21

M
MACRODANTIN .	15
margesic	14
MESTINON	25
metformin hcl	19
methimazole	.33
methyldopa	21
methylprednisolone	34
metoclopramide hcl	20
metolazone	24
metoprolol succinate er	22, 23
metoprolol tartrate	23
metoprolol-hydrochlorothiazide	23
metronidazole	15
mexiletine hcl	30
montelukast sodium	37
mupirocin	31

N
nabumetone	13
naproxen	13
neomycin-polymyxin-dexamethasone .	36
neomycin-polymyxin-hc	37
NEULASTA	29
NEULASTA DELIVERY KIT	29
nitrofurantoin macrocrystal	15
nitrofurantoin monohyd macro .	15
NITROSTAT	31
nystatin	31

O
omeprazole	.32
ONGLYZA	19
oxcarbazepine	18

P
penicillin v potassium .	16
phenazopyridine hcl	33
phenobarbital	18, 19
phenytoin	18
phenytoin sodium extended	18

Page 33 of 83

pioglitazone hcl	20
pramipexole dihydrochloride	26
prednisolone acetate	36
prednisone	34
prednisone (pak)	34
primidone	18
probenecid	21
prochlorperazine	20
prochlorperazine maleate	20
promethazine hcl	38
propafenone hcl	30
propranolol hcl	23, 29
propylthiouracil	33
pyrazinamide	25
pyridostigmine	25
pyridostigmine bromide	25

Q
quinidine gluconate er	30
quinidine sulfate	30
quinidine sulfate er	30

R
ranitidine hcl	32
rifabutin	25
RIFAMATE	26
rifampin	25
rivastigmine tartrate	19
ropinirole hcl	26
S
salsalate	13
selegiline hcl	19, 27
SENSIPAR	33
silver sulfadiazine	31
simvastatin	32
sotalol hcl	29
sotalol hcl (af)	29
spironolactone	24
sulfamethoxazole-tmp ds	17

sulfamethoxazole-trimethoprim	17
sulfasalazine	35
SYNTHROID	34

T
terazosin hcl	21, 28
terbutaline sulfate	38
timolol maleate	36
tobramycin	36
topiramate	18, 25
tramadol hcl	14
TRECATOR	26
triamterene-hctz	24
trimethobenzamide hcl	20

U
ursodiol	32

V
valganciclovir hcl	27
VENTOLIN HFA	38
verapamil hcl	22

W
warfarin sodium	28

Page 34 of 83

ASES

Puerto Rico Healthcare Insurance Administration

Sub-formulary of

Mental Health

2017

Formulary of Drugs Covered by

the Government Healthcare Plan (GHP)

Authorized by the P.R. Elections Commission CEE-SA-16-2732

Page 35 of 83

		GOVERNMENT OF PUERTO RICO		Hon. Ricardo A. Rosselló Nevares Governor Ms. Ángela M. Ávila Marrero Executive Director
		Healthcare Insurance Administration

May 1, 2017

TO ALL GOVERNMENT HEALTHCARE PLAN (GHP) PROVIDERS

Dear provider:

I urge you to keep this guide for future reference. It is also available on our webpage, www.asespr.org .

Cordially,

[signed]

Ángela M. Ávila Marrero

Executive Director



PO Box 195661, San Juan, PR 00919-5661 · Tel.: 787.474.3300 · Fax: 787.474.3348 · www.ases.pr.gov

Page 36 of 83

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE

OF THE GOVERNMENT HEALTHCARE PLAN (GHP)

1.	Drug Formulary

Non-formulary drugs may only be used in exceptional cases through the Exception Process that we will explain in point number 2.

2.	Exception Process

Contraindication to the drug(s) included in the FDC;

History of a clinically significant adverse reaction to the drug(s) included in the FDC;

Evidence of therapeutic failure of all alternatives available in the FDC; and/or

Lack of a therapeutic alternative in the FDC.

3.	Other Aspects of the Prescription Drug Coverage

The prescription drug coverage of the GHP establishes that using generic bioequivalent products as the first option is mandatory.

Page 37 of 83

The maximum supply dispensed for acute conditions will cover a fifteen (15) day therapy. The treatment period may be extended, as applicable, when medically necessary.

ASES requires the use of generic bioequivalent drugs approved by the Food and Drug Administration (FDA) coded as “AB” and those authorized under applicable local regulations in Puerto Rico.

Page 38 of 83

Drug prescriptions will be filled by a pharmacy contracted by the PBM that is duly authorized under the law of the Commonwealth of Puerto Rico and has been freely chosen by the beneficiary.

4.	Emergency Rule

The products that appear in the Integrated Emergency Formulary (IEF) will be dispensed for five (5) business days, except as otherwise specified.

The same thing applies to analgesics, narcotics, combination drugs, and nonsteroidal anti-inflammatory drugs, which will also be dispensed in amounts sufficient for five (5) business days.

If you have any questions about the prescription drug coverage, you may contact the insurance company contracted by ASES in your region and/or the Pharmacy Benefit Manager (PBM) contracted by ASES.

Page 39 of 83

SUB MENTAL

GOVERNMENT HEALTHCARE PLAN

FORMULARY OF DRUGS COVERED BY THE GHP (FDC)

2017

TABLE OF CONTENTS

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE
OF THE GOVERNMENT HEALTHCARE PLAN	3
DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND
REFERENCE GUIDES	7
MONTHLY NET COST RANGE	7
GENERIC DRUGS	8
ANTIANXIETY AGENTS	9
Benzodiazepines	9
Sedating Histamine 1 Blocking Agents	9
ANTIDEPRESSANTS	9
Miscellaneous Antidepressants	9
Serotonin and/or Norepinephrine Modulators	9
Tricyclic Agents	10
ANTIPARKINSON AGENTS	10
Anticholinergics	10
ANTIPSYCHOTICS	10
Atypical - Second Generation	10
Typical - First Generation	10
DETOX TREATMENT	11
Detox Treatment	11
MOOD STABILIZERS	11
Bipolar Agents	11
PSYCHOSTIMULANTS	11
ADHD Amphetamines	11
ADHD Non-Amphetamines	12
SLEEP DISORDER AGENTS	12
Benzodiazepines	12
Miscellaneous Sleep Disorder Agents	12

Page 40 of 83

SUB MENTAL

DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES

The example below illustrates the information provided for the drugs included in the FDC.

Drug Name	Net Cost	Tier	Reference Name	Requirements/ Limits
THERAPEUTIC CATEGORY
Therapeutic Class
ANTIANXIETY AGENTS
Benzodiazepines
diazepam 10 mg tab, 2 mg tab, 5 mg tab	1	Preferred	VALIUM	QL=5 days
lorazepam 0.5 mg tab, 1 mg tab	1	Preferred	ATIVAN	QL=5 days
Sedating Histamine 1 Blocking Agents
hydroxyzine pamoate 100 mg cap, 25 mg cap, 50 mg cap	1	Preferred	VISTARIL	QL=30 days
ANTIDEPRESSANTS
Miscellaneous Antidepressants
bupropion hcl 75 mg tab	1	Preferred	WELLBUTRIN	QL=30 days
bupropion hcl er (sr) 100 mg tab er 12 hr, 150 mg tab er 12 hr, 200 mg tab er 12 hr	1	Preferred	WELLBUTRIN SR	QL=30 days

MONTHLY NET COST RANGE

Page 41 of 83

SUB MENTAL

1	less than $20	Least costly per month
2	$20 - $49
3	$50 - $99
4	$100 - $199
5	$200 - $349
6	$350 - $549
7	$550 - $799
8	$800 - $1,099
9	$1,100 - $1,499
10	$1,500 - $1,999
11	$2,000 - $2,499
12	$2,500 - $2,999
13	$3,000 - $3,499
14	$3,500 - $3,999
15	$4,000 - $4,499
16	$4,500 - $4,999
17	$5,000 - $5,499
18	$5,500 - $5,999
19	$6,000 - $6,499
20	$6,500 - $6,999
21	$7,000 - $7,499
22	$7,500 - $7,999
23	$8,000 - $8,499
24	$8,500 - $9,000
25	more than $9,000	Most costly per month

The net cost analysis is an ongoing exercise subject to constant changes. Net costs as published here are current as of the date of this edition of the FDC.

GENERIC DRUGS

• PA – Prior Authorization [Pre Autorización] • aPA – Administrative Prior Authorization [Pre Autorización

Administrativa] • QL – Quantity Limit [Límite de Cantidad] • ST – Step Therapy [Terapia Escalonada] • AL –

Age Limit [Límite de Edad] • Net Cost [Costo Neto] – Please refer to page 7 for monthly net cost range [Ver de 14 página 7 para rangos de costo neto mensual] • P – Preferred Contracted Product [Producto Contratado Preferido] Revisado 5/12/2017

Page 42 of 83

SUB MENTAL

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Terapéutica]
ANTIANXIETY AGENTS [AGENTES PARA LA ANXIEDAD]
Benzodiazepines [Benzodiazepinas]
diazepam 10 mg tab, 2 mg tab, 5 mg tab	1	Preferred	VALIUM	QL=5 días
lorazepam 0.5 mg tab, 1 mg tab	1	Preferred	ATIVAN	QL=5 días
Sedating Histamine 1 Blocking Agents [Sedantes Bloqueadores Histamine 1]
hydroxyzine pamoate 100 mg cap, 25 mg cap, 50 mg cap	1	Preferred	VISTARIL	QL=30 días
ANTIDEPRESSANTS [ANTIDEPRESIVOS]
Miscellaneous Antidepressants [Antidepresivos Misceláneos]
bupropion hcl 75 mg tab	1	Preferred	WELLBUTRIN	QL=30 días
bupropion hcl er (sr) 100 mg tab er 12 hr, 150 mg tab er 12 hr, 200 mg tab er 12 hr	1	Preferred	WELLBUTRIN SR	QL=30 días
mirtazapine 15 mg tab, 30 mg tab, 45 mg tab, 7.5 mg tab	1	Preferred	REMERON	QL=30 días
trazodone hcl 100 mg tab, 150 mg tab, 50 mg tab	1	Preferred	DESYREL	QL=30 días
bupropion hcl 100 mg tab	2	Non-Preferred	WELLBUTRIN	QL=30 días
bupropion hcl er (xl) 150 mg tab er 24 hr, 300 mg tab er 24 hr	2	Non-Preferred	WELLBUTRIN XL	QL=30 días
mirtazapine 15 mg odt, 30 mg odt, 45 mg odt	3	Non-Preferred	REMERON	QL=30 días
Serotonin and/or Norepinephrine Modulators [Moduladores De Serotonina y/o Norepinefrina]
citalopram hydrobromide 10 mg tab, 20 mg tab, 40 mg tab	1	Preferred	CELEXA	QL=30 días
fluoxetine hcl 10 mg cap, 20 mg cap	1	Preferred	PROZAC	QL=30 días

Page 43 of 83

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	R eference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
paroxetine hcl 20 mg tab, 30 mg tab, 40 mg tab	1	Preferred	PAXIL	QL=30 días
sertraline hcl 100 mg tab, 25 mg tab, 50 mg tab	1	Preferred	ZOLOFT	QL=30 días
venlafaxine hcl 100 mg tab, 25 mg tab, 37.5 mg tab, 50 mg tab, 75 mg tab	1	Preferred	EFFEXOR	QL=30 días
Tricyclic Agents [Tricíclicos]
amitriptyline hcl 10 mg tab, 100 mg tab, 150 mg tab, 25 mg tab, 50 mg tab, 75 mg tab	1	Preferred	ELAVIL	QL=30 días
doxepin hcl 10 mg cap, 25 mg cap, 50 mg cap, 75 mg cap	1	Preferred	SINEQUAN	QL=30 días
imipramine hcl 10 mg tab, 25 mg tab, 50 mg tab	1	Preferred	TOFRANIL	QL=30 días
nortriptyline hcl 10 mg cap, 25 mg cap, 50 mg cap, 75 mg cap	1	Preferred	PAMELOR	QL=30 días
doxepin hcl 100 mg cap, 150 mg cap	2	Preferred	SINEQUAN	QL=30 días
ANTIPARKINSON AGENTS [AGENTES ANTIPARKINSON]
Anticholinergics [Anticolinérgicos]
benztropine mesylate 0.5 mg tab, 1 mg tab, 2 mg tab	1	Preferred	COGENTIN	QL=30 días
ANTIPSYCHOTICS [ANTIPSICÓTICOS]
Atypical - Second Generation [Atípicos - Segunda Generación]
risperidone 0.25 mg tab, 0.5 mg tab, 1 mg tab, 2 mg tab, 3 mg tab, 4 mg tab	1	Preferred	RISPERDAL	QL=5 días
Typical - First Generation [Típicos - Primera Generación]
haloperidol 0.5 mg tab, 1 mg tab, 2 mg tab	1	Preferred	HALDOL	QL=5 días
haloperidol 5 mg tab	2	Preferred	HALDOL	QL=5 días
haloperidol 10 mg tab	3	Preferred	HALDOL	QL=5 días
haloperidol 20 mg tab	4	Preferred	HALDOL	QL=5 días

Page 44 of 83

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
DETOX TREATMENT [TRATAMIENTO DE DETOX]
Detox Treatment [Tratamiento De Detox]
clonidine hcl 0.1 mg tab	1	Preferred	CATAPRESS	QL=7 días
folic acid 1 mg tab	1	Preferred	FOLIC ACID	QL=7 días
ibuprofen 800 mg tab	1	Preferred	MOTRIN	QL=7 días
loperamide hcl 2 mg cap	1	Preferred	IMODIUM	QL=7 días
vitamin b-1 100 mg tab	1	Preferred	THIAMINE	QL=7 días
MOOD STABILIZERS [ESTABILIZADORES DEL ÁNIMO]
Bipolar Agents [Agentes Para Bipolaridad]
divalproex sodium 125 mg tab dr, 250 mg tab dr, 500 mg tab dr	1	Preferred	DEPAKOTE	QL=30 días
lamotrigine 100 mg tab, 150 mg tab, 200 mg tab, 25 mg tab	1	Preferred	LAMICTAL	QL=30 días
valproic acid 250 mg cap, 250 mg/5ml soln, 250 mg/5ml syr	1	Preferred	DEPAKENE	QL=30 días
PSYCHOSTIMULANTS [PSICOESTIMULANTES]
ADHD Amphetamines [Anfetaminas ADHD]
amphetamine- dextroamphetamine 15 mg tab, 30 mg tab	2	Preferred	ADDERALL	QL=30 días, AL 4-20 años, PA ≥ 21 años
amphetaminedextroamphetamine 10 mg tab, 12.5 mg tab, 20 mg tab, 5 mg tab, 7.5 mg tab	3	Preferred	ADDERALL	QL=30 días, AL 4-20 años, PA ≥ 21 años
dextroamphetamine sulfate 10 mg tab, 5 mg tab	3	Preferred	DEXEDRINE	QL=30 días, AL 4-20 años, PA ≥ 21 años
dextroamphetamine sulfate er 5 mg cap er 24 hr, 10 mg cap er 24 hr	4	Non-Preferred	DEXEDRINE SR	QL=30 días, AL 4-20 años, PA ≥ 21 años
dextroamphetamine sulfate er 15 mg cap er 24 hr	5	Non-Preferred	DEXEDRINE SR	QL=30 días, AL 4-20 años, PA ≥ 21 años
DYANAVEL XR oral susp. er 2.5 mg/ mL	4	Non-Preferred	DYANAVEL XR	PA, AL 6-20 años

Page 45 of 83

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
ADHD Non-Amphetamines [No-Anfetaminas ADHD]
clonidine hcl 0.1 mg tab	1	Preferred	CATAPRESS	QL=7 días
dexmethylphenidate hcl 2.5 mg tab, 5 mg tab	2	Preferred	FOCALIN	QL=30 días, AL 6-20 años, PA ≥ 21 años
methylphenidate hcl 5 mg tab	2	Preferred	RITALIN	QL=30 días, AL 6-20 años, PA ≥ 21 años
dexmethylphenidate hcl 10 mg tab	3	Preferred	FOCALIN	QL=30 días, AL 6-20 años, PA ≥ 21 años
methylphenidate hcl 10 mg tab, 20 mg tab	3	Preferred	RITALIN	QL=30 días, AL 6-20 años, PA ≥ 21 años
STRATTERA 10 mg cap, 100 mg cap, 18 mg cap, 25 mg cap, 40 mg cap, 60 mg cap, 80 mg cap	4	Preferred		PA, QL=30 días, AL 6-20 años, PA ≥ 21 años, P
SLEEP DISORDER AGENTS [DESORDENES DEL SUEÑO]
Benzodiazepines [Benzodiazepinas]
flurazepam hcl 15 mg cap, 30 mg cap	1	Preferred	DALMANE	QL=5 días
temazepam 15 mg cap, 30 mg cap	1	Preferred	RESTORIL	QL=5 días
Miscellaneous Sleep Disorder Agents [Agentes Misceláneos Desordenes Del Sueño]
zolpidem tartrate 10 mg tab, 5 mg tab	1	Preferred	AMBIEN	QL=5 días

Page 46 of 83

A
amitriptyline hcl	10
amphetamine-dextroamphetamine	11

B
benztropine mesylate	10
bupropion hcl	9
bupropion hcl er (sr)	9
bupropion hcl er (xl)	9

C
citalopram hydrobromide	9
clonidine hcl	11, 12

D
dexmethylphenidate hcl	12
dextroamphetamine sulfate	12
dextroamphetamine sulfate er	12
diazepam	9
divalproex sodium	11
doxepin hcl	10
DYANAVEL XR	12

F
fluoxetine hcl	10
flurazepam hcl	12
folic acid	11

H
haloperidol	11
hydroxyzine pamoate	9

I
ibuprofen	11
imipramine hcl	10

L
lamotrigine	11
loperamide hcl	11
lorazepam	9

M
methylphenidate hcl	12
mirtazapine	9

N
nortriptyline hcl	10

P
paroxetine hcl	10

R
risperidone	10

S
sertraline hcl	10
STRATTERA	12

T
temazepam	12
trazodone hcl	9

V
valproic acid	11
venlafaxine hcl	10
vitamin b-1	11

Z
zolpidem tartrate	13

Page 47 of 83

ASES

Puerto Rico Healthcare Insurance Administration

HIV-AIDS

2017

Formulary of Drugs Covered by

the Government Healthcare Plan (GHP)

Authorized by the P.R. Elections Commission CEE-SA-16-2732

Page 48 of 83

		GOVERNMENT OF PUERTO RICO		Hon. Ricardo A. Rosselló Nevares Governor
		Healthcare Insurance Administration		Ms. Ángela M. Ávila Marrero Executive Director

May 1, 2017

TO ALL GOVERNMENT HEALTHCARE PLAN (GHP) PROVIDERS

Dear provider:

I urge you to keep this guide for future reference. It is also available on our webpage, www.asespr.org .

Cordially,

[signed]

Ángela M. Ávila Marrero

Executive Director




PO Box 195661, San Juan, PR 00919-5661 · Tel.: 787.474.3300 · Fax: 787.474.3348 · www.ases.pr.gov

Page 49 of 83

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE

OF THE GOVERNMENT HEALTHCARE PLAN (GHP)

1.	Drug Formulary

Non-formulary drugs may only be used in exceptional cases through the Exception Process that we will explain in point number 2.

2.	Exception Process

Contraindication to the drug(s) included in the FDC;

History of a clinically significant adverse reaction to the drug(s) included in the FDC;

Evidence of therapeutic failure of all alternatives available in the FDC; and/or

Lack of a therapeutic alternative in the FDC.

3.	Other Aspects of the Prescription Drug Coverage

The prescription drug coverage of the GHP establishes that using generic bioequivalent products as the first option is mandatory.

Page 50 of 83

No entity contracted by ASES or by healthcare companies or organizations (for example, primary care medical groups, independent providers, specialists, among others) may use a formulary other than the PDL or create an internal drug formulary different than the formularies established by ASES. Furthermore, they may not limit the drugs included in the ASES FDC in any way contrary to the provisions in the contract between ASES and the contracted entities or in this coverage. Insurance companies will be responsible for supervising their providers and employees with regard to their compliance with these provisions.

The maximum supply dispensed for acute conditions will cover a fifteen (15) day therapy. The treatment period may be extended, as applicable, when medically necessary.

ASES requires the use of generic bioequivalent drugs approved by the Food and Drug Administration (FDA) coded as “AB” and those authorized under applicable local regulations in Puerto Rico.

Page 51 of 83

Drug prescriptions will be filled by a pharmacy contracted by the PBM that is duly authorized under the law of the Commonwealth of Puerto Rico and has been freely chosen by the beneficiary.

4.	Emergency Rule

The products that appear in the Integrated Emergency Formulary (IEF) will be dispensed for five (5) business days, except as otherwise specified.

The same thing applies to analgesics, narcotics, combination drugs, and nonsteroidal anti-inflammatory drugs, which will also be dispensed in amounts sufficient for five (5) business days.

If you have any questions about the prescription drug coverage, you may contact the insurance company contracted by ASES in your region and/or the Pharmacy Benefit Manager (PBM) contracted by ASES.

Page 52 of 83

de mayo de 2017

VIH-SIDA

GOVERNMENT HEALTHCARE PLAN

FORMULARY OF DRUGS COVERED BY THE GHP (FDC)

2017

TABLE OF CONTENTS

GENERAL ASPECTS OF THE PRESCRIPTION DRUG COVERAGE
OF THE GOVERNMENT HEALTHCARE PLAN		3
DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND
REFERENCE GUIDES		8
	MONTHLY NET COST RANGE	8
	GENERIC DRUGS	9
THERAPEUTIC CATEGORY		10
ANESTHETICS		10
	Local Anesthetics	10
ANTIBACTERIALS		10
	Macrolides	10
	Miscellaneous Antibacterials	11
	Penicillins	11
	Quinolones	11
	Sulfonamides	12
	Tetracyclines	12
ANTIMYCOBACTERIALS		12
	Antituberculars	12
	Miscellaneous Antimycobacterials	12
ANTIMYCOTIC AGENTS		12
	Antifungals	12
ANTIPARASITICS		13
	Anthelmintics	13
	Antimalarials	13
	Antiprotozoals - Non-Antimalarials	13

Page 53 of 83

Revisado: 18 de mayo de 2017

VIH-SIDA

ANTIVIRALS		13
	Anti-Cytomegalovirus (CMV) Agents	13
	Antiherpetic Agents	13
	Non-Nucleoside Reverse Transcriptase Inhibitors	13
	Nucleoside/Nucleotide Reverse Transcriptase Inhibitors	14
BLOOD MODIFIERS		14
	Erythropoiesis-Stimulating Agents	14
	Iron	15
CHEMOTHERAPIES		15
	Antineoplastic Progestins	15
	Folic Acid Antagonists Rescue Agents	15
DENTAL AND ORAL AGENTS		15
	Antifungals	15
HORMONAL AGENTS		16
	Mineralocorticoids	16
IMMUNOSUPPRESSANTS		16
	Glucocorticosteroids	16

Page 54 of 83

Revisado: 18 de mayo de 2017

VIH-SIDA

DESIGN OF THE 2017 FORMULARY OF DRUGS COVERED BY THE GHP (FDC) AND REFERENCE GUIDES

The example below illustrates the information provided for the drugs included in the FDC.

Drug Name	Net Cost	Tier	Reference Name	Requirements/ Limits
THERAPEUTIC CATEGORY
Therapeutic Class
ANESTHETICS
Local Anesthetics
lidocaine viscous 2% mouth/throat soln	1	Preferred	XYLOCAINE
ANTIBACTERIALS
Aminoglycosides
streptomycin sulfate 1 gm im soln	4	Preferred	STREPTOMYCIN
Macrolides
azithromycin 250 mg tab, 500 mg tab	1	Preferred	ZITHROMAX
azithromycin 1 gm pckt, 100 mg/5 ml susp, 200 mg/5 ml susp, 600 mg tab	2	Preferred	ZITHROMAX
clarithromycin 125 mg/5 ml susp, 250 mg tab, 500 mg tab	2	Preferred	BIAXIN
clarithromycin 250 mg/5 ml susp	3	Preferred	BIAXIN
ERY-TAB 500 mg tab dr	3	Preferred

Page 55 of 83

Revisado: 18 de mayo de 2017

VIH-SIDA

MONTHLY NET COST RANGE

1	less than $20	Least costly per month
2	$20 - $49
3	$50 - $99
4	$100 - $199
5	$200 - $349
6	$350 - $549
7	$550 - $799
8	$800 - $1,099
9	$1,100 - $1,499
10	$1,500 - $1,999
11	$2,000 - $2,499
12	$2,500 - $2,999
13	$3,000 - $3,499
14	$3,500 - $3,999
15	$4,000 - $4,499
16	$4,500 - $4,999
17	$5,000 - $5,499
18	$5,500 - $5,999
19	$6,000 - $6,499
20	$6,500 - $6,999
21	$7,000 - $7,499
22	$7,500 - $7,999
23	$8,000 - $8,499
24	$8,500 - $9,000
25	more than $9,000	Most costly per month

The net cost analysis is an ongoing exercise subject to constant changes. Net costs as published here are current as of the date of this edition of the FDC.

Page 56 of 83

Revisado: 18 de mayo de 2017

VIH-SIDA

GENERIC DRUGS

Page 57 of 83

Revisado: 18 de mayo de 2017

VIH-SIDA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
THERAPEUTIC CATEGORY [CATEGORÍA TERAPÉUTICA]
Therapeutic Class [Clase Terapéutica]
ANESTHETICS [ANEST ÉSICOS]
Local Anesthetics [Anestésicos Locales]
lidocaine viscous 2 % mouth/throat soln	1	Preferred	XYLOCAINE
ANTIBACTERIALS [ANTIBACTERIANOS]
Macrolides [Macrólidos]
azithromycin 250 mg tab, 500 mg tab	1	Preferred	ZITHROMAX
azithromycin 1 gm pckt, 100 mg/5ml susp, 200 mg/5ml susp, 600 mg tab	2	Preferred	ZITHROMAX
clarithromycin 125 mg/5ml susp, 250 mg tab, 500 mg tab	2	Preferred	BIAXIN
clarithromycin 250 mg/5ml susp	3	Preferred	BIAXIN
ERY-TAB 500 mg tab dr	3	Preferred
erythromycin base 250 mg cap dr prt, 250 mg tab, 500 mg tab	3	Preferred	ERY-TAB
erythromycin ethylsuccinate 400 mg tab	3	Preferred	E.E.S.
ERYTHROCIN STEARATE 250 mg tab	4	Non-Preferred
E.E.S. GRANULES 200 mg/5ml susp	5	Preferred
ERYPED 200 200 mg/5ml susp	5	Preferred
ERYPED 400 400 mg/5ml susp	6	Preferred

Page 58 of 83

Revisado: 18 de mayo de 2017

VIH-SIDA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
Miscellaneous Antibacterials [Antibacterianos Misceláneos]
clindamycin hcl 150 mg cap, 300 mg cap, 75 mg cap	1	Preferred	CLEOCIN
Penicillins [Penicilinas]
amoxicillin 125 mg/5ml susp , 200 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 400 mg/5ml susp, 500 mg cap, 500 mg tab, 875 mg tab	1	Preferred	AMOXIL
amoxicillin-pot clavulanate 200-28.5 mg/5ml susp, 40057 mg/5ml susp, 500-125 mg tab, 875-125 mg tab	1	Preferred	AUGMENTIN
ampicillin 125 mg/5ml susp, 250 mg cap, 250 mg/5ml susp, 500 mg cap	1	Preferred	PRINCIPEN
penicillin v potassium 125 mg/5ml soln, 250 mg tab, 250 mg/5ml soln, 500 mg tab	1	Preferred	VEETIDS
amoxicillin-pot clavulanate 250-125 mg tab, 250-62.5 mg/5ml susp	3	Preferred	AUGMENTIN
BICILLIN L-A 600000 unit/ml im susp	3	Non-Preferred
penicillin g procaine 600000 unit/ml im susp	3	Non-Preferred	BICILLIN LA
BICILLIN L-A 1200000 unit/2ml im susp	4	Non-Preferred
BICILLIN L-A 2400000 unit/4ml im susp	5	Non-Preferred
Quinolones [Quinolonas]
ciprofloxacin hcl 250 mg tab, 500 mg tab, 750 mg tab	1	Preferred	CIPRO
levofloxacin 250 mg tab, 500 mg tab, 750 mg tab	1	Preferred	LEVAQUIN
ciprofloxacin 500 mg/5ml (10%) susp	3	Preferred	CIPRO

Page 59 of 83

Revisado: 18 de mayo de 2017

VIH-SIDA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
ciprofloxacin 250 mg/5ml (5%) susp	4	Preferred	CIPRO
Sulfonamides [Sulfonamidas]
sulfamethoxazole -tmp ds 800-160 mg tab	1	Preferred	SEPTRA
sulfamethoxazoletrimethoprim 200-40 mg/5ml susp, 400-80 mg tab	1	Preferred	SEPTRA
sulfadiazine 500 mg tab	4	Preferred	SULFADIAZINE
Tetracyclines [Tetraciclinas]
minocycline hcl 100 mg cap, 50 mg cap, 75 mg cap	1	Preferred	MINOCIN
doxycycline monohydrate 50 mg cap, 100 mg cap	2	Non-Preferred	MONODOX
ANTIMYCOBACTERIALS [ANTIMICOBACTERIANOS]
Antituberculars [Antituberculosos]
isoniazid 100 mg tab, 300 mg tab	1	Preferred	ISONIAZID
rifampin 150 mg cap	1	Preferred	RIFADIN
ethambutol hcl 100 mg tab	2	Non-Preferred	MYAMBUTOL
pyrazinamide 500 mg tab	2	Non-Preferred	PYRAZINAMIDE
rifampin 300 mg cap	2	Preferred	RIFADIN
ethambutol hcl 400 mg tab	3	Non-Preferred	MYAMBUTOL
isoniazid 50 mg/5ml syr	5	Non-Preferred	ISONIAZID
rifabutin 150 mg cap			MYCOBUTIN	Puerto Rico Health Department Tuberculosis Control Program
cycloserine 250 mg cap			SEROMYCIN
RIFAMATE 50-300 mg cap
TRECATOR 250 mg tab
CAPASTAT 1 gm inj
Miscellaneous Antimycobacterials [Antimicobacterianos Misceláneos]
dapsone 100 mg tab, 25 mg tab	2	Preferred	DAPSONE
ANTIMYCOTIC AGENTS [ANTIMICÓTICOS]
Antifungals [Antifungales]
fluconazole 10 mg/ml susp, 100 mg tab, 150 mg tab, 200 mg tab, 50 mg tab	1	Preferred	DIFLUCAN

Page 60 of 83

Revisado: 18 de mayo de 2017

VIH-SIDA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
ketoconazole 200 mg tab	1	Preferred	NIZORAL
terbinafine hcl 250 mg tab	1	Preferred	LAMISIL
fluconazole 40 mg/ml susp	2	Preferred	DIFLUCAN
voriconazole 40 mg/ml susp	4	Preferred	VFEND
itraconazole 100 mg cap	5	Preferred	SPORANOX
SPORANOX 10 mg/ml soln	6	Preferred
voriconazole 50 mg tab	8	Preferred	VFEND
voriconazole 200 mg tab	10	Preferred	VFEND
ANTIPARASITICS [ANTIPARASITARIOS]
Anthelmintics [Antihelmínticos]
ALBENZA 200 mg tab	9	Preferred
Antimalarials [Antimaláricos]
DARAPRIM 25 mg tab	7	Non-Preferred		PA
Antiprotozoals - Non-Antimalarials [Antiprotozoarios No-Antimalaráricos]
NEBUPENT 300 mg inh soln	4	Preferred
atovaquone 750 mg/5ml susp	9	Non-Preferred	MEPRON
ANTIVIRALS [ANTIVIRALES]
Anti-Cytomegalovirus (CMV) Agents [Agentes Anti-Citomegalovirus]
valganciclovir hcl 450 mg tab	13	Non-Preferred	VALCYTE
Antiherpetic Agents [Agentes Antiherpéticos]
acyclovir 200 mg cap, 400 mg tab, 800 mg tab	1	Preferred	ZOVIRAX
acyclovir 200 mg/5ml susp	2	Preferred	ZOVIRAX
Non-Nucleoside Reverse Transcriptase Inhibitors [Inhibidores No Nucleósidos De La Transciptasa Reversa]
nevirapine 200 mg tab	1	Preferred	VIRAMUNE
nevirapine 50 mg/5ml susp	5	Non-Preferred	VIRAMUNE
RESCRIPTOR 200 mg tab	6	Non-Preferred
SUSTIVA 200 mg cap	6	Preferred		P
nevirapine er 100 mg tab er 24 hr, 400 mg tab er 24 hr	7	Non-Preferred	VIRAMUNE XR
SUSTIVA 50 mg cap, 600 mg tab	7	Preferred		P
zidovudine 300 mg tab	2	Non-Preferred	RETROVIR

Page 61 of 83

Revisado: 18 de mayo de 2017

VIH-SIDA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors [Inhibidores Nucleósidos/Nucleótidos De La Transcriptasa Reversa]
stavudine 1 mg/ml soln, 15 mg cap, 20 mg cap, 30 mg cap, 40 mg cap	3	Preferred	ZERIT
didanosine 125 mg cap dr, 200 mg cap dr, 250 mg cap dr	4	Non-Preferred	VIDEX EC
lamivudine 10 mg/ml soln	4	Preferred	EPIVIR
lamivudine 150 mg tab	4	Preferred	EPIVIR
zidovudine 100 mg cap, 50 mg/5ml syr	4	Non-Preferred	RETROVIR
abacavir sulfate 300 mg tab	5	Non-Preferred	ZIAGEN
didanosine 400 mg cap dr	5	Non-Preferred	VIDEX EC
lamivudine 300 mg tab	5	Preferred	EPIVIR
VIDEX 2 gm soln	5	Non-Preferred
lamivudine 100 mg tab	6	Preferred	EPIVIR	PA
lamivudine-zidovudine 150300 mg tab	6	Preferred	COMBIVIR
ZIAGEN 20 mg/ml soln	6	Non-Preferred
abacavir-lamivudinezidovudine 300-150-300 mg tab	10	Non-Preferred	TRIZIVIR
BLOOD MODIFIERS [MODIFICADORES DE LA SANGRE]
Erythropoiesis-Stimulating Agents [Agentes Estimulantes De Eritropoiesis]
ARANESP (ALBUMIN FREE) 100 mcg/0.5ml inj soln	1	Preferred		PA, P
PROCRIT 3000 unit/ml inj soln	5	Preferred		PA, P
ARANESP (ALBUMIN FREE) 25 mcg/0.42ml inj soln, 25 mcg/ml inj soln	6	Preferred		PA, P
PROCRIT 10000 unit/ml inj soln	6	Preferred		PA, P
ARANESP (ALBUMIN FREE) 40 mcg/0.4ml inj soln	7	Preferred		PA, P

Page 62 of 83

Revisado: 18 de mayo de 2017

VIH-SIDA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
ARANESP (ALBUMIN FREE) 40 mcg/ml inj soln, 60 mcg/ml inj soln	8	Preferred		PA, P
ARANESP (ALBUMIN FREE) 150 mcg/0.3ml inj soln, 150 mcg/0.75ml inj soln, 200 mcg/0.4ml inj soln, 200 mcg/ml inj soln, 300 mcg/0.6ml inj soln, 300 mcg/ml inj soln, 500 mcg/ml inj soln, 60 mcg/0.3ml inj soln	9	Preferred		PA, P
ARANESP (ALBUMIN FREE) 100 mcg/ml inj soln	11	Preferred		PA, P
PROCRIT 40000 unit/ml inj soln	11	Preferred		PA, P
Iron [Hierro]
iron 325 (65 fe) mg tab	1	Preferred	IRON
CHEMOTHERAPIES [QUIMIOTERAPIAS]
Antineoplastic Progestins [Antineoplásicos De Progestina]
megestrol acetate 20 mg tab, 40 mg tab	1	Preferred	MEGACE
megestrol acetate 40 mg/ml susp, 400 mg/10ml susp	2	Preferred	MEGACE
Folic Acid Antagonists Rescue Agents [Antagonistas De Ácido Fólico]
leucovorin calcium 5 mg tab	3	Preferred	LEUCOVORIN
leucovorin calcium 10 mg tab, 15 mg tab	4	Preferred	LEUCOVORIN
leucovorin calcium 25 mg tab	9	Preferred	LEUCOVORIN
leucovorin calcium 50 mg inj, 100 mg inj, 200 mg inj, 350 mg inj, 500 mg inj	9	Non-Preferred	LEUCOVORIN
DENTAL AND ORAL AGENTS [AGENTES DENTALES Y ORALES]
Antifungals [Antifungales]
clotrimazole 10 mg mouth/throat lozenge, 10 mg mouth/throat troche	1	Preferred	MYCELEX

Page 63 of 83

Revisado: 18 de mayo de 2017

VIH-SIDA

Drug Name [Nombre del Medicamento]	Net Cost [Costo Neto]	Tier [Tier]	Reference Name [Nombre de Referencia]	Requirements/ Limits [Requerimientos/ Límites]
nystatin 100000 unit/ml mouth/throat susp	1	Preferred	MYCOSTATIN
HORMONAL AGENTS [AGENTES HORMONALES]
Mineralocorticoids [Mineralocorticoides]
fludrocortisone acetate 0.1 mg tab	1	Preferred	FLORINEF
IMMUNOSUPPRESSANTS [IMMUNOSUPRESORES]
Glucocorticosteroids [Glucocorticoides]
dexamethasone 0.5 mg tab, 0. 5 mg/5ml oral elix, 0.5 mg/5ml soln, 0.75 mg tab, 1 mg tab, 1.5 mg tab, 2 mg tab, 4 mg tab, 6 mg tab	1	Preferred	DECADRON
MEDROL 2 mg tab	1	Preferred
methylprednisolone 32 mg tab, 4 mg tab	1	Preferred	MEDROL
methylprednisolone (pak) 4 mg tab	1	Preferred	MEDROL
prednisolone 15 mg/5ml soln, 15 mg/5ml syr	1	Preferred	PRELONE
prednisone 1 mg tab, 10 mg tab, 2.5 mg tab, 20 mg tab, 5 mg tab, 50 mg tab	1	Preferred	DELTASONE
prednisone (pak) 10 mg tab, 5 mg tab	1	Preferred	DELTASONE
hydrocortisone 10 mg tab, 20 mg tab, 5 mg tab	2	Preferred	CORTEF
methylprednisolone 16 mg tab, 8 mg tab	2	Preferred	MEDROL

Page 64 of 83

VIH-SIDA

A
abacavir sulfate	14
abacavir-lamivudine-zidovudine	14
acyclovir	13
ALBENZA	13
amoxicillin	11
amoxicillin-pot clavulanate	11
ampicillin	11
ARANESP (ALBUMIN FREE)	14, 15
atovaquone	13
azithromycin	10

B
BICILLIN L-A	11

C
CAPASTAT	12
ciprofloxacin	11, 12
ciprofloxacin hcl	11
clarithromycin	10
clindamycin hcl	11
clotrimazole	15
cycloserine	12

D
dapsone	12
DARAPRIM	13
dexamethasone	16
didanosine	14
doxycycline monohydrate	12

E
E.E.S. GRANULES	10
EPIVIR	14
ERYPED 200	10
ERYPED 400	10
ERY-TAB	10
ERYTHROCIN STEARATE	10
erythromycin base	10
erythromycin ethylsuccinate	10
ethambutol hcl	12

F
fluconazole	12, 13
fludrocortisone acetate	16

H
hydrocortisone	16

I
iron	15
isoniazid	12
itraconazole	13

K
ketoconazole	13

L
lamivudine	14
lamivudine-zidovudine	14
leucovorin calcium	15
levofloxacin	11
lidocaine viscous	10

M
MEDROL	16
megestrol acetate	15
methylprednisolone	16
methylprednisolone (pak)	16
minocycline hcl	12

N
NEBUPENT	13
nevirapine	13
nevirapine er	13
nystatin	16

P
penicillin g procaine	11
penicillin v potassium	11
prednisolone	16
prednisone	16
prednisone (pak)	16
PROCRIT	14, 15
pyrazinamide	12

Page 65 of 83

VIH-SIDA

R
RESCRIPTOR	13
rifabutin	12
RIFAMATE	12
rifampin	12

S
SEROMYCIN	12
SPORANOX	13
stavudine	14
sulfadiazine	12
sulfamethoxazole-tmp ds	12

sulfamethoxazole-trimethoprim	12
SUSTIVA	13

T
terbinafine hcl	13
TRECATOR	12

V
valganciclovir hcl	13
VIDEX	14
voriconazole	13

Z
ZIAGEN	14
zidovudine	13, 14

Page 66 of 83

Anexo 1: Lista de Descuentos para Medlcamentos de Alto costo que sean despachados por las Farmadas de C3denas Nadonales (2017) Category GP! Drug Name GPI Name Actual Discount Agents for Gaucher Disease 82700020002020 Ceredase Alglucerase IV Soln 80Unit/ML 18.00% Agents for Gaucher Disease 82700085102120 Vpriv Vetaglucerase Alfa For lnj 400 Unit 18.00¼ Agents for Gaucher Disease 82700040600120 Cerdelga Elig[ustat TartrateCap84 MG {Base Equivalent) 18.00% Agents for Gaucher Disease 82700050002110 Cere2yme lmiglucerase For lnj 200 Unit 18.00% Agents for Gaucher DJsease 82700070000120 zavesca Miglustat cap 100 MG 18.00% Agents for Gaucher OJsease 82700080102120 Elelvso TaHglucerase Alfa For lnj 200 Unit 18.00% Agents for Gaucher Disease 82700050002120 Cerezyme lm!glucerase For lnj 400 Unit 18.00% ANALGES!CS-ANTHNFlAMMATORY 66200030002015 Gold Sodium Thiomalate Gold Sodium Thioma\ate lnj 50 MG/Ml 18.00% ANALGESICS - NonNarcotic 64154090102020 Prlalt Ziconotide Acetate lntrathecal lnj 100 MCG/ML 18.00% ANALGESICS- NonNarcotic 64154090102030 Pria!t Ziconotide Acetate lntrathecal lnj SOO MCG/SML 18.00% ANALGESICS· NonNarcotic 64154090102010 Prialt Ziconotide Acetate lntrathecal lnJ 500 MCG/20Ml {25 MCG/Ml) 18.00% ANDROGENS-ANABOLIC 23100030802030 Aveed Testosterone Undecanoate IM lnj in Oil 750 MG/3Ml (2SOMG/ML) 18.00% ANTIARRHYTHMICS 35400025000110 Tlkosyn Dofefrlide Cap 125 MCG {0,125 MG) 18.00% ANTIARRHYTHMICS 35400025000120 T!kosyn DofetiHde Cap 250 MCG {0.25 MG) 18.00% ANTIARRHYTHMICS 35400025000130 Tikosyn Dofetllide Cap500 MCG {0.5 MG} 18.00% ANTJASTHMATIC AND BRONCHOD!lATOR AGENTS 44603060002120 Xolair Omaliwmab Forlnj 150 MG 18.00% ANTIBIOTICS-AMINOGLYCOSIDES 07000070102030 Tobramydn Sulfate TOBRAMYCtN SULFATE INJ 40 MG/ML 41.75% ANTIBIOTICS- AMINOGLYCOSIDES 07000070102020 Tobramydn Sulfate Tobramycin Sulfate tnj 10 MG/ML 41.75% ANTIBIOTICS-AMINOGLYCOSIDES 07000070102034 Tobramycin Sulfate Tobramycln Sulfate Jnj 80 MG/2ML {40 MG/ML) 41.75% ANTIBIOTICS· AMINOGLYCOSIOES 07000070102105 Tobramycln Sulfate Tobramycln Sulfate For lnj 1.2 GM 41,75% ANTIBIOTICS· AMINOGLYCOSIDES 07000070102039 Tobramycfn Sulfate Tobramyc!n Sulfate lnj 2 GM/SOML (40 MG/Ml) 41.75% ANTIBIOTICS· AMINOGLYCOSIDES 07000070102022 Tobramycln Sulfate Tobramycln Sulfate IV Soln 10 MG/Ml 41.75% ANTIBIOTICS-AMINOGLYCOSlDES 07000070102038 Tobramycin Sulfate Tobramycin Sulfate In] 1.2 GM/30ML (40 MG/Ml) 41.75% Anti-Cataplectic Agents 62450060202020 Xyrem Sodium Oxybate Oral Solution 500 MG/ML 18.00% ANTICOAGUlANTS 83101010102020 Fragmin Dalteparin Sodium In] 2500 Unlt/0.2ML 18.00¾ ANTICOAGUlANTS 83101020102013 Lovenox Enoxaparln Sodium lnj 40 MG/0.4ML 18.00% ANTICOAGULANTS 83103030102035 Arixtra FondaparinuxSodlum Subcutaneous tnj 5 MG/0.4Ml 18.00% ANTICOAGULANTS 83101010102065 Fragmin Dalteparin Sodium lnj 25000 Unit/ML 18.00% ANTICOAGULANTS 831010201020S0 Lovenox Enoxaparln Sodium lnj 300 MG/3ML 18.00% ANTICOAGULANTS 83370060000340 xarelto Rivaroxaban Tab 20 MG 18.00% ANTICOAGULANTS 83101010102040 Fragmin Dalteparin Sodium lnj 5000 Unit/0,2ML 18.00% ANTICOAGULANTS 83101020102014 Lovenox Enoxaparin Sodium lnJ 60 MG/0,6Ml 18.00% ANTICOAGULANTS 83103030102040 Arixtra Fondaparinux Sodium Subcutaneous lnj 7.5 MG/0.6ML 18.00% ANTICOAGULANTS 83101010102015 Fragmin Dalteparin Sodium In] 10000 Unit/ML 18.00% ANTICOAGULANTS 83101020102012 Lovenox Enoxaparin Sodium lnj 30 MG/0,3ML 18.00% ANTICOAGULANTS 83103030102020 Arixtra FondaparinuxSodium Subcutaneous lnj 2.S MG/0.SML 18.00% ANTICOAGULANTS 83101010102045 Fragmin DalteparinSodium lnj 7500 Unlt/0.3ML 18.00% ANTICOAGULANTS 83101020102015 lovenox Enoxaparin Sodium lnj 80 MG/0.8ML 18.00% ANTICOAGUlANTS 83103030102045 Arixtra FondaparinuxSodium Subcutaneous lnj 10 MG/0.SML 18.00% ANTICOAGULANTS 83101010102056 Fragmin Da\teparin Sodium lnj 15000 Unit/0.6Ml 18.00% ANTICOAGULANTS 83101020102018 Lovenox Enoxaparln Sodium lnj 120 MG/0.8ML 18.00% ANTICOAGULANTS 83370060000320 Xarelto RivaroxabanTab 10 MG ,,,· 18.00% ANTICOAGULANTS 83101010102060 Fragmin Dalteparin Sodium lnj 18000 Unit/0.72ML ,;· />-- _ ;_ ,·{c-.. 18.00% ANTICOAGULANTS 83101020102020 Lovenox Enoxaparln Sodium lnj 150 MG/ML f/ d,..., .....Z\' 18.00¾ ANTICOAGULANTS 83370060000330 xarelto Rivaroxaban Tab 15 MG /iJ ·= OA "-'<>, 18.00% ANTICOAGULANTS 83101010102053 Fragmin Da!teparin Sodium lnj 12500 Unit/0.SML !J ,A ".? -- 1-: "\'.': 18.00% ""'" '<11:(l -1&,- Ii ! 6 t:iJ.,"J, " \I0-s., IJJ/ ,,, 'Ii "'"• _,-,, ,,t

ANTICOAGULANTS 83101020102016 Lovenox ANTICOAGULANTS 83334050102120 Refludan ANT!CONVULSANTS 72600043002020 Keppra Enoxaparin Sodium 1nj 100 MG/ML lepirudln For IV Soln 50 MG Levetlracetam Oral Soln 100 MG/Ml 18.00% 18.00%18J)0% ANTICONVULSANTS 72600043000340 Keppra Levetiracetam Tab 750 MG 18.00% ANTICONVULSANTS 72600043002060 Keppra levetkacetam lnj 500 MG/5Ml (100 MG/ML) 18.00¼ ANTICONVULSANTS ANTICONVULSANTS 72600043000350 Keppra 72170085000320 Sabril Levetiracetam Tab 1000 MG Vigabatrin Tab 500 MG 18.00%18.00% ANTICONVULSANTS 72600043007520 Keppra XR 72600043000320 Keppra Levetiracetam Tab SR 24HR 500 MG 18.00% ANTICONVULSANTS Levetiracetam Tab 250 MG 18.00% ANTICONVULSANTS ANTJCONVULSANTS 72600043000330 Keppra 72170085003020 Sabril Levetiracetam Tab 500 MG Vigabatrin Powd Pack 500 MG 18.00%18.00% ANTICONVULSANTS 72600043007530 Keppra XR Levetiracetam Tab SR 24HR 750 MG 18.00% ANTIEMETICS 50250025200330 Anzemet Dolasetron Mesylate Tab 100 MG 18.00% ANTlEMETICS 50280035102130 Emend Fosaprepitant Dimeglumine For IV Infusion 150 MG {Base Eq) 18.00% ANTIEMETICS 50280020000130 Emend ANTIEMETICS 50250025202020 Anzemet AprepltantCapsule125 MG Dolasetron Mesylate JV lnj 20 MG/Ml 18.00% 18.00% ANTIEMETICS 50250025200320 Anzemet 18.00% ANTIEMETICS 50280020006320 Emend Do!asetron Mesy/ateTab 50 MG Aprepitant Capsule Therapy Pack 80 & 125 MG 18.00% ANTIEMETICS 50250070102010 Afoxl Palonosetron HCI IV Sain 0.075 MG/1.SML (Base Equiv) Antiemetics 50250065052030 Zofran Ondansetron HCI lnj 40 MG/20ML (2 MG/Ml} 26.75% 18.00% ANTIEMETICS 50280020000110 Emend AprepitantCapsule 40 MG 18.00% ANTIEMETICS 50280020000120 Emend Aprepitant Capsule 80 MG 18.00% Antiemetics 5025006S052024 Ondansetron HO Ondansetron HCI lnj 4 MG/2ML (2 MG/ML) 18.00% ANTJEMETICS 50250070102020 Aloxi ANTJFUNGALS 11000010101920 Amphotec Palonosetron HCI IVSoln 0.25 MG/5Ml {Base Equivalent) Amphotericin 8 Cholesteryl Sulfate Complex For lnj 100 MG 26.75%18.00% ANTIFUNGAlS 11407060001820 Noxafll ANTIFUNGALS 11500025102130 Cancldas Posaconazole Susp 40 MG/ML Caspofungin Acetate For IV Sofn 70 MG 18.00% 18.00% ANTJFUNGALS 11000010002105 Amphotericln B ANTIFUNGALS 11407015022020 Diflucan In Dextrose Amphotericin B For lnj 50 MG F!uconazoleln Dextrose lnj 400 MG/200Ml 18.00%18.00% ANTIFUNGALS 11500010002130 Eraxis ANTIFUNGALS 11000010301820 Abelcet ANTIFUNGALS 11407080000320 Vfend Anidulafungin For IV Soln 100 MGAmphotericin B llpld lnjSusp (For IV Infusion) 5 MG/Ml Voriconazole Tab 50 MG 18.00%18.00% 18.00% ANTIFUNGAlS ANTIFUNGALS 11500050102120 Mycamine Micafungin Sodium For IV So!n 50 MG 11407015012020 Diflucan in Sodium Ch!oti Fluconazole in NaCl 0.9% lnj 400 MG/200Ml 18.00%18.()()% ANTJFUNGALS ANTIFUNGALS ANTIFUNGALS 11407080002120 Vfend IV Voriconazofe For lnj 200 MG 11407015022010 Dif/ucan in Dextrose Fluconazo/e in Dextrose lnj 200 MG/lOOMl 11500010002120 Eraxis Anidulafungin For IV So!n 50 MG 18.00% 18.00%18.00% ANT/FUNGALS ANTIFUNGALS 11407015012010 omucan In Sodium Ch!ori F!uconazofe in NaCl 0.9% lnj 200 MG/100Ml 11407080001920 Vfend Voriconazole For Susp 40 MG/ML 18.00%18.00% ANTIFUNGALS ANTIFUNGALS ANTIFUNGALS 11000010101910 Amphotec Amphoteridn B Cholesteryl Sulfate Complex For fnj SO MG 11407035002020 Sporanox11500025102120 Cancidas ltraeonazole Oral Soln 10 MG/Ml Caspofungin Acetate For JVSoln SO MG 18.00% 18.00%18.00% ANTIFUNGALS ANTJFUNGALS 11000010401920 AmBlsome11407080000340 Vfend Amphotericin B Uposome IV ForSusp SO MG Voriconazole Tab 200 MG 18.00%18.00% ANTIFUNGALS Antihemophillc Products Antihemophilic Products 11500050102130 Mycamine85100010002139 Hemofll M85100010006460 Monoclate-P Antihemophl!ic Products Antihemophilic Products 85100010202145 Recomblnate 85100010252150 Advate Micafungin Sodium For IV So!n 100 MG Antihemophlllc Factor {Human) For lnj 801-1700 Unit Antihemophilic Factor (Human) For lnj Kit 1000 Unit Antihemophi!ic Factor (Recombinant) For lnj 1241-1800 Unit Antihemophilic Factor rAHF-PFM For lnj 1500 Unit -· <,fl / -•\ \.:J l,//,,,.. - - - er , 18.00%42.00%30.00% ,,' ,..,._, 1f 40.00% 37.75%

Antihemophilic Products Antihemophilic Products Antihemophilic Products 85100028202150 BeneFIX 85100010266470 Xyntha Solofuse Coagulation Factor IX {Recombinant) For lnj 2000 Unit Antihemophl!ic Factor Recombinant PAF For lnj Kit 3000 Unit 21.00%38.00% Antihemophilic Ptoducts Antihemophilic Products 85100010502130 Obizur 85100015102139 Wilate85100020002100 Feiba NF Antihemophilic Factor (Recomb Pore) rpFVIII For lnj 500 Unit Antihemophilic Factor/VWF {Human) For lnj 1000--1000 Unit*AntifnhlbitorCoagulant Complex For tnj"'• 20.00%40.00%40.00% Antihemophillc Products 85100028002160 Mononine Coagulation Factor IX For lnj 250 Unit 40.00% Antihemophi!ic Products Antihemophllic Products Antihemophilic Products Antihemophillc Products 85100030002115 Profilnine SD85100010002125 Hemofil M Antihemophilic Products AntihemophiHc Products 85100010006410 Monodate-P85100010202135 Recombinate Factor IX Complex For lnj 1500 UnitAntihemophilic Factor {Human) For tnj 401-800 Unit Antihemophilic Factor {Human) For lnj Kit 250 Unit Antihemophilic Factor (Recombinant) For lnj 801-1240 Unit Antihemophllic Products 85100010252130 Advate85100010266440 Xyntha 85100010002140 Hemofil M Antlhemophillc Factor rAHF-PFM For tnj 500 Unit Antihemophilic Factor Recombinant PAF For lnj Kit 1000 Unit Antihemophilic Factor {Human) For lnj 1000 Unit 19.75%42.00¾30.00%40.00% 37.75%38.00%42.00% Antihemophillc Products Antihemophllfc Products 85100010006475 Monoclate-P AntihemophiHc Factor {Human) For lnj Kit 1500 Unit 30.00% 85100010302155 Eloctate Antlhemophillc Factor {Recomb) rFVJIIFc For lnj 2000 Unit 20.00% Antihemophl!ic Products Antihemophllic Products Antihemophilic Products Antihemophlltc Products 85100028202140 BeneFIX Coagulation factor JX {Recombinant) For lnj 1000 Unit 21.00% 37.00%40.00% Antihemophilic Products 31.75% 19.75% Antihemophllic Products Antihemophillc Products 85100015102132 Humate-P Antihemophllic Factor/VWF (Human) For lnj 500 1200 Unit 85100015102190 Alphanate/VWF Compfe) Antihemophlllc Factor/VWF (Human) For lnj 1500 Unit 85100026202145 NovoSeven RT Coagulation Factor Vila (Re.comb) For lnj 5 MG (5000 MCG) 85100030002105 Profilnlne SD Factor IX Complex For lnj 500 Unit85100060106420 Kcentra Prothrombin Complex Cone Human For lnj Kit 500 Unit 20.00% Antihemophilic Products Antihemophl!ic Products 85100010202150 Novoeight85100010252170 Advate Antihemophllic Factor {Recombinant) For tnj1500 Unit Antihemophilic Factor rAHF-PFM For lnj 2000 Unit 20.00%37.75% Antihemophilic Products Antihemophilic Products 85100028202160 BeneFlX Coagulation Factor IX {Recombinant) For lnj 3000 Unit 85100010302120 E!octate Antihemophll!c Factor {Recomb) rFVIIIFc For lnj 250 Unit 21.00% 20.00% Antihemophilic Products Antihemophllic Products 85100015102120 Humate-P 85100015102140 Humate-P85100026202117 NovoSeven RT Antihemophllic Factor/VWF (Human) For lnj 250-500 Unit Antihemophlllc Factor/VWF (Human) For tnj1000-2000 Unit Coagulation Factor Vita {Recomb) For Inf 1 MG (1000 MCG) 37.00%37.00%31.75% Antihemophi!ic Products Antihemophilic Products 85100028002185 AlphaNJne SD85100030002150 Bebulin Coagulation Factor IX For lnJ 1500 Unit Factor IX Complex For lnj 200-1200 Unit 30.00%20.00% Antihemophilic Products Antihemophilic Products Antihemoph!lic Products 85100010206440 Hellxate FS85100010002130 Hemofil M Antihemophilic Factor (Recomblnant) For lnJ Kit 1000 Unit Antlhemoph11!c Factor (Human} For lnJ 500 Unit 41.75%42.00% 85100010006430 Monoclate-P Antihemophillc Factor (Human) For lnj Kit 500 Unit 30.00% Antihemophi!Jc Products Antihemophilic Products 85100010202140 B!OClATE84100040002010 Cyklokapron ANTlHEMOPHILIC FACTOR (RECOMBINANT) FOR INJ 1000 UNITTranexamlc Acid lnj 100 MG/Ml 20.00%18.00¼ Antihemoph11!c Products Antihemoph!llc Products Antihemophlllc Products 85100010002146 Hemofi1 M85100010202115 Recomblnate Antihemophilic Factor (Human) For lnj 1700 Unit Antihemophilic Factor(Recombinant) For lnj 220-400 Unit 42.00%40.00¾ Antihemophi!ic Products Ant!hemophi!ic Products 85100010252140 Advate85100010266460 Xyntha Antihemoph1Hc Factor rAHF-PFM For lnj 1000 Unit Antlhemophllic Factor Recombinant PAF For lnj Kit 2000 Unit 37.75%38.00% Antlhemophilic Products Antihemophll!c Products 85100028202120 BeneFIX Coagulation Factor IX (Recombinant) For lnj 250 Unit 85100010302165 Eloctate85100015102138 Wilate Antihemophilic Factor {Re.comb) rfVIIIFc For lnj 3000 Unit Antihemophilic Factor/VWF (Human) For lnj 900-900 Unit 21.00% 20.00%40.00% Antihemophilic Products Antihemophilic Products Antihemophllic Products 85100015102193 A!phanate/VWF Complex Antihemophilic Factor/VWF {Human} For lnj 2000 Unlt 85100026202160 NovoSeven RT Coagulation Factor Vila (Recomb) For lnj 8 MG {8000 MCG) 40.00%31.75% Antihemophi!lc Products Antihemophi!ic Products 85100030002110 Profllnlne SD 85100060106430 Kcentra Factor IX Complex Forlnj 1000 UnitProthrombln Complex Cone Human For Jnj Kit 1000 Unit 19.75%20.00% 85100028002170 AlphaNine SD Coagulation Factor IX For lnj 500 Unit AntihemophiHc Products Antihemophllic Products 85100010202155 Recombinate85100010252180 Advate Antlhemophilic Factor (Recombinant) For lnj 1801-2400 Unit Antihemophilic Factor rAHF-PFM For lnj 3000 Unit 40.00%40.00%37.75%

Anti.hemophilic Products 85100010302125 Eloctate Antihemophilic Factor (Recomb) rFVIJIFc For lnj 500 Unit 20.00¾ Antihemophi!ic Products 85100015102122 Humate-P Antihemoph!lic FactorNWF (Human) For lnj 250-600 Unit 37.00% Antihemophll!c Products 85100015102144 Humate-P Antihemophilic Factor/VWF (Human) For Jnj 1000-2400 Unit 37.00% AntihemophiHc Products 85100026202120 NovoSeven Coagulation Factor VIia (Recomb) For lnj 1.2 MG (1200 MCG) 31.75% Antihemophilic Products 85100028402110 Alprolix Coagulation Factor IX (Recomb) (rFIXFc) For Jnj 500 Unit 22.00% Antihemophilic Products 85100030002180 Profilnlne SD FACTOR 1X COMPLEX FOR INJ 1000-1500 UNIT 20.05% Antihemophilic Products 85100028002180 AlphaNine SD Coagulation Factor IX For lnj 1000 Unit 40.00% Antihemophllic Products 85100010206460 Helixate FS Antihemoph!llc Factor (Recombinant) For lnj Kit 3000 Unit 41.75% Antihemophilic Products 85100010002110 HemofilM Antihemophilic Factor (Human) For lnj 250 Unit 42.00% Antihemophilic Products 85100010002160 Hemofi!M Antihemophilic Factor (Human) For lnj 801-1500 Unit 42.00% Antihemophilic Products 85100010202125 Recombinate Ant!hemophilic Factor (Recombinant) For lnj 401-800 Unit 40.00% AntihemophHic Products 85100010202170 Novoeight Antihemophiltc Factor (Recombinant) For lnj 3000 Unit 20.00% Antihemophi!ic Products 85100010266420 Xyntha Antihemophllic Factor Recombinant PAF For lnj Kit 250 Unit 38.00% Antihemophilic Products 85100010302135 Eloctate Antihemophilic Factor (Recomb) rfVIIIFc For lnj 1000 Unit 20.00% Antihemophilic Products 85100015102129 Wilate Antihemophilic Factor/VWF (Human) For lnj 500-500 Unit 40.00% Antihemophllic Products 85100015102170 Alphanate/VWF Complex Antlhemophilic Factor/VWF (Human) For lnj 500 Unit 40.00% Antihemophilic Products 85100026202130 NovoSeven Coagulation Factor VIia (Recomb) For lnj 2.4 MG (2400 MCG) 30.50¾ Antihemophil!c Products 85100028402130 Alprolix Coagulation Factor IX (Recomb} (rFIXFc) For lnj 2000 Unit 22.00% Antihemophilic Products 85100033006440 Cori-fact Factor XU! Concentrate (Human) For lnj Kit 1000-1600 Unit 21.00% Antihemophll!c Products 85100010206420 Hefo:ate FS Antihemophilic Factor (Recombinant} For lnj Kit 250 Unit 41.75% Antihemophilic Products 85100010002112 ALPHANATE ANTIHEMOPHIUC FACTOR (HUMAN) FOR INJ 250-500 UNIT 41.75% Antihemophillc Products 85100010002170 HemofilM Antihemophilic Factor {Human} For lnj 1501-2000 Unit 42.00% Antihemophilic Products 85100010202130 BIOCLATE ANTIHEMOPHILIC FACTOR (RECOMBINANT) FOR INJ 500 UNIT 20.00% Antihemophilic Products 85100010252120 Advate Antlhemophilic Factor rAHF-PFM For lnj 250 Unit 37.75% Antihemophllic Products 85100010266430 Xyntha Antihemophilic Factor Recombinant PAF For lnj Kit 500 Unit 38.00% Antihemophilic Products 85100010302145 Eloctate Antihemophllic Factor {Recomb) rFVIIIFc For lnj 1500 Unit 20.00% Ant!hemophHJc Products 85100028202130 BeneFIX Coagulation Factor IX (Recombinant) For In] 500 Unit 21.00% Antlhemophl!Jc Products 85100015102130 Humate-P Antihemophlllc Factor/VWF (Human) For lnj 500-1000 Unit 37.00% Antihemophilic Products 85100015102180 A!phanateNWF Complex Antihemophilic Factor/VWF (Human) For lnj 1000 Unit 40.00% Antihemophilic Products 85100026202140 NovoSeven Coagulation Factor VIia (Recomb) For lnJ 4.8 MG {4800 MCG) 31.75% Antihemophilic Products 85100028402140 A!prolix Coagulation Factor IX (Recomb) (rFIXFc) For lnj 3000 Unit 22.00% Antihemophllic Products 85100035002120 Ria5TAP Fibrinogen Cone {Human) lnj Approximately 1 GM (900---1300 MG) 21.00% Antihemoph1Hc Products 85100010206430 Helixate FS Antihemophlllc Factor (Recombinant) For lnj KJtSOO Unit 41.75% AntihemophlHc Products 85100010002109 Hemofil M Antihemophllic Factor (Human} For lnj 220-400 Unit 42.00% Antihemophil!c Products 85100010002147 HemofilM Antihemophllic Factor (Human) For lnj 1701-2000 Unit 42.00% Antihemophilic Products 85100010202120 BIOCLATE ANTIHEMOPHIUC FACTOR {RECOMBINANT) FOR INJ 250 UNIT 20.00% Antihemophilic Products 85100010202160 Novoeight Antlhemoph!lic Factor {Recombinant) For lnj 2000 Unit 20.00% Antihemophi1ic Products 85100010252185 Advate Antihemoph!lic Factor rAHF-PFM For lnj 4000 Unit 37.75% Antihemophilic Products 85100010302130 Efoctate Antlhemophilic Factor (Recomb) rFVlllFc For Jnj 750 Unit 20.00% Antihemoph11ic Products 85100015102128 Wi!ate Antihemophll!c Factor/VWF (Human) For lnj 450-450 Unit 40.00% AntihemophlHc Products 85100015102160 Atphanate/VWF Complex Antihemophilic Factor/VWF (Human) For lnJ 250 Unlt 40.00% Antihemophilic Products 85100026202126 NovoSeven RT Coagulation Factor Vlla (Recomb) For lnj 2 MG (2000 MCG) 31.75% Antihemophilic Products 85100028402120 Alpro!ix Coagulation Factor IX {Recomb) {rFIXFc) For lnj 1000 Unit 22.00% Antihemoph1Hc Products 85100032102130 Tretten Coagulation Factor XHI A-Subunit For lnJ 2000-3125 Unit 18.00% Antlhemophl!ic Products 85100010206450 Helixate FS Antfhemophi1ic Factor (Recombinant) For Jnj Kit 2000 Unit 41.75% ANTIHEMOPHILICS 30201010102015 Stimate Desmopressin Acetate Nasal Soln 1.5 MG/ML 18.00% ANTIHISTAMINES 41200030102900 DiphenhydrAMINE HCI Diphenhydramine HCI Powder .\\..\, ::>·1 '"v<lr'\' 18.00% ANTIHYPERLIPIDEMICSANTIHYPERUPIDEMICS 3950004010E52039480050200120 KynamroJuxtapid Mipomersen Sodium So!n Pref!lled Syringe 200 MG/MLLomltapide Mesylate Cap 5 MG (Base Equiv) ,:,., - ·...,_ "('\_"'c-,.Yu· <;-1,,' 18.00%18.00% .,r, ·-· t;" "F<.,OntratoN- ·-o.-.J, ,j - , urnero..m\t()". us,,' \ii:-------...._ y tr;., . '((,,\ ' : , 9. '/y .-,. ,v .,;2_& DE. 5J>.,,.

, ANTIHYPERLIPIDEMICS 39480050200130 Juxtap!d Lomitaplde Mesylate Cap 10 MG {Base Equiv) 18.00% ANTIHYPERLIPIDEMICS 39480050200140 Juxtapid Lomitapide Mesylate Cap 20 MG (Base Equiv} ANTI-INFECTIVE AGENTS- MISC. 16000005402120 Cayston Aztreonam Lysine For lnhal Soln 75 MG (Base Equlvalent} 18.00%18.00% ANTI-INFECTIVE AGENTS- MISC. 16000049000320 Xifaxan Rifaximin Tab 200 MG 18.00% ANTI-INFECTIVE AGENTS- MISC. 16000049000340 Xifaxan Rifaxlmin Tab 550 MG 18.00¾ Antfneoplastics 21353045001360 Arzerra Ofatumumab Cone For JV Infusion 1000 MG/50ML 18.00% Antineoplastics 213530600020110 Rituxan Rituximab For IV lnj Cone 10 MG/ML 18.00% Antineoplastks 21534007100120 Alecensa Alectinib HCI Cap 150 MG (Base Equfva!ent) 18.00% Antineop!astics 21370060200120 Odomzo SON!DEGIB PHOSPHATE CAP 200 MG (BASE EQUIVALENT) 18.00% Antlneop!astics 21755050102030 Levoleucovorin Calcium Levoleucovor!n Calcium IV Soln PF 250 MG/25ML (Base Equiv) 18.00% Antineoplastics 21100010002020 Busulfex Busulfan lnj 6 MG/ML 18.00% Antineoplastics 21574070401820 lmlygic Talimogene Laherparepvec lntralesional lnj 1000000 Unit/ML 18.00% Antineoplastics 21535570200320 Rubraca Rucaparib Camsylate Tab 200 MG {Base Equivalent) 18.00% Antineoplastics 21353060002040 Rltuxan Rltuximab For IV lnj Cone 10 MG/ML 18.00% Antineoplastics 21250010402125 Erwinaze Asparaginase Erw!nia Chrysantheml for IM lnj 10000 Unit 18.00% Antineoplastics 21353060002040 Rituxan Rltuximab For IV lnj Cone 10 MG/ML 18.00% Antineoplastics 2147008000b720 Venclexta Starting Pack VenetodaxTab Therapy Starter Pack 10 & SO & 100 MG 18.00% Ant!neoplastlcs 21755040102150 Leucovorin Calcium Leucovorin Calcium For lnj 200 MG 18.00% Antineoplastlcs 21500012001325 PACUtaxel Paditaxel IV Cone 30 MG/SML (6 MG/ML) 18.00% Antineoplast!cs 21300050100320 Trexal! Methotrexate Sodium Tab 5 MG (Base Equiv) 18.00% Antineop!astics 21353027002030 Darzalex Daratumumab JV Sein 400 MG/20ML 18.00% Antineop!astics 21534013100320 cabometyx cabozantinib 5-Malate Tab 20 MG (Base Equfva!ent) 18.00% Antineop!astics 21990002750320 Lonsurf TRIFLURIDJNE-TIPIRAC!L TAB 15-6.14 MG 18.00% Antineoplast!cs 21708080000110 Vesanold Tretinoln cap 10 MG 18.00% Antineoplastics 21300050100350 Trexall Methotrexate Sodium Tab 15 MG (Base Equiv) 18.00% Antineoplastics 21755040102130 Leucovorin Calcium Leucovorln calcium For lnj 100 MG 18.00% Antineoplastics 21100015002045 CARBOplatln Carboplatin IV Soln 600 MG/60ML 18.00% Antineoplastics 21536045100140 Ninlaro lxazomlb Citrate Cap 4 MG (Base Equivalent) 18.00% Antineoplastics 21100009102005 Bendeka Bendamustine HCI IV Soln 100 MG/4ML {25 MG/ML) 18.00% Antineoplastics 21700013001930 Tice BCG BCG Live lntravesical For Susp 50 MG 18.00% Antineoplastlcs 21700020002110 Dacarbazine Dacarbazine For lnj 200 MG 18.00% Antineoplastics 21200010102105 B!eomycin Sulfate B!eomycin Sulfate For lnJ 15 Unit 18.00% Antineoplastics 21100015002030 CARBOplatin carboplatin IV So!n SO MG/5ML 18.00% Antineoplastks 21574070401840 lmlygic Talimogene Laherparepvec fntralesional lnj 100000000 Unit/ML 18.00% Antineoplastics 21353030002120 Empllclti Elotuzumab For rv Soln 300 MG 18.00% Antineoplastics 21535570200330 Rubraca Rucaparib Camsylate Tab300 MG (Base Equivalent} 18.00% Antineoplastics 21200050002120 Mitomydn Mltomycin For lnJ 40 MG 18.00% Antineoplastics 21300007002015 Cladribine dadribine IV So!n 10 MG/10ML {1 MG/ML} 18.00% Antineoplastics 21470080000320 Venc\exta Venetociax Tab 10 MG 18.00% Antineoplastlcs 21534013100330 cabometyx cabozantinib S-Malate Tab 40 MG {Base Equivalent) 18.00% Antlneoplastics 21990002750330 Lonsurf TRIFLURlDINE-TlPIRACIL TAB 20-8.19 MG 18.00% Antineop\astics 21550040202220 Onlvyde lrfnotecan HCI Llposome IV lnj 43 MG/10ML (4.3 MG/ML} 18.00% Antineop\astlcs 21100020002020 CISplatin Osplatln lnj 50 MG/50Ml {1MG/ML) 18.00% Antineoplastics 21100015002040 CARBOplatin carboplatin 1V Soln 450 MG/45ML 18.00% Antineoplastics 21533530200320 Cotelllc Coblmetinib Fumarate Tab 20 MG (Base Equivalent) ,,-·.\\...- - _:_ - 18.00% Antineoplastics 21353030002130 Empliciti Elotuzumab For IV Sein 400 MG 18.00% Antineoplastics 21500005002075 DOCEtaxel (Non-Alcohol) Docetaxel (Non-Alcohol Formula) IV 5oln 80 MG/4ML ~· ,y ,:1..',v .'.. 18.00% Antineoplastics 21470080000340 Venclexta VenetoclaxTab 50 MG ; ."' 'i- " _ 18.00% Antineoplastics 21500012001350 Onxol Paclitaxe! IV Cone 300 MG/50ML {6 MG/ML) ' VOnfratn ,.,,_. V 18.00% . !) ., --,.., '. Ill \,IJ\<J\.\ ,.," . . ; > ,9 .. 'v ' \(",'·· -.- ,, . s'\·'\; f'L. ,, 0 .s D..E.. 51", -

) Antineoplastics 21100020002025 C!Splatin Cisplatin lnj 100 MG/lOOML (1 MG/ML) 18.00% Antineoplastics 21500020102005 VinCRIStine Sulfate Vincristine Sulfate IV So!n 1 MG/ML 18.00% Antineoplastlcs 21534065200330 Tagrisso Osimertlnib Mesylate Tab 80 MG {Base Equivalent) 18.00% Antineoplastics 21536045100120 Nlnlaro lxazomlb Citrate Cap 2,3 MG (Base Equivalent) 18.00% Antineoplastics 21500005002080 DOCEtaxel (Non-Alcohol) Docetaxel (Non-Alcohol Formula) IV Sotn 160 MG/8ML 18.00% Antineoplastics 21470080000360 Venclexta Venetoclax Tab 100 MG 18.00% Antineoplastics 21755050102020 levoleucovorincatcium Levo!eucovorin calcium lnj 175 MG/17.5Ml {Base Equiv) 18.00% Antineoplastks 21755040102160 Leucovorln Calcium Leucovorln Calcium For lnj 350 MG 18.00% Antineoptastics 21755040102120 Leucovorin Calcium Leucovorln Calcium For lnJ 50 MG 18.00% Antlneoptasttcs 21100015002035 CARBOplatin Carbop!atin IV Soln 150 MG/15ML 18.00% Antineoplastics 21353027002020 Darzalex Daratumumab IV So!n 100 MG/5ML 18.00% Antineop!astics 21536045100130 Ninlaro lxazomib Citrate Cap 3 MG (Base Equivalent) 18.00% Antineop!astlcs 21500005002070 DOCEtaxel {Non-Alcohol Docetaxel (Non-Alcohol Formula) IVSoln 20 MG/Ml 18.00% Antineop!astics 21101040102115 Evomela Mefphalan HCI For lnj SO MG (Propylene Glycol {PG) Free) 18.00% Antineop!astics 21534013100340 Cabometyx Cabozantinib 5-Ma!ate Tab 60 MG (Base Equivalent) 18.00% Antineop!astlcs 21107075002140 Yondelis Trabectedin For lnj 1 MG 18.00% Antineop!astics 21200010102115 Bleomycin Sulfate Bleomycln Sulfate For lnj 30 Unit 18.00% Antineop!astics 21500012001335 PACLitaxel Paclitaxel IV Cone 100 MG/16.7ML (6 MG/ML) 18.00% Antineop!astics 21534065200320 Tagrlsso Oslmert!nib Mesylate Tab 40 MG {Base Equivalent) 18.00% Antineoplast!cs 21353047002020 Lartruvo O!aratumab Soln for IV Infusion 500 MG/50ML {10 MG/Ml) 18.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21100009102010 Treanda BendamusUne HCI IV Soln 45 MG/0.SML (90 MG/ML) 18.00% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21100028002120 Oxa!iplatin Oxa!iplatln For IV lnj 50 MG 30.00% ANTlNEOPlASTICS ANO ADJUNCTIVE THERAPIES 21101025002025 lfosfamlde lfosfamlde IV lnj 1 GM/20ML (SO MG/ML) 18.00% ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 21102020000110 CeeNU Lomustfne Cap 10 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200030102210 DAUNOrubicin HCI Daunorubkin Hd lnj 5 MG/Ml {Base Equiv) 18.00% ANTlNEOPlASTlCS AND ADJUNCTIVE THERAPIES 21200042102040 Epirubicin HCI Epirubicin HCI lnj 150 MG/75ML (2 MG/ML) 18.00% ANT1NEOPlASTlCS AND ADJUNCTIVE THERAPIES 21200055001325 Mitoxantrone HCI Mitoxantrone Hd lnj Cone 25 MG/12.SML {2 MG/Ml) 18.00% ANTlNEOPlASTlCS AND ADJUNCTIVE THERAPIES 21300010002115 Cytarabine Cytarabine For lnj 1 GM 18.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21300034102040 Gemcitabine HCl Gemcltabine HCI lnj 1 GM/26.3ML {38 MG/ML) (Base Equiv) 30.00% ANTlNEOPlASTlCS AND ADJUNCTIVE THERAPIES 21300054002025 Folotyn Pralatrexate IV lnj 40 MG/2Ml 18.00¾ ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES 21352020002120 Bl!ncyto Bl!natumomab For IV Infusion 35 MCG 18.00% ANTlNEOPlASTlCS AND ADJUNCTIVE THERAPIES 21402430000120 Xtandi Enzalutamide Cap 40 MG 18.00% ANTlNEOPlASTlCS AND ADJUNCTIVE THERAPIES 21405010106410 Lupron Depot leuprollde Acetate For lnj Kit 7.5 MG 18.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21405010256450 Lupron Depot leuprolide Acetate {6 Month) For lnj Klt45 MG 18.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21450080000115 Pomalyst Pomalidom!de Cap 2 MG 18.25% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500005002040 DOCEtaxel Docetaxel Soln for IV Infusion 80 MG/8Ml 35.00% ANTINEOPlASTICS ANO ADJUNCTIVE THERAPIES 21500012201920 Abraxane Paclitaxel Protein-Bound Particles For IV Susp 100 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21531060000130 tbrance Palboclcllb Cap 100 MG 18.00% ANTlNEOPlASTICSANO ADJUNCTIVE THERAPIES 21532025100120 Tafin!ar Dabrafenib Mesylate Cap 50 MG {Base Equivalent} 18.00% ANTINEOPlASTICS ANO ADJUNCTIVE THERAPIES 21532530007320 Aflnltor Disperz Everolimus Tab for Oral Susp 3 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21533070300140 Sutent Sunltinib Malate Cap 50 MG {Base Equivalent) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534012000320 Bosu!if Bosutlnib Tab 100 MG 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534020000320 Sprycel Dasatlnib Tab 20 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534025100360 Tarceva Erlotinib HCI Tab 150 MG (Base Equivalent)- 18.00% ANT!NEOPlASTICS AND ADJUNCTIVE THERAPIES 21534054208240 Lenvima 14 MG Daily Do Lenvatinlb Cap Therapy Pack 10 &4 MG {14 MG Daily Dose) . 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21536015002120 Vekade Bortezomlb For !nj 3.5 MG t\\ ...•- .-- ....i.c, "-' 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21538040000330 Zydeltg ldelalisib Tab 150 MG / /l' 4"" ':'V;, 18.00% ANTlNEOPlASTJCS AND ADJUNCTIVE THERAPIES 21700020002105 Dat.:lrbazine Dacarbazine For lnj 100 MG i v E 18.00% ANTlNEOPlASTlCS ANO ADJUNCTIVE THERAPIES 21700060202135 lntron A Interferon Alfa-2B For lnj 18000000 Unit : vOntratn ,.. I, \.I 18.00% -··· l 9 n --0 tll '> I" · l- ,;ff/f •.. ' \ -\{.,\' -9 ,, IV ' ' '' (, 'I' ··. .,.... ,>' :---·. •, N .. '-, O,oe:; 0'" sf•· ¾. '--· ..

ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700075206420 Sylatron Peginterferon affa-2b For lnj Kit 300 MCG 18.00% ANTJNEOPLASTICSAND ADJUNCTIVE THERAPIES 2175S040100325 leucovorin Calcium leucovorin Calcium Tab 10 MG 18.00% ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 21764065002140 Elite!< Rasburicase For IV Soln 7.5 MG 18.00% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21100020002030 CISplatin Cisp!atin lnj 200 MG/200ML (1 MG/ML} 20.00% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21101020002125 Cyclophospham!de Cyclophosphamide For lnj 1 GM 32.30% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21101040102110 Atkeran Melphalan HCIFor lnj SO MG (Base Equiv} 18.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21200030052210 DaunoXome Daunorubicin Citrate Liposome lnJ 2 MG/ML 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200042102025 Epirubicin HCI Eplrubicin HCI lnj 10 MG/SML (2 MG/ML) 18.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21200045102035 ldamycin PFS ldarubidn HCI IV lnj 20 MG/20Ml {1MG/ML) 18.00% ANTlNEOPlASTlCS AND ADJUNCTIVE THERAPIES 21300010002105 Cytarabine Cytarabine For lnj 100 MG 18.00% ANTlNEOPlASTlCS AND ADJUNCTIVE THERAPIES 21300030002025 Fluorouracil F!uorouracil lnj 1 GM/20Ml (SO MG/ML) 18.00% ANTJNEOPlAST1CS AND ADJUNCTIVE THERAPIES 21300053102120 Alimta Pemeuexed Dlsodium For JV Soln 500 MG (Base Equiv) 18.00% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 2133S070002020 Cyramza Ramucirumab IV So!n 100 MG/10ML{For Infusion) 18.00% ANTINEOPLASTlCS AND ADJUNCTIVE THERAPIES 21353043002025 Gazyva Obinutuwmab Sofn for IV Infusion 1000 MG/40ML (25 MG/Ml) 18.00% ANTINEOPlASTICSAND ADJUNCTIVE THERAPIES 213530S4002020 Perjeta Pertuwmab Soln for IV Infusion 420 MG/14Ml (30 MG/ML) 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21402250000320 lysodren Mitotane Tab 500 MG 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405007106450 Vantas Histrelin Acetate Implant Kit 50 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21405010206435 Eligard leuprollde Acetate {4 Month) For Subcutaneous fnj Kit 30 MG 25.00% ANTINEOPlAST!CS AND ADJUNCTIVE THERAPIES 21100009102030 Treanda Bendamustine HCI IVSoln 180 MG/2Ml {90 MG/Ml) 18.00% ANTINEOPLAST!CS AND ADJUNCTIVE THERAPIES 21100028002130 Oxaliplatln Oxaliplatin For IV lnj 100 MG 30.00% ANTINEOPlAST!CS AND ADJUNCTIVE THERAPIES 21101025002030 lfosfam!de lfosfam!de IV lnj 3 GM/60ML (50 MG/ML) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21102020000115 CeeNU lomustine Cap 40 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200040102010 Adtiamydn Doxorubicin HCI lnj 2 MG/Ml 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200042102045 Ellence Epirublcln HCI IV Soln 200 MG/lOOMl (2 MG/Ml) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200055001330 Mitoxantrone HCI Mitoxantrone HCI lnj Conc30 MG/1SML{2 MG/ML) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300010002120 Cytarablne Cytarablne For lnj 2 GM 18.00% ANT1NEOPlASTICS AND ADJUNCTIVE THERAPIES 21300034102000 Gemcltab!ne HCl Gemcitablne HCl lnJ 2 GM/S2.6ML{38 MG/Ml) (Base Equiv) 30.00'% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300060000305 Tabloid Thioguanlne Tab 40 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21353010002040 Campath A!emtuzumab IV lnj 30 MG/ML (For Infusion) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21353050002025 Vectibix Panitumumab IVSoln 100 MG/5Ml 18.00% ANTINEOPLAST1CS AND ADJUNCTIVE THERAPIES 21353070002120 Herceptin Trastuzumab For IV Soln 440 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21403020100105 Emcyt Estramustlne Phosphate Sodium cap 140 MG 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405010106415 Ellgard LeuproHde Acetate For Subcutaneous lnj Kit 7.5 MG 25.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21100010000305 Myleran Busulfan Tab 2MG 18,00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21101020000310 Cyclophosphamide Cyc!ophosphamide Tab SO MG 32.30% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21101030102105 Mustargen Mechlorethamlne HCI For lnj 10MG 18.00% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21104070002120 Temodar Temozolomide For IV Soln 100 MG 18.00% ANTlNEOPlASTtCS AND ADJUNCTIVE THERAPIES 21200040102115 Adrlamydn Ooxorubkin HCI For lnj SO MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200045102025 ldamydn PFS !darubidn HCI IV lnj S MG/5Ml (1MG/ML) 18.00¾ ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21250060002020 Oncaspar Pegaspargase lnj 750 Unit/ML 18.00% ANTINEOPLASTJCS AND ADJUNCTIVE THERAPIES 21300025102020 F!udarabine Phosphate Fludarablne Phosphate lnj 25 MG/Ml 18.00% ANTINEOPlASTJCS AND ADJUNCTIVE THERAPIES 21300052002020 Arranon Nelarabine N Soln S MG/Ml 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21335020002025 Avastin Bevacizumab IV Soln 100 MG/4ML (For Infusion) 18.00 ANTJNEOPlASTICSAND ADJUNCTIVE THERAPIES 21353032002020 Yervoy lpilimumab Soln for IV Infusion SO MG/lOML (S MG/Ml} 18.00 ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21353053002030 Keytruda Pembro!izumab JV Soln 100 MG/4Ml {25 MG/Ml) 18.00¾ ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21355070302130 Kadcyla Ado-Trastuzumab Emtansine For IVSoln 160 MG ,/ ,,5TRA ·--,, 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21405005102310 Zoladex Gosere!ln Acetate Implant 3.6 MG .h'". •...:;. -.,.I'\,._ 18.00 ANTtNEOPlASTJCS ANO ADJUNCTIVE THERAPIES 21405010156432 Ellgard Leuprotide Acetate (3 Month} For Subcutaneous lnJ Kit 22.SMG I /,-V '\,"I;, 25.00 ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21100015002120 CARBOplatin Carboplatin IV For lnj 150 MG ; Q" //,,., \ \ 18.00 -' ,-,y Y'''' ' i t 9 - '" ttmo,0 '.I\\ll , m\\)' ',-J,.0ii2· t 'v e,V, 1y "?..-=- v " 0 8 oF-sl>,/

ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21101020002120 Cyc!ophosphamide Cydophosphamide For lnj 500 MG ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21101040000305 Alkeran Melphalan Tab 2 MG 32.30% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200020002105 Cosmegen Dactinomycin For lnj 0.5 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200040402210 Doxil Doxorubicin HCI Liposomal lnj {For IV Infusion) 2 MG/Ml 18.00% ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 21200045102030 ldamycin PFS ldarublcin HCI IV lnj 10 MG/10Ml {1MG/Ml) 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300007002010 C!adribine Cladribine In] 1 MG/ML 18.00¾ ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300025102120 F1udara Fludarabine Phosphate For lnj 50 MG 18.00%18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300053102110 Alimta Pemetrexed Dlsodlum For IV So!n 100 MG (Base Equiv) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21335020002030 Avastin Bevacizi.Jmab N Solo 400 MG/16Ml (For Infusion) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21353032002040 Yervoy Jpllimumab So!n for IV Infusion 200 MG/40Ml {5 MG/Ml) ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21353053002120 Keytruda Pembrolizumab For IV So!n SO MG 18.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21370070000120 Erivedge Vismodegib Cap 150 MG 18.00% ANTlNEOPl.ASTICS AND ADJUNCTIVE THERAPIES 21405005102330 Zoladex Goserelin Acetate Implant 10.8 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21405010206430 Lupron Depot LeuprolideAcetate (4 Month) For lnj Kit 30 MG 18.00% ANTINEOPlASTJCS AND ADJUNCTIVE THERAPIES 21104070000147 Temodar Temozolomide Cap 180 MG 35.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 99392070000135 Thalomid Thalfdomide Cap 150 MG 18.00% ANTJNEOPlASTICS AND ADJUNCT/VE THERAPIES 21300034102140 Gemcltabine HCI Gemcitablne HCI For lnj 1 GM 30.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21406010200320 Zytiga Ab!raterone Acetate Tab 250 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500005001325 DOCEtaxel Docetaxel For lnj Cone 80 MG/2ML {40 MG/Ml) '>35.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500011002140 lxempra Kit txabeplfone For IV lnfuslon 45 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500050802025 Navelblne Vinorelbine Tartrate lnj 50 MG/5ML (10 MG/Ml) (Base Equiv) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21S31560002120 lstodax Romidepsin For IV lnj 10 MG 18.1)0% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21532530000330 Afinltor Everolimus Tab 10 MG 18.00¾ ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21533070300130 Sutent Sunitinib Malate Cap 25 MG (Base Equivalent) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534008000320 lnlyta Axit!nlb Tab 1 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534015000120 Xalkori Crizotinib Cap 200 MG 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534025100320 Tarceva Erlotinib HCI Tab 25 MG {Base Equivalent) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 2153405420B220 Lenvima 10 MG Daily Doi lenvatlnlb Cap Therapy Pack 10 MG (10 MG Daily Dose) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534075100340 lclusig Ponatinib HCI Tab 45 MG {Base Equiv} 22.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21537560200335 Jakafi Ruxolitinib Phosphate Tab 25 MG (Base Equivalent) 18.00¾ ANT/NEOPlASTICS AND ADJUNCTIVE THERAPIES 21700008102020 Trlsenox Arsenic Trioxide fnj 10 MG/10Ml (1MG/Ml) 18.00% ANTlNEOPlASTJCS AND ADJUNCTIVE THERAPIES 21700060202030 lntron-A Interferon A!fa-2B lnj 10000000 Unit/ML 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21700060702020 Actimmune Interferon Gamma-18 lnj 100 MCG/0.5Ml (2000000 Unlt/0.SML) 18.00% ANTINEOPlASTJCS AND ADJUNCTIVE THERAPIES 21707070102140 Photofrin Porfimer Sodium For lnj 75 MG 18.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21758050002010 Mesna Mesna lnj 100 MG/ML 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21405525102120 Firmagon Degarelix:Acetate For lnj 80 MG {Base Equiv) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500005001317 DOCEtaxel Docetaxel For lnj Cone 160 MG/8Ml (20 MG/Ml) 35.00% ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 21500010602120 Etopophos Etoposide Phosphate IV For lnj 100 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500030102105 VinBlASt!ne Sulfate Vinblastlne Sulfate For lnj 10 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21531550100130 Farydak Panoblnostat lactate Cap 15 MG {Base Equivalent) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21532530000320 Aflnltor Everolimus Tab 5 MG 18.00% ANTINEOPlASTICS ANO ADJUNCTIVE THERAPIES 21533060400320 NexAVAR Sorafenib Tosylate Tab 200 MG {Base Equivalent) 18.00% ANTINEOPlASTICS ANO ADJUNCTIVE THERAPIES 21534006100330 Gi!otrif Afatinib Dlmaleate Tab 30 MG (Base Equivalent) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534013106480 Cometriq (140 mg Daily [ Cabozantinib S-Ma\ Cap 1 X 80 MG & 3 X 20 MG {140 Dose) Kit 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534020000360 Sprycel Dasatlnlb Tab 100 MG 18.00¾ ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534035100340 Gleevec lmatinlb Mesylate Tab 400 MG (Base Equivalent) .....l\,::, I I,/{('\,"-. 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534070100320 Votrient Pazopanib HCI Tab 200 MG (Base Equiv) h_\\ .a: .... 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21537560200325 Jakafi Ruxo!itin!b Phosphate Tab 15 MG (Base Equivalent) (/ -- 18.00% ANTINEOPlASTlCSAND ADJUNCTIVE THERAPIES 21550080100140 Hycamt!n Topotecan HCI Cap 1 MG {Base Equiv) ' l/c ·.· "'... \V \_J 18.00% . ,ro ._ \\ \ 9 '. (,I,- :1 (i '.• U1 ----- , ' . \.\\(\,\-.'.. ,._) r·, -,-- , V';,'i:->i ·:-o:- ...:c•'_-'-,-,•-.-,-r_•-"s"-'l-.·- V·

ANTINEOPLASTIC$ AND ADJUNCTIVE THERAPIES 21700050100105 Matulane Procarbazine HCI Cap SO MG 18.00";-6 ANT!NEOPLASTlCS AND ADJUNCTIVE THERAPIES 21700060206470 lntron-A Interferon A!fa-2B lnJ Kit 10000000 Unit/0.2Ml 18.00¾ ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700075206470 Sytatron Peginterferon a!fa-2b For lnj Kit 4 X 600 MCG 18.00¾ ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21755050102120 Fusi!ev levoteucovorin Calcium For IV lnj 50MG (Base Equiv) 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405050201920 Trelstar Depot Triptorelin Pamoate For IM Susp 3.75 MG 22.50% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21450080000120 Pomalyst Pomalfdomlde Cap 3 MG 18.25% ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES 21500005002050 OOCEtaxel Docetaxel Soln for IV Infusion 160 MG/16ML 35.00% ANTINEOPL.ASTICS AND ADJUNCTIVE THERAPIES 21500015002020 Teniposide Teniposide IV Soln 10 MG/ML 18.00% ANTINEOPL.ASTICS AND ADJUNCTIVE THERAPIES 21531060000140 lbrance Palbocidib Cap 125 MG 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21532025100130 Tafin!ar Dabrafenib Mesylate Cap 75 MG (Base Equivalent) 18.00% ANTINEOPL.ASTICS AND ADJUNCTIVE THERAPIES 21532530007340 Aflnitor Disperz Everolimus Tab for Oral Susp 5 MG 18.00¾ ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21533570100310 Mek!nlst Trametinib Dimethyl Sulfoxide Tab 0.5 MG {Base Equivalent) 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534012000340 Bosulif Bosutinib Tab 500 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534020000340 Sprycel Dasatln!b Tab 50 MG 18.00% ANTINEOPlAST[CS AND ADJUNCTIVE THERAPIES 21534030000320 lressa Gefitinib Tab 250 MG 18.00% ANTlNEOPlAST!CSAND ADJUNCTIVE THERAPIES 2153405420B250 Lenvima 24 MG Dally Do lenvatinib Cap Therapy Pack 10 {2) & 4 MG (24 MG Daily Dose) 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21536025002120 Kyprolls Carfi!zomib For lnj 60 MG 18.00% ANTINEOPL.ASTICS AND ADJUNCTIVE THERAPIES 21550040102035 Camptosar lrlnotecan HCI lnJ 300 MG/1SML (20 MG/ML) 18.00% ANTlNEOPLASTlCS AND ADJUNCTIVE THERAPIES 21700024002020 Ontak Oenlleukin Diftitox IV Soln 150 MCG/Ml 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21700060202160 lntron A Interferon Alfa-2B For lnj 50000000 Unit 18.00% ANTINEOPlAST!CS AND ADJUNCTIVE THERAPIES 21700075206430 Sylatron Peginterferon alfa-2b For lnj Kit 600 MCG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21755040100335 Leucovorin Calcium Leucovorin Calcium Tab 15 MG 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21765060002120 Keplvance Pa!ifermin For IV lnj 6.25 MG 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 2140SS25102130 firmagon Oegarelix Acetate For lnj 120 MG {Base Equiv) 18.00% ANTINEOPlAST1CS AND ADJUNCTIVE THERAPIES 21500005001320 OOCEtaxel Docetaxel For lnj Cone 20 MG/0.SML (40 MG/ML) 35.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500011002120 lxempra Kit lxabepi!one For IV Infusion 15 MG 18.00% ANTINEOPLASTlCS AND ADJUNCTIVE THERAPIES 21500050802020 Navelb!ne Vinorelbine Tartrate lnj 10 MG/ML (Base Equiv) 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21531550100140 Farydak Panoblnostat Lactate Cap 20 MG (Base Equivalent) 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21532530000325 Aflnitor Everollmus Tab 7.5 MG 18.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21533070300120 Sutent Sunltinib Malate Cap 12.S MG {Base Equivalent) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534006100340 Gilotrif Afatinib Dimaleate Tab 40 MG (Base Equivalent) 18.00% ANTlNEOPlAST!CS AND ADJUNCTIVE THERAPIES 21534014000130 Zykadia Ceritinib Cap 150 MG 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534020000380 Sprycel Dasatinlb Tab 140 MG 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534050100320 Tykerb Lapatinib Ditosylate Tab 250 MG (Base Equiv) 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534075100320 lclusig Ponatinib HCI Tab 15 MG {Base Equiv} 22.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21537560200330 Jakafi Ruxolitinib Phosphate Tab 20 MG {Base Equivalent) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21550080102020 Topotecan HCI Topotecan HCI lnj 4 MG/4Ml {Base Equiv) (For Infusion) 18.00% ANTINEOPlASTfCS AND ADJUNCTIVE THERAPIES 21700060202022 lntron·A Interferon A!fa-28 lnj 6000000 Unit/ML 18.00% ANT/NEOPLASTICS AND ADJUNCTIVE THERAPIES 21700060302020 Alferon N Interferon A!fa-n3 lnj 5000000 Unit/ML 18.00% ANTINEOPL.ASTICS AND ADJUNCTIVE THERAPIES 21703020002120 Proleukin Aldesleukin For IV Soln 22000000 Unit 18.00% ANTINEOPL.ASTlCS AND ADJUNCTIVE THERAPIES 21758050000320 Mesnex Mesna Tab 400 MG 18.00% ANTINEOPlASTICSAND ADJUNCTIVE THERAPIES 21100009102120 Treanda Bendamustine HCl For IV Sein 100 MG 18.00% ANT1NEOPLASTtC5 AND ADJUNCTIVE THERAPIES 21101020000305 Cydophosphamlde Cyclophosphamlde Tab 25 MG 32.30% ANTINEOPlASTJCS AND ADJUNCTIVE THERAPIES 21101025002130 lfex lfosfamide For lnj 3 GM 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21102030002105 Zanosar Streptozodn For lnj 1 GM 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200040102110 Adrlamycin Doxorubicin HCI For lnj 20 MG ,s,.. .-,·r•- "v 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200042102170 Epirubicin HCI Eplrubicin HCI For lnj 200 MG )' ,,,... . -:;,-"'1.' "' 18.00% ANTlNEOPL.ASTICS AND ADJUNCTIVE THERAPIES 21300025100320 Oforta Fludarab!ne Phosphate Tab 10 MG ",', 18.00 ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300040001830 Purixan Mercaptopurine Susp 2000 MG/100ML {20 MG/ML) t,·_ % 18.00 .· vvmrato N,imero ' 01 ': .19-a •• ' (/1 ·.·--- f ·- ; \\\ ·,. s 2,,. - ,_ Q ' , , 0 0() ., \ 0/:> \

ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21335010102030 Zaltrap Ziv-Aflibercept IV Soln 200 MG/8ML (For Infusion) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21353025002025 Erbltux Cetuximab IV Solo 200 MG/lOOML {2 MG/ML) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 213S3050002035 Vectibix Panitumumab IV Soln 400 MG/20Ml 18.00% ANTJNEOPlA5TICS AND ADJUNCTIVE THERAPIES 21355070302120 Kadcyla Ado-Trastuzumab Emtansine For IV Soln 100 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21403530002024 Faslodex Fulvestrant Jnj 250 MG/SML 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21405010156430 lupron Depot Leuprolide Acetate (3 Month) For lnj Kit 22.5 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21100028002035 Eloxatin Oxaliplatin IV So!n 200 MG/40Ml 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21101020002130 Cyclophosphamide Cyclophosphamide For lnj 2 GM 32.3CY'76 ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21102010002105 BiCNU Carmustine For lnj 100 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200030102105 Cerubidine Daunorubicin HCI For Inf 20 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200042102030 Ellence Ep!rublcin HCI IVSoln 50 MG/25ML(2 MG/ML) 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200055001320 Mitoxantrone HCI Mitoxantrone HCI lnj Cone 20 MG/10ML (2 MG/ML) 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300010002110 Cytarabine Cytarabine For lnj 500 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300034102020 Gemcltablne HCI Gemcitabine HCI lnj 200 MG/5.26Ml (38 MG/ML) (Base Equiv) 30.00% ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 21300054002020 Folotyn Pralatrexate IV lnj 20 MG/Ml 18.00% ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES 21335070002040 Cyramza Ramuclrumab 1V Soln 500 MG/50ML (For Infusion) 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21353045001320 Arzerra Ofatumumab Cone For IV Infusion 100 MG/5ML 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21402420000320 Casodex Bicalutamide Tab 50 MG 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21100009102110 Treanda Bendamustine HCI For IVSoln 25 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21101010000305 leukeran Chlorambucil Tab 2 MG 18.00% ANT1NEOPLASTICS ANO ADJUNCTIVE THERAPIES 21101025002110 lfex lfosfamide For lnj 1 GM 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21102020000120 CeeNU Lomustine Cap 100 MG 18.00% ANTINEOPI.ASTICS AND ADJUNCTIVE THERAPIES 21200040102105 Adriamyc!n Doxorub!cin HCI For lnj 10 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200042102140 Eplrubicin HCI Epirubicin HCI For lnj 50 MG 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200080002020 Va!star Valrubicin Soln For lntraveslcal Instillation 40 MG/ML 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300010301825 OepoCyt Cytarabine Uposome lnj 50 MG/5ML 18.00% ANTINEOPlAST!CS AND ADJUNCTIVE THERAPIES 21300034102160 Gemcitabine HCI Gemcltabine HCI For lnj 2 GM 30.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21335010102020 Zaltrap Ziv-Afllbercept IV Soln 100 MG/4Ml (For Infusion) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21353025002020 Erbitux Cetuximab N So!n 100 MG/SOML (2 MG/Ml) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21353050002030 Vectibix Panitumumab IV Soln 200 MG/10Ml 18.00% ANTINEOPlAST!CS AND ADJUNCTIVE THERAPIES 21355020202120 Adcetris Brentuximab Vedotin For N So!n 50 MG 18.00% ANTINEOPlASTlCSAND ADJUNCTIVE THERAPIES 21403530002022 Faslodex Fufvestrant lnj 125 MG/2.SML 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405050201930 Tre!star lA Triptorelin Pamoate For IM Susp 11.25 MG 22.50% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21104070000140 Temodar Temozolom!de Cap 100 MG 35.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500005001310 DOCEtaxel Docetaxel For tnj Cone 20 MG/Ml 35.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 99392070000120 Thalomld Thalidom!de Cap 50 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 99394050000145 Revlim!d Lenalldom!de Cap 20 MG 18.00¾ ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21405010256445 Eligard leuprolide Acetate (6 Month) For Subcutaneous lnJ Kit 45 MG 25.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21450080000110 Pomalyst Pomalidomide Cap 1 MG 18.25% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500005002030 DOCEtaxel Docetaxel Solo for IV Infusion 20 MG/2Ml 35.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500012001340 PACUtaxel Paclitaxel IV Cone 150 MG/25Ml {6 MG/ML) 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21531060000120 lbrance Palbociclib Cap 75 MG 18.00% ANTINEOPlASTICS ANO ADJUNCTIVE THERAPIES 21531575000120 Zo!ima Vorinostatcap 100 MG 18.00% ANTJNEOPlASTlCS ANO ADJUNCTIVE THERAPIES 21532530007310 Afinitor Disperz Evero!imus Tab for Oral Susp 2 MG 18.00% ANTINEOPLASTlCS AND ADJUNCTNE THERAPIES 21533070300135 Sutent Sunitinib Malate Cap 37.5 MG {Base Equivalent} . . 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534008000340 lnlyta Axitinib Tab 5 MG . <:\\ :,, I ,_ 01 "'- 18.00% ANTINEOPI.ASTICS AND ADJUNCTIVE THERAPIES 21534015000125 Xalkori Crlzotlnlb Cap 250 MG •;;\\ 4,,-,.. :-.'-' ' ' 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534025100330 Tarceva Erlotinib HCl Tab 100 MG (Base Equivalent) /' \, 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 2153405420B230 Lenvima 20 MG Dally Do lenvatlnib Cap Therapy Pack 10 (2) MG (20 MG Daily Dose) I ', Con1r,,,,,... ,.,, 18.00% ,.,.- #,,,,, :'_l I) 5 (ll ..\\,·. () 'I - <> ·- ·0 --v 'il(f"',. "' ·- ' \Qs or'.0 .1.V· (

ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21535560000120 lynparza ANTINEOPlASTICS ANO ADJUNCTIVE THERAPIES lolaparib Cap SO MG ldelal!sib Tab 100 MG 18.00% 18.00% ANTINEOPLAST[CS AND ADJUNCTIVE THERAPIES 21538040000320 Zydelig 21700013001940 TheraCys BCG Live lntravesical For Susp 81 MG/VIAL 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700060202130 lntron A Interferon Alfa-2B For lnj 10000000 Unit 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700075206410 Sylatron Peginterferon alfa-2b For lnj Kit 200 MCG 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTlCS AND ADJUNCTIVE THERAPIES 21708220000120 Targretin 21764065002120 Elitek Bexarotene Cap 75 MG Rasburicase For IV Soln 1.5 MG 18.00%18.ocr ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21104070000150 Temodar ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 99392070000140 Thalomid Temozo!omide Cap 250 MG Thalidomide Cap 200 MG 35.1)0% 18.00% ANTINEOPLASTICS ANO ADJUNCTIVE THERAPIES 21405010106407 leuprolide Acetate ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 21300015002120 Dacogen21500010002025 Etoposide21500010002030 Etoposide21450080000125 Poma!yst21500009202020 Halaven21500020201820 Marqibo leuprolideAcetate lnj Kit 5 MG/ML Dedtabine For lnj SO MGEtoposide lnj 100MG/5Ml(20 MG/ML)Etopos!de lnj 500MG/25Ml (20 MG/ML) Pomalidomlde Cap 4 MGEribulin Mesylate lnj 1 MG/2Ml {O.S MG/ML)Vincristine Sulfate Uposome 1V Susp 5 MG/31ML (0.16 MG/Ml} 52,25% 25.00%27.55%27.55%18.25%18.00¼18.00% ANTINEOPLAST!CS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21531520002120 Beleodaq21532080000320 Zelboraf BeHnostat For IV Inf 500 MG Vemurafenib Tab 240 MG 18.00%18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21532570002020 Torisel Temslro!imusSo!n For IV Infusion 25 MG/Ml 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 18.00% ANTINEOPlAST!CS AND ADJUNCTIVE THERAPIES 21533570100330 Meklnlst Trametinib Dimethyl Sulfoxide Tab 2 MG (Base Equivalent) 21534013106460 Cometriq (60 mg Daily n, Cabozantinib S-Mafate Cap 3 X 20 MG {60 MG Dose) Kit 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534020000350 Sprycel21534033000120 lmbruvica Dasatinib Tab 70 MG lbrutlnlb Cap 140 MG 18.00%18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534060200115 Tasigna Nllot!n!b HCI Cap 150 MG {Base Equivalent) 21537560200310 Jakafl Ruxolitinib Phosphate Tab 5 MG {Base Equivalent) 21550040102040 lrinotecan HCI !rinotecan Hd lnj 500 MG/25ML (20 MG/ML) 18.00% 18.00% 30.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTlCS AND ADJUNCTIVE THERAPIES 21700040102120 Synribo21700060206450 lntron-A Omacetaxine Mepesucdnate For lnj 3.5 MG Interferon Atfa-2B lnj Kit 3000000 Unlt/0.2ML 18,00%18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLAST!CS AND ADJUNCTIVE THERAPIES 2170007S206450 Sylatron 21755040102030 Leucovorin Calcium Peginterferon alfa-2b For lnj Kit4 X 200 MCG Leucovorin Calcium lnj 10 MG/Ml 18.00%18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21104070000143 Temodar21500005001315 DOCEtaxel Temozofomide Cap 140 MGDocetaxel For lnj Cone 80 MG/4Ml (20 MG/ML) 35.00%35.00% ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 99392070000130 Thalomid Thalidomide Cap 100 MG 18.00% ANTINEOPLASTIC$ AND ADJUNCTIVE THERAPIES ANTINEOPIAST!CS AND ADJUNCTIVE THERAPIES 99394050000150 Revlimid21100028002030 Eloxatin lenaltdomlde Cap 25 MG Oxaliplatin 1V So!n 100 MG/20Ml 18.00%30.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 99394050000110 Rev!imld21534085000320 Capre!sa lenalidomide Caps 2.5 MG Vandetanlb Tab 100 MG 18.00%18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21550040102025 camptosar lrinotecan HCI lnj 40 MG/2Ml (20 MG/Ml} 30.00% ANTINEOPtAST1CS AND ADJUNCTIVE THERAPIES ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21550080102120 Hycamtin21300034102110 Gemcitablne HCI Topotecan HCI For lnj 4 MG Gemdtabine HCI For lnj 200 MG 18.00%30.00% ANTINEOPLAST!CS AND ADJUNCTIVE THERAPIES ANT!NEOPlASTICS AND ADJUNCTIVE THERAPIES 21500010002040 Etoposlde21550040102030 Camptosar Etoposide !nj 1 GM/50ML (20 MG/ML) lrinotecan Hd !nJ 100 MG/5Ml {20 MG/ML) 27.55%30.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21250010402120 Erwinaze ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21104070000110 Temodar Asparaginase Erwlnia Chrysantheml For lnj 10000 Unit Temozolomide Cap 5 MG 18.00% 35.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300005000350 Capecitablne Capecitabine Tab 500 MG 40.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 99394050000130 Revlimld 21300030002030 Adrucil lenalidornide Cap 10 MG Fluorouraci! lnj 2.5 GM/SOMl(SO MG/ML) - ....... · .,' 18.00% 7._,"0- .,..c.-,-. - ,, ....... 18.00% ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES 21104070000120 Ternodar ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300030002020 Adrucil Temozolomide Cap 20 MG Fluorouracll lnj 500 MG/lOMl (SO MG/Ml) ! .--->'--.., { '-\ ( ) 8.00%

ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 99394050000140 Rev!imid lenalidomide Cap 15 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300030002035 Adrucll Fluorouracil lnj 5 GM/100Ml (SO MG/Ml) 18.00% ANTINEOPLASTIC$ AND ADJUNCTIVE THERAPIES 21300003001920 AzaCITIDlne Azacitidine For lnj 100 MG 25.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21405050201940 Trelstar Mixject Triptorelin Pamoate For IM Susp 22.5 MG 22.50% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500003002020 Jevtana Caba2itaxel lnj 60 MG/1.SMl (For N Infusion) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500010000120 Etoposide Etoposide Cap 50 MG 27.55% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500030102020 VinBLAStine Sulfate Vinblastine Sulfate lnj 1 MG/Ml 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21531550100120 Farydak Panobinostat lactate Cap 10 MG {Base Equivalent) 18.00% ANTINEOPLASTIC$ AND ADJUNCTIVE THERAPIES 21532530000310 Afinitor Evero!imus Tab 2.5 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 2153305000-0320 Stlvarga Regorafenib Tab 40 MG 18.00% ANTINEOPlAST!CS AND ADJUNCTIVE THERAPIES 21534006100320 Gilotrif Afatin!b Dlmaleate Tab 20 MG (Base Equlvalent) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534013106470 Cometriq (100 mg Daily I Cabozantinib S-Mal Cap 1 X 80 MG & 1 X 20 MG (100 Dose) Kit 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534020000354 Sprycel Dasatinlb Tab 80 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534035100320 Gleevec lmatinib Mesylate Tab 100 MG (Base Equivalent) 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534060200125 Tasigna Nilotinib HCI Cap 200 MG {Base Equivalent) 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21537560200320 Jakafi Ruxolitinib Phosphate Tab 10 MG (Base Equivalent) 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21550080100120 Hycamtin Topotecan HCI Cap 0.25 MG {Base Equiv) 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700045002120 Nipent Pentostatin For lnJ 10 MG 18.00% ANTINEOPlASTICS ANO ADJUNCTIVE THERAPIES 21700060206460 lntron-A Interferon Alfa-2B lnj Kit 5000000 Unlt/0.2Ml 18.00% ANTtNEOPLA.STICS AND ADJUNCTIVE THERAPIES 21700075206460 Sylafron Peginterferon alfa-2b For lnj Kit 4 X 300 MCG 18.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21755040102170 leucovorin calcium leucovorfn Calcium For lnj 500 MG 18.00%, ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21100028002025 Eloxatin Oxalfp!atln N Sein 50 MG/10Ml 30.00% ANT!NEOPLASTICS AND ADJUNCTIVE THERAPIES 21300005000320 capecitabine capecitabine Tab 150 MG 40.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 99394050000120 Revlimid lenaUdomlde Cap 5 MG 18.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534085000340 Caprelsa Vandetanib Tab 300 MG 18.00% ANTINEOPLASTICSTOPJCAlS 90371050204030 Valchlor Mech!orethamine HCI Gel 0.016% {Base Equivalent) 18.00% ANTINEOPLASTICS TOPICAlS 90376015004020 Panretin Alitretinoin Gel 0.1% 18.00% Antiparasitics 13000040000310 Darapr!m Pyrimethamlne Tab 25 MG 18.00% ANTIPARKINSON AGENTS 73203010102020 Apokyn Apomorphlne Hydrochloride lnj 10 MG/Ml 18.00% Antipsychotics 59070070101930 RisperDAL Consta R!speridone Microspheres For lnj 37.5 MG 18.00% Antipsychotics 59250015001930 Abilify Maintena Aripiprazole lM For Extended Release Susp 400 MG 18.00% Antipsychotlcs 59070070101920 RisperDAl Consta Risperidone Microspheres For Inf 25 MG 18.00% Antipsychotics 59070070101910 R!sperDAL Consta Rlsper!done Mlcrospheres For lnj 12.5 MG 18.00"76 Antfpsychot!cs 59070050101837 lnvega Sustenna Pal!peridone Palmitate IM Extended-Release Susp 39 MG/0.25ML 18.00% Antipsychotics 59070070101940 RisperDAL Consta Risperidone Mlcrospheres For lnj 50 MG 18.00% Antipsychotics 59070050101845 lnvega Sustenna PaHperldone Pa!mitate \M Extended-Release Susp 234 MG/1.5Ml 18.00% Antlpsychotics 59070050101838 lnvega Sustenna Paliperidone Pa!mltate IM Extended-Release Susp 78 MG/0.5ML 18.00% Antipsychotics 59070050101850 lnvega Trima Pal!peridone Pa!mitate IM Extend-Release Susp 273 MG/0.875ML 18.00% Antlpsychotics 59250015001920 Abilify Maintena Arlplprazole IM For Extended Release Susp 300 MG 18.00% Antipsychotics 5925001520E430 Aristada ARlPIPRAZOLE lAUROXIL lM ER SUSP PREFlllED SYR 662 MG/2.4Ml 18.00% Antlpsychotics 59070050101839 lnvega Sustenna Pallperidone Palmltate IM Extend-Release Susp 117 MG/0.75Ml 18.00% Antipsychotics 59070050101870 lnvega Trima Paliperidone Palmitate IM Extend•Release Susp 546 MG/1.75Ml 18.00% Antipsychotics 5925001520E440 Arlstada AR1PIPRAZOLE lAUROXll IM ERSUSP PREFILLED SYR 882 MG/3.2ML 18.00% Antipsychotics 59070050101880 lnvega Trinza Paliperidone Palmitate 1M Extend-Release Susp 819 MG/2.625Ml 18.00% Antipsychotics 5925001520E420 Arlstada ARIPIPRAZOLE LAUROXIL IM ER SUSP PREFlllED SYR 441MG/1.6ML 18.00% Antipsychotics 59070050101840 lnvega Sustenna Paliperidone Palmitate IM Extended-Release Susp 156 MG/Ml ---1:,,,r, --<...... 18.00% Antipsychotics 59070050101860 lnvega Trinta Pa!iper!done Palmitate IM Extend•Release Susp 410 MG/1.315Ml .,.. \--.::-'" . -<·.•..t.o ··, 18.00% ANTIPSYCHOTICS/ANTlMANICAGENTS 59157060101950 ZyPREXA Relprew Olanzap!ne Pamoate For Extended Rel IM Susp 210 MG {Base Eq) ,J•,._, p:v ..",' · 18.00% ANTIPSYCHOTICS/ANTIMAN!CAGENTS 59157060101970 ZyPREXA Relprew Olamapine Pamoate For Extended Rel JM Susp 405 MG (Base Eq} / \ 18.00% X , Contrato Numero '" \ 1 9 (I ,) ' ' l Y(J . "''\·. /..:, <;& ·,. .-w ly "y "'"· ty0 , 0 SLh .

ANTlPSYCHOTICS/ANTIMANIC AGENTS S9157060101960 ZyPREXA Relprew Olanzapine Pamoate For Extended Rel IM Susp 300 MG (Base Eq) 18.00% Antivirals 12200020102030 Foscavir FoscarnetSod!um lnj 6000 MG/250ML (24 MG/ML) 18.00% Antivirals 12359902300320 Zepatier Elbasvir-Grazoprev!rTab 50-100 MG 18.00% Antivirals 12200020102040 Foscarnet Sodium FoscarnetSodium lnj 12000 MG/SOOML (24 MG/ML} 18.00% ANTIVIRALS INFLUENZA 12504065002020 Rapivab Peramivir lnj 200 MG/20Ml (10 MG/ML) 18.00% Bisphosphonates 30042048100360 Bonlva lbandronate Sodium Tab 150 MG (Base Equivalent) 18.00% BLEEDING DISORDERS 84100010000320 Am!car Aminocaproic Acid Tab 1000 MG 18.00% BLEEDING DISORDERS 8410001000120S Amicar Aminocaproic Acid Syrup 25% 18.00% BLEEDING DISORDERS 84100010000305 Amlcar AmlnocaproicAcid Tab 500 MG 18.00% Blood Products/ Modifiers/Volume Expanders 8240101510E556 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 5oln lnj 60 MCG/ML 18.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E575 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 150 MCG/0.3ML 18.00% Blood Products/ Modifiers/Volume Expanders 82401015102080 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80 So!n Jnj 500 MCG/ML 18.00% Blood Products/ Modifiers/Volume Expanders 8240102000E545 Epogen Epoetin Alfa \nj10000 Unit/Ml 18.00% Blood Products/ Modifiers/Volume Expanders 8240104010E515 Mircera Methoxy Polyethylene Glycol-Epoetin Beta Jnj 50 MCG/0.3ML 18.00% Blood Products/ Modifiers/Volume Expanders 8240152000E545 Neupogen Filgrastim lnj 300 MCG/O.SML(600 MCG/Ml} 18.00% B!ood Products/ Modifiers/Volume Expanders 85100028402105 A!pro!ix Coagulation Factor IX (Recomb) {rFIXFc} For lnj 250 Unit 18.00% Blood Products/ Modifiers/Volume Expanders 85100015106440 Wilate Antihemophilic Factor/WJF {Human) For lnJ 1000-1000 Unit Kit 18.00% Blood Products/ Modifiers/Volume Expanders 85100028202145 lxinity Coagulation Factor IX (Recombinant) For lnj 1500 Unit 18.00% Blood Products/ Modifiers/Volume Expanders 85100010402130 Adynovate AntihemophHic Factor Recomb Pegylated For lnj 500 Unit 18.00% Blood Products/ Modifiers/ Volume Expanders 85100031002140 Coagadex Coagulat!on FactorX {Human) For lnj 500 Unit 18.00% Blood Products/ Modifiers/Volume Expanders 8240101510E543 Aranesp (Albumin Free) Darbepoetin A!fa-Po[ysorbate 80 Solo lnj 40 MCG/0.4Ml 18.00% Blood Products/ Modifiers/Volume Expanders 8240101510E560 Aranesp (Albumin Free} 18.00% B!ood Products/ Modifiers/Volume Expanders 8240101510E582 Aranesp {Albumin Free) Darbepoetin Alfa-Po!ysorbate 80 So!n lnj 100 MCG/0.SML Darbepoetin Alfa-Polysorbate 80 Soln lnj 200 MCG/0.4Ml 18.00% Blood Products/ Modifiers/Volume Expanders 85100028206430 BeneFIX Coagulation Factor 1X (Recombinant) For lnj Kit 500 Unit 21.00% Blood Products/ Modifiers/Volume Expanders 8240101510E543 Aranesp {Albumin Free) Darbepoetin Alfa-Potysorbate 80 Solo lnj 40 MCG/0.4Ml 18.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E560 Aranesp (Albumin Free} 18.00% Blood Products/ Modifiers/ Volume Expanders 82401015102070 Aranesp (Albumin Free) Darbepoetin A!fa-Polysorbate 80 Soln lnj 100 MCG/0.SML Darbepoetin Alfa-Polysorbate 80 Soln lnj 300 MCG/ML 18.00% Blood Products/ Modifiers/Volume Expanders 8240102000E545 Epogen Blood Products/ Modifiers/Volume Expanders 8240102000E575 Epogen Epoetln Alfa lnj 10000 Unit/ML Epoet!n Alfa lnj 40000 Unit/Ml 18.00%18.00% Blood Products/ Modifiers/Volume Expanders Blood Products/ Modifiers/Volume Expanders 8240152000E525 Neupogen 82401015102010 Aranesp (Albumin Free) Fi1grastim lnj 300 MCG/MLDarbepoetin Alfa-Polysorbate 80 Soln lnj 25 MCG/Ml 18.00%18.1)0% Blood Products/ Modifiers/Volume Expanders 8240101510ES52 Aranesp (Album!n Free) Darbepoetln Alfa-Polysorbate 80 Soln lnj 60 MCG/0.3Ml 18.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E558 Aranesp (Albumin Free) Darbepoetin Alfa-Po!ysorbate 80 Soln lnj 200 MCG/Ml 18.00% Blood Products/ Modifiers/Volume Expanders 82401015102080 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80Sain lnj 500 MCG/Ml 18.00% Blood Products/ Modifiers/ Volume Expanders 8240102000E545 Epogen 18.00% Blood Products/ Modifiers/ Volume Expanders 8240104010E520 Mircera Epoetin Alfa lnj 10000 Unit/MLMethoxy Polyethylene Glycol-Epoetln Beta lnj 75 MCG/0.3Ml 18.00% Blood Products/ Modifiers/ Volume Expanders 8240152000E550 Neupogen Filgrastim lnj 480 MCG/0.SML (600 MCG/ML) 18.00% Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/Volume Expanders 85100028352130 ldelvion85100028402150 Alprollx Coagulation Factor IX (Recomb) {rlX-FP} For lnj 1000 Unit Coagulation Factor IX (Recomb} {rFIXFc) For lnj 4000 Unit 18.00%18.00% Blood Products/ Modifiers/Volume Expanders Blood Products/ Modifiers/Volume Expanders 8240104010E525 Mircera82401015102020 Aranesp (Albumin Free} Methoxy Polyethylene G!ycol-Epoetln Beta lnJ 100 MCG/0.3ML Darbepoetin Alfa-Polysorbate 80 So!n lnj 40 MCG/ML 18.00%18.00% Blood Products/ Modifiers/ Volume Expanders 82401015102040 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Sain lnj 100 MCG/ML Blood Products/ Modifiers/Volume Expanders 8240101510E558 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80 Solo lnj 200 MCG/ML 18.00%18.00% Blood Products/ Modifiers/Volume Expanders Blood _Products/ Modifiers/Volume Expanders 85100028206420 BeneFIX8240101510E556 Aranesp {Albumin Free) Coagulation Factor IX {Recombinant) For In] Kit 250 Unit Darbepoetin Alfa-Polysorbate 80 Soln lnj 60 MCG/ML c-·-, .,_, 21.00%18.00% Blood Products/ Modifiers/Volume Expanders 82401015102050 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 150 MCG/0.75Ml ....,\ :. ""TC:1'/.,......"-- 18.0<Y';,£ Blood Products/ Modifiers/ Volume Expanders 8240101510E588 Aranesp (Albumin Free} Darbepoetln Alfa-Polysorbate 80 So[n lnj 300 MCG/0.6Ml ,<.._....fP.. "'-·· 'YI 18.00% Blood Products/ Modifiers/ Volume Expanders 8240102000E545 Epogen Epoetfn Alfa lnj 10000 Unit/Ml -:, I; " :, 18.00% B!ood Products/ Modifiers/Volume Expanders 8240102000E575 Epogen Epoetin Alfa lnj 40000 Unit/Ml ' vuntfato Nli......A- - i 18.00% I _I 9 r; , J 5 2 q ,- '·• (fl• -- - - '--- ?"!J ' ' ••(.,\(,".), -= V ·v·- SP·,, Os DF 01'· >)._,_,,, ••

Blood Products/ Modifiers/ Volume Expanders 8240101510E528 Aranesp {Albumin Free} Darbepoet!nAlfa Polysorbate 80 Soln lnj 25 MCG/0.42ML 18.00% Blood Products/ Modifiers/Volume Expanders 82401015102040 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 100 MCG/ML 18.00% Blood Products/ Modifiers/Volume Expanders 8240101510E558 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 200 MCG/ML 18.W/4 Blood Products/ Modifiers/ Volume Expanders 8240102000E510 Epogen Epoetin Alfa lnj 2000 Unit/Ml 18.00% B!ood Products/ Modifiers/Volume Expanders 8240102000E545 Epogen Epoet!n Alfa lnj 10000 Unit/Ml 18.00% Blood Products/ Modifiers/Volume Expanders 8240104010E525 Mircera Methoxy Polyethylene Glycol-Epoetin Beta lnj 100 MCG/0.3ML 18J)O% Blood Products/ Modifiers/Volume Expanders 85100028352140 ldelvion Coagulation Factor IX (Recomb) {rlX-FP) For lnj 2000 Unit 18.W/4 Blood Products/ Modifiers/ Volume Expanders 85100015106430 Wilate Antihemophlltc FactorMVF {Human} For lnj S00-500 Unit Kit 18.00% Blood Products/ Modifiers/ Volume Expanders 85100010402140 Adynovate Antihemophll!c Factor Re.comb Pegylated For lnj 1000 Unit 18.00% Blood Products/ Modifiers/Volume Expanders 8240157000£520 Neulasta Pegfilgrastim lnj 6 MG/0.6ML 18.00% Blood Products/ Modifiers/ Volume Expanders 82401015102070 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 300 MCG/ML 18.00% Blood Products/ Modifiers/ Volume Expanders 8240104010E520 Mlrcera Methoxy Polyethyfene Glycol-Epoetin Beta lnj 75 MCG/0.3Ml 18.00% Blood Products/ Modifiers/Volume Expanders 85100028206450 BeneFIX Coagulation Factor IX {Recombinant) For lnj Kit 2000 Unit 21.00% Blood Products/ Modifiers/Volume Expanders 85100010402150 Adynovate AntihemophiHc Factor Recomb Pegy!ated For lnj 2000 Unit 18.00% Blood Products/ Modifiers/ Volume Expanders 82401015102010 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnJ 25 MCG/Ml 18.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E556 Aranesp (Albumin Free) Darbepoetln Alfa-Polysorbate 80 Soln lnj 60 MCG/ML 18.00% Blood Products/ Modifiers/Volume Expanders 82401015102050 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80 So!n lnj 150 MCG/0.75Ml 18.00% Blood Products/ Modifiers/Volume Expanders 85100010402120 Adynovate Antihemophllic Factor Recomb Pegy!ated For lnj 250 Unit 18.00% Blood Products/ Modifiers/ Volume Expanders 85100031002120 Coagadex Coagulation FactorX {Human) For lnj 250 Unit 18.00% Blood Products/ Modifiers/ Volume Expanders 8240102000E545 Epogen Epoetin Alfa lnj 10000 Unit/Ml 18.00% Blood Products/ Modifiers/Volume Expanders 8240152000E545 Neupogen Filgrastim lnj 300 MCG/0.5Ml {600 MCG/Ml) 18.00% Blood Products/ Modifiers/Volume Expanders 8240102000E575 Epogen Epoetin Alfa lnj 40000 Unit/ML 18.00% Blood Products/ Modifiers/ Volume Expanders 85100028206460 BeneFIX Coagulation Factor IX (Recombinant) For lnj Kit 3000 Unit 21.00% Blood Products/ Modifiers/Volume Expanders 82401015102020 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 40 MCG/ML 18.00% Bloo<I Products/ Modifiers/Volume Expanders 82401015102040 Aranesp (Albumin Free) Darbepoetln Affa-Polysorbate 80 Soln lnj 100 MCG/ML 18.00% Blood Products/ Modifiers/Volume Expanders 8240101510E558 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 200 MCG/Ml 18.00% Blood Products/ Modifiers/Volume Expanders 8240102000ES20 Epogen Epoetin Alfa lnj 4000 Unit/ML 18.00% Blood_ Products/ Modifiers/ Volume Expanders 8240102000E575 Epogen Epoetin Alfa lnj 40000 Unit/Ml 18.00% Blood Products/ Modifiers/ Volume Expanders 8240157000E520 Neulasta Pegfilgrastim lnj 6 MG/0.6Ml 18.00% B!ood Products/ Modifiers/Volume Expanders 85100028352110 ldelvion Coagulation Factor IX (Recomb) {rlX·FP) For lnj 250 Unit 18.00% Blood Products/ Modifiers/Volume Expanders 85100010402145 Adynovate Antihemophil[c Factor Recomb Pegylated For lnj 1500 Unit 18.00% Blood Products/ Modifiers/Volume E>tpanders 8240101510E528 Aranesp {Albumin Free) Darbepoetln Alfa-Polysorbate 80 So!n lnj 25 MCG/0.42ML 18.00% Blood Products/ Modlflers/Volume Expanders 8240101510E552 Aranesp {Albumin Free) Darbepoetln Alfa-Polysorbate 80 So!n lnj 60 MCG/0.3ML 18.00% Blood Products/ Modifiers/Volume Expanders 8240101510E575 Aranesp {Album!n Free) Darbepoetfn Alfa-Polysorbate 80 Sein lnj 150 MCG/0.3Ml 18.00% Blood Products/ Modifiers/ Volume Expanders 82401015102020 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 40 MCG/ML 18.00% Blood Products/ Modifiers/ Volume Expanders 82401015102040 Aranesp {Albumin Free) Darbepoetln Alfa-Polysorbate80 Soln lnj 100 MCG/ML 18.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E582 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 200 MCG/0.4ML 18.00% B!ood Products/ Modifiers/Volume Expanders 8240102000ES45 Epogen Epoetin Alfa lnj 10000 Unit/Ml 18.00% Blood Products/ Modifiers/ Volume Expanders 8240102000E575 Epogen Epoetin Alfa lnj 40000 Unit/Ml 18.00% Blood Products/ Modifiers/ Volume Expanders 8240157000E520 Neulasta Pegfilgrastim lnj 6 MG/0.6Ml 18.00% Blood Products/Modifiers/Volume Expanders 83334030002120 lprivask Des!rudin For lnj 15 MG 18.00% Blood Products/ Modifiers/ Volume Expanders 85100028352120 ldetvion Coagulation Factor IX {Recomb) {rlX-FP) For lnj 500 Unit 18.00% Blood Products/ Modifiers/ Volume Expanders 8240152000E525 Neupogen Filgrastim lnJ 300 MCG/Ml 18.00% Blood Products/ Modifiers/Volume Expanders 8240101510E588 Aranesp (Albumin Free) Darbepoetln Alfa-Polysorbate 80 Soln lnj 300 MCG/0.6Ml 18.00% Blood Products/ Modifiers/Volume Expanders 8240104010E51S Mircera Methoxy Polyethylene Glycol-Epoetin Beta lnj 50 MCG/0.3Ml /" ,, • .,-..Tl=> A...........,.r...,."-., 18.00% Blood Products/ Modifiers/Volume Expanders 8240102000£520 Epogen Epoetin Alfa lnj 4000 Unit/ML , _t ,~ 18.00% Blood Products/ Modifiers/Volume Expanders 8240152000E550 Neupogen Fi!grastim lnj 480 MCG/0.8ML(600 MCG/Ml) , E 4" '-.', 18.00% Blood Products/ Modifiers/Volume Expanders 85100028206440 BeneFIX Coagulation Factor JX {Recombinant) For lnj Kit 1000 Unit V N ,a I 21.00% Blood Products/ Modifiers/Volume Expanders 82401015102020 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Sein lnj 40MCG/Ml :v -.,uaro NU1n{:)_R- ' 18.00% , ,, J ,, (j (Jl' U/j2 \i\ fi <J ,, () v,""' · •=,.,,/•. .,>/5 '"'' t N,,, O.SDE3/,., --- ,9-'

Blood Products/ Modifiers/Volume Expanders Blood Products/ Modifiers/Volume Expanders 82401015102040 Aranesp {Albumin Free) 8240101510E558 Aranesp {Albumin Free) Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/ Volume Expanders 8240104010E545 Mlrcera85100010402135 Adynovate Darbepoet!n Alfa-Polysorbate 80 Soln lnj 100 MCG/ML Darbepoetin Alfa-Polysorbate 80 Soln lnj 200 MCG/ML Methoxy Polyethylene Glycol-Epoetin Beta lnj 200 MCG/0.3ML Antlhemophilic Factor Recomb Pegylated For lnj 750 Unit 18.00%18.00% 18.00%18.00% Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/Volume Expanders 84100040002025 Cyklokapron 8240102000E510 Epogen82401015102080 Aranesp (Albumin Free) Blood Products/ Modifiers/ Volume Expanders Bone Density Regulators 8240104010E545 Mircera30044530002020 Prolia TranexamicAdd IVSo!n 1000 MG/10ML (100 MG/ML) Epoetin Alfa lnj 2000 Unit/MLDarbepoetin Alfa-Polysorbate 80 Soln lnj 500 MCG/ML Bone Density Regulators Bone Density Regulators 3004405510E140 Natpara3004405510E110 Natpara Methoxy Polyethylene G[ycol-Epoetin Beta lnj 200 MCG/0.3ML Denosumab lnj 60 MG/ML Bone Density Regulators 30044070002020 Forteo Parathyroid Hormone (Recombinant) For lnj Cartridge 100 MCG Parathyroid Hormone (Recombinant) For lnj Cartridge 25 MCG Teriparatide {Recombinant) lnj 600 MCG/2.4ML 18.00%18.00%18.00¾ 18.00%18.00% 18.00%18.00% 18.00% Bone Density Regulators Bone Density Regulators 30044530002030 Xgeva Denosumab lnj 120 MG/1.7ML 18.00% 3004405510E120 Natpara Bone Density Regulators Cardiovascular Agents 3004405510E130 Natpara37100020000305 Keveyis Parathyroid Hormone (Recombinant) For lnj Cartridge 50 MCG CASTLEMAN DISEASE 99473080002120 Sylvant Parathyroid Hormone {Recombinant) For tnj Cartridge 75 MCG D!ch!orphenamfde Tab 50 MG Siltuximab For IV Infusion 100 MG 18.00% 18.00%18.00% 18.00% CASTLEMAN DISEASE 18.00% Central Nervous System Agents 18.00% Central Nervous System Agents Central Nervous System Agents Central Nervous System Agents central Nervous System Agents Central Nervous System Agents 18.00% 18.00% 18.00% 18.00% 18.00% Central Nervous System Agents Central Nervous System Agents 99473080002140 Sylvant Siltuximab For IV Infusion 400 MG6240306045DS60 Rebif Rebldose Titration Interferon Beta-la lnj 6 X 8.8 MCG/0.2ML & 6 X 22 MCG/0.SML 6240306045E540 Rebif Interferon Beta-la lnj 44 MCG/0.5ML{24MU/ML) {88 MCG/ML)6240306045D560 Reblf Rebidose litratlon Interferon Beta-la lnj 6X 8.8 MCG/0.2:ML & 6 X 22 MCG/0.5ML 74400020202140 Xeomin tncobotu!tnumtoxinA For IM lnj 200 Unit6240306045E540 Reblf Interferon Beta-la lnj 44 MCG/0.5ML (24MU/ML) (88 MCG/ML)6240306045D520 Reblf Rebldose Interferon Beta-la lnj 22 MCG/0.5ML {12MU/ML) (44 MCG/ML) 6240306045D520 Reblf Rebidose Interferon Beta-la lnj 22 MCG/0.5Ml (12MU/Ml) (44MCG/ML) 6240306045DS60 Reblf Rebidose Titration Interferon Beta-la lnj 6 X 8.8 MCG/0.2Ml & 6 X 22 MCG/0.SML 18.00% 18.00% Central Nervous System Agents 624030604SD520 Reblf Rebidose Central Nervous System Agents 6240306045F530 Avonex Pen Interferon Beta-la lnj 22 MCG/0.5ML(12MU/ML) (44 MCG/ML) Interferon Beta-la IM lnj Klt30 MCG/0.5ML 18.00%18.00% Central Nervous System Agents Central Nervous System Agents Central Nervous System Agents Central Nervous System Agents Central Nervous System Agents Central Nervous System Agents 62609902300120 Nuedexta Dextromethorphan HBr-Quinidine Sulfate Cap 20-10 MG 6240306045FS30 Avonex Pen 624030604SES40 Rebif Interferon Beta-la IM lnj Kit 30 MCG/0.SMLInterferon Beta-la lnJ 44 MCG/0.SML {24MU/Ml) (88 MCG/ML) 6240306045DS20 Rebif Rebidose 6240306045F530 Avonex Pen Interferon Beta-la lnj 22 MCG/0.5Ml {12MU/ML) (44 MCG/ML) Interferon Beta-la lM lnj Kit 30 MCG/0.SML 18.00% 18.00%18.00% 18.00%18.00% CMV Agents 6240306045E540 Rebif Interferon Beta-la lnj 44 MCG/0.SML {24MU/ML) (88 MCG/ML) 12200010002020 Vistide Cidofovir IV lnj 75 MG/ML 18.00% 18.00% CMVAgents 12200020102020 FoscarnetSodium FoscarnetSodium lnj 24 MG/ML 18.00% CMV Agents CMV Agents 12200066102120 Valcyte 12200066100320 Valcyte Valganc!clovir HCl For Soln SO MG/ML {Base Equiv} Valganciclovir HCI Tab 450 MG (Base Equivalent) 18.00%18.00% CMV Agents 12200030102110 Cytovene Gandc!ovlrSodfum For lnJ 500 MG 60.00% CONGESTIVE HEART FAILURE CORTICOSTEROIDS 401800S0002120 Natrecor Neslritlde For Jnj 1.5 MG22100020202011 Dexamethasone Sod Pho Dexamethasone Sod Phosphate Preservative Free lnj 10 MG/ML 18.00%18.00% CORTICOSTEROlDS CORTICOSTEROlDS 18.00% 18.00% CORTICOSTEROIDS CORTICOSTEROIDS CORTICOSTEROIDS CORTICOSTEROIDS CORTICOSTEROIDS CORTICOSTEROIDS 22100030202115 Solu-MEDROL Methylprednlsolone Sodium Succlnate For lnj 500 MG 22100020002900 Dexamethasone Dexamethasone Powder22100030202105 Solu-MEDROL Methylprednisolone Sodium Succlnate For lnj 40 MG 22100020001320 Dexamethasone lntensol Dexamethasone Cone 1 MG/Ml22100025402161 Solu-CORTEF Hydrocortisone SodiumSuccinate PF For lnj 500 MG 22100050101810 Kenalog Triamcinolone Acetonlde lnj Susp 40 MG/ML22100020202900 Dexamethasone Sodium Dexamethasone Sodium Phosphate Powder 22100030202120 5o!u-MEDROL Methylpredn\solone Sodium Succinate For lnj 1000 MG ' • ' Contrat.... •··1 18.00% 18.00%18.00% 18.00%18.00%18.00%

, CORTICOSTEROIDS 22100020002005 Dexamethasone Oexamethasone Soln 0.S MG/5ML CORTICOSTEROIDS 22100025402165 Solu-CORTEF Hydrocortisone Sodium Sucdnate PF For lnj 1000 MG 18.00% CORTICOSTEROIDS 22100020102900 Dexamethasone Acetate Dexamethasone Acetate Powder 18.00% CORTICOSTEROIDS 22100030202110 Solu-MEDROL Methylprednisolone Sodium Succinate For lnj 125 MG 18.00% Corticosteroids 22100017001830 Emf!aza DeflazacortSusp 22.75 MG/ML 18.00% CORTICOSTEROIDS 22100020000325 Dexamethasone Dexamethasone Tab 1 MG 18.00%18.00% CORTICOSTEROIDS 22100025402150 Solu-CORTEF Hydrocortisone Sodium Succinate PF For lnj 100 MG 18.00'.i CORTICOSTEROIDS 22100030202130 Sofu-MEDROl Methylprednisolone Sodium Succinate For lnj 2000 MG Corticosteroids 22100017000340 Emflaza DeflazacortTab 6 MG 18.00%18.00% Corticosteroids 22100017000360 Emflaza Deflazacort Tab 30 MG Corticosteroids 22100017000365 Emflaza DeflazacortTab 36 MG 18.00%18.00% CORTICOSTEROIDS 22100020000335 Dexamethasone Dexamethasone Tab 2MG 18.00% CORTICOSTEROIDS 22100025402155 So!u-CORTEF Hydrocortlsone Sodium Sucdnate PF For lnj 250 MG 18.00% CORTICOSTEROIDS 22100050101805 Kena!og Triamcinolone Acetonide lnj Susp 10 MG/ML 18.00% Corticosteroids 22100017000350 Emflaza DeflazacortTab 18 MG 18.00% CVSTIC FIBROSIS AGENTS 07000070000120 Tobi Podhaler Tobramydn lnhal Cap 28 MG 18.00% CVSTIC FIBROSIS AGENTS 45302030003030 Kalydeco lvacaftor Packet 75 MG 18.00% CYSTIC FIBROSIS AGENTS 07000070002530 Bethkis Tobramycin Nebu So1n 300 MG/4Ml 18.00% CYSTIC FIBROSIS AGENTS 45302030000320 Kalydeco lvacaftor Tab 150 MG 18.00% CYSTIC FIBROSlS AGENTS 45304020002010 Pulmozyme Dornase Alfa lnhal Soln 1 MG/Ml 18.00% CVSTIC FIBROSlS AGENTS 07000070002520 Kitabis Pak Tobramycin Nebu Soln 300 MG/SML 41.75% CYSTIC FIBROSIS AGENTS 45302030003020 Ka!ydeco lvacaftor Packet 50 MG 18.00% CystlnoslsAgents 56400030106530 Procysbi Cysteamlne Bitartrate Cap Delayed Release 75 MG (Base Equiv) 18.00% Cystinosis Agents 56400030100140 Cystagon Cysteamine Bltartrate Cap 150 MG 18.00% Cystinosls Agents 56400030106520 Procysbi Cy:steamine Bitartrate Cap Delayed Release 25 MG (Base Equiv) 18.00% Cystinosis Agents 56400030100120 Cystagon Cysteamine Bitartrate cap SO MG 18.00% DERMATOLOGICALS 90890020002110 Botox Cosmetic OnabotuHnumtoxinA {Cosmetic) For lnj 50 Unit 18.00% DERMATOLOG!CALS 90890020002120 Botox Cosmetic OnabotulinumtoxinA {Cosmetic) For lnj 100 Unit 18.00% DERMATOLOGICALS 90890018002120 Dysport {Glabellar lines) AbobotulinumtoxinA (Glabel!ar Lines) For lnj 300 Unit 18.00% DERMATOLOG!CALS 90550085103400 Kena!og Triamcinolone Acetonide Aerosol Soln 18.00% DIAGNOSTIC PRODUCTS 94200037002105 Cortrosyn Cosyntropln For lnj 0.25 MG 18.00% DIAGNOSTIC PRODUCTS 94200090102120 Thyrogen Thyrotropin Alfa For lnj 1.1 MG 18.00% Digestive Enzymes S1200024006760 Creon Pancre11pase jllp-Prot-Amyl) DR Cap 24000-76000-120000 Unit 18.00% Digestive Enzymes 51200024006750 Pancreaze Pancrellpase (Up-Prot-Amyl) DR Cap 16800·40000-70000 Un!t 18.00% Digestive Enz.ymes 51200024006705 Creon Pancrel!pase jlip-Prot-Amyl) DR Cap 3000-9500-15000Unit 18.00% Digestive Enzymes 51200024006780 Creon Pancrelipase {Up-Prot-Amyl) DR Cap 36000-114000--180000 Unit 18.00% Digestive Enzymes 51200024006754 Pancreaze Pancrelipase (Up-Prot-Amyl} DR Cap 21000-37000-61000 Unit 18.00% Digestive Enzymes 51200024006710 Pancreaze Pancrelipase (Up-Prot-Amyl) DR Cap 4200-10000-17500 Unit 18.00% Digestive Enzymes 51200060002030 Sucra!d Sacros!dase Soln 8500 Unit/Ml 18.00% Digestive Enzymes 51200024006734 Pancreaze Pancrelipase {llp-Prot-Amyl) DR Cap 10500-25000-43750 Unit 18.00% Digestive Enzymes 51200024006740 Creon Pancre!Jpase (Lip-Prot-Amyl) DR Cap 12000·38000-60000 Unit 18.00% Digestive Enzymes 51200024006720 Creon Pancre!ipase (Llp--Prot-Amyl) DR Cap 6000-19000-30000 Unit 18.00% Direct Muscle Relaxants 75200010101920 Ryanodex Dantrolene Sodium For IV Susp 250 MG 18.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30080050106440 Lupron Depot-Ped leupro!ide Acetate For lnj Pediatrfc Kit 15 MG ... 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170070106420 SandoSTATIN LAR Depot OctreotideAcetate For IM lnj Kit 20 MG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30180060002120 Somavert Pegvisomant For lnJ 10 MG (As Protein) ..r"..,\-\\':> -"'n........... 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30454060000330 Samsca To!vaptan Tab 30 MG / ,,,,t-. #"- v, 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30905070000120 Zemplar Paricalcltol cap 2 MCG I' rr' I. -s,,v.i 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30906550002020 Atdurazyme Laronidase Soln For IV Infusion 2.9 MG/SMl ' : V0ntratn ,., • v_ 18.00% ... ·-•O,1 fl , {-·} r . 111 l, "' f \ \(,)' ¾,..-- ' ) v \ ,.,.,. 1-V r, N. ¼. S DE5 '• -.,.,. -;- ·-

,,,,,,.= ENDOCRINE AND METABOLIC AGENTS- MISC. 30908565107320 Kuvan Sapropterin Dihydroch!oride Soluble Tab 100 MG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30908060002950 Buphenyl Sodium Phenylbutyrate Oral Powder 3 GM/Teaspoonful 24.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30080050106420 lupron Depot-Ped leupro!ideAcetate for lnj Pediatric Kit 7.5 MG 18.00¾ ENDOCRINE AND METABOLIC AGENTS- MISC. 30170050102040 Somatuline Depot Lanreotlde Acetate Extended Release In] 120 MG/0.SML 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170075401930 Signifor LAR Pasireotide Pamoate For IM ER Susp 40 MG {Base Equiv) 18.00-% ENDOCRINE AND METABOLIC AGENTS- MISC. 30904520002920 Cystadane *Betaine Powder For Oral Solution*"'* 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30905225100340 Sensipar Cinacalcet HCI Tab 90 MG {Base Equiv) 18.00¾ ENDOCRINE AND METABOLIC AGENTS- MISC. 30908230000320 Carbaglu CarglumfcAcid Tab 200 MG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30090040102020 GanirelixAcetate Ganlrellx Acetate lnj 250 MCG/0.SMl 18.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30170050102025 Somatuline Depot lanreotlde Acetate Extended Release lnj 60 MG/0.2Ml 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170075202040 Signifor Pasireotide Diaspartate lnj 0.9 MG/Ml {Base Equiv) 18.00% ENDOCRINE ANO METABOLIC AGENTS- MISC. 30180060002160 Somavert Pegvisomant For lnj 30 MG{As Protein) 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30904045000120 Orfadin Nftlsinone Cap 5 MG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30905225100320 Sensipar Cinacalcet HCI Tab 30 MG (Base Equiv) 18.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30908030000920 Ravicti Glycerol Phenylbutyrate liquid1,1GM/ML 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC, 30080050156420 lupron Depot-Ped Leuprolide Acetate {3 Month) For lnj Pediatric Kit 11.25 MG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30150085102120 Egrifta Tesamorelln Acetate For lnj 1 MG (Base Equiv) 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170070106430 SandoSTATIN lAR Depot Octreotide Acetate For IM lnj Kit 30 MG 18.00¾ ENDOCRINE AND METABOLIC AGENTS- MISC. 30180060002130 Somavert Pegvisomant For lnj 15 MG{As Protein} 18.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30903610102110 Fabrazyme Agalsidase beta For IV Soln 5 MG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30905070000140 Zemplar Parlca!citol Cap 4 MCG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30906850002020 Elaprase ldursulfase Sain for IV Infusion 6 MG/3ML (2 MG/Ml) 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30080045106450 Supprel!n LA Histrelin Acetate {CPP) Implant Kit 50 MG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170050102030 Somatuline Depot Lanreotide Acetate Extended Release lnj 90 MG/0.3Ml 18.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30170075401920 Signifor LAR Pasireotide Pamoate For IM ER Susp 20 MG (Base Equiv) 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30904045000130 Orfadin Nitisinone Cap 10 MG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30905225100330 Sensipar Cinacalcet HCITab 60 MG (Base Equiv) 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30908060000320 Buphenyl Sodium Phenylbutyrate Tab SOO MG 18.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30080050106430 Lupron Depot-Ped leuprolideAcetate For lnj Pediatric Kit 11.25 MG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170070106410 SandoSTATIN LAR Depot Octreotide Acetate For IM lnj Kit 10 MG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170075401940 Signifor LAR Pasireotide Pamoate For IM ER Susp 60 MG {Base Equiv) 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30454060000320 Samsca To!vaptan Tab 15 MG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30905070000110 Zemp!ar Parlcalcitol Cap 1 MCG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30906050002120 Myalept Metreleptln For Subcutaneous fnj 11.3 MG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30908S65103020 Kuvan Sapropterln DlhydrochtoridePowder Packet 100 MG 18.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30170070102030 Octreotlde Acetate Octreotide Acetate lnj 1000 MCG/ML (1 MG/ML) 52.25% ENDOCRINE AND METABOLIC AGENTS- MISC. 30080050156440 Lupron Depot-Ped leuprolideAcetate (3 Month) For lnj Pediatric Kit30 MG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30150085102130 Egrifta Tesamorelfn Acetate For lnj 2MG {Base Equiv) 18.00% ENDOCRINE AND METABOUCAGENTS- MISC. 30170075202020 Signifor Pasireotide Diaspartate lnj 0.3 MG/Ml(Base Equiv) 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30180060002140 Somavert Pegvisomant For In] 20 MG (As Protein) 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC, 30903610102120 Fabrazyme Agals!dase beta For IVSo!n 35 MG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30905070002010 Zemplar Paricalcitol IV So!n 2 MCG/Ml 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30907030052020 Vimizim Elosulfase Alfa Soln For IV lnfuslon S MG/SML (1 MG/Ml) 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170070102005 Octreotide Acetate Octreotide Acetate lnj 50 MCG/ML (0.05 MG/Ml) ,.. ·.isTR--" . 52.25% ENDOCRINE AND METABOLIC AGENTS- MISC. 30907715002120 Lumizyme Alglucosidase Alfa For IV Soln 50 MG 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170070102015 Octreotide Acetate Octreotide Acetate lnj 200 MCG/ML (0.2 MG/ML) ,<",,._J·:'-" -....Ir-."\\_ 52.25% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170070102020 Octreotide Acetate Octreotide Acetate lnj 500 MCG/ML(0.5 MG/ML) 1,.,,/f - ,,.,, 52.25% ENDOCRINE AND METABOLIC AGENTS- MISC. 30080055102020 Synarel Nafarelfn Acetate Nasal Soln 2 MG/ML ./ 'I I ('"\ 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30160045002020 lncrelex Mecasermin lnj 40 MG/4ML (10 MG/ML) ., ..,JfV(JmA/'A ' 18.00% 9 . (i ' ' (J\ ·\ Ii 51; -./ .d \Q(,,'-rii!JY - ,:,, '°'• -~· V •. -, ¾I"'·• 'Os OS sf', •, - ..

•-"-- ENDOCRINE AND METABOLIC AGENTS- MISC. 30170075202030 Signffor Pasireotlde Diaspartate lnj 0.6 MG/Ml {Base Equiv) 18.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30180060002150 Somavert Pegvisomant For lnj 25 MG {As Protein) 18.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30904045000110 Orfadin Nitisinone Cap 2 MG 18.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30905070002020 Zemplar Paricalcltol IV Soln 5 MCG/Ml 18.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30907535002020 Naglazyme Galsulfase Solo For IV Infusion 1 MG/Ml 18.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30170070102010 Octreotide Acetate Octreotide Acetate In] 100 MCG/Ml (0.1MG/Ml) 52.25% ENZVME REPLACEMENT 20000050002025 Adagen Pegademase Bovine lnj 250 Unit/Ml 18.00"/4 Enzyme Replacements/Modifiers 30903875203020 Xur!den Urid!ne Triacetate Oral Granules Packet 2 GM 18.00% Enzyme Replacements/Modifiers 30905610002040 Strensiq Asfotase Alfa Subcutaneous lnj 40 MG/Ml 18.00% Enzyme Replacements/Modifiers 30906360002020 Kanuma Sebelipase Alfa IV Soln 20 MG/10Ml {2 MG/ML) 18.00% Enzyme Replacements/Modifiers 30905610002050 Strens!q AsfotaseA!fa Subcutaneous lnj 80 MG/0.8ML 18.00% Enzyme Replacements/Modifiers 30905610002020 Strensiq AsfotaseAffa Subcutaneous lnj 18 MG/0.45Ml 1800% Enzyme Replacements/Modifiers 30905610002030 Strensiq Asfotase Alfa Subcutaneous lnj 28 MG/0.7Ml 18.00% Enzymes 99350035002120 Xiaflex Collagenase C!ostridium Histo!yticum For lnj 0.9 MG 18.00% Enzymes 99350040102020 Hylenex Hya!uronidase Human lnj 150 Unit/Ml 18.00% Fertility Regulators 30062030052020 Gonal-f RFF Pen Follitrop!n Alfa lnj 300 Unlt/0.5Ml 18.00% fertility Regulators 30062030102030 Fo!llstimAQ Follitropin Beta lnj 600 Unit/0.72Ml 22.80% fertility Regulators 30062030102006 Folllstlm AQ Fol!itropin Beta lnj 150 Unit/0.SML 22.80% Fertllity Regulators 30062030052150 Gonal-f Follltropln Alfa For lnj 1050 Unit 18.00% Fertility Regulators 30062090102112 Bravelle Urofollitropin Purified For lnj 75 Unit 18.00% Fertility Regulators 30062030052040 Gonal·f RFF Pen Fo!litropln Alfa lnJ 900 Un!t/1.5Ml 18.00% Fertility Regulators 30062030102040 Fol!istfmAQ Follitropin Beta lnj 900 Unit/1.0SML 22.80¼ Fertility Regulators 30062030102003 FollistlmAQ Follitrop!n Beta lnj 75 Unlt/0.SML 22.80% Fertility Regulators 30062030102020 Fo!listimAQ FolHtropln Beta lnj 300 Unit/0.36Ml 22.80% Fertility Regulators 30062030052115 Gonal-f RFF Fol!Jtropin Alfa For lnj 75 Unit 18.00% Fertility Regulators 30062050002155 Repronex Menotropins For lnj 75 Unit 18,00% Fertility Regulators 30062030052140 Gonal-f Fo!litropln Alfa For lnj 450 Unit 18.00% Fert!lity Regulators 30062050002175 Menopur Menotropins For Subcutaneous lnJ 75 Unit 18.00% GASTROINTESTINAL AGENTS - MISC. 52300020112900 Metodopram!de HCI Mo Metoclopramlde HCl Monohydrate Powder 18.00% GASTROINTESTINAL AGENTS- MISC. 52700025000140 Cholbam Cholic Acid Cap 250 MG 18.00% GASTROINTESTINAL AGENTS- MISC. 52300020102900 Metoc!opramide HCI Metodopramide HCI Powder 18.00% GASTROINTESTINAL AGENTS- MISC. 52700025000120 Cholbam Ch olic Acid Cap SO MG 18.00% Genitourinary Agents 99200030000110 cuprimine Penicillamine Cap 250 MG 18.00% GENITOURINARY AGENTS - MISCELLANEOUS 56500010002010 Rlmso-50 Dimethyl Sulfoxlde Soln 50% 18.00% GOUT AGENTS 68000050002020 Krystexxa Pegloticase lnj 8 MG/Ml (For IV Infusion) 18.00% Growth Hormones 30100020002066 Norditropin FlexPro Somatropin lnj 30 MG/3Ml 18.00% Growth Hormones 30100020002140 Nutropin Somatropln For lnj 10 MG 18.00% Growth Hormones 30100020002178 Genotropin MiniQuick Somatropin For [nj 1.4 MG 18.(){)% Growth Hormones 30100020102130 Salzen Somatropin (Non-Refrigerated) For lnj 8.8 MG 18.00 Growth Hormones 30100020002050 Norditrop!n Somatropln tnJ 5 MG/1.5Ml 18.00% Growth Hormones 30100020002062 Nordltropin Somatropln lnj 15 MG/1.5Ml 18.00% Growth Hormones 30100020002132 Humatrope Somatropin For lnj 12 MG {36 Unit) 18.00% Growth Hormones 30100020002174 Genotropln MiniQuick Somatropin For lnj 1 MG 18.00% Growth Hormones 30100020102121 serostim Somatropin {Non-Refrigerated} For Subcutaneous lnj 5 MG 18.00 Growth Hormones 30100020002125 Humatfope Somatrop!n For lnJ 6 MG {18 Unit) . 18.00% Growth Hormones 30100020002170 Genotropin M!niQuick Somatropin For lnj 0.6 MG jlj)..o I ,.._ .................. 18.00% Growth Hormones 30100020102118 Serostim Somatropin {Non-Refrigerated) For Subcutaneous lnj 4 MG ,?'...P' --s --·1...." -" 18.00% Growth Hormones 30100020002118 Norditropin SOMATROPJN FOR lNJ 4 MG (12 UNIT) ()' /;-'. 18.00 Growth Hormones 30100020002150 Humatrope Somatropin For lnj 24 MG . I ·t•'- ' 18.00 ,P=·- t -f,, 9i"-"O(Q3Nume1ro j rn..,_ f.1 ·' 1,11 - (;\ ."" ,,Q - (,"' • - ,,_?-' ,>' --., . O& DE sf>· " ";,- - --

Growth Hormones 30100020002180 Genotropln M1n1Qulck Somatropln For tnj 1.6 MG Growth Hormones 30100020002015 Nutrop!n AQNuSpln 5 Somatropln lnj 5 MG/2Ml Growth Hormones 30100020002127 Norditropln SOMATROPIN FOR INJ 8 MG Growth Hormones 30100020002172 Genotropin MiniQuick Growth Hormones 30100020102120 Saizen Somatropin for lnj 0.8 MG Somatropin (Non-Refrigerated) for lnj 5 MG Growth Hormones 30100020102132 Serostlm Somatropin (Non-Refrigerated) For Subcutaneous lnj 8.8 MG Growth Hormones Growth Hormones 30100020002064 Nutropin AQNuSpin 20 30100020002134 Genotropin Somatropin lnj 20 MG/2Ml Somatropin For lnj 12 MG {13.8 MG overfill) Growth Hormones 30100020002176 Genotropln Mln!Qulck Growth Hormones Growth Hormones Growth Hormones Growth Hormones Growth Hormones Growth Hormones Grovlf:h Hormones Growth Hormones Growth Hormones Gro\'lf:h Hormones H-2 Antagonists H-2 Antagonists HEMATOLOGICALAGENTS- MISC. HEMATOLOGICAL AGENTS - MISC. HEMATOLOGICAL AGENTS- MISC. Hematopoletic Growth Factors Hematopoietic Growth Factors Hematopo!eticGrovlthFactors Hematopoietic Growth Factors Hematopoietlc Grovlth Factors Hematopoletic Growth Factors Hematopoietic Growth factors Hematopoietic Grovtth Factors Hematopoletic Growth Factors 30100020102125 Serostim30100020002121 Genotropin30100020002120 Humatrope30100020002166 Genotropin MiniQuick30100020002182 Genotropin MiniQuick30100020002056 Norditropin FlexPro30100020002020 Nutropin AQ30100020002123 Omnltrope30100020002168 Genotropin MiniQuick30100020002184 Genotropin MJnlQuick49200030112020 Famotidfne Premixed49200010002900 Cimetidine 85550060102120 Ceprotln85550060102140 Ceprotin85800050002020 Soliris82403060002120 Neumega82402050002025 leukine82405060002130 Nplate82405030100310 Promacta82401520002012 Neupogen82402050002120 leukine 8240152070E530 Granlx82405030100320 Promacta82401060102050 Dmontys Somatrop!n For lnj 1.2 MG Somalropin {Non-Refrigerated) For Subcutaneous lnj 6 MG Somatropin For Subcutaneous lnj 5 MGSomatropin For lnj 5 MG Somatropin For lnj 0.2 MG Somatropin For Jnj 1.8 MG Somatropin lnj 10 MG/1.SMLSomatropin lnj 10 MG/2Ml Somatropin For lnj 5.8 MG Somatropin For Jnj 0.4 MG Somatrop!n for lnJ 2 MGfamotfdine In NaCl 0.9% IV Soln 20 MG/SOMl Cimetidine PowderProtein C Concentrate (Human) For IVSoln 500 Unit Protein C Concentrate (Human) For IV Soln 1000 Unit Eculizumab IV Soln 10 MG/Ml {For Infusion) Oprelvekin for lnj 5 MGSargramostim lnj 500 MCG/Ml Romlp/ostim For lnj 500 MCGEltrombopag Olamine Tab 12.5 MG (Base Equfv)Fi1grastim lnj 480 MCG/1.6Ml (300 MCG/Ml) Sargramostim lyophi!ized for lnJ 250 MCGTbo-Fflgrastim Soln Prefllled Syringe 300 MCG/0.5Ml EltrombopagOlamine Tab 25 MG {Base Equiv) Peginesatlde Acetate Soln lnj 10 MG/Ml Hematopoletic Growth Factors 82405030100340 Promacta Hematopoletic Growth Factors 82401060102055 Omontys Eltrombopag Olamine Tab 75 MG (Base Equiv) Peginesatide Acetate So1n lnj 20 MG/2Ml Hematopoletic Gro\•lth Factors Hematopolet!cGrowth factors 82405060002120 Nplate 82401020002015 Epogen Romipfostim For lnj 250 MCG Epoetln Alfa lnj 3000 Unit/Ml Hematopoletic Growth Factors Hematopoietic Growth Factors Hematopoietic Growth Factors HEREDITARY ANGIOEOEMA HEREDITARY ANGIOEDEMA HEREDITARY ANGIOEDEMA HEREDITARY ANGIOEDEMA HEREDITARY ANGtOEOEMA Hormonal Agents, Suppressant (Pituitary) HYPNOTICS/SEDATIVES/SLEEP DISORDER AGENTS 82401020002050 Epogen8240152070E540 Granix82405030100330 Promacta85820040102020 f!razyr85840030002020 Kalbltor85802022006420 Berlnert85802022102130 Ruconest85802022002120 Cinryze Hormonal Agents, Stimu!ant/Replacement/Modifylni 30062022052220 Dvidrel 21404010101840 Depo•Provera60250070000130 Hetlioz Epoetfn Alfa lnj 20000 Unit/MlTbo-Fi!grastlm Sotn Prefilled Syringe 480 MCG/0.8Ml Eltrombopag Olamine Tab SO MG {Base Equiv) lcatibant Acetate lnj 30 MG/3Ml (Base Equivalent) Ecallantlde lnj 10 MG/MlCl Esterase Inhibitor (Human) for IV lnj Kit 500 UnitCl Esterase Inhibitor (Recombfnant) For IV lnj 2100 Unit Cl Esterase Inhibitor (Human) For IV lnj 500 Unit Choriogonadotropln Alfa 1nj 250 MCG/0.SMl Hormonal Agents, Stimulant/Rep!acement/Modifyini 30062020002140 Chorionfc Gonadotropin Chorlonic Gonadotropin For lnj 10000 Un!t Medroxyprogesterone Acetate IM Susp 400 MG/Ml Taslmelteon capsule 20 MG ------ 18.00% 18.00% 18.00% 18.00% 18.00¼ 18.00% 18.00% 18.00% 18.00% 18.00"18.00%18.00%18.00%18.00%18.00%18.00% 18.00%18.00% 18.00%18.00% 18.00%18.00¾18.00%18.00%18.00%18.00%18.00%18.00%18.00%18.00%18.00%18.00%18.00% 18.00% 18.00% 18.00% 18.00% \ . \ 18.00%18.00%18.00%18.00%18.00%18.00%18.00%18.00%18.00%18.00%18.00%18.00% t

IMMUNOGLOBULINS 19100020102046 Octagam Immune Globulin (Human) IV Sain 25 GM/500ML 24.25% IMMUNOGLOBULINS 19100020102125 CARIMUNE Immune Globulin {Human) IV For Soln 6 GM 25.00"70 IMMUNOGLOBULINS 19100020302080 Gammagard Immune Globulin {Human) IV or Subcutaneous Soln 30 GM/300ML 27.55% IMMUNOGLOBULINS 19100020102020 Flebogamma Immune Globulin (Human) IV Soln 0,5 GM/10Ml 18.00¾ IMMUNOGLOBUUNS 19100020102113 Gammagard S/D Immune Globulin (Human) IVFor So!n 0,5 GM 27.55% IMMUNOGlOBUUNS 19100020202058 Hizentra 20% Immune Globulin {Human) Subcutaneous In] 4 GM/20Ml 24.50% IMMUNOGLOBULINS 191000SOOOES40 RhoGAM Ultra-Filtered Pl Rho O Immune Globulin IM Sotn Pref Syr 1500 Unlt(300MCG) 18.00% IMMUNOGLOBULINS 19990002356450 Hyqvia lmmun Glob lnj 30 GM/300ML-Hyaluron lnj 2400 Unt/15 ML Kit 20.00% IMMUNOGLOBULINS 19100020102060 Gamunex Immune Globulin (Human) IVSoln 1 GM/10Ml 24.25% IMMUNOGLOBULINS 19100020102130 Gammagard 5/D Immune Globulin (Human) IV For So!n 10 GM 27.55% IMMUNOGLOBULINS 19100020302084 Gamunex-C Immune Globulfn (Human) IV or Subcutaneous So!n 40 GM/400ML 23.00¾ IMMUNOGLOBULINS 19100020102090 Privigen Immune Globu!fn (Human) IV Soln 40 GM/400ML 19.00% IMMUNOGLOBUUNS 19100020202050 Hizentra 20% Immune Globulin (Human) Subcutaneous lnj 1 GM/SML 24.50% IMMUNOGLOBULINS 19100050002060 WinRhoSDF Rho D Immune G!obufln (Human) lnj 1S00 Unlt/1.3ML 18.00% IMMUNOGLOBUUNS 19990002356430 Hyqvia lmmun G!ob lnJ 10GM/100ML-Hyaluron tnj 800 Unt/5 MLKit 20.00% IMMUNOGLOBULINS 1910000S002200 Cytogam Cytomegalovirus Immune Globulin (Human} IV lnj 18.00% IMMUNOGLOBULINS 19100020102112 GAMMAR-P 1.V. IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 1 GM 31.25% IMMUNOGLOBUUNS 191000202020S4 Hizentra 20% Immune Globulin {Human) Subcutaneous lnj 2 GM/lOML 24.50% IMMUNOGLOBULINS 1910005000206S WinRhoSDF Rho D Immune Globulin {Human) In] 15000 Unit/13Ml 18.00% IMMUNOGLOBULINS 19990002356440 Hyqvia lmmun Glob lnj 20 GM/200ML-Hyaluron lnj 1600 Unt/10 Ml Kit 20.()()% IMMUNOGLOBULINS 19100020102120 Gammagard S/0 Immune Globulin (Human) IV For Sofn 5 GM 27.55% IMMUNOGLOBULINS 19100020102034 Flebogamma Immune Globulin (Human) IV Soln 2.S GM/SOML 25.00% IMMUNOGLOBUUNS 19100020102068 Biv!gam Immune Globulin {Human) IVSo!n5 GM/SOML 24.25% IMMUNOGLOBULINS 19100020302068 Gammagard Immune Globulin (Human} IV or Subcutaneous Soln 5 GM/SOML 27.55% IMMUNOGLOBUUNS 19100020102064 Gamunex Immune Globulin (Human) IVSoln 2.5 GM/25ML 24.25% IMMUNOGLOBUUNS 19100020202020 Vivaglobin Immune Globulin (Human) Subcutaneous lnj 160 MG/Ml (16%) 23.75% IMMUNOGLOBULINS 19100050002055 WinRho SDF Rho D Immune Globulin (Human) lnj 5000 Unit/4.4Ml 18.00% IMMUNOGLOBULINS 19990002356425 Hyqv!a lmmun Glob lnj S GM/SOMl-Hya!uron lnj 400 Unt/2.5 ML Kit 20.00% IMMUNOGLOBULINS 19100020102030 Octagam Immune Globulin (Human) IV Soln 1 GM/20Ml 24.25% IMMUNOGLOBULINS 19100020102117 Qirimune NF Immune Globulin (Human) IV ForSoln 3 GM 25.00% IMMUNOGLOBULINS 19100020202065 Hizentra Immune Globulin (Human) Subcutaneous lnj 10 GM/SOML 24.50% IMMUNOGLOBULINS 1910005000E550 Rhophylac Rho D Immune Globulin Sol Pref Syr 1500 Unt/2Ml {300MCG/2Ml) 18.25% IMMUNOGLOBULINS 19100020102063 Octagam Immune Globulin (Human) IV Soln 2 GM/20ML 24.25% IMMUNOGLOBULINS 19100020102135 Carimune NF Immune Globulin {Human) IV For Sotn 12 GM 25.00% IMMUNOGLOBUUNS 191000S0002050 W!nRhoSDF Rho D Immune Globulin (Human} lnj 2500 Unit/2.2ML 18.00% lMMUNOGLOBULINS 19990002356420 Hyqvia lmmun Glob lnj 2.5 GM/25ML-Hyaluron lnj 200 Unt/1,25 Ml Kit 20.00% IMMUNOGLOBULINS 19100020002200 GamaSTAN S/D Immune Globulin (Human) lnj 23.75% IMMUNOGLOBULINS 19100020102044 Flebogamma DIF Immune Globulin {Human) IVSoln 20 GM/400ML 25.00% IMMUNOGLOBULINS 19100020302064 Gammagard Immune Globul!n {Human) IV or Subcutaneous Soln 2.5 GM/25ML 27.55% IMMUNOGLOBULINS 19100020102115 Gammagard S/D Immune Globulin {Human) lV For Soln 2.5 GM 27.55% IMMUNOGLOBULINS 19100020102205 GAMIMUNEN IMMUNE GLOBULIN (HUMAN) IV SOlN 5% 47.75% IMMUNOGLOBUUNS 1910CH)20302060 Gammagard Immune G!obulfn (Human} IV or Subcutaneous So!n 1 GM/10ML 27.55% IMMUNOGLOBUUNS 19100020102034 F!ebogamma Immune Globulin (Human) IV Soln 2.5 GM/SOML 25.00% IMMUNOGLOBUUNS 19100020102072 BivJgam Immune Globulin (Human) IV Soln 10 GM/100Ml 24.25% IMMUNOGLOBULINS 19100020302072 Gammagard Immune Globulin (Human) IV or Subcutaneous Soln 10 GM/lOOML ··-. 27.55% IMMUNOGLOBULINS 19100020102038 Flebogamma Immune Globulin {Human) IVSoln S GM/lOOML _ .,.-r·, , 51 1 V i_n, _ 25.00% IMMUNOGLOBULINSIMMUNOGLOBULINS 1910002010207219100020302072 BivigamGammagard Immune Globulin (Human) IV So!n 10 GM/100MLImmune Globulin (Human) IV or Subcutaneous Soln 10 GM/lOOML ,I ,.l•f ·z7 /-' .'()'<'.1 \ 24.25%27.55% IMMUNOGLOBULINS 19100020102068 Bivigam Immune Globulin (Human) IV Sain 5 GM/SOML •uu,,ro"t I) 24.25% ··- I.I (Jl ._91·. •.t ,2 ,j·j ----- \\c\,,... /..,(). C'y . ('l,)> - \'.- ' \s DE£-,•

fl\; IMMUNOGlOBUUNS 19100020302068 Gammagard Immune Globu!Jn {Human) IV or Subcutaneous Soln 5 GM/SOMl 27.55% IMMUNOGLOBULINS 19100020102042 Flebogamma 1lmrnune Globulin (Human) IV So!n 10 GM/200ML 25.00% 19100020102076 Ffebogarnrna Dlf Immune Globulln {Human) IV Soln 20 GM/200ML 24.25% IMMUNOGLOBULINSIMMUNOGLOBULINS 19100020302076 Garnmagard Immune Globulin (Human) IV or Subcutaneous Soln 20 GM/200Ml 27.55% IMMUNOGLOBULINS 19100020102042 Flebogamrna Immune Globulin {Human} !VSoln 10 GM/200ML 25.00¾ IMMUNOGLOBULINS 19100020302064 Gammagard Immune Globulin (Human) lVor Subcutaneous Sain 2.5 GM/25Ml 27.55% IMMUNOGLOBULINS 19100020102038 Flebogamma Immune Globulin (Human) IVSoln s GM/100Ml 25.00¾ lMMUNOGLOBULINS 19100020102076 Flebogamma DJF Immune Globulin (Human) IV Sain 20 GM/200ML 24.25% IMMUNOGlOBULINS 19100020302076 Gammagard Immune Globulin {Human) IV or Subcutaneous Sain 20 GM/200ML 27.55% lmmunological Agents 9025055400e520 Taltz lxeklwmab Subcutaneous Soln Prefilled Syringe 80 MG/Ml 18.00% lmrnuno!ogkal Agents 4460405S002120 Nucala Mepollzumab For lnj 100 MG 18.00% Immunological Agents 19200040002100 Antivenin Micrurus Fulvi1 Antivenin Micrurus Fulvius For IV Soln 18.00% Immunological Agents 99450060203030 Ve!tassa Patiromer Sorbltex Calcium For Susp Packet 16.8 GM (Base Eq) 18.00% Immunological Agents 52SOS040202120 lnflectra lnflixlmab--dyybFor IV lnj 100 MG 18.00% Immunological Agents 994S0060203040 Veltassa Patiromer Sorbitex Calcium For Susp Packet 25.2 GM (Base Eq) 18.00% lmmunologlcal Agents 66290030002120 Enbrel Etanercept For Subcutaneous lnj 25 MG 18.00% lmmuno!oglcal Agents 99450060203020 Veltassa Pat!romerSorbitex Calcium For Susp Packet8.4 GM {Base Eq) 18.00% lmmunosuppressive Agents 99402020000110 SandlMMUNE Cyc!osporine Cap 25 MG 18.00% lmmunosuppressive Agents 99402540102220 Atgam Lymphocyte Immune Globulin Anti-Thymocyte G lnj 50 MG/Ml(Eq) 18.00% lmmunosuppressive Agents 9940403S000325 Zortress Everollmus Tab 0.5 MG 18.00% lmmunosuppressive Agents 99404080000120 Prograf Tacro!imus Cap 5 MG 18.00% 11mmunosuppr essive Agents 99402020300150 Neoral Cydosporine Modified Cap 100 MG 18.00¾ lmmunosuppressive Agents 99403030300630 Myfortic Mycophenolate Sodium Tab DR 360 MG (MycophenolicAdd Equiv) 18.00% lmmunosuppress!ve Agents 99404080000105 Prograf Tacro!imus Cap 0.5 MG 18.00% lmmunosuppressive Agents 99402020000140 SandlMMUNE Cyc!osporine Cap 100 MG 18.00% lmmunosuppressive Agents 99403030100120 Cel!Cept Mycophenolate Mofetil Cap 250 MG 18.00% lmmunosuppressive Agents 9940403S000330 Zortress Everolimus Tab 0.75 MG 18.00% lmmunosuppresslve Agents 99404080002010 Prograf Tacro!imus lnj 5 MG/Ml 18.00% lmmunosuppressive Agents 99402020302020 Neoral Cyc!osporine Modified Oral Sain 100 MG/Ml 18.00% lmmunosuppressive Agents 99404035000320 Zortress Everollmus Tab 0.25 MG 18.00% lmmunosuppressive Agents 99404080000110 Prograf Tacrolimus Cap 1 MG 18.00% lmmunosuppressive Agents 99402020002005 SandlMMUNE Cyclosporine IV Soln 50 MG/ML 18.00% lmmunosuppressive Agents 99403030100330 Cel!Cept Mycopheno1ate Mofetil Tab 500 MG 18.00% lmmunosuppressive Agents 99404070000310 Rapamune Sirolimus Tab 0.5 MG 18.00% lmmunosuppressive Agents 99405015002110 5imulect Basiliximab For IV So!n 10 MG 18.00% lmmunosuppressive Agents 99402020300120 Neoral Cydosporine Modified Cap 25 MG 18.00% lmmunosuppressive Agents 99403030202120 Cel!Cept Intravenous Mycophenolate Mofetil HCI For IV Solo 500 MG {Base Equiv} 18.00% lmmunosuppressive Agents 99404070000330 Rapamune Sirolimus Tab 2 MG 18.00% lmmunosuppresslve Agents 99406010000305 lmuran Azathioprlne Tab SO MG 18.00% lmmunosuppressive Agents 99402020300130 CydoSPORINE Modified Cyc!osporine Modified cap SO MG 18.00% Immunosuppressive Agents 99403030300620 Myfort!c Mycophenolate Sodium Tab DR 180 MG (MycophenolicAcidEquiv) 18.00% lmrnunosuppressive Agents 99404070002020 Raparnune srro11mus Oral So!n 1 MG/ML 18.00% lmmunosuppressive Agents 99408020002120 Nu!ojlx Belatacept For IV Infusion 250 MG 18.00% Immunosuppresslve Agents 99402020002010 SandlMMUNE Cyclosporine Oral Sain 100 MG/Ml 18.00% Immunosuppressive Agents 99403030101920 CellCept Mycophenolate Mofetil For Oral Susp 200 MG/Ml.,Cl p,. _-,.. 18.00% lmmunosuppressive Agents 99404070000320 Rapamune Sirolimus Tab 1 MG ._(:,;• . ,,. •· "' 18.00% lmmunosuppressive AgentsInflammatory Bowel Agents 994050150021205250308000212 Sfmu!ect0 Entyvio Baslliximab For IV Sofn 20 MGVedolizumab For 1V Solution 300 MG I)'# "' ., 18.00%18.00% Interleukin ! Blockers 6645006000212 0 Arca[yst R!lonacept For lnj 220 MG . ([.fl ' l 18.00% i [=-m.• . -- ; U\l\\ --------:(} ,r!/_'2Q, r, ['() I"· (; .,) (,/.A_'),as-n- '.::-eJ•\/.....,.,,.. ·••------0•-,..,.-...

Anakinra Subcutaneous Soln Prefilled Syringe 100 MG/0.67ML Deferoxamine Mesylate For lnj 500 MG 18.00%18.00% Deferiprone Tab 500 MGDeferasirox Tab For Oral Susp 250 MG 18.00%18.00% Deferoxamine Mesylate For lnj 2 GM DeferasiroxTab For Oral Susp 500 MG 18.00% 18.00% Deferasirox Tab 90 MG 18.00% DeferasiroxTab 360 MG 18.00% Deferasirox Tab For Oral Susp 125 MG 18.()0% Deferas!rox Tab 180 MG 18.00% Sod Ferric Gluc Cmplx in Sucrose IVSoln 12.5 MG/ML {Fe Eq) 18.00% Iron Sucrose lnj 20 MG/ML {Fe Equiv) 18.00% Leuprolide Acetate For lnj Klt3.7S MG 18.00¾ lnterJeukin-1 Receptor Antagonist {lL-1Ra) RHEUMAT 6626001000ES20 Kineret IRON OVERLOAD-ANTIDOTES 93000020102110 Desfera1IRON OVERLOAD-ANTIDOTES 93100028000320 FerriproxIRON OVERLOAD-ANTIDOTES 93100025007330 &:jadeIRON OVERLOAD-ANTIDOTES 93000020102130 DesferalIRON OVERLOAD-ANTIDOTES 93100025007340 ExjadeIRON OVERLOAD-ANTIDOTES 93100025000320 JadenuIRON OVERLOAD-ANTIDOTES 93100025000340 JadenuIRON OVERLOAD-ANTIDOTES 93100025007320 &:jadeIRON OVERLOAD-ANTIDOTES 93100025000330 JadenuIRON REPlACEMENTS 82300085102020 FerrlecltIRON REPLACEMENTS 82300048002020 VenoferLHRH Analogs 21405010106405 Lupron DepotLHRH Analogs 21405010156420 lupron Depot Leupro!fde Acetate (3 Month) For lnj Kit 11.25 MG 18.00% Local Anesthetics - Topical 90850025306420 Qutenza Capsaidn Patch 8% & Cleansing Gel Kit 18.00% MEDICAL DEVICES MOUTH/THROAT/DENTAL AGENTS Movement Disorder Drug Therapy Movement Disorder Drug Therapy 88501000002000 Caphosol62380070000310 Xenazine 62380070000320 Xenazine 97051050106300 Omnitrope Pen 10 lnj De *Injection Device- Mi sc0 * *Artificial Saliva - Solution•*• Tetrabenazfne Tab 12.5 MG Tetrabenazine Tab 25 MG 18.00% 18.00%18.00% 18.00% MULTIPLE SCLEROSIS 30300010004010 Acthar HP Corticotropin lnj Gel 80 Unit/Ml 18.00% MULTIPLE SCLEROSIS AGENTS 6240003010ES20 Copaxone Glatlramer Acetate Sotn Prefi!led Syringe 20 MG/Ml 18,00% MULTIPLE SCLEROSIS AGENTS MULTIPLE SCLEROSIS AGENTS 6240307530D2SO Plegridy Starter Pack 62405525006520 Tecfidera Peginterferon Beta-la So!n Pen-lnj 63 & 94 MCG/0.SML Pack Dlmethyf Fumarate Capsule Delayed Release 120 MG 18.00%18.00% MULTIPLE SCLEROSIS AGENTS 62403060506420 Betaseron Interferon Beta-lb For lnJ Kit0.3 MG Nata!izumab for IV lnj Cone 300 MG/15Ml 18.00% MULTIPLE SCLEROSIS AGENTS 62405050001320 Tysabri 18.00% MULTIPLE SCLEROSIS AGENTS MULTIPLE SCLEROSIS AGENTS 6240003010E540 Copaxone 6240307530ES20 Plegridy Glatiramer Acetate So!n Prefilled Syringe 40 MG/Ml Peginterferon Beta-la Soln Prefilled Syringe 125 MCG/0.SML 18.00%18,00% MULTIPLE SCLEROSIS AGENTS 62405525006540 Tecfidera MULTIPLE SCLEROSIS AGENTS 6240307530D220 Plegridy Dlmethy[ Fumarate Capsule Delayed Release 240 MG Peginterferon Beta-la Soln Pen-injector 125 MCG/0.5ML 18.00% 18.00% MULTIPLE SCLEROSIS AGENTS 62405525006320 Tecfidera Dimethyl Fumarate Capsule DR Starter Pack 120 MG & 240 MG 18.00% MULTIPLE SCLEROSIS AGENTS 62403060456420 Avonex MULTIPLE SCLEROSIS AGENTS 6240307530E550 PlegridyStarter Pack Interferon Beta-la For IM lnj Kit 30MCG {33MCG{6.6 MU}/Vial) Peginterferon Beta-la Soln Pref Syr 63 & 94 MCG/0.SML Pack 18.00% 18.00% MULTIPLE SCLEROSIS AGENTS MULTIPLE SCLEROSIS AGENTS 62406030007420 Ampyra62404070000330 Aubagio Dalfamprldine Tab SR 12HR 10 MG Teriflunomide Tab 14 MG 18.00%23.75% MULTIPLE SCLEROSIS AGENTS 62403060S02120 Betaseron MULTIPLE SCLEROSIS AGENTS 62405010002020 Lemtrada Interferon Beta-lb For Jnj 0.3 MG Atemtuzumab JV lnj 12 MG/1.2ML (10 MG/ML) MULTIPLE SCLEROSIS AGENTS 62404070000320 Aubagio Teriflunom!de Tab 7 MG 18.00%18.00% 23.75% MULTIPLE SCLEROSIS AGENTS MUSCULOSKELETALTHERAPY AGENTS 6240702S100120 Gilenya7S840015002300 Carticel Fingol!mod HCI Cap 0.5 MG (Base Equiv)*Autofogous Cultured Chondrocytes for lmplantatfon° 18.00%18.00% Neurogen!c Orthostatic Hypotension (NOH) Agents 38700030000150 Northera Neurogenlc Orthostatic Hypotens!on (NOH)-Agents 38700030000130 Northera Droxidopa Cap 300 MG Droxidopa Cap 100 MG 18.00%18.00% Neurogenic Orthostatic Hypotension {NOH)-Agents 38700030000140 Northera NEUROMUSCULAR AGENTS 74400020052140 Botox Drox!dopa Cap 200 MG OnabotullnumtoxinA For lnj 200 Unit 18.00%18.00% AbobotulinumtoxinA For lnj 500 Unit 18.00% NEUROMUSCULAR AGENTS 74400020032120 DysportNEUROMUSCULAR AGENTS 74503070000320 Rilutek Ri!uzole Tab 50 MG R!mabotulinumtoxinB lnj 2500 Unlt/0.SML NEUROMUSCULAR AGENTS 74400020102018 Myob!ocNEUROMUSCUlARAGENTS 74400020052120 Botox Onabotu!lnumtoxinA For tnj 100 Unit RlmabotulinumtoxinB Jnj 5000 Unit/Ml NEUROMUSCULAR AGENTS 74400020102020 MyoblocNEUROMUSCULAR AGENTS 74400020202120 Xeomin lncobotulinumtoxinA For lnj 50 Unit 18.00%18.00%18.00%18.00%18.00%

NEUROMUSCULAR AGENTS 74400020032115 Dysport AbobotullnurntoxinA For lnj 300 Unit 18.00% NEUROMUSCULAR AGENTS 74400020202130 Xeornin lncobotu!inurntoxinAFor lnj 100 Unit 18.00% NEUROMUSCULAR AGENTS 74400020102022 Myobloc RirnabotuHnurntoxinB lnj 10000 Unit/2ML 18.00"Ai OBSOLETO 90250515002120 AMEVIVE ALEFACEPT FOR IV INJ 7.5 MG 18.00% OPHTHALMIC AGENTS 86300010002320 Ozurdex Dexarnethasone lntravitreal lrnplant0.7 MG 18.00% OPHTHALMIC AGENTS 86700065002120 Visudyne OPHTHALMIC AGENTS 86300017102320 Retisert Verteporfin For IV Soln 15 MG (2 MG/ML) Fluocinolone Acetonide lntravitreal lmp!ant0.59 MG 18.00-Yo 18.00% OPHTHALMIC AGENTS 86801060002020 Jetrea OPHTHALMIC AGENTS 86655010002020 Ey!ea Ocriplasmin lntravitreal lnj 0.5 MG/0.2ML (2.S MG/Ml) Afllbercept lntravitreal lnj 2 MG/0.05ML {40 MG/ML) 18.00% 18.00% OPHTHALMIC AGENTS 86655060002012 Lucentis OPHTHALMIC AGENTS 86655060002020 Lucentls Ranlblzumab lntravitreal lnj 0.3 MG/0.05ML (6 MG/ML) Ranibizumab lntravitreal lnJ 0.5 MG/0.05ML (10 MG/ML) OPHTHALMIC AGENTS 86655050302020 Macugen Ophthalmic Agents 86300080101820 Triesence Pegaptanlb Sodfum lntravitreous 1nj 0.3 MG/90 Microllter Triamcinolone AcetonideOphth tnj 40 MG/ML OSTEOARTHRITIS OF THE !{NEE OSTEOARTHRITIS OF THE KNEE 7580004000E530 Synvisc 7580004000E560 Synvlsc One Hylan Intra-articular Solution Prefilled Syringe 16 MG/2ML Hylan Intra-articular Solution Prefi1!ed Syringe 48 MG/6ML OSTEOARTHRITIS OF THE KNEE 7580006000E520 OrthoVisc OSTEOARTHRITIS OF THE KNEE 7580007010ES20 Euf!exxa Hya!uronan Intra-articular So!n Prefilled Syringe 30 MG/2ML Sodium Hya!uronate Intra-articular So!n PrefSyr 20 MG/2ML OSTEOARTHRITIS OF THE KNEE OSTEOARTHRITIS OF THE KNEE 7580007010E525 Supartz 75800070102024 Hyalgan Sodium Hyaluronate Intra-articular Soln Pref5yr 25 MG/2.SML Sodium Hyaluronate lntra articular lnj 20 MG/2ML 18.00%18.00% 18.00%18.00% 18.00%18.00% 18.00%18.00% 18.00%18.00% OSTEOPOROSIS- BISPHOSPHONATES 30042090002120 Zoledronic Acid ZotedronicAcid For IV Soln 4 MG 35.00% OSTEOPOROSIS- BISPHOSPHONATES 30042090001320 Zoledronlc Acid Zoledronic Add lnj Cone For N Infusion 4 MG/SML 34.20% OSTEOPOROSIS- BlSPHOSPHONATES 30042060102012 Pamidronate Dlsodium Pamidronate Dlsodlum IV Soln 9 MG/ML 18.00% OSTEOPOROSIS- B!SPHOSPHONATES 30042060102006 Pamidronate Disodium Pamidronate Disocffum IV Soln 3 MG/ML 18.00% OSTEOPOROSIS- BISPHOSPHONATES 30042060102009 Pamldronate Disodium OSTEOPOROSIS- B\SPHOSPHONATES 30042090002016 Zoledronlc Acid Pamldronate Disodium IV Soln 6 MG/ML Zoledronfc Acid IV So!n 4 MG/100ML 18.00%35.00% OSTEOPOROSIS- BISPHOSPHONATES 30042060102120 Aredia OSTEOPOROSIS- BISPHOSPHONATES 30042090002020 Reclast Pamidronate Disodium For lnj 30 MG ZoledronlcAcld IVSoln 5 MG/100ML 18.00%35.00% OSTEOPOROSIS· BISPHOSPHONATES OSTEOPOROSIS- BISPHOSPHONATES 30042060102140 Ared[a 30042048102030 Bonlva Pamidronate Dlsodium For lnj 90 MG lbandronateSodlum 1V Soln 3 MG/3ML (Base Equivalent) 18.00%18.00% Progesterone Receptor Antagonists ANTIDIABETICS Progestin Contraceptives - IUD 273040S0000330 Korfym 25200050005320 Mirena Mifepristone Tab 300 MGLevonorgestrel Releasing IUD 20 MCG/24HR {52 MG Total) Progestin Contraceptives- IUD PROGESTlNS 25300005002320 lmplanon26000010101710 Makena PSORIASIS 9025058500E520 Ste!ara Etonogestrel Subdermal Implant 68 MG Hydroxyprogesterone Caproate IM In Oil 250 MG/ML Usteklnumab Soln Prefilled Syringe 45 MG/0.SML 18.00%18.00% 18.00%18.00%18.00% PSORIASIS 66700015000330 Otezla ApremilastTab 30 MG PSORIASIS PSORIASIS 9025058500E540 Stelara 90250515002130 AMEVlVE Ustekinumab Sain Prefi1!ed Syringe 90 MG/ML Alefacept For IM lnj 15 MG 18.00% 18.00%18.00% PSORIASIS 9025057500ES20 Cosentyx PSORIASIS 90250585002020 Stelara Secukinumab Subcutaneous Soln Prefilled Syringe 150 MG/ML USTEKlNUMAB lNJ 45 MG/0.5Ml 18.00%18.00% PSORIASIS PSORIASIS 6670001500B720 Otezla ApremilastTab Starterlllerapy Pack 10 MG & 20 MG & 30 MG 9025057500D520 CosentyxSensoready Pen Secukinumab Subcutaneous Solo Auto-injector 150 MG/ML PULMONARY ARTERIAL HYPERTENSION PULMONARY ARTERIAL HYPERTENSION 401340S0000340 Adempas4016001S000330 Tracleer PULMONARY ARTERIAL HYPERTENSION 40170080050415 Orenitram Riociguat Tab 2 MG Bosentan Tab 125 MGTreprostlnil Dio!amine Tab CR 0.25 MG {Base Equiv) 18.00% 18.00%18.00%18.00%18.00% PULMONARY ARTERIAL HYPERTENSION 40134050000320 Adempas RioclguatTab 1 MG PULMONARY ARTERIAL HYPERTENSION PULMONARY ARTERIAL HYPERTENSION PULMONARY ARTERIAL HYPERTENSION 40160007000320 Letairis40170080002020 Tyvaso40134050000350 Adempas PULMONARY ARTERIAL HYPERTENSION 40160050000320 Opsumit Ambrisentan Tab 10 MGTreprostinil lnhalatlon Solution 0.6 MG/ML RloclguatTab 2.5 MG Macitentan Tab 10 MG ·•STl'vi --"- '·"h'' ,,.., - .- •r ,.,., 18.00%18.00%18.00%18.00%18.00% (

PULMONARY ARTERIAL HYPERTENSION PULMONARY ARTERIAL HYPERTENSION 40134050000310 Adempas 40160007000310 Letairis Rioc!guat Tab 0.5 MG Ambrisentan Tab 5 MG 18.00%18.00% PULMONARY ARTERIAL HYPERTENSION 40170080102040 Remodulin PULMONARY ARTERIAL HYPERTENSION 40170080050420 Orenitram Treprostin1\Sodlum lnj 10 MG/ML (Base Equiv) Treprostinil Dio!arnine Tab CR 1 MG {Base Equiv) 18.00% 18.00% PULMONARY ARTERIAL HYPERTENSION PULMONARY ARTERIAL HYPERTENSION 40134050000330 Adempas 40160015000320 Trac!eer RlociguatTab 1.5 MG Bosentan Tab 62.5 MG 18.00%18.00¾ PULMONARY ARTERIAL HYPERTENSION 40143060101920 Revatio PULMONARY ARTERIAL HYPERTENSION 401700800S041D orenitram Sildenafil Citrate For Suspension 10 MG/ML Treprostinil Diolam!ne Tab CR 0.125 MG (Base Equiv) 18.00%18.00% PULMONARY ARTERIAL HYPERTENSION 40170040102110 Epoprostenol Sodium PULMONARY ARTERIAL HYPERTENSION 40170080050425 orenitrarn PULMONARY ARTERIAL HYPERTENSION 40143060100320 Revat!o Epoprostenol Sodium For lnj 0.5 MG Treprostini1 D!olarnine Tab CR 2.5 MG {Base Equiv) Sildenafll Citrate Tab 20 MG 18.00%18.00% 40.00% PULMONARY ARTERIAL HYPERTENSION 40143080000320 Adclrca Tadalafll Tab 20 MG {PAH) lloprost Inhalation Solution 10MCG/ML 18.00% PULMONARY ARTERIAL HYPERTENSION 40170060002020 Ventavis 18.00% PULMONARY ARTERIAL HYPERTENSION 40170080102020 Remodulin PULMONARY ARTERIAL HYPERTENSION 40170060002040 ventavis Treprostinil Sodium lnJ 2.5 MG/ML (Base Equiv) lloprost Inhalation Solution 20 MCG/ML 18.00% 18.00% PULMONARY ARTERIAL HYPERTENSION 40170080102030 Remodulin PULMONARY ARTERIAL HYPERTENSION 40143060102020 Revatio Treprostinll Sodium lnj 5 MG/ML (Base Equiv) Sildenafil Citrate IV Sofn 10 MG/12.5ML (Base Equivalent) 18.00% 18.00% PULMONARY ARTERIAL HYPERTENSION 40170040102130 Epoprostenol Sodium PULMONARY ARTERIAL HYPERTENSION 40170080102010 Remodulin Pulmonary Fibrosis Agents Pulmonary Fibrosis Agents 45550060000120 Esbriet45554050200130 Ofev Epoprostenol Sodium For lnJ 1.5 MG Treprostinil Sodium lnj 1 MG/ML(Base Equ'rv) Pulmonary Fibrosis Agents 45554050200120 Ofev Pirfenidone cap 267 MGNintedanib Esy!ate Cap 150 MG (Base Equivalent) Nintedanib Esy!ate Cap 100 MG {Base Equivalent) 18.00%18.00% 18.00%18.00% 18.00% RESPIRATORY AGENTS- MISC. 45100010102110 Aralast NP RESPIRATORY AGENTS- MISC. 45000070001820 surfaxin Alphal-Protelnase Inhibitor (Human) For IV Soln 500 MG Lucinactant lntratracheal Susp 30 MG/ML 18.00% 18.00% RESPIRATORY AGENTS - MISC. 45100010102108 Aralast RESPIRATORY AGENTS - MISC. 45100010102118 Aralast Alphal-Proteinase Inhibitor (Human) For IV Sain 400 MG Alphal-Proteinase Inhibitor (Human) For IV Soln 800 MG 18.00%18.00% RESPIRATORY AGENTS - MISC. 45100010102020 Glassia RESPIRATORY AGENTS - MISC. 45100010102120 Aralast NP ResplratorySyncytia[ Virus (RSV) Agents Respiratory Syncytial Virus (RSV) Agents 19502060002015 Synagis19502060002020 Synagis Alphal-Protelnase Inhibitor (Human) Jnj 1000 MG/SOML Alpha1-Prote!nase Inhibitor (Human) For IV Sain 1000 MG Palivhumab lM Soln 50 MG/0.SML Palivizumab IM Soln 100 MG/ML 18.00%18.00% 18.00"7618.00% RespiratorySyncytial Virus {RSV) Agents 12604075002120 VJrazoJe Ribavirin For lnhat Soln 6 GM 18.00% Respiratory Tract Agents Resplratory Tract Agents 40120070000310 Uptravi 40120070000340 Uptravi SelexlpagTab 200 MCGSe!exipagTab 1400 MCG 18.00%18.00% Respiratory Tract Agents Respiratory Tract Agents 40120070000315 Uptrav/40120070000320 Uptravi Setexipag Tab 400 MCG SelexipagTab 600 MCG SelexipagTab Therapy Pack 200 MCG {140) & 800 MCG {60) 18.00%18,00% ResplratoryTract Agents 4012007000B720 Uptravi 18.00% Respiratory Tract Agents 40120070000345 Uptravi Selexipag Tab 1600 MCG 18.00% Respiratory Tract Agents 40120070000330 Uptravi Se/exipag Tab 1000 MCG 18.00% Respiratory Tract Agents Respiratory Tract Agents 40120070000335 Uptravi40120070000325 Uptravi SelexipagTab 1200 MCG Selexipag Tab 800 MCG 18.00%18.00% RHEUMATOID ARTHRITIS MISC 6650007000ES20 Actemra Tocilizumab Subcutaneous Soln Pref!lled Syringe 162 MG/0.9ML 18.00% RHEUMATOID ARTHRITIS MISC 66S00070002035 Actemra RHEUMATOID ARTHRJTJS MISC 66400010002120 Orencia Tocilfzumab IV lnj 200 MG/lOML Abatacept For IVSoln 250 MG 18.00% 18.00% RHEUMATOID ARTHRITJS MISC 66603065100320 Xeljanz RHEUMATOID ARTHRITlS MISC 66S00070002040 Actemra Tofacitinib Citrate Tab 5 MG (Base Equivalent) Tocl!izumab IV lnj 400 MG/20ML 18.00%18.00% RHEUMATOID ARTHRITIS MISC 6640001000E520 Orencia AbataceptSubcutaneous Soln Prefilled Syringe 125 MG/Ml RHEUMATOID ARTHRITIS MISC 66280050000320 Arava Leflunomlde Tab 20 MG RHEUMATOID ARTHRITIS MISC 66460020002120 llaris Canaklnumab For lnj 180 MG RHEUMATOID ARTHRITIS MISC 66500070002030 Actemra Toc!l!zumab IV lnj 80 MG/4Ml - .. 18.00% 18.00%18.00%18.00%

RHEUMATO!D ARTHRITIS MISC 66280050000310 Arava leflunomide Tab 10 MG 18.00% Short Bowel Syndrome (SBS) Agents 52533070006420 Gattex Teduglutide {rDNA) For lnj Kit 5 MG 18.00% Stem Cell Mobilizers 82502060002020 Mozobi1 P!erixaforSubcutaneous lnj 24 MG/1.2Ml {20 MG/ML) 18.00% Systemic Lupus Erythematosus Agents 99422015002120 Benlysta Belimumab For 1V Soln 120 MG 18.00% Systemic lupus Erythematosus Agents 99422015002140 Benlysta Be!imumab For IV Soln 400 MG 18.00% Therapeutic Nutrients/Minerals/Electrolytes 93100028002020 Ferriprox Deferiprone Oral So!n 100 MG/ML 18.00% TUBERCULOSIS 09000015100320 Sirturo Bedaquiline Fu ma rate Tab 100 MG (Base Equiv) 18.00% Tumor Necrosis Factor Alpha Blockers 52505020106460 Cimzia Starter Kit Certollzumab Pegol lnj Kit 6 X 200 MG/ML 18.00% Tumor Necrosis Factor Alpha Blockers 6627004000D540 Simponi Golimumab Subcutaneous Solo Auto-.-injector 100 MG/ML 18.00% Tumor Necrosis Factor Alpha Blockers 6629003000E530 Enbrel Etanercept Subcutaneous Solo Prefi!led Syringe SO MG/ML 18,00% Tumor Necrosis Factor Alpha Blockers 52505020106420 Cimzla Certolizumab Pegol For lnj Kit 2 X 200 MG 18.00% Tumor Necrosis Factor Alpha Blockers 66270040002015 S!mponl Aria Go!imumab IV Soln SO MG/4ML 18.00% Tumor Necrosis Factor Alpha Blockers 6629003000D530 Enbrel SureClick EtanerceptSubcutaneousSolution Auto ln]ector 50 MG/ML 18,00% Tumor Necrosis Factor Alpha Blockers 52505040002120 Remicade lnfliximab Fot IV lnj100 MG 18,00% Tumor Necrosis Factor Alpha Blockers 6627004000E520 Simponi Golimumab Subcutaneous Sotn Prefil!ed Syringe SO MG/0,5ML 18.00% Tumor Necrosis Factor Alpha Blockers 52505020106440 Cimzia Certolizumab Pegol lnJ Kit 2 X 200 MG/Ml 18.00% Tumor Necrosis Factor Alpha Blockers 6627004000D520 Simponi Golimumab Subcutaneous So!n Auto-injector SO MG/0,SML 18,00¼ Tumor Necrosis Factor Alpha Blockers 6629003000E525 Enbrel EtanerceptSubcutaneousSoln Prefilled Syringe 25 MG/0.SML 18.00% Tumor Necrosis Factor Alpha Blockers 6627001500F420 Humira Pen Adalimumab Pen-injector Kit40 MG/0.8ML 18.00% Tumor Necrosis Factor Alpha Blockers 6627004000£540 S!mponi Golimumab Subcutaneous Soln Prefllled Syringe 100 MG/Ml 18.00% Tumor Necrosis Factor Alpha Blockers 6627001500F810 Humira Adalimumab Prefilled Syringe Kit 20 MG/0.4Ml 18.00% Tumor Necros!s Factor Alpha Blockers 6627001500F820 Humira Adalimumab Prefi!led Syringe Kit 40 MG/0.8Ml 18.00% Tumor Necrosis Factor Alpha Blockers 66290030006420 Enbrel Etanercept For Subcutaneous lnj Kit 25 MG 18.00% Tumor Necrosis Factor Alpha Blockers 6627001500F805 Humira Adalimumab Prefllled Syringe Kit 10 MG/0,2Ml 18.00% Viscosupp!ements 7580006000e515 Hymovis Hyaluronan Intra-articular Soln Prefllled Syringe 24 MG/3Ml 18.00% {blank) 96544244002900 Gabapentin Gabapentin Powder 18.00% {blaok) 30201010102030 DDAVP Desmopressin Acetate In] 4 MCG/ML 18.00% {blank) 30089902506420 Lupaneta Pack leuprolide (1 Mon) lnj 3.75 MG & Norethlndrone Tab 5 MG Kit 18.00% (blank) 21700030000105 Hydroxyurea Hydroxyurea Cap 500 MG 18.00% {blank) 85153060101310 Aggrastat Tirofiban HC! IV Cone 3.75 MG/15ML (250 MCG/ML) {Base Equiv) 18.00%

Anexo 1: Lista de Desc.uentos para Medkamentos de Alto Costo que sean despachados por las Farmacias Extemas de Hospitales y CDT (2017) Category Agents for Gaucher Disease Agents for Gaucher Disease GP! Drug Name 82700020002020 Ceredase GP! Name A!glucerase IV Solo 80 Unit/ML Actual Discount 16.00"/4 82700085102120 Vpriv Agents for Gaucher Disease 82700040600120 Cerdelga Velaglucer.ise Alfa For lnj 400 Unit EliglustatTartrate Cap 84 MG (Base Equivalent) 16.00% 16.00% Agents for Gaucher Disease 82700050002110 Cerezyme lmiglucerase For lnJ 200 Unit 16.00% 11aents for Gaucher Disease Agents for Gaucher Disease 82700070000120 zavesca Mfglustat Cap 100 MG 82700080102120 Efelyso Tafiglucerase Alfa For Jnj 200 Unit 16.00% 16.00% Agents for Gaucher Disease ANALGESICS -ANTI-INFLAMMATORY 82700050002120 Cerezyme lmiglucerase For lnj 400 Unit 66200030002015 Gold Sodium Thiomalate Gold Sodium Thiomalate lnJ 50 MG/ML 16.00%16.00% ANALGESICS - NonNarcotic ANALGESICS- NonNarcotic 64154090102020 Prialt 64154090102030 Prialt Ziconotide Acetate lntrathecal lnj 100 MCG/Ml Ziconotide Acetate lntrathecal Jnj 500 MCG/5Ml 16.75%16.75% ANALGESICS- NonNarcotic ANDROGENS-ANABOLIC ANTIARRHYTHMICS 641S4090102010 Prialt Ziconotide Acetate lntrathecal lnj 500 MCG/20Ml {25 MCG/Ml) 23100030802030 Aveed 35400025000110 Tikosyn Testosterone Undecanoate IM lnj in Oil 750 MG/3Ml {250MG/ML) Dofet!llde Cap 125 MCG {0.125 MG) 16.75% 16.00".i15.50" ANTIARRHYTHMICS ANTIARRH'l'THM!CS 35400025000120 Tikosyn35400025000130 Tikosyn Dofetilide Cap 250 MCG {0.25 MG) Dofetilide Cap SOO MCG (0.5 MG) 15.50%15.50% ANTIASTHMATlCAND BRONCHODILATORAGENTS ANTIB!OTICS-AMINOGLYCOSIDES ANTIBIOTICS-AMINOGLYCOSIDES 44603060002120 Xola!r07000070102030 Tobramycin Sulfate Omalizumab For lnj 150 MG TOBRAMYCIN SULFATE INJ 40 MG/Ml 07000070102020 Tobramycin Sulfate Tobramycin Sulfate lnj 10 MG/ML 16.25%41.75% 41.75% ANTIBIOTICS- AMINOGLYCOSIDES ANTIBIOTICS- AMlNOGLYCOSIDES 07000070102034 Tobramydn Sulfate07000070102105 Tobramycin Sulfate Tobramycin Sulfate lnj 80 MG/2Ml {40 MG/Ml) Tobramycin Sulfate For lnj 1.2 GM 41.75%41.75% ANTIB!OTICS-AMINOGLYCOSIDES ANTIBIOTICS- AMINOGLYCOSIDES 07000070102039 Tobramydn Sulfate07000070102022 Tobramycln Sulfate Tobramycin Sulfate lnJ 2 GM/SOMl {40 MG/Ml) Tobramydn Sulfate IV Sotn 10 MG/Ml 41.75%41.75% ANT!BIOTICS-AMINOGLYCOSIDES Anti-Catap!ectic Agents ANTICOAGULANTS ANTICOAGULANTS 07000070102038 Tobramyc!n Sulfate62450060202020 Xyrem8310101010f020 Fragmin 83101020102013 Lovenox Tobramycin Sulfate lnj 1.2 GM/30ML {40 MG/ML) Sodium Oxybate Oral Solution 500 MG/Ml Dalteparin Sodium lnj 2500 Unit/0.2Ml Enoxaparin Sodium lnJ 40 MG/0.4Ml 41.75%16.00%16.00%16.00% ANTICOAGULANTS ANTICOAGULANTS ANTICOAGULANTS 83103030102035 Arixtra83101010102065 Fragmin Fondaparinux Sodium Subcutaneous lnj 5 MG/0.4ML Dalteparin Sodium lnj 25000 Unit/Ml 83101020102050 Lovenox Enoxaparin Sodium lnj 300 MG/3Ml 16.00%16.00% 16.00% ANTICOAGULANTS 83370060000340 Xarelto Rivaroxaban Tab 20 MG 16.00% ANTICOAGULANTS 83101010102040 Fragmin Dalteparin Sodium lnj 5000 Unit/0.2Ml 16.00% ANTICOAGULANTS 83101020102014 lovenox ANTICOAGULANTS 83103030102040 Arixtra ANTICOAGULANTS 83101010102015 Fragmin Enoxaparin Sodium lnj 60 MG/0.6Ml FondaparinuxSodium Subcutaneous lnj 7.5 MG/0.6Ml Dalteparin Sodium lnj 10000 Unit/ML 16.00%16.00% 16.00% ANTICOAGULANTS 83101020102012 Lovenox ANTICOAGULANTS 83103030102.020 Arixtra Enoxaparin Sodium lnj 30 MG/0,3MlFondaparinux Sodium Subcutaneous. lnj 2.5 MG/0.5Ml 16.00%16.00% ANTICOAGULANTS 83101010102045 Fragmin ANTICOAGULANTS 83101020102015 Lovenox ANTICOAGULANTS 83103030102045 Arixtra Dalteparin Sodium lnj 7500 Unit/0.3Ml Enoxaparin Sodium lnj 80 MG/0.8Ml FondaparinuxSodium Subcutaneous lnj 10 MG/0.8ML 16.00%16.00% 16.00% ANTICOAGULANTS ANTICOAGULANTS 83101010102056 Fragmin83101020102018 Lovenox Dalteparin Sodium lnJ15000 Un!t/0.6Ml Enoxaparin Sodium lnj 120 MG/0.8Ml 16.00%16.00% ANTICOAGULANTS 83370060000320 Xarelto Rivaroxaban Tab 10 MG -·-... 16.00% ANTICOAGULANTS 83101010102060 Fragmin Dalteparin Sodium lnj 18000 Unit/0.72Ml ·.,::-...\\•:> ' "{().°""-- ANTICOAGULANTS 8310102.0102020 Lovenox ANTICOAGULANTS 83370060000330 Xarelto •:)' '.,,,p--,-.•·- ---, \.-' "<:I. Enoxaparin Sodium lnj 150 MG/ML Rivaroxaban Tab 15 MG '-/ .('" 's.'\ v 16.00%16.00%16.00%

. ¾ ANTICOAGULANTS ANTICOAGULANTS ANTICOAGULANTS ANTICONVULSANTS ANTICONVULSANTS ANTICONVULSANTS ANTICONVULSANTS ANTICONVULSANTS ANTICONVULSANTS ANTICONVULSANTS ANTICONVULSANTS ANTICONVULSANTS ANTICONVULSANTS ANTIEMETICS ANTIEMETICS ANTIEMETICS ANTIEMETICS ANTIEMETICS ANTIEMETICS ANTIEMETICSAntiemeticsANTIEMETICS ANTIEMETICSAntiemeticsANTIEMETICS ANTIFUNGALS ANTIFUNGALS ANTIFUNGALS ANTIFUNGALS ANTIFUNGALS ANTIFUNGALS ANTIFUNGALS ANTIFUNGALS ANTIFUNGALS ANTIFUNGALS ANTIFUNGALS ANTIFUNGAlS ANTIFUNGALS ANTIFUNGALS ANTIFUNGALS ANTIFUNGALS ANTIFUNGALS ANTIFUNGALS ANTIFUNGALS ANTIFUNGALS ANTIFUNGALSAntlhemophilic ProductsAntihemoph!lic Products Antihemoph!llc Products q t::r Ir···· 85100010002139 Hemofi!M 83101010102053 Fragmin83101020102016 lovenox83334050102120 Refludan72600043002020 Keppra72600043000340 Keppra72600043002060 Keppra72600043000350 Keppra72170085000320 Sabril72600043007520 Keppra XR72600043000320 Keppra72600043000330 Keppra72170085003020 Sabril72600043007530 Keppra XR50250025200330 Anzemet50280035102130 Emend50280020000130 Emend50250025202020 Anzemet50250025200320 Anzemet50280020006320 Emend50250070102010 Aloxi50250065052030 Zofran50280020000110 Emend50280020000120 Emend50250065052024 Ondansetron HCl50250070102020 Aloxi11000010101920 Amphotec11407060001820 Noxafil11500025102130 Cancldas11000010002105 Amphotericin B 11407015022020 Diflucan in Dextrose 11500010002130 Eraxis11000010301820 Abeket11407080000320 Vfend11500050102120 Mycamine Dafteparin Sodium lnj 12500 Unit/0.SML Enoxaparln Sodium lnJ 100 MG/ML Leplrudin For IV Sain 50 MG levetiracetam Oral Solo 100 MG/Ml levetiracetam Tab 750 MGlevetiracetam lnj 500 MG/SML {100 MG/ML) Levetiracetam Tab 1000 MGVigabatrin Tab 500 MG levetiracetam Tab SR 24HR 500 MG levetiracetam Tab 2S0 MG levetiracetam Tab 500 MG Vigabatr!n Powd Pack 500 MG levet!racetam Tab SR 24HR 750 MG Dolasetron Mesylate Tab 100 MGFosaprepitant Dlmeglum!ne For IV Infusion 150 MG {Base Eq) Aprepitant Capsule 125 MGDolasetron Mesylate IV lnj 20 MG/Ml Dolasetron Mesy!ate Tab 50 MGAprepitant Capsule Therapy Pack 80 & 125 MG Pa!onosetron HCI IV Soln0.075 MG/1.SML {Base Equiv) Ondansetron HCI lnj 40 MG/20Ml {2 MG/ML) Aprepitant Capsule 40 MGAprepitant Capsule 80 MGOndansetron HCI lnj 4 MG/2ML(2 MG/ML) Palonosetron Hd IV Sofn 0.25 MG/SML (Base Equivalent)Amphotericin B Cholesteryl Sulfate Complex For lnj 100 MG Posaconazole Susp 40 MG/MlCaspofungin Acetate For IV So!n 70 MGAmphoteridn B For lnj 50 MGFluconazole in Dextrose lnj 400 MG/200ML Anldulafungln For JV So1n 100 MGAmphoterlcln B Lipid lnj Susp (For IV Infusion) 5 MG/MLVoriconazole Tab 50 MGMicafungin Sodium For IVSoln 50 MG 11407015012020 Diflucan In Sodium Ch!ori F!uconazole In NaCl 0.9% lnj 400 MG/200Ml 11407080002120 Vfend IV11407015022010 Diflucan in Dextrose 11500010002120 Eraxis Vorkonazole For lnj 200 MGFluconazole In Dextrose lnj 200 MG/100ML Anidulafungin For IV Sain 50 MG 11407015012010 Diflucan in Sodium Chlori F[uconazo!e in NaCl 0.9% lnj 200 MG/lOOML 11407080001920 Vfend11000010101910 Amphotec11407035002020 Sporanox11500025102120 Cancidas11000010401920 AmBisome11407080000340 Vfend11500050102130 Mycamine Vorkonazole ForSusp40 MG/MlAmphoterlcln B Cho!esteryl Sulfate Complex For lnj 50 MG ltraconazole Oral Soln 10 MG/MlCaspofungin Acetate For IV So!n 50 MGAmphoteridn 8 Uposome IV For Susp 50 MG Voriconazole Tab 200 MGMlcafung!n Sodium For IV Sain 100 MG Antihemophil!c Factor (Human) For lnj 801 1700 Unit 85100010006460 Monodate-P 85100010202145 Recombinate Antihemophilic Factor {Human) For lnj Kit lOOO•Unit--, ,,t. Antihemophl!ic Factor (Recombinant) Fnr.lhfti.11:::l!U'V't!l'nu_"- 16.00%16.00%16.00%16.00%16.00%16.00%16.00%15.75%16.00%16.00%16.00%15.75%16.00%16.00%16.00%16.00%16.00%16.00%16.00%26.75%15.50%16.00%16.00%15.50%26.75%16.00%16.00%16.00%16.00%15.25%16.00%16.00%16.00%16.00%15.25%16.00%15.25%16.00%15.25%16.00%16.00%16.00%16.00%16.00%16.00%16.00% 42.00% 30.00%40.00%

AntihemophiHc Products 85100010252150 Advate Antihemophilic Factor rAHF-PFM For lnj 1500 Unit 37.75% Antihemophil!c Products 85100028202150 BeneFIX Coagulation Factor IX (Recombinant) For lnj 2000 Unit 21.00% Antihemophllic Products 85100010266470 Xyntha So!ofuse Antihemophilic Factor Recombinant PAF For lnj Kit 3000 Unit 38.00% Antihemophilic Products 85100010502130 Obizur Antlhemophllic Factor(Recomb Pore) rpFVIII For lnj 500 Unit 20.00% Antihemophi!ic Products 85100015102139 Wilate AntihemophHic Factor/VWF (Human) For lnj 1000--1000 Unit 40.00% Antihemophi!ic Products 85100020002100 Feiba NF *Antiinhibitor Coagulant Complex For Jnj*t 40.00% Antlhemophllic Products 85100028002160 Mononine Coagulation Factor IX For lnJ 250 Unit 40.00% Antihemophllic Products 85100030002115 Profilnine SO FactorlX Complex For lnj 1500 Unit 19.75% Antihemophllic Products 85100010002125 HemofilM Antihemophllic Factor (Human) For lnj 401-800 Unit 42.00% Antihemophilic Products 85100010006410 Monodate-P Antihemophi!ic Factor (Human) For lnj Kit 250 Unit 30.00";{; Antihemophilic Products 85100010202135 Recombinate Antihemophi!ic Factor {Recombinant) For lnj 801-1240 Unit 40.00% Antihemophilic Products 85100010252130 Advate AntihemophiHc Factor rAHF-PFM For lnj 500 Unit 37.75% Antihemophi!iC Products 85100010266440 Xyntha Antihemophilic Factor Recombinant PAF For lnj Kit 1000 Unit 38.00% Antihemophi!rc Products 85100010002140 Hemofi\M Antihemophilic Factor (Human) For lnj 1000 Unit 42.00% Antihemophilic Products 85100010006475 Monoc!ate•P Antihemophilic Factor {Human) For lnj Kit 1500 Unit 30.00% Antihemophilic Products 85100010302155 Eloctate Antihemophilic Factor {Recomb} rFVIIIFc For lnj 2000 Unit 20.00% Antihemophilic Products 85100028202140 BeneflX Coagulation Factor IX {Recombinant) For lnj 1000 Unit 21.00% Antihemophilic Products 85100015102132 Humate-P Antihemophilic Factor/VWF (Human) For lnj 500-1200 Unit 37.00% Antihemophlllc Products 85100015102190 Alphanate/VWF Complex Antlhemophilic Factor/VWF (Human} For lnj 1500 Unit 40.00% Antihemophflic Products 85100026202145 NovoSeven RT Coagulation Factor VJla (Recomb) For lnj 5 MG (5000 MCG) 31.75% Antihemophilic Products 85100030002105 Profilnfne SO Factor IX Complex For lnj 500 Unit 19.75% Antihemophiltc Products 85100060106420 Kcentra Prothrombin Complex Cone Human For lnj Klt500 Unit 20.00% Antihemoph!lfc Products 85100010202150 Novoeight Antihemophilic Factor (Recombinant) For lnj 1500 Unit 20.00% Antihemophllic Products 85100010252170 Advate Antihemophilic Factor rAHF-PFM For lnj 2000 Unit 37.75% Antihemophilic Products 85100028202160 BeneFIX Coagulation Factor IX (Recombinant) For lnj 3000 Unit 21.00% Antihemophi!ic Products 85100010302120 Eloctate Antihemophi!ic Factor {Recomb) rFVIIIFc For lnj 250 Unit 20.00% Antihemophi!!c Products 85100015102120 Humate-P Antihemophi!ic Factor/VWF {Human) For lnj 250-500 Unit 37.00% Antihemophllic Products 85100015102140 Humate-P Antihemophl!ic Factor/WJF (Human) For lnj 1000--2000 Unit 37.00% Antihemophilic Products 85100026202117 NovoSeven RT Coagulation Factor VIia {Recomb} For lnj 1 MG (1000 MCG) 31.75% Antihemophilic Products 85100028002185 AlphaNine SO Coagulation Factor IX For lnj 1500 Unit 30.00% Antihemophilic Products 85100030002150 Bebulin Factor IX Complex For lnJ 200-1200 Unit 20.00% Antihemophilic Products 85100010206440 Helixate FS Antihemophi!ic Factor (Recombinant) For lnJ Kit 1000 Unit 41.75% Antihemophilic Products 85100010002130 Hemofi!M Antihemophilic Factor {Human) For lnj 500 Unit 42.00% Antihemophil!c Products 85100010006430 Monoclate-P Antihemophi!ic Factor (Human) For lnj Kit 500 Unit 30.00% Antihemophil!c Products 85100010202140 BIOClATE ANT\HEMOPHlllC FACTOR (RECOMBINANT) FOR INJ 1000 UNIT 20.00% Antihemophilic Products 84100040002010 Cyklokapron TranexamicAcid lnj 100 MG/ML 16.00% Antihemophilic Products 85100010002146 Hemofil M Antihemophilic Factor (Human) For lnj 1700 Unit 42.00% Antihemophil!c Products 85100010202115 Recomblnate AntihemophHic Factor (Recombinant) For lnj 220-400 Unit 40.00% Antihemophilic Products 85100010252140 Advate Antihemophillc Factor rAHF-PFM For lnj 1000 Unit 37.75% Antihemophilic Products 85100010266460 Xyntha Antihemophllic Factor Recombinant PAF For lnj Kit 2000 Unit 38.00% Antlhemophilic Products 85100028202120 BeneFIX Coagulation Factor IX {Recombinant) For lnj 250 Unit 21.00%, Antihemophilic Products 85100010302165 Eloctate Antihemophilic Factor (Recomb) rFVIIIFc For lnj 3000 Unit 20.00¾ Antihemophil!c Products 85100015102138 Wilate Antihemophilic Factor/VWF (Human) For lnj 900-900 Unit 40.00% Antihemophilic Products 85100015102193 Alphanate/VWF Complex Antihemophilic Factor/VWF (Human) For lnj 2000 Unit 40.00% Antihemophilic Products 85100026202160 NovoSeven RT Coagulation Factor VIia (Recomb) For lnj 8 MG (8000 MCG) . 31.75% Antlhemophllic Products 85100030002110 Profilnine SO Factor IX Complex For lnj 1000 Unit 19.75% Antlhemophl!ic Products 85100060106430 Kcentra Prothrombin Complex Cone Human For lnj Kit 1000 Unit /t"--..1\\\ ,..,,_. I '( .i '.'<. 20.00% Antlhemophific Products 85100028002170 AlphaNine SD Coagulation Factor IX For lnj 500 Unit i -..."-..... -/ ....... 40.00% Antihemophilic Products 85100010202155 Recombinate Antlhemophllic Factor (Recombinant) For lnj 1801-2400 un·( '" ,1;,'_ 40.00% ,1- -,,,r8to ([)9·'.'.() NvflJe,IO , #•'"' \ Q ' .. . - •.. \ l . 'v ,,\·, .. . .9 ..·

Antihemophllic Products 851000102S2180 Advate AntihemophHic Factor rAHF-PFM For lnj 3000 Unit 37.75% Antihemophil!c Products 85100010302125 Eloctate Antihemophillc Factor (Recomb) rFVIIJFc For lnj 500 Unit 20.00% Antihemophi!ic Products 8510001S102122 Humate-P Antihemophilic Factor/VWF (Human) For lnj 250-600 Un[t 37.00% Antihemophlfic Products 85100015102144 Humate-P Antihemophilic FactorMVF (Human) For lnj 1000-2400 Unit 37.00¼ Antihemophilic Products 85100026202120 NovoSeven Coagulation Factor VIia {Recomb) For lnj 1.2 MG (1200 MCG} 31.75% Antihemophillc Products 85100028402110 A!prolix Coagulation Factor IX (Recomb) (rFIXFc) For lnj SOO Unit 22.00% Antihemophi1ic Products 85100030002180 Profilnine SD FACTOR IX COMPLEX FDR INJ 1000-1500 UNIT 20.05% Antihemophilic Products 85100028002180 AlphaNine SD Coagulation Factor IX For lnj 1000 Unit 40.00% Antihemoph!lic Products 85100010206460 Helixate FS Antihemophilic Factor(Recomb!nant) For lnJ !<it 3000 Unit 41.75% Antihemophlllc Products 85100010002110 Hemofi!M Antihemoph!licFactor (Human) For lnj 250 Unit 42.00% Antihemophilic Products 85100010002160 HemofilM AntihemophiHc Factor (Human) For lnj 801-1500 Unit 42.00% Antihemophi!ic Products 85100010202125 Recombinate Antihemophi!Jc Factor {Recombinant) For lnj 401-800 Unit 40.00% Antihemophilic Products 85100010202170 Novoefght Antihemophilic Factor (Recombinant) For In] 3000 Unit 20.00% Antihemophilfc Products 85100010266420 Xyntha Antihemophillc Factor Recombinant PAF For lnj Kit 250 Unit 38.00% Antihemophilic Products 85100010302135 Eloctate Antihemophitic Factor {Recomb) rFVIIIFc For lnj 1000 Unit 20.00% Antihemophmc Products 85100015102129 Wilate Antihemophl!ic Factor/VWF (Human) For fnj 500-500 Unit 40.00% Antihemophilic Products 85100015102170 Alphanate/VWF Complex Antihemophllic Factor/VWF (Human) For lnj 500 Unit 40.00% Antihemophilic Products 85100026202130 NovoSeven Coagulation Factor VIia {Recomb) For lnj 2.4 MG {2400 MCG) 30.50% AntihemophilJc Products 85100028402130 Alprolix Coagulation Factor IX {Recomb) (rFJXFc) For fnj 2000 Unit 22.00% Antihemophllic Products 85100033006440 Corifact Factor XU! Concentrate {Human) For lnj Kit 1000-1600 Unit 21.00% Antihemophl!ic Products 85100010206420 Helixate FS Antihemophilic Factor (Recombinant) For lnj Kit 250 Unit 41.75% Antihemophillc Products 85100010002112 AlPHANATE ANTIHEMOPHILJC FACTOR (HUMAN) FOR INJ 2S0-500 UNIT 41.75% Antlhemophilic Products 85100010002170 Hemofil M Antihemophi!ic Factor (Human) For JnJ 1501-2000 Unit 42.00% Antihemophilic Products 85100010202130 B!OClATE ANTIHEMOPHIUC FACTOR (RECOMBINANT) FOR !NJ 500 UNIT 20.00% Antihemophi!ic Products 85100010252120 Advate Antihemophilic Factor rAHF-PFM For lnj 250 Unit 37.75% Antihemoph!IJc Products 85100010266430 Xyntha Antihemophi!ic Factor Recombinant PAF for /nj Kit 500 Unit 38.00% Antihemophllic Products 85100010302145 Eloctate AntihemophHlc Factor (Recomb} rFVHIFc For In] 1500 Unit 20.00% Antihemophl!ic Products 85100028202130 BeneFtX Coagulation Factor IX (Recombinant) For In] 500 Unit 21.00% Antihemophilic Products 85100015102130 Humate-P Antihemophilic Factor/VWF {Human) For lnj 500-1000 Unit 37.()()% Antihemoph!l!c Products 85100015102180 Alphanate/VWF Complex Antihemophi!ic Factor/VWF (Human} Forlnj 1000 Unit 40.00% Antihemophllic Products 85100026202140 NovoSeven Coagulation Factor VIia (Recomb} For Jnj 4.8 MG (4800 MCG) 31.75% Antihemophi!ic Products 85100028402140 Alprolix Coagulation Factor IX (Recomb) (rFJXFc} For fnJ 3000 Unit 22.00% Antihemophitic Products 85100035002120 RiaSTAP Fibrinogen Cone (Human) lnj Approximatety 1 GM {900-1300 MG) 21.00% Antihemophilic Products 85100010206430 Helixate FS Antihemophillc Factor {Recombinant) For lnj Kit 500 Unit 41.75% Antihemophi!ic Products 85100010002109 HemofilM Antihemophilic Factor (Human) Forlnj 220-400 Unit 42.00% Antihemophilic Products 85100010002147 HemofilM Antihemophillc Factor(Human) For lnj 1701-2000 Unit 42.00% Antihemophilic Products 85100010202120 BIOClATE ANTJHEMOPHIUC FACTOR (RECOMBINANT) FOR INJ 250 UNIT 20.00% Antihemophilic Products 85100010202160 Novoelght Antlhemophi!ic Factor {Recombinant) for lnj 2000 Unit 20.00% Antihemophillc Products 85100010252185 Advate Antihemophillc factor rAHF-PFM For Jnj 4000 Unit 37.75% Antihemophllic Products 85100010302130 Eloctate Antihemophilic Factor (Recomb) rFVIIIFc For lnj 750 Unit 20.00% Antihemophi!ic Products 85100015102128 Wl!ate Antihemophilic Factor/VWF (Human) For lnj 450-450 Unit 40.00% Ant!hemophilfc Products 85100015102160 Alphanate/VWF Complex Ant!hemophilfc Factor/VWF {Human) For lnj 250 Unit 40.00% Antihemophil!cProducts 85100026202126 NovoSeven RT Coagulation Factor VIia (Recomb} For Jnj 2 MG (2000 MCG) 31.75% Antihemophlllc Products 85100028402120 Alprolix Coagulation Factor IX {Recomb) {rFIXFc) For lnj 1000 Unit 22.00% Antihemophilic Products 85100032102130 Tretten Coagulation Factor XUI A-Subunit For lnj 2000-3125 Unit 16.00% Antihemophi!ic Products 85100010206450 He!ixate FS Antihemophi!ic Factor{Recombinant) For lnj Kit 2000 Unit -- -,- " 41.75% ANTIHEMOPHIUCS 30201010102015 Stimate Desmopressin Acetate Nasal Soln 1.5 MG/Ml 3 -- 1('\.,', 15.75% ANTIHISTAMINES 41200030102900 DiphenhydrAMINE HCI Diphenhydramine HCI Powder () """...;u. 16.00% ANTIHYPERUPIDEMICS 3950004010E520 Kynamro MipomersenSodium Soln Prefllled Syringe 200 MG/Ml X.u,..,. 16.00% ; .."'«to Nurr, 1_ 1\ $ .. •·· ero,m! . fl f• 2. '• I· A r (IJ ·,--(\\<>):,.' .§) ........ (

ANTIHVPERLIPIDEMlCS 39480050200120 Juxtapid lomitapide Mesylate Cap 5 MG {Base Equiv) 16.00% ANTJHYPERLIPJDEMICS 39480050200130 Juxtapid lomitapide Mesylate Cap 10 MG {Base Equ1v) 16.00% ANTlHYPERUPIDEMICS 39480050200140 Juxtapid lomitaplde Mesylate Cap 20 MG (Base Equiv) 16.00% ANTl·INFECTIVE AGENTS - MISC. 16000005402120 Cayston Aztreonam lysine For lnhal So!n 75 MG {Base Equivalent) 16.00% ANTI-INFECTIVE AGENTS- MISC. 16000049000320 Xifaxan Rifaximin Tab 200 MG 16.00-¾ ANTI-INFECTIVE AGENTS- MISC. 16000049000340 Xifaxan Rifaximin Tab 550 MG 16.00% Antineop!astics 21353045001360 Arzerra Ofatumumab Cone for IV Infusion 1000 MG/50ML 16.75% Antineoplastics 21353060002040 Rituxan Rltuximab for IV lnjCone 10 MG/Ml 16.00% Antineoplastks 21534007100120 Alecensa Afectinib HCI Cap 150 MG (Base Equivalent) 15.50% Antlneop!astfcs 21370060200120 Odomzo SONIDEGIB PHOSPHATE CAP 200 MG {BASE EQUIVALENT) 15.50% Antineoplastics 21755050102030 Levo!eucovorin Calcium I Levoleucovorin Calcium IV Solo PF 250 MG/25ML {Base Equiv) 15.50% Antineoplastics 21100010002020 Busulfex Busulfan lnj 6 MG/ML 15.50% Antineoplastlcs 21574070401820 lmlygic Talimogene Laherparepvec lntralesional lnj 1000000 Unit/ML 15.50% Antineop!astics 21535570200320 Rubraca Rucaparib Camsylate Tab 200 MG (Base Equivalent) 15.50¾ Ant!neoplastics 21353060002040 Rituxan Rituxlmab For IV lnj Cone 10 MG/Ml 16.00% Antineoplastics 21250010402125 Erwinaze Asparaginase Erwlnia Chrysanthemi For IM lnj10000 Unit 16.00% Antineoplastics 21353060002040 Rituxan Rituximab For IV lnjCone 10 MG/Ml 16.00% Antineop!astics 2147008000b720 Venclexta Starting Pack Venetoclax Tab TherapyStarter Pack 10 & 50 & 100 MG 15.50% Antineoplastics 21755040102150 Leucovorin Ca!clum Leucovorin calcium For lnj 200 MG 15.50% Antineoplastics 21500012001325 PAClitaxel Paclitaxel IV Cone 30 MG/SML (6 MG/ML) 15.50% Antineoplastlcs 21300050100320 Trexall Methotrexate Sodium Tab 5 MG (Base Equiv) 15.50% Antineoplastics 21353027002030 Danalex Daratumumab IVSo!n 400 MG/20ML 15.50% Antineop!astics 21534013100320 Cabometyx Cabozantln!b S-Malate Tab 20 MG (Base Equlva!ent) 15.50% Antineoplastics 21990002750320 Lonsurf TRlFLURIDINE-TIPIRACIL TAB 15-6.14 MG 15.50% Ant!neoplastics 21708080000110 Vesanold Tretlno!n Cap 10 MG 15.50% Antineoplastics 21300050100350 Trexall Methotrexate Sodium Tab 15 MG {Base Equiv) 15.50% Antlneoplastics 21755040102130 leucovorin Calcium leucovorin Calcium For lnj100 MG 15.50% Antineop!astics 21100015002045 CARBOp!atin Carboplatin IV Solo 600 MG/60ML 15.50% Antineoplast!cs 21536045100140 Ninlaro lxazomib Citrate Cap4 MG (Base Equivalent) 15.50% Antineop!astics 21100009102005 Bendeka Bendamustine HCI IV Soln 100 MG/4ML (25 MG/Ml) 15.50% Antineoplastics 21700013001930 Tice BCG BCG live lntravesical For Susp 50 MG 15.50% Antineoplastics 2170002000?110 Dacarbazlne Dacarbazine For lnj 200 MG 15.50% Antlneoptastics 21200010102105 Bleomycin Sulfate B!eomydn Sulfate For lnj15 Unit 15.50% Antlneop!astics 21100015002030 CARBOp!at!n Carboplatin IV Soln 50 MG/SML 15.50% Antlneop!astics 21574070401840 lmlygie Talimogene laherparepvee lntralesional lnj100000000 Unit/ML 15.50% Ant!neoplastics 21353030002120 Empl!citi Elotuzumab For IVSoln 300 MG 15.50% Antineoplastics 21535570200330 Rubraca Rucaparib Camsylate Tab 300 MG {Base Equll/alent} 15.50% Antineoplastics 21200050002120 Mitomycin Mitomycin For lnj 40 MG 15.50% Antineoplastics 21300007002015 Cladribine Cladribine IV Sain 10 MG/10ML (1 MG/ML) 16.00% Antineoplastics 21470080000320 Venclexta Venetoclax Tab10 MG 15.50% Antlneoptastics 21534013100330 Cabometyx Cabozantinib S·Malate Tab 40 MG (Base Equivalent) 15.50% Antfneoplastfcs 21990002750330 lonsurf TRIFlURlDINE-TIPIRACIL TAB 20-8.19 MG 15.50% Antineop!astics 21550040202220 Onivyde lrinotecan HCI Liposome IV lnj 43 MG/10Ml {4.3 MG/Ml} 15.50% Antineop!ast!cs 21100020002020 CISplatin Cisp!atin lnj 50 MG/50ML (1 MG/ML) 15.50% Antineoplastics 21100015002040 CARBOp!atin Carboplatin IV So!n 450 MG/45ML 15.50% Antineop!astics 21533530200320 Cotelllc Cobimetinlb Fumarate Tab 20 MG {Base Equivalent)., T'- .,. - 15.50% Antineoplastics 21353030002130 Empliciti E!otuzumab For IVSoln 400 MG(- 15.50% Antineoplastics 21500005002075 DOCEtaxel (Non-Alcohol} Docetaxel (Non-Alcohol Formula) IV So!n 80 MG/4ML ,:;_J•\\ T ...,._- I ' "\,( J /-_,... ... \\ 15.50% Antineoplastics 21470080000340 Venclexta Venetoclax Tab 50 MG 15.50% '<f ,v, 0 \ j Contrato N'l .. • '.Iii - a Umeroim . ' (JI ·- I /i Z, I - \i\ ·• -----.,i,i' ;~, \ i'l-·, \,Cc _/,fl A) .-" o r•'' ·, ... ,.,DE5 .

Antineoplastics 21500012001350 Onxol Paclitaxel IV Cone 300 MG/50Ml (6MG/Ml) 15.50% Antineoplastics 21100020002025 Cl5p!atin Cisplatln lnj 100 MG/100Ml{1MG/Ml) 15.50% Antineop!astics 21500020102005 VinCRIStine Sulfate Vincristine Sulfate IV Sofn 1 MG/Ml Antineop!astics 21534065200330 Tagris.so Oslmertinib Mesylate Tab 80 MG (Base Equivalent) 15.50%15.50% Antineop!ast!cs 21536045100120 Ninlaro lxazomib Citrate Cap 2.3 MG (Base Equivalent) 15.50% Antineop!astics 21500005002080 DOCEtaxel {Non-Alcohol) Docetaxel (Non-Alcohol Formula) IV 5o!n 160 MG/8ML 15.50% Antineop!astics 21470080000360 Venclexta Venetoclax Tab 100 MG 15.50% Antineoplastics 21755050102020 Levoleucovorin calcium Levoleucovorin calcium lnj 175 MG/17.5Ml (Base Equiv) 15.50% Antineoplastfcs 21755040102160 Leucovorin calcium Leucovorln calclum For lnj 350 MG 15.50% Antlneop!astics 21755040102120 Leucovorin Calcium Leucovorin Calcium For lnj SO MG 15.50";{; Antineoplastics 21100015002035 CARBOplatin carboplatin IV Soln 150 MG/15Ml 15.50% Antineop!ast!cs 21353027002020 Darzalex Daratumumab N Soln 100 MG/SML 15.50% Antineop!ast!cs 21536045100130 Ninlaro lxazom!b Citrate Cap 3 MG {Base Equivalent) 15.50% Antineop!astics 21500005002070 DOCEtaxel {Non-Alcohol) Docetaxel (Non-Alcohol Formula) IV Soln 20 MG/Ml 15.50% Antineoplastics 21101040102115 Evomela Melphalan HCl For lnj SO MG {Propylene Glycol {PG) Free) 15.50% Antineoplastics 21534013100340 cabometyx cabozantinib S-Malate Tab 60 MG (Base Equivalent) 15.50% Antineop!astics 21107075002140 Yondells Trabectedin For lnJ 1 MG 15.50% Antineop!ast!cs 21200010102115 Bleomycin Sulfate Bleomycin Sulfate For lnj 30 Unit 15.50% Antineop!astics 21500012001335 PACLltaxel Paclitaxel IV Cone 100 MG/16.7Ml {6 MG/ML) 15.50% Antineoplastics 21534065200320 Tagris.so Osimertinib Mesylate Tab 40 MG {Base Equivalent) 15.50% Antineoplastics 21353047002020 lartruvo Olaratumab Sofn for 1V Infusion 500 MG/50ML {10 MG/ML) 15.50% ANT1NEOPLASTICS AND ADJUNCTIVE THERAPIES 21100009102010 Treanda Bendamustine HCl IVSo!n 45 MG/0.5ML (90 MG/ML) 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21100028002120 Oxaliplatin Oxalip!atin For IV Jnj 50 MG 30.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21101025002025 lfosfamide lfosfam!de IV lnj 1 GM/20Ml {SO MG/Ml) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21102020000110 CeeNU Lomustine Cap 10 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200030102210 DAUNOrubicin HCI Daunorubicin Hd lnj 5 MG/Ml(Base Equiv) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200042102040 Epirubicin HCI Epirublcin HCI lnj 150 MG/75ML {2 MG/ML) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200055001325 Mitoxantrone HCI Mitoxantrone HCI lnj Cone 25 MG/12.5Ml (2 MG/ML) 15.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300010002115 Cytarablne Cytarabine For tnj 1 GM 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300034102040 Gemc!tabine HCI Gemcitabine HC! lnj 1 GM/26.3ML {38 MG/ML) {Base Equiv) 30.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300054002025 Folotyn Pralatrexate IV lnj 40 MG/2Ml 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21352020002120 Blincyto Btrnatumomab For IV Infusion 35 MCG 16.00% ANTJNEOPLASTJCS AND ADJUNCTIVE THERAPIES 21402430000120 Xtandl Enzalutamide Cap 40 MG 16.00% ANTINEOP1A5TICS ANO ADJUNCTIVE THERAPIES 21405010106410 Lupron Depot Leuprolide Acetate For Jnj Kit 7.5 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405010256450 Lupron Depot Leuprolide Acetate (6 Month) For lnj Kit 45 MG 16.00% ANTINEOPlASTICS ANO ADJUNCTIVE THERAPIES 21450080000115 Pomalyst Pomalidomide Cap 2MG 18.25% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500005002040 DOCEtaxel Oocetaxel Soln for IV Infusion 80 MG/BML 35.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500012201920 Abraxane Paclitaxel Protein-Bound Particles For IV Susp 100 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21531060000130 lbrance Palbocidib Cap 100 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 2153202S100120 Tafinlar Dabrafenib Mesylate Cap 50 MG (Base Equivalent) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21532530007320 Afinitor Dlsperz Everolimus Tab for OralSusp 3 MG 16.00% ANTINEOPLA5TICS ANO ADJUNCTIVE THERAPIES 21533070300140 Sutent Sunitinib Malate Cap 50 MG {Base Equivalent) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534012000320 Bosulif Bosutinib Tab 100 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534020000320 Sprycel Dasatinlb Tab 20 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534025100360 Tarceva Erlotinib HC!Tab 150 MG {Base Equivalent) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 2153405420B240 Lenvima 14 MG Daily Do Lenvatinib Cap Therapy Pack 10 & 4 MG (14 MG Dalfy Dose) ,,1\STt ... ·s, 16.00% ANTINEOPlAST/CS AND ADJUNCTIVE THERAPIES 21536015002120 Vekade Bortezomib For lnJ 3,5 MG c-.1' ...,-_.!:"''--,...;;,:;.,._,,:'-/-'\. 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21538040000330 Zydefig ldelalisib Tab 150 MG ,..,,r- "'i_,_'-':. \\f 'I' f c(' . 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700020002105 Dacarbazine Dacarbaz!ne For lnj 100 MG._) \\" 16.00% ':,,. fVrjniero0.;,V m0j. ,u,•/J- n .., . 1\\ . •J ?)',

ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700060202135 Jntron A Interferon Alfa-2B For lnj 18000000 Unit 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700075206420 Sylatron Peginterferon alfa-2b For lnj Kit 300 MCG 16.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21755040100325 leucovorin Calcium leucovorin Calcium Tab 10 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21764065002140 Elitek Rasbur!case For IV Solo 7.5 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21100020002030 C/Splatin Cisplatin lnj 200 MG/200ML (1 MG/ML} 20.00% ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES 21101020002125 Cydophosphamide Cydophosphamide For lnj 1 GM 32.30¾ ANTlNEOPlASTICSAND ADJUNCTIVE THERAPIES 21101040102110 Alkeran Melphalan HCI For lnj SO MG (Base Equiv) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200030052210 DaunoXome Daunorub!cin Citrate Uposome lnj 2 MG/Ml 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200042102025 Epirubicin HCI Ep!rub!cln HCI lnj 10 MG/5Ml (2 MG/Ml) 16.00% ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES 21200045102035 ldamycin PFS tdarublcin HCI IV lnj 20 MG/20ML{1MG/ML) 16.00% ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES 2130001000210S Cytarabine Cytarabine For lnj 100 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300030002025 Fluorourac!I F!uorouracll lnj 1 GM/20ML (SO MG/ML) 16.25% ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES 21300053102120 Allmta Pemetrexed Disodfum For IV Soln 500 MG (Base Equiv) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21335070002020 Cyramza Ramucirumab IV Soln 100 MG/10Ml {For Infusion) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21353043002025 Gazyva Obinutuzumab Solo for IV Infusion 1000 MG/40Ml (25 MG/ML) 16.00% ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES 21353054002020 Perjeta Pertuzumab So!n for IV lnfuslon 420 MG/14Ml (30 MG/ML) 16.00% ANTINEOPLASTIC$ AND ADJUNCTIVE THERAPIES 21402250000320 Lysodren Mltotane Tab 500 MG 16.00% ANTINEOPLASTIC$ AND ADJUNCTIVE THERAPIES 21405007106450 Vantas Histrelin Acetate Implant Kit 50 MG 15.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21405010206435 Ellgard Leupro!ideAcetate(4 Month) For Subcutaneous lnj Kit 30 MG 25.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21100009102030 Treanda Bendamustine HCI IV Solo 180 MG/2Ml (90 MG/ML) 16.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21100028002130 Oxaliplatin Oxalip!atln For IV lnj 100 MG 30.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21101025002030 lfosfamide lfosfamide IV lnj 3 GM/GOML {50 MG/Ml) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21102020000115 CeeNU Lomustlne cap 40 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200040102010 Adriamycin Doxorublcin HCI lnj 2 MG/Ml 16.00% ANTINEOPLASTlCS AND ADJUNCTIVE THERAPIES 21200042102045 Ellence Ep!rubicin HCI IV Soln 200 MG/lOOML (2 MG/ML) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200055001330 Mitoxantrone HCI Mitoxantrone HCI lnj Cone 30 MG/15ML {2MG/ML) 15.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300010002120 Cytarabine Cytarablne For lnj 2 GM 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300034102060 Gemcitablne HC\ Gemcltabine HCI lnj 2 GM/52.6Ml {38 MG/ML) (Base Equiv} 30.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300060000305 Tabloid Thioguanine Tab 40 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21353010002040 campath Alemtuzumab IV lnj 30 MG/ML(For Infusion) 16.00% ANTINEOPLASTICSANDADJUNCTIVE THERAPIES 21353050002025 Vectibix Panitumumab IVSo!n 100 MG/5Ml 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21353070002120 Herceptin Trastuzumab For IV Soln 440 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21403020100105 Emcyt Estramustine Phosphate Sodium cap 140 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21405010106415 E!fgard LeuprolideAcetate For Subcutaneous lnj Kit7.5 MG 25.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21100010000305 Myleran Busulfan Tab 2 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21101020000310 Cyc!ophosphamide Cyclophosphamlde Tab SO MG 32.30% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21101030102105 Mustargen Mechlorethamine HCI For lnj 10 MG 16.00% ANTINEOPLASTJCS AND ADJUNCTIVE THERAPIES 21104070002120 Temodar Temozo!omide For IV So!n 100 MG 16.00% ANTINEOPLASTICS ANO ADJUNCTIVE THERAPIES 21200040102115 Adriamycin Doxorubicin HCI For lnj 50 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200045102025 ldamycin PFS ldarublcin HCIIV lnj 5 MG/SML {1 MG/Ml) 16.00% ANTINEOPLASTICS ANO ADJUNCTIVE THERAPIES 21250060002020 Oncaspar Pegaspargase lnj 750 Unit/ML 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300025102020 Fludarabine Phosphate Fludarab!ne Phosphate lnj 25 MG/ML 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300052002020 Arranon Ne!arabine IV Soln 5 MG/ML 16.00% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21335020002025 Avastin Bevacizumab IV So!n 100 MG/4ML (For Infusion) 15.50% ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES 21353032002020 Yervoy lpiHmumab Soln for IV Infusion 50 MG/10ML {5 MG/ML) 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21353053002030 Keytruda Pembrolizumab IVSoln 100 MG/4ML {25 MG/Ml) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21355070302130 Kadcyla Ado Trastuzumab Emtans!ne For IV Soln 160 MG -:' _\\S CR;-.:i;.- ...,, 16.00% ANTINEOPLASTICS ANO ADJUNCTIVE THERAPIES 21405005102310 Zoladex Goserelin Acetate lmp!ant3.6 MG <;-,J\ ·_..... .::-•...-, "' /f'-\ "\ 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405010156432 Ellgard leuprolfdeAcetate {3 Month) For Subcutaneous lnj Kit 22.5MG YF '\_'\·1., 25.00% l .., ff C , '· 0 0 i ntrat N, () ' " y 9. urnero ; Ill '. to·- 052 i ,, \\(\ ,)\ \ ,/l9 r·,,.. "'' 0'Yo "=,"';.",'.7,0 (

I Am1NEOPLASTJCS AND ADJUNCTIVE THERAPIES 21100015002120 CARBOplatin Carboplatin IV For lnj 150 MG 16.25% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21101020002120 Cydophosphamide Cyclophosphamide For lnj 500 MG 32.30% ANT1NEOPlAST!CS AND ADJUNCTIVE THERAPIES 21101040000305 Alkeran Melphalan Tab 2 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200020002105 Cosmegen Dactinomycin For lnj 0.5 MG 16.00% ANTINEOPLASTIC$ AND ADJUNCTIVE THERAPIES 21200040402210 Doxil Doxorublcin HCI Liposomal lnj {For IV Infusion) 2 MG/ML 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200045102030 ldamycin PFS \darubicin HCI JV lnj 10 MG/10ML (1 MG/ML} 16.00% ANTINEOPLASTJCS AND ADJUNCTIVE THERAPIES 21300007002010 Cladribine dadribine lnJ 1 MG/ML 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300025102120 Fludara F!udarabine Phosphate For lnj so MG 16.00% ANTINEOPLASTIC$ AND ADJUNCTIVE THERAPIES 21300053102110 Alimta Pemetrexed Disodlum For JV Soln 100 MG (Base Equiv) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21335020002030 Avastin Bevacizumab JV Sotn 400 MG/16ML {For Infusion) 15.50¼ ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21353032002040 Yervoy lpilimumab Soln for IV Infusion 200 MG/40ML (5 MG/Ml) 16.75% ANTINEOPLASTJCS AND ADJUNCTIVE THERAPIES 21353053002120 Keytruda Pembrolizumab For IVSoln 50 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21370070000120 Erivedge Vismodegib Cap 150 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405005102330 Zoladex Goserel!n Acetate Implant 10.8 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 2140S010206430 lupron Depot leuprolldeAcetate(4 Month) For lnj Kit 30 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21104070000147 Temodar Temozolomide Cap 180 MG 35.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 99392070000135 Tha!omid Thalidomide Cap 150 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300034102140 Gemcitabine HO Gemcitabine HCI For lnj 1 GM 30.00% ANTINEOPlAST!CS AND ADJUNCTIVE THERAPIES 21406010200320 Zytiga Abiraterone Acetate Tab 250 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500005001325 DOCEtaxel Docetaxel For lnj Cone 80 MG/2Ml (40 MG/ML) 35.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500011002140 lxempra Kit lxabepilone For IV Infusion 45 MG 16.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500050802025 Nave\b!ne Vinore!blne Tartrate lnj 50 MG/SML (10 MG/ML) (Base Equiv) 16.00¼ ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21531S60002120 lstodax Romldepsln For IVlnj10 MG 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21532530000330 Afinltor Evero11mus Tab 10 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21533070300130 Sutent Sunitinlb Ma\ate Cap 25 MG (Base Equivalent) 16.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21534008000320 lnlyta Axitinib Tab 1 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534015000120 Xalkorl Crizotinib Cap 200 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534025100320 Tarceva Erlotinib HCI Tab 25 MG (Base Equivalent) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 215340S420B220 Lenvlma 10 MG Daily Do Lenvatlnib Qlp Therapy Pack 10 MG {10 MG Dally Dose) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534075100340 lcluslg Ponatinib HCI Tab 45 MG {Base Equiv} 22.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21537560200335 Jakafi Ruxolitinib Phosphate Tab 25 MG {Base Equivalent} 15.25% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700008102020 Trlsenox Arsenlc Trioxide lnj 10 MG/10Ml (1MG/ML) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21700060202030 lntron-A Interferon Alfa-2B lnj 10000000 Unit/ML 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21700060702020 Actimmune Interferon Gamma-18 lnj 100 MCG/0.5Ml {2000000 Unit/0.SML) 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21707070102140 Photofrin Porfimer Sodium For lnj 75 MG 16.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21758050002010 Mesna Mesna lnj 100 MG/ML 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405525102120 Firmagon Degarelix.Acetate For lnj 80 MG (Base Equiv) 15.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500005001317 DOCEtaxel Docetaxel For lnj Cone 160 MG/8ML (20 MG/Ml) 35.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21500010602120 Etopophos Etoposide Phosphate JV For lnj 100 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 2150003010210S VinBLA5tine Sulfate Vinb!astine Sulfate For lnj 10 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21531550100130 Farydak Panoblnostat lactate Cap 15 MG (Base Equivalent) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21532530000320 Aflnitor Everolimus Tab 5 MG 16.00¾ ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21533060400320 NexAVAR Sorafenib Tosylate Tab 200 MG (Base Equivalent) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534006100330 Gilotrif Afatinlb Dimaleate Tab 30 MG (Base Equivalent) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534013106480 Cometrlq {140 mg Daily Cabozantinib S·Mal Qlp lX 80 MG & 3 X 20 MG (140 Dose} Kit 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534020000360 Sprycel Dasatinib Tab 100 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534035100340 Gleevec lmatinib Mesylate Tab 400 MG {Base Equivalent} P ·\S-11-..)/, 17.25%,.,-," ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 2153407010032021537560200325 Votrient Jakafi Pazopanib HCI Tab 200 MG {Base Equiv) .'7 ,.J..... "Ruxo!itinib Phosphate Tab 15 MG {Base Equivalent) l <J /7 -._-1,, \ 16.00%1s.2s% •. , ., .... ''l'f[-..',\\)) \ IJ 5 2(. \\\ () rt , 0 Qv,,y =,s:9 ', OsDE::J•· (

¾ ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTlNEOPLASTlCS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANT/NEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlAST!CS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPtASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND-ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTJCS AND ADJUNCTIVE THERAPIES ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTJNEOPlASTJCS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLAST/CS AND ADJUNCTIVE THERAPIES .'t,,.,, -- -""'""'''- 21550080100140 Hycamtin21700050100105 Matulane21700060206470 lntron-A21700075206470 Syfatron21755050102120 Fusilev21405050201920 Trelstar Depot21450080000120 Poma!yst21500005002050 DOCEtaxel21500015002020 Teniposide21531060000140 lbrance 21532025100130 Tafin\ar21532530007340 Afinitor Disperz21533570100310 Mekinlst21534012000340 Bosullf Topotecan HCI Cap 1 MG {Base Equiv) Procarbazine HCI Cap SO MGInterferon Alfa-2B lnJ Kit 10000000 Unit/0,2ML Peglnterferon alfa-2b For lnj Kit 4 X 600 MCG Levoleucovorln Calcium For IV lnj 50 MG {Base Equiv)Triptorelin Pamoate For IM Susp 3.75 MG Pomaffdomide Cap 3 MGDocetaxel Solo for IV Infusion 160 MG/16ML TeniposJde IVSoln 10 MG/MLPalboc!dib Cap 125 MGDabrafenib Mesylate Cap 75 MG (Base Equivalent) Evero!imus Tab for Oral Susp 5 MGTrametin"1b Dimethyl Sulfoxide Tab 0.5 MG (Base Equivalent)Bosutinib Tab 500 MG 21534020000340 Sprycel21534030000320 lressa Dasatinib Tab 50 MG Gefitinib Tab 250 MG 21534054208250 Lenvima 24 MG Daily Do lenvatin·1b c.ap Therapy Pack 10 (2) & 4 MG {24 MG Daily Dose) Carfifzomib For lnj 60 MG frinotecan HCI lnj 300 MG/15Ml (20 MG/ML) Deni!eukln Diftitox JV Soln 150 MCG/ML Interferon Alfa-2B For lnj 50000000 Unit Peginterferon alfa-2b For lnj Kit 600 MCG Leucovorln Calcium Tab 15 MG Pafifermln For JV In] 6.25 MG DegarelixAcetate For lnj 120 MG (Base Equiv) Docetaxel for lnj Cone 20 MG/0.SML (40 MG/ML) Jxabepilone For IV Infusion 15 MG Vinorelblne Tartrate lnj 10 MG/ML {Base Equiv} Panoblnostat Lactate Cap 20 MG (Base Equivalent) 21536025002120 Kyprolis21550040102035 Camptosar21700024002020 Ontak21700060202160 lntron A21700075206430 Sylatron21755040100335 Leucovorin Calcium21765060002120 Kepivance21405525102130 Firmagon21500005001320 DOCEtaxel21500011002120 lxempra Kit21500050802020 Navelbine21531550100140 Farydak21532530000325 Afinitor21533070300120 Sutent21534006100340 Gilotrif21534014000130 Zykadla21534020000380 Sprycel21534050100320 Tykerb21534075100320 lclusig21537560200330 Jakafi21550080102020 Topotecan HCI21700060202022 lntron-A21700060302020 Alferon N21703020002120 Profeukin21758050000320 Mesnex21100009102120 Treanda21101020000305 Cyclophosphamide21101025002130 lfex21102030002105 Zanosar21200040102110 Adriamycin21200042102170 Epirubicin HCI EverolimusTab 7.5 MGSunitinib Malate Cap 12.5 MG {Base Equivalent) Afatinib Dima!eate Tab 40 MG {Base Equivalent) Cerltinib Cap 150 MGDasatlnlb Tab 140 MGlapatlnfb Ditosy!ate Tab 250 MG {Base Equiv) Ponatlnlb HCI Tab 15 MG {Base Equiv)Ruxo!itinib Phosphate Tab 20 MG (Base Equivalent) Topotecan HCl lnj 4 MG/4Ml{Base Equiv} {For Infusion} Interferon Alfa-2B fnj 6000000 Unit/ML Interferon Alfa-n3 Jnj 5000000 Unit/ML A!des!eukin For IV Soln 22000000 Unit Mesna Tab 400 MGBendamustine HCI For IV Soln 100 MG Cyclophosphamide Tab 25 MG lfosfamlde For lnj 3 GM Streptozocin For tnj 1 GM Doxorubicin HCJ For lnj 20 MG 21300025100320 Oforta EplrubiclnHCI ForlnJ 200 MG Fludarabine Phosphate Tab 10MG 16.00%16.00"/416.00%16.75%16.75%22.50%18.25%3S.00%16.00%16.00%16.00"/416.00%16.00"/416.00% ( 16.00%15.25% .,,,,. , ?TRA, "-J ·I• .._,- , .,, , ,"'{\, s.' V 16.00%16.00%16.00%16.00%16.00%16.75%16.00%16.CJO%15.75%35,00%16.75%16.00¾16.00%16.00%16.00%16.00%16.00%16.00%16.00%22.75%15.25%17.00%16.00%15.75%16.75%16.00%16.75%32.30%16.00%16.00%16.00%16.00% I ( ',,Y.;v ll- \\'.J S.75%

Q, l '(IICont1-810 Numero ; (it\ -9-(lr • (j) •- . ., 2 ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21300040001830 Purixan Mercaptopurine Susp 2000 MG/lOOMl (20 MG/Ml) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21335010102030 Zaltrap Ziv-Aflibercept JV Soln 200 MG/8ML (For Infusion) 16.00% ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES 21353025002025 Erbitux Cetuximab IV Solo 200 MG/100ML (2 MG/ML) 16.25% 21353050002035 Vectibix Panitumumab IV Soln 400 MG/20ML 16.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIESANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21355070302120 Kadcyla Ado-Trasrozumab Emtansine For IV So!n 100 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21403530002024 Fastodex Fufvestrant lnj 250 MG/5ML 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21405010156430 lupron Depot leuprolide Acetate {3 Month) For lnj Kit 22.5 MG 16.00% ANTINEOPLAST!CS AND ADJUNCTIVE THERAPIES 21100028002035 Eroxatin Oxaliplatln IV Soln 200 MG/40ML 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21101020002130 Cydophosphamide Cydophosphamide For In] 2 GM 32.30% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21102010002105 BiCNU Carmustlne For lnj 100 MG 16.00"1,i ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200030102105 Cerubidine Daunorubidn HCI For lnj 20 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200042102030 Ellence Epirublcin HCI IV Soln 50 MG/25Ml{2. MG/ML) 16.00¾ ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200055001320 Mitoxantrone HCI Mltoxantrone HCI lnj Cone 20 MG/10Ml (2 MG/Ml) 15.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300010002110 Cytarabine Cytarabine For lnj 500 MG 16.00% ANTINEOPlAST!CS AND ADJUNCTIVE THERAPIES 2.1300034102020 Gemdtabine HCI Gemcltablne HCI tnj 200 MG/5.26Ml {38 MG/ML} {Base Equiv) 30.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300054002020 Folotyn Pralatrexate IV lnj 20 MG/ML 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21335070002.040 Cyramza Ramucirumab IVSoln 500 MG/50Ml {For Infusion) 16.00% ANTlNEOPlASTICSAND ADJUNCTIVE THERAPIES 21353045001320 Arzerra Ofatumumab Cone For IV Infusion 100 MG/5Ml 16.75% ANTINEOPLASTlCS AND ADJUNCTIVE THERAPIES 21402420000320 Casodex Bicalutamide Tab 50 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21100009102110 Treanda Bendarnustine HCI For IV So!n 25 MG 16.75% ANTINEOPLA5TICS AND ADJUNCTIVE THERAPIES 21101010000305 Leukeran Chlorambucil Tab 2 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21101025002110 lfex lfosfamide For lnj 1 GM 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21102.020000120 CeeNU Lomustlne Cap 100 MG 16.00% ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES 21200040102105 Adriamycln Doxorubicin HCI For lnj 10 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200042102.140 Epirubicin HCI Ep!rubicin HCI For lnj 50MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200080002020 Valstar Valrub!cln So!n For lntravesical Instillation 40 MG/Ml 16.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300010301825 DepoCyt Cytarablne Uposome lnj 50MG/5Ml 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300034102160 Gemcltabine HCI Gemcitabine HCI For lnj 2 GM 30.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21335010102020 Zaltrap Ziv-Aflibereept IV Soln100 MG/4Ml {For Infusion) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21353025002020 Erbitux Cetuximab NSoln 100 MG/50Ml (2 MG/ML) 16.25% ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES 21353050002030 Veetibix Panitumumab lVSoln 200 MG/10ML 16.75% ANTINEOPLASTlCS AND ADJUNCTIVE THERAPIES 21355020202120 Adcetris Brentuximab Vedotin For IV Soln 50 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21403530002022 Fas!odex Fulvestrant lnj 125 MG/2.5ML 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 214050502.01930 Trelstar LA Triptorelin Pamoate For IM Susp 11.25 MG 22.50% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21104070000140 Temodar Temozolomide cap 100 MG 35.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 2150000S001310 DOCEtaxel Docetaxel For lnj Cone 20 MG/Ml 35.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 9939207000012.0 Thalomid Thalidomide Cap 50 MG 16.00% ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES 99394050000145 Revlimid leoalidomlde cap 20 MG 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405010256445 Eligard leuprolideAcetate {6 Month) For Subcutaneous lnJ Kit 45 MG 25.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21450080000110 Pomafyst Pomaltdomlde Cap 1 MG 18.25% ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 21500005002030 DOCEtaxel Docetaxel So!n for IV Infusion 20 MG/2ML 3S.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500012001340 PACUtaxel Paditaxel IV Cone 150 MG/25Ml (6MG/ML) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21531060000120 lbrance Palbocidib Cap 75 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21531575000120 Zol!nza Vorlnostat Cap 100 MG 16.00% ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES 21532530007310 Afinitor Disperz Everol!musTab for Oral Susp 2 MG -- 16.00"/2 ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES 21533070300135 Sutent Sunitinib Malate Cap 37.5 MG {Base Equivalent) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534008000340 lnlyta Axitinlb Tab 5 MG J . o\5 11«.,,,., -...,_ 16.00% ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 2153401500012521534025100330 Xa\kori Tarceva Crizotinib Cap 250 MG /' .;.:1:• ..,.0·v'-''· 16.00%16.00% Erlotln!b HCJ Tab 100 MG (Base Equivalent) .I VF --·~ \t,.-:-:---:;;<.:? ' r"'v : ..• VA'l --' :v \0 8 nr;_sr_.. -

ANTINEOPlAST[CS AND ADJUNCTIVE THERAPIES 2153405420B230 lenvlma 20 MG Daily Do Lenvatinlb cap Therapy Pack 10 {2) MG (20 MG Dally Dose) ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21535560000120 lynparza Olaparib Cap 50 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21538040000320 Zydelig ldelalisib Tab 100 MG ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21700013001940 TheraCys BCG live lntravesicat For Susp 81 MG/VIAL ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700060202130 lntron A Interferon Alfa-28 For lnj 10000000 Unit 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21700075206410 Sylatron Peginterferon a!fa-2b For lnj Kit 200 MCG 16.00% ANTINEOPlAST!CS AND ADJUNCTIVE THERAPIES 21708220000120 Targretin Bexarotene Cap 75 MG 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21764065002120 Elitek Rasburicase For IVSoln 1.5 MG 16,00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21104070000150 Temodar Temozolomide Cap 250 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 99392070000140 Thalomid Thalidomide Cap 200 MG 35.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21405010106407 Leuprolide Acetate leuprolide Acetate lnj Kit 5 MG/Ml 16.00%52.25% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300015002120 Dacogen Dedtab!ne For lnj SO MG 25.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500010002025 Etoposide Etoposlde lnj 100MG/5Ml (20 MG/ML) 27.55% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500010002030 Etoposide Etoposide lnj 500MG/25ML (20 MG/ML) 27.55% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21450080000125 Pomalyst Pomalidomide Cap 4 MG ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES 21500009202020 Halaven Erlbutin Mesylate lnj 1 MG/2Ml (0.5 MG/Ml) 16.75% ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES 21500020201820 Marqibo Vincristine Sulfate Uposome IV Susp 5 MG/31Ml (0.16 MG/ML) 16.00% ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES 21531520002120 Beleodaq Belinostat For IV lnj 500 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21532080000320 Zelboraf Vemurafenib Tab 240 MG ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21532570002020 Torisel Temsiro!imus So!n For IV Infusion 25 MG/Ml 16.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21533570100330 Meklnlst Trametinib Dimethyl Sulfoxide Tab 2MG (Base Equivalent) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534013106460 Cometriq (60 mg Daily D, Cabozantlnib S-Ma!ate Cap 3 X 20 MG (60 MG Dose} Kit 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534020000350 Sprycel Dasatinib Tab 70 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534033000120 lmbruvlca lbrutinib Cap 140 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534060200115 Taslgna Nilotinlb HCI Cap 150 MG (Base Equivalent} 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21537560200310 Jakafi Ruxolitinib Phosphate Tab 5 MG (Base Equivalent} 15.25% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21550040102040 lrinotecan HC! lrinotecan HCI lnj 500 MG/2SML (20 MG/Ml) 30.00% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21700040102120 Synribo Omacetaxine Mepesuccinate For lnj 3.5 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21700060206450 lntron-A Interferon Alfa-28 lnj Kit 3000000 Unit/0.2ML 16.00% ANTINEOPLA5TICS AND ADJUNCTIVE THERAPIES 21700075206450 Sylatron Peginterferon alfa-2b For lnj Kit 4 X 200 MCG 16.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21755040102030 leucovorin calcium leucovorin Calcium lnJ10 MG/Ml 16.00% ANTINEOPI.ASTICS AND ADJUNCTIVE THERAPIES 21104070000143 Temodar Temozolomlde cap 140 MG 35.00% ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES 21500005001315 OOCEtaxel Docetaxel For lnj Cone BO MG/4Ml{20 MG/ML) 35.00% ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES 99392070000130 Thalomld Thalidomfde cap 100 MG 16.00% ANTlNEOPI.ASTICS AND ADJUNCTIVE THERAPIES 99394050000150 Revllmfd Lenc:11idomide Cap 2S MG 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21100028002030 Efoxatin Oxaliplatin IV Soln 100 MG/20Ml 30.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 99394050000110 Revlimid Lenafldomide caps 2.5 MG 16.75% ANTINEOPLASTICS ANO ADJUNCTIVE THERAPIES 21534085000320 Caprelsa Vandetanib Tab 100 MG 16.00% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21550040102025 Camptosar lrinotecan HCI lnj 40 MG/2Ml (20 MG/ML) 30.00% ANTlNEOPLASTICS ANO ADJUNCTIVE THERAPIES 21550080102120 Hycamtin Topotecan HCIFor lnj 4 MG 17,00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300034102110 Gemcitabine HCt Gemcitablne HCIFor lnj 200 MG 30.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500010002040 Etoposide Etoposide lnj 1 GM/SOML {20 MG/Ml) 27.55% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21550040102030 Camptosar lrinotecan HCI lnj 100 MG/SMl (20 MG/ML) 30.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21250010402120 Erwinaze Asparaginase Erwinia Chrysanthemi For lnj 10000 Unit 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21104070000110 Temodar Temozolomide Cap 5 MG 35.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 213000050003SO C.apecitablne CapecitabineTab 500 MG . , c .:1 r--. 40.00% ANTINEOPLASTJCS AND ADJUNCTIVE THERAPIES 99394050000130 Revlimid lenalidomlde cap 10 MG <;S,\' "' - 1<....'.,....'.\ 16.75% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21300030002030 Adrucil F!uorouracil lnj 2.5 GM/SOML (50 MG/ML) '(}·.1,.,,- '<:,Y.,.1..%.., 16.25% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21104070000120 Temodar Temozolomide Cap 20 MG j ff- -, 35.00% iV' 9 ..'."'O·.N( mero 1 '!11\ , <fl ,- (I •'> 2 . ,, .. J ' ·-- I \ \\ (.,\ /_0 :--, ,_c,,v"" -=,--. \v ",..,o... c:::; OE sf .... " , ...,.. ,,,,,,, . (

"v ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300030002020 Adrucil Fluorouracil lnj 500 MG/lOML {SO MG/ML) 16.25% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES . 99394050000140 RevHmld Lenalidomide Cap 1S MG 16.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 2130003000203S Adruci\ Fluorouracil lnj 5 GM/lOOML{SO MG/ML) 16.25% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300003001920 AzaCITIDine Azacitidine For lnj 100 MG 25.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405050201940 Trelstar Mlxject Triptorelin Pamoate For IM Susp 22.5 MG 22.50% ANTINEOPl.ASTICS AND ADJUNCTIVE THERAPIES 21500003002020 Jevtana Cabazitaxel lnj 60 MG/1.SML {For IV Infusion) 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500010000120 Etoposide Etoposide Cap so MG 27.55% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500030102020 VinBlAStine Sulfate Vlnblastine Sulfate lnj 1 MG/Ml 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21531550100120 Farydak Panobinostat lactate cap 10 MG {Base Equivalent) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21532530000310 Afinitor Everolimus Tab 2.5 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 215330S0000320 Stivarga Regorafenib Tab 40 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534006100320 Gilotrif Afatinib Dimaleate Tab 20 MG (Base Equivalent) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534013106470 Cometriq {100 mg Daily [ cabozantinib S-Mal Cap 1 X 80 MG & 1 X 20 MG (100 Dose) K!t 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534020000354 Sprycel Dasatin!b Tab 80 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534035100320 G!eevec lmatlnib Mesylate Tab 100 MG (Base Equivalent} 17.25% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534060200125 Taslgna Nilotinib HCI Cap 200 MG {Base Equivalent) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21537560200320 Jakafl Ruxo!itinib Phosphate Tab 10 MG {Base Equivalent) 15.25% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21550080100120 Hycamtin Topotecan HCI Cap 0.25 MG (Base Equiv) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21700045002120 Nlpent Pentostatin For lnj 10 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21700060206460 lntron-A Interferon Alfa-2B lnj Kit5000000 Unlt/0.2Ml 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21700075206460 Sy!atron Peginterferon alfa-2b For lnj Kit 4 X 300 MCG 16.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21755040102170 Leucovorin catcJum Leucovorin Calcium For lnj 500 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21100028002025 Eloxatin Oxa!ip1atln IV Soln 50 MG/10ML 30.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300005000320 Capedtabine Capecitablne Tab 150 MG 40.00% ANTINEOPLAST\CS AND ADJUNCTIVE THERAPIES 99394050000120 Revlimid lenalldomlde Cap 5 MG 16.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534085000340 Caprelsa Vandetanlb Tab 300 MG 16.00% ANTINEOPLASTICS TOPICAL$ 90371050204030 Valchlor Mech1orethamine HCI Gel 0.016% {Base Equivalent) 16.00% ANTINEOPlASTICSTOPICALS 90376015004020 Panretin Alitretinoin Gel 0.1% 16.00% Antiparasitics 13000040000310 Daraprlm Pyrimethamine Tab 25 MG 15.50% ANTIPARKINSON AGENTS 73203010102020 Apokyn Apomorphine Hydrochloride lnj 10 MG/Ml 15.75% Antipsychotics 59070070101930 RisperDAl Consta Rlsperldone Mlcrospheres For lnj 37.5 MG 15.50¼ Antipsychotics 59250015001930 Abilify Maintena Aripiprazo!e IM For Extended Release Susp 400 MG 15.50% Antipsychotics 59070070101920 RlsperDAL Consta Risperidone Microspheres For lnj 25 MG 15.50% Antlpsychotics 59070070101910 RisperDALConsta Rlsperidone Microspheres For lnj 12.5 MG 15.50% Antipsychotics 59070050101837 lnvega Sustenna Paliperidone Palmitate IM Extended-Release Susp 39 MG/0.25Ml 15.50% Antipsychotics 59070070101940 RisperDAL Consta Rlsperidone Microspheres For lnJ SO MG 15.50% Antipsychotics 59070050101845 lnvega Sustenna Paliperidone PaImitate IM Extended-Release Susp 234 MG/1.SML 15.50% Antipsychotics 59070050101838 lnvega Sustenna Pa[iperidone Palmitate IM Extended-Release Susp 78 MG/0.SML 15.50% Antipsychotics 59070050101850 lnvega Trinza Pa!fperidone Palmitate IM Extend-Release Susp 273 MG/0.875Ml 15.50% Antlpsychotics 59250015001920 Abilify Ma!ntena Aripiprazo!e IM For Extended Release Susp 300 MG 15.50% Antipsychotics 5925001520E430 Aristada ARIPlPRAZOLE l.AUROXtLIM ERSUSP PREFILLED SYR 662 MG/2.4Ml 15.50% Antipsychotics 590700S0101839 lnvega Sustenna Paliperidone Pa!mitate 1M Extend-Release Susp 117 MG/0.75Ml 15.50% Antipsychotics 59070050101870 lnvega Trinza Pal!peridone Palmitate IM Extend-Release Susp 546 MG/1.75Ml 15.50% Antipsychotics 5925001520£.440 Aristada ARlPIPRAZOLE lAUROXU IM ER SUSP PRE.FILLED SYR882 MG/3.2Ml 15.50% Antipsychotics 59070050101880 lnvega Trlnza Pallperidone Palmitate IM Extend-Release Susp 819 MG/2.62SML 15.50% Antipsychotics 5925001520E420 Aristada ARIPIPRAZOLE LAUROXIL IM ER SUSP PREFlllED SYR 441MG/1.6ML 15.50% Antipsychotics 59070050101840 lnvega Sustenna Paliperidone Palmitate IM Extended-Release Susp 156 MG/ML .,.,<, tS fD /.'.i "'- 15.50% Antipsychotics ANTIPSYCHOTICS/ANTIMANJCAGENTS 5907005010186059157060101950 lnvega Trinza ZyPREXA Relprew Pallperidone Palmitate IM Extend-Release Susp 410 MG/1.3).S L•,. "i'..--..,,0/anzapine Pamoate For Extended Rel IM Susp 210 MG (Bas' e'." }.1_-:, -'-;,;I< 15.50%16.00"ii -- -'-"" ' ,Ir Contrato N' ' 0,,; JJsi umero,m(.f:\ - ' () ) _/\-\\ :' -- C>}_/-- _,// Q \; - ·"'0 ""=, ,-;> ls-..:....,._c---y--:-:=:---e- f>·

59157060101970 ZyPREXA Relprew59157060101960 ZyPREXA Relprew12200020102030 Foscavlr12359902300320 Zepatier12200020102040 FoscarnetSodium 1250406S002020 Rapivab30042048100360 Boniva84100010000320 Amicar84100010001205 Amicar84100010000305 Amlcar 8240102000ES45 Epogen8240104010E515 Mircera8240152000E545 Neupogen 85100028402105 Alprolix85100015106440 W!late85100028202145 lxinity85100010402130 Adynovate 8S100031002140 Coagadex 85100028206430 BeneFIX 8240102000E545 Epogen8240102000E575 Epogen8240152000E525 Neupogen 8240102000£545 Epogen8240104010E520 Mircera8240152000E550 Neupogen 85100028352130 Jdelvion85100028402150 A!pro!ix8240104010E525 Mircera ANTIPSYCHOTICS/ANTIMANlC AGENTS ANTlPSYCHOTICS/ANTIMANIC AGENTSAntivirals Antivirals AntiviralsANTIVIRALS INFLUENZABisphosphonates BLEEDING DISORDERS BLEEDING DISORDERSBLEEDING DISORDERSBlood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/Volume Expanders Blood Products/ Modifiers/Volume Expanders Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/Volume Expanders Blood Products/ Modlf!ers/ Volume Expanders Blood Products/ Modifiers/Volume Expanders Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/Volume Expanders Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/Volume Expanders Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/Volume Expanders Blood Products/ Modifiers/Volume Expanders Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/Volume Expanders Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/Volume Expanders Blood Products/ Modifiers/Volume Expanders Blood Products/ Modifiers/Volume ExpandersBlood Products/ Modifiers/Volume Expanders Blood Products/ Modiffers/ Volume ExpandersBlood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/Volume Expanders Blood Products/ Modifiers/Volume Expanders Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/ Volume Expanders Blood Products/ Modifiers/ Volume- Expanders Blood Products/ Modifiers/Volume Expanders Blood Products/ Mocfifiers/ Volume Expanders Blood Products/ Modifiers/Volume Expanders Blood Products/ Modifiers/Volume Expanders Olamaplne Pamoate For Extended Rel IM Susp 405 MG (Base Eq) Olanzaplne Pamoate For Extended Rel 1M Susp 300 MG {Base Eq) FoscarnetSodium lnj 6000 MG/250ML(24 MG/ML)Elbasv!r-GrazoprevirTab 50·100 MG FoscarnetSodium lnj 12000 MG/500ML (24 MG/ML)Peramivir lnj 200 MG/20ML (10 MG/ML)lbandronate Sodium Tab 1S0 MG (Base Equivalent) Aminocaproic Add Tab 1000 MGAminocaproic Add Syrup 25% Am1nocaproicAdd Tab 500 MG 8240101510E556 Aranesp {Albumin Free) Darbepoetln Affa•Polysorbate 80 Sain lnj 60 MCG/ML 8240101510E575 Aranesp (Albumin Free) Darbepoetin Atfa-Polysorbate- 80 Sain lnj 150 MCG/0.3ML 82401015102080 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 500 MCG/ML Epoetin Alfa lnj 10000 Unit/MLMethoxy Polyethylene Glycol-Epoetin Beta lnj SO MCG/0.3ML Filgrastlm lnj 300 MCG/0.5ML (600 MCG/ML}Coagulation Factor IX {Recomb) (rFIXFc} For lnj 250 Unit Antihemophllic Factor/WJF (Human) For lnj 1000-1000 Unit KitCoagulation Factor IX (Recombinant) For lnj 1500 Unit Antihemophillc Factor Recomb Pegyfated For lnj 500 Unit Coagulation FactorX (Human) For lnj 500 Unit 8240101510E543 Aranesp (A!bum!n Free} Darbepoetin Alfa-Po!ysorbate 80Soln lnj 40 MCG/OAML 8240101510E560 Aranesp (Albumin Free} Darbepoetin A!fa-Polysorbate 80 Sain lnj 100 MCG/0.SML 8240101510E582 Aranesp (Albumin Free) Darbepoetln A!fa-Pofysorbate 80 Soln lnj 200 MCG/0.4ML Coagulation Factor IX (Recombinant) For lnJ Kit 500 Unit 8240101510ES43 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Sain lnj 40 MCG/0.4ML 8240101510ES60 Aranesp (Albumin Free) Darbepoetln Alfa-Polysorbate80 Soln lnj 100 MCG/0.5ML 82401015102070 Aranesp (Albumin Free) Darbepoetln Alfa-Polysorbate 80 So!n lnj 300 MCG/ML Epoet!n Alfa lnj 10000 Unit/ML Epoetin Alfa lnj 40000 Unit/ML Fifgrastim lnj 300 MCG/ML 82401015102010 Aranesp {Albumin Free) Darbepoetin Affa-Polysorbate 80 Soln lnj 25 MCG/Ml 8240101510ES52 Aranesp (Albumin Free) Darbepo-etin Alfa-Polysorbate 80Soln lnj 60 MCG/0.3ML 8240101510E558 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate80 Soln lnj 200 MCG/Ml 82401015102080 Aranesp (Albumin Free) DarbepoetinAlfa-Polysorbate80 Sain lnj 500 MCG/ML Epoetin Alfa lnj 10000 Unit/MLMethoxy Polyethylene Glycol-Epoetin Beta lnj 75 MCG/0.3ML Filgrastim tnj 480 MCG/0.8ML{600 MCG/ML)Coagulation Factor IX (Recomb) (rlX-FP) For lnj 1000 Unit Coagulatlon Factor IX (Recomb) (rFIXFc) For lnj 4000 Unit Methoxy Polyethylene G!yco!-EpoetinBeta !nj 100 MCG/0.3Ml 82401015102020 Aranesp (Albumin Free} Darbepoetin Alfa-Po!ysorbate 80 Sain lnJ 40 MCG/ML 82401015102040 Aranesp (Albumin Free) Darbepoetln A!fa-Polysorbate 80 Soln lnj 100 MCG/ML 8240101510E558 Aranesp {Albumin Free) Darbepoetin Atfa-Potysorbate 80Soln lnj 200MCG/ML 85100028206420 Bene-FIX Coagulation Factor IX (Recombinant) For lnJ Kit 250 Unit 8240101510E556 Aranesp {Albumin Free) Darbepoetln Alfa-Polysorbate 80 So!n fnj 60 MCG/ML 82401015102050 Aranesp {Albumin Free) Darbepoetln Alfa-Polysorbate 8DSo!n lnj 150 MCG/0.75ML 8240101510E588 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80 Sain lnj 300 MCG/0.6ML 8240102000E545 Epogen Epoetin Alfa lnj 10000 Unit/ML ' 16.00%16.00%16.00%15.50%16.00%16.00%16.00%16.{)0%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%15.50%15.50%15.50%15.50%15.50%16.00%16.00%16.00%21.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00¼16.00%15.50%15.50%16.00%16.00%16.00%16.00%21.00%16.00%16.00%16.00%16.00%

Blood Products/ Modifiers/Volume Expanders 8240102000E575 Epogen Epoetin Alfa lnj 40000 Unit/ML 16.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E528 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 So!n lnj 25 MCG/0.42Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 82401015102040 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 100 MCG/Ml 16.00% Blood Products/ Modifiers/Volume Expanders 8240101510E558 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 200 MCG/Ml 16.00"ii Blood Products/ Modifiers/Volume Expanders 8240102000E510 Epogen Epoetin Alfa lnj 2000 Unit/ML 16.00% Blood Products/ Modifiers/Volume Expanders 8240102000E545 Epogen Epoetin Alfa lnj 10000 Unit/Ml 16.00% Blood Products/ Modifiers/Volume Expanders 8240104010E525 Mlrcera Methoxy Polyethylene Gtycol-Epoetin Beta lnj 100 MCG/0.3ML 16.00% Blood Products/ Modifiers/ Volume Expanders 85100028352140 ldelvion Coagulation Factor IX (Recomb) (rlX-FP) For lnj 2000 Unit 15.50% Blood Products/ Modifiers/ Volume Expanders 85100015106430 Wllate Antihemophilic Factor/WJF {Human) For lnj 500-500 Unit Kit 15.50% Blood Products/ Modifiers/Volume Expanders 85100010402140 Adynovate Antihemophl!ic Factor Recomb Pegylated For lnj 1000 Unit 15.50% Blood Products/ Modifiers/ Volume Expanders 8240157000E520 Neulasta Pegfilgrastim lnj 6 MG/0.6ML 16.00% Blood Products/ Modifiers/ Volume Expanders 82401015102070 Aranesp (Albumin Free) Darbepoetin Alfa-Po\ysorbate 80 Soln lnj 300 MCG/ML 16.00% Blood Products/ Modifiers/Volume Expanders 8240104010E520 Mircera Methoxy Polyethylene Glycol-Epoetin Beta lnj 75 MCG/0.3ML 16.1)0% Blood Products/ Modifiers/ Volume Expanders 85100028206450 BeneFIX Coagulation Factor IX (Recombinant) For lnj Kit 2000 Unit 21.00% Blood Products/ Modifiers/Volume Expanders 85100010402150 Adynovate Antlhemophillc Factor Recomb Pegylated For lnj 2000 Unit 15.50% Blood Products/ Modifiers/Volume Expanders 82401015102010 Aranesp (A!bumin Free) OarbepoetlnAlfa-Polysorbate 80 Soln lnj 25 MCG/ML 16.00% Blood Products/ Modifiers/Volume Expanders 8240101510E556 Aranesp (Albumin Free) Darbepoetin Alfa-Po!ysorbate 80 Soln lnj 60 MCG/ML 16.00% Blood Products/ Modifiers/ Volume Expanders 82401015102050 Atanesp (Albumin Free) Darbepoetfn Alfa-Polysorbate 80 Soln lnj 150 MCG/0.75ML 16.00% Blood Products/ Modifiers/ Volume Expanders 85100010402120 Adynovate Antihemophl!ic Factor Recomb Pegylated For lnj 250 Unit 15.50% Blood Products/ Modifiers/ Volume Expanders 85100031002120 Coagadex Coagulation Factor X {Human) For lnj 250 Unit 15.50% Blood Products/ Modifiers/ Volume Expanders 8240102000ES45 Epogen Epoetin Alfa lnj 10000 Unit/ML 16.00% Blood Products/ Modifiers/ Volume Expanders 8240152000£545 Neupogen Filgrastim lnj 300 MCG/0.SML (600 MCG/ML) 16.00¼ Blood Products/ Modifiers/ Volume Expanders 8240102000E575 Epogen Epoet!n Alfa lnj 40000 Unit/ML 16.00% Blood Products/ Modifiers/Volume Expanders 85100028206460 BeneFIX Coagulation Factor IX (Recombinant) For lnJ Kit 3000 Unit 21.00¼ Blood Products/ Modifiers/Volume Expanders 82401015102020 Aranesp (Albumin Free} Darbepoetin A!fa-Polysorbate 80 Soln lnj 40 MCG/ML 16.00% Blood Products/ Modifiers/Volume Expanders 82401015102040 Aranesp (Albumin Free} Darbepoetin Alfa-Polysorbate 80 Soln lnj 100 MCG/ML 16.00% Blood Products/ Modifiers/Volume Expanders 8240101510E558 Aranesp (Albumin Free) Darbepoetln Alfa-Polysorbate 80 Soln lnj 200 MCG/ML 16.00% Blood Products/ Modifiers/ Volume Expanders 8240102000E520 Epogen EpoetinAlfa lnj 4000 Unit/Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 8240102000E575 Epogen Epoetin Alfa lnJ 40000 Unit/ML 16.00% Blood Products/ Modifiers/Volume Expanders 8240157000ES20 Neu!asta Pegfilgrastim lnj 6 MG/0.6ML 16.00% Blood Products/ Modifiers/ Volume Expanders 85100028352110 ldelvion Coagulation Factor IX (Recomb) (rlX-FP) For lnj 250 Unit 15.50% Blood Products/ Modifiers/ Volume Expanders 85100010402145 Adynovate Antihemophilic Factor Reconlb Pegylated For lnj 1500 Unit 15.50% Blood Products/ Modifiers/ Volume Expanders 8240101510E528 Aranesp (Albumin Free} Darbepoetin Alfa-Po!ysorbate 80 Soln lnj 25 MCG/0.42ML 16.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E552 Aranesp (Albumin Free} Darbepoetin Alfa-Po!ysorbate 80 Soln lnj 60 MCG/0.3ML 16.00% Blood Products/ Modifiers/ Volume Expanders 8240101510£575 Aranesp (Albumin Free} Darbepoet!nAJfa-Polysorbate 80 Soln lnj 150 MCG/0.3ML 16.00% Blood Products/ Modifiers/ Volume Expanders 82401015102020 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 40 MCG/ML 16.00% Blood Products/ Modifiers/Volume Expanders 82401015102040 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 100 MCG/Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E582 Aranesp (Albumin Free) Darbepoetfn Alfa-Polysorbate 80 Soln lnj 200 MCG/0.4ML 16.00% Blood Products/ Modifiers/ Volume Expanders 8240102000ES45 Epogen Epoetin Alfa lnj 10000 Unit/ML 16.00% Blood Products/ Modifiers/Volume Expanders 8240102000E575 Epogen Epoetin Alfa lnj 40000 Unit/ML 16.00% Blood Products/ Modifiers/Volume Expanders 8240157000E520 Neulasta Pegfilgrastim Jnj 6 MG/0.6ML 16.ocr Blood Products/ Modifiers/ Volume Expanders 83334030002120 lprivask Desirudin For lnj 15 MG 15.50% Blood Products/ Modifiers/ Volume Expanders 85100028352120 ldelvlon Coagulation Factor IX (Recomb} (rlX-FP) For lnj 500 Unit 15.50% Blood Products/ Modifiers/ Volume Expanders 8240152000E525 Neupogen Fflgrastfm lnJ 300 MCG/ML 16.00% Blood Products/ Modifiers/Volume Expanders 8240101510E588 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 300 MCG/0.GML 16.00% Blood Products/ Modifiers/Volume Expanders 8240104010£515 Mircera Methoxy Polyethylene Glycol-Epoetin Beta lnj 50 MCG/0.3ML 16.00% Blood Products/ Modifiers/ Volume Expanders 8240102000E520 Epogen Epoetin Alfa lnJ 4000 Unit/ML ---,._).\STl1'A '< 16.00% Blood Products/ Modifiers/ Volume Expanders 8240152000E550 Neupogen Fl1grastim lnj 480 MCG/0.8ML (600 MCG/ML) _<;S<· o----- - -:;-.,._ _.....h,. '\, 16.00% Blood Products/ Modifiers/ Volume Expanders 85100028206440 BeneFIX Coagulation Factor IX (Recombinant) For lnj Kit 1000 Unit ://" '/,"- 21.00% - --- ' { Com_r.ato N. \ (l/: 1 9 umero;m\,f,, ·. ----0-."..;.:::,! ,' -..,. ),. f''k Q,•, -() \V'"v -' =- ,0 ' fr,_,, -os o-r.:: C. r,,.v --- ·•°"<-c;,-,,': =- ...., (

Blood Products/ Modifiers/ Volume Expanders 82401015102020 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Sein lnj 40 MCG/ML 16.00% Blood Products/ Modifiers/ Volume Expanders 82401015102040 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 100 MCG/ML 16.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E558 Aranesp (Albumin Free} Darbepoetin Alfa-Polysorbate 80 Soln lnj 200 MCG/ML 16.00% Blood Products/ Modifiers/Volume Expanders 8240104010E545 Mircera Methoxy Polyethylene Glycol-Epoetin Beta lnj 200 MCG/0.3ML 16.00% Blood Products/ Modifiers/Volume Expanders 85100010402135 Adynovate Anlihemoph!llc Factor Recomb Pegylated For _]nj 750 Unit 15.50% Blood Products/ Modifiers/Volume Expanders 84100040002025 Cyklokapron TranexamfcAcid NSoln 1000 MG/10Ml {100 MG/ML) 16.00¾ Blood Products/ Modifiers/Volume Expanders 8240102000E510 Epogen Epoetin Alfa lnj 2000 Unit/ML . 16.00% Blood Products/ Modifiers/Volume Expanders 82401015102080 Aranesp {Albumin Free) Darbepoetin Alfa-Po!ysorbate 80 So!n fnj 500 MCG/ML 16.00% Blood Products/ Modifiers/ Volume Expanders 8240104010E545 Mircera Methoxy Polyethylene Glycol-Epoetin Beta lnj 200 MCG/0.3ML 16.00% Bone Density Regulators 30044530002020 Pro!ia Denosumab lnj 60 MG/Ml 15.75% Bone Density Regulators 3004405510E140 Natpara Parathyroid Hormone {Recombinant) For lnj Cartridge 100 MCG 16.00% Bone Density Regulators 3004405510E110 Natpara Parathyroid Hormone (Recombinant) For lnj Cartridge 25 MCG 16.00% Bone Density Regulators 30044070002020 Forteo Teriparatide {Recombinant) lnj 600 MCG/2.4Ml 16.00% Bone Density Regulators 30044530002030 Xgeva Denosumab lnj 120 MG/1.7ML 16.00% Bone Density Regulators 3004405510E120 Natpara Parathyroid Hormone {Recombinant) For lnj Cartridge 50 MCG 16.00% Bone Density Regulators 3004405510E130 Natpara Parathyroid Hormone (Recombinant) For lnj Cartridge 75 MCG 16.00% Cardiovascular Agents 37100020000305 Keveyis Dlchlorphenamide Tab 50 MG 15.50% CASTLEMAN DISEASE 99473080002120 Sytvant Si1tuximab For IV Infusion 100 MG 16.00% CASTLEMAN DISEASE 99473080002140 Sylvant Siltuximab For IV Infusion 400 MG 16.00% Central Nervous System Agents 62403060450560 Rebif Rebidose Titration Interferon Beta-la lnj 6 X 8.8 MCG/0.2ML & 6X 22 MCG/0.5ML 16.50% Central Nervous System Agents 624030604SE540 Rebif Interferon Beta-la lnj 44 MCG/O.SML(24MU/ML) (88 MCG/ML) 16.50% Central Nervous System Agents 6240306045D560 Rebif Rebidose Titration Interferon Beta-la lnj 6 X 8.8 MCG/0.2Ml & 6X 22 MCG/0.5ML 16.50% Central Nervous System Agents 74400020202140 Xeomin lncobotu!inumtoxlnA For IM lnj 200 Unit 15.50% Central Nervous System Agents 6240306045E540 Rebif Interferon Beta-la lnj 44 MCG/0.5Ml (24MU/ML) {88 MCG/Ml) 16.50% Central Nervous System Agents 62403060450520 Rebif Rebidose Interferon Beta-la lnJ 22 MCG/0.5ML {12MU/ML} (44 MCG/Ml} 16.50% Central Nervous System Agents 624030604-50520 Rebif Rebidose Interferon Beta-la fnj 22MCG/0.SML (12MU/ML) (44 MCG/ML) 16.50% Central Nervous System Agents 624030604-50560 Rebif Rebldose TTtration Interferon Beta-la lnj 6X 8.8 MCG/0.2Ml& 6 X 22 MCG/0.5Ml 16.50% Central Nervous System Agents 62403060450520 Reb!f Rebldose Interferon Beta-la lnj 22 MCG/0.SML (12MU/Ml) (44 MCG/ML) 16.50% Central Nervous System Agents 6240306045F530 AvonexPen Interferon Beta-la IM lnj Kit30 MCG/0.SML 16.75% Central Nervous System Agents 62609 2300120 Nuedexta DextromethorphanHBr-Quinidine Sulfate Cap 20-10 MG 15.50% Central Neivous System Agents 6240306045F530 AvonexPen Interferon Beta-la IM lnj Kit 30 MCG/0.SML 16.75% Central Nervous System Agents 624030604SE540 Rebif Interferon Beta-la lnj 44 MCG/0.SML (24MU/ML) (88 MCG/Ml) 16.50% Central Nervous System Agents 6240306045D520 Rebif Rebldose Interferon Beta-la lnj 22 MCG/0.SML {12MU/ML) {44 MCG/ML) 16.50% Central Nervous System Agents 624030604-5FS30 AvonexPen Interferon Beta-la IM lnj Kit30 MCG/0.SML 16.75% Central Nervous System Agents 624030604-SES40 Reblf Interferon Beta-la lnj 44 MCG/O.SML(24MU/Ml) (88 MCG/ML} 16.50% CMV Agents 12200010002020 Vistide Cidofovir IVlnJ 75 MG/ML 16.00% CMVAgents 12200020102020 Foscarnet Sodium Foscarnet Sodium lnJ 24 MG/ML 16.00% CMV Agents 12200066102120 Va!cyte Va!gancidovir HCI ForSoln 50 MG/ML (Base Equiv) 16.00% CMV Agents 12200066100320 Valcyte Valganciclovfr HCI Tab 450 MG {Base Equivalent) 16.00% CMV Agents 12200030102110 Cytovene Ganciclovir Sodium For lnj 500 MG 60.00% CONGESTIVE HEART FAILURE 40180050002120 Natrecor Neslrit!de For lnj 1.5 MG 16.00% CORTICOSTEROIDS 22100020202011 Dexamethasone Sod Pho Dexamethasone Sod Phosphate Preservative Free lnj 10 MG/ML 16.00% CORTICOSTEROIDS 22100030202115 Solu-MEDROL Methyfprednisolone Sodium Succinate For lnJ 500 MG 16.00% CORTICOSTEROIDS 22100020002900 Dexamethasone Dexamethasone Powder 16.00% CORTICOSTEROIDS 22100030202105 Solu-MEDROL Methylprednlsolone Sodium Succlnate For lnj 40 MG 16.00% CORTICOSTEROIDS 22100020001320 De>:amethasone Intense! Dexamethasone Cone 1 MG/ML 16.00% CORTICOSTEROIDS 22100025402161 Solu-CORTEF Hydrocortisone Sodium Succinate PF For lnj 500 MG 16.00% CORTICOSTEROIDS 22100050101810 Kena!og TriamcinoloneAcetonide JnjSusp 40 MG/ML .,.. ,-,.-.-.... 16.00% CORTICOSTEROIDS 22100020202900 Dexamethasone Sodium Dexamethasone Sodium Phosphate Powder t.\\·\\•...._.' -.ri.("\' 16.00% ()·,- -- ,_,,_ 1-,',1 V. '-' 'f Contra/oN- \ 0 ., V''' ";J!J. .,, {.j"5mer,,o1\m:: (J .. ': l_ ·.- , ' 2. I, I n... - \ \\\ '--------------4

0 CORTICOSTEROJDS 22100030202120 Solu-MEDROL Methylprednisolone Sodium Succlnate For lnj 1000 MG 16.00% CORTICOSTEROIDS 2210002000200S Dexamethasone Dexamethasone So!n 0.S MG/5Ml 16.00% CORTICOSTEROIDS 22100025402165 Solu-CORTEF Hydrocortisone Sodium Succlnate PF For lnj 1000 MG 16.00% CORTICOSTEROIDS 22100020102900 Dexamethasone Acetate Dexamethasone Acetate Powder 16.1)0% CORTICOSTEROIDS 22100030202110 So!u-MEDROL Methylprednlsofone Sodium Sucdnate For Jnj 125 MG 16.00" Corticosteroids 22100017001830 Emflaza Deflazacort Susp 22,75 MG/Ml lS.50% CORTICOSTEROIDS 22100020000325 Dexamethasone Dexamethasone Tab 1 MG 16.00% CORTICOSTEROIDS 22100025402150 Solu-CORTEF Hydrocortlsone Sodium Succinate PF For lnj 100 MG 16.00% CORTICOSTEROIDS 22100030202130 Solu-MEDROL Methylprednlsolone Sodium Sucdnate For lnj 2000 MG 16J)0% Corlicosterofds 22100017000340 Emflaza Def/azacortTab 6 MG 15.50% Corticosteroids 22100017000360 Emflaza Deflazacort Tab 30 MG 15.50% Corticosteroids 22100017000365 Emflaza Deflazacort Tab 36 MG 15.50% CORTICOSTEROIDS 22100020000335 Dexamethasone Dexamethasone Tab 2 MG 16.00% CORTICOSTEROIDS 22100025402155 Solu-CORTEF Hydrocortisone Sodium Succinate PF For lnj 250 MG 16.00% CORTICOSTEROIDS 22100050101805 Kenalog Triamdno!one Acetonide lnj Susp 10 MG/Ml 16.00% Corticosteroids 22100017000350 Emflaza Deflazacort Tab 18 MG 15.50% CYSTIC FIBROSIS AGENTS 07000070000120 Tobi Podha!er Tobramycin lnhal Cap 28 MG 17.10% CYSTIC FIBROSIS AGENTS 45302030003030 Katydeco fvacaftor Packet 75 MG 15.75% CYSTIC FIBROSIS AGENTS 07000070002530 Bethk!s Tobramycin Nebu So!n 300 MG/4Ml 16.00% CYSTIC FIBROSIS AGENTS 45302030000320 Kalydeco lvacaftor Tab 150 MG 15.75% CYSTIC FIBROSIS AGENTS 45304020002010 Pu1mozyme Dornase Alfa fnhal Soln 1 MG/Ml 16.00% CYSTIC FIBROSIS AGENTS 07000070002520 Kitabls Pak Tobramycin NebuSoln 300 MG/SML 41.75% CVSTIC FIBROSIS AGENTS 45302030003020 Kalydeco lvacaftor Packet SO MG 15.75% Cystinosis Agents 56400030106530 Procysbi Cysteamine Bitartrate Cap Delayed Release 75 MG {Base Equiv) 16.00% Cystinosls Agents 56400030100140 Cystagon Cysteamlne Bitartrate Cap 150 MG 15.25% Cystinosls Agents 56400030106520 Procysbl Cysteamine Bitartrate Cap Delayed Release 25 MG (Base Equiv} 16.00% Cystinosis Agents 56400030100120 Cystagon Cysteamine Bltartrate Cap 50 MG 15.25% DERMATOLOGICALS 90890020002110 BotoxCosmet!c OnabotutinumtoxinA (Cosmetic) For lnj 50Unit 16.75% DERMATOLOGICAlS 90890020002120 Botox Cosmetic OnabotulinumtoxinA {Cosmetic) For lnj 100 Unit 16.75% OERMATOLOGICAlS 90890018002120 Oysport (Glabellar lines) AbobotuHnumtoxinA {Glabellar Unes) For lnj 300 Unit 16.75% DERMATOLOGICAL$ 90550085103400 Kenalog Triamcinolone AcetonldeAerosol Soln 16.00% DIAGNOSTIC PRODUCTS 94200037002105 Cortrosyn CosyntroplnForlnj 0.25 MG 16.00% DIAGNOSTIC PRODUCTS 94200090102120 Thyrogen Thyrotropin Alfa For lnj 1.1 MG 16.7S% Digestive Enzymes 51200024006760 Creon Pancrelipase {lip-Prot-Amyl) DR Cap 24000-76000-120000 Unit 16.00% Digestive Enzymes 51200024006750 Pancreaze Pancrellpase (Up-Prot•Amyl} OR Cap 16800-40000-70000 Unit 16.00% Digestive Enzymes 51200024006705 Creon Pancrefipase {llp•Prot-Amyl) DR Cap 3000-9500---15000 Unit 16.00% Digestive Enzymes 51200024006780 Creon Pancrelipase (Lip-Prot-Amyl) DR Cap 36000-114000-180000 Unit 16.00% Digestive Enzymes 51200024006754 Pancreaze Pancrel!pase (Up-Prot-Amyl) DR Cap 21000-37000-61000 Unit 16.00% Digestive Enzymes 51200024006710 Pancreaze Pancre!ipase (lip-Prot-Amyl) DR Cap 4200-10000-17500 Unit 16.00% Digestive Enzymes 51200060002030 Sucraid Sacrosldase Soln 8500 Unit/Ml 16.00% Digestive Enzymes 51200024006734 Pancreaze Pancrelipase {lip-Prot-Amyl) DR Cap 10500-25000-43750 Unit 16.00% Digestive Enzymes 51200024006740 Creon Pancrelipase (Up-Prot-Amyl) OR Cap 12000-38000-60000 Unit 16.00% Digestive Enzymes 51200024006720 Creon Pancreflpase (Lip-Prot-Amyl) DR Cap 6000-19000-30000 Unit 16.00% Direct Muscle Relaxants 75200010101920 Ryanodex Dantrolene Sodium For IV Susp 250 MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30080050106440 lupron Depot-Ped leuprolide Acetate For lnj Pediatric Kit 15 MG 16.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30170070106420 SandoSTATIN LAR Depot Octreotide Acetate For IM lnj Kit 20 MG 16.50% ENDOCRINE AND METABOLIC AGENTS- MISC. 30180060002120 Somavert Pegvisomant For lnj 10 MG (As Protein) ,,,';_ \\S l R/..• ~''.(,_ 15.75% ENDOCRINE AND METABOLIC AGENTS - MISC. 30454060000330 Samsca Tolvaptan Tab 30 MG ,.,i·,• .6 •-.rr,"., 16.75% ENDOCRINE AND METABOLIC AGENTS - MISC. 30905070000120 Zemplar Parica[citol Cap 2 MCG .(_/ µ "i,,, "I 16.00% t '{tContrato N • ! () umero : ' ,1 5 # , tf(> y [" "'·-· . ' , \ \\\ ', c,1." o \ v'\'· ., . _.'7, v '8o.,,. E-51'-'

' 1 .. (f i ' . !!7 . ' ENDOCRINE AND METABOLIC AGENTS- MISC. 30906550002020 Aldurazyme Laronidase Soln For IV Infusion 2.9 MG/5Ml 15.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30908565107320 l(uvan Sapropterin Dlhydrochloride Soluble Tab 100 MG 16.75% ENDOCRINE ANO METABOLIC AGENTS- MISC. 30908060002950 Buphenyl Sodium Phenylbutyrate Oral Powder 3 GM/Teaspoonful 24.00% ENDOCRINE AND METABOLIC AGEITTS- MISC. 30080050106420 lupron Depot-Ped leupro!ide Acetate For lnj Pediatric Kit 7.S MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170050102040 Somatuline Depot Lanreotide Acetate Extended Release lnj 120 MG/0.SML 16.75% ENDOCRINE AND METABOLIC AGENTS- MISC, 30170075401930 Slgnlfor LAR Pasireotide Pamoate For IM ERSusp 40 MG {Base Equiv) 16.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30904520002920 Cystadane *Betalne Powder For Oral Solution*•• 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30905225100340 Senslpar Clnacalcet HCI Tab 90 MG {Base Equiv) 16.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30908230000320 Carbaglu Carglumic Acid Tab 200 MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30090040102020 Ganlrelix Acetate GanfrellxAcetate lnj 250 MCG/0.5Ml 15.25% ENDOCRINE AND METABOLIC AGENTS- MISC, 30170050102025 Somatuline Depot lanreotideAcetateExtended Release lnj 60 MG/0.2Ml 16.75% ENDOCRINE ANO METABOLIC AGENTS- MISC. 30170075202040 Signifor Pasireotide Diaspartate lnj 0.9 MG/Ml(Base Equiv) 16.00% ENDOCRINE AND METABOLIC AGENTS MISC. 30180060002160 Somavert Pegvlsomant For lnj 30 MG {As Protein) 15.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30904045000120 Orfadln Nitisinone Cap 5 MG 16.00% ENDOCRINE ANO METABOLIC AGENTS MISC. 30905225100320 Sensipar Cinacalcet HCl Tab 30 MG {Base Equiv) 16.75% ENDOCRINE ANO METABOLIC AGENTS MISC. 30908030000920 Ravicti Glycerol Phenylbutyrate Uquld 1.1 GM/Ml 16.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30080050156420 Lupron Depot-Ped leuprolideAcetate {3 Month) For lnj Pediatric Kit 11.25 MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30150085102120 Egrifta Tesamorelin Acetate For lnj 1 MG {Base Equiv) 16.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170070106430 SandoSTATIN lAR Depot Octreotide Acetate For IM lnj Kit 30 MG 16.50% ENDOCRINE AND METABOLIC AGENTS- MISC. 30180060002130 Somavert Pegvlsomant For lnj 15 MG (As Protein) 15.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30903610102110 Fabrazyme Agalsidase beta For IV Soln 5 MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30905070000140 Zemp!ar Parkalcitol Cap 4 MCG 16,00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30906850002020 Elaprase ldursulfase So!n for IV Infusion 6 MG/3Ml (2 MG/Ml) 15.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30080045106450 Supprelin lA Histrelin Acetate (CPP) Implant Kit 50 MG 15.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170050102030 Somatuline Depot Lanreotide Acetate Extended Release lnJ 90 MG/0.3Ml 16.75% ENDOCRINE AND METABOLIC AGENTS- MISC, 30170075401920 Signifor LAR Paslreotide Pamoate For 1M ER Susp 20 MG (Base Equiv} 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30904045000130 Orfadin Nltls!none Cap 10 MG 16.00% ENDOCRINE AND METABOLIC AGENTS - MISC, 30905225100330 Sensipar Cinaca!cet HCI Tab 60 MG {Base Equiv) 16.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30908060000320 Buphenyl Sodium Phenylbutyrate Tab 500 MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30080050106430 Lupron Depot-Ped Leupro!ide Acetate For lnj Pediatric Kit 11.25 MG 16.00% ENDOCRINE AND METABOllCAGENTS- MISC. 30170070106410 SandoSTATIN LAR Depot Octreotide Acetate For IM !nj Kit 10 MG 16.50% ENDOCRINE AND METABOLIC AGENTS - MISC. 30170075401940 Slgnifor LAR Pasireotide Pamoate For IM ERSusp 60 MG (Base Equiv) 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30454060000320 Samsca Tolvaptan Tab 15 MG 16.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30905070000110 Zemplar Paricakitol Cap 1 MCG 16.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30906050002120 Myalept Metreleptln For Subcutaneous lnj 11.3 MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30908565103020 Kuvan Sapropterin Oihydrochloride Powder Packet 100 MG 16.75% ENDOCRINE AND METABOllC AGENTS- MISC. 30170070102030 Octreotide Acetate Octreotide Acetate lnj 1000 MCG/Ml (1 MG/Ml) 52.25% ENDOCRINE ANO METABOLIC AGENTS- MISC, 30080050156440 lupron Depot-Ped leupro!ide Acetate (3 Month) For lnj Pediatric Kit 30MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30150085102130 Egrifta Tesamorelin Acetate For lnj 2 MG (Base Equiv) 16.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170075202020 Slgnifor Pas!reotlde Diaspartate lnj 0.3 MG/Ml(Base Equiv} 16.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30180060002140 Somavert Pegvisomant For lnJ 20 MG {As Protein) 15.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30903610102120 Fabrazyme Agalsidase beta For IV Soln 35 MG 16.00% ENDOCRINE ANO METABOllCAGENTS- MISC. 30905070002010 Zemplar Paricalcitol IV So!n 2 MCG/Ml 16.00¾ ENDOCRINE AND METABOllCAGENTS-MISC. 30907030052020 Vimlzim E!osulfase Alfa Sain For JV Infusion 5 MG/SMl (1MG/ML) 16.00% ENDOCRINE AND METABOLIC AGENTS - MISC, 30170070102005 Octreotide Acetate Octreotide Acetate lnj 50 MCG/Ml {0.05 MG/Ml) .,- ,<: ,,- -. - ., 52.25% ENDOCRINE AND METABOllCAGENTS-MISC. 30907715002120 lumizyme A!glucosfdase Alfa For IV Soln 50 MG 15.75% ENDOCRINE AND METABOLIC AGENTS - MISC. 30170070102015 Octreotide Acetate Octreotide Acetate lnj 200 MCG/ML (0.2 MG/Ml} /: \·\'.,_.,_,_ - < "' "l (.:'., "'--. 52.25% . ENDOCRINE AND METABOLIC AGENTS- MISC. 30170070102020 Octreotide Acetate Octreotide Acetate tnj 500 MCG/Ml {O.S MG/Ml) .t /:f'- ,,""'i' \\. 52.25% ENDOCRINE AND METABOLIC AGENTS- MISC, 30080055102020 Synarel Nafarelln Acetate Nasal Soln 2 MG/ML i v' // \\ l,i :;\\ 16.00% -,..., .•.. i ! ·~,uraro Ntimero X•;'\(1 \\ (fl -,..''"(,\ ',·. -;•J 0

ENDOCRINE AND METABOLJCAGENTS- MISC. 30160045002020 lncre!ex Mecasermin Jnj 40 MG/4Ml (10 MG/Ml) 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170075202030 Signifor Pasireotide Diaspartate lnj 0.6 MG/ML (Base Equiv) 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30180060002150 Somavert Pegvisomant For lnj 25 MG {As Protein) 15.75% ENDOCRINE AND METABOLIC AGEITTS- MISC. 30904045000110 Orfadfn Nitisinone Cap 2 MG 16.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30905070002020 Zemplar Parica!citol IV Sain 5 MCG/ML 16.00% ENDOCRINE AND METABOUCAGENTS- MISC, 30907535002020 Nagla2.yme Galsulfase Soln For JV Infusion 1 MG/Ml 15.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170070102010 Octreotide Acetate Octreotide Acetate lnj 100 MCG/ML {0.1MG/Ml) 52.25% ENZVME REPLACEMENT 20000050002025 Adagen Pegademase Bovine lnj 250 Unit/ML 16.00% Emyme Replacements/Modifiers 30903875203020 Xuriden Uridlne Triacetate Oral Granules Packet2 GM 15.50% Enzyme Replacements/Modifiers 30905610002040 Strenslq Asfotase Alfa Subcutaneous lnj 40 MG/Ml 15.50% Enzyme Replacements/Modifiers 30906360002020 Kanuma Sebelipase Alfa IV Sain 20 MG/10Ml (2MG/ML) 15.50% Enzyme Replacements/Modifiers 309056100020S0 Strenslq Asfotase Alfa Subcutaneous Jnj 80 MG/0.8ML 15.50% En2.yme Replacements/Modifiers 30905610002020 Strensiq Asfotase Alfa Subcutaneous lnj 18 MG/0.45Ml 15.50¾ Emyme Replacements/Modifiers 30905610002030 Strensiq Asfotase Alfa Subcutaneous lnj 28 MG/0.7Ml 15.50¾ Emymes 99350035002120 Xiaflex Co!lagenase dostridium Histo!ytkum For lnj 0.9 MG 16.75% Enzymes 99350040102020 Hyfenex. Hyaturonidase Human lnj 150 Unit/Ml 16.00% Fertility Regulators 30062030052020 Gona\-f RFF Pen Follitrop!n Alfa lnj 300 Unit/0.SML 15.25% Fertility Regulators 30062030102030 FollistimAQ Fo!litropin Beta lnj 600 Unit/0.72Ml 22.80% Fertility Regulators 30062030102006 FollistimAQ Follltropin Beta lnj 150 Unit/0.5Ml 22.80% Fertility Regulators 30062030052150 Gonal-f Follitropin Alfa For Jnj 1050 Unit 15.25% Fertility Regulators 30062090102112 Brave!le UrofollitroplnPurified For fnj 75 Unit 15.25% Fertility Regulators 30062030052040 Gonal-f RFF Pen Follltropin Alfa lnj 900 Unit/1.5ML 15.25% Fertility Regulators 30062030102040 FollistlmAQ Follitropin Beta lnj 900 Unit/1.08ML 22.80% Fertility Regulators 30062030102003 FollistimAQ Follitropln Beta lnj 75 Unit/0.SML 22.80% fertility Regulators 30062030102020 FollistimAQ Fol!itrop!n Beta lnj 300 Unit/0.36Ml 22.80% Fertility Regulators 30062030052115 Gona\-fRFF Follttropin Alfa For lnJ 75 Unit 15.25% Fertility Regulators 30062050002155 Repronex. Menotroplns For lnj 75 Unit 15.25% Fertility Regulators· . 30062030052140 Gonal-f FolHtrop!n Alfa For lnj 450 Unit 15.25% Fertility Regulators 30062050002175 Menopur Menotropins For Subcutaneous lnj 75 Unit 15.25% GASTROINTESTINAL AGENTS- MISC. 52300020112900 Metoclopramide HCI Mo Metoc!opramide HCI Monohydrate Powder 16.00% GASTROINTESTINAlAGENTS- MISC. 52700025000140 Cholbam Cholic Acid Cap 250 MG 16.00% GASTROINTESTINAL AGENTS - MISC. 52300020102900 Metodopramide HCI Metodopramide HCI Powder 16.00% GASTROINTESTINAlAGENTS- MISC. 52700025000120 Cho!bam CholJc Acid Cap 50 MG 16.00% Genitourinary Agents 99200030000110 Cuprimine Pen!dllamine Cap 250 MG 15.50% GENITOURINARY AGENTS- MISCEllANEOUS 56500010002010 Rimso-50 Dlmethyl Sulfoxide Soln 50% 16.00% GOUT AGENTS 68000050002020 Krystexxa Peglot!case lnj 8 MG/Ml(For IV Infusion) 16.75% Growth Hormones 30100020002066 Nordltropin Flex.Pro Somatropln lnj 30 MG/3Ml 17.25% Growth Hormones 30100020002140 Nutropin Somatropin For lnJ 10 MG 16.75% Growth Hormones 30100020002178 Genotropin MiniQuick Somatropln For lnj 1.4 MG 16.75% Growth Hormones 30100020102130 Salzen Somatropln {Non-Refrigerated) For lnJ 8.8 MG 16.25% Growth Hormones 301000200020$0 Norditrop!n Somatropin lnJ 5 MG/1.5Ml 17.25% Growth Hormones 30100020002062 Norditropin Somatropin lnj 15 MG/1.5Ml 17.25% Growth Hormones 30100020002132 Humatrope Somatropin For lnJ 12 MG {36 Unit) 16.75% Growth Hormones 30100020002174 Genotropin MiniQu!ck Somatropin For lnj 1 MG 16.75% Growth Hormones 30100020102121 Serostlm Somatropin {Non-Refrigerated) For Subcutaneous lnj 5 MG 16.00% Growth Hormones 30100020002125 Humatrope Somatropln For lnJ 6 MG (18 Unit) 16.75% Growth Hormones 30100020002170 Genotropin MJniQuick Somatropin For lnj 0.6 MG ,,,, ·-··-- 16.75% Growth Hormones 30100020102118 Serostim Somatropin {Non-Refrigerated) For Subcutaneous lnj 4 MG ,i" r'-8• ::T-:'_,._v 16.00% Growth Hormones 30100020002118 Nordftropin SOMATROPJN FOR !NJ 4 MG {12 UNIT) / .,,,., ....---- ... "()·'\.,_ 16.50% ! <',? .• \i- \ ". 1 mer0, 11\" --.,.,,., I [""9 ... r •' \tr(-··.1521 , ,,... f r, ri,, \.(,\.·"' Ji' 0 v -.;-',,.,, ''-"..--=!:•---- ,,,Y 1: ?s o!:=. sr (

Growth Hormones 30100020002150 Humatrope Somatrop!n For Jnj 24 MG 16.75% Growth Hormones 30100020002180 Genotropin MlniQuick Somatropin For lnj1.6 MG 16.75% Growth Hormones 30100020002015 Nutropin AQ NuSpin 5 Somatropin lnj 5 MG/2ML 16.75% Growth Hormones 30100020002127 Norditropln SOMATROPIN FOR INJ 8 MG 16.50% Growth Hormones 30100020002172 Genotropln MinJQukk Somatropin For lnj 0.8 MG 16.75% Growth Hormones 30100020102120 Saizen Somatropin (Non-Refrigerated) For lnj 5 MG 16.25% Growth Hormones 30100020102132 Serostim Somatropin {Non-Refrigerated) For Subcutaneous lnj8.8 MG 16.25% Growth Hormones 30100020002064 Nutropin AQ NuSpin 20 Somatropin lnj 20 MG/2ML 16.75% Growth Hormones 30100020002134 Genotrop!n Somatropln For lnj 12 MG {13.8 MG overfill) 16.75% Growth Hormones 30100020002176 Genotropin MiniQuick Somatropin For lnj1.2 MG 16.75% Growth Hormones 30100020102125 Serostim Somatropin (Non-Refrigerated) For Subcutaneous lnj 6 MG 16.00% Growth Hormones 30100020002121 Genotropln Somatropln For Subcutaneous lnj 5 MG 16.75% Growth Hormones 30100020002120 Humatrope Somatropin For lnj 5 MG 16.75% Growth Hormones 30100020002166 Genotropin MiniQuick Somatropln For lnj 0.2 MG 16.75% Growth Hormones 30100020002182 Genotrop!n MiniQuick Somatropln For Jnj1.8 MG 16.75% Growth Hormones 30100020002056 Nordltropln FlexPro Somatropin lnj10 MG/1.SML 17.25% Growth Hormones 30100020002020 NutropinAQ Somatropin lnj10 MG/2Ml 16.75% Grmvth Hormones 30100020002123 Omnitrope Somatropin For lnj5.8 MG 16.25% Growth Hormones 30100020002168 Genotropin MiniQuick Somatropln For lnj 0.4 MG 16.75% Growth Hormones 30100020002184 Genotropin MiniQuick Somatropln For Jnj 2 MG 16.75% H-2 Antagonists 49200030112020 Famotidine Premixed Famotldine in NaCl 0.9% IV Soln 20 MG/SOML 16.00% H·2 Antagonists 49200010002900 Cimetidlne Cimetidine Powder 16.00% HEMATOLOGICAL AGENTS - MISC. 85550060102120 Ceprotin Protein C Concentrate {Human) For IV Soln 500 Unit 16.00% HEMATOLOGICAL AGENTS- MISC. 85550060102140 Ceprotin Protein C Concentrate {Human) For IV Soln 1000 Unit 16.00% HEMATOlOGICALAGENTS- MISC. 85800050002020 Soliris Ecul!wmab IV Soln 10 MG/Ml {For Infusion) 15.75% Hematopoietic Growth Factors 82403060002120 Neumega Oprelvekln For lnj 5 MG 16.25% Hematopoietic Growth Factors 82402050002025 Leukine 5argramostim lnj500 MCG/ML 16.75% Hematopoietic Growth Factors 8240S060002130 Nplate Romiplostim For lnJ 500 MCG 16.75% Hematopoletic Growth Factors 82405030100310 Promacta Eltrombopag O!amine Tab 12.5 MG (Base Equiv) 16.75% Hematopoietic Growi:h Factors 82401520002012 Neupogen F!lgrastim lnj 480 MCG/1.6Ml (300 MCG/Ml) 16.00% Hematopoletic Growth Factors 82402050002120 Leukine Sargramostim Lyophftlzed For lnJ 250 MCG 16.75% Hematopoietic Growth Factors 8240152070£530 Grano: Tbo-Fi!grastim Soln Prefil!ed Syringe 300 MCG/0.SML 16.00% Hematopoietic Growth Factors 82405030100320 Promacta EltrombopagO!amine Tab 25 MG (Base Equiv) 16.75% Hematopoietic Growth Factors 82401060102050 Omontys Peginesatide Acetate 5oln lnj10 MG/Ml 16.00% Hematopoietic Growth Factors 82405030100340 Promacta EltrombopagOlamine Tab 75 MG {Base Equiv) 16.75% Hematopoietic Growth Factors 82401060102055 Omontys Peglnesatlde Acetate Soln lnj 20 MG/2ML 16.00% Hematopoietic Growth Factors 82405060002120 Np!ate Romiplostim For lnJ 250 MCG 16.75% Hematopoietic Growth Factors 82401020002015 Epogen Epoetin Alfa lnj 3000 Unit/ML 16.00% Hematopoietlc Growth Factors 82401020002050 Epogen Epoetin Alfa lnj 20000 Unit/ML 16.00% Hematopoietic Growth Factors 8240152070E540 Granix Tbo-Filgrastim Sain Prefil/ed Syringe 480 MCG/0.8ML 16.00% Hematopoietic Growth Factors 82405030100330 Promacta Eltrombopag Olamine Tab 50 MG (Base Equiv) 16.75% HEREDITARY ANGIOEDEMA 85820040102020 Firazyr lcatibant Acetate lnj 30 MG/3Ml {Base Equivalent) 15.75% HEREDITARY ANGIOEDEMA 85840030002020 Kalb!tor Ecallantide loj10 MG/ML 16.00% HEREDITARY ANGIOEDEMA 85802022006420 Berinert Cl Esterase Inhibitor (Human) For IV lnj Kit 500 Unit 16.25% HEREDITARY ANGlOEDEMA 85802022102130 Ruconest Cl Esterase Inhibitor (Recombinant) For IV lnJ 2100 Unit 16.00% HEREDITARY ANGIOEDEMA 85802022002120 Cinryze Cl Esterase Inhibitor (Human) For IV lnj 500 Unit- 15.25% Hormonal Agents, Stimulant/Replacement/Modifying 30062022052220 Ovidrel Choriogonadotropln Alfa loj 250 MCG/0.5Ml 15.50% Hormonal Agents, Stimulant/Replacement/Modifying 30062020002140 Chorionic Gonadotropin ChorionlcGonadotropin For lnj10000 Unit ;,,• , ,\\,:, I J-..{_/:., - ''<.._/ f '' .,...-_,_.:. ·· ".. '-t,,_ 15.50% Hormonal Agents, Suppressant {Pituitary) 21404010101840 Depo•Provera Medroxyprogesterone Acetate IM Susp 400 MG/ML ·':c., t'"\ 15.50% , ,C'/!rjc" ""'/,-· 0 / · ' ntrato N·umero '0j\ \I\ : ,, 9 ( - ' ,,, (f f)')i \_ ) -- " ,, ' h\ \; (.,\;1 -;;-Q' I N-, \.,½y .._"--""'--=!.:.:; - ., 0 .-:::: c.J>,,,,.

HYPNOT!CS/SEDAllVES/SLEEP DISORDER AGENTS 60250070000130 Hetlioz Tasimelteon Capsule 20 MG 16.00% IMMUNOGLOBUUNS 19100020102046 Octagam Immune Globulfn (Human) IV Soln 25 GM/SOOML 24.25% IMMUNOGLOBULINS 19100020102125 CARIMUNE Immune Globulfn (Human) IV For Soln 6 GM 25.00% IMMUNOGLOBULINS 19100020302080 Gammagard Immune Globulin {Human) IV or Subcutaneous Soln 30 GM/300Ml 27.55% IMMUNOGLOBULINS 19100020102020 Flebogamma Immune Globulin {Human) IVSoln 0.5 GM/10Ml 18.00¼ IMMUNOGLOBULINS 19100020102113 Gammagard S/D Immune Globulin (Human) IV For Soln 0.5 GM 27.55% IMMUNOGLOBULINS 19100020202058 Hizentra 20% Immune Globulin (Human) Subcutaneous lnj 4 GM/20Ml 24.50% IMMUNOGLOBULINS 191000SOOOE540 RhoGAM Ultra-Filtered P l Rho D Immune Globulin IM So1n PrefSyr 1500 Unit (300MCG} 16.00% IMMUNOGLOBUUNS 19990002356450 Hyqvia Im mun Glob lnj 30 GM/300Ml-Hyaluron lnj 2400 Unt/15 Ml Kit 20.00% IMMUNOGLOBULINS 19100020102060 Gamunex Immune Globulfn (Human) IVSoln 1 GM/10Ml 24.25% IMMUNOGLOBULINS 19100020102130 Gammagard S/D Immune Globulfn (Human) IV For Soln 10 GM 27.55% IMMUNOGLOBULINS 19100020302084 Gamunex-C Immune Globulin (Human) IV or Subcutaneous So!n 40 GM/400Ml 23.00% IMMUNOGLOBULINS 19100020102090 Privigen Immune Globulin {Human} IV Soln 40 GM/400ML 19.00% IMMUNOGLOBULINS 19100020202050 Hfzentra 20% Immune Globulin (Human} Subcutaneous lnj 1 GM/5ML 24.50% IMMUNOGLOBULINS 19100050002060 WinRhoSDF Rho D Immune Globulin (Human) lnj 1500 Unit/1.3ML 17.75% IMMUNOGLOBULINS 19990002356430 Hyqvia Im mun Glob lnj 10 GM/100ML-Hya1uron fnj 800 Unt/5 Ml Kit 20.00% IMMUNOGLOBULINS 19100005002200 Cytogam Cytomegalovirus Immune Globulin (Human) IV lnj 18.00% IMMUNOGLOBULINS 19100020102112 GAMMAR-P I.V. IMMUNE GLOBULIN (HUMAN} IV FORSOLN 1 GM 31.25% IMMUNOGLOBULINS 19100020202054 Hizentra 20% Immune Globulin (Human) Subcutaneous lnJ 2 GM/10ML 24.50% IMMUNOGLOBULINS 19100050002065 WinRhoSDF Rho D Immune Globulin (Human) lnj 15000 Unit/13ML 17.75% IMMUNOGLOBULINS 19990002356440 Hyqvla lmmun Glob lnj 20 GM/200ML-Hyaluron lnj 1600 Unt/10 ML Kit 20.00% IMMUNOGLOBULINS 19100020102120 Gammagard S/D Immune Globuffn (Human} JV For So!n 5 GM 27.55% IMMUNOGLOBULINS 19100020102034 Flebogamma Immune Globulin (Human) lVSo!n 2.5 GM/50ML 25.00% IMMUNOGLOBULINS 19100020102068 Blvlgam Immune Globulin (Human) N So!n 5 GM/50ML 24.25% JMMUNOGLOBULINS 19100020302068 Gammagard Immune Globulin {Human) IV or Subcutaneous Sain 5 GM/50ML 27.55% IMMUNOGLOBULIN5 19100020102064 Gamunex Immune G!obultn {Human) IVSo!n 2.5 GM/25ML 24.25% IMMUNOGLOBULINS 19100020202020 Vivaglobln Immune G!obulfn (Human} Subcutaneous lnj 160 MG/ML (16%) 23.75% IMMUNOGLOBUUNS 19100050002055 WinRhoSDF Rho D Immune Globulin (Human) lnj 5000 Unit/4.4Ml 17.75% IMMUNOGLOBUUNS 19990002356425 Hyqvia lmmun Glob lnJ 5 GM/50ML-Hya!uron lnj 400 Unt/2.5 ML Kit 20.00% IMMUNOGLOBULINS 19100020102030 Octagam Immune Globulin {Human) IV Soln 1 GM/20ML 24.25% IMMUNOGLOBULINS 19100020102117 carimune NF Immune Globulin (Human} N For Sain 3 GM 25.00% IMMUNOGLOBULINS 19100020202065 Hizentra Immune Globulin (Human) Subcutaneous lnj 10 GM/SOML 24.50% IMMUNOGLOBULINS 1910005000ES50 Rhophylac Rho D Immune Globulin Sol Pref Syr 1500 Unt/2ML (300MCG/2ML) 18.25% IMMUNOGLOBULINS 19100020102063 Octagam Immune Globulin {Human} IV Sain 2 GM/20ML 24.25% IMMUNOGLOBULINS 19100020102135 Carimune NF Immune Globulin (Human) IV For Sain 12 GM 25.00% IMMUNOGLOBULINS 19100050002050 WinRhoSDF Rho D Immune Globulin (Human) lnj 2500 Unlt/2.2ML 17.75% IMMUNOGLOBULINS 19990002356420 Hyqvia lmmun Glob lnj 2.5 GM/2SML-Hyaluronlnj 200 Unt/1.25 ML Kit 20.00% IMMUNOGLOBULINS 19100020002200 GamaSTAN S/D Immune Globulin (Human) tnj 23.75% IMMUNOGLOBULINS 19100020102044 F!ebogamma DIF Immune Globulin (Human) IV Solo 20 GM/400ML 25.00% IMMUNOGLOBUUNS 19100020302064 Gammagard Immune Globulin (Human) IV or Subcutaneous Sain 2.5 GM/2SML 27.55% IMMUNOGLOBULINS 19100020102115 Gammagard 5/D Immune Globulin {Human) JV ForSo!n 2.5 GM 27.55% IMMUNOGLOBULINS 19100020102205 GAMJMUNEN IMMUNE GLOBULIN (HUMAN) IV SOLN 5% 47.75% IMMUNOGLOBULINS 19100020302060 Gammagcird Immune Globulin !Human) IV or Subcutaneous Sain 1 GM/lOMl 27.55% IMMUNOGLOBULINS 19100020102034 Flebogamma Immune Globulin (Human) IV Sain 2.5 GM/SOML 25.00% IMMUNOGLOBULINS 19100020102072 Blvigam Immune Globulin {Human) IV Sain10 GM/100Ml 24.25% IMMUNOGLOBULINS 19100020302072 Gammagard Immune Globulin (Human) IV or Subcutaneous Sain 10 GM/lOOML 27.55% IMMUNOGLOBULINS 19100020102038 Flebogamma Immune GlobuHn (Human) IV Sain 5 GM/lOOML' 25.00% lMMUNOGLOBULINS 19100020102072 Bivigam Immune Globulin (Human) IV So!n 10 GM/100ML ,-•;,_</.;\:::-;;>'l'.f'¼r,' 24.25% IMMUNOGLOBULINS 19100020302072 Gammagard Immune Globulin (Human} IV or Subcutaneous Soln 10 GM/lOOML ,:.-: -4,..:> ---"'(\_\' 27.55% "-f.' '¾','t, ' · mcro rt Ill . 9 \: ( · £; I k " \Q'' ' I '(/[ --- V 2,J , t \ \\ .._ -----------! ' "l \(,1. '-, ,/_"'◊ , .'<vo.'.\0' ·• .=,;·c·'."f\·>·:>

IMMUNOGLOBULINS IMMUNOGLOBULINS IMMUNOGLOBULINS IMMUNOGLOBUUNS IMMUNOGLOBULINS IMMUNOGLOBULINS IMMUNOGLOBULINS IMMUNOGLOBULINS lMMUNOGLOBULINS ' ,-.... --..._,_ ¾ " IMMUNOGLOBULINSImmunological Agents Immunological AgentsImmunological Agents lmmunolog!cal Agents Immunological Agents Immunological Agents Immunological Agents Immunological Agents lmmunosuppressive Agents lmmunosuppressive Agents lmmunosuppressive Agents lmmunosuppresslve Agents tmmunosuppressive Agents lmmunosuppressive Agents lmmunosuppressive Agents lmmunosuppressive Agents lmmunosuppressive Agents lmmunosuppresslve Agents lmmunosuppressive Agents lmmunosuppressive Agents lmmunosuppressive Agents lmmunosuppressive Agents lmmunosuppressive Agents lmmunosuppressive Agents ImmunosuppressiveAgents lmmunosuppressive Agents fmmunosuppressive Agents lmmunosuppressive Agents lmmunosuppressive Agents lmmunosuppresslve Agents ImmunosuppressiveAgents ImmunosuppressiveAgents lmmunosuppressive Agents lmmunosuppressive Agents lmmunosuppressive Agents lmmunosuppressive Agents lmmunosuppressive Agents lmmunosuppresslve Agents Inflammatory Bowel Agents :',"' 19100020102068 Bivigam19100020302068 Gammagard19100020102042 Flebogamma19100020102076 F!ebogamma Dlf19100020302076 Gammagard19100020102042 Flebogamma19100020302064 Gammagard19100020102038 F!ebogamma19100020102076 Flebogamma DIF19100020302076 Gammagard 9025055400e520 Taltz 44604055002120 Nuca!a 99403030300620 Myfortic99404070002020 Rapamune99408020002120 Nulojix99402020002010 SandlMMUNE99403030101920 CelJCept99404070000320 Rapamune99405015002120 51mulect Immune Globulin {Human) lVSoln S GM/50MLImmune GlobuHn (Human) IV or Subcutaneous Soln 5 GM/50ML Immune Globul!n (Human) JV Soln 10 GM/200MLImmune Globulin (Human) IV Soln 20 GM/200MLImmune Globulin (Human) IV or Subcutaneous Soln 20 GM/200ML Immune Globulin {Human) IVSoln 10 GM/200MlImmune Globulin (Human} JV or Subcutaneous Soln 2.5 GM/25MLImmune Globulin {Human) IV Soln 5 GM/lOOML Immune Globulin (Human) IV Soln 20 GM/200MLImmune Globulin {Human) JV or Subcutaneous Soln 20 GM/200MLlxekizumab Subcutaneous Soln Prefil!ed Syringe 80 MG/ML Mepol!zumab For lnj 100 MG 19200040002100 Antivenin Micrurus Fulvil Antivenin Micrurus Fulvlus For IVSoln Patlromer Sorbitex calcium For Susp Packet 16.8 GM (Base Eq) lnfllximab-dyyb For IV lnj 100 MGPatiromer Sorbitex Calcium For Susp Packet 25.2 GM (Base Eq) Etanercept For Subcutaneous lnj 25 MG 99450060203030 Veltassa52505040202120 lnflectra99450060203040 Veltassa66290030002120 Enbrel99450060203020 Ve!tassa99402020000110 SandlMMUNE99402540102220 Atgam99404035000325 Zortress99404080000120 Prograf99402020300150 Neoral99403030300630 Myfortic99404080000105 Prograf99402020000140 SandlMMUNE99403030100120 Ce!ICept99404035000330 Zortress99404080002010 Prograf99402020302020 Neora!99404035000320 Zortress99404080000110 Prograf99402020002005 SandlMMUNE99403030100330 CelfCept99404070000310 Rapamune99405015002110 S!mulect99402020300120 Neoral99403030202120 CelJCept Intravenous99404070000330 Rapamune99406010000305 lmuran Patkomer Sorbitex calcium For Susp Packet 8.4 GM {Base Eq) Cydosporine Cap 25 MGLymphocyte Immune Globulin Anti-Thymocyte G lnj 50 MG/ML(Eq}Everollmus Tab 0.5 MG Tacro!imus cap 5 MGCyclosporine Modified cap 100 MGMycophenolate Sodium Tab DR 360 MG (Mycophenolic Add Equiv} Tacrolimus Cap 0.5 MGCyclosporinecap 100 MG Mycophenolate Mofetil Cap 250 MG Evero!imusTab 0.75 MGTacrolimus lnJ 5 MG/MLCyclosporine Modified Oral So!n 100 MG/Ml Everolimus Tab 0.25 MGTacrolimus Cap 1 MG Cyclosporine IV So!n 50 MG/MLMycophenolate Mofeti1Tab 500 MG Siro!imus Tab 0.5 MGBaslliximab For IV Soln 10 MGCyclosporlne Modified cap 25 MGMycopheno!ate Mofetil Hd For IV Soln 500 MG (Base Equiv)Sirolimus Tab 2 MG Azathioprine Tab SO MG 99402020300130 CycloSPORINE Modified Cyclosporlne Modified Cap 50 MG Mycophenolate Sodium Tab DR 180 MG (Mycophenoltc Add Equiv) Skolimus Oral Soln 1 MG/MLBelatacept For IV Infusion 250 MG Cyclosporine Oral Soln 100 MG/MLMycophenolate Mofetil For Oral Susp 200 MG/ML Sirolimus Tab 1 MGBasi!ix!mab For IV Soln 20 MG ,/ ,5..),\,-:,. I f"{"i- -, ,.;.-.;!' .o· ,,......._. - ·r," 52503080002120 Entyvio Vedolizumab For IV Solution 300 MG 24.25%27.55%25.00% 24.25%27.55%25.00% 27.SS% 25.00%24.25%27.55%15.50%15.50%15.50%15.50%15.50%15.50%16.75%15.50%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16J)0%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00% ,_'::;I// ''\ •·l,t, : 16.00%

lnterleukin•l Blockers 66450060002120 Arcalyst Rilonacept For lnj 220 MG 16.75% lnterleukin-1Receptor Antagonist{lL-lRa) RHEUMAT 6626001000E520 Kineret Anakinra Subcutaneous So!n Prefilled Syringe 100 MG/0.67ML 16.00% IRON OVERLOAD-ANTIDOTES 93000020102110 Desferal Deferoxamine Mesylate For lnj 500 MG 16.75% IRON OVERLOAD-ANTIDOTES 93100028000320 Ferriprox Deferlprone Tab 500 MG 16.00% IRON OVERLOAD-ANTIDOTES 93100025007330 ExJade Deferasirox Tab For Oral Susp 250 MG 15.25% IRON OVERLOAD-ANTIDOTES 93000020102130 Desferal Deferoxamine Mesylate For lnj 2 GM 16.7S% IRON OVERLOAD-ANTIDOTES 93100025007340 Exjade Deferaslrox Tab For Oral Susp 500 MG 15.25% IRON OVERLOAD-ANTIDOTES 93100025000320 Jadenu DeferaslroxTab 90 MG 16.00% IRON OVERLOAD-ANTIDOTES 9310002S000340 Jadenu Deferasirox Tab 360 MG 16.00% IRON OVERLOAO-ANTIDOTES 93100025007320 Exjade DeferasiroxTab For Oral Susp 125 MG 15.25% IRON OVERLOAD-ANTIDOTES 93100025000330 Jadenu DeferaslroxTab 180 MG 16.00% IRON REPLACEMENTS 82300085102020 Ferr!ecit Sod Ferric Gluc Cmplx In Sucrose IV Soln 12.S MG/Ml {Fe Eq) 16.00% IRON REPLACEMENTS 82300048002020 Venofer Iron Sucrose fnj 20 MG/ML (Fe Equiv) 16.00% LHRH Analogs 21405010106405 Lupron Depot leuprofide Acetate For lnj Kit3.75 MG 16.00% LHRH Analogs 21405010156420 Lupron Depot leupro!ide Acetate {3 Month) For lnj Kit 11.25 MG 16.00% Local Anesthetics- Topical 90850025306420 Qutenza Capsalcln Patch 8% & Cleansing Gel Kit 16.00% MEDICAL DEVICES 97051050106300 Omnitrope Pen 10 lnJ De *Injection Device - Misc*** 16.25% MOUTH/THROAT/DENTAL AGENTS 88501000002000 Caphosol *Artificial Saliva - Solution*0 16.00% Movement Disorder Drug Therapy 62380070000310 Xenazine TetrabenazineTab 12.5 MG 16.75% Movement Disorder Drug Therapy 62380070000320 Xenazine Tetrabenazine Tab 25 MG 16.75% MULTIPLE SCLEROSIS 30300010004010 Acthar HP Cortkotropin lnj Gel 80 Unit/ML 16.00% MULTIPLE SCLEROSIS AGENTS 6240003010E520 Copaxone Glatiramer Acetate Soln Prefllled Syringe 20 MG/Ml 16.75% MULTIPLE SCLEROSIS AGENTS 62403075300250 Plegridy Starter Pack Peginterferon Beta-la So!n Pen·lnj 63 & 94 MCG/0.SMl Pack 16.00% MULTIPLE SCLEROSIS AGENTS 62405525006520 Tecftdera Dimethyl Fumarate Capsule Delayed Release 120 MG 16.00% MULTIPLE SCLEROSIS AGENTS 62403060506420 Betaseron Interferon Beta-lb For lnj Kit 0.3 MG 16.25% MULTIPLE SCLEROSIS AGENTS 62405050001320 Tysabri Natal!zumab for IV lnj Cone 300 MG/15Ml 18.00% MUlTJPLE SCLEROSIS AGENTS 6240003010ES40 Copaxone Glatiramer Acetate Soln Prefilled Syringe 40 MG/ML 16.75% MUlTIPLE SCLEROSIS AGENTS 6240307530E520 Plegridy Peginterferon Beta-la Soln Prefi!led Syringe 125 MCG/0.SML 16.00% MULTIPLE SCLEROSIS AGENTS 62405525006540 Tetfidera Dimethyl Fumarate Capsule Delayed Release 240 MG 16.00% MULTIPLE SCLEROSIS AGENTS 62403075300220 Plegricly Peglnterferon Beta-la Soln Pen-injector 125 MCG/0.5Ml 16.00% MULTIPLE SCLEROSIS AGENTS 62405525006320 Tecfidera Dimethyl Fumarate Capsule DR Starter Pack 120 MG & 240 MG 16.00% MULTIPLE SCLEROSIS AGENTS 62403060456420 Avonex Interferon Beta-la For IM lnj Kit30MCG (33MCG{6.6MU)/Vial) 16.75% MULTIPLE SCLEROSIS AGENTS 6240307530ESSO P/egridy Starter Pack Peginterferon Beta-la Soln Pref Syr 63 & 94 MCG/0.SML Pack 16.00% MULTJPLE SCLEROSIS AGENTS 62406030007420 Ampyra Dalfamprfdine Tab SR 12HR 10 MG 15.25% MULTIPLE SCLEROSIS AGENTS 62404070000330 Aubagio Terlffunomlde Tab 14 MG 23.75% MULTIPLE SCLEROSIS AGENTS 62403060502120 Betaseron Interferon Beta-lb For In] 0.3 MG 16.25% MULTIPLE SCLEROSIS AGENTS 62405010002020 Lemtrada Alemtuzumab IV lnj 12 MG/1.2ML (10 MG/ML) 16.00% MUlTIPLE SCLEROSIS AGENTS 62404070000320 Aubaglo Teriflunomide Tab 7 MG 23.75% MULTIPLE SCLEROSIS AGENTS 62407025100120 Gilenya Flngofimod HCI Cap 0.5 MG (Base Equiv) 16.50% MUSCULOSKELETAL THERAPY AGENTS 75840015002300 Carticel *Autologous Cultured Chondrocytes for Implantation*" 16.00% Neurogenic Orthostatic Hypotenslon (NOH) Agents 38700030000150 Northera Droxldopa Cap 300 MG 16.00% Neurogenic Orthostatic Hypotension (NOH) -Agents 38700030000130 Northera Droxidopa Cap 100 MG 16.00% Neurogenic Orthostatic Hypotension {NOH) - Agents 38700030000140 Northern Droxidopa Cap 200 MG 16.00% NEUROMUSCULAR AGENTS 74400020052140 Botox OnabotulinumtoxinA For lnj 200 Unit 16.75% NEUROMUSCULAR AGENTS 74400020032120 Dysport Abobotul!numtoxfnA For lnj 500 Unit 16.75% NEUROMUSCULAR AGENTS 74503070000320 Ri1utek Riluzole Tab 50MG 16.00% NEUROMUSCULAR AGENTS 74400020102018 Myobloc RimabotufinumtoxinB lnj 2500 UniVO.SML -\1STP.z,L "- 16.25% NEUROMUSCULAR AGENTS 74400020052120 Botox Onabotulinumtox!nA For lnj 100 Unit <,-_\:-, _i;:;;::,· ~/:---.....'\ 16.75% NEUROMUSCULAR AGENTS 74400020102020 Myobloc Rimabotulinumtox!nB lnj 5000 Unit/ML <)j7 -¥/. " 16.25% ')'', , ' ,V Ye r, !.'] omrato Ntim \ • Gro;H\, \lf' ··o,,,i. ......., )_ >----' •} '/ \\"' . , ,.,// (J i°"• ''"' \ \(;V\ r;,·.,,._ ,Y'cc=1,5"' _ ' .. (

NEUROMUSCULAR AGENTS NEUROMUSCULAR AGENTS NEUROMUSCUlAR AGENTS NEUROMUSCULAR AGENTS OBSOLETO OPHTHALMIC AGENTS OPHTHALMIC AGENTS OPHTHALMIC AGENTS OPHTHALMIC AGENTS OPHTHALMIC AGENTS OPHTHALMIC AGENTS OPHTHALMIC AGENTS OPHTHALMIC AGENTS Ophthalmic Agents OSTEOARTHRITIS OF THE KNEE OSTEOARTHRITIS OF THE KNEE OSTEOARTHRITIS OF THE KNEE OSTEOARTHRITIS OF THE KNEE OSTEOARTHRITIS OF THE KNEE OSTEOARTHRITIS OF THE KNEE OSTEOPOROSIS- BISPHOSPHONATES OSTEOPOROSIS- BlSPHOSPHONATES OSTEOPOROSIS- BlSPHOSPHONATES OSTEOPOROSIS- BlSPHOSPHONATES OSTEOPOROSIS· BISPHOSPHONATES OSTEOPOROSIS- BISPHOSPHONATES OSTEOPOROSIS· BISPHOSPHONATES OSTEOPOROSIS· BISPHOSPHONATES OSTEOPOROSIS· BISPHOSPHONATES OSTEOPOROSIS- BISPHOSPHONATES Progesterone Receptor Antagonists ANTIDlABETICS Progestin Contraceptives- IUD Progestln Contraceptives - IUD PROGESTINS PSORIASIS PSORIASIS PSORIASIS PSORIASIS PSORIASIS PSORIASIS PSORIASIS PSORIASIS PULMONARY ARTERIAL HYPERTENSION PUlMONARY ARTERIAL HYPERTENSION PULMONARY ARTERIAL HYPERTENSION PULMONARY ARTERIAL HYPERTENSION PULMONARY ARTERIAL HYPERTENSION PULMONARY ARTERIAL HYPERTENSION PULMONARY ARTERIAL HYPERTENSION 74400020202120 Xeomln 74400020032115 Dysport 74400020202130 Xeomin 74400020102022 Myob!oc 90250515002120 AMEVIVE 86300010002320 Ozurdex86700065002120 Visudyne86300017102320 Retisert86801060002020 Jetrea86655010002020 Eylea8665S060002012 Lucentls 86655060002020 lucentis86655050302020 Macugen86300080101820 Triesence 7580004000ES30 Synvlsc7580004000E560 Synvlsc One 7580006000E520 OrthoVisc 7580007010ES20 Euf!exxa7580007010ES25 Supartz75800070102024 Hyafgan30042090002120 Zoledronic Acid30042090001320 Zo!edronic Add30042060102012 Pamldronate Disodium30042060102006 Pam!dronate Dlsodlum30042060102009 Pamldronate Dlsodium30042090002016 2oledron!c Acid 30042060102120 Aredia30042090002020 Redast 30042060102140 Aredla30042048102030 Boniva 27304050000330 Korlym25200050005320 Mirena25300005002320 lmplanon26000010101710 Makena 9025058500E520 Stelara 66700015000330 otezla 9025058500E540 Stelara90250515002130 AMEVIVE 9025057500E520 Cosentyx 90250585002020 Ste1ara 66700015008720 otezla 40134050000340 Adempas40160015000330 Tracleer40170080050415 Orenltram40134050000320 Adempas40160007000320 Letairis40170080002020 Tyvaso40134050000350 Adempas lncobotulinumtoxinA For lnJ 50 Unit AbobotuHnumtoxinA For lnj 300 Unit lncobotulinumtoxinA For lnj 100 Unit RimabotulinumtoxinB lnj 10000 Unit/2Ml ALEFACEPT FOR IV INJ 7.5 MG Dexamethasone lntravitreal lmplant0.7 MG Verteporfin For IV So!n 15 MG {2 MG/ML) F!uoclnolone Acetonide lntravitreal lmp!ant0.59 MG Ocrip!asmin lntravitreal lnj 0.5 MG/0.2ML (2.5 MG/ML) Aflibercept lntravitreal lnj 2 MG/0.0SML (40 MG/ML) Ranibizumab lntravitreal lnJ 0.3 MG/0.05Ml {6 MG/ML) Ranibizumab lntravitreal lnj 0.5 MG/0.0SML (10 MG/ML) Pegaptanib Sodium lntravitreous lnj 0.3 MG/90 Micro!iter Triamcinolone Acetonlde Ophth lnj 40 MG/MLHylan Intra-articular Solution Prefilled Syringe 16 MG/2MLHylan Intra-articular Solution Prefilled Syringe 48 MG/6ML Hyaluronan lntra-articularSofnPrefi![ed Syringe 30 MG/2ML Sodium Hyaluronate lntra-art!CtJ!ar Soln Pref Syr 20 MG/2Ml Sodium Hyaluronate Intra-articular Solo PrefSyr 25 MG/2.5Ml Sodium Hyaluronate Intra-articular lnj 20 MG/2MLZoledronlc Acid For IV Soln 4 MGZoledronic Acid lnj Cone For N Infusion 4 MG/SML Pamidronate Dlsodtum IV So!n 9 MG/MlPamidronate Disodium IV So!n 3 MG/Ml Pamidronate Disodium IV Soln 6 MG/Ml 2oledron!c Acid IV Soln 4 MG/lOOMLPam!dronate Dlsodium For lnj 30 MG Zo!edronic Acid IV Soln 5 MG/lOOMl Pamidronate Dlsodium For lnj 90 MGlbandronate Sodium IVSoln 3 MG/3ML (Base Equivalent)Mifepristone Tab 300 MGlevonorgestrel Re!easlng IUD 20 MCG/24HR {52 MG Total) Etonogestrel Subdermal Implant 68 MG Hydroxyprogesterone Caproate lM in Oil 250 MG/ML Ustekinumab Soln Prefilled Syringe 45 MG/0.5Ml ApremilastTab 30 MGUstekinumab Soln Prefilled Syringe 90 MG/ML Alefacept For IM lnj 15 MGSecukinumab Subcutaneous So!n Prefilled Syringe 150 MG/Ml U5TEKINUMAB INJ 45 MG/0.SMLApremilastTab Starter Therapy Pack 10 MG & 20 MG & 30 MG 90250575000520 Cosentyx Sensoready Pe Secukinumab Subcutaneous Soln Auto-injector 150 MG/ML Riociguat Tab 2 MG Bosentan Tab 125 MGTreprostlnll Ololamfne Tab CR 0.25 MG (Base Equiv) RiociguatTab 1 MGAmbrlsentan Tab 10 MGTreprostinil Inhalation Solution 0.6 MG/Ml RiociguatTab 2.5 MG 16.25%16.75%16.25%16.25%15.50%16.00%16.25%16.00%16.00%16.75%16.75%16.75%16.25%15.50%16.75%16.75%16.75%16.75%16.25%16.75%.35.00%34.20%16.00%16.00%16.00%35.00%16.00%35.00%16J)O%16.00%16.00%15.50%15.25%16.75%16.00%16.00%16.00%15.50%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%16.00%

q:-.{S, PULMONARY ARTERIAL HYPERTENSION 40160050000320 Opsumit Macitentan Tab 10 MG 16.00% PULMONARY ARTERIAL HYPERTENSION 40134050000310 Adempas Riodguat Tab 0.5 MG PULMONARY ARTERIAL HYPERTENSION 40160007000310 Letairis Ambrisentan Tab S MG 16.00%16.00% PULMONARY ARTERIAL HYPERTENSION 40170080102040 Remodulin Treprostinil Sodium JnJ 10 MG/ML(Base Equiv) 16.00% PULMONARY ARTERIAL HYPERTENSION 40170080050420 Orenitram Treprostinil Diolamine Tab CR 1 MG (Base Equiv) 16.00% PULMONARY ARTERIAL HYPERTENSION 40134050000330 Adempas Riodguat Tab 1.5 MG 16.00% PULMONARY ARTERIAL HYPERTENSION 40160015000320 Tradeer Bosentan Tab 62.5 MG 16.00% PULMONARY ARTERIAL HYPERTENSION 40143060101920 Revatio Si1denafil Citrate For Suspension 10 MG/ML 16.75% PULMONARY ARTERIAL HYPERTENSION 40170080050410 o,enitram Treprostinil Diolamine Tab CR 0.125 MG (Base Equiv) 16.00% PULMONARY ARTERIAL HYPERTENSION 40170040102110 Epoprostenol Sodium Epoprostenol Sodium For Inj 0.5 MG 16.00% PULMONARY ARTERIAL HYPERTENSION 40170080050425 Orenitram Treprostinil Diolamlne Tab CR 2.5 MG (Base Equiv) 16.00% PULMONARY ARTERIAL HYPERTENSION 40143060100320 Revatio Si!denafil Citrate Tab 20 MG 40.00% PULMONARY ARTERIAL HYPERTENSION 40143080000320 Adcirca Tadalafil Tab 20 MG (PAH) 15.75% PULMONARY ARTERIAL HYPERTENSION 40170060002020 Ventavls lloprost Inhalation Solution 10 MCG/ML 16.00% PULMONARY ARTERIAL HYPERTENSlON 40170080102020 Remodulln Treprostinil Sodium lnj 2.5 MG/Ml {Base Equiv) 16.00% PULMONARY ARTERIAL HYPERTENSION 40170060002040 Ventavis l!oprost Inhalation Solution 20 MCG/ML 16.00% PULMONARY ARTERIAL HYPERTENSlON 40170080102030 RemoduHn Treprostinll Sodium lnj 5 MG/ML {Base Equiv} 16.00% PULMONARY ARTERIAL HYPERTENSION 40143060102020 Revatio Sildenafil atrate IV Soln 10 MG/12.SML (Base Equivalent) 16.75% PUlMONARY ARTERIAL HYPERTENSION 40170040102130 Epoprostenol Sodium Epoprostenol Sodium For lnj 1.5 MG 16.00% PULMONARY ARTERIAL HYPERTENSION 40170080102010 Remodulin Treprostinll Sodium lnj 1 MG/Ml(Base Equiv) 16.00% Pulmonary Fibrosis Agents 45550060000120 Esbriet Pirfenidone Cap 267 MG 16.00% Pulmonary Fibrosis Agents 45554050200130 Ofev Nintedanib Esylate Cap 150 MG {Base Equivalent) 16.00% Pulmonary Fibrosis Agents 45554050200120 Ofev Nintedanib Esylate Cap 100 MG (Base Equivalent} 16.00% RESPIRATORY AGENTS- MISC. 45100010102110 Ara!astNP Alphal-Proteinase Inhibitor (Human) For IVSoln 500 MG 16.00% RESPIRATORY AGENTS - MISC. 45000070001820 Surfaxin Lucinactant lntratracheal Susp 30 MG/ML 16.00% RESPIRATORY AGENTS- MISC. 45100010102108 Arafast A!phal-Proteinase Inhibitor (Human) For IV Solo 400 MG 15.50% RESPIRATORY AGENTS - MISC. 45100010102118 Aralast Afphal-Proteinase Inhibitor (Human) For JV Soln 800 MG 15.50% RESPIRATORY AGENTS- MISC. 45100010102020 Glassia Alphal-ProteinaseInhibitor (Human) lnj 1000 MG/SOML 15.75% RESPIRATOR'r AGENTS- MISC. 45100010102120 Aralast NP Alphal-ProteinaseInhibitor {Human) For IV Solo 1000 MG 16.00% ResplratorySyncytia!Virus {RSV) Agents 19502060002015 Synagis Palivlzumab IM So!n 50MG/0.SML 15.75% Respiratory Syncytial Virus {RSV) Agents 19502060002020 synagis Palivizumab IM Soln 100 MG/Ml 15.75% Respiratory Syncytial Virus (RSV) Agents 1260407S002120 Vlrazole Rlbavirin For lnhal Soln 6 GM 16.00% Respiratory Tract Agents 40120070000310 Uptravi SelexipagTab 200 MCG 15.50% Respiratory Tract Agents 40120070000340 Uptravi SelexipagTab 1400 MCG 15.50% Respiratory Tract Agents 40120070000315 Uptravi Selexlpag Tab 400 MCG 15.50% Respiratory Tract Agents 40120070000320 Uptravi Selexipag Tab 600 MCG 15.50% Respiratory Tract Agents 40120070008720 Uptravi Se!exipagTab Therapy Pack200 MCG (140) & 800 MCG (60) 15.50% Respiratory Tract Agents 40120070000345 Uptravi Selexipagfab 1600 MCG 15.50% Respiratory Tract Agents 40120070000330 Upt,avi Selexipag Tab 1000 MCG 15.50% Respiratory Tract Agents 40120070000335 Uptravl Selexipag Tab 1200 MCG 15.50% Respiratory Tract Agents 40120070000325 Uptravi Selexipag Tab 800 MCG 15.50% RHEUMATOID ARTHRITIS MISC 6650007000E520 Actemra Tocilizumab Subcutaneous Solo Prefilled Syringe 162 MG/0.9Ml 15.50% RHEUMATOID ARTHRITIS MISC 66500070002035 Actemra Toci!izumab IV lnj 200 MG/lOML 15.50% RHEUMATOJD ARTHRITIS MISC 66400010002120 Orenda Abatacept For IV So!n 250 MG 16.25% RHEUMATOJD ARTHRITIS MISC 66603065100320 Xeljanz Tofacitinib Citrate Tab 5 MG (Base Equivalent) 16.00% RHEUMATOID ARTHRITIS MISC 66500070002040 Actemra Tocftizumab IVlnj 400 MG/20ML 15.50% RHEUMATOID ARTHRITIS MISC 6640001000£520 Orencia Abatacept Subcutaneous Sofn Prefil!ed Syringe 125 MG/ML . ---··.-1- 16.25% RHEUMATOID ARTHRITIS MISC 66280050000320 Arava Leflunomlde Tab 20 MG ( \\•l1::T._'c,••- • 1(,'J"" 16.00% RHEUMATOID ARTHRITIS MISC 66460020002120 llaris canak:!numab For lnJ 180 MG /;''.r,:'7 ...,_i,J'\-v.),,,,\- \ 16.75% I ' f Contrato Nu \ \) \. 1 mer, i

RHEUMATOID ARTHRITIS MISC 66500070002030 Actemra Tocilfzumab IV lnj80 MG/4Ml RHEUMATOID ARTHRITIS MISC 66280050000310 Arava leflunomide Tab 10 MG 15.50%16.00% Short Bowel Syndrome (SBS) Agents 52533070006420 Gattex Teduglutide (rDNA) For lnj Kit 5 MG Stem Cell Mobllizers 82502060002020 Mozobil Plerixafor Subcutaneous lnj 24 MG/1.2Ml (20 MG/Ml) 16.00%16.75% Systemic lupus Erythematosus Agents 99422015002120 Ben!ysta Belimumab For IVSoln 120 MG 16.75% Systemic lupus Erythematosus Agents 99422015002140 Benlysta Belimumab For IV Soln 400 MG 16.75% Therapeutic Nutrients/Minerals/Elect,olytes 93100028002020 Ferriprox Deferiprone Oral Soln 100 MG/ML 15.50% TUBERCULOSIS 09000015100320 Sirturo Bedaquiline Furna rate Tab 100 MG (Base Equiv) 16.00% Tumor Nec,osls Factor Alpha Blockers 52S05020106460 Cimzia Starter Kit Certo!izumab Pegol lnj Kit 6X 200 MG/Ml 16.75% Tumor Nec,osis Factor Alpha Blockers 6627004000DS40 Simponi Go!imumab Subcutaneous Sein Auto-injector 100 MG/ML 16.25% Tumor Necrosis Factor Alpha Blockers 6629003000ES30 Enbrel EtanerceptSubcutaneous Soln Prefilled Syringe SO MG/ML 16.75% Tumor Necrosis Factor Alpha Blockers 52505020106420 Cimzia Certo!izumab Pegol For lnj Kit 2 X 200 MG 16.75% Tumor Necrosis Factor Alpha Blockers 66270040002015 SimponiAria Gofimumab IV Soln SO MG/4ML 16.25% Tumor Necrosis Factor Alpha Blockers 6629003000D530 Enbrel SureC!ick EtanerceptSubcutaneous Solution Auto-injector 50 MG/Ml 16.75% Tumor Necrosis Factor Alpha Blockers 52505040002120 Remicade lnflbdmab Fot IV lnj100 MG 16.00% Tumor Necrosis Factor Alpha Blockers 6627004000E520 5imponi Golimumab Subcutaneous So!n Prefi!led Syringe SO MG/0.SML 16.2S% Tumor Necrosis Factor Alpha Blockers S2S05020106440 Cimzia Certolizumab Pegol lnj Kit 2X 200 MG/Ml 16.75% Tumor Necrosis Factor Alpha Blockers 6627004000D520 Simponi Golimumab Subcutaneous Soln Auto-injector 50 MG/0.SML 16.25% Tumor Necrosis Factor Alpha Blockers 6629003000E525 Enbrel Etanercept Subcutaneous Soln Prefi!led Syringe 25 MG/0.SML 16.75% Tumor Necrosis Factor Alpha Blockers 6627001500F420 Humira Pen Ada!Jmumab Pen-injector Kit 40 MG/0.8Ml 16.75% Tumor Necrosis Factor Alpha Blockers 6627004000E540 Simponi Golimumab Subcutaneous Soln Prefilled Syringe 100 MG/ML 16.25% Tumor Necrosis Factor Alpha Blockers 6627001500F810 Humira Adaflmumab Prefilled Syringe Kit 20 MG/0.4Ml 16.75% Tumor Necrosis Factor Alpha Blockers 6627001500F820 Humira Ada!imumab Prefllled Syringe Kit 40 MG/0.SML 16.7S% Tumor Necrosis Factor Alpha Blockers 66290030006420 Enbrel Etanercept For Subcutaneous Jnj Kit 25 MG 16.75% Tumor Necrosis Factor Alpha Blockers 6627001500F805 Humira Adalimumab Prefilled Syringe Kit 10 MG/0.2Ml 16.75% Viscosupplements 7580006000e515 Hymovis Hya!uronan Intra-articular Soln Ptefilled Syringe 24 MG/3Ml 15.50% (blank) 96544244002900 Gabapentin Gabapentin Powder 15.50% (blank) 30201010102030 DDAVP Desmopressin Acetate lnj 4 MCG/Ml 15.50% (blank) 30089902506420 lupaneta Pack leuproltde (1 Mon) lnj 3.75 MG & Norethindrone Tab 5 MG Kit 15.50% {blank) 21700030000105 Hydroxyurea Hydroxyurea Cap 500 MG 15.50% (blank) 85153060101310 Aggrastat Tlroflban HCI IV Cone 3.75 MG/lSML {250 MCG/ML) (Base Equiv) 15.50%

Anexo 1: Lista de Descuentos para Medicamentos de Alto Cosio que sean despachados por las Farmacias Jndependlentes y Cadenas Locales {2017) Category GPI Drug Name GP! Name Actual Discount Agents for Gaucher Disease 82700020002020 Ceredase A!glucerase IV Soln 80 Unit/ML 16.00% Agents for Gaucher Disease 82700085102120 Vptiv Ve!aglucerase Alfa For lnj 400 Unit 16.00% Agents for Gaucher Disease 82700040600120 Cerdelga Elig!ustat Tartrate Cap 84 MG {Base Equivalent) 16.00% Agents for Gaucher Disease 82700050002110 Cerezyme lmiglucerase For lnj 200 Unit 16.00% Agents for Gaucher Disease 82700070000120 Zavesca Miglustat Cap 100 MG 16.00% Agents for Gaucher Disease 82700080102120 Elelyso Taliglucerase Alfa For lnj 200 Unit 16.00% Agents for Gaucher Disease 82700050002120 Cerezyme lmiglucerase For lnj 400 Unit 16.00% ANALGESICS -ANTI-INFLAMMATORY 6620003000201S Gold Sodium Thiomalate Gold Sodium Thiomalate lnj 50 MG/ML ANALGESICS - NonNarcotic 64154090102020 Prialt Zlconotide Acetate lntrathecal lnj 100 MCG/Ml 16.00% ANALGESICS- NonNarcotic 64154090102030 Malt Ziconotide Acetate Jntrathecal Jnj 500 MCG/SML 16.75% ANALGESICS - NonNarcotic 64154090102010 Prialt Ziconotlde Acetate lntrathecal lnj 500 MCG/20ML {25 MCG/ML) 16.75% ANDROGENS-ANABOLIC 23100030802030 Aveed Testosterone Undecanoate IM Jnj In Oil 750 MG/3ML (250MG/ML) 16.75% ANTIARRHYTHM!CS 35400025000110 Tikosyn Dofeti1ide Cap 125 MCG (0.125 MG) 16.00%15.50% ANTIARRHYTHMICS 35400025000120 Tikosyn Dofetilide Cap 250 MCG (0.25 MG) 15.50% ANTIARRHYTHM!CS 35400025000130 Tikosyn Dofetilide cap 500 MCG {0.5 MG) 15.50% ANTIASTHMATICAND BRONCHODILATORAGENTS 44603060002120 Xolalr Omalizumab For In] 150 MG 16.25% ANTIB!OTICS- AMINOGlYCOStDES 07000070102030 Tobramycin Sulfate TOBRAMVCIN SULFATE INJ 40 MG/ML 41.75% ANTIBIOTICS-AMINOGLVCOStDES 07000070102020 Tobramycin Sulfate Tobramycln Sulfate lnj 10 MG/ML 41.75% ANTIBIOTICS-AMINOGlVCOStDES 07000070102034 Tobramycin Sulfate Tobramycin Sulfate In] 80 MG/2ML {40 MG/ML) 41.75% ANTIBIOTICS-AMINOGLYCOSIDES 07000070102105 Tobramycin Sulfate Tobramycin Sulfate For lnj 1.2 GM 41.75% ANTIBIOTICS-AMINOGLVCOSIDES 07000070102039 Tobramycin Sulfate Tobramycin Sulfate lnj 2 GM/50Ml {40 MG/Ml} 41.75% ANTIBIOTICS-AMINOGLVCOSIDES 07000070102022 Tobramycln Sulfate Tobramycin Sulfate IV So!n 10 MG/ML 41.75% ANTIBIOTJCS-AMINOGLVCOSIDES 07000070102038 Tobramycln Sulfate Tobramycin Sulfate lnj 1.2 GM/30ML{40 MG/ML) 41.75% Anti-Catap!ect!c Agents 62450060202020 Xyrem Sodium Oxybate Oral Solution 500 MG/Ml 16.00% ANTICOAGULANTS 83101010102020 Fragmin Dalteparin Sodium lnj 2500 Unit/0.2Ml 16.00% ANTICOAGULANTS 83101020102013 lovenox Enoxap.irin Sodium lnj 40 MG/0.4ML 16.00% ANTICOAGULANTS 83103030102035 Arixtra FondaparinuxSodium Subcutaneous lnj 5 MG/0.4ML 16.00% ANTICOAGULANTS 83101010102065 Fragmin Dalteparin Sodium In] 25000 Unit/Ml 16.00% ANTICOAGULANTS 83101020102050 Lovenox Enoxaparin Sodium lnj 300 MG/3Ml 16.00% ANTICOAGULANTS 83370060000340 Xarelto Rivaroxaban Tab 20 MG 16.00% ANTICOAGULANTS 83101010102040 Fragmin Dalteparin Sodium lnj 5000 Unit/0.2Ml 16.00% ANTICOAGULANTS 83101020102014 lovenox Enoxaparin Sodium In] 60 MG/0.6ML 16.00% ANTICOAGULANTS 83103030102040 Arixtra FondaparinuxSodlumSubcutaneous lnj 7.5 MG/0.6Ml 16.00% ANTICOAGULANTS 83101010102015 Fragmin Da!teparin Sodium lnJ 10000 Unit/Ml 16.00% ANTICOAGULANTS 83101020102012 Lovenox Enoxaparin Sodium lnj 30 MG/0.3ML 16.00% ANTICOAGULANTS 83103030102020 Arixtra Fondaparinux Sodium Subcutaneous Jnj 2.5 MG/0.SML 16.00% ANTICOAGULANTS 83101010102045 Fragmin Dalteparin Sodium lnj 7500 Unit/0.3Ml 16.00% ANTICOAGULANTS 83101020102015 lovenox EnoxaparinSodlurn lnj 80 MG/0.8ML 16.00% ANTICOAGULANTS 83103030102045 Arixtra Fondaparinux Sodium Subcutaneous JnJ 10 MG/0.8ML 16.00% ANTICOAGULANTS 83101010102056 Fragmin Dalteparin Sodium lnj 15000 Unlt/0.6ML 16.00% ANTICOAGULANTS 83101020102018 Lovenox Enoxaparin Sodium lnj 120 MG/0.8ML 16.00% ANTICOAGULANTS 83370060000320 Xarelto Rivaroxaban Tab 10 MG 16.00% ANTICOAGULANTS 83101010102060 Fragmin Dalteparin Sodium lnj 18000 Unit/0.72Ml _,,..·,,s·yi=.zrv'"' -.....:..• 16.00% ANTICOAGULANTS 83101020102020 Lovenox Enoxaparin Sodium lnj 150 MG/ML / t.\' ...<P·- i--.¾'I..}... 16.00% ANTICOAGULANTS 83370060000330 Xarelto Rivaroxaban Tab 15 MG //(:',;Y -_v.r,\\ 16.00% /'t'"••·)"' t ' 1 ii i, ! .l 9 · . v•m ' ' o, 5' 9/I tu, - --vo ' :'y 0, ''"' \,;.,.,,·. '•. /,,y_:S \ ·,.-....:.:...,-:,:...,.:: ,_....,• . /.

ANTICOAGULANTS ANTICOAGUlANTS ANTICOAGULANTS ANTICONVULSANTS ANTICONVUL5ANTS ANTICONVULSANTS ANTICONVULSANTS ANTICONVUL5ANTS ANTICONVUISANTS ANTICONVULSANTS ANTICONVULSANTS ANTICONVULSANTS ANTICONVULSANTS ANTIEMETICS ANTIEMETICS ANTIEMETICS ANTIEMETICS ANTIEMETJCS ANTIEMETICS ANTIEMET1CS Antiemetics ANTIEMETICS ANTIEMETICS Antiemetics ANTIEMETICS 83101010102053 Fragmin83101020102016 Lovenox83334050102120 Refludan72600043002020 Keppra72600043000340 Keppra72600043002060 Keppra72600043000350 Keppra72170085000320 Sabril72600043007520 Keppra XR72600043000320 Keppra72600043000330 Keppra72170085003020 Sabril72600043007530 Keppra XR50250025200330 Anzemet50280035102130 Emend50280020000130 Emend50250025202020 Anzemet50250025200320 Anzemet50280020006320 Emend50250070102010 Aloxl50250065052030 Zofran50280020000110 Emend50280020000120 Emend502S0065052024 Ondansetron HCI 50250070102020 Aloxi ANTIFUNGALS ANTIFUNGALS 11000010101920 Amphotec 11407060001820 Noxafil Dalteparin Sodium lnj 12500 Unit/0.SML Enoxaparin Sodium lnj 100 MG/ML Lepirudin For IV So!n 50 MG Levetiracetam Oral Soln 100 MG/Ml levetiracetam Tab 750 MGlevetiracetam lnj 500 MG/SML{lOO MG/ML) Levetiracetam Tab 1000 MGVigabatrin Tab 500 MG levetiracetam Tab SR 24HR 500 MG levetiracetam Tab 250 MG levetiracetam Tab 500 MG Vigabatrin Powd Pack 500 MG levetiracetam Tab SR 24HR 750 MG Do!asetron Mesylate Tab 100 MGFosaprepitant Dirneglumlne For IV Infusion 150 MG (Base Eq) Aprepitant Capsule 125 MGDolasetron Mesylate IV lnj 20 MG/Ml Dolasetron Mesylate Tab SO MGAprepitant Capsule Therapy Pack 80 & 125 MGPalonosetron HCI IV Soln 0.075 MG/1.SML {Base Equiv) Ondansetron HCI lnj 40 MG/20ML {2 MG/ML) AprepltantCapsule 40 MGAprepitant Capsule 80 MGOndansetron HCI lnj 4 MG/2ML {2 MG/ML)Palonosetron HCI IV So!n 0.25 MG/SML {Base Equivalent} Amphotericin B Cho!esteryl Sulfate Complex: For lnj 100 MG ANTIFUNGALS 11500025102130 Cancidas Posaconazole 5usp 40 MG/ML 16.00%16.00%16.00%16.00%16.00%16.00%16.00%15.75%16.00%16.00%16.00%15.75%16.00%16.00%16.00%16.00%16.00%16.00%16.00%26.75%15.50",616.00%16.00%15.50%26.75% 16.00% ANTIFUNGALS Caspofungin Acetate For IV So!n 70 MG 16.00% 11000010002105 Amphotericin B 16.00% ANTIFUNGALS 11407015022020 Diflucan in Dextrose Amphotericin B For lnj 50 MG ftuconazole in Dextrose lnj 400 MG/200ML 16.00% ANTIFUNGAlS 11500010002130 Eraxis ANTIFUNGALS 11000010301820 Abe!cet ANTIFUNGALS 11407080000320 Vfend Anidu!afungin For IV 5oln 100 MGAmphoterfcln B lipid lnjSusp {For IV Infusion) 5 MG/Ml 15.25% Voriconazole Tab 50 MG 16.00%16.00% ANTIFUNGALS 16.00% ANTJFUNGALS 11500050102120 Mycamlne Micafungin Sodium For IVSoln 50 MG 11407015012020 Diflucan in Sodium Chlori Fluconazofe In NaCl 0.9% lnj 400 MG/200ML 16.00% 15.25% ANTIFUNGALS ANTIFUNGAL5 11407080002120 Vfend IV Voriconazo!e For Jnj 200 MG 16.00% ANTIFUNGALS ANTIFUNGALS 11407015022010 Diflucan in Dextrose 11500010002120 Eraxis Fluconazole in Dextrose lnj 200 MG/lOOMl Anidu!afungin For IVSoln 50 MG 15.25%16.00% ANTIFUNGALS 15.25% ANTIFUNGALS 16.00% ANTIFUNGALS ANTIFUNGALS 11407015012010 Dif!ucan In Sodium Ch!ori Fluconazole in NaCl 0.9% lnJ 200 MG/100Ml 11407080001920 Vfend Voriconazole For Susp 40 MG/ML11000010101910 Amphotec Amphoterlcln B Cho!esteryl Sulfate Complex For lnj 50 MG 11407035002020 Sporanox Jtraconazole Oral Soln 10 MG/Ml ANTJFUNGALS 11500025102120 Cancldas Caspofungin Acetate For IV So!n 50 MG ANTIFUNGALS 11000010401920 ArnBisome Amphoter!cin B liposome IV For Susp 50 MG 11407080000340 Vfend Voriconazole Tab 200 MG 16.00% 16.00% 16.00% 16.00% ANTIFUNGALS Antihemophi!ic Products 11500050102130 Mycamine 16.00% Micafungin Sodium For JV So!n 100 MG 85100010002139 Hemofil M 16.00% Antihemophific Products 85100010006460 Monodate-P AntihemophiHc Factor {Human) For lnj 801-1700 Unit Antihemophilic Products 85100010202145 Recomblnate Antihemophilic Factor (Human) For lnj Kit 1000 Unit Antihemophilic Factor {Recombinant) For lnj 1241-1800 Unit 42.00%30.00% 40.00%

Antihemoph!lic Products 85100010252150 Advate Antihemophllic Factor rAHF-PFM For lnj 1500 Unit 37.75% Antihemophilic Products 85100028202150 BeneFIX Coagulation Factor IX (Recombinant) For lnj 2000 Unit 21.00% Antihemophilic Products 85100010266470 Xyntha So!ofuse Antihemophillc Factor Recombinant PAF For lnj Kit 3000 Unit 38.00% Antihemophllic Products 85100010502130 Obizur Antihemophilic Factor (Recomb Pore) rpFVJH For lnj 500 Unit 20.00% Antihemophilic Products 85100015102139 Wilate Antihemophilic Factor/VWF (Human) For lnj 1000-1000 Unit 40.00% Antihemophilic Products 85100020002100 Feiba NF *Antiinhibitor Coagulant Complex For lnj** 40.00% Antihemophllic Products 85100028002160 Mononine Coagulation Factor IX For lnj 250 Unit 40.00% Antihemophi1ic Products 85100030002115 Profilnine SD Factor IX Complex For lnj 1500 Unit 19.75% Antihemophi!ic Products 85100010002125 HemofilM Antihemophflic Factor (Human) For lnj 401-800 Unit 42.00% Antihemophi!ic Products 85100010006410 Monodate-P Antihemophilic Factor {Human) For lnj Kit 250 Unit 30.00% Antihemophific Products 85100010202135 Recomblnate Antihemophi!ic Factor (Recombinant) For lnj 801-1240 Unit 40.00% Antihemophilic Products 85100010252130 Advate Antihemophl!lc Factor rAHF-PFM For lnj 500 Unit 37.75% Antihemophllic Products 85100010266440 Xyntha Antihemophilic Factor Recombinant PAF For lnJ Kit 1000 Unit 38.00% Antihemophilic Products 85100010002140 HemofilM Antihemophilic Factor (Human) For lnj 1000 Unit 42.00% Antihemophillc Products 85100010006475 Monoclate-P Antihemophilic Factor (Human) For lnj Kit 1500 Unit 30.00% Antihemophilic Products 85100010302155 Eloctate Antihemophi1ic Factor(Recomb) rFVIIIFc For lnj 2000 Unit 20.00% Antihemoph'ilic Products 85100028202140 BeneFIX Coagulation Factor IX (Recombinant) For lnj 1000 Unit 21.00% Antihemophil!c Products 85100015102132 Humate•P Antihemophi!ic Factor/WJF {Human) For lnj 500-1200 Unit 37.00% Ant!hemophi!lc Products 85100015102190 Afphanate/VWF Complex Antihemophilic Factor/VWF (Human) For fnj 1500 Unit 40.00% Antihemophllic Products 85100026202145 NovoSeven RT Coagulation Factor VIia {Recomb) For lnj 5 MG {5000 MCG) 31.75% Antihemophilic Products 85100030002105 Profilnine SD Factor IX Complex For lnj 500 Unit 19.75% AntihemophJl!c Products 85100060106420 Kcentra Prothrombin Complex Cone Human For lnj Kit 500 Unit 20.00% AntihemophiHc Products 85100010202150 Novoeight Antihemophillc Factor (Recombinant) For lnj 1500 Unit 20.00% Antihemophilic Products 85100010252170 Advate Antihemophllic Factor rAHF-PFM For lnj 2000 Unit 37.75% Ant!hemophi!ic Products 85100028202160 BeneFIX Coagulation Factor IX {Recombinant} For lnj 3000 Unit 21.00% Antlhemophillc Products 85100010302120 Eloctate Antihemophilic Factor {Recomb) rFVIIIFc For lnj 250 Unit 20.00% Antihemoph!lic Products 85100015102120 Humate-P Antihemophi!fc Factor/VWF (Human) For lnj 250-500 Unit 37.00% Antihemophilic Products 85100015102140 Humate-P Antihemophilic Factor/VWF (Human) For lnj 1000-2000 Unit 37.00% Antihemophilic Products 85100026202117 NovoSeven RT Coagulation Factor VIia {Recomb) For Jnj 1 MG {1000 MCG) 31.75% Ant!hemophi!ic Products 85100028002185 AlphaN!ne SD Coagulation Factor JX For lnj 1500 Unit 30.00% Antihemophiltc Products 85100030002150 Bebu!in Factor IX Complex For lnj 200-1200 Unit 20.00% Antihemophllic Products 85100010206440 Helixate FS Antlhemophl!ic Factor {Recombinant) For lnj Kit 1000 Unit 41.75% Antihemophilic Products 85100010002130 Hemofil M Antihemophilic Factor (Human) For lnj 500 Un!t 42.00% Ant!hemophil!c Products 85100010006430 Monodate-P Antihemophlllc Factor (Human) For lnj Kit500 Unit 30.00% Antihemophific Products 85100010202140 BIOClATE ANTJHEMOPHJUC FACTOR (RECOMBINANT) FOR INJ 1000 UNIT 20.00% Antihemophilic Products 84100040002010 Cyk!okapron TranexamicAcid lnj 100 MG/Ml 16.00% Antihemophll!c Products 85100010002146 HemofilM Ant!hemoph!lic Factor (Human) For lnj 1700 Unit 42.00% Ant!hemophilic Products 85100010202115 Recombinate Antlhemophll!c Factor (Recombinant) For lnj 220-400 Unit 40.00% Antihemophilic Products 85100010252140 Advate Antihemophi!ic Factor rAHF-PFM For lnj 1000 Unit 37.75% Antihemophilic Products 85100010266460 Xyntha Antihemophilic Factor Recombinant PAF For lnj Kit 2000 Unit 38.00% Antihemophil!c Products 85100028202120 BeneFIX Coagulation Factor IX (Recombinant) For lnj 250 Unit 21.00% Ant!hemophi!ic Products 85100010302165 E[octate AntihemophiHc Factor (Recomb) rFVIIIFc For lnj 3000 Unit 20.00% Antihemoph!lic Products 85100015102138 Wilate Antihemophi!ic Factor/VWF (Human) For lnj 900-900 Unit 40.00% Antihemophilic Products 85100015102193 Alphanate/VWF Complex Antlhemophinc Factor/VWF (Human) For lnj 2000 Unit 40.00% Antihemophilfc Products 85100026202160 NovoSeven RT Coagulation Factor Vila (Recomb) For lnj 8 MG (8000 MCG) 31.75% Antihemophi!ic Products 85100030002110 Profilnine SD Factor IX Complex For lnj 1000 Unit 19.75% Antihemophilic Products 85100060106430 Kcentra Prothrombin Complex Cone Human For lnj Kit 1000 Unit _, c•-Cf-.-7 /· - -'. 20.00% Antihemoph'llic Products 85100028002170 AlphaNine SD Coagulation Factor IX For lnJ 500 Unit ;,,•, :i• -;,-:-c---_-_;_'--l.-,'.-.., 40.00% Antihemophl!ic Products 85100010202155 Recombinate Antihemophi!ic Factor {Recombinant) For lnj 1801-2400 Unit -/ :· .. P 's,.'1,.... 40.00% _ _:c: /4 r ) - '{( Contrato Nlimoro.•.\,·• ···•· '·' 9 ., .'I/. ,,}. 2, 1' u, >·--- . ' , . -------·' -

Antihemophi!ic Products 85100010252180 Advate Antihemophilic Factor rAHF-PFM For tnj 3000 Unit 37.75% Antihemophi!ic Products 85100010302125 Eloctate Antihemophillc Factor {Recomb) rFVlllFc For lnj 500 Unit 20.00% Antihemophil!c Products 85100015102122 Humate-P Antihemoph!llc Factor/VWF (Human) For lnj 250-600 Unit Antihemophillc Products 85100015102144 Humate-P Antihemoph!l!c Factor/VWF (Human) For lnj 1000-2400 Unit 37.00% Antihemophillc Products 85100026202120 Novo5even Coagulation Factor VIia (Recomb) For lnj 1.2 MG {1200 MCG) 37.00% Antihemophi11c Products 85100028402110 Alpro!ix Coagulation Factor IX (Recomb) {rFIXFc) For lnj 500 Unit 31.75%22.00% Antihemophillc Products 85100030002180 Profilnine SO FACTOR IX COMPLEX FOR INJ 1000-1500 UNIT 20.05% Antihemophilic Products 85100028002180 AlphaNine SD Coagulation Factor IX For lnj 1000 Unit 40.00% Antihemophilic Products 85100010206460 Helixate FS Antihemophilic Factor (Recombinant) For lnj Kit 3000 Unit 41.75% Antihemophilic Products 85100010002110 Hemof!I M Antihemophilic Factor (Human) For fnj 250 Unit 42.00% Antihemophilic Products 85100010002160 HemofilM Antihemophilic Factor (Human) For lnj 801-1500 Unit 42.00''/4 Antihemophllic Products 85100010202125 Recombinate Antihemophilic Factor {Recombinant) For lnj 401-800 Unit 40.00% Antihemophilic Products 85100010202170 Novoeight Antihemophi!Jc Factor {Recombinant) For lnj 3000 Unit 20.00% Antihemophi1ic Products 85100010266420 Xyntha Antihemophi!ic Factor Recombinant PAF For lnj Kit 250 Unit 38.00% Antihemophilic Products 85100010302135 Eloctate Antihemophi!ic Factor {Recomb) rFVl!!Fc For lnj 1000 Unit 20.00% Antihemophllic Products 85100015102129 Wilate Antihemophilic Factor/VWF (Human) For lnj 500-500 Unit 40.00% Antihemophilic Products 85100015102170 Alphanate/VWF Complex Antihemophllic Factor/VWF (Human) For lnj 500 Unit 40.00% Antlhemophilic Products 85100026202130 NovoSeven Coagulation Factor Vila (Recomb) For lnj 2.4 MG {2400 MCG) 30.50% Antihemophil!c Products 85100028402130 Alprolix Coagulation Factor IX (Recomb) (rFIXFc) For lnj 2000 Unit 22.00% Antihemophi1ic Products 85100033006440 Corifact Factor XIII Concentrate (Human) For lnj Kit 1000-1600 Unit 21.00% Antihemophilic Products 85100010206420 Helixate FS Antihemoph!llc Factor {Recombinant} For lnj Kit 250 Unit 41.75% AntihemophiHc Products 85100010002112 ALPHANATE ANTlHEMOPHILIC FACTOR (HUMAN) FOR INJ 250-500 UNIT 41.75% Antihemophilic Products 85100010002170 HemofilM Antihemophi1!c Factor {Human) For Jnj 1501-2000 Unit 42.00% Antihemophl!ic Products 85100010202130 B!OClATE ANTIHEMOPHILICFACTOR {RECOMBINANT) FOR INJ 500 UNIT 20.00% Antihemophi!ic Products 85100010252120 Advate Antihemophilic Factor rAHF-PFM For lnj 250 Unit 37.75% Ant!hemophi!ic Products 85100010266430 Xyntha Antihemophi!ic Factor Recombinant PAF For lnj Kit 500 Unit 38.00% Ant!hemophilic Products 85100010302145 Eloctate Antihemophi!ic Factor {Recomb) rFVJIIFc For lnj 1500 Unit 20.00% Antihemophilic Products 85100028202130 BeneFIX Coagulation Factor IX (Recombinant) For lnj 500 Unit 21.00% Ant!hemoph!llc Products 85100015102130 Humate-P Antihemophilic Factor/VWF {Human) For lnj 500-1000 Unit 37.00¼ Antihemophilic Products 85100015102180 Alphanate/VWF Complex Antfhemophilic Factor/VWF (Human) For lnj 1000 Unit 40.00% Antihemophi11c Products 85100026202140 NovoSeven Co;;gulation FactorVUa {Recomb} For lnJ 4.8 MG (4800 MCG} 31.75% AntihemophiHc Products 85100028402140 Alprollx Coagulation Factor IX {Recomb) (rFIXFc) For lnj 3000 Unit 22.00% Antihemophilic Products 85100035002120 RlaSTAP FJbrinogen Cone (Human) lnj Approximately 1 GM (900-1300 MG) 21.00% Antihemophi!ic Products 8S100010206430 Helixate FS Antihemophi!ic Factor {Recombinant) For lnj Kit 500 Unit 41.75% Ant!hemophi!ic Products 85100010002109 Hemofil M Ant!hemophilic Factor {Human) For !nj 220-400 Unit 42.00% Antihemophilic Products 85100010002147 HemofilM Antihemophllic Factor (Human) For lnj 1701-2000 Unit 42.00% Antihemophilic Products 85100010202120 BIOClATE ANTIHEMOPHIL!CFACTOR {RECOMBINANT) FOR INJ 250 UNIT 20.00% Antihemophilic Products 85100010202160 Novoeight Antihemophilic Factor {Recombinant) For lnj 2000 Unit 20.00% AntihemophiHc Products 85100010252185 Advate Antihemophil!c Factor rAHF-PFM For lnj 4000 Unit 37.75% Antihemophl!ic Products 85100010302130 Eloctate Antihemophl!ic Factor (Recomb) rFVIIIFc For lnj 750 Unit 20.00% Antihemophl!ic Products 85100015102128 Wilate Antihemophllic Factor/VWF (Human} For lnj 450-450 Unit 40.00% Antlhemophi!ic Products 85100015102160 Alphanate/VWF Complex Antihemoph!llc Factor/VWF {Human) For lnj 250 Unit 40.00% Antihemophilic Products 85100026202126 NovoSeven RT Coagulation Factor VIia (Recomb) For lnj 2 MG (2000 MCG) 31.75% Antihemqphillc Products 85100028402120 Alpro11x Coagulation Factor JX (Recomb) {rFIXFc) For !nj 1000 Unit 22.00% Antihemophilic Products 85100032102130 Tretten Coagulation Factor XIIf A+Subunit For tnj 2000-3125 Unit 16.00% Antihemophi1ic Products 85100010206450 Helixate FS Antihemophilic Factor (Recombinant) For lnj Kit2000 Unit 41.75% ANTIHEMOPHILICS 30201010102015 Stimate Desmopressin Acetate Nasal Soln 1.5 MG/ML ,/, Nf--\C;', " 15.75% ANTIHISTAMINESANTlHYPERUPJDEMICS 412000301029003950004010ES20 DiphenhydrAMINE HCIKynamro Diphenhydramine HC1 PowderMipomersen Sodium Soln Prefilled Syringe 200 MG/ML ,,c-,- ·, ,_iYF ' :... . 16.00%'J"'t'' 16.00% i\_I :]:' f fontrato Numerol . "-· ._r • 7.''4··1 5?1. CJ ' I '.-,- ,c•• ·• ,,/ ..) ,,, \l,>,,,..·,_ . l,-... \ Q .,., ..;., V -- <...r. - ,.., """" <--Y· , - .

ANTIHYPERLIPIDEMICS 39480050200120 hixtapld Lomitapide Mesylate Cap 5 MG (Base Equiv) 16.00% ANTlHYPERLIPJDEMICS 39480050200130 Juxtapid lomitapide Mesylate Cap 10 MG (Base Equiv) 16.00% ANTlHYPERLIPIDEM!CS 39480050200140 Juxtapid lomitap!de Mesylate Cap 20 MG {Base Equiv) 16.00% ANTI-INFECTIVE AGENTS - MISC. 16000005402120 cayston Aztreonam Lysine For lnha!Sofn 75 MG (Base Equivalent) 16.00% ANTI-INFECTIVE AGENTS- MISC. 16000049000320 Xifaxan Rifaximin Tab 200 MG 16.00% ANTI-INFECTIVE AGENTS- MISC. 16000049000340 Xifaxan Rifaximln Tab 550 MG 16.00% Antineoplastics 21353045001360 Arzerra Ofatumumab Cone for IV Infusion 1000 MG/SOML 16.75% Antineoplastics 21353060002040 Rituxan Rituximab For IV lnj Cone 10 MG/ML 16.00% Antineoplastics 21534007100120 Alecensa Alectinib HCI Cap150 MG {Base Equivalent) 15.50% Antineop!astics 21370060200120 Ddomzo SONJDEGIB PHOSPHATE CAP 200 MG (BASE EQUIVALENT) 15.50% Antineop!astics 2175S050102030 Levo!eucovorin Calcium Levoleucovorin Calcium IV Sofn PF 250 MG/25ML {Base Equiv) 15.50% Antineoplastics 21100010002020 Busulfex Busu!fan lnj 6 MG/ML 15.50% Antineop[ast/cs 21574070401820 lmlyglc Talimogene Laherparepvee lntralesional lnj1000000 Unit/ML 15.50% Antineoplastlcs 21535570200320 Rubraca Rucaparib Camsylate Tab 200 MG (Base Equivalent) 15.50% Antineoplastics 21353060002040 Rltuxan Rituximab For IV lnj Cone 10 MG/Ml 16.00% Antineoplastlcs 21250010402125 Erwlnaze Asparaginase Erwin!a Chrysanthemi for IM lnJ 10000 Unit 16.00% Antineoplastics 21353060002040 Rituxan Ritux!mab For IV lnj Cone 10 MG/ML 16.00% Antineoplastics 2147008000b720 Vendexta Starting Pack Venetodax Tab Therapy Starter Pack 10 & 50 & 100 MG 15.50% Antfneoplastks 21755040102150 Leucovorin Cafdum Leucovorin Calcium For lnj 200 MG 15.50% Antineop!astics 21500012001325 PAClitaxel Paditaxel IV Cone 30 MG/SML (6 MG/ML) 15.50% Antineoplastlcs 21300050100320 Trexall Methotrexate Sodium Tab 5 MG {Base Equiv) 15.50% Antineoplastics 21353027002030 Darzalex Daratumumab IVSoln 400 MG/20ML 15.50% Antineoplastics 21534013100320 cabometyx cabozantinib S-Malate Tab 20 MG {Base Equivalent) 15.50% Antineoplastics 21990002750320 Lonsurf TRIFLURlDINE-TIPlRACIL TAB 15-6.14 MG 15.50% Antlneoplastics 21708080000110 Vesanoid Tret!noin Cap 10 MG 15.50% Antineoplastlcs 21300050100350 Trexalf MethotrexateSodium Tab15 MG (Base Equiv) 15.50% Antineoplastics 21755040102130 Leucovorin Calcium Leucovorin calcium For lnj 100 MG 15.50% Antineoplastics 21100015002045 CARBOplatin carboplatin JV Soln 600 MG/60ML 15.50% Antineoplastlcs 21536045100140 Ninlaro Jxazomib Citrate cap 4 MG {Base Equivalent) 15.50% Antineoplastlcs 21100009102005 Bendeka Bendamustine HCI IVSoln 100 MG/4Ml (25 MG/Ml) 15.50% Antineoplastics 21700013001930 Tice BCG BCG live lntraveslcal For Susp 50 MG 15.50% Antineoplastics 21700020002110 Dacarbazine Dacarbazine For lnj 200 MG 15.50% Antineoplastics 21200010102105 Bleomycln Sulfate B!eomydn Sulfate for lnj15 Unit 15.50% Antineoplastics 21100015002030 CARBOplatin carboplatin IV Soln 50 MG/SML 15.50% Antineoplastics 21574070401840 lmlyglc Talimogene Laherparepvec lntralesional lnj100000000 Unit/Ml 15.50% Antineoplastlcs 21353030002120 Emplidti Etotuzumab For rvSoln 300 MG 15.50% Antineoplastics 21535570200330 Rubraca Rucaparib Camsylate Tab 300 MG (Base Equivalent) 15.50% Antineoplastics 21200050002120 Mitomycln Mitomycln For lnj 40 MG 15.50% Antineoplastics 21300007002015 Cladribine Cladrlblne IVSofn 10 MG/lOML (1 MG/ML) 16.00% Antineoplast!cs 21470080000320 Venclexta VenetodaxTab 10 MG 15.50% Antineoplastlcs 21534013100330 Cabometyx cabozant!nib S-Malate Tab 40 MG (Base Equivalent) 15.50% Antineoplastics 21990002750330 Lonsurf TRIFLURIDINE-TIPlRAC!L TAB 20-8.19 MG 15.50% Antineoptastic.s 21550040202220 Onl\.'yde lrinotecan HCI Liposome IV lnj 43 MG/lOML (4.3 MG/ML) 15.50% Antineoplastlcs 21100020002020 CISplatin Cisplatin lnj50 MG/SOML {1 MG/ML} 15.50% Antineop!astics 21100015002040 CARBOplatin carboplatin JV Sain 450 MG/4SML 15.50% Antineoplastic.s 21533530200320 Cotellie Coblmetinlb fumarate Tab 20 MG {Base Equivalent) 15.50% Antineoplastics 21353030002130 Empliciti Elotuzumab For rv Soln 400 MG 15.50% Antineoplastics 21500005002075 DOC£taxel (Non-Alcohol} Docetaxel {Non-Alcohol Formula) IVSoln 80 MG/4Ml ., :,v..,·,--,· J c\ \·-:4";_;;._.,. , - '1 ... 15.50% Antineoplastics 21470080000340 Vendexta Venetodax Tab 50 MG ,._ /'! 15.50% -"//i \, - \ ( rCorilrato N(rme1i" ,, .. " ., ,.11:1-()5 JI

Antineoplastic.s 21500012001350 Onxot Paditaxe! IV Conc300 MG/SOML {6 MG/ML) 15.50% Antlneop!astic.s 21100020002025 CISplatin Cisp!atin lnJ 100 MG/100Ml {1MG/Ml) 15.50% Aotineoplastic.s 21500020102005 VinCRIStine Sulfate Vinc.ristine Sulfate IV Soln 1 MG/Ml 15.50'-'/4 Antineoplastks 21534065200330 Tagrisso Osimertinlb Mesylate Tab 80 MG {Base Equivalent) 15.50% Antineoplastks 21536045100120 Ninlaro lxazomib Citrate Cap 2.3 MG {Base Equivalent) 15.50% Antineoplastics 21500005002080 DOCEtaxel (Non-Alcohol) Docetaxel {Non-Alcohol Formula} IV Soln 160 MG/8Ml 15.50% Antineoplastic.s 21470080000360 Venclexta Venetodax Tab 100 MG 15.50% Antineop!astics 21755050102020 levoleucovorln Calcium levofeucovorin Calcium lnj 175 MG/17.SMl (Base Equiv) 15.50% Antineoplastics 21755040102160 leucovorln Calcium Leucovorin Calcium Forlnj350 MG 15.50% Antineoplastic.s 21755040102120 Leucovorin Calcium Leucovorin Calcium For lnj 50 MG 15.50% Antineop!astics 21100015002035 CARBOp!atin Carboplatin JV So!n 150 MG/lSML 15.50% Antineop!ast!cs 21353027002020 Darzalex Daratumumab IV Soln 100 MG/5Ml 15.50% Antineoplastics 21536045100130 Ninlaro lxazomib Citrate Cap 3 MG (Base Equivalent) 15.50% Antineoplastics 21500005002070 DOCEtaxel {Non-Alcohol) Docetaxel {Non-Alcohol Formula} IV Solo 20 MG/ML 15.50% Antlneoplastics 21101040102115 Evome!a Melphalan HCI For lnj 50MG {Propylene Glycol {PG) Free) 15.50% Antineoplastics 21534013100340 Cabometyx CabozantinibS-Malate Tab 60 MG (Base Equivalent) 15.50% Antineoplastics 21107075002140 Yondelis Trabectedin For lnj 1 MG 15.50% Antineoplastic.s 21200010102115 B!eomycin Sulfate Bleomycln Sulfate For fnj 30Unit 15.50'-'/4 Antineoplastfcs 21500012001335 PAClitaxel Pac!itaxe! IV Cone 100 MG/16.7ML (6 MG/Ml) 15.50% Antineoplastics 21534065200320 Tagrisso Osimertinib Mesylate Tab 40 MG (Base Equivalent) 15.50% Antineoplastics 21353047002020 lartruvo Ofaratumab Solo for IV Infusion 500 MG/SOML {10 MG/ML) 15.50% ANTINEOPLASTJCS AND ADJUNCTIVE THERAPIES 21100009102010 Treanda Bendamustine HCI IV So!n 45 MG/0,SML {90 MG/ML) 16.75% ANTINEOPlASTICS ANO ADJUNCTIVE THERAPIES 21100028002120 Dxallplatin Oxalip!atin For IV lnj 50 MG 30.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21101025002025 lfosfamide lfosfamlde IV lnj 1 GM/20Ml {SO MG/ML) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21102020000110 CeeNU Lomustine Cap 10 MG 16.£)0% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200030102210 DAUNOrubicin HCI Daunorublcin HO lnj 5 MG/ML {Base Equiv) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200042102040 Epirublcln HCI Epirubicin HCI lnj 150 MG/75ML (2 MG/ML) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200055001325 Mftoxantrone HCI Mitoxantrone HCI lnj Conc25 MG/12.5Ml (2 MG/ML) 15.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300010002115 Cytarab!ne Cytarabine For lnj 1 GM 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300034102040 Gemcitabine HCI Gemcltabine HCl lnj 1 GM/26,3ML{38 MG/ML) {Base Equiv) 30.00% ANTINEOPLASTICS AND ADJUNCTJVE THERAPIES 21300054002025 Folotyn Pra!atrexate IVlnj 40 MG/2ML 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21352020002120 Blincyto Blinatumomab For IV Infusion 35 MCG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21402430000120 Xtandi Enzalutamide Cap 40 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 2140S010106410 lupron Depot Leuprolide Acetate For lnj Kit 7.5 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405010256450 lupron Depot leupro!ide Acetate (6Month} For lnj Kit45 MG 16.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21450080000115 Pomalyst Pomalidomide Cap 2 MG 18.25% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500005002040 DOCEtaxel Docetaxel Solo for IV Infusion 80 MG/8ML 35.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500012201920 Abraxane Paclitaxel Protein-Bound Particles For 11/Susp 100 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21531060000130 lbrance Palbociclib Cap 100 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21532025100120 Tafinlar Dabrafenib Mesylate Cap SO MG (Base Equivalent) 16.00% ANTINEOPLASTIC$ AND ADJUNCTIVE THERAPIES 21532530007320 Afinitor Disperz Evero!imus Tab for Oral Susp 3 MG 16.00% ANTINEOPlA5TICS AND ADJUNCTIVE THERAPIES 21533070300140 Sutent Sunitfnib Malate Cap 50 MG {Base Equlvalent) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534012000320 Bosulif Bosutinlb Tab 100 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534020000320 Sprycel Dasatinlb Tab 20 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534025100360 Tarceva Erlotinib HC/Tab 150 MG (Base Equivalent) 16.00% ANTINEOPLASTIC$ AND ADJUNCllVE THERAPIES 21534054208240 Lenvima 14 MG Daily Do Lenvatinlb Cap Therapy Pack 10 & 4 MG (14 MG Daily Dose) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21536015002120 Velcade Bortewmlb For lnj 3.5 MG .- •. \\ -:.,I _l'i:f-\ '.)-.''-. 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21538040000330 Zydelig /delalisib Tab 150 MG ,,\:-:,ye.- "'- 1;,., : ,;1.6.00% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21700020002105 Dacarbazine Dacarbazlne For tnj100 MG t-r·Pr "-, /.'l:(i.00% Contrato N(unero \1h \ f1 ) J r le\ ' ' . y f} s ?.i ' ··- p••· \ti\·--;-- . ,,, - ,. \\\ ,./<§) (;,, , •. ''" \,\,,\

ANTINEOPLAST!CS AND ADJUNCTIVE THERAPIES 21700060202135 lntron A Interferon Alfa-2B For lnj 18000000 Unit 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700075206420 Sylatron Peginterferon alfa-2b For lnj Kit 300 MCG 16.75% ANTINEOPLAST!CS AND ADJUNCTIVE THERAPIES 21755040100325 Leucovorin Calcium Leucovorin Calcium Tab 10 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21764065002140 Elitek Rasburicase For IVSoln 7.5 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21100020002030 CISplatln Cisplatin lnj 200 MG/200ML {1 MG/ML) 20.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21101020002125 Cyclophosphamide Cyclophosphamlde For lnj 1 GM 32.30% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21101040102110 Alkeran Me!phalan HCI For lnj 50 MG {Base Equiv) 16.00% AmlNEOPLASTICSAND ADJUNCTIVE THERAPIES 212000300S2210 oaunoXome Daunorubicin Citrate Uposome lnj 2 MG/ML 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200042102025 Epirubkin HCI Epirubicin HCI lnJ 10 MG/5ML (2 MG/ML} 16.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21200045102035 ldamycin PFS ldarubkln HCI IV lnJ 20 MG/20ML (1 MG/ML) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300010002105 Cytarablne Cytarabine For tnj 100 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300030002025 Fluorouracil Fluorouracll fnj 1 GM/20ML {SO MG/Ml) 16.25% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300053102120 Alimta Pemetrexed Dlsodium For IV Soln 500 MG {Base Equiv) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21335070002020 Cyramza Ramucirumab tVSoln 100 MG/10ML (For Infusion) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21353043002025 Gazyva Ob!nutuzumab Soln for IV Infusion 1000 MG/40ML {25 MG/ML) 16.00% ANTINEOPLAST!CS AND ADJUNCTIVE THERAPIES 21353054002020 Perjeta Pertuzumab So!n for IV Infusion 420 MG/14ML {30 MG/ML) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21402250000320 Lysodren Mitotane Tab 500 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405007106450 vantas H!stre!in Acetate Implant Kit 50 MG 15.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405010206435 Eligard leuprolide Acetate {4 Month} For Subcutaneous fnj Kit 30 MG 25.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21100009102030 Treanda Bendamustine HCI IVSoln 180 MG/2ML {90 MG/Ml} 16.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21100028002130 Oxalip!atin Oxalip!atin For IV lnj 100 MG 30.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21101025002030 Jfosfamlde lfosfamide IV lnJ3 GM/60Ml {SO MG/ML) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21102020000115 CeeNU Lomustine Cap 40 MG 16.00% ANTINEOPLASTtCS AND ADJUNCTIVE THERAPIES 21200040102010 Adriamycln Doxorubicin HCI lnj 2 MG/ML 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200042102045 Ellence Epfrubidn HCI IV Sofn 200 MG/lOOML (2 MG/Ml) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200055001330 MitoxantroneHCI Mitoxantrone HCI lnj Cone 30 MG/15Ml (2 MG/ML) 15.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300010002120 Cytarabine Cytarablne For lnJ 2 GM 16.00% ANTINEOPLASTICSAND ADJUNCTIVE THERAPIES 21300034102060 Gemcitab!ne HCI Gemcltabine Hd lnj 2 GM/52.GML {38 MG/ML) (Base Equfv) 30.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300060000305 Tabloid Thfoguanine Tab 40 MG 16.00% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21353010002040 campath A!emtuzumab IV lnj 30 MG/Ml(For Infusion) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21353050002025 Vectibix Panitumumab IV Soln 100 MG/SMl 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21353070002120 Herceptln Trastuzumab For lVSoln 440 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21403020100105 Emcyt Estramustine Phosphate Sodium Cap 140 MG 16.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21405010106415 E!igard leuprolfdeAcetate For Subcutaneous lnj Kit 7.5 MG 2S.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21100010000305 Myleran Busulfan Tab 2 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21101020000310 Cyclophosphamide Cydophosphamide Tab 50 MG 32.30% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21101030102105 Mustargen Mechlorethamtne HCl For lnj 10MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21104070002120 Temodar Temozo!omide For IV Soln 100 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200040102115 Adriamycin Doxorubicin HCI For lnj 50 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200045102025 ldamycin PFS ldarubicin HCf IV lnj 5 MG/5Ml(1MG/Ml) 16.00% ANT!NEOPlASTICS AND ADJUNCTIVE THERAPIES 21250060002020 Oncaspar Pegaspargase lnj 750 Unit/Ml 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300025102020 Fludarabine Phosphate Fludarabine Phosphate lnj 25 MG/ML 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300052002020 Arranon Ne!arabine IV So!n 5 MG/ML 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21335020002025 Avastin Bevaclzumab IV Soln100 MG/4Ml(For Infusion) 15.50% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21353032002020 Yervoy lpilimumab Soln for IV Infusion 50 MG/10Ml (5 MG/ML) 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21353053002030 Keytruda Pembro!izumab IV Soln 100 MG/4ML {25 MG/ML) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21355070302130 Kadcyla Ado-Trastuzumab Emtansine For IV Soln 160 MG />,\',_:7 '- -'\-..,'fl""'' 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 214050051023.10 Zoladex Goserelin Acetate Implant 3.6 MG /t::,.··£;"'" ·::- i- \., 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405010156432 E!igard LeuprolfdeAcetate(3 Month) For Subcutaneous lnj Kit 22.SMG /)'" // .. () 25.00% -···· , q;·;t fl Conhato N(1meroi l q (} ,51' (_j \ \ ' v -·-·\ \'' 0 ·- (_;,.

ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES 21100015002120 CARBOplatin Carboplatin JV For lnj 150 MG 16.25% ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 21101020002120 cyclophosphamide Cyclophosphamide For lnj 500 MG 32.30% ANTINEOPLASTIC$ AND ADJUNCTIVE THERAPIES 21101040000305 Alkeran Melphalan Tab 2 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21200020002105 Cosmegen Dactfnomycin For lnj 0.5 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200040402210 Doxil Doxorubicin HCI Liposomal lnj (For lV Infusion) 2 MG/ML 16.00% ANT!NEOPLASTICS AND ADJUNCTIVE THERAPIES 21200045102030 ldamycin PFS ldarubicin HCI IV tnj 10 MG/lOML {1 MG/ML) 16.00% ANT!NEOPLASTICS AND ADJUNCTIVE THERAPIES 21300007002010 Cladtibine C!adriblne lnj 1 MG/ML 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300025102120 Fludara Fludarablne Phosphate For lnj 50 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300053102110 Alimta Pemetrexed Disodium For IV Sofn 100 MG (Base Equiv) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21335020002030 Avastin Bevacizumab IV Soln 400 MG/16ML {For Infusion) 15.50% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21353032002040 Yervoy lpilimumab Soln for IV Infusion 200 MG/40ML (5 MG/ML} 16.75% ANTINEOPLAST!CS AND ADJUNCTIVE THERAPIES 21353053002120 Keytruda Pembrolizumab For IV Sotn 50 MG 16.00% ANTINEOPLASTICSAND ADJUNCTIVE THERAPIES 21370070000120 Erivedge Vismodegib Cap 150 MG 16.00% ANTINEOPlASTJCS AND ADJUNCTIVE THERAPIES 21405005102330 Zoladex Goserelin Acetate Implant 10.8 MG 16.00% ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES 21405010206430 Lupron Depot LeuprolideAcetate (4 Month) For Jnj Kit 30 MG 16.00% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21104070000147 Temodar Temozolomide Cap 180 MG 35.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 99392070000135 Tha!omid Thalidomide C.ap 150 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300034102140 Gemdtablne HCI Gemcitabine HC\ For lnJ1 GM 30.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21406010200320 Zytiga Abiraterone Acetate Tab 250 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500005001325 DOCEtaxe! Docetaxel For lnj Cone 80 MG/2ML {40 MG/ML} 35.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500011002140 1xempra Kit rxabepilone For IV Infusion 45 MG 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500050802025 Navelbine V!norelbine Tartrate lnj 50 MG/SML (10 MG/ML) (Base Equiv) 16.00% !\NTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21531560002120 [stodax Romidepsin For IV lnj 10 MG 16.75% ANTINEOPLAST!CS AND ADJUNCTIVE THERAPIES 21532530000330 Afinitor Everotimus Tab 10 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21533070300130 Sutent Sunitinlb Malate Cap 25 MG {Base Equivalent) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534008000320 lnlyta Axltinib Tab 1 MG 16.00% ANTINEOPlAST/CS AND ADJUNCTIVE THERAPIES 21534015000120 Xalkori Crizotinib cap 200 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534025100320 Tarceva Er!otin!b HC!Tab 25 MG (Base Equivalent} 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 2153405420B220 Lenvima 10 MG Dally Do Lenvatinib cap Therapy Pack 10 MG {10 MG Daily Dose} 16.00% ANTINEOPI.ASTICS AND ADJUNCTIVE THERAPIES 21534075100340 Jclus!g Ponatinib HCI Tab 45 MG {Base Equiv) 22.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21537560200335 Jakafi RuxoHtinib Phosphate Tab 25 MG (Base Equlvalent) 15.25% ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 21700008102020 Trisenox Arsenic Trioxide lnj 10 MG/10Ml{1MG/ML} 16.()0% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21700060202030 lntron-A lnterferonAlfa-28 Jnj 10000000 Unit/ML 16.00% ANTINEOPI.ASTICS AND ADJUNCTIVE THERAPIES 21700060702020 Actlmmune Interferon Gamma-1B lnj 100 MCG/0.5ML'(2000000 Unit/0.5ML) 16.75% ANTINEOPLASTJCS AND ADJUNCTIVE THERAPIES 21707070102140 Photofrin Porflmer Sodium For lnj 75 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21758050002010 Mesna Mesna lnj 100 MG/ML 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405525102120 Firmagon Degarelix:AcetateFor lnJ 80 MG {Base Equiv} 15.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500005001317 DOCEtaxeJ Docetaxel For !nj Cone 160 MG/8Ml (20 MG/ML) 35.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500010602120 Etopophos Etoposlde Phosphate IV For lnj 100 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500030102105 VinBlAStine Sulfate Vinb!astine Sulfate For lnJ 10 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21531550100130 Farydak Panobinostat Lactate cap 15 MG {Base Equivalent) 16.00% ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES 21532530000320 Afinitor Evero!imus Tab 5 MG 16.00% ANTINEOPI.ASTICS AND ADJUNCTIVE THERAPIES 21533060400320 NexAVAR Sorafenib Tosylate Tab 200 MG {Base Equivalent) 16.00% ANTINEOPI.ASTICS AND ADJUNCTIVE THERAPIES 21534006100330 Gilotrif Afatinib Dimaleate Tab 30 MG (Base Equivalent) 16.00% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21534013106480 Cometriq (140 mg Daily I cabozantin!b S-Mal cap 1 X 80 MG & 3 X 20 MG (140 Dose) Kit 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21534020000360 Sprycet Dasatinib Tab 100 MG 16.00% ANTINEOPLAST!CS AND ADJUNCTIVE THERAPIES 21534035100340 Gleevee lmatfnib Mesylate Tab 400 MG {Base Equivalent} 17.25% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21534070100320 Votrient Pazopan!b HCI Tab 200 MG {Base Equiv} c ..l, hi/_, -,.-.;_-} ' ~,r-, -- 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21537560200325 Jakafi Ruxotitinib Phosphate Tab 15 MG (Base Equivalent) 15.25% /i'r1,·/' ,, ()' ,,,,-' {( Contra to Numero\\ \\I'', 1- 9 - 1, fi '.a'' "' U\ ;- - J/f), , ... f"•,,,, °"'··· \0 \ ,, ,0

ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21550080100140 Hycamtin Topotecan HCI Cap 1 MG {Base Equiv) 16.00";,6 ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700050100105 Matulane Prncarbazine HC/ cap 50 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700060206470 lntron-A Interferon Atfa-28 lnj Kit 10000000 Unit/0.2ML 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700075206470 5ytatron Peginterferon a!fa-2b For Jnj Kit4 X 600 MCG 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21755050102120 Fusilev Levoleucovorin Calcium For IV lnj SO MG {Base Equiv) 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405050201920 Trelstar Depot Triptorelin Pamoate For IM Susp 3.75 MG 22.50% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21450080000120 Pomalyst Pomalidomide Cap 3 MG 18.25% ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 21500005002050 DOCEtaxel Docetaxel Soln for IVInfusion 160 MG/16ML 35.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500015002020 Teniposlde Tenfposide IVSoln 10 MG/ML 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21531060000140 lbrance Palbociclib Cap 125 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21S32025100130 Tafinlar Dabrafenib Mesylate cap 75 MG {Base Equivalent) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21532530007340 Afinitor Disperz Everolimus Tab for Oral Susp 5 MG 16.00% ANTINEOPIASTICS AND ADJUNCTIVE THERAPIES 21533570100310 Mekinist Trametin!b Dimethyl Sulfoxlde Tab 0.5 MG {Base Equivalent) 16.00",{; ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534012000340 Bosulif Bosutinib Tab 500 MG 16.00";,6 ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534020000340 Sprycel Dasatinlb Tab 50 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534030000320 lressa Gefrtfnlb Tab 250 MG 15.25% ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES 2153405420B250 Lenv1ma 24 MG Daily Do Lenvatinib cap Therapy Pack 10 (2) & 4 MG (24 MG Daily Dose) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21536025002120 Kyprol!s Carfilzomib For lnj 60 MG 16.00% ANTINEDPLASTICS AND ADJUNCTIVE THERAPIES 21550040102035 Camptosar lrinotecan HCI lnj 300 MG/lSML (20 MG/ML) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700024002020 Ontak Denileukin Diftitox IV Soln 150 MCG/ML 16.00% ANTINEDPlASTICSAND ADJUNCTIVE THERAPIES 21700060202160 lntron A Interferon Alfa-2B For lnj 50000000 Unit 16.00% ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES 21700075206430 Sylatron Peginterferon alfa-2b For lnj Kit 600 MCG 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21755040100335 Leucovorin calcium Leucovorin calcium Tab 15 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21765060002120 Kepivance Palifermin For IV lnj 6.25 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21405525102130 Flrmagon Degarellx Acetate For Jnj 120 MG {Base Equiv) lS.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21S00005001320 DOCEtaxel Docetaxel For lnj Cone 20 MG/0.5ML (40 MG/ML) 35.00% ANTINEDPLASTICS AND ADJUNCTIVE THERAPIES 21500011002120 lxempra Kit lxabepi!one For IV Infusion 15 MG 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500050802020 Navelb!ne Vlnore!bine Tartrate lnj 10 MG/ML {Base Equiv) 16.00% ANTINEDPlASTICSAND ADJUNCTIVE THERAPIES 21531550100140 Farydak Panoblnostat Lactate cap 20 MG (Base Equivalent) 16.00% ANTINEOPlASTJCS AND ADJUNCTIVE THERAPIES 21532530000325 Aflnitor Everolimus Tab 7.5 MG 16.00% ANT!NEOPLASTICS AND ADJUNCTIVE THERAPIES 21533070300120 Sutent Sunitinib Malate Cap 12.S MG {Base Equivalent) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534006100340 Gilotrif Afatinib Dimaleate Tab 40 MG (Base Equivalent) 16.00% ANTINEOPlASTICSAND ADJUNCTIVE THERAPIES 21S34014000130 Zykadia Ceritinib Cap 150 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534020000380 Sprycel Dasatinib Tab 140 MG 16.00% ANTINEDPLASTICS AND ADJUNCTIVE THERAPIES 21534050100320 Tykerb Lapatinfb Ditosy!ate Tab 250 MG (Base Equiv) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534075100320 lclusig Ponatlnib HCI Tab 15 MG (Base Equiv) 22.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21537560200330 Jakafl Ruxolitinib Phosphate Tab 20 MG (Base Equivalent) lS.25% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21550080102020 Topotecan Hd Topotecan HCl lnj 4 MG/4ML(Base Equlv) (For Infusion) 17.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700060202022 lntron•A Interferon A!fa-2B lnJ 6000000 Unit/ML 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700060302020 Alferon N Interferon Alfa-n3 lnj 5000000 Unit/ML 15.75% ANTINEOPLASTIC$ AND ADJUNCTIVE THERAPIES 21703020002120 Proleukln Aldes!eukin For IV Soln 22000000 Unit 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21758050000320 Mesnex Mesna Tab 400 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21100009102120 Treanda Bendamustine HC1 For IV Soln 100 MG 16.75% ANTINEOPlASTICSAND ADJUNCTIVE THERAPIES 21101020000305 Cydophosphamlde Cyc!ophosphamide Tab 25 MG 32.30% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21101025002130 lfex ffosfamide For lnj 3 GM 16.00% ANTINEDPLA5TICS AND ADJUNCTIVE THERAPIES 21102030002105 Zanosar Streptozodn Forlnj 1 GM - - ·---.., 16.00% ANTINEDPLASTICS AND ADJUNCTIVE THERAPIESANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 2120004010211021200042102170 Adr!amycinEpirubicln HCI Doxorubicin HCI For lnj 20 MGEp!rubicin HCI For lnj 200 MG /< \\:JI l'<i:i'--\f'\I"v . ·<_,,,,,:,A'\.\ 16.00%16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300025100320 Dforta fludarablne Phosphate Tab 10MG .0// 15.75% ,- . {I If f Contrato NOmero f,\\I,",., 9 - () 5 :::C\ \.fl, ---f'

ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300040001830 Purixan Merc.aptopurine Susp 2000 MG/lOOML (20 MG/ML) 16.00% ANTINEOPLASTJCS AND ADJUNCTIVE THERAPIES 21335010102030 Zaltrap Ziv-Aflibercept IV Solo 200 MG/8ML {For Infusion) 16.00% ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 21353025002025 Erbitux Cetuximab N Solo 200 MG/lOOMl (2 MG/ML} 16.25% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21353050002035 Vectibix Panitumumab IV Solo 400 MG/20Ml 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21355070302120 Kadcyla Ado-Trastuzumab Emtans!ne For IVSoln 100 MG 16.00¾ ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21403530002024 Faslodex Fulvestrant lnj 250 MG/5ML 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405010156430 Lupron Depot leuprolide Acetate {3 Month) For lnj Kit 22.5 MG 16.00% ANTINEOPlASTICSAND ADJUNCTIVE THERAPIES 21100028002035 Eloxatin Oxaliplatin IV Soln 200 MG/40ML 16.00% ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES 21101020002130 Cyclophosphamide Cydophosphamlde For lnj 2 GM 32.30% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21102010002105 BiCNU Carmustlne For lnj 100 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200030102105 Cerubidine Daunorubicin HCl For lnJ 20 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21200042102030 Ellence Epirubicin HCI IVSoln 50 MG/25Ml {2 MG/ML) 16.00% ANTINEOPlAST\CS AND ADJUNCTIVE THERAPIES 21200055001320 Mitoxa ntrone HCI Mitoxantrone HCI lnj Cone 20 MG/lOML {2 MG/ML) 15.75% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21300010002110 Cytarabine Cytarabine For lnj 500 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300034102020 Gemcitablne HCl Gemcitabine HCI lnJ 200 MG/5.26ML {38 MG/Ml) {Base Equiv) 30.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300054002020 Folotyn Pra!atrexate IV lnj 20 MG/Ml 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21335070002040 Cyramza Ramucirumab IV Sohl 500 MG/50ML (For Infusion) 16.00% ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES 21353045001320 Arzerra Ofatumumab Cone For IV Infusion 100 MG/5Ml 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21402420000320 Casodex Blcalutamide Tab 50 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21100009102110 Treanda Bendamustine Hd For JV So!n 25 MG 16.75% ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 21101010000305 leukeran Chlorambucil Tab 2 MG 16.00% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21101025002110 lfex lfosfamide For lnj 1 GM 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21102020000120 CeeNU lomustine Cap 100 MG 16.00% ANTINEOPLASTICSAND ADJUNCTIVE THERAPIES 21200040102105 Adriamycin Doxorublcin HCI Forlnj10 MG 16.00% ANTINEOPLASTlCS AND ADJUNCTIVE THERAPIES 21200042102140 Epirubicin HCI Epirubidn HCI For lnj 50 MG 16.00% ANTJNEOPlASTICS ANO ADJUNCTIVE THERAPIES 21200080002020 Valstar Va!rubicln Solo For lntraveslcal Instillation 40 MG/ML 16.75% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21300010301825 DepoCyt Cytarabine Llposome lnj SO MG/SML 16.00% ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 21300034102160 Gemdtabine HCI Gemcitabine HCI For lnj 2 GM 30.00% ANTlNEOPlASTlCS AND ADJUNCTIVE THERAPIES 2133S010102020 Zaltrap Ztv-Aflibercept IV Solo 100 MG/4ML {For Infusion) 16.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21353025002020 Erbitux Cetwcimab N Solo 100 MG/50ML (2 MG/ML} 16.25% ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 21353050002030 Vectibix Panitumumab IV So!n 200 MG/10ML 16.75% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 21355020202120 Adcetris Brentuximab Vedotin For IV So[n SO MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21403530002022 Faslodex Fulvestrant Jnj 125 MG/2.SML 16.00% ANTINEOPI.ASTICS AND ADJUNCTIVE THERAPIES 21405050201930 Tre!star LA Triptorelln Pamoate For IM Susp 11.25 MG 22.50% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21104070000140 Temodar Temozolomide Cap 100 MG 35.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21S00005001310 DOCEtaxel Docetaxel For lnJ Cone 20 MG/Ml 35.00% ANT!NEOPlASTICS AND ADJUNCTIVE THERAPIES 99392070000120 Thalomid Thalidomide Cap 50 MG 16.00% ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES 99394050000145 Revlim!d lenalidomide Cap 20 MG 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405010256445 Eligard leuprotide Acetate (6Month) For Sul?cutaneous fnj Kit45 MG 25.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21450080000110 Pomalyst Pomalidomide Cap 1 MG 18.25% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500005002030 DOCEtaxel DocetaxelSoln for IV Infusion 20 MG/2ML 35.00% ANTINEOPLASTJCS AND ADJUNCTIVE THERAPIES 21500012001340 PACUtaxel Paditaxel IV Cone 150 MG/25ML {6 MG/ML) 16.00% ANTlNEOPlASTICS AND ADJUNCTIVE THERAPIES 21531060000120 lbrance Pa!bociclib Cap 75 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21531575000120 Zolinza VorinostatCap 100 MG 16.00% ANT/NEOPlASTICS AND ADJUNCTIVE THERAPIES 21532530007310 Afinitor Disperz Evero!Jmus Tab for Ora! Susp 2 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21533070300135 Sutent Sunitinib Malate Cap 37.5 MG {Base Equivalent) 16.00% ANT!NEOPLASTICS AND ADJUNCTIVE THERAPIES 21534008000340 lnlyta Axitinib Tab 5 MG , .,,.---- 16.00% ANTlNEOPLASTICS AND ADJUNCTIVE THERAPIES 21534015000125 !Xa!kori Crizotinib Cap 250 MG /• _1\-l> _;, I•\,,(', 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534025100330 (Tarceva Erlotinib HCI Tab 100 MG {Base Equivalent) ·,:-;-•·. """<'('\ ·. 16.00% '/ J r ",, \ ,,. . {ContratoI . " ·' \ () { : J 1,1 '"n ero : rn ·. ri:12· ... (.() - ---- P. .,.. -- •-= ~·, \\ \ici;,_ .- ---------,j•i

ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 215340S4208230 Lenvima 20 MG Daily Do Lenvatinib Cap Therapy Pack 10 (2) MG {20 MG Daily Dose) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21535560000120 Lynparza Olaparib Cap 50 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21538040000320 Zydelig ldela!isib Tab 100 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700013001940 TheraCys BCG Live lntravesical For Susp 81 MGNIAL 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21700060202130 lntron A Interferon Alfa-28 For lnj 10000000 Unit 16.00¼ ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 21700075206410 Sylatron Peginterferon a!fa-2b For lnJ Kit 200 MCG 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21708220000120 rargretin Bexarotene Cap 75 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21764065002120 Elitek Rasbur!case For IV Soln 1.5 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21104070000150 Temodar Temozolomide cap 250 MG 35.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 99392070000140 Thalomid Thalidomide Cap 200 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21405010106407 Leuprolide Acetate Leupro!ide Acetate lnj Kit S MG/ML 52.25% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300015002120 Dacogen Dedtablne For Jnj SO MG 25.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500010002025 Etopos!de Etoposlde I nj 100MG/5ML (20 MG/ML) 27.55% ANTINEOPLAST!CS AND ADJUNCTIVE THERAPIES 21500010002030 Etoposide Etoposide lnj 500MG/25ML {20 MG/ML) 27.55% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21450080000125 Pomalyst Pomalidomlde Cap 4 MG 18.25% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21500009202020 Halaven Eribulln Me::.y!ate lnj 1 MG/2ML {0.5 MG/ML) 16.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500020201820 Marqibo Vincristine Sulfate Liposome IV Susp S MG/31ML (0.16 MG/ML) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21531520002120 Beleodaq Bellnostat For IV lnj 500 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21532080000320 Ze!boraf Vemurafenib Tab 240 MG 16.(){)% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21532570002020 Torlsel Temsirolimus Soln For JV Infusion 25 MG/ML 16.75% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21533570100330 Mekinist Trametinib Dimethyl Sulfoxide Tab 2 MG (Base Equivalent) 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534013106460 Cometriq (60 mg Daily 0( cabozantinib 5-Malate Cap 3 X 20 MG (60 MG Dose) Kit 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534020000350 Sprycel Dasat!nib Tab 70 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21534033000120 lmbruvica lbrutinib Cap 140 MG 16.00% ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES 21534060200115 Tasigna Nllotinib HCI Cap 150 MG {Base Equivalent) 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21537560200310 Jakafi Ruxolitinlb Phosphate Tab 5 MG {Base Equivalent) 15.25% ANTINEOPLASTlCS AND ADJUNCTIVE THERAPIES 21550040102040 trinotecan HCI lrinotecan HCI lnj 500 MG/25ML {20 MG/ML) 30.00% ANTINEOPLAST!CS AND ADJUNCTIVE THERAPIES 21700040102120 Synribo Omacetaxine Mepesuccinate For lnj 3.5 MG 16.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21700060206450 lntron-A lnterferonAlfa-2B lnj Kit 3000000 Unit/0.2ML 16.00% ANTINEOPLASTlCS AND ADJUNCTIVE THERAPIES 21700075206450 Sylatron Peginterferon alfa-2b For lnj Kit 4X 200 MCG 16.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21755040102030 Leucovorin Calcium Leucovorin Calcium lnj 10 MG/ML 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21104070000143 Temodar Temozolomlde Cap 140 MG 35.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21500005001315 DOCEtaxel Docetaxel For lnj Cone 80 MG/4ML {20 MG/ML) 35.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 99392070000130 Thalomid Thalidomide Cap 100 MG 16.00% ANTINEOPLASTlCS AND ADJUNCTIVE THERAPIES 99394050000150 Revlimid Lenalidomide Cap 25 MG 16.75% ANTINEOPLASTICS AND ADJUNCTIVE TI-IERAPIES 21100028002030 Eloxatin Oxa!iplatin IV Soln 100 MG/20ML 30.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 99394050000110 Revlim!d Lenalidomide Caps 2.5 MG 16.75% ANTINEOPLASTIC$ AND ADJUNCTIVE THERAPIES 21534085000320 Caprelsa Vandetanlb Tab 100 MG 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21550040102025 Camptosar lrinotecan HCI lnj 40 MG/2ML {20 MG/ML) 30.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21550080102120 Hycamtin Topotecan HCI For Jnj 4 MG 17.00% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300034102110 Gemdtablne HCI Gemcitabine HCI For lnj 200 MG 30.00% ANTINEOPLASTJCS AND ADJUNCTIVE THERAPIES 21500010002040 Etoposide Etoposfde lnj 1 GM/SOML (20 MG/ML) 27.55% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21550040102030 Camptosar lrinotecan HCI lnj 100 MG/5ML {20 MG/ML) 30.00% ANTfNEOPLAST!CS AND ADJUNCTIVE THERAPIES 21250010402120 Erwinaze Asparaginase Erwinia Chrysanthemi For !nj 10000 Unit 16.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21104070000110 Temodar Temozo!om!de Cap 5 MG 35.00% ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21300005000350 Capecitabine Capedtabine Tab 500 MG 40.00% ANT!NEOPLASTICS AND ADJUNCTIVE THERAPIES 99394050000130 Revlimid Lenalidomide Cap 10 MG 16.75% ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES 21300030002030 Adrucil Ftuorouracil Jnj 2.5 GM/SOML {SO MG/ML) ....'-\'-l\;:, I iY.<-. 16.25% ANTINEOPlASTJCS AND ADJUNCTIVE THERAPIES 21104070000120 Temodar Temozolomide Cap 20 MG / f '.,_.?,.V-= , . - , ,. \. 35.00% v, I ••,,., '0 / ,- Vurr,r::1 i _ ' ,',J -ro Ill ,,,,, ((1_· if:: 1(1, 2, ,- ,,,, 0,,' -:; " "',,,, (,;'.'(<,, ,Ch', "'='=_/ \v9, ----- oc. st:-..;,, (

21300030002020 Adrucil ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 99394050000140 Revnmid 21300030002035 Adrucil21300003001920 AzaCITIDlne21405050201940 Trelstar Mb:ject21500003002020 Jevtana21500010000120 Etoposide21500030102020 VinBlAStine Sulfate21531550100120 Farydak21532530000310 Afinitor21533050000320 Stivarga21534006100320 Gilotrif ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTlCS AND ADJUNCTIVE THERAPIES ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTJNEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS ANO ADJUNCTIVE THERAPIES 21534020000354 Sprycel21534035100320 Gleevec21534060200125 Tasigna ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21537560200320 Jakafi ANTJNEOPLASTICS AND ADJUNCTIVE THERAPIES 21550080100120 Hycamtin ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES 21700045002120 Nipent ANTINEOPlASTICS AND ADJUNCTIVE THERAPIES ANTINEDPlASTlCS ANO ADJUNCTIVE THERAPIES ANTINEDPlASTICS AND ADJUNCTIVE THERAPIES ANTINEDPlASTICS AND ADJUNCTIVE THERAPIES ANTINEDPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES ANTINEOPLAST!CS TOPICALSANTINEDPlASTICS TOP!CALSAntiparasitics ANTIPARKINSON AGENTSAntipsychotics Antipsychotics Antipsychotics AntipsychoticsAntipsychotics Antipsychotics Antipsychotics Antipsychotfcs Antipsychotics Antipsychotks Antipsychotics Antipsychotks Antipsychotks Antipsychotics Antipsychot!cs 21700060206460 lntron-A21700075206460 Sylatron21755040102170 leucovorin Calcium21100028002025 Eloxatin21300005000320 Capecitabine99394050000120 Revlimid21534085000340 Caprelsa90371050204030 Valchlor90376015004020 Panretin13000040000310 Daraprim73203010102020 Apokyn59070070101930 RisperDAL Consta59250015001930 Abilify Maintena59070070101920 RlsperOAL Consta59070070101910 R!sperDAL Consta59070050101837 fnvega Sustenna59070070101940 RisperDAl Consta59070050101845 lnvega Sustenna 590700S0101838 lnvega Sustenna 59070050101850 lnvega Trinza59250015001920 Abllify Malntena5925001520E430 Aristada 59070050101839 lnvega Sustenna59070050101870 lnvega Trinza5925001520E440 Aristada 59070050101880 lnvega Trinza Antipsychotics 5925001520E420 Aristada ¾ Antipsychotics 59070050101840 lnvega Sustenna Ant/psychotics 59070050101860 lnvega Trinza :, ANTJPSYCHOTICS/ANTIMANICAGENTS 59157060101950 ZyPREXA Relprew ····• .•. , .., Fluorouracil lnj 500 MG/lOMl {SO MG/Ml) lenalidomide Cap 15 MG 16.25% 16.75% Ffuorouracll lnj 5 GM/lOOML {SO MG/ML) Azadtidine For lnj 100 MGTriptorelln Pamoate For 1M Susp 22.5 MGCabazitaxel lnj 60 MG/1.5Ml (For IV Infusion) Etoposlde Cap 50 MGVlnblastine Sulfate lnj 1 MG/MlPanoblnostat lactate Cap 10 MG (Base Equivalent) Everolimus Tab 2.5 MGRegorafenib Tab 40 MGAfatin!b Dimaleate Tab 20 MG {Base Equivalent) 21534013106470 Cometriq (100 mg Daily Cabozantinlb S-Mal Cap lX 80 MG & 1 X 20 MG (100 Dose) Kit Dasatinib Tab 80 MGlmatinib Mesylate Tab 100 MG {Base Equivalent) Nilotinib HCI Cap 200 MG {Base Equivalent) 16.25%25.00%22.50%16.75%27.55%16.00%16.00%16.00%16.00%16.00%16.00%16.00%17.25%16.00% Ruxolitinib Phosphate Tab 10 MG {Base Equivalent) Topotecan HCI Cap 0,25 MG (Base Equiv) 15.25%16.00% Pentostat!n For lnj 10MG Interferon Alfa-2B lnj Kit 5000000 Unit/0.2ML Peginterferon alfa-2b For lnJ Kit 4X 300 MCG leucovorin Calcium For lnj 500 MG Oxaliplatin IV Soln 50 MG/lOML Capecitabine Tab 150 MG lena!idomide Cap 5 MG Vandetanib Tab 300 MGMech!orethamine HCI Gel 0.016% (Base Equivalent) Alitretlnoin Gel 0.1%Pyrimethamine Tab 25 MGApomorphine Hydrochloride lnj 10 MG/Ml Risper/done Mlcrospheres For lnj 37.5 MG Aripiprazole IM For Extended Release Susp 400 MG Risperidone Mlcrospheres For rnJ 25 MG Risperidone Mfcrospheres For Jnj 12.5 MG Pa!iperidone Palmitate IM Extended-Release Susp 39 MG/0,25ML Risper/done Mlcrospheres For !nj SO MGPaliperidone Palmitate IM Extended-Release Susp 234 MG/1.SML Pafiperidone PalmitatelM Extended-Release Susp 78 MG/0.SMl Paliperidone Palmitate IM Extend-Release Susp 273 MG/0.875Ml Arlplprazole !M For Extended Release Susp 300 MGARIPIPRAZOLE lAUROXILIM ERSUSP PREFlllED SYR 662 MG/2.4MlPaliperidone Palmitate IM Extend-Release Susp 117 MG/0.75ML Pa!!peridone Palmltate IM Extend-Release Susp 546 MG/1.75MlARIPIPRAZOLE lAUROXU 1M ERSUSP PREFILLED SYR 882 MG/3.2MlPalipericfone Palmitate IM Extend-Release Susp 819 MG/2.625Ml 16.00%16.00%16.75%16.00%30.00%40.00%16.75%16.00%16.00%16.00%15.50%15.75%15.50%15.50%15.50%15.50%15.50%15.50%15.50%15.50%15.50%15.50%15.50%15.50%15.50%15.50%15.50% ARIPIPRAZOLE lAUROXIL lM ER SUSP PREFILLEO SYR 441MG/1.6ML 15.50% Paliperidone Palmitate IM Extended-Release Susp 156 MG/ML Paliperidone Palmltate IM Extend-ReleaseSusp 410 MG/1.315ML Olanzap!ne Pamoate For Extended Rel JM Susp210 MG (Base Eq) 15.50%15.50% 16.00% (

\ ''·· ANTIPSYCHOTICS/ANTIMANICAGENTS 59157060101970 ZyPREXA Relprew Olanzapine Pamoate For Extended Rel IM Susp 405 MG {Base Eq) 16.00% ANTIPSYCHOTICS/ANTIMANICAGENTS 59157060101960 ZyPREXA Relprew OJanzapine Pamoate For Extended Rel IM susp 300 MG (Base Eq) 16.00% Antivirals 12200020102030 Foscavir FoscarnetSodium tnj 6000 MG/2SOML {24 MG/Ml) 16.00% Antivirals 12359902300320 Zepatier Elbasvlr-Grazoprevir Tab 50-100 MG 15.50% Antivirals 12200020102040 FoscametSodium Foscarnet Sodium lnj12000 MG/500ML (24 MG/ML) 16.00% ANTIVIRALS INFLUENZA 12504065002020 Rapivab Peramlvir Jnj 200 MG/20Ml {10 MG/ML) 16.00% Bisphosphonates 300420481D0360 Boniva fbandronate Sodium Tab 150 MG (Base Equivalent} 16.00% BLEEDING DISORDERS 84100010000320 Amicar AminocaproicAcid Tab 1000 MG 16.00% BLEEDING DISORDERS 84100010001205 Amicar Aminocaproic Acid Syrup 25% 16.00% BLEEDING DISORDERS 8410001000030S Amicar Aminotaprolc Add Tab 500 MG 16.00% Blood Products/ Modifiers/Volume Expanders 8240101510ES56 Aranesp (Albumin Free) Darbepoetln Affa-Polysorbate 80 Soln lnj 60 MCG/Ml 16.00% Blood Products/ Modifiers/Volume Expanders 8240101510E575 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate80 Soln lnj150 MCG/0.3Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 82401015102080 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 500 MCG/ML 16.00% Blood Products/ Modifiers/Volume Expanders 8240102000E545 Epogen Epoetin Alfa lnj10000 Unit/Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 8240104010E515 Mircera Methoxy Polyethylene Glycol-Epoetin Beta lnj 50 MCG/0.3Ml 16.00% Blood Products/ Modifiers/Volume Expanders 8240152000ES45 Neupogen Fl!grastlm lnj 300 MCG/0.5ML{600 MCG/MLJ 16.00% Blood Products/ Modifiers/ Volume Expanders 85100028402105 Alprolix Coagulation Factor IX {Recomb) {rFIXFc} For lnj 250 Unit 15.50% Blood Products/ Modifiers/ Volume Expanders 85100015106440 Wi/ate Antihemophilic Factor/V\VF {Human) For lnj 1000-1000 Unit Kit 15.50% Blood Products/ Modifiers/ Volume Expanders 85100028202145 lxinity Coagulation Factor IX (Recombinant) For lnj1500 Unit 15.50% Blood Products/Modifiers/Volume E:icpanders 85100010402130 Adynovate Antihemophilic Factor Recomb Pegylated For lnj 500 Unit 15.50% Blood Products/ Modifiers/ Volume Expanders 85100031002140 Coagadex Coagulation Factor X (Human} For lnj500 Unit 15.50% Blood Products/ Modifiers/ Volume Expanders 8240101510E543 Aranesp {Albumfn Free) Darbepoetin Alfa-Po!ysorbate 80 Soln lnj 40 MCG/0.4Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E560 Aranesp (Albumin Free) Darbepoetin A!fa-Polysorbate 80 So!n lnj100 MCG/0.SML 16.00% Blood Products/ Modifiers/Volume Expanders 8240101510E582 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 200 MCG/0.4ML 16.00% Blood Products/ Modifiers/Volume Expanders 85100028206430 BeneFIX Coagulation Factor IX (Recombinant) For lnj Kit 500 Unit 21.00% Blood Products/ Modifiers/Volume Expanders 8240101510E543 Aranesp (Albumin Free) Darbepoetin A!fa-Polysorbate 80 Sain lnJ 40 MCG/0.4Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 8240101510ES60 Aranesp (Albumin Free) Darbepoetin Atfa-Polysorbate 80 Soln lnj100 MCG/0.SML 16.00% Blood Products/ Modifiers/ Volume Expanders 82401015102070 Aranesp {Albumin Free) Oarbepoetln Alfa-Pofysorbate 80 Sain lnj 300 MCG/ML 16.00% Blood Products/ Modifiers/ Volume Expanders 8240102000E54S Epogen Epoetin Alfa lnj10000 Unit/ML 16.00% Blood Products/ Modifiers/ Volume Expanders 8240102000E575 Epogen Epoetin Alfa lnj 40000 Unit/Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 8240152000E525 Neupogen Fifgrastim lnJ 300 MCG/Ml 16.00% Blood Products/ Modifiers/Volume Expanders 82401015102010 Aranesp (Albumin Free) Darbepoetln Alfa-Polysorbate 80 Sain lnJ 25 MCG/Ml 16.00% Blood Products/ Modifiers/Volume Expanders 8240101510E552 Aranesp (Albumin Free) Darbepoetin Alfa-Po!ysorbate 80 Soln lnJ 60 MCG/0.3Ml 16.00% Blood Products/ Modifiers/Volume Expanders 8240101510ES58 Aranesp (Albumin Free) Darbepoetln Alfa-Polysorbate 80 So!n lnj 200 MCG/ML 16.00% Blood Products/ Modifiers/ Volume Expanders 82401015102080 Aranesp (Albumin Free) Darbepoetln Alfa-Po!ysorbate80 Soln lnj 500 MCG/Ml 16.00% Blood Products/ Modifiers/Volume Expanders 8240102000£545 Epogen EpoetinAlfa lnj 10000 Unit/Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 8240104010E520 Mircera Methoxy Polyethylene G!ycol-Epoetin Beta lnj 75 MCG/0.3Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 8240152000E550 Neupogen Fi!grastim lnJ 480 MCG/0.8Ml (600 MCG/ML) 16.00% Blood Products/ Modifiers/ Volume Expanders 85100028352130 ldetvion Coagulation Factor IX{Retomb} (r!X-FP) For lnj1000 Unit 15.50% Blood Products/ Modifiers/Volume Expanders 85100028402150 Alprolix Coagulation Factor IX{Recomb) (rFlXFc) For lnj 4000 Unit 15.50¾ Blood Products/ Modifiers/Volume Expanders 8240104010E525 Mlrcera Methoxy Potyethylene Glycol-Epoetin Beta lnj100 MCG/0.3Ml 16.00% Blood Products/ Modifiers/Volume Expanders 82401015102020 Aranesp {Albumin Free) O:arbepoetin Alfa-Polysorbate80 Soln lnj 40 MCG/Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 82401015102040 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Sain lnj100 MCG/Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E558 Aranesp (Albumin Free) Darbepoetln Alfa-Polysorbate 80 Sain lnj 200 MCG/Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 85100028206420 BeneFIX Coagulation Factor IX (Recombinant) For !nj Kit 250 Unit 21.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E556 Aranesp (Albumin Free) Darbepoetin Affa-Polysorbate 80 Sein lnj60 MCG/ML 16.00% Blood Products/ Modifiers/Volume Expanders 82401015102050 Aranesp (Albumin Free) DarbepoetfnAlfa-Po!ysorbate80 5oln JnJ 150 MCG/0.75Ml ,r.\\8Tf?.c:-, ' 16.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E588 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 So!n lnj 300 MCG/0.6Ml ,;,-,--l'<•: p:'"'*TI:.:Z-{?"-."...f, 16.00% Blood Products/ Modifiers/ Volume Expanders 8240102000E545 Epogen Epoetin Alfa lnj 10000 Unit/Ml _:;,_/ _(,r' 16.00% ,,,~···,:v , .. •c! !Ir ontmro Nu.ine\ro·0mt! , .f • r, I!}_((} ·._ ./ /i {'\\\\ ', ---------------1·.-o ,' ,-./0DES!" /

".-, \\)i\ ..:c_ ·,J) \-,, I ,,1 'I' I::'"'•\ lctd Prod cts/ Modifiers/ Volume Expanders 8240102000ES75 Epogen Epoetin A!fa Jnj 40000 Unit/ML 16.00% Bloo rod.l1cts/ Modifiers/ Volume Expanders 8240101510ES28 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80 Sein fnj 25 MCG/0.42Ml 16.00% s,~ Pfoducts/ Modifiers/ Volume Expanders 82401015102040 Aranesp (Albumin Free} Darbepoetln Alfa-Polysorbate 80 Sein lnj100 MCG/ML 16.00% tfffc19 I-Products/ Modifiers/Volume Expanders 8240101510ES58 Aranesp (Albumin Free) Darbepoetin A!fa-Polysorbate 80Solo lnj 200 MCG/ML 16.00% §1obd Products/ Mod'rfiers/ Volume Expanders 8240102000E510 Epogen Epoetin Alfa Jnj 2000 Unit/ML 16.00% BtOod Products/ Modifiers/ Volume Expanders 8240102000E545 Epogen Epoetin Alfa lnj10000 Unit/ML 16.00% Blood Products/ Modifiers/ Volume Expanders 8240104010E525 Mircera Methoxy Polyethylene Glycol-Epoetin Beta lnj100 MCG/0.3Ml 16.00% Blood Products/ Modifiers/Volume Expanders 85100028352140 ldelvion Coagulation Factor IX{Recomb) {rlX-FP) For lnj 2000 Unit 15.50% Blood Products/ Modifiers/ Volume Expanders 85100015106430 Wi!ate Antihemophilic Factor/VWF (Human) For lnJ 500-500 Unit Kit 15.50% Blood Products/ Modifiers/Volume Expanders 85100010402140 Adynovate Antihemophilic Factor Recomb Pegylated Forlnj1000 Unit 15.50% Blood Products/ Modifiers/ Volume Expanders 8240157000E520 Neulasta Pegfi!grastim lnj6 MG/0.6Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 82401015102070 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj300 MCG/ML 16.00% Blood Products/ Modifiers/Volume Expanders 8240104010E520 Mircera Methoxy Polyethylene Glycol-Epoetin Beta lnj 75 MCG/0.3Ml 16.00% Blood Products/ Modifiers/Volume Expanders 85100028206450 BeneFIX Coagulation Factor IX{Recombinant) For lnj Kit 2000 Unit 21.00% Blood Products/ Modifiers/ Volume Expanders 85100010402150 Adynovate Antihemophi!fc Factor Recomb Pegylated For lnJ 2000 Unit 15.50% Blood Products/ Modifiers/Volume Expanders 82401015102010 Aranesp (Albumin Free) Darbepoetin Alfa-Po!ysorbate 80 Soln lnj 25 MCG/Ml 16.00% Blood Products/ Modifiers/Volume Expanders 8240101510E556 Aranesp {Albumin Free) Darbepoetin A!fa-Po[ysorbate 80Sain lnj 60 MCG/Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 82401015102050 Aranesp (Albumin Free) Darbepoetln Alfa-Polysorbate 80 So!n lnJ 150 MCG/0.75ML 16.00% Blood Products/ Modifiers/ Volume Expanders 85100010402120 Adynovate Antihemophilic Factor Recomb Pegylated For lnj 250 Unit 15.50% Blood Products/ Modifiers/Volume Expanders 85100031002120 Coagadex Coagulation FactorX {Human) For Jnj 250 Unit 15.50% Blood Products/ Modifiers/ Volume Expanders 8240102000ES45 Epogen Epoetin Alfa lnJ 10000 Unit/Ml .16.00% Blood Products/ Modifiers/ Volume Expanders 8240152000E545 Neupogen F!lgrastim lnj300 MCG/0.SML {600 MCG/ML) 16.00% Blood Products/ Modifiers/Volume Expanders 8240102000E575 Epogen Epoetin Alfa fnj 40000 Unit/Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 85100028206460 BeneFIX Coagulation Factor IX {Recombinant) For lnJ Kit 3000 Unit 21.00% Blood Products/ Modifiers/Volume Expanders 82401015102020 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 40 MCG/Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 82401015102040 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 So!n Jnj100 MCG/ML 16.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E558 Aranesp (Albumin Free} Darbepoetin Alfa-Polysorbate 80Soln lnJ 200 MCG/ML 16.00% Blood Products/ Modifiers/ Volume Expanders 8240102000E520 Epogen Epoetin Alfa Jnj 4000 Unit/Ml 16.00% Blood Products/ Modifiers/Volume Expanders 8240102000E575 Epogen Epoetin Alfa Jnj 40000 Unit/ML 16.00% B!ood Products/ Modifiers/Volume Expanders 8240157000E520 Neulasta Pegfllgrastim lnj6 MG/0.6Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 85100028352110 ldelvlon Coagulation Factor IX (Recomb) {rlX-FP) For lnj 250 Unit 15.50% Blood Products/ Modifiers/ Volume Expanders 85100010402145 Adynovate Antihemophillc Factor Recomb Pegylated For fnj1500 Unit 15.50% Blood Products/ Modifiers/Volume Expanders 8240101510E528 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnJ 25 MCG/0.42Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E552 Aranesp (Albumin Free} Darbepoetin Alfa-Polysorbate 80Soln Jnj 60 MCG/0.3Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E575 Aranesp {Albumin Free) Darbepoetin Affa-Polysorbate 80 So!n fnj150 MCG/0.3Ml 16.00% Blood Products/ Modifiers/Volume Expanders 82401015102020 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Soln lnj 40 MCG/Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 82401015102040 Aranesp (Albumin free) DarbepoetinAlfa-Polysorbate80 Soln lnj100 MCG/Ml 16.00% Blood Products/ Modifiers/Volume Expanders 8240101510E582 Aranesp(Albumin free) Darbepoetin Alfa-Polysorbate 80 So!n fnj 200 MCG/0.4Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 8240102000ES45 Epogen Epoetin Alfa lnj10000 Unit/ML 16.00% Blood Products/ Modifiers/Volume Expanders 8240102000E575 Epogen Epoetin Alfa Jnj40000 Unit/Ml 16.00% 81000 Products/ Modifiers/Volume Expanders 8240157000E520 Neulasta Pegfllgrastim lnj 6 MG/0.6ML 16.00% Blood Products/ Modifiers/Volume Expanders 83334030002120 lprivask Desirudln For lnj15 MG 15.50% B!ood Products/ Modifiers/ Volume Expanders 85100028352120 ldelvion Coagulation Factor IX{Recomb) (rlX-FP) For lnj500 Unit 15.50% Blood Products/ Modifiers/ Volume Expanders 8240152000E525 Neupogen F!lgrast!m lnj300 MCG/Ml 16.00% Blood Products/ Modifiers/ Volume Expanders 8240101510E588 Aranesp {Albumin free) Darbepoetin Alfa-Po!ysorbate 80 Soln lnj 300 MCG/0.6Ml 16.00% Blood Products/ Modifiers/Volume Expanders 8240104010E515 Mircera Methoxy Polyethylene Glycol-Epoetin Beta lnj50 MCG/0.3ML 16.00% Blood Products/ Modifiers/ Volume Expanders 8240102000E520 Epogen Epoetin Alfa lnj 4000 Unit/Ml 16.00% Blood Products/ Modifiers/Volume Expanders 8240152000E550 Neupogen Fi!grastim lnj 480 MCG/0.8Ml (600 MCG/ML) 16.00% Blood Products/ Modifiers/ Volume Expanders 85100028206440 BeneFIX Coagulation Factor IX (Recombinant) For lnj Kit 1000 Unit 21.00% (

' ·•. · •.·.,'\<,,,)\'- . "iJ) . "I·, IBUiod. rodutts/ Modifiers/Volume Expanders 82401015102020 Aranesp (Albumin Free) Darbepoetin Alfa-Po!ysorbate 80 Soln lnj 40 MCG/ML 16.00% Hlnnd.-' rodu'tts/ Modifiers/ Volume Expanders 82401015102040 Aranesp {Albumin Free) Darbepoetin Alfa-Polysorbate 80 Sofn lnj 100 MCG/ML 16.00% Bl otleffldllcts/ Modifiers/ Volume Expanders 8240101510E558 Aranesp (Albumin Free) Darbepoetin Alfa-Polysorbate 80 Solo lnJ 200 MCG/Ml 16.00% w69ieroducts/ Modifiers/Volume Expanders 8240104010E545 Mlrcera Methoxy Polyethylene G!ycol-Epoetin Beta lnj 200 MCG/0.3ML 16.00% _ruQ d-Products/ Modifiers/Volume Expanders 85100010402135 Adynovate Antihemophilic Factor Recomb Pegylated For lnj 750 Unit 15.50% Blood Products/ Modifiers/Volume Expanders 84100040002025 Cyklokapron TranexamlcAcid IV Soln 1000 MG/lOML {100 MG/ML) 16.00% Blood Products/ Modifiers/ Volume Expanders 8240102000ES10 Epogen Epoetin Alfa lnj 2000 Unit/ML 16.00% Blood Products/ Modifiers/Volume Expanders 8240101S102080 Aranesp (Albumin Free) DarbepoetinAlfa-Polysorbate80 Sain lnj 500 MCG/ML 16.00% Blood Products/ Modifiers/ Volume Expanders 8240104010ES45 Mircera Methoxy Polyethylene Gtycol-Epoetin Beta lnj 200 MCG/0.3ML 16.00% Bone Density Regulators 30044530002020 Prolia Denosumab lnj 60 MG/ML 15.75% Bone Density Regulators 3004405510E140 Natpara Parathyroid Hormone (Recombinant) For lnj Cartridge 100 MCG 16.00% Bone Density Regulators 3004405510E110 Natpara Parathyroid Hormone (Recombinant) For tnj Cartridge 25 MCG 16.00% Bone Density Regulators 30044070002020 Forteo Teriparatide (Recomblnant) lnj 600 MCG/2.4ML 16.00% Bone Density Regulators 30044530002030 Xgeva Denosumab lnJ 120 MG/1.7ML 16.00% Bone Density Regulators 3004405S10E120 Natpara Parathyroid Hormone (Recombinant) For lnJ Cartridge 50 MCG 16.00% Bone Density Regulators 3004405510E130 Natpara Parathyroid Hormone {Recombinant) For lnj Cartridge 75 MCG 16.00% cardiovascular APents 37100020000305 Keveyfs Dichlorphenamide Tab SO MG 15.50% CASTLEMAN DISEASE 99473080002120 Sylvant Siltuxlmab For IV Infusion 100 MG 16.00% CASTLEMAN DISEASE 99473080002140 Sylvant Si!tuximab For 1V Infusion 400 MG 16.00% Central Nervous System Agents 624030604SDS60 Rebif Rebidose Titration Interferon Beta-la lnj6X 8.8 MCG/0.2ML& 6 X 22 MCG/0.SML 16.50% Central Nervous System Agents 624030604SE540 Rebif Interferon Beta-la lnj44 MCG/0.SML (24MU/ML) {88 MCG/ML) 16.50% Central Nervous System Agents 62403060450560 Rebff Rebidose Titration Interferon Beta-la lnJ 6 XS.8 MCG/0.2ML & 6X 22 MCG/0.SML 16.50% Central Nervous System Agents 74400020202140 Xeomin lncobotu!inumtoxinA For IM lnj 200 Unit 15.50% Central Nervous System Agents 6240306045E540 Rebif Interferon Beta-la lnj 44 MCG/0.5ML {24MU/ML) (88 MCG/ML) 16.50% Central Nervous System Agents 624030604SD520 Rebif Rebidose Interferon Beta-la lnj 22 MCG/0,SML (12MU/Ml) {44 MCG/ML) 16.50% Central Nervous System Agents 6240306045D520 Reblf Rebidose Interferon Beta-la lnj22 MCG/0.SML {12MU/ML) (44 MCG/ML) 16.50% Central Nervous System Agents 6240306045D560 Rebif Rebidose Titration Interferon Beta-la lnj 6X 8.8 MCG/0.2ML & 6 X 22 MCG/0.SML 16.50% Central Nervous System Agents 6240306045DS20 Rebif Rebidose Interferon Beta-la lnj 22 MCG/0.SML (12MU/ML) {44 MCG/ML) 16.50% Central Nervous System Agents 6240306045FS30 AvonexPen Interferon Beta-la IM lnj Kit30 MCG/0.5ML 16.75% Central Nervous System Agents 62609902300120 Nuedexta Dextromethorphan HBr-Quinldine Sulfate Cap 20-10 MG 15.50% Central Nervous System Agents 624030604SF530 AvonexPen Interferon Beta-la IM lnj Kit30 MCG/0.SML 16.75% Central Nervous System Agents 624030604SES40 Rebif Interferon Beta-la lnj 44 MCG/0.SML (24MU/ML) {88 MCG/ML) 16.50% Central Nervous System Agents 62403060450520 Rebif Rebidose Interferon Beta-la lnj 22 MCG/0.SML {12MU/ML) {44 MCG/Ml) 16.50% Central Nervous System Agents 624030604SF530 AvonexPen Interferon Beta-la IM lnj Kit 30 MCG/0.SML 16.75% Central Nervous System Agents 624030604SE540 Rebif Interferon Beta-la lnj44 MCG/0.5ML(24MU/ML){88 MCG/ML) 16.50% CMV Agents 12200010002020 Vistide Cidofovir IV lnj 75 MG/ML 16.00% CMV Agents 12200020102020 FoscarnetSodium Foscarnet Sodium lnj 24 MG/ML 16.00% CMV Agents 12200066102120 Valcyte Valganciclovlr HCI For Soln SO MG/ML (Base Equiv) 16.00% CMV Agents 12200066100320 Vafcyte Vafgandc!ovir HC1 Tab 450 MG (Base Equivalent) 16.00% CMVAgents 12200030102110 Cytovene Gandclovir Sodium For lnj 500 MG 60.00% CONGESTIVE HEART FAILURE 40180050002120 Natrecor Nesiritlde For lnj 1.5 MG 16.00% CORTICOSTEROIDS 22100020202011 Dexamethasone Sod Pho Dexamethasone Sod Phosphate Preservative Free lnj 10 MG/ML 16.00% CORTICOSTEROIDS 22100030202115 Solu-MEDROL Methylprednisolone Sodium Sucdnate For lnj 500 MG 16.00% CORTICOSTEROIDS 22100020002900 Dexamethasone Oexamethasone Powder 16.00% CORTICOSTEROIDS 2210003020210S Solu-MEDROL Methylprednlsolone Sodium Succinate For lnj 40 MG 16.00% CORTICOSTEROIDS 22100020001320 Dexamethasone lntensol Dexamethasone Cone 1 MG/ML 16.00% CORTICOSTEROIDS 22100025402161 Solu-CORTEF Hydrocortisone Sodium Succinate PF For Jnj 500 MG 16.00% CORTICOSTEROIDS 221000S0101810 Kenalog Triamcinolone Acetonide lnj Susp 40 MG/ML 16.00% CORTICOSTEROIDS 22100020202900 Dexamethasone Sodium Dexamethasone Sodium Phosphate Powder 16.00%

_:, ,<,J) "\ l wa· COSi'EROIDS 22100030202120 Solu-MEDROL Methylprednisotone Sodium Sucdnate For lnj 1000 MG 16.00% co" COSlEROIDS 22100020002005 Dexamethasone Dexamethasone Solo 0.5 MG/SML 16.00% 9R l(i.OSTEROIDS 22100025402165 Sofu-CORTEF Hydrocortisone Sodium Sucdnate PF For lnj 1000 MG 16.00% l\ll,COSTEROIDS 22100020102900 Dexamethasone Acetate DexamethasoneAcetate Powder 16.00% <.; lAiJCOSTEROIDS 22100030202110 Solu-MEDROL Methylprednisolone Sodium Sucdnate For lnj 125 MG 16.00% orticosteroids 22100017001830 Emflaza Deflazacort Susp 22.75 MG/ML 15.50% CORTICOSTEROIDS 22100020000325 Dexamethasone Dexamethasone Tab 1 MG 16.00"76 CORTICOSTEROIDS 22100025402150 Solu-CORTEF HydrocortisoneSodfumSucdnate PF For Jnj100 MG 16.00% CORTICOSTEROIDS 22100030202130 Solu-MEDROL Methylprednisolone Sodium Succinate For Jnj 2000 MG 16.00% Corticosteroids 22100017000340 Emflaza Deflazacort Tab 6MG 15.50% corticosteroids 22100017000360 Emftaza DeflazacortTab 30 MG 15.50% Corticosteroids 22100017000365 EmfJaza Deftazacort Tab 36 MG 15.50% CORTICOSTEROIDS 22100020000335 Dexamethasone Dexamethasone Tab 2 MG 16.00% CORTICOSTEROIDS 22100025402155 So]u.CQRTEF Hydrocortisone Sodium Sucdnate PF For lnj 250 MG 16.00% CORTICOSTEROIDS 22100050101805 Kenalog Triamdno!one Acetonfde Jnj Susp 10 MG/Ml 16.00% Corticosteroids 22100017000350 Emflaza Def!azacortTab 18 MG 15.50% CYSTIC FIBROSIS AGENTS 07000070000120 Tobi Podhaler Tobramydn lnha! Cap 28 MG 17.10% CYSTIC FIBROSIS AGENTS 45302030003030 Kalydeco lvacaftor Packet75 MG 15.75% CYSTIC FIBROSIS AGENTS 07000070002530 Bethkis Tobramycin Nebu Sofn 300 MG/4Ml 16.00% CYSTIC FIBROSIS AGENTS 45302030000320 Ka!ydeco lvacaftorTab 150 MG 15.75% CYSTIC FIBROSIS AGENTS 45304020002010 PulmoJ..yme Dornase Alfa lnhal So!n 1 MG/ML 16.00% CYSTIC FIBROSIS AGENTS 07000070002520 Kltabis Pak Tobramycin Nebu So/n 300 MG/5ML 41.75% CYSTIC FIBROSIS AGENTS 45302030003020 Kalydeco lvacaftor Packet 50 MG 15.75% Cystfnosls Agents 56400030106530 Procysbi Cysteamine Bitartrate Cap Delayed Release 75 MG {Base Equiv) 16.00% Cystinosls Agents 56400030100140 Cystagon Cysteam!ne Bitartrate Cap 150 MG 15.25% Cystinosls Agents 56400030106520 Procysbi Cysteamfne Bitartrate Cap Delayed Release 25 MG (Base Equiv) 16.00% Cystfnosis Agents 564-00030100120 Cystagon Cyst amine Bltartrate Cap 50 MG 15.25% DERMATOLOG\CAl5 90890020002110 Botox Cosmetic OnabotulinumtoxinA {Cosmetic) For lnj SO Unit 16.75% DERMATOLOG!CAl5 90890020002120 Botox Cosmetic OnabotulinumtoxinA (Cosmetic) For lnj 100 Unit 16.75% DERMATOlOGICAl5 90890018002120 Dysport (Glabellar lines) Abobotu!inumtoxinA (Glabellar Lines) For lnj 300 Unit 16.75% DERMATOlOGICAl5 90550085103400 Kenalog Triamcinolone Acetonlde Aerosol Solo 16.00% DIAGNOSTIC PRODUCTS 94200037002105 Cortrosyn Cosyntropin For lnj 0.25 MG 16.00% DIAGNOSTIC PRODUCTS 94200090102120 Thyrogen Thyrotropin Alfa For lnj 1.1 MG 16.75% Digestive Enzymes 51200024006760 Creon Pancrelipase (llp-Prot-Amyl) DR Cap 24000-76000-120000Unit 16.00% Digestive EnJ..ymes 51200024006750 Pancreaze Pancrelipase {llp-Prot-Amyl) DR Cap 16800-40000-70000 Unit 16.00% Digestive Enzymes 51200024006705 Creon Pancrelipase {Lip-Prot-Amyl) DR Cap 3000-9500-15000 Unit 16.00% Dlgest!Ve Enzymes 51200024006780 Creon Pancrel!pase (Lip-Prot-Amyl) DR Cap 36000-114000-180000 Unit 16.00% Digestive Enzymes 51200024006754 Pancreaze Pancre!ipase {Lip-Prot-Amyl) DR Cap 21000-37000-61000 Unit 16.00% Digestive Enzymes 51200024006710 Pancreaze Pancrellpase (Up-Prot-Amyl) DR Cap 4200-10000-17500Unit 16.00% Digestive Enzymes 51200060002030 Sucraid Sacrosidase Soln 8500 Unit/Ml 16.00% Digestive Enzymes 51200024006734 Pancreaze Pancrellpase {Up-Prot-Amyl) DR Cap 10500-25000-43750 Unit 16.00% Digestive Enzymes 51200024006740 Creon Pancrelipase {Lip-Prat-Amyl) DR Cap 12000-38000-60000 Unit 16.00% Digestive Enzymes 51200024006720 Creon Pancrelipase {Up-Prot-Amyl) DR Cap 6000-19000-30000 Unit 16.00% Direct Muscle Relaxants 75200010101920 Ryanodex Dantro!ene Sodium For JV Susp 250 MG 16.0D% ENDOCRINE AND METABDUCAGENTS- MISC. 30080050106440 Lupron Depot-Ped leuprofide Acetate For lnj Pediatric Kit 15 MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170070106420 SandoSTATJN lAR Depot Octreotide Acetate For IM lnj Kit 20 MG 16.50% ENDOCRINE ANO METABOLIC AGENTS - MISC. 30180060002120 Somavert PegvisomantFor lnj 10 MG (As Protein) 15.75% ENDOCRINE AND METABOUCAGENTS- MISC. 30454060000330 Samsca Tolvaptan Tab 30 MG 16.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30905070000120 Zemplar Paricafcitol Cap 2 MCG 16.00%

,- '---..,/). ,,,, '\').. '• ,,\ . -/U.4ti --'.6· (J)' r:N , · CRlNE AND METABOLIC AGENTS- MISC. 30906550002020 Aldurazyme Laronidase Soln For IV Infusion 2.9 MG/SML 15.75% E IJOtRlNE AND METABOLIC AGENTS- MISC. 30908565107320 Kuvan Sapropterin Dlhydroch!orlde Soluble Tab 100 MG 16.75% Q'9CRINE AND METABOUCAGENTS- MISC. 30908060002950 Buphenyl Sodium Phenylbutyrate Oral Powder 3 GM/Teaspoonful 24.00% DOCRINE AND METABOLIC AGENTS- MISC. 30080050106420 lupron Depot-Ped leuprol!de Acetate For lnJ Pediatric Kit 7.5 MG 16.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30170050102040 Somatu!ine Depot lanreotide Acetate Extended Release lnj 120 MG/0.SMl 16.75% ENDOCRINE AND METABOLIC AGENTS - MISC. 30170075401930 Signifor lAR Pasireotide Pamoate For IM ERSusp 40 MG (Base Equiv) 16.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30904520002920 Cystadane "'Betaine Powder For Oral Solution**• 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30905225100340 Senslpar Cinaca!cet HCI Tab 90 MG (Base Equiv) 16.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30908230000320 Carbaglu Carg!umicAcidTab 200 MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30090040102020 Ganirefix Acetate Ganirellx Acetate lnj 250 MCG/0.SMl 15.25% ENDOCRINE AND METABOLIC AGENTS - MISC. 30170050102025 Somatu!ine Depot lanreotideAcetate Extended Release lnj 60 MG/0.2Ml 16.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170075202040 Signifor Pasireotide Diaspartate lnj 0.9 MG/Ml(Base Equiv) 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30180060002160 Somavert Pegvlsomant For lnj 30 MG (As Protein) 15.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30904045000120 Orfadln Nitisinone Cap 5 MG 16.00% ENDOCRINE AND METABOUCAGENTS- MISC. 30905225100320 Senslpar Cinacalcet HCI Tab 30 MG {Base EqulV) 16.75% ENDOCRINE AND METABOUCAGENTS- MISC. 30908030000920 Ravicti Glycerol Phenylbutyrate Liquid 1.1 GM/Ml 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 300800501S6420 lupron Depot-Ped leupro!JdeAcetate (3 Month) For lnj Pediatric Kit 11.25 MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30150085102120 Egrifta Tesamorelin Acetate For Jnj1 MG {Base Equiv) 16.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170070106430 SandoSTATIN lAR Depot Octreotide Acetate For IM lnj Kit 30 MG 16.50% ENDOCRINE AND METABOLIC AGENTS- MISC. 30180060002130 Somavert Pegvisomant For lnJ 15 MG (As Protein) 15.75% ENDOCRINE AND METABOLIC AGENTS- MISC, 30903610102110 Fabrazyme Agalsidase beta For IV Soln 5 MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30905070000140 Zemplar Paricaldtol Cap 4 MCG 16.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30906850002020 Elaprase ldursulfase Soln for JV Infusion 6 MG/3ML (2 MG/Ml) 15.75% ENDOCRINE AND METABOUCAGENTS- MISC. 30080045106450 Supprelin lA Histrelin Acetate (CPP) Implant Kit SO MG 15.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170050102030 SomatuHne Depot lanreot!de Acetate Extended Release lnj 90 MG/0.3Ml 16.75% ENDOCRINE AND METABOLIC AGENTS- MISC, 30170075401920 Signifor lAR Pasireotide Pamoate For IM ER Susp 20 MG {Base Equiv) 16.00% ENDOCRINE AND METABOLIC AGENTS· MISC. 30904045000130 Oriadin Nitisinone Cap 10 MG 16.00% ENDOCRINE AND METABOUCAGENTS- MISC. 30905225100330 Sensipar Cinaca!cet HC!Tab 60 MG {Base Equiv) 16.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30908060000320 Buphenyl Sodium Phenylbutyrate Tab 500 MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30080050106430 Lupron Depot-Ped leuprolideAcetate For lnj Pediatric Kit 11.25 MG 16.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 301700701064-10 SandoSTATIN LAR Depot Octreotide Acetate For IM lnj Kit 10 MG 16.50% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170075401940 Sign!for LAR Paslreotide Pamoate For IM ER Susp 60 MG {Base Equiv) 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC, 30454060000320 Samsca Tolvaptan Tab 15 MG 16.75% ENDOCRINE ANO METABOLIC AGENTS- MISC. 30905070000110 Zemplar Paricalcltol Cap 1 MCG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30906050002120 Myalept Metre!eptin For Subcutaneous lnJ 11.3 MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30908565103020 Kuvan Sapropterin Dihydrochloride Powder Packet 100 MG 16.75% ENDOCRINE AND METABOUCAGENTS-MISC, 30170070102030 Octreotide Acetate Octreotide Acetate lnj 1000 MCG/Ml (1MG/Ml) 52.25% ENDOCRINE AND METABOLIC AGENTS - MISC. 30080050156440 lupron Depot-Ped Leuprofide Acetate (3 Month) For lnj Pediatric Kit 30 MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30150085102130 Egrifta Tesamorelin Acetate Forlnj 2 MG (Base Equiv) 16.75% ENDOCRINE AND METABOllCAGENTS- MISC. 30170075202020 Signifor Pasfreotide Dlaspartate lnj 0.3 MG/ML {Base Eauiv) 16.00% ENDOCRINE AND METABOLIC AGENTS - MISC. 30180060002140 Somavert Pegvisomant Forlnj 20 MG (As Protein} 15.75% ENDOCRINE AND METABOLIC AGENTS- MJSC. 30903610102120 Fabrazyme Agalsidase beta For IV So!n 35 MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30905070002010 Zemp!ar Parlca!dtol JV Soln 2 MCG/Ml 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30907030052020 vtmizim Elosu)fase Alfa So!n For JV Infusion S MG/SML (1 MG/Ml} 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170070102005 Octreotide Acetate Octreotide Acetate lnj 50 MCG/Ml (0.05 MG/Ml) 52.25% ENDOCRINE AND METABOLIC AGENTS- MISC, 30907715002120 lumi2.yme Alglucosidase Alfa For IV Sain 50MG 15.75% ENDOCRINE AND METABOLIC AGENTS - MISC. 30170070102015 Octreotide Acetate Octreotide Acetate !nj 200 MCG/Ml (0.2 MG/Ml) 52.25% ENDOCRINE AND METABOLIC AGENTS - MISC. 30170070102020 Octreotide Acetate Octreotide Acetate lnj 500 MCG/ML (0.5 MG/ML) 52.25% ENDOCRINE AND METABOLIC AGENTS- MISC. 30080055102020 Synarel NafareHn Acetate Nasal So!n 2 MG/Ml 16.00%

',d, ,,I Ul!)OC:RINE AND METABOLIC AGENTS- MISC. 30160045002020 lncre!ex Mecaserm!n lnj 40 MG/4ML {10 MG/ML) 16.00% i.N1 QCRINE AND METABOLIC AGENTS- MISC. 30170075202030 Signifor Pasireotide Diaspartate lnj 0,6 MG/Ml (Base Equiv) 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30180060002150 Somavert Pegvisomant For lnj 25 fy'!G (As Protein) 15.75% ENDOCRINE AND METABOLIC AGENTS - MISC. 30904045000110 Orfadin Nitisinone Cap 2 MG 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30905070002020 zemplar Paricaldtol IV Soln 5 MCG/ML 16.00% ENDOCRINE AND METABOLIC AGENTS- MISC. 30907535002020 Nagla2.yme Galsu!fase So!n For IV Infusion 1 MG/Ml 15.75% ENDOCRINE AND METABOLIC AGENTS- MISC. 30170070102010 Octreotide Acetate Octreotide Acetate lnj 100 MCG/ML {0.1MG/ML) 52.25% ENZVME REPLACEMENT 2ooooos000202s Adagen Pegademase Bovine lnj 250 Unit/Ml 16.00% Enzyme Replacements/Modifiers 30903875203020 Xuriden Uridine Triacetate Oral Granules Packet 2 GM 15.50% Enzyme Replacements/Modifiers 30905610002040 5trenslq Asfotase Alfa Subcutaneous lnj 40 MG/ML 15.50% Enzyme Replacements/Modifiers 30906360002020 Kanuma SebeHpase Alfa IVSoln 20 MG/lOML {2 MG/ML) 15.50% Enzyme Replacements/Modifiers 30905610002050 Strensiq AsfotaseAlfa Subcutaneous lnj 80 MG/0.8ML 15.50% Enzyme Replacements/Modifiers 30905610002020 Strensiq Asfotase Alfa Subcutaneous lnJ18 MG/0.45ML 15.50% Enzyme Replacements/Modifiers 30905610002030 Strensiq AsfotaseAlfa Subcutaneous Jnj 28 MG/0.7Ml 15.50% Enzymes 99350035002120 Xiaflex Collagenase Clostridium Histolyticum For lnj 0.9 MG 16.75% Enzymes 99350040102020 Hylenex Hyaluronidase Human lnj 150 Unit/ML 16.00% Fertility Regulators 30062030052020 Gonal-f RFF Pen Follitropin Alfa lnj 300 Unit/0.5Ml 15.25% Fertility Regulators 30062030102030 Fol!istimAQ Folfitropln Beta lnj 600 Unit/0.72Ml 22.80% Fertilfty Regulators 30062030102006 Follistim AQ Follitropin Beta lnj 150 Unit/0.SML 22.80% Fertility Regulators 30062030052150 Gonal-f Fo!litropin Alfa For In] 1050 Unit 15.25% Fertility Regulators 30062090102112 Bravel!e Urofo!litropin Purified For lnj 75 Unit 15.25% Fertility Regulators 30062030052040 Gonal-f RFF Pen Fol!itropin Alfa Jnj 900 Unlt/1.5ML 15.25% Fertility Regulators 30062030102040 FolfisflmAQ Foltitropin Beta lnj 900 Unit/1.0SMl 22.80% Fertility Regulators 30062030102003 FollistimAQ Folfltropin Beta Jnj 75 Unit/0.SML 22.80% Fertility Regulators 30062030102020 FoltistlmAQ Follitropin Beta lnj 300 Unit/0.36ML 22.80% Fertilfty Regulators 30062030052115 Gonal-f RFF Fol!itrop!n Alfa For lnj 75 Unit 15.25% Fertility Regulators 30062050002155 Repronex Menotropins For lnj 75 Unit 15.25% Fertility Regulators 30062030052140 Gonal-f Fo!litropin Alfa For lnJ 450 Unit 15.25% Fertility Regulators 30062050002175 Menopur Menotropins For Subcutaneous lnj 75 Unit 15.25% GASTROINTESTINALAGENTS- MISC. 52300020112900 Metoclopramide HCI Mo Metodopramide HCl Monohydrate Powder 16.00¾ GASTROINTESTINAL AGENTS- MISC. 52700025000140 Cholbam Cho!ic Acid Cap 250 MG 16.00% GASTROINTESTINAL AGENTS - MISC. 52300020102900 Metoclopramide HCI Metoclopramide HCI Powder 16.00% GASTROINTESTJNALAGENTS- MISC. 52700025000120 Cholbam Chol!cAcid Cap 50 MG 16.00% Genitourinary Agents 99200030000110 Cuprimine Penicillam!ne Cap 250 MG 15.50% GENITOURINARY AGENTS - MISCEllANEOUS 56500010002010 Rimso-50 Dimethyl Sulfoxide So!n 50% 16.00% GOUT AGENTS 68000050002020 Krystexxa Peglotlcase lnj 8 MG/Ml {For IV Infusion) 16.75% Growth Hormones 30100020002066 Norditrop!n FlexPro Somatropin lnJ 30 MG/3ML 17.25% Growth Hormones 30100020002140 Nutropin Somatropin For lnj 10 MG 16.75% Growth Hormones 30100020002178 Genotropin MiniQuick Somatropln For lnj 1.4 MG 16.75% Growth Hormones 30100020102130 Saizen Somatropin (Non-Refrigerated) For lnj 8.8 MG 16.25% Growth Hormones 30100020002050 Norditropin Somatropin lnj 5 MG/1.SML 17.25% Growth Hormones 30100020002062 Norditropin Somatropin lnj 15 MG/1.SML 17.25% Growth Hormones 30100020002132 Humatrope Somatropln Forlnj 12 MG (36 Unit) 16.75% Growth Hormones 30100020002174 Genotropin MiniQulck Somatropln For Jnj 1 MG 16.75% Growth Hormones 30100020102121 Serostim Somatropin (Non-Refrigerated} For Subcutaneous lnj 5 MG 16.00% Growth Hormones 30100020002125 Humatrope Somatropln For Jnj 6 MG (18 Unit) 16.75% Gro\-vth Hormones 30100020002170 Genotropin MiniQulck Somatropln For Jnj 0.6 MG 16.75% Growth Hormones 30100020102118 serostim Somatropin {Non-Refrigerated) For Subcutaneous lnJ 4 MG 16.00% Growth Hormones 30100020002118 Nordltropin SOMATROPIN FOR INJ 4 MG (12 UNIT) 16.50%

h• (J) l Gr,i-u,t Hon'hones 30100020002150 Humatrope Somatropin For lnJ 24 MG 16.75% "'' wt Hor(nones 30100020002180 Genotropin MlniQuick Somatropin For lnJ 1.6 MG 16.75% G :_vf(h)Mofmones 3010002000201S Nutropin AQ NuSpin 5 Somatropin lnj 5 MG/2Ml 16.75% G« " •ef.1-Hormones 30100020002127 Norditropin SOMATROPIN FOR INJ 8 MG 16.50% , Gr'C\ifth Hormones 30100020002172 Genotropin Min!Qulck Somatropin For lnJ 0.8 MG 16.75% GrO\;lth Hormones 30100020102120 Saizen Somatropin {Non-Refrigerated) For lnj 5 MG 16.25% Growth Hormones 30100020102132 Serostim Somatropin (Non-Refrigerated) For Subcutaneous lnj 8.8 MG 16.25% Growth Hormones 30100020002064 Nutropin AQNuSpin 20 Somatropin lnj 20 MG/2Ml 16.75% Growth Hormones 30100020002134 Genotropln Somatropln For lnj 12 MG {13.8 MG overfill) 16.75% Growth Hormones 30100020002176 Genotropin MiniQuick Somatropin For Jnj 1.2 MG 16.75% Growth Hormones 3010002010212S Serostirn Somatropin (Non-Refrigerated) For Subcutaneous lnj 6 MG 16.00% Growth Hormones 30100020002121 Genotropln Sornatrop!n For Subcutaneous lnj s MG 16.75% Growth Hormones 30100020002120 Humatrope Somatropin For lnj S MG 16.75% Growth Hormones 30100020002166 Genotrop!n MlniQuick Sornatropin For lnj 0.2 MG 16.75% Growth Hormones 30100020002182 Genotrop!n M!niQuick Sornatropin For lnj 1.8 MG 16.75% Growth Hormones 30100020002056 Nordltropln FlexPro Somatropin tnj 10 MG/1.SMl 17.25% Growth Hormones 30100020002020 NutropinAQ Somatropin lnj 10 MG/2ML 16.75% Growth Hormones 30100020002123 Omnitrope Somatropin For lnj 5.8 MG 16.25% Growth Hormones 30100020002168 Genotropin MiniQulck Somatropin For lnj 0.4 MG 16.75% Growth Hormones 30100020002184 Genotropin MiniQulck Somatropin For lnj 2 MG 16.75% H-2 Antagonists 49200030112020 Famotidine Premixed Famotidine in NaCl 0.9% IV Soln 20 MG/SOML 16.00% H-2 Antagonists 49200010002900 Cimetidine Cimetidine Powder 16.00% HEMATOLOGICAL AGENTS- MISC. 85550060102120 Ceprotin Protein C Concentrate (Human} For IV Soln 500 Unit 16.00% HEMATOLOGICAL AGENTS- MISC. 85550060102140 Ceprotin Protein C Concentrate {Human) For IVSoln 1000 Unit 16.00% HEMATOLOGICALAGENTS- MISC. 85800050002020 Soliris Eculizumab IVSoln 10 MG/ML (For Infusion) 15.75% Hematopoietic Growth Factors 82403060002120 Neumega Oprelvek!n For fnj 5 MG 16.25% Hematopoietic Growth Factors 8240205000202S Leukfne Sargramostim lnj 500 MCG/Ml 16.75% Hematopoietic Growth Factors 82405060002130 Np!ate Romlplostlm For lnj 500 MCG 16.75% Hematopoletic Growth Factors 82405030100310 Promacta Eltrombopag O!amine Tab 12.5 MG {Base Equiv) 16.75% Hematopoietic Grovtth Factors 82401520002012 Neupogen Fi!grastim lnj 480 MCG/1.6Ml (300 MCG/ML) 16.00% Hematopoletic Growth Factors 82402050002120 Leukine Sargramostim Lyophi!ized For lnj 250 MCG 16.75% Hematopoietic Growth Factors 8240152070ES30 Granix Tbo-Fifgrastim Soln Prefilled Syringe 300 MCG/0.5ML 16.00% Hematopoletic Growth Factors 82405030100320 Promacta EltrombopagOlamine Tab 25 MG {Base Equiv) 16.75% Hematopo!etic Growth Factors 82401060102050 Omontys Peginesat!de Acetate Soln Jnj 10 MG/ML 16.00% Hematopoietic Growth Factors 82405030100340 Promacta Eltrombopag Olamine Tab 75 MG {Base Equiv) 16.75% Hematopoietic Growth Factors 82401060102055 Omontys Peginesatide Acetate Soln lnJ 20 MG/2Ml 16.00% Hematopoietic Grovil:h Factors 82405060002120 Nplate Rom!p!ostim For lnj 250 MCG 16.75% Hematopoietic Growth Factors 82401020002015 Epogen Epoetin Alfa lnj 3000 Unit/Ml 16.00% Hematopoietic Growth Factors 82401020002050 Epogen Epoetin Alfa lnj 20000 Unit/Ml 16.00% Hematopoietic Growth Factors 8240152070E540 Granix Tbo-Fflgrastim Soln Prefil!ed Syringe 480 MCG/0.8ML 16.00% Hematopoietic Growth Factors 82405030100330 Promacta Eltrombopag Olamine Tab 50 MG (Base Equiv) 16.75% HEREDITARY ANGIOEDEMA 85820040102020 Firazyr lcatibant Acetate lnj 30 MG/3Ml {Base Equivalent) 15.75% HEREDITARY ANG!OEDEMA 85840030002020 Kalbitor Eca!lantlde lnj 10 MG/ML 16.00% HEREDITARY ANGIOEDEMA 85802022006420 Berinert C1Esterase Inhibitor (Human) For IV lnj Klt500 Unit 16.25% HEREDITARY ANGIOEDEMA 85802022102130 Ruconest Cl Esterase Inhibitor (Recombinant) For JV lnj 2100 Unit 16.00% HEREDITARY ANGIOEDEMA 85802022002120 Cinryze Cl £sterase Inhibitor (Human) For IV lnj 500 Unit 15.25% Hormonal Agents, Stimulant/Replacement/Modifying 30062022052220 Ovidrel Choriogonadotropin Alfa lnJ 250 MCG/0.5Ml 15.50% Hormonal Agents, StfmulanVReplacement/Modifying 30062020002140 Chorionic Gonadotropin ChorionicGonadotropin for lnj 10000 Unit 15.50% Hormonal Agents, Suppressant {Pituitary) 21404010101840 Depo-Provera Medroxyprogesterone Acetate IM Susp 400 MG/ML 15.50%

'S,o, 'Y,.) ', \') ' ,1\. iJ)ii' ... . I If .Nonts/SEDATIVES/SLEEP DISORDER AGENTS 60250070000130 HetliOl Tasfmelteon Capsule 20 MG 16.00% 'lllJo I"" ;INOGLOBULINS 19100020102046 Octagam Immune Globul!n (Human) IV Sofn 25 GM/SOOML 24.25% ,w\ mNOGLOBUUNS 1910002010212S CARIMUNE Immune Globulfn {Human) IV For So!n 6 GM 25.00% UNOGLOBULINS 19100020302080 Gammagard Immune Globulin {Human) JV or Subcutaneous Soln 30 GM/300ML 27.55% MUNOGLOBULINS 19100020102020 Flebogamma Immune Globulin {Human) IV So!n 0.5 GM/10ML 18.00% -- IMMUNOGLOBULINS 19100020102113 Gammagard 5/D Immune Globulin {Human) IV For Soln 0.5 GM 27.55% \IMMUNOGLOBUUNS 19100020202058 Hizentra 20% Immune Globulin (Human) Subcutaneous lnj 4 GM/20ML 24.50% IMMUN6GLOBULINS 191000SOO0ES40 RhoGAM Ultra-Filtered P Rho D Immune Globulin IM Sein PrefSyr 1500 Unit (300MCG) 16J)0% IMMUNOGLOBULINS 19990002356450 Hyqvia 1lmmun Glob lnJ 30 GM/300Ml-Hyaluron lnJ 2400 Unt/15 Ml Kit 20.00% IMMUNOGLOBUUNS 19100020102060 Gamunex \Immune Globulin (Human) IV Soln 1 GM/10Ml 24.25% IMMUNOGLOBULINS 19100020102130 Gammagard 5/D Immune Globulin {Human) IV For Soln 10 GM 27.55% IMMUNOGLOBULINS 19100020302084 Gamunex-C 1 l mmuneGlobulfn {Human) IV or Subcutaneous Soln 40 GM/400ML 23.00% IMMUNOGLOBULINS 19100020102090 Privigen IImmune Globulin (Human) IV Soln 40 GM/400Ml 19.00% IMMUNOGLOBULINS 19100020202050 Hizentra 20% Immune Globulin (Human) Subcutaneous !nj 1 GM/SML 24.50% IMMUNOGLOBULINS 19100050002060 WinRhoSOF Rho D Immune Globulin (Human} lnj 1500 Unit/1.3Ml 17.75% IMMUNOGLOBULINS 19990002356430 Hyqvla lmmun Glob lnj 10 GM/lOOML-Hyaluron lnj 800 Unt/5 Ml Kit 20.00% IMMUNOGlOBULINS 19100005002200 Cytogam cytomegalovirus Immune Globulin {Human) !VlnJ 18.00% IMMUNOGLOBULINS 19100020102112 GAMMAR-P I.V. IMMUNE GLOBULIN {HUMAN) IV FOR SOLN 1 GM 31.25% IMMUNOGLOBUUNS 19100020202054 Hizentra 20% Immune Globulin (Human) Subcutaneous fnj 2 GM/10Ml 24.50% IMMUNOGLOBULINS 19100050002065 WinRhoSDF Rho D Immune Globulin {Human) lnj 15000 Unlt/13Ml 17.75% IMMUNOGLOBULINS 19990002356440 Hyqvla lmmun Glob lnj 20 GM/200Ml-Hyafuron lnj 1600 Unt/10 Ml Kit 20.00% IMMUNOGLOBULINS 19100020102120 Gammagard S/D Immune Globu!!n (Human) IVFor Soln S GM 27.55% IMMUNOGlOBUUNS 19100020102034 Flebogamma Immune Globul!n (Human) IV Soln 2.5 GM/50Ml 25.00% lMMUNOGLOBULINS 19100020102068 Bivigam Immune Globulin {Human) IV Soln 5 GM/SOML 24.25% IMMUNOGLOBUUNS 19100020302068 Gammagard Immune Globulin (Human} IV or Subcutaneous Sein 5 GM/50Ml 27.55% IMMUNOGLOBUUNS 19100020102064 Gamunex Immune GlobuUn (Human) IVSoln2.5 GM/25Ml 24.25% lMMUNOGLOBULINS 19100020202020 Vivaglobin Immune Globulln {Human) Subcutaneous lnj 160 MG/Ml {16%} 23.75% IMMUNOGLOBULINS 19100050002055 WinRhoSOF Rho D Immune Globulfn {Human) lnj 5000 Unit/4.4Ml 17.75% IMMUNOGLOBULINS 19990002356425 Hyqvia Immun Glob lnj 5 GM/50Ml-Hyaluron lnj 400 Unt/2.5 ML Kit 20.00% IMMUNOGLOBULINS 19100020102030 Octagam Immune Globulin (Human) IVSoln 1 GM/20Ml 24.25% IMMUNOGLOBULINS 19100020102117 Carimune NF Immune Globulin (Human) IV For So!n 3 GM 25.00% IMMUNOGLOBULINS 19100020202065 Hiientra Immune Globulin (Human) Subcutaneous lnj 10 GM/SOMl 24.50% IMMUNOGLOBULINS 1910005000E550 Rhophylac Rho D Immune Globulin Sol PrefSyr 1500 Unt/2Ml {300MCG/2ML) 18.25% IMMUNOGLOBULINS 19100020102063 Octagam Immune Globulin (Human) IVSoln 2 GM/20Ml 24.25% IMMUNOGLOBUUNS 19100020102135 Carimune NF Immune Globulin (Human) IV For Sofn 12 GM 25.00% IMMUNOGLOBUUNS 19100050002050 WinRhoSDF Rho D lmmuneGlobunn (Human} lnj 2500 Unlt/2.2ML 17.75% IMMUNOGLOBULINS 19990002356420 Hyqvia lmmun Glob Jnj 2.5 GM/25ML-Hya!uron lnj 200 Unt/1.25 ML Kit 20.00% IMMUNOGLOBULINS 19100020002200 GamaSTAN S/D Immune Globulin (Human) lnj 23.75% JMMUNOGLOBUUNS 19100020102044 Flebogamma DIF Immune Globulin (Human) IV Soln 20 GM/400Ml 25.00% IMMUNOGLOBUUNS 19100020302064 Gammagard Immune Globulin (Human) IV or Subcutaneous Sein 2.5 GM/25ML 27.55% IMMUNOGLOBULINS 19100020102115 Gammagard 5/D Immune Globulin (Human) IV For So!n 2.5 GM 27.55% IMMUNOGLOBULINS 19100020102205 GAMIMUNEN IMMUNE GLOBULIN (HUMAN) JV SOLN 5% 47.75% lMMUNOGLOBUUNS 19100020302060 Gammagard Immune Globulin (Human) IV or Subcutaneous Soln 1 GM/10Ml 27.55% IMMUNOGLOBULINS 19100020102034 F!ebogamma Immune Globulin (Human) IVSoln 2.5 GM/SOML 25.00% IMMUNOGLOBULINS 19100020102072 Blvigam Immune Globulin (Human) IV Solo 10 GM/100Ml 24.25% IMMUNOGLOBULINS 19100020302072 Gammagard Immune Globulin (Human) IV or Subcutaneous Soln 10 GM/lOOMl 27.55% IMMUNOGLOBUUNS 19100020102038 Flebogamma Immune Globulin (Human) IVSoln 5 GM/lOOML 25.00% JMMUNOGLOBULINS 19100020102072 Bivigam Immune Globulin (Human) N Soln 10 GM/100Ml 24.25% IMMUNOGLOBULINS 19100020302072 Gammagard Immune Globulin (Human) IV or Subcutaneous Soln 10 GM/lOOMl 27.55%

lU 0 l y,_-::----._ " ',\\ t- I ' l (, '.r' , ,,1 \ j UUAJll·INQG[OBUUNS 19100020102068 Bivigam Immune Globulin (Human) IV Soln 5 GM/SOML 24.25% 01 UJl)N O/e_ IMMl1NOG!OBUUNS0 19100020302068 Gamrnagard Immune G!obulln {Human) IV or Subcutaneous So!n 5 GM/SOML 27.55% \: ,'JJ! fMMUN,OG'LOBUUNS., ·._ 19100020102042 Flebogamma Immune Gfobul!n (Human) IVSoln 10 GM/200ML 25.00% t1NoGLOBULINS 19100020102076 Flebogamma DIF Immune Globulin {Human) IVSoln 20 GM/200Ml 24.25% \.)..• "• -. _._,_ v iMM(JNOGlOBULINS 19100020302076 Gammagard Immune Globulin (Human) IV or Subcutaneous Soln 20 GM/200Ml 27.55% . : t,,- LtSW IMMUNOGLOBULINS 19100020102042 Flebogamma Immune Globulin (Human) IV So!n 10 GM/200ML 25.00% IMMUNOGLOBULINS 19100020302064 Gammagard Immune Globulin {Human) IV or Subcutaneous Soln 2.5 GM/25ML 27.55% IMMUNOGLOBULINS 19100020102038 F!ebogamma Immune Globulin (Human) IV Solri 5 GM/100Ml 25.00% [MMUNOGlOBULINS 19100020102076 Flebogamma DIF Immune Globulin (Human) IV Soln 20 GM/200Ml 24.25% IMMUNOGlOBULINS 19100020302076 Gammagard Immune Globulin (Human) IV or Subcutaneous Soln 20 GM/200Ml 27.55% Immunological Agents 902S055400e520 Taltz lxekizumab Subcutaneous Solo Prefilled Syringe 80 MG/Ml 15.50% Immunological Agents 44604055002120 Nucala Mepollzumab For lnj 100 MG 15.50% l1mmuno!oglcal Agents 19200040002100 Antivenin Micrurus FulviL Antivenin Micrurus Fu!vius For JV Sain 15.50% lmmunofoglcal Agents 99450060203030 Veltassa Patiromer Sorbitex Calcium For Susp Packet 16.8 GM {Base Eq) 15.50% Immunological Agents 52505040202120 rnflectra lnflbdmab-dyyb For IV lnj 100 MG 15.50% Immunological Agents 99450060203040 Veltassa Patiromer SorbitexCalcium For Susp Packet 25.2 GM (Base Eq} 15.50% Immunological Agents 66290030002120 Enbrel Etanercept For Subcutaneous lnj 25 MG 16.75% Immunological Agents 99450060203020 Veltassa Patiromer Sorbitex Calcium For Susp Packet 8.4 GM {Base Eq) 15.50% lmmunosuppressive t1°ents 99402020000110 SandlMMUNE Cyc!osporine Cap 25 MG 16.00% !mmunosuppresslve Agents 99402540102220 Atgam Lymphocyte Immune Globulin Anti-Thymocyte G lnj 50 MG/Ml(Eq) 16.00% Immunosuppressive Agents 99404035000325 Zortress Everolimus Tab 0.5 MG 16.00% lmmunosuppressive11.oents 99404080000120 Prograf Tacrolimus Cap 5 MG 16.00% rmmunosuppressive Agents 99402020300150 Neoral Cyc!osporine Modified Cap 100 MG 16.00% lmmunosuppressive Agents 99403030300630 Myfortic Mycophenolate Sodium Tab DR 360 MG (MycophenolicAcldEquiv) 16.00% lmmunosuppressive Agents 99404080000105 Prograf Tacrolfmus Cap 0.5 MG 16.00% lmmunosuppressive Agents 99402020000140 SandlMMUNE Cyclosporine Cap 100 MG 16.00% lmmunosuppressive Agents 99403030100120 CellCept Mycopheno!ate Mofetil Cap 250 MG 16.00% lmmunosuppressive Agents 99404035000330 Zortress Evero!Jmus Tab 0.75 MG 16.00% lmmunosuppresslve Agents 99404080002010 Prograf Tacrolimus Jnj 5 MG/Ml 1600% Immunosuppressive Agents 99402020302020 Neoral Cyclosporine Modified Oral Solo 100 MG/ML 16.00% Im munosuppresslve Agents 99404035000320 Zortress Everolimus Tab 0.25 MG 16.00% lmmunosuppressive Agents 99404080000110 Prograf Tacrolimus Cap 1 MG 16.00% [mmunosuppressive Agents 99402020002005 SandlMMUNE Cyclosporine IV Soln 50 MG/Ml 16.00% lmmunosuppressive Agents 99403030100330 Ce!ICept Mycopheno!ate Mofetil Tab 500 MG 16.00% Im munosuppressive Agents 99404070000310 Rapamune Sirolimus Tab 0.5 MG 16.00% lmmunosuppressive Agents 99405015002110 Simu!ect Basiliximab For IV So!n 10 MG 16.00% lmmunosuppressive Agents 99402020300120 Neoral Cyclosporine Modified Cap 25 MG 16.00% ImmunosuppresslveAgents 99403030202120 CelJCept Intravenous Mycophenolate Mofetil HCI For IV Solo 500 MG {Base Equiv) 16.00% Jmmunosuppressive Agents 99404070000330 Rapamune Sirolimus Tab 2 MG 16.00% lmmunosuppressive Agents 99406010000305 lmuran Azath!oprine Tab SO MG 16.00% (mmunosuppressive Agents 99402020300130 CycloSPORINE Modified Cyc!osporine Modified Cap 50 MG 16.00% Im munosuppressive Agents 99403030300620 Myfortlc Mycophenolate Sodium Tab DR 180 MG {MycophenolicAcid Equiv) 16.00% Jmmunosuppressive Agents 99404070002020 Rapamune Sirolimus Oral So!n 1 MG/ML 16.00% lmmunosuppressive Agents 99408020002120 Nulojix Be!atacept For IV Infusion 250 MG 16.00% l mmunosuppressive Agents 99402020002010 5andlMMUNE Cyclosporine Oral So!n 100 MG/ML 1600% /mmunosuppressive Agents 99403030101920 CellCept Mycopheno!ate Mofetil For Oral Susp 200 MG/ML 16.00% lmmunosuppressive Agents 99404070000320 Rapamune Sirolfmus Tab 1 MG 16.00% Jmmunosuppres.sive Agents 99405015002120 S!mulect Basmx!mab For IV So!n 20 MG 16.00% Inflammatory Bowel Agents 52503080002120 Entyvio Vedolizumab For IV Solution 300 MG 16.00% ( ,"°"'-

:,, '0., ,o,-·\,, ,- elJl<i -1 Blockers 66450060002120 Arcalyst Rilonacept For lnj 220 MG 16.75% Int£:: euki -1 Receptor Antagonist{ll-lRa) RHEUtv1AT 6626001000ES20 Kineret Anakinra Subcutaneous So!n Prefilled Syringe 100 MG/0.67Ml 16.00% 11{9 OVI RLOAD-ANTIDOTES 93000020102110 Desferal Deferoxamlne Mesylate For lnj 500 MG 16.75% 1Rbµ.o,VERLOAD-ANTIDOTES 93100028000320 Ferriprox Deferiprone Tab 500 MG 16.00% &'- OVERLOAD-ANTIDOTES 93100025007330 Exjade DeferaslroxTab For Oral susp 250 MG 15.25% (({ON OVERLOAD-ANTIDOTES 93000020102130 Desferal Deferoxamine Mesy!ate For lnj 2 GM 16.75% IRON OVERLOAD-ANTIDOTES 93100025007340 Exjade DeferasiroxTab For Oral susp 500 MG 15.25% IRON OVERLOAD-ANTIDOTES 93100025000320 Jadenu DeferaslroxTab 90 MG 16.00% IRON OVERLOAD-ANTIDOTES 9310002S000340 Jadenu DeferasiroxTab 360 MG 16.00% IRON OVERLOAD-ANTIDOTES 93100025007320 Exjade DeferaslroxTab For Oral susp 125 MG 15.25% IRON OVERLOAD-ANTIDOTES 93100025000330 Jadenu DeferaslroxTab 180 MG 16.00% IRON REPlACEMENTS 82300085102020 Ferrlecit Sod Ferric Gluc Cmpix fn Sucrose IV Soln 12.5 MG/Ml {Fe Eq) 16.00% IRON REPLACEMENTS 82300048002020 Venofer Iron Sucrose lnj 20 MG/Ml {Fe Equiv) 16.00% LHRH Analogs 21405010106405 lupron Depot leupro!ide Acetate For lnj Kit 3.75 MG 16.00% LHRH Analogs 21405010156420 lupron Depot leuprolideAcetate (3 Month) For lnj Kit 11.25 MG 16.00% local Anesthetics - Topical 90850025306420 Qutenza Capsaicin Patch 8% & Cleansing Gel Kit 16.00% MEDICAL DEVICES 97051050106300 Omnitrope Pen 10 lni De "-Injection Device - Misc*** 16.25% MOUTH/rHROAT/DENTALAGENTS 88501000002000 caphosot *Artificial Saliva - Solution•"'* 16.00% Movement Disorder Drug Therapy 62380070000310 Xenazlne Tetrabenazine Tab 12.5 MG 16.75% Movement Disorder Drug Therapy 62380070000320 Xenazine Tetrabena2ine Tab 25 MG 16.75% MULTIPLE SCLEROSIS 30300010004010 Acthar HP Corticotropin lni Gel 80Unit/Ml 16.00% MULTIPLE SCLEROSIS AGENTS 6240003010E520 Copaxone Glatiramer Acetate Soln Prefil!ed Syringe 20 MG/Ml 16.75% MULTIPLE SCLEROSIS AGENTS 6240307530D250 Plegridy Starter Pack Peginterferon Beta-la Soln Pen-inj 63 & 94MCG/0.SML Pack 16.00% MULTlPLE SCLEROSIS AGENTS 62405525006520 Tecfidera Dimethyl Fumarate Capsule Delayed Release 120 MG 16.00% MULTIPLE SCLEROSIS AGENTS 62403060506420 Betaseron Interferon Beta-lb For lnj Kit0.3 MG 16.25% MULTIPLE SCLEROSIS AGENTS 62405050001320 Tysabri Natalizumab for IV lnj Cone 300 MG/15Ml 18.00% MULTIPLE SCLEROSIS AGENTS 6240003010E540 Copaxone Glatiramer Acetate Soln Prefilled Syringe 40 MG/Ml 16.75% MULTIPLE SCLEROSIS AGENTS 6240307530E520 Plegridy Peglnterferon Beta-la Soln Prefilfed Syringe 125 MCG/0.SML 16.00% MULTIPLE SCLEROSIS AGENTS 62405525006540 Tecfidera Dimethyl Fumarate Capsule Delayed Release 240 MG 16.00% MULTIPLE SCLEROSIS AGENTS 6240307530D220 Plegrldy Peginterferon Beta-la Soln Pen-injector 125 MCG/0.SMl 16,00% MULTIPLE SCLEROSIS AGENTS 62405525006320 Tetfidera Dimethyl Fumarate Capsule DR Starter Pack 120 MG & 240 MG 16.00% MULTIPLE SCLEROSIS AGENTS 62403060456420 Avonex Interferon Beta-la For IM lnj Kit30MCG (33MCG{6.6 MU),N!a\) 16.75% MULTIPLE SCLEROSIS AGENTS 6240307530ESSO PlegridyStarter Pack Peginterferon Beta-la Sofn Pref Syr 63 & 94 MCG/0.SML Pack 16.00% MULTIPLE SCLEROSIS AGENTS 62406030007420 Ampyra Dalfamprldine Tab SR 12HR 10MG 15.25% MULTIPLE SCLEROSIS AGENTS 62404070000330 Aubagio Teriflunomide Tab 14 MG 23.75% MULTIPLE SCLEROSIS AGENTS 62403060S02120 Betaseron Interferon Beta-lb For lnj 0.3 MG 16.25% MULTIPLE SCLEROSIS AGENTS 62405010002020 lemtrada Alemtuzumab IV lnj 12MG/1.2ML(10 MG/Ml) 16.00% MULTIPLE SCLEROSIS AGENTS 62404070000320 Aubagio Teriflunomide Tab 7 MG 23.75% MULTtPLE SCLEROSIS AGENTS 62407025100120 Gilenya Fingolimod HCl Cap 0.5 MG (Base Equ·1v) 16.50% MUSCULOSKELETAL THERAPY AGENTS 75840015002300 Carticel *Autologous Cultured Chondrocytes for Implantation""* 16.00% Neurogenic Orthostatic Hypotension (NOH)-Agents 38700030000150 Northera Droxldopa cap 300 MG 16.00% Neurogenic Drthostatic Hypotension (NOH)-Agents 38700030000130 Northern Droxidopa Cap 100 MG 16.00% NeurogenicOrthostatic Hypotenslon (NOH)-Agents 38700030000140 Northera Droxidopa cap 200 MG 16.00% NEUROMUSCULAR AGENTS 74400020052140 Botox OnabotullnumtoxinA For lnj 200 Unit 16.75% NEUROMUSCULAR AGENTS 74400020032120 Dysport AbobotulinumtoxinA For lnj 500 Unit 16.75% NEUROMUSCULAR AGENTS 74503070000320 Rifutek Riluzo!e Tab SO MG 16.00% NEUROMUSCULAR AGENTS 74400020102018 Myobloc RimabotulinumtoxinB lnj 2500 Unit/0.SML 16.25% NEUROMUSCULAR AGENTS 74400020052120 Botox OnabotulinumtoxinA For lnj 100 Unit 16.75% NEUROMUSCULAR AGENTS 74400020102020 Myobloc RimabotulinumtoxinB lnj 5000 Unit/ML 16.25%

'\\ .,. \)\\ -\, !J) :,J/{ EUR . MU ULARAGENTS 74400020202120 Xeomln lncobotulinumtoxinA For Jnj SO Unit 16.25% NIH MU$CULAR AGENTS 74400020032115 Dysport AbobotultnumtoxinA For lnj 300 Unit 16.75% M :Ufl!tMUSCULARAGENTS 74400020202130 Xeomin lncobotulinumtoxinA For lnj 100 Unit 16.25% IN{LJJi;0MUSCUlAR AGENTS 74400020102022 Myobloc RimabotulinumtoxinB lnj 10000 Unit/2ML 16.25% ,w 10 ·sbLETO 90250515002120 AMEVNE ALEFACEPT FPR IV INJ 7.5 MG 15.50% OPHTHALMIC AGENTS 86300010002320 Ozurdex Dexamethasone lntravitreal Implant 0.7 MG 16.00% OPHTHALMIC AGENTS 86700065002120 Visudyne Verteporfin For IVSoln 15 MG {2 MG/ML) 16.25% OPHTHALMIC AGENTS 86300017102320 Retisert Fluocinolone Acetonlde lntravitreal Implant 0.59 MG 16.00% OPHTHALMIC AGENTS 86801060002020 Jetrea Ocrip!asmin lntravitreal lnj 0.5 MG/0.2ML (2.5 MG/ML) 16.00% OPHTHALMIC AGENTS 86655010002020 Eylea Aflibercept lntravitreal lnj 2 MG/0.05Ml (40 MG/ML) 15j5% OPHTHALMIC AGENTS 86655060002012 Lucentis Ranibizumab lntravJtreal lnj 0.3 MG/0.05ML {6 MG/ML) 16.75% OPITTHALMIC AGENTS 86655060002020 Lucentis Ranibizumab lntravltreal lnj 0.5 MG/0.05ML (10 MG/ML) 16.75% OPHTHALMIC AGENTS 86655050302020 Macugen Pegaptanib Sodium lntravitreouslnj0.3 MG/90 Micronter 16.25% Ophthalmic Agents 86300080101820 Triesence Triamcinolone Acetonide Ophth lnj 40 MG/ML 15.50% OSTEOARTHRITIS OF THE KNEE 7580004000E530 Synvisc Hylan Intra-articular Solution Prefllled Syringe 16 MG/2Ml 16.75% OSTEOARTHRITIS OF THE KNEE 7580004000E560 Synvlsc One Hylan Intra-articular Solution Prefilled Syringe48 MG/6Ml 16.75% OSTEOARTHRITIS OF THE KNEE 7580006000E520 OrthoVisc Hyaluronan Intra-articular Solo Prefilled Syringe 30 MG/2ML 16.75% OSTEOARTHRITIS OF THE KNEE 7580007010E520 Euflexxa Sodium Hyaluronate Intra-articular Soln PrefSyr 20 MG/2ML 16.75% OSTEOARTHRITIS OF THE KNEE 7580007010ES25 Supartz Sodium Hyaluronate Intra-articular Soln Pref Syr 25 MG/2.SML 16.25% OSTEOARTHRITIS OF THE KNEE 75800070102024 Hyalgan Sodium Hyaluronate Intra-articular lnj 20 MG/2ML 16.75% OSTEOPOROSIS-- BISPHOSPHONATES 30042090002120 Zoledronic Acid Zoledronic Acid For IV So!n 4 MG 35.00% OSTEOPOROSIS- BISPHOSPHONATES 30042090001320 Zoledron!c Acid Zoledronic Acid lnj Cone For N Infusion 4 MG/SML 34.20% OSTEOPOROSIS- BlSPHOSPHONATES 30042060102012 Pamldronate Disodium Pamidronate Dlsodium JV Soln 9 MG/ML 16.00% OSTEOPOROSIS-- BISPHOSPHONATES 30042060102006 Pamidronate Disodium Pamidronate Disodium IV Soln 3 MG/ML 16.00% OSTEOPOROSIS-- BlSPHOSPHONATES 30042060102009 Pamidronate Dlsodium Pam!dronate Disodium IV Soln 6 MG/ML 16.00% OSTEOPOROSIS- BISPHOSPHONATES 30042090002016 ZoledronicAcid Zo!edronic Acid IV Soln 4 MG/lOOML 35.00% OSTEOPOROSIS- BISPHOSPHONATES 30042060102120 Aredia Pamidronate Dlsodium For lnj 30 MG 16.00% OSTEOPOROSIS- BISPHOSPHONATES 30042090002020 Rec!ast Zoledronic Acid IV Soln 5 MG/lOOML 35.00% OSTEOPOROSIS- BISPHOSPHONATES 30042060102140 Aredia Pamidronate Disodium For lnj 90MG 16.00% OSTEOPOROSIS- BISPHOSPHONATES 30042048102030 Boniva lbandronate Sodium IV Soln 3 MG/3ML {Base Equivalent) 16.00% Progesterone Receptor Antagonists ANTIDIABET!CS 27304050000330 Korlym Mifepristone Tab 300 MG 16.00% Progestin Contraceptives- IUD 25200050005320 Mirena levonorgestrelReleas!ng IUD 20 MCG/24HR (52 MG Total) 15.50% Progestin Contraceptives- IUD 25300005002320 lmplanon Etonogestrel Subdermal Implant 68 MG 15.25% PROGESTINS 26000010101710 Makena HydroYVprogesterone Caproate IM In Oil 250 MG/ML 16.75% PSORIASIS 9025058500ES20 Stelara Ustekinumab So!n Prefi!led Syringe 45 MG/0.5ML 16.00% PSORIASIS 66700015000330 Otezla ApremilastTab 30 MG 16.00% PSORIASIS 9025058500ES40 Stelara Usteklnumab Soln Prefilled Syringe 90MG/ML 16.00% PSORIASIS 90250515002130 AMEVIVE Alefacept For IM lnj 15 MG 15.50% PSORIASIS 9025057500E520 Cosentyx Secukinumab Subcutaneous Soln Prefil!ed Syringe 150 MG/ML 16.00% PSORIASIS 90250S85002020 Stelara USTEKINUMAB INJ 45 MG/0.SML 16.oo% PSORIASIS 66700015008720 Otezla ApremilastTab Starter Therapy Pack 10 MG & 20 MG & 30 MG 16.00% PSORIASIS 9025057500D52 0 Cosentyx Sensoready Pei Secukfnumab Subcutaneous Soln Auto-Injector 150 MG/ML 16.00% PULMONARY ARTERIAL HYPERTENSION 40134050000340 Adempas Riociguat Tab 2 MG 16.00% PULMONARY ARTERIAL HYPERTENSION 40160015000330 Tracleer Bosentan Tab 125 MG 16.00% PULMONARY ARTERIAL HYPERTENSION 40170080050415 Orenltram Treprostinil Dio!amfne Tab CR 0.25 MG (Base Equiv) 16.00% PULMONARY ARTERIAL HYPERTENSION 40134050000320 Adempas RiociguatTab 1 MG 16.00% PULMONARY ARTERIAL HYPERTENSION 40160007000320 Letairis Ambr!sentan Tab 10MG 16.00% PULMONARY ARTERIAL HYPERTENSION 40170080002020 Tyvaso Treprostinil Inhalation Solution 0.6 MG/Ml 16.00% PULMONARY ARTERIAL HYPERTENSION 40134050000350 Adempas RiociguatTab 2.5 MG 16.00%

<!,'.). -S'o... -,- . ' -'-'()'' \_\\'-, U) ,'' l'i fpal ;:iNA ARTERIAL HYPERTENSION 40160050000320 Opsumit Macitentan Tab 10 MG 16.00"76 P.Ul NAS v ARTERIAL HYPERTENSION 40134050000310 Adempas RiociguatTab 0.5 MG 16.00% ""y( 3N 1W ARTERIAL HYPERTENSION 40160007000310 Letairis Ambrisentan Tab 5 MG 16.00% f!II. r lNARY ARTERIAL HYPERTENSION 40170080102040 Remodulin Treprostlnil Sodium lnj 10 MG/ML(Base Equiv) 16.00% P_LILMONARY ARTERIAL HYPERTENSION 40170080050420 Orenitram Treprostinil Diolamine Tab CR 1 MG (Base Equiv) 16.00% PULMONARY ARTERIAL HYPERTENSION 40134050000330 Adempas RiociguatTab 1.5 MG 16.00% PULMONARY ARTERIAL HYPERTENSION 40160015000320 Tracleer Bosentan Tab 62.5 MG 16.00% PULMONARY ARTERIAL HYPERTENSION 40143060101920 Revatio Sildenafil Citrate For Suspension 10 MG/Ml 16.75% PULMONARY ARTERIAL HYPERTENSION 40170080050410 Orenitram Treprostln!I Diolamine Tab CR 0.125 MG (Base Equiv) 16.00% PULMONARY ARTERIAL HYPERTENSION 40170040102110 Epoprostenol Sodium Epoprostenol Sodium For lnj 0.5 MG 16.00% PULMONARY ARTERIAL HYPERTENSION 40170080050425 Orenitram Treprostinil Oio!amlne Tab CR 2.5 MG {Base Equiv) 16.00% PULMONARY ARTERIAL HYPERTENSION 40143060100320 Revatlo S!ldenafil Citrate Tab 20 MG 40.00% PULMONARY ARTERIAL HYPERTENSION 40143080000320 Adcirca Tada!afil Tab 20 MG {PAH} 15.75% PULMONARY ARTERIAL HYPERTENSION 40170060002020 Ventavls lloprostlnhalation Solution 10 MCG/ML 16.00% PULMONARY ARTERIAL HYPERTENSION 40170080102020 Remodulin Treprostinll Sodium lnj 2.5 MG/Ml(Base Equiv) 16.00% PULMONARY ARTERIAL HYPERTENSION 40170060002040 Ventavis lloprost Inhalation Solution 20 MCG/ML 16.00% PULMONARY ARTERIAL HYPERTENSION 40170080102030 Remodulin Treprostinil Sodium lnJ 5 MG/Ml (Base Equiv) 16.00% PULMONARY ARTERIAL HYPERTENSION 40143060102020 Revatio Sitdenafll Citrate IV Soln 10 MG/12.5Ml {Base Equivalent) 16.75% PULMONARY ARTERIAL HYPERTENSION 40170040102130 Epoprostenol Sodium Epoprostenol Sodium For lnj 1.5 MG 16.00% PULMONARY ARTERIAL HYPERTENSION 40170080102010 Remodulin Treprostinll Sodium lnj 1 MG/ML(Base Equiv} 16.00% Pulmonary Fibrosis Agents 45550060000120 Esbrlet Pirfenldone Cap 267 MG 16.00% Pulmonary Fibrosis Agents 45554050200130 Ofev Nintedanib Esylate cap150 MG (Base Equivalent) 16.00% Pulmonary Fibrosis Agents 45554050200120 Ofev Nintedanib Esylate Cap 100 MG (Base EQuivalent) 16.00% RESPIRATORY AGENTS- MISC. 45100010102110 Aralast NP A!phal-Protelnase Inhibitor {Human) For IV Soln 500 MG 16.00% RESPIRATORY AGENTS- MISC. 45000070001820 Surfaxln lucinactant Jntratracheal Susp 30 MG/ML 16.00% RESPIRATORY AGENTS- MISC. 45100010102108 Aralast Alphal-Proteinase Inhibitor (Human) For IV Soln 400 MG 15.50% RESPIRATORY AGENTS- MISC. 45100010102118 Aralast Alpha1-ProtelnaseInhibitor {Human) For IV Sofn 800 MG 15.50% RESPIRATORY AGENTS - MISC. 45100010102020 G!assia Alpha1-ProteinaseInhibitor (Human) lnj 1000 MG/SOML 15.75% RESPIRATORY GENTS- MISC. 45100010102120 AralastNP Alphal-Proteinase lnh!bitor(Human) For IV Soln 1000 MG 16.00% RespiratorySyncytial Virus (RSV) Agents 19502060002015 Synag!s Palivizumab JM Soln 50 MG/0.SML 15.75% Respiratory Syncytial Virus (RSV) Agents 19502060002020 Synagis Pa!ivizumab IM So!n 100 MG/Ml 15.75% Respiratory Syncytial Virus {RSV) Agents 12604075002120 Virazole Ribavifin For lnhal Soln 6 GM 16.00¾ Respiratory Tract Agents 40120070000310 Uptravi Selexipag Tab 200 MCG 15.50% Respiratory Tract Agents 40120070000340 Uptravi SelexipagTab 1400 MCG 15.50% Respiratory Tract Agents 40120070000315 Uptravi SelexipagTab 400 MCG 15.50% Respiratory Tract Agents 40120070000320 Uptravi SelexipagTab 600 MCG 15.50% Respiratory Tract Agents 40120070008720 Uptravi SelexipagTab Therapy Pack 200 MCG (140) & 800 MCG (60) 15.50% Respiratory Tract Agents 40120070000345 Uptravi SelexipagTab 1600 MCG 15.50% Respiratory Tract Agents 40120070000330 Uptravi Selexipag Tab 1000 MCG 15.50% Respiratory Tract Agents 40120070000335 Uptravi SelexipagTab 1200 MCG 15.50% Respiratory Tract Agents 40120070000325 Uptrav/ SelexipagTab 800 MCG 15.50% RHEUMATOID ARTHRITIS MISC 6650007000£520 Actemra Tocilizumab Subcutaneous So!n Prefilled Syringe 162 MG/0.9ML 15.50% RHEUMATOID ARTHRITIS MISC 66500070002035 Actemra Toci!izumab IV lnj 200 MG/lOML 15.50% RHEUMATOID ARTHRITIS MISC 66400010002120 Orencia Abatacept For JV Soln 250 MG 16.25% RHEUMATOID ARTHRITIS MISC 66603065100320 Xeljanz Tofacitinib Citrate Tab 5 MG (Base Equivalent) 16.00% RHEUMATOID ARTHR/TIS MISC 66500070002040 Actemra Tociliwmab /VlnJ 400 MG/20Ml 15.50% RHEUMATOID ARTHRITIS MISC 6640001000E520 Orencia AbataceptSubcutaneous Soln Prefifled Syringe 125 MG/ML 16.25% RHEUMATOID ARTHRITIS MISC 66280050000320 Arava Leflunomlde Tab 20 MG 16.00% RHEUMATOID ARTHRITIS MISC 66460020002120 llaris Canakinumab For lnj 180 MG 16.75%

66S0007000203066280050000310525330700064208250206000202099422015002120 ActemraArava GattexMozobl1 Ben!ysta Benlysta ferriprox SlrturoCimzia Starter Kit SimponiEnbrelCimzia Simponi ArlaEnbrel 5ureClick RemicadeSimponi Cimzia Simponi Enbrel Humira Pen Simponi Humira Humira Enbrel Humira Hymovls Gabapentin DDAVPLupaneta Pack HydroxyureaAggrastat ToclHzumab IV lnj 80 MG/4MlLeflunomide Tab 10 MG Teduglutide (rDNA) For lnj Kit 5 MGPlerixaforSubcutaneous lnj 24 MG/1.2ML(20 MG/ML) Belimumab For IV Sein 120 MGBe!imumab For IV So!n 400 MG Deferiprone Oral So!n 100 MG/MLBedaqu!lfne Fumarate Tab 100 MG (Base Equiv) Certoli2umab Pegol Jnj Kit 6X 200 MG/MLGolimumab Subcutaneous Sein Auto-injector 100 MG/MLEtanerceptSubcutaneous Sein Prefilled Syringe SO MG/ML Certolizumab Pegol For lnj Kit 2 X 200 MGGolimumab JV Soln 50 MG/4MlEtanerceptSubcutaneous Solution Auto-injector 50 MG/ML lnfliximab For IV lnj 100 MGGolimumab Subcutaneous Sein Prefi!led Syringe SO MG/0.SML Certoli2umab Pegol lnj Kit 2X 200 MG/MlGolimumab Subcutaneous Sein Auto-injector SO MG/0.SMLEtanerceptSubcutaneous Solo Prefilled Syringe 25 MG/0.5Ml Ada!fmumab Pen-injector Kit 40 MG/0.8MlGolimumab SubcutaneousSoln Prefilfed Syringe 100 MG/Ml Adalfmumab Prefil!ed Syringe Kit 20 MG/0.4MLAdallmumab PrefiHed Syringe Kit40 MG/0.BML Etanercept For Subcutaneous lnJ Kit 25 MG AdaHmumab Prefilled Syringe Kit 10 MG/0.2MLHyaluronan lntra-articularSoln Prefi!led Syringe 24 MG/3ML Gabapentin PowderDesmopressinAcetate lnj 4 MCG/MLLeuprollde {1 Mon) lnj 3.75 MG & Norethlndrone Tab 5 MG Kit Hydroxyurea Cap 500 MGTirofiban HCI IV Cone 3.75 MG/15ML (250 MCG/ML) (Base Equiv) 15.50%16.00%16.00%16.75%16.75%16.75%15.50%16.00";>'616.75%16.25%16.75%16.75%16.25%16.75%16.00%16.25%16.75%16.25%16.75%16.75%16.25%16.75%16.75%16.75%16.7S%15.50%15.50%15.50%15.50%15.50%15.50% Systemic Lupus Erythematosus Agents 9942201500214093100028002.02009000015100320525050201064606627004000D5406629003000ES305250502010642066270040002.0156629003000D53052SOS0400021206627004000ES20525050201064406627004000DS206629003000E5256627001500F4206627004000ES406627001500F8106627001500F820662900300064206627001500F80S7580006000e5159654424400290030201010102030300899025064202170003000010585153060101310 Therapeutic Nutrients/Minerals/Electrolytes TUBERCULOSIS Tumor Necrosis Factor Alpha Blockers Tumor Necrosis Factor Alpha Blockers Tumor Necrosis Factor Alpha Blockers Tumor Necrosis Factor Alpha Blockers Tumor Necrosis Factor Alpha Blockers Tumor Necrosis Factor Alpha Blockers Tumor Necrosis Factor Alpha Blockers Tumor Necrosis Factor Alpha Blockers Tumor Necrosis Factor Alpha Blockers Tumor Necrosis Factor Alpha Blockers Tumor Necrosis Factor Alpha Blockers Tumor Necrosis Factor Alpha Blockers Tumor Ne<:rosis Factor Alpha Blockers Tumor Necrosis Factor Alpha Blockers Tumor Necrosis Factor Alpha Blockers Tumor Necrosis Factor Alpha Blockers Tumor Necrosis Factor Alpha Blockers Viscosupplements (blank) (blank) (blank) {blank} (blank)

Puerto Rico		66-0555678
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1441 F.D. Roosevelt Avenue
San Juan, Puerto Rico		00920
(Address of principal executive offices)		(Zip code)

	Large accelerated filer ☐	Accelerated filer ☑
	Non-accelerated filer ☐	Smaller reporting company ☐
	Emerging growth company ☐

Title of each class		Outstanding at September 30, 2018
Common Stock Class A, $1.00 par value		950,968
Common Stock Class B, $1.00 par value		21,985,524

Part I – Financial Information			3

	Item 1.	Financial Statements	3

	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	34


	Item 3.	Quantitative and Qualitative Disclosures about Market Risk	47

	Item 4.	Controls and Procedures	48

Part II – Other Information			48

	Item 1.	Legal Proceedings	48

	Item 1A.	Risk Factors	48

	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	49

	Item 3.	Defaults Upon Senior Securities	49

	Item 4.	Mine Safety Disclosures	49

	Item 5.	Other Information	49

	Item 6.	Exhibits	49

SIGNATURES			50

	Cautionary Statement Regarding Forward-Looking Information	34
	Overview	34
	Recent Developments	35
	Recent Accounting Standards	37
	Managed Care Membership	38
	Consolidated Operating Results	39
	Managed Care Operating Results	41
	Life Insurance Operating Results	44
	Property and Casualty Insurance Operating Results	45
	Liquidity and Capital Resources	46

	September 30, 2018			December 31, 2017
Assets
Investments and cash:
Fixed maturities available for sale, at fair value	$	1,224,050		$	1,216,788
Fixed maturities held to maturity, at amortized cost		2,490			2,319
Equity investments, at fair value		306,360			342,309
Other invested assets, at net asset value		73,127			34,984
Policy loans		9,680			9,077
Cash and cash equivalents		107,091			198,941
Total investments and cash		1,722,798			1,804,418
Premiums and other receivables, net		632,897			899,327
Deferred policy acquisition costs and value of business acquired		209,205			200,788
Property and equipment, net		78,445			74,716
Deferred tax asset		83,593			65,123
Goodwill		25,397			25,397
Other assets		66,093			46,996
Total assets	$	2,818,428		$	3,116,765
Liabilities and Stockholders' Equity
Claim liabilities	$	1,038,114		$	1,106,876
Liability for future policy benefits		355,366			339,507
Unearned premiums		78,544			86,349
Policyholder deposits		174,126			176,534
Liability to Federal Employees' Health Benefits and
Federal Employees' Programs		41,880			52,287
Accounts payable and accrued liabilities		246,750			354,894
Deferred tax liability		3,210			21,891
Long-term borrowings		29,681			32,073
Liability for pension benefits		30,919			33,672
Total liabilities		1,998,590			2,204,083
Stockholders’ equity:
Triple-S Management Corporation stockholders' equity
Common stock Class A, $1 par value. Authorized 100,000,000 shares; issued and outstanding 950,968 at September 30, 2018 and December 31, 2017, respectively		951			951
Common stock Class B, $1 par value. Authorized 100,000,000 shares; issued and outstanding 21,985,524 and 22,627,077 shares at September 30, 2018 and December 31, 2017, respectively		21,986			22,627
Additional paid-in capital		34,231			53,142
Retained earnings		772,872			785,390
Accumulated other comprehensive (loss) income		(9,531	)		51,254
Total Triple-S Management Corporation stockholders' equity		820,509			913,364
Non-controlling interest in consolidated subsidiary		(671	)		(682	)
Total stockholders' equity		819,838			912,682
Total liabilities and stockholders' equity	$	2,818,428		$	3,116,765

	Three months ended September 30,						Nine months ended September 30,
	2018			2017			2018			2017
Revenues:
Premiums earned, net	$	742,445		$	714,325		$	2,236,249		$	2,139,489
Administrative service fees		3,802			3,391			11,216			12,318
Net investment income		16,168			12,395			45,630			37,109
Other operating revenues		1,575			941			4,234			3,027
Total operating revenues		763,990			731,052			2,297,329			2,191,943
Net realized investment (losses) gains		(956	)		3,753			1,065			8,143
Net unrealized investment gains (losses) on equity investments		5,632			-			(11,343	)		-
Other income, net		1,943			3,409			3,600			6,521
Total revenues		770,609			738,214			2,290,651			2,206,607
Benefits and expenses:
Claims incurred		648,580			583,625			1,959,707			1,815,785
Operating expenses		141,026			119,145			408,772			348,811
Total operating costs		789,606			702,770			2,368,479			2,164,596
Interest expense		2,000			1,709			5,515			5,116
Total benefits and expenses		791,606			704,479			2,373,994			2,169,712
(Loss) income before taxes		(20,997	)		33,735			(83,343	)		36,895
Income tax (benefit) expense		(3,430	)		11,824			(30,944	)		6,622
Net (loss) income		(17,567	)		21,911			(52,399	)		30,273
Net (loss) income attributable to non-controlling interest		-			(1	)		1			(2	)
Net (loss) income attributable to Triple-S Management Corporation	$	(17,567	)	$	21,912		$	(52,400	)	$	30,275

	2018			2017
Balance at January 1	$	913,364		$	863,163
Share-based compensation		3,462			1,651
Repurchase and retirement of common stock		(23,014	)		(12,553	)
Comprehensive (loss) income		(73,303	)		45,148
Total Triple-S Management Corporation stockholders' equity		820,509			897,409
Non-controlling interest in consolidated subsidiary		(671	)		(679	)
Balance at September 30	$	819,838		$	896,730

	Nine months ended September 30,
	2018			2017
Cash flows from operating activities:
Net (loss) income	$	(52,399	)	$	30,273
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization		9,933			9,835
Net amortization of investments		3,747			7,396
Additions to the allowance for doubtful receivables		7,085			2,043
Deferred tax benefit		(33,006	)		(9,993	)
Net realized investment gain on sale of securities		(1,065	)		(8,143	)
Net unrealized loss on equity investments		11,343			-
Interest credited to policyholder deposits		4,288			3,151
Share-based compensation		3,462			1,651
Decrease (increase) in assets:
Premium and other receivables, net		259,345			(646,650	)
Deferred policy acquisition costs and value of business acquired		(5,943	)		(7,139	)
Deferred taxes		606			(218	)
Other assets		(19,657	)		2,976
(Decrease) increase in liabilities:
Claim liabilities		(68,762	)		620,755
Liability for future policy benefits		15,859			15,286
Unearned premiums		(7,805	)		86,509
Liability to Federal Employees' Health Benefits and Federal Employees' Programs		(10,407	)		12,372
Accounts payable and accrued liabilities		(120,552	)		71,745
Net cash (used in) provided by operating activities		(3,928	)		191,849

	September 30, 2018
	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value

Fixed maturities available for sale:
Obligations of government- sponsored enterprises	$	11,460	$	-	$	(130	)	$	11,330
U.S. Treasury securities and obligations of U.S. government instrumentalities		225,968		11		(1,488	)		224,491
Obligations of the Commonwealth of Puerto Rico and its instrumentalities		8,234		-		(5	)		8,229
Municipal securities		679,796		13,967		(4,521	)		689,242
Corporate bonds		213,048		9,525		(1,007	)		221,566
Residential mortgage-backed securities		59,483		-		(987	)		58,496
Collateralized mortgage obligations		11,054		-		(358	)		10,696
Total fixed maturities available for sale	$	1,209,043	$	23,503	$	(8,496	)	$	1,224,050

	December 31, 2017
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value

Securities available for sale:
Fixed maturities:
Obligations of government- sponsored enterprises	$	1,431	$	13	$	-		$	1,444
U.S. Treasury securities and obligations of U.S. government instrumentalities		118,858		41		(550	)		118,349
Obligations of the Commonwealth of Puerto Rico and its instrumentalities		8,059		34		-			8,093
Municipal securities		771,789		30,468		(1,467	)		800,790
Corporate bonds		217,046		17,767		(489	)		234,324
Residential mortgage-backed securities		32,465		2		(355	)		32,112
Collateralized mortgage obligations		22,003		10		(337	)		21,676
Total fixed maturities		1,171,651		48,335		(3,198	)		1,216,788
Equity securities:
Mutual funds		292,460		50,072		(223	)		342,309
Alternative investments		34,669		559		(244	)		34,984
Total equity securities		327,129		50,631		(467	)		377,293
Total	$	1,498,780	$	98,966	$	(3,665	)	$	1,594,081

	September 30, 2018
	Less than 12 months							12 months or longer							Total
	Estimated Fair Value		Gross Unrealized Loss			Number of Securities		Estimated Fair Value		Gross Unrealized Loss			Number of Securities		Estimated Fair Value		Gross Unrealized Loss			Number of Securities

Fixed maturities available for sale:
Obligations of government- sponsored enterprises	$	11,330	$	(130	)		2	$	-	$	-			-	$	11,330	$	(130	)		2
U.S. Treasury securities and obligations of U.S. governmental instrumentalities		196,342		(1,488	)		21		-		-			-		196,342		(1,488	)		21
Obligations of the Commonwealth of Puerto Rico and its instrumentalities		7,485		(5	)		4		-		-			-		7,485		(5	)		4
Municipal securities		306,834		(3,727	)		56		23,631		(794	)		2		330,465		(4,521	)		58
Corporate bonds		128,028		(1,007	)		44		-		-			-		128,028		(1,007	)		44
Residential mortgage-backed securities		53,395		(741	)		21		5,100		(246	)		4		58,495		(987	)		25
Collateralized mortgage obligations		6,333		(148	)		2		4,115		(210	)		1		10,448		(358	)		3
Total fixed maturities	$	709,747	$	(7,246	)		150	$	32,846	$	(1,250	)		7	$	742,593	$	(8,496	)		157
Other invested assets - Alternative investments	$	13,460	$	(224	)		5	$	8,817	$	(78	)		2	$	22,277	$	(302	)		7

	Three months ended September 30,						Nine months ended September 30,
	2018			2017			2018			2017
Realized gains (losses)
Fixed maturity securities:
Securities available for sale:
Gross gains	$	587		$	933			2,099		$	1,334
Gross losses		(2,892	)		(194	)		(13,695	)		(830	)
Total fixed securities		(2,305	)		739			(11,596	)		504
Equity investments:
Gross gains		1,218			3,014			9,972			7,641
Gross losses		(67	)		-			(1,091	)		(2	)
Total equity investments		1,151			3,014			8,881			7,639
Other invested assets:
Gross gains		311			-			4,104			-
Gross losses		(113	)		-			(324	)		-
Total other invested assets		198			-			3,780			-
Net realized investment (losses) gains	$	(956	)	$	3,753		$	1,065		$	8,143

	September 30, 2018		December 31, 2017
Premium	$	73,624	$	103,027
Self-funded group receivables		34,851		39,859
FEHBP		13,670		13,346
Agent balances		26,076		32,818
Accrued interest		12,243		14,331
Reinsurance recoverable		428,298		661,679
Other		84,460		70,150
		673,222		935,210
Less allowance for doubtful receivables:
Premium		31,379		26,490
Other		8,946		9,393
		40,325		35,883
Total premium and other receivables, net	$	632,897	$	899,327

	September 30, 2018
	Level 1		Level 2		Level 3		Total

Fixed maturity securities available for sale:
Obligations of government-sponsored enterprises	$	-	$	11,330	$	-	$	11,330
U.S. Treasury securities and obligations of U.S government instrumentalities		224,491		-		-		224,491
Obligations of the Commonwealth of Puerto Rico and its instrumentalities		-		8,229		-		8,229
Municipal securities		-		689,242		-		689,242
Corporate bonds		-		221,566		-		221,566
Residential agency mortgage-backed securities		-		58,496		-		58,496
Collateralized mortgage obligations		-		10,696		-		10,696
Total fixed maturities		224,491		999,559		-		1,224,050

Equity investments	$	143,638	$	162,722	$	-	$	306,360

	September 30, 2018
	Carrying		Fair Value
	Value		Level 1		Level 2		Level 3		Total
Assets:
Policy loans	$	9,680	$	-	$	9,680	$	-	$	9,680

Liabilities:
Policyholder deposits	$	174,126	$	-	$	174,126	$	-	$	174,126
Long-term borrowings:
Loans payable to bank - variable		29,924		-		29,924		-		29,924
Total liabilities	$	204,050	$	-	$	204,050	$	-	$	204,050

	Nine months ended September 30, 2018
	Managed Care			Other Business Segments *			Consolidated

Claim liabilities at beginning of period	$	367,357		$	739,519		$	1,106,876
Reinsurance recoverable on claim liabilities		-			(633,099	)		(633,099	)
Net claim liabilities at beginning of period		367,357			106,420			473,777
Claims incurred:
Current period insured events		1,764,038			80,774			1,844,812
Prior period insured events		(30,404	)		122,951			92,547
Total		1,733,634			203,725			1,937,359
Payments of losses and loss-adjustment expenses:
Current period insured events		1,438,611			40,317			1,478,928
Prior period insured events		249,073			40,621			289,694
Total		1,687,684			80,938			1,768,622
Net claim liabilities at end of period		413,307			229,207			642,514
Reinsurance recoverable on claim liabilities		-			395,600			395,600
Claim liabilities at end of period	$	413,307		$	624,807		$	1,038,114

	Nine months ended September 30, 2017
	Managed Care			Other Business Segments *			Consolidated

Claim liabilities at beginning of period	$	349,047		$	138,896		$	487,943
Reinsurance recoverable on claim liabilities		-			(38,998	)		(38,998	)
Net claim liabilities at beginning of period		349,047			99,898			448,945
Claims incurred:
Current period insured events		1,724,890			95,227			1,820,117
Prior period insured events		(19,158	)		(5,920	)		(25,078	)
Total		1,705,732			89,307			1,795,039
Payments of losses and loss-adjustment expenses:
Current period insured events		1,456,098			38,222			1,494,320
Prior period insured events		242,384			35,325			277,709
Total		1,698,482			73,547			1,772,029
Net claim liabilities at end of period		356,297			115,658			471,955
Reinsurance recoverable on claim liabilities		-			636,743			636,743
Claim liabilities at end of period	$	356,297		$	752,401		$	1,108,698

Incurred Year	Total of IBNR Liabilities Plus Expected Development on Reported Claims
2017	$	11,965
2018		325,427

	Three months ended September 30,						Nine months ended September 30,
Components of net periodic benefit cost:	2018			2017			2018			2017
Components of net periodic benefit cost:
Interest cost	$	1,713		$	1,652		$	5,099		$	5,248
Expected return on assets		(2,255	)		(2,021	)		(6,817	)		(6,419	)
Amortization of actuarial loss		240			79			670			251
Settlement loss		395			580			1,045			1,211
Net periodic benefit cost	$	93		$	290		$	(3	)	$	291

	September 30, 2018			December 31, 2017
Deferred tax assets
Gross deferred tax assets	$	127,563		$	87,058
Less: valuation allowance		(12,696	)		(8,283	)
Deferred tax assets		114,867			78,775

Deferred tax liabilities
Gross deferred tax liabilities		(34,485	)		(35,543	)
Net deferred tax asset	$	80,382		$	43,232

	September 30, 2018			December 31, 2017
Assets:
Managed care	$	1,130,401		$	1,092,715
Life insurance		852,750			853,289
Property and casualty insurance		762,705			1,094,773
Other segments *		20,787			19,027
Total business segments		2,766,643			3,059,804
Unallocated amounts related to TSM:
Cash, cash equivalents, and investments		59,496			81,169
Property and equipment, net		21,326			22,257
Other assets		23,547			22,763
		104,369			126,189
Elimination entries-intersegment receivables and others		(52,584	)		(69,228	)
Consolidated total assets	$	2,818,428		$	3,116,765

	As of September 30,
	2018		2017
Managed care enrollment:
Commercial ¹		453,823		492,498
Medicare		111,389		123,194
Medicaid		394,149		379,199
Total		959,361		994,891
Managed care enrollment by funding arrangement:
Fully-insured		819,267		831,170
Self-insured		140,094		163,721
Total		959,361		994,891

	Three months ended September 30,					Nine months ended September 30,
(dollar amounts in millions)	2018			2017		2018			2017
Revenues:
Premiums earned, net	$	742.4		$	714.3	$	2,236.3		$	2,139.5
Administrative service fees		3.8			3.4		11.2			12.3
Net investment income		16.2			12.4		45.6			37.1
Other operating revenues		1.6			1.0		4.2			3.0
Total operating revenues		764.0			731.1		2,297.3			2,191.9
Net realized investment (losses) gains		(0.9	)		3.7		1.1			8.1
Net unrealized investment gains (losses) on equity investments		5.6			-		(11.3	)		-
Other income, net		1.9			3.4		3.6			6.6
Total revenues		770.6			738.2		2,290.7			2,206.6
Benefits and expenses:
Claims incurred		648.6			583.6		1,959.7			1,815.8
Operating expenses		141.0			119.2		408.8			348.8
Total operating expenses		789.6			702.8		2,368.5			2,164.6
Interest expense		2.0			1.7		5.5			5.1
Total benefits and expenses		791.6			704.5		2,374.0			2,169.7
(Loss) income before taxes		(21.0	)		33.7		(83.3	)		36.9
Income tax (benefit) expense		(3.4	)		11.8		(30.9	)		6.6
Net (loss) income attributable to TSM	$	(17.6	)	$	21.9	$	(52.4	)	$	30.3

(Dollar amounts in millions, except per share data)	Total Number of Shares Purchased		Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Programs ¹		Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs

July 1, 2018 to July 31, 2018		-	$	-		-	$	18.5
August 1, 2018 to August 31, 2018		115,626		25.93		115,626		15.5
September 1, 2018 to September 30, 2018		144,299		20.77		144,299		12.5

Exhibits	Description

10.1*	Contract between the Administración de Seguros de Salud de Puerto Rico (ASES) and Triple-S Salud, Inc. for the provision of physical & behavioral health services under the Government Health Plan Program (File No. 001-33865).

11	Statement re computation of per share earnings; an exhibit describing the computation of the earnings per share for the three and nine months ended September 30, 2018 and 2017 has been omitted as the detail necessary to determine the computation of earnings per share can be clearly determined from the material contained in Part I of this Quarterly Report on Form 10-Q.

31.1*	Certification of the President and Chief Executive Officer required by Rule 13a-14(a)/15d-14(a).

31.2*	Certification of the Executive Vice President and Chief Financial Officer required by Rule 13a-14(a)/15d-14(a).

32.1*	Certification of the President and Chief Executive Officer required pursuant to 18 U.S.C Section 1350.

32.2*	Certification of the Executive Vice President and Chief Financial Officer required pursuant to 18 U.S.C Section 1350.

		Triple-S Management Corporation

		Registrant

Date:	November 8, 2018	By:	/s/ Roberto García-Rodríguez
			Roberto García-Rodríguez
			President and Chief Executive Officer

Date:	November 8, 2018	By:	/s/ Juan J. Román-Jiménez
			Juan J. Román-Jiménez
			Executive Vice President and Chief Financial Officer

TABLE OF CONTENTS	2
WHO CAN I CALL FOR HELP?	4
WHAT INFORMATION CAN I FIND ONLINE?	4
YOUR RIGHT TO PRIVACY (HIPAA)	5
DO YOU NEED HELP UNDERSTANDING THIS GUIDE?	5
DO YOU NEED HELP TALKING WITH YOUR INSURER OR READING WHAT THEY SEND YOU?	5
PART 1: GETTING STARTED	6
HOW DO I SIGN UP FOR MI SALUD?	6
WHAT IF I HAVE A NEWBORN?	6
HOW DO I KEEP MY MI SALUD BENEFITS?	6
HOW DO I CHOOSE AN INSURER?	6
CAN I CHANGE MY INSURER?	7
CAN MY MEMBERSHIP WITH MY INSURER STOP?	7
HOW DO I REPORT CHANGES?	8
YOUR ID CARD	8
PART 2: YOUR PRIMARY CARE PHYSICIAN AND OTHER DOCTORS	10
HOW CAN I SEE MY PCP?	10
WHAT IF IT’S AN EMERGENCY AND I NEED CARE AFTER MY PCP’S OFFICE CLOSES?	11
CAN I CHANGE MY PCP?	12
WHAT HAPPENS AFTER I ASK FOR THE CHANGE?	13
WHAT ABOUT OTHER DOCTORS OR PROVIDERS I NEED TO SEE?	13
HELP WITH GETTING TO YOUR HEALTH CARE VISITS	15
PART 3: SERVICES MI SALUD PAYS FOR	16
GENERAL INFORMATION	16
DENTAL SERVICES	17
MENTAL HEALTH, ALCOHOL AND DRUG ABUSE SERVICES	17
PHARMACY SERVICES	18
NON-COVERED SERVICES	18
PART 4: WILL I HAVE TO PAY TO GET HEALTH CARE SERVICES?	21
COPAY CHARTS	21
PART 5: SPECIAL PROGRAMS	23
SPECIAL COVERAGE	23
SPECIAL COVERAGE FOR HIV-AIDS	25
CARE MANAGEMENT	26
HIGH COST HIGH NEEDS PROGRAM	27

[PLACEHOLDER for Insurer to add information about any other special programs]	27
PART 6: FOR YOUR PROTECTION	28
YOUR RIGHTS	28
YOUR RIGHT TO PRIVACY (HIPAA)	29
YOUR RESPONSIBILITIES	29
ADVANCE DIRECTIVES	29
FRAUD AND ABUSE	30
PART 7: COMPLAINTS AND APPEALS	32
NEED TO MAKE A COMPLAINT ABOUT YOUR CARE?	32
WHAT HAPPENS IF MY COMPLAINT ISN’T FIXED?	32
WHAT IS AN APPEAL?	32
WHAT WILL HAPPEN WHEN MY INSURER GETS THE APPEAL?	33
WHAT CAN I DO IF I DON’T AGREE WITH THE DECISION?	33
CAN I KEEP GETTING SERVICES DURING MY APPEAL OR HEARING?	34
PART 8: HOW MI SALUD WORKS WITH OTHER HEALTH INSURANCE	35
HOW MI SALUD WORKS WITH MEDICARE	35
HOW MI SALUD WORKS WITH OTHER INSURANCE	36
HOW MI SALUD WORKS IF YOU ARE A PUBLIC EMPLOYEE OR RETIREE	36
HOW MI SALUD WORKS IF YOU ARE A MEMBER OF THE POLICE DEPARTMENT OF PUERTO RICO	37
DEFINITIONS	38

	Medicaid Program Call Center 787-641-4224

	ASSMCA (Linea PAS) Mental Health Service Line 1-800-981-0023

	Patient Advocate Office Toll-free 1-800-981-0031 TTY 787-710-7057

	Puerto Rico Health Insurance Administration (ASES) MI Salud Toll-free 1-800-981-2737

Emergencies might be things like:	These are usually not emergencies:

· Shortness of breath, not able to talk	· Sore throat

· A bad cut, broken bone, or a burn	· Cold or flu

· Bleeding that cannot be stopped	· Lower back pain

· Strong chest pain that does not go away	· Earache

· Strong stomach pain that doesn’t stop	· Stomachache

· Seizures that cause someone to pass out	· Small, superficial, cuts

· Not able to move your legs or arms	· Bruise

· A person who will not wake up	· Headache, unless it is very bad and like you’ve never had before

· Drug overdose	· Arthritis

REGION	TELEPHONE/FAX	ADDRESS

ARECIBO	(787) 878-7895 Fax. (787) 881-5773 Fax. (787) 878-8288 Tel. (787) 879-3168	Antiguo Hosp. Distrito (Dr Cayetano Coll y Toste) Carretera 129 hacia Lares Arecibo, PR 00614 PO Box 140370 Arecibo, PR 00614

BAYAMON	(787) 787-5151 Ext. 2224, 2475 (787) 787-5154 Fax. (787) 778-1209 (787) 787-4211	Antigua Casa de Salud Hosp. Regional Bayamón Dr. Ramón Ruíz Arnau, Ave. Laurel Santa Juanita Bayamón, PR 00956

CAGUAS CLINICA SATELITE HUMACAO	(787) 653-0550 Ext. 1142, 1150 Fax (787) 746-2898; 744-8645 (787) 285-5660	Hosp. San Juan Bautista PO Box 8548 Caguas, PR 00726-8548 CDT de Humacao, Dr. Jorge Franceshi Calle Sergio Peña Almodovar Esq. Flor Gerena Humacao, Puerto Rico 00791